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Abstract	  	  
	  
Multiple	   Sclerosis	   (MS)	   evolution	   varies	   from	   benign	   to	   aggressive	   forms,	   and	   its	  
prognosis	   remains	   largely	   unpredictable,	   especially	   in	   individual	   cases.	   Relapse	  
frequency	  is	  commonly	  used	  as	  indicator	  of	  disease	  activity	  and	  as	  primary	  endpoint	  
in	  randomized	  clinical	  trials	  (RCTs).	  However,	  the	  role	  of	  inflammatory	  attacks	  on	  the	  
disease	  progression	  is	  still	  largely	  debated.	  The	  lack	  of	  reliable	  predictors	  of	  the	  long-­‐
term	   evolution	   prevents	   from	   applying	   a	   rational	   and	   individualized	   therapeutic	  
approach.	   In	   addition,	   RCTs	   methodology	   is	   still	   not	   sufficiently	   rigorous	   for	  
protecting	  against	  the	  bias	  due	  to	  the	  large	  variability	  of	  the	  clinical	  outcome.	  	  
	  
The	  project	  was	  carried	  out	  by	  analysing	  the	  London	  Ontario	  (LO)	  database,	  one	  of	  
the	   largest	  collections	  of	  natural	  history	  data	  from	  untreated	  patients,	   followed	  up	  
for	   28	   years.	   We	   analysed	   factors	   affecting	   prognosis	   and	   predicting	   disease	  
evolution	   up	   to	   its	   latest	   stages.	   We	   first	   investigated	   in	   details	   the	   relationship	  
between	   relapses	   and	   long-­‐term	   outcome.	   The	   analysis	   demonstrated	   poor	  
correlation	   between	   number	   of	   attacks	   and	   the	   attainment	   of	   severe	   disability,	  
invalidating	  relapse	  frequency	  as	  surrogate	  marker	  for	   late	  outcome.	   In	  addition,	   it	  
evidenced	  the	  onset	  of	  the	  secondary	  progressive	  (SP)	  phase	  as	  the	  key	  determinant	  
of	  prognosis,	  differentiating	  patients’	  outcome	  and	  accounting	  for	  the	  variability	  of	  
disease	   course.	   We	   therefore	   analysed	   in	   details	   factors	   affecting	   the	   rate	   of	  
conversion	   to	   SP	  MS,	   in	   order	   to	   calculate	   how	   the	   risk	   of	   becoming	   progressive	  
varies	  with	  disease	  duration.	  This	  information	  can	  be	  used	  for	  designing	  RCTs	  using	  
SP	  onset	  as	  primary	  outcome.	  We	  then	  extensively	  investigated	  the	  effect	  of	  age	  on	  
the	   disease	   evolution,	   before	   and	   after	   the	   onset	   of	   progression.	   The	   analysis	  
highlighted	  age	  as	  the	  strongest	  determinant	  of	  MS	  prognosis,	  exerting	  its	  predictive	  
effect	  primarily	  by	  affecting	  the	  evolution	  of	  the	  relapsing	  remitting	  (RR)	  phase	  and	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Abbreviations:	  	  
	  
9HPT	  –	  9-­‐Hole	  Peg	  Test	  
25(OH)D–	  25-­‐hydroxyvitamin	  D	  	  
APC	  –	  Antigen	  presenting	  cell	  	  
ARR–	  Annualized	  relapse	  rate	  
ATP	  –	  Adenosine	  triphosphate	  
BBB	  –	  blood	  brain	  barrier	  
CSF	  –	  Cerebrospinal	  fluid	  
CIS	  –	  Clinically	  isolated	  syndrome	  
CDMS	  –	  Clinically	  definite	  MS	  
CNS	  –	  Central	  nervous	  system	  	  
CSF	  –	  Cerebrospinal	  fluid	  
DMT	  –	  Disease	  modifying	  treatment	  
DSS	  –	  Disability	  status	  scale	  
EAE–	  Experimental	  autoimmune	  encephalomyelitis	  
EBV	  –	  Epstein	  Barr	  Virus	  	  	  
EBNA	  –	  EBV	  nuclear	  antigens	  
EDSS	  –	  Expanded	  disability	  status	  scale	  
FLS	  –	  Flu	  like	  syndrome	  
FDA	  –	  Food	  and	  drug	  administration	  
FoxP3	  –Forkhead	  box	  protein	  P3	  
FS	  –	  Functional	  system	  
GA	  –	  Glatiramer	  acetate	  	  
HLA	  –	  Human	  Leukocyte	  Antigen	  
HR	  –	  Hazard	  ratio	  
IFN	  –	  Interferon	  	  
Ig	  –	  Immunoglobulin	  
IL	  –	  Interleukin	  
IM	  –	  Infectious	  mononucleosis	  	  
IM	  –	  Intramuscular	  	  
ISR	  –	  Injection	  site	  reaction	  
LO	  –	  London	  Ontario	  
LTF	  –	  Long	  term	  follow	  up	  
MC	  –	  Middlesex	  County	  	  
MHC	  –	  Major	  histocompatibility	  complex	  
MBP	  –	  Myelin	  basic	  protein	  
MOG	  –	  Myelin	  oligodendrocytes	  glycoprotein	  
MRI	  –	  Magnetic	  resonance	  imaging	  
MRS	  –	  Magnetic	  resonance	  spectroscopy	  
MSFC	  –	  Multiple	  Sclerosis	  Functional	  Composite	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NAWM–	  Normal	  appearing	  white	  matter	  
NAA	  –	  N-­‐acetylaspartate	  
NFs	  –	  Neurofilaments	  
NO	  –	  Nitric	  oxide	  	  
NTZ	  –	  Natalizumab	  	  
NNH	  –	  Number	  needed	  to	  harm	  
OCT–	  Optical	  coherence	  tomography	  
OR	  –	  Odd	  ratio	  
PASAT–	  Paced	  Auditory	  Serial	  Addition	  Test	  
PLP–	  Proteolipid	  protein	  
PML	  –	  progressive	  multifocal	  leukoenchephalopathy	  
PP	  –	  Primary	  progressive	  
PR	  –	  Progressive	  relapsing	  
RCT	  –	  Randomized	  controlled	  trial	  
RIS	  –	  Radiologically	  isolate	  syndrome	  
RNFL	  –	  Retinal	  nerve	  fibre	  layer	  
RR	  –	  Relapsing	  remitting	  	  
S1P	  –	  Sphingosine-­‐1-­‐phosphate	  
SC	  –	  Subcutaneous	  	  
SLC	  –	  Silvia	  Lawry	  Centre	  
SO	  –	  Seen	  from	  onset	  
SP	  –	  Secondary	  progressive	  	  
T25FW	  –	  Timed	  25-­‐Foot	  Walk	  
TNF	  –	  Tumour	  necrosis	  factor	  
Tregs–	  Regulatory	  CD4+	  T	  cells	  
TRAL	  –Treatment	  related	  acute	  leukaemia	  
VCAM	  –	  Vascular	  cell	  adhesion	  molecule	  	  
VCA	  –	  Viral	  capsid	  antigen	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1.1 Multiple	  Sclerosis	  	  
	  
	  
Multiple	   Sclerosis	   (MS)	   is	   an	   immune	   mediated	   disorder	   of	   the	   central	   nervous	  
system	  (CNS),	  characterized	  by	  acute	   focal	   inflammatory	  demyelination	  and	  axonal	  
loss	  (Compston	  and	  Coles,	  2002).	  It	  affects	  around	  2.5	  millions	  individuals	  around	  the	  
world	   (Compston,	   2005)	   and	   it	   is	   considered	   one	   of	   the	   most	   common	   cause	   of	  
disability	  among	  young	  adults,	  exerting	  a	  significant	  burden	  on	  health	  care	  costs	  and	  
quality	  of	  life	  of	  those	  affected.	  	  
	  
The	  clinical	  and	  pathological	  features	  of	  MS	  were	  first	  described	  by	  Charcot,	  Carswell	  
and	  others	  more	   than	  100	  years	  ago	   (Compston,	  2005)	  however,	   its	   aetiology	  and	  
pathogenesis	   remain	   largely	   unknown.	   The	   disease	   probably	   develops	   in	   genetic	  
susceptible	   populations,	   as	   a	   results	   of	   environmental	   exposures	   (Ebers,	   2008).	   Its	  
clinical	   course	   is	   unpredictable	   and	   ranges	   widely	   from	   benign	   to	   severe	   cases	  
(Lublin	  and	  Reingold,	  1996).	  About	  50%	  of	  patients	  are	  expected	  to	  require	  walking	  
assistance	   within	   15	   years	   from	   disease	   onset	   (Compston	   and	   Coles,	   2008).	   MS	  
prognosis	  continues	  to	  puzzle	  clinicians	  and	  scientists	  around	  the	  world,	  engaged	  in	  
the	  challenging	  task	  to	  prevent	  the	  progression	  of	  the	  disease.	  
	  
1.1.1 Incidence	  and	  prevalence	  
	  
Despite	  the	  wealth	  of	  information	  from	  several	  prevalence	  studies,	  carried	  out	  in	  the	  
past	   70	   years,	   defining	   the	  MS	  worldwide	   frequency	   remains	  difficult.	   The	  disease	  
appears	   to	   be	   unevenly	   distributed	   across	   the	   world,	   with	   a	   higher	   prevalence	  
among	  white	  people	  of	  Nordic	  origin,	   living	  in	  temperate	  zones	  and	  in	  high-­‐income	  
countries	  (Figure	  1.1)	  (Compston,	  2005).	  	  
	  
1.1.1.1	  Frequency	  and	  prevalence	  	  
	  
The	   general	   trend	   seems	   to	   indicate	   that	   the	  disease	   frequency	   rose	   steadily	   over	  
the	   years,	   however	   studies	   from	   different	   areas	   showed	   contradicting	   data.	   The	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incidence	   of	  MS	   (number	   of	   new	   cases	   per	   year)	  was	   reported	   to	   be	   increased	   in	  
some	  regions	  (Granieri	  et	  al.,	  2000;	  Grytten	  et	  al.,	  2006;	  Houzen	  et	  al.,	  2008;	  Larsen	  
et	   al.,	   1984b;	   McLeod	   et	   al.,	   1994;	   Noonan	   et	   al.,	   2002)	   or	   to	   be	  
unchanged/decreased	   in	   others	   (Svenningsson	   et	   al.,	   1990;	   Wender	   et	   al.,	   1987).	  
Differences	  in	  the	  ascertainment	  methodology	  and	  the	  variable	  social,	  economic	  and	  
genetic	   backgrounds	   of	   populations	   surveyed,	   make	   hard	   the	   comparison	   of	   data	  
from	  separate	  geographical	  areas	  (Pugliatti	  et	  al.,	  2002).	  
	  
Figure	  1.1	  The	  world	  geography	  of	  MS:	  prevalence	  for	  100.000	  habitants	  (world	  MS	  atlas	  2008).	  	  
	  
	  
To	   exemplify	   MS	   distribution,	   ≥	   30	   cases,	   5-­‐29	   cases	   and	   ≤	   5	   cases	   per	   100.000	  
habitants	  are	  considered	  high,	  medium	  and	  low	  prevalence	  (number	  of	  patients	  alive	  
at	   specific	   date),	   respectively	   (Kurtzke,	   2000).	   Despite	   Europe	   and	  North	   America,	  
where	   MS	   is	   relatively	   common,	   are	   disproportionally	   represented	   among	  
epidemiological	   studies,	   the	   disease	   frequency	   undoubtedly	   varies	   substantially	  
among	  continents.	  An	  high	  prevalence	  was	  consistently	  reported	  in	  Western	  Europe	  
(Celius	  and	  Vandvik,	  2001;	  Edland	  et	  al.,	  1996;	  Forbes	  et	  al.,	  1999;	  Gray	  et	  al.,	  2008;	  
Grytten	   et	   al.,	   2006;	   Kinnunen,	   1984;	   Kurtzke	   et	   al.,	   1982;	   Larsen	   et	   al.,	   1984a;	  
Midgard	  et	  al.,	  1991;	  Poser	  et	  al.,	  1989;	  Rothwell	  and	  Charlton,	  1998;	  Shepherd	  and	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Downie,	  1978;	  Sumelahti	  et	  al.,	  2001)	  and	  in	  North	  America	  (Hader,	  1982;	  Hader	  et	  
al.,	  1988;	  Hader	  and	  Yee,	  2007;	  Helmick	  et	  al.,	  1989;	  Mayr	  et	  al.,	  2003;	  Sweeney	  et	  
al.,	  1986;	  Wynn	  et	  al.,	  1990).	  Central	  and	  eastern	  Europe	  (Gross	  et	  al.,	  1993;	  Milanov	  
et	   al.,	   1997;	   Pekmezovic	   et	   al.,	   2001;	   Verdes	   et	   al.,	   1978;	   Wender	   et	   al.,	   1985),	  
Australia	  and	  New	  Zealand	   (Barnett	  et	  al.,	  2003;	  McLeod	  et	  al.,	  1994;	  Skegg	  et	  al.,	  
1987)	   represent	  medium	  prevalence	  areas.	  Asia	   (Cheng	  et	  al.,	  2007;	  Houzen	  et	  al.,	  
2008;	  Lau	  et	  al.,	  2002),	  Middle	  East	  and	  Africa	  (Alshubaili	  et	  al.,	  2005;	  Bhigjee	  et	  al.,	  
2007;	   El-­‐Salem	   et	   al.,	   2006;	   Radhakrishnan	   et	   al.,	   1985)	   have	   the	   lowest	   reported	  
prevalence.	  	  
	  
Scotland	   and	   its	   offshore	   Faroe	   Islands	   have	   the	   highest	   prevalence	   rates	   so	   far	  
detected	  anywhere	   in	   the	  world,	   ranging	   from	  145	  to	  193	  cases/100.000	  habitants	  
(Forbes	   et	   al.,	   1999;	   Kurtzke	   and	   Heltberg,	   2001;	   Rothwell	   and	   Charlton,	   1998).	  
Interestingly,	   it	  has	  been	  claimed	  that	  MS	  appeared	  in	  the	  Faroe	  Islands	  during	  the	  
World	   War	   II,	   following	   the	   occupation	   by	   British	   troops,	   and	   reoccurred	  
subsequently	  in	  4	  separate	  epidemics	  (Kurtzke	  and	  Hyllested,	  1975).	  This	  led	  to	  the	  
ambitious	   and	   questionable	   (Poser	   et	   al.,	   1988)	   hypothesis	   of	   a	   widespread	  
asymptomatic,	  transmissible	  infection	  behind	  its	  aetiology	  (Kurtzke	  et	  al.,	  1993).	  
	  
1.1.1.2	  The	  “latitude	  effect”	  
	  
The	   frequency	   of	   MS	   seems	   to	   have	   a	   distinct	   latitudinal	   variation;	   the	   risk	   of	  
developing	  the	  disease	  is	  higher	  in	  areas	  at	  high	  geographic	  latitude	  (Simpson	  et	  al.,	  
2011).	  This	  was	  observed	  in	  Australia	  (Hammond	  et	  al.,	  1988),	  Europe	  (Vukusic	  et	  al.,	  
2007)	   and	   North	   America	   (Kurtzke	   et	   al.,	   1979),	   however	   other	   studies	   could	   not	  
confirm	  the	  same	  trend	  (Melcon	  et	  al.,	  2008;	  Poppe	  et	  al.,	  2008).	  	  
	  
In	  addition,	  in	  some	  Mediterranean	  European	  regions	  the	  prevalence	  of	  the	  disease	  
is	  much	   higher	   than	   expected	   for	   their	   latitude,	   suggesting	   the	   presence	   of	   gene-­‐
environment	  interactions	  (Grimaldi	  et	  al.,	  2007;	  Nicoletti	  et	  al.,	  2005;	  Pugliatti	  et	  al.,	  
2005;	  Rosati	  et	  al.,	  1996).	  The	  “latitude	  effect”	  hypothesis	  remains	   largely	  debated	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(Alonso	   and	   Hernan,	   2008;	   Koch-­‐Henriksen	   and	   Sorensen,	   2010;	   Rosati,	   2001;	  
Simpson	  et	  al.,	  2011).	  	  
	  
1.1.1.3	  The	  sex	  ratio	  
	  
At	   the	  beginning	  of	   the	  20th	   century,	  MS	  was	   thought	   to	  be	  a	  predominantly	  male	  
disease	  (Brain,	  1935).	  Since	  then,	   there	  has	  been	  a	  steady	   increase	  of	   its	   incidence	  
among	  women	  (Bentzen	  et	  al.,	  2010;	  Debouverie	  et	  al.,	  2007;	  Hader	  and	  Yee,	  2007;	  
Hirst	  et	  al.,	  2009;	  Midgard	  et	  al.,	  1996;	  Orton	  et	  al.,	  2006;	  Sahraian	  et	  al.,	  2010).	  For	  
instance,	   the	   sex	   ratio	   in	   Japan	   rose	   from	  1:1	   to	   2.9:1	   in	   between	   1972	   and	   2004	  
(Osoegawa	   et	   al.,	   2009),	   in	   Canada	   from	   1.9	   to	   3.2:1	   in	   between	   1940	   and	   1980	  
(Orton	   et	   al.,	   2006)	   and	   in	   northern	   climates	   it	   now	  exceeds	   3.1:1	   (Dyment	   et	   al.,	  
2004).	  	  
	  
The	   female	   preponderance,	   among	  MS	   patients,	   is	   now	   commonly	   agreed,	  with	   a	  
consensus	   that	  women	  are	   about	   twice	   as	   likely	   to	  develop	   the	  disease	   than	  men	  
(Compston	  and	  Coles,	  2008).	  The	  reasons	  behind	  the	   increasing	  number	  of	  women	  
with	   MS	   have	   been	   long	   discussed,	   without	   reaching	   any	   definitive	   conclusion.	  
Smoking,	  known	  to	  affect	  the	  risk	  of	  MS	  (Hernan	  et	  al.,	  2001)	  and	  to	  have	  become	  
more	  diffuse	  among	  women	  over	  the	  years,	  as	  well	  as	  the	  changes	  in	  lifestyle	  factors	  
in	   women	   and	   an	   improved	   access	   to	   the	   health	   care	   for	   women,	   have	   been	  
proposed	  as	  factors	  possibly	  contributing	  to	  the	  variation	  of	  the	  sex	  ratio	  over	  time	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1.1.2	  The	  role	  of	  vitamin	  D	  
	  
The	  primary	  sources	  of	  vitamin	  D	   (colecalciferol)	   in	  human	  beings	  are	   the	  diet	  and	  
the	  skin	  exposure	  to	  ultraviolet	  (UVB)	  radiation	  in	  sunlight.	  The	  diet	  provides	  only	  a	  
modest	   amount	   of	   vitamin	   D	   (40-­‐400	   IU	   per	   food	   serving)	   (Brannon	   et	   al.,	   2008),	  
compared	  to	  the	  sun	  exposure	  (20	  minutes	  during	  summer	  produces	  around	  10.000	  
IU)	   (Holick,	  2004).	  UVB	  allows	  the	  7-­‐dehydrocholesterol	   in	   the	  skin	   to	   transform	   in	  
pre-­‐vitamin	   D3,	   which	   then	   isomerises	   to	   colecalciferol	   (Holick,	   2003).	   The	  
colecalciferol	   is	   also	   available	   from	   fortified	   foods	   (milk,	   cereals,	   chesses	   and	   dark	  
fishes).	   It	   remains	   biologically	   inactive	   until	   it	   is	   converted	   in	   the	   liver	   to	   25-­‐
hydroxyvitamin	  D,	   and	   finally	   to	   1,25-­‐hydroxyvitamin	  D,	  which	  binds	   and	   activates	  
the	  vitamin	  D	  receptors	  (VDR).	  	  
	  
1.1.2.1	  Sun	  exposure	  	  
	  
The	  hypothesis	   that	  vitamin	  D	  deficiency	   is	  a	   risk	   factor	   for	  MS	  was	   first	  proposed	  
almost	  40	  years	  ago	  (Agranoff	  and	  Goldberg,	  1974).	  Supporting	  evidence	  come	  from	  
epidemiological	   studies,	   which	   showed	   an	   increased	   frequency	   of	   MS	   at	   higher	  
latitudes	   (Hammond	   et	   al.,	   1988;	   Kurtzke	   et	   al.,	   1979;	   Ramagopalan	   et	   al.,	   2011;	  
Simpson	  et	  al.,	  2011;	  Vukusic	  et	  al.,	  2007),	  where	  the	  population	  is	  exposed	  to	  low	  
UVB	   radiations	   intensity	   and	   is	   known	   to	   have	   low	   vitamin	   D	   blood	   levels.	   In	  
addition,	   other	   studies	   demonstrated	   that	   the	   average	   annual	   hours	   of	   sunshine	  
during	   childhood	   inversely	   correlated	  with	   the	   prevalence	   of	  MS	   (Leibowitz	   et	   al.,	  
1967;	   van	   der	   Mei	   et	   al.,	   2001;	   van	   der	   Mei	   et	   al.,	   2003).	   Interestingly,	   the	  
association	  between	  the	  sun	  exposure	  during	  childhood	  and	  the	  risk	  of	  MS	  was	  also	  
observed	  among	  monozygotic	  twins	  discordant	  for	  MS	  (Islam	  et	  al.,	  2006).	  Even	  the	  
outdoor	  activity,	  as	  an	  occupational	  exposure,	  seems	  to	  affect	  the	   incidence	  of	  MS	  
and	  its	  mortality	  rate	  (Freedman	  et	  al.,	  2000).	  	  
	  
Migration	   studies	   further	   supported	   an	   association	   between	   vitamin	   D	   and	   the	  
incidence	  of	   the	  disease.	  The	  risk	  of	  MS	  was	  shown	  to	  decrease	  among	   individuals	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migrating	   from	   high	   to	   low	   latitude	   areas	   (Gale	   and	  Martyn,	   1995;	   Kurtzke	   et	   al.,	  
1985),	  possibly	  in	  relation	  to	  the	  different	  sun	  exposure	  intensity.	  	  
	  
1.1.2.2	  The	  vitamin	  D	  intake	  	  
	  
Although	   the	   sun	   light	   exposure	   plays	   a	   primary	   role,	   the	   vitamin	   D	   diet	   intake	  
becomes	  relevant	   in	  winter,	  especially	  at	  high	   latitudes.	  For	   instance,	   in	  Norway,	  a	  
lower	  MS	  prevalence	  was	  found	  among	  coastal	  communities	  consuming	  greater	  fish	  
than	   inland	   agricultural	   populations	   (Kampman	   et	   al.,	   2007;	   Swank	   et	   al.,	   1952;	  
Westlund,	  1970).	   Similarly,	   a	   recent	   longitudinal	   study	  demonstrated	   that	  a	  higher	  
total	  vitamin	  D	  intake	  correlates	  with	  a	  significantly	  lower	  risk	  of	  MS	  (Munger	  et	  al.,	  
2004).	  However,	  studying	  the	  association	  between	  the	  vitamin	  D	  diet	  intake,	  which	  is	  
often	   assessed	   retrospectively,	   and	   the	   risk	   of	   MS,	   is	   difficult	   and	   potentially	  
complicated	  by	  recall	  bias.	  	  
	  
1.1.2.3	  The	  vitamin	  D	  serum	  levels	  
	  
Notwithstanding	   the	   methodological	   difficulties	   due	   to	   the	   large	   longitudinal	  
assessments	  and	  the	  repeated	  blood	  samples	  collections	  required,	  the	  role	  of	  serum	  
levels	   of	   25-­‐hydroxyvitamin	   D	   (25(OH)D),	   which	   is	   the	   main	   circulating	   form	   of	  
vitamin	  D,	  in	  relation	  to	  MS	  incidence	  has	  also	  been	  studied.	  A	  41%	  reduction	  of	  the	  
risk	   of	   MS,	   for	   every	   50	   nmol/L	   increase	   of	   25(OH)D	   level,	   was	   demonstrated,	  
independently	  of	  the	  place	  of	  birth	  and	  of	  the	  latitude	  of	  residence	  during	  childhood	  
(Munger	  et	  al.,	  2006).	  	  
	  
In	  addition,	  recent	  studies	  found	  an	  association	  between	  an	  higher	  concentration	  of	  
serum	  25(OH)D	  and	  a	  lower	  risk	  of	  clinical	  exacerbations	  (Runia	  et	  al.,	  2012;	  Simpson	  
et	   al.,	   2010),	   further	   supporting	   a	   protective	   effect	   exerted	  by	   the	   vitamin	  D.	   This	  
hypothesis	  might	  be	  contradicted	  by	  the	  lower	  incidence	  of	  the	  disease	  among	  black	  
people	  (Kurtzke	  et	  al.,	  1979),	  known	  to	  be	  vitamin	  D	  deficient	  (Looker	  et	  al.,	  2008).	  
However,	   the	   genetic	   differences	  with	  white	   people	   probably	   compensate	   for	   the	  
low	  vitamin	  D	  levels	  (Ascherio	  et	  al.,	  2010).	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1.1.2.4	  Immunological	  effects	  of	  the	  vitamin	  D	  
	  
Immunological	  studies	  offer	  further	  evidence,	  suggesting	  a	  potential	  role	  of	  vitamin	  
D	  in	  the	  pathogenesis	  of	  the	  disease.	  Vitamin	  D	  exerts	  immunomodulatory	  effects	  on	  
a	  wide	  range	  of	  immune	  cells,	  including	  T-­‐lymphocytes,	  B-­‐lymphocytes	  and	  dendritic	  
cells	  (Arnson	  et	  al.,	  2007;	  Deluca	  and	  Cantorna,	  2001).	  In	  addition,	  different	  cells	  of	  
the	  immune	  system	  contain	  VDRs	  (Chen	  et	  al.,	  2007;	  Veldman	  et	  al.,	  2000).	  	  
	  
Indeed,	  the	  disease	  progression	  in	  the	  experimental	  autoimmune	  encephalomyelitis	  
(EAE),	   the	   most	   commonly	   studied	   animal	   model	   of	   MS	   (Pachner,	   2011),	   can	   be	  
prevented	  or	  improved	  with	  the	  administration	  of	  vitamin	  D	  (Cantorna	  et	  al.,	  1996;	  
Lemire	   and	   Archer,	   1991;	   Nataf	   et	   al.,	   1996;	   Spach	   et	   al.,	   2006),	   and	   with	   the	  
exposure	  to	  UVB	  (Hauser	  et	  al.,	  1984).	  	  
	  
1.1.3	  Smoking	  and	  MS	  
	  
1.1.3.1	  Smoking	  and	  the	  incidence	  of	  MS	  	  
	  
Smoking	   is	   an	   important	   risk	   factor	   for	   MS.	   Early	   studies	   indicated	   a	   possible	  
worsening	  of	  MS	  symptoms	  with	  smoking	  (Emre	  and	  de	  Decker,	  1992;	  Perkin	  et	  al.,	  
1975).	   More	   recently,	   in	   3	   large	   prospective	   cohorts	   studies,	   ever-­‐smokers	   were	  
shown	  to	  have	  a	  40-­‐80%	   increased	  risk	  of	  MS,	  compared	  to	  never-­‐smokers,	  with	  a	  
relative	  risk	  varying	  between	  1.4	  (Thorogood	  and	  Hannaford,	  1998),	  1.7	  (Hernan	  et	  
al.,	  2001)	  and	  1.8	  (Villard-­‐Mackintosh	  and	  Vessey,	  1993).	  	  
	  
Given	   that	   smoking	   has	   generally	   become	   more	   diffuse	   among	   women	   over	   the	  
recent	  years,	  the	  changes	  in	  the	  males/females	  ratio	  has	  been	  considered	  a	  possible	  
confounding	   factor.	   This	   was	   recently	   addressed	   in	   a	   large	   study,	   which	   assessed	  
whether	   the	  males/females	   incidence	  of	  MS	  changed	  concomitantly	  with	   smoking.	  
The	   results	   demonstrated	   a	   40%	   average	   increase	   in	   the	   incidence	   of	   MS	   among	  
both	  women	  and	  men	  ever-­‐smokers	  (Palacios	  et	  al.,	  2011).	  In	  addition,	  the	  risk	  of	  MS	  
appears	  significantly	  higher,	  even	  among	  individuals	  who	  had	  smoked	  at	  some	  point	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during	   their	   life,	   compared	   to	   those	   who	   never	   smoked.	   This	   was	   observed	   in	  
Sweden	   (Odds	   Ratio	   [OR]	   =	   1.5)	   (Hedstrom	   et	   al.,	   2009),	   in	   the	   U.K.	   (OR	   =	   1.3)	  
(Hernan	  et	  al.,	  2005)	  and	  in	  Norway	  (OR	  =	  1.8)	  (Riise	  et	  al.,	  2003).	  Interestingly,	  the	  
risk	  of	  developing	  MS	  in	  adult	  life	  was	  shown	  to	  remain	  unchanged,	  among	  offspring	  
whose	  mothers	  smoked	  during	  pregnancy	  (Montgomery	  et	  al.,	  2008).	  	  
	  
1.1.3.2	  Smoking	  and	  the	  disease	  severity	  	  
	  
Among	  MS	  patients,	  smoking	  was	  shown	  to	  affect	  significantly	  the	  disease	  severity.	  
Being	  a	  smoker	  associates	  with	  a	  higher	  probability	  (Hazard	  Ratio	  [HR]	  =	  3.6	  (Hernan	  
et	  al.,	  2005)	  and	  2.5	  (Healy	  et	  al.,	  2009))	  of	  experiencing	  disease	  progression	  and	  of	  
developing	  more	  severe	  disability	  (Zivadinov	  et	  al.,	  2009a).	  Neurotoxic	  (Smith	  et	  al.,	  
1963)	   and	   immunomodulatory	   (Sopori	   and	   Kozak,	   1998)	   effects,	   exerted	   by	  
constituents	   of	   cigarettes	   smoke,	   are	   possible	   biological	   explanations	   of	   how	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1.1.4	  Epstein	  Barr	  Virus	  and	  MS	  
	  
Epstein	  Barr	  Virus	   (EBV)	   is	  a	  potentially	  oncogenic	  herpes	  virus,	  which	   infects	  over	  
90%	   of	   human	   beings,	   within	   the	   first	   decades	   of	   life.	   Following	   the	   primary	  
infection,	  usually	  occurring	   through	  contact	  with	   infected	  saliva,	  EBV	  remains	   in	  B-­‐
lymphocytes	  of	  the	  host	  in	  a	  “latency	  state”	  (Thorley-­‐Lawson,	  2001)	  and	  tends	  to	  be	  
asymptomatic,	   especially	   in	   young	   children.	   However,	   in	   up	   to	   40%	   of	   infected	  
individuals,	   EBV	   leads	   to	   infectious	   mononucleosis	   (IM)	   during	   the	   adult	   life	  
(Andersson,	   1991).	   In	   addition,	   it	   can	   cause	   lymphomas	   in	   immunosuppressed	  
subjects	  (Kutok	  and	  Wang,	  2006).	  
	  
1.1.4.1	  The	  EBV	  primary	  infection	  	  
	  
The	   EBV	   seronegativity	   is	   rare	   among	   MS	   patients	   (Pakpoor	   et	   al.,	   2012).	   EBV-­‐
positive,	   compared	   to	   EBV-­‐negative,	   individuals	   have	   a	  much	   higher	   probability	   of	  
developing	  MS	  (Ascherio	  et	  al.,	  2001;	  Ascherio	  and	  Munger,	  2007;	  Levin	  et	  al.,	  2010).	  
The	   risk	   of	   MS	   was	   shown	   to	   be	   greatly	   increased	   (OR	   =	   13.5)	   by	   being	   EBV-­‐
seropositive	   (Ascherio	   and	   Munch,	   2000)	   and,	   on	   the	   contrary,	   to	   be	   greatly	  
decreased	  (OR	  =	  0.06	  (Ascherio	  and	  Munger,	  2007)	  and	  0.18	  (Pakpoor	  et	  al.,	  2012))	  
by	   being	   EBV-­‐seronegative.	   Interestingly,	   in	   a	   large	   cohort	   of	   EBV-­‐negative	   young	  
adults,	   the	   incidence	   of	   MS	   was	   observed	   to	   increase	   sharply	   following	   the	   EBV	  
infection;	  all	  MS	  patients	  had	  seroconverted	  before	  the	  onset	  of	  symptoms,	  strongly	  
indicating	   the	  EBV	   infection	  precede	   the	   immune	  deregulation,	  which	   leads	   to	   the	  
development	  of	  the	  disease	  (Levin	  et	  al.,	  2010).	  	  
	  
1.1.4.2	  EBV	  antibodies	  	  
	  
Among	   EBV	   infected	   healthy	   individuals,	   the	   incidence	   of	   MS	   appears	   to	   rise	  
proportionally	  with	  the	  serum	  titres	  of	  EBV	  related	  antibodies	  (Ascherio	  et	  al.,	  2001;	  
DeLorenze	  et	  al.,	  2006;	  Levin	  et	  al.,	  2005).	  From	  a	  large	  meta-­‐analysis,	  the	  calculated	  
ORs	  for	  MS	  risk,	  in	  relation	  to	  seropositivity	  for	  antibodies	  anti	  EBV	  nuclear	  antigens	  
(EBNA)	  complex,	  anti-­‐EBNA-­‐1	  and	  anti	  viral	  capsid	  antigen	  (VCA),	  were	  5.4,	  12.1	  and	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5.5,	  respectively	  (Santiago	  et	  al.,	  2010).	   Interestingly,	  the	  association	  between	  anti-­‐
EBNA	  antibodies	  titres	  and	  the	  risk	  of	  MS	  was	  shown	  to	  be	  independent	  of	  the	  HLA-­‐
DRB1*1501	  allele	  status	  (De	  Jager	  et	  al.,	  2008;	  Simon	  et	  al.,	  2010;	  Sundstrom	  et	  al.,	  
2008),	   but	   to	   vary	   according	   to	   the	   smoking	   status,	   being	   about	   two	   folds	   greater	  
among	  ever-­‐smokers	   compared	   to	  never-­‐smokers	   (Simon	  et	  al.,	  2010).	   In	  addition,	  
young	  adulthood	  appears	  to	  be	  the	  potential	  window	  for	  the	  risk	  of	  MS.	  Anti	  EBNA	  
and	  EBV	  antigen	  antibodies	  were	  found	  to	  occur	  in	  similar	  titres	  in	  cases	  and	  control,	  
but	   to	   increase	  dramatically	  after	   the	  age	  of	  25	  among	  those	  who	   later	  developed	  
the	  disease	  (Levin	  et	  al.,	  2005)	  
	  
Antibodies	   anti	   EBV	  might	   also	   associate	   to	   the	   disease	   severity	   and	   progression.	  
Two	  independent	  studies	  reported	  a	  positive	  correlation	  between	  increased	  titres	  of	  
anti-­‐EBNA	   and	   anti-­‐VCA	   antibodies	   and	   the	   brain	   volume	   at	   magnetic	   resonance	  
imaging	  (MRI)	  and	  the	  disability	  severity	  (Farrell	  et	  al.,	  2009;	  Zivadinov	  et	  al.,	  2009b).	  
These	   results	   suggest	   that	   immunological	   parameters	   of	   EBV	   infection	   could	   be	  
potentially	  used	  as	  biomarker	   in	  MS,	  however	   further	   investigations	  are	  needed	  to	  
better	   explore	   this	   hypothesis	   and	   to	   elucidate	   whether	   EBV	   contributes	   to	   the	  
disease	  progression	  (Ascherio	  and	  Munger,	  2010).	  
	  
1.1.4.3	  Mononucleosis	  	  
	  
The	  hypothesis	  linking	  EBV	  infection	  (IM)	  and	  the	  risk	  of	  MS	  was	  first	  driven	  by	  their	  
similarities	   in	   the	   geographical	   and	   socioeconomic	   distribution	   (Ascherio	   and	  
Munger,	   2007;	  Disanto	   et	   al.,	   2012;	  Warner	   and	   Carp,	   1981).	   Both	   diseases	   affect	  
mostly	   young	   adults,	   are	  more	   prevalent	   among	  women,	   follow	   a	   similar	   latitude	  
gradient	   and	   are	   more	   frequent	   in	   high-­‐income	   populations.	   Despite	   several	  
evidences	  from	  epidemiological,	  laboratory	  and	  pathology	  studies,	  supporting	  a	  role	  
of	  EBV	  infection	  in	  the	  pathogenesis	  of	  MS,	  definitive	  conclusions	  on	  whether	  EBV	  is	  
simply	   a	   concomitant	   epiphenomenon	   of	   an	   immune	   derangement	   or	   a	   causative	  
risk	  factor	  for	  MS,	  have	  never	  been	  reached.	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Independent	  studies	  cohere	  in	  demonstrating	  that	  MS	  risk	  is	  2-­‐3	  folds	  higher	  among	  
people	  with	  a	  history	  of	  IM	  (Ahlgren	  et	  al.,	  2009;	  Nielsen	  et	  al.,	  2007;	  Ramagopalan	  
et	  al.,	  2009c;	  Zaadstra	  et	  al.,	  2008).	  In	  a	  recent	  large	  meta-­‐analysis,	  combining	  case	  
control	  and	  cohort	  studies,	  the	  calculated	  relative	  risk	  (RR)	  of	  MS	  for	  a	  past	  history	  of	  
IM	  was	  2.17	   (Handel	   et	   al.,	   2010c).	   The	   risk	   seems	   to	   increase	  proportionally	  with	  
the	  age	  at	  infection	  (Hunter	  and	  Hafler,	  2000),	  and	  to	  be	  much	  larger	  among	  patients	  
HLA-­‐DRB1*1501	  allele	  positive	  (Nielsen	  et	  al.,	  2009),	  which	  is	  the	  strongest	  genetic	  
predictor	  of	  MS.	  	  
	  
1.1.4.4	  EBV	  infection	  and	  MS	  pathogenesis	  
	  
The	  mechanisms	   linking	   the	   EBV	   infection	   and	   the	   pathogenesis	   of	  MS	   have	   been	  
long	  debated	   and	   remain	   controversial	   (Ascherio	   and	  Munger,	   2007;	  Ascherio	   and	  
Munger,	  2010;	  Lassmann	  et	  al.,	  2011;	  Lucas	  et	  al.,	  2011).	  It	  has	  been	  postulated	  that	  
the	   EBV	   infection,	   asymptomatic	   in	   early	   life,	   might	   indirectly	   trigger	   the	  
autoimmune	   reaction,	  which	   leads	   to	   the	  development	  of	  MS	   in	   adult	   life,	   among	  
susceptible	   individuals	   (Ascherio	   and	   Munger,	   2007;	   Hunter	   and	   Hafler,	   2000).	  
However,	   this	   attractive	   hypothesis	   cannot	   sufficiently	   explain	   why	   MS	   remains	  
relatively	   rare,	   despite	   the	   widespread	   diffusion	   of	   the	   EBV	   infection	   in	   the	   adult	  
population.	   This	   suggests	   that	   genetic	   determinants	   possibly	   influence	   the	  
susceptibility	  to	  both	  EBV	  infection	  and	  MS	  (Ascherio	  and	  Munger,	  2007;	  Handel	  et	  
al.,	  2010b).	  	  
	  
Pathological	   studies	   offer	   contradicting	   evidences	   and	   cannot	   help	   to	   further	  
elucidate	  these	  hypotheses.	  In	  nearly	  100%,	  of	  22	  brains	  analysed,	  a	  high	  proportion	  
of	  EBV-­‐infected	  B-­‐lymphocytes	  was	   found	   in	  meningeal	   follicles,	   infiltrating	   the	  MS	  
lesions	  (Serafini	  et	  al.,	  2007).	  These	  findings	  might	   indicate	  that	  antigen-­‐presenting	  
EBV-­‐infected	   B-­‐cells	   infiltrate	   the	   central	   nervous	   system	   (CNS)	   and	   trigger	   a	  
cytotoxic	   response,	   resulting	   in	   the	  chronic	   inflammatory	  process	  and	   in	   the	   tissue	  
damage	  (Pender,	  2011).	  However,	  results	  from	  Serafini	  et	  al.	  could	  not	  be	  replicated	  
in	   other	   studies,	   using	   similar	   technologies,	   but	   showing	   no	   evidence	   of	   EBV	  
infection	  in	  the	  CNS	  (Peferoen	  et	  al.,	  2010;	  Sargsyan	  et	  al.,	  2010;	  Willis	  et	  al.,	  2009).	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In	   an	   attempt	   to	   identify	   the	   reason	   underlying	   these	   discrepant	   results,	   a	   joint	  
meeting	  of	  all	  research	  groups	  involved	  in	  the	  EBV	  infection	  and	  MS	  brains	  analyses	  
was	  recently	  held	  (Vienna,	  July	  2010)	  (Lassmann	  et	  al.,	  2011).	  It	  was	  concluded	  that	  
the	   differences	   among	   studies	   are	   probably	   due	   to	   technical	   issues	   and	   different	  
interpretations	   of	   the	   immunocytochemistry	   (Lassmann	   et	   al.,	   2011).	   The	   EBV	  
infection	  in	  the	  CNS,	  when	  present	  at	  all,	  is	  probably	  restricted	  to	  a	  very	  low	  number	  
of	  B	  cells	  and	  current	  evidence	  are	  not	  sufficient	  for	  judging	  if	  EBV	  is	  concomitant	  or	  
causal	  to	  MS	  (Lassmann	  et	  al.,	  2011).	  	  
	  
The	   lack	   of	   convincing	   evidence	   of	   the	   presence	   of	   EBV,	   within	   the	   CNS	   of	   MS	  
patients,	   possibly	   indicates	   that	   EBV	   plays	   an	   indirect	   role	   in	   the	   disease	  
pathogenesis,	  through	  a	  T-­‐cells	  activation	  (Ascherio	  and	  Bar-­‐Or,	  2010).	  Other	  studies	  
highlighted	  the	  intriguing	  hypothesis	  of	  a	  common	  pathogenic	  mechanism	  between	  
EBV	   and	   vitamin	   D,	   both	   exerting	   an	   adverse	   effect	   on	   the	   risk	   of	   MS,	   through	  
changes	   in	   the	   level	  of	   interleukin	  10	   (IL-­‐10)	   (Hayes	  and	  Donald	  Acheson,	  2008)	  or	  
through	  an	  activation	  of	  auto-­‐reactive	  T	  cells,	  which	  is	  facilitated	  by	  a	  low	  vitamin	  D	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1.1.5	  Genes	  and	  MS	  
	  
1.1.5.1	  The	  familial	  risk	  of	  MS	  
	  
A	   genetic	   influence	  on	  MS	   susceptibility	  was	   first	   suggested	  many	  decades	   ago	  by	  
observations	   of	   the	  disease	   aggregation	   in	   families	   (Mackay,	   1950;	   Schapira	   et	   al.,	  
1963),	   later	   confirmed	   in	   other	   studies	   (Ebers	   et	   al.,	   2004;	   Robertson	  et	   al.,	   1996;	  
Willer	  et	  al.,	  2003).	  First-­‐degree	  relatives	  have	  10-­‐25	  times	  greater	  risk	  of	  MS	  than	  
the	  general	  population;	  this	  risk	  correlates	  directly	  with	  the	  degree	  of	  kinship	  (Figure	  
1.2)	   (Compston	   and	   Coles,	   2002).	   Further	   supporting	   evidence	   come	   from	   twin	  
studies	  from	  different	  populations,	  consistently	  showing	  that	  a	  monozygotic	  twin	  of	  
an	  affected	  individual	  has	  much	  higher	  risk	  of	  developing	  the	  disease	  than	  a	  dizygotic	  
twin	  (Hansen	  et	  al.,	  2005;	  Willer	  et	  al.,	  2003).	  	  
	  
Figure	  1.2	  The	  recurrence	  risk	  for	  MS	  in	  families:	  age	  adjusted	  recurrence	  risk	  for	  different	  relatives	  




1.1.5.2	  HLA	  and	  MS	  susceptibility	  
	  
For	   the	   first	   time	   in	   the	   early	   70s	   it	   was	   highlighted	   that	   the	   Human	   Leukocyte	  
Antigen	   (HLA)	   genes,	   residing	   within	   the	   major	   histocompatibility	   complex	   (MHC)	  
region,	  play	  a	  primary	  role	  in	  determining	  the	  genetic	  susceptibility	  to	  MS	  (Jersild	  et	  
al.,	  1973).	  HLA-­‐class	  ΙΙ	  types	  exert	  the	  strongest	  effect,	  accounting	  for	  20-­‐60%	  of	  the	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genetic	  risk	  (Haines	  et	  al.,	  1998),	  however	  the	  association	  is	  not	  straightforward	  and	  
changes	   in	   relation	  to	   the	  geographic	  areas.	  Some	  haplotypes	   (HLA-­‐DRB1*03,	  HLA-­‐
DRB1*10,	  HLA-­‐DRB1*11,	  HLA-­‐DRB1*14)	  are	  known	  to	  correlate	  with	  the	  risk	  of	  MS	  
in	  northern	  Europe	   (Barcellos	  et	  al.,	   2003),	  with	  a	  predominant	   role	  played	  by	   the	  
HLA-­‐DRB1*15	   in	   virtually	   all	   populations	   (Caillier	   et	   al.,	   2008;	   Lincoln	   et	   al.,	   2005;	  
Ramagopalan	  et	  al.,	  2009a).	  However,	  different	  haplotypes	  affect	   the	  susceptibility	  
in	   other	   populations,	   such	   as	   Sardinians	   (HLA-­‐DRB1*03,	   HLA-­‐DRB1*04,	   HLA-­‐
DRB1*13)	   (Marrosu	   et	   al.,	   2001),	   Canadians	   (HLA-­‐DRB1*11,	   HLA-­‐DRB1*14)	  
(Ramagopalan	   et	   al.,	   2007),	   Japanese	   (HLA-­‐DRB1*09)	   	   (Matsuoka	   et	   al.,	   2008)	   and	  
Spanish	  (HLA-­‐DRB1*03,	  HLA-­‐DRB1*08,	  HLA-­‐DRB1*14)	  (Pina	  et	  al.,	  1999).	  	  
	  
MHC	  class	  ΙΙ	  molecules	  are	  cell	  surface	  glycoproteins,	  presenting	  the	  antigen	  CD4+	  
to	  T-­‐helper	  cells	  and	  therefore	  implicated	  in	  the	  maintenance	  of	  the	  immune	  system	  
self	   tolerance	   and	   in	   its	   adaptive	   response	   to	   pathogens	   (Watts,	   2004).	   HLA-­‐DRB1	  
alleles	  are	  thought	  to	  affect	  the	  risk	  of	  developing	  the	  disease	  risk,	  by	  influencing	  T-­‐
cell	   repertoires,	  which	   are	   involved	   into	   the	   disease	   pathogenesis	   (McFarland	   and	  
Martin,	  2007)	  However,	  this	  hypothesis	  requires	  further	  clarifications	  (Ramagopalan	  
et	  al.,	   2009b).	  Other	   studies	  have	   identified,	  within	  HLA-­‐class	   Ι	   alleles,	   some	  other	  
few	  loci	  affecting	  MS	  susceptibility,	  independently	  of	  class	  ΙΙ	  loci	  (Bergamaschi	  et	  al.,	  
2010;	  Cree	  et	  al.,	  2010;	  Link	  et	  al.,	  2010).	  
	  
Complex	   gene-­‐to-­‐gene	   interactions	   (epistasis)	   affect	   the	   MS	   susceptibility	   in	  
different	   ways.	   For	   instance,	   while	   carrying	   the	   HLA-­‐DRB1*15	   allele	   roughly	  
triplicates	  the	  risk	  of	  MS,	  when	  this	   is	  associated	  with	  the	  HLA-­‐DRB1*14	  allele,	   the	  
risk	   dramatically	   drops	   to	   1	   (Dyment	   et	   al.,	   2005;	   Ramagopalan	   et	   al.,	   2007).	  
Similarly,	  although	  the	  HLA-­‐DRB1*08	  allele	  on	   its	  own	  exerts	  a	  very	  modest	  effect,	  
its	  association	  with	  a	  single	  copy	  of	  the	  HLA-­‐DRB1*15	  allele	  doubles	  the	  probability	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1.1.5.3	  Genome	  wide	  association	  
	  
The	   MHC	   is	   not	   the	   only	   genetic	   region	   associated	   with	   the	   risk	   of	   MS.	   Recent	  
genome	  wide	   association	   (GWA)	   studies	   highlighted	   the	   role	   of	  multiple	   non-­‐MHC	  
loci,	  affecting	  the	  risk	  of	  developing	  the	  disease	  (Baranzini	  et	  al.,	  2009;	  Sawcer	  et	  al.,	  
2011).	  The	  majority	  of	  these	  genes	  are	  involved	  in	  the	  immune	  system,	  in	  agreement	  
with	   the	   immune-­‐mediated	  pathogenesis	  of	   the	  disease:	   interleukin	   (IL)-­‐2	   and	   IL-­‐7	  
receptors,	  CD6,	  CD58,	  IRF8	  genes.	  However,	  all	  of	  them	  were	  found	  to	  exert	  a	  rather	  
modest	  effect	  and	  their	  exact	  role	  in	  the	  disease	  aetiology	  and	  pathogenesis	  remains	  
to	  be	  elucidated.	  	  
	  
1.1.5.4	  Genes	  and	  the	  disease	  severity	  
	  
The	  role	  of	  genes	  affecting	  the	  disease	  severity	  is	  extremely	  controversial.	  The	  HLA-­‐
DRB1*01	   allele	   was	   found	   to	   exert	   a	   protective	   effect	   against	   a	   severe	   disease	  
course,	  as	   it	  was	  overrepresented	  among	  patients	  with	  benign,	  compared	  to	  those	  
with	   severe	   outcome	   (DeLuca	   et	   al.,	   2007).	   Similar	   results	   were	   reported	   by	   an	  
Australian	  study	  (Stankovich	  et	  al.,	  2009).	  However,	  in	  a	  Spanish	  MS	  cohort,	  the	  HLA-­‐
DRB1*01	  allele	  associated	  with	  a	  more	  rapid	  disability	  development	   (Romero-­‐Pinel	  
et	  al.,	  2011).	   In	  addition,	   in	  a	   large	  French	  study,	  the	  HLA-­‐DRB1*15	  allele	  positively	  
correlated	  with	  a	  faster	  disease	  progression	  (Cournu-­‐Rebeix	  et	  al.,	  2008).	  Differences	  
in	   the	   study	  design	  and	  methodology	  might	  partially	  account	   for	   the	  discrepancies	  
among	   studies,	   and	   further	   analyses	   are	  needed	   for	   validating	   the	  hypothesis	   that	  
the	  disease	  severity	  is	  regulated,	  to	  some	  extent,	  by	  a	  genetic	  control	  (Ramagopalan	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1.1.6	  Environmental	  factors	  
	  
Results	  from	  migration	  studies	  (Gale	  and	  Martyn,	  1995),	  the	  geographical	  gradient	  of	  
the	   distribution	   of	   the	   disease	   (Simpson	   et	   al.,	   2011)	   and	   the	   high	   rates	   of	  
discordancy	   in	   identical	   twins	   (Islam	   et	   al.,	   2006;	  Willer	   et	   al.,	   2003),	   suggest	   that	  
environmental	   factors,	   such	   as	   the	   sunlight	   exposure	   or	   viral	   infections,	   play	   a	  
relevant	  role	  in	  the	  development	  of	  MS.	  Whether	  such	  factors	  act	  as	  triggers	  or	  are	  
directly	   involved	   into	   the	   pathogenesis	   of	   the	   disease	   remain	   unknown	   and	   has	  
therapeutic	  implications.	  	  
	  
1.1.6.1	  The	  time	  of	  exposure	  
	  
The	   timing	   of	   exposure	   is	   of	   crucial	   importance	   with	   regards	   to	   the	   potential	  
prevention	  of	   the	  disease.	  Environmental	   factors	  might	  act	   in	  utero	  and	  affect	   the	  
susceptibility	   to	  MS	   later	   in	   life.	  For	   instance,	   some	  studies	  suggested	  a	  “month	  of	  
birth	  effect”;	  	  the	  risk	  of	  developing	  MS	  was	  shown	  to	  be	  higher	  among	  those	  born	  in	  
May	  and	  lower	  among	  those	  born	  in	  November	  (Willer	  et	  al.,	  2005).	  This	  association	  
could	  be	  mediated	  by	  the	  sunlight	  exposure	  and	  its	  effect	  on	  vitamin	  D	  levels,	  known	  
to	  be	  low	  among	  pregnant	  women	  and	  among	  new	  born	  during	  winter	  (Newhook	  et	  
al.,	   2009).	   This	   hypothesis	   is	   reinforced	   by	   other	   studies,	   supporting	   a	   maternal	  
parent-­‐of-­‐origin	  effect	  on	  the	  MS	  susceptibility	  (Chao	  et	  al.,	  2009).	  By	  analysing	  the	  
parent-­‐child	   concordance	   in	   MS,	   it	   has	   been	   demonstrated	   an	   excess	   of	   mother-­‐
daughter	  pairs	  and	  a	  paucity	  of	  father-­‐son	  pairs	  (Sadovnick	  et	  al.,	  1991a).	  In	  addition,	  
family	   studies	   showed	   a	   much	   higher	   concordance	   for	   MS	   between	   maternally	  
related	   half	   siblings	   than	   between	   paternally	   related	   ones	   (Ebers	   et	   al.,	   2004;	  
Herrera	  et	  al.,	  2008).	  	  
	  
Migration	  studies	  helped	  to	  better	  address	  the	  role	  of	  the	  timing	  of	  exposure	  on	  the	  
risk	  of	  developing	  the	  disease.	  It	  has	  been	  suggested	  that,	  by	  migrating	  from	  a	  high	  
to	   a	   low	   incidence	   area,	   individuals	   acquire	   a	   lower	   risk	   of	   MS	   only	   if	   migration	  
occurs	  in	  early	  adolescence,	  within	  the	  age	  of	  15	  (Dean	  and	  Kurtzke,	  1970;	  Kurtzke	  et	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al.,	   1970),	   or	   at	   latest	   within	   the	   third	   decade	   of	   life	   (Hammond	   et	   al.,	   2000).	  
Interestingly,	  among	  migrants	  to	  Canada	  from	  Europe,	  features	  of	  sex	  ratio	  from	  the	  
original	  country	  are	  retained	  if	  migration	  occurs	  after	  the	  age	  of	  21	  only	  (Orton	  et	  al.,	  
2010).	   In	   addition,	   the	   level	   of	   summer	   sun	   exposure	   during	   early	   stages	   of	   life	  
correlates	   inversely	  with	   the	  probability	   of	   developing	  MS	   (Kampman	  et	   al.,	   2007;	  
van	  der	  Mei	  et	  al.,	  2003),	  even	  among	  monozygotic	  twins	  discordant	  for	  MS	  (Islam	  et	  
al.,	  2007).	  	  	  
	  
Taken	  together,	  these	  data	  indicate	  that	  there	  is	  a	  “cut	  off	  period	  of	  susceptibility”,	  
most	   likely	   early	   in	   life.	   Environmental	   factors,	   probably	   during	   childhood	   and	  
adolescence,	  interact	  with	  genetic	  factors	  and	  determine	  the	  overall	  susceptibility	  to	  
MS	   (Goodin,	   2009).	   EBV	   infection	   is	   unambiguously	   present	   among	   MS	   patients	  
(Ascherio	  and	  Munger,	   2007)	   and	  vitamin	  D	  deficiency	  early	   in	   life	  might	   alter	   the	  
immune	   response	   and	   eventually	   predispose	   the	   individual	   to	   develop	  MS	   (Hayes	  
and	  Donald	  Acheson,	   2008).	  Other	   factors	   are	   likely	   to	   play	   a	   relevant	   role	   during	  
different	  stages	  of	  life,	  as	  confirmed	  by	  the	  wide	  range	  of	  age	  at	  which	  the	  disease	  




The	   epigenetic	   effect	   implies	   heritable	   changes	   in	   gene	   expression	   caused	   by	  
mechanisms	  not	  involving	  the	  underlying	  DNA	  sequence	  (Urdinguio	  et	  al.,	  2009).	  As	  
they	  can	  be	  modulated	  by	   the	  environment,	   these	  mechanisms	  provide	   the	  bridge	  
between	   external	   factors	   and	   internal	   genetic	   system	   (Handel	   et	   al.,	   2010a).	  
Environmentally	  induced	  changes	  to	  the	  epigenome	  can	  persist	  through	  generations.	  
The	   exact	   role	   of	   epigenetics	   in	  MS	   aetiology	   remains	   unknown.	  However,	   several	  
observations	   lend	   support	   to	   the	   hypothesis	   that	   epigenetic	   modifications,	   by	  
mediating	   the	  effect	   of	   the	  environmental	   factors,	   affect	   the	  disease	   susceptibility	  
and	  pathogenesis.	  Identical	  monozygotic	  twins	  discordant	  for	  MS	  (Islam	  et	  al.,	  2006;	  
Willer	   et	   al.,	   2003),	   the	   month	   of	   birth	   effect	   (Willer	   et	   al.,	   2005),	   the	   maternal	  
parent-­‐of-­‐origin	   effect	   (Chao	   et	   al.,	   2009)	   and	   the	   associations	   between	   vitamin	  D	  
deficiency	   (Munger	   et	   al.,	   2006),	   EBV	   infection	   (Levin	   et	   al.,	   2010)	   and	   smoking	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(Palacios	   et	   al.,	   2011),	   and	   the	   incidence	   of	  MS,	   imply	   changes	   to	   the	   epigenome	  
induced	  by	  the	  environment.	  	  
	  
Epigenetic	  effect	  has	  also	  been	  observed	  in	  in	  the	  HLA	  region	  of	  MS	  patients.	  Among	  
aunt/uncle/niece/nephew	  MS	  pairs,	  the	  frequency	  of	  the	  HLA-­‐DRB1*1501	  allele	  was	  
found	   to	   be	   different	   between	   the	   first	   and	   the	   second	   generation	   of	   females.	  
Affected	  aunts	  had	  a	  significantly	  lower	  HLA-­‐DRB1*1501	  allele	  frequency	  compared	  
to	  their	  affected	  nieces	  (Chao	  et	  al.,	  2009).	  Therefore,	  as	  the	  HLA-­‐DRB1*1501	  allele	  
frequency	   remains	   unchanged	   among	   affected	   males,	   it	   has	   been	   suggested	   that	  
epigenetics	  modifications	  might	  play	  a	  role	  in	  the	  MS	  preponderance	  among	  women	  
(Hoppenbrouwers	  and	  Hintzen,	  2011).	  	  
	  
The	  complexity	  of	  MS	  aetiology	  derives	   from	  the	   interaction	  between	   the	  external	  
environmental	   risk	   factors	   and	   the	   internal	   genetic	   landscape.	   The	   epigenetic	  
mechanisms	  are	  therefore	  likely	  to	  play	  a	  primary	  role	  in	  the	  MS	  susceptibility,	  which	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1.2 Clinical	  presentation	  and	  disease	  course	  
	  
	  	  
MS	   follows	   different	   patterns	   of	   evolution	   and	   the	   rate	   of	   disability	   accumulation	  
largely	   varies,	   among	  patients.	   The	  disease	   course	   and	   the	   clinical	   phenotypes	   are	  
characterized	  by	  relapses	  and	  progression,	  which	  present	  alone	  or	  in	  combination.	  	  
	  
For	  the	  majority	  of	  patients,	  during	  the	  initial	  stages	  of	  the	  disease,	  relapses	  are	  the	  
exclusive	   clinical	   feature,	   defining	   the	   relapsing	   remitting	   (RR)	   phase.	   This	   is	  
followed,	   in	   most	   of	   the	   cases,	   within	   a	   variable	   lapse	   of	   time,	   by	   a	   steady	   and	  
progressive	   accumulation	   of	   irreversible	   disability,	   which	   characterizes	   the	  
secondary	   progressive	   (SP)	   phase.	   A	   minority	   of	   patients	   experience	   a	   primary	  
progressive	  (PP)	  course,	  featured	  by	  the	  accumulation	  of	  unremitting	  disability	  since	  
the	   disease	   onset.	   Relapses	   can	   present	   during	   both	   the	   PP	   and	   SP	   phase,	   in	   a	  
variable	  percentage	  of	  patients.	  	  
	  
1.2.1	  Relapses	  	  
Relapses	  are	  episodic,	  acute	  neurological	  symptoms,	  lasting	  for	  more	  than	  24	  hours,	  
in	  patients	  otherwise	  free	  from	  concomitant	  illness	  (typically	  an	  infection	  producing	  
fever)	   (Lublin	  and	  Reingold,	  1996).	  They	  represent	   the	  clinical	  manifestation	  of	  on-­‐
going	  inflammatory	  activity	  and	  can	  virtually	  manifest	  with	  any	  kind	  of	  neurological	  
symptom,	  according	  to	  where	  the	  inflammation	  localizes,	  within	  the	  CNS	  (Compston	  
and	  Coles,	  2008).	  It	  is	  commonly	  agreed	  that	  events	  occurring	  within	  1-­‐month	  period	  
are	  considered	  part	  of	  the	  same	  acute	  episode	  (McDonald	  et	  al.,	  2001;	  Poser	  et	  al.,	  
1983).	  The	  onset	  of	  the	  functional	  impairment	  is	  commonly	  acute	  or	  sub-­‐acute	  and	  
can	  be	  followed	  by	  a	  partial	  or	  complete	  remission	  over	  weeks	  (Bethoux	  et	  al.,	  2001;	  
Lublin	   and	   Reingold,	   1996)	   and,	   in	   some	   cases,	   even	   after	   12	   months	  
(Kremenchutzky	   et	   al.,	   2006a).	   A	   permanent	   severe	   motor	   disability	   (requiring	  
unilateral	   walking	   assistance	   or	   worse)	   only	   rarely	   results	   from	   a	   lack	   of	   recovery	  
(Bejaoui	  and	  Rolak,	  2010;	  Tutuncu	  et	  al.,	  2012).	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1.2.2	  Progression	  	  
Progression	  is	  characterized	  by	  a	  steady	  accumulation	  of	  irreversible	  disability,	  for	  at	  
least	  1	  year,	  although	  occasional	  plateaus	  and	  minor	  temporary	   improvements	  can	  
be	  observed	  (Lublin	  and	  Reingold,	  1996).	  This	  definition	  remains	  controversial	  and	  it	  
is	  often	  mistaken	  with	  the	  worsening	  of	  disability	  from	  baseline	  (Liu	  and	  Blumhardt,	  
2000).	  In	  the	  majority	  of	  patients,	  progression	  initially	  presents	  clinically	  with	  a	  long	  
tract	   involvement	   of	   lower	   limbs,	   causing	   deterioration	   of	   ambulation	  
(Kremenchutzky	   et	   al.,	   2006b).	   The	   date	   at	   which	   progression	   starts	   is	   invariably	  
assigned	   in	   retrospect,	   once	   the	   required	   12	   months	   duration	   of	   continuous	  
worsening	  is	  confirmed.	  Nevertheless,	  in	  some	  cases	  relapses	  with	  lack	  of	  complete	  
recovery	   can	   cloud	   the	  onset	  of	  progression,	  making	   the	   task	  of	  pinpointing	  when	  
the	  progressive	  phase	  begins	  particularly	  challenging	  (Kremenchutzky	  et	  al.,	  2006b).	  	  	  
	  
1.2.3	  The	  disease	  course	  	  
	  
The	  lack	  of	  clear	  biological	  markers,	  allowing	  to	  distinguish	  the	  various	  forms	  of	  MS,	  
contributed,	   over	   the	   years,	   to	   the	   difficulties	   of	   finding	   unanimous	   definitions	   of	  
course	   patterns.	   The	   long	   debate	   came	   to	   an	   end	   in	   1996	   when,	   following	   the	  
Advisory	  Committee	  on	  Clinical	   Trials	  of	  New	  Agents	   in	  MS	   survey,	  definitions	  and	  
terminologies	   used	   to	   describe	   the	   disease	   courses	  were	   standardized	   (Lublin	   and	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1.2.3.1	  Relapsing-­‐remitting	  MS	  
	  
Figure	  1.3	  RR	  MS	  is	  characterized	  by	  clearly	  acute	  attacks	  with	  full	  recovery	  (A)	  or	  with	  residual	  deficit	  




Approximately	  80%	  to	  85%	  of	  MS	  patients	  experience	  a	  RR	  phase	   (Confavreux	  and	  
Vukusic,	  2006a;	  Kantarci	  et	  al.,	  1998;	  Leray	  et	  al.,	  2010;	  Phadke,	  1987;	  Poser	  et	  al.,	  
1983;	  Runmarker	  and	  Andersen,	  1993;	  Scalfari	  et	  al.,	  2010;	  Tremlett	  et	  al.,	  2009b).	  
This	  is	  characterized	  by	  clearly	  defined	  relapses,	  followed	  by	  full	  or	  partial	  recovery,	  
with	   a	   stable	   disease	   course	   between	   attacks	   (Figure	   1.3)	   (Lublin	   and	   Reingold,	  
1996).	  	  
	  
Motor,	   sensory	   and	   visual	   disturbances	   represent	   the	   most	   commonly	   observed	  
symptoms	  at	  the	  onset	  of	  the	  RR	  phase.	  However,	  these	  figures	  vary	  among	  natural	  
history	   cohorts,	   reflecting	   different	   methodologies	   of	   studies	   (Confavreux	   and	  
Vukusic,	   2006a;	   Kantarci	   et	   al.,	   1998;	   Leray	   et	   al.,	   2010;	   McDonald	   et	   al.,	   2001;	  
Phadke,	   1987;	   Poser	   et	   al.,	   1983;	   Runmarker	   and	  Andersen,	   1993;	   Tremlett	   et	   al.,	  
2009b).	   The	   type	   of	   symptoms	   featuring	   the	   relapses	   over	   the	   course	   of	   the	   RR	  
phase	  has	  never	  been	  systematically	  ascertained.	  	  
	  
The	   frequency	   of	   the	   attacks	   averages	   1	   relapse/year	   in	   the	   early	   stage	   of	   the	  
disease	   (Confavreux	   et	   al.,	   1980;	   Goodkin	   et	   al.,	   1989;	   Patzold	   and	   Pocklington,	  
1982),	   and	   decreases	   over	   time,	   due	   to	   the	   “regression	   to	   mean”	   phenomenon	  
(Patzold	  and	  Pocklington,	  1982;	  Tremlett	  et	  al.,	  2008b).	   For	   instance,	   in	   the	  British	  
Columbia	   database	   population,	   annualized	   relapse	   rate	   reduced	   by	   17%	   every	   5	  
years	  of	  disease	  duration	  (Tremlett	  et	  al.,	  2008b).	  In	  addition,	  77%	  of	  patients	  stayed	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free	   of	   relapses	   for	   at	   least	   5	   years,	   highlighting	   the	   unpredictable	   pattern	   of	   the	  
evolution	  of	  inflammatory	  attacks	  (Tremlett	  et	  al.,	  2008b).	  	  	  
	  
1.2.3.2	  Secondary	  progressive	  MS	  	  
	  
Figure	   1.4	   SP	   MS	   begins	   with	   an	   initial	   RR	   course,	   followed	   by	   progression	   at	   variable	   rate	   (A).	  
Occasional	  relapses	  and	  minor	  remission	  can	  occur	  (B)	  (Lublin	  and	  Reingold,	  1996).	  	  	  
	  
	  
The	   RR	   course	   can	   be	   followed	   by	   the	   SP	   phase,	   which	   is	   characterized	   by	  
progression,	   with	   or	   without	   superimposed,	   occasional	   relapses,	   minor	   remission	  
and	  plateau	  (Lublin	  and	  Reingold,	  1996).	  It	  has	  been	  estimated	  that	  more	  than	  80%	  
of	   patients,	   with	   an	   initial	   RR	   course,	   convert	   to	   SP	   MS	   after	   25	   years	   from	   the	  
disease	   onset	   (Weinshenker	   et	   al.,	   1989b).	   However,	   a	   minority	   can	   remain	  
progression	  free	  even	  after	  50	  years	  of	  disease	  course	  (Skoog	  et	  al.,	  2012).	  	  
	  
It	   is	   commonly	   accepted	   that,	   once	   the	   baseline	   between	   relapses	   begins	   to	  
progressively	  worsen,	  the	  patient	  has	  switched	  to	  the	  secondary	  progression	  (Lublin	  
and	   Reingold,	   1996).	   Nevertheless,	   the	   boundaries	   between	   the	   RR	   and	   the	   SP	  
phases	  remain	  somehow	  arbitrary.	  Establishing	  when	  the	  SP	  phase	  begins	  can	  be	  a	  
challenging	  task,	  particularly	  when	  patients	  start	  to	  progress,	  while	  still	  experiencing	  
relapses,	  as	  the	  progression	  of	  disability	  is	  not	  discretely	  attributable	  either	  to	  lack	  of	  
recovery	   from	   the	   inflammatory	   attack	   or	   to	   the	   underlying	   progression	  
(Kremenchutzky	  et	  al.,	  2006b).	  	  	  
	  
The	  rate	  of	  worsening	  varies	  among	  SP	  MS	  patients,	  although	  the	  evolution	  of	   the	  
progressive	  phase,	  eventually,	  invariably	  leads	  to	  the	  attainment	  of	  severe	  disability	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(Kremenchutzky	  et	  al.,	  2006b;	  Tutuncu	  et	  al.,	  2012).	  Relapses	  can	  still	  occur	  during	  
the	   SP	   phase	   in	   about	   40%	   of	   patients,	   without	   significantly	   impacting	   on	   its	  
evolution	  (Confavreux	  et	  al.,	  2000).	  
	  
	  1.2.3.3	  Primary	  progressive	  MS	  (PP-­‐MS)	  
	  
Figure	  1.5	  PP	  MS	  is	  characterized	  by	  progression	  of	  disability	  from	  onset	  (A)	  with	  occasional	  plateaus	  
and	   temporary	   minor	   improvements	   allowed.	   Clear	   acute	   relapses	   can	   overlap	   the	   PP	   course	   (B)	  
(formerly	  progressing	  relapsing	  [PR]	  MS)	  (Lublin	  and	  Reingold,	  1996).	  
	  
	  
A	  minority	  of	   patients,	   ranging	   from	  15%	   to	  20%	   (Confavreux	   and	  Vukusic,	   2006a;	  
Kantarci	  et	  al.,	  1998;	  Leray	  et	  al.,	  2010;	  Phadke,	  1987;	  Poser	  et	  al.,	  1983;	  Runmarker	  
and	   Andersen,	   1993;	   Tremlett	   et	   al.,	   2009b),	   experiences	   a	   PP	   course.	   This	   is	  
characterized	   by	   progression	   from	   onset,	   with	   occasional	   plateau	   and	   temporary	  
minor	  improvements	  allowed	  (Lublin	  and	  Reingold,	  1996).	  The	  essential	  requirement	  
in	   PP	   MS	   cases	   is	   a	   gradual,	   nearly	   continuously	   worsening	   and	   accumulation	   of	  
disability,	  with	  minor	  fluctuations,	  but	  no	  distinct	  relapses.	  	  
	  
A	  progressive	  disease	   course	   from	  onset,	   overlapped	  by	   clear	   acute	   relapses,	  with	  
full	   or	   partial	   recovery,	   and	   with	   continuous	   progression	   in	   between	   relapses,	  
characterizes	  the	  progressive	  relapsing	  (PR)	  forms	  of	  MS	  (Lublin	  and	  Reingold,	  1996).	  
It	   has	   been	   estimated	   that	   about	   30-­‐40%	   of	   PP	   patients	   can	   experience	  
superimposed	   relapses	   (Confavreux	   et	   al.,	   2000;	   Kremenchutzky	   et	   al.,	   1999b),	  
mostly	   occurring	  within	   10	   years	   from	   disease	   onset,	   although	   in	   a	  minority	   even	  
after	   20	   years	   (Kremenchutzky	   et	   al.,	   1999b).	   	   In	   view	   of	   the	   similar	   clinical	   and	  
demographic	   features	   and	   of	   the	   same	   long-­‐term	   outcome	   between	   PR	   and	   PP	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patients,	  it	  has	  been	  suggested	  that	  the	  two	  subgroups	  should	  be	  considered	  a	  single	  
clinical	  entity	  (Confavreux	  and	  Vukusic,	  2006a;	  Kremenchutzky	  et	  al.,	  1999b).	  	  
	  
1.2.3.4	  Clinically	  isolated	  syndrome	  	  
	  
Clinically	   isolated	   syndrome	   (CIS)	   is	   a	   term	   that	   describes	   a	   first	   clinical	   episode,	  
lasting	   at	   least	   24	   hours,	  with	   features	   suggestive	   of	  MS	   (Miller	   et	   al.,	   2008).	   The	  
episode	   generally	   presents	   acutely	   or	   sub-­‐acutely,	   and	   reaches	   its	   peak	  within	   2-­‐3	  
weeks.	  To	  be	  termed	  CIS,	  symptoms	  have	  to	  occur	   in	  absence	  of	   fever	  or	   infection	  
and	  should	  not	  have	  features	  of	  encephalopathy	  (Miller	  et	  al.,	  2008).	  CIS	  is	  generally	  
a	  mono-­‐focal	  syndrome	  that	  can	  affect	  the	  optic	  nerve	  (more	  commonly),	  the	  spinal	  
cord,	  the	  brainstem	  or	  the	  cerebellum	  however,	  and,	  in	  a	  minority	  of	  cases,	  presents	  
with	  multi-­‐focal	  involvement	  (Miller	  et	  al.,	  2008).	  	  	  
	  
The	  risk	  of	  conversion	  to	  clinically	  definite	  (CD)	  MS,	  among	  patients	  with	  CIS,	  varies	  
according	  to	  the	  type	  of	  clinical	  presentation	  (Miller	  et	  al.,	  2012).	  MS	  was	  reported	  
to	  develop	  in	  10%-­‐85%	  of	  patients	  presenting	  with	  optic	  neuritis	  (2008),	  in	  41%-­‐61%	  
of	  patients	  presenting	  with	   transverse	  myelitis	   (Young	  et	  al.,	  2009),	   in	  53%-­‐60%	  of	  
patients	  presenting	  with	  brainstem	  symptoms	  (Tintore	  et	  al.,	  2010).	  These	  different	  
figures	  might	  be	  accounted	   for	  by	   the	  different	  geographic	   location	  of	   studies	  and	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1.3 The	  immunology	  of	  Multiple	  Sclerosis	  
	  
	  
Initial	  evidence	  of	  the	  autoimmune	  and	  inflammatory	  nature	  of	  MS	  date	  back	  many	  
decades	   ago	   when,	   for	   the	   first	   time,	   high	   levels	   of	   immunoglobulins	   (Ig)	   were	  
detected	   in	   the	   cerebrospinal	   fluid	   (CSF)	   of	   patients	   (Kabat	   et	   al.,	   1948).	   The	  
development	   of	   the	   disease	   is	   likely	   to	   be	   preceded	   by	   an	   activation,	   in	   the	  
peripheral	   immune	  system,	  of	  reactive	  CD4+	  Th1	  cells,	  which	  subsequently	  migrate	  
across	   the	   blood	   brain	   barrier	   (BBB)	   into	   the	   CNS,	   targeting	   myelin	   components.	  
Sclerotic	   plaques,	   involving	   the	   white	   matter	   of	   the	   CNS,	   are	   the	   pathological	  
hallmark	   of	  MS	   (Lassmann	   et	   al.,	   2001)	   and	   represent	   the	   end	   stage	   of	   a	   process	  
primarily	   driven	   by	   inflammation	   and	   demyelination,	   and	   accompanied	   by	  
remyelination,	  astrocytosis	  and	  axonal	  degeneration	  (Lassmann	  et	  al.,	  2001).	  White	  
matter	   lesions	  are	  characterized	  by	  a	  perivascular	  T	   lymphocytes	   infiltration,	  which	  
tends	   to	   spill	   into	   the	   surrounding	   parenchyma	   (Lassmann	   et	   al.,	   2001).	   However,	  
the	   presence	   of	   IgG	   oligoclonal	   bands	   into	   the	   CSF	   of	   up	   to	   95%	   of	   patients	  
(Freedman	  et	  al.,	  2005)	  indicates	  also	  an	  abnormal	  B	  cells	  activation,	  highlighting	  the	  




1.3.1.1	  The	  antigen	  specificity	  	  
T-­‐lymphocytes	   migrate	   into	   the	   CNS,	   trigger	   an	   immune	   response,	   targeting	  
specifically	  myelin	   and	   non-­‐myelin	   antigens	   components,	   and	   expand	   clonally	   into	  
the	   perivascular	   space,	   causing	   cytotoxic	   damage	   (Kivisakk	   et	   al.,	   2009).	   However,	  
the	   initiation	   of	   the	   antigen-­‐specific	   response	   remains	   largely	   unclear	   and	  
environmental	   factors	   are	   considered	   the	   most	   likely	   triggers	   (Marrie,	   2004;	  
Sospedra	  and	  Martin,	  2005).	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Myelin	   basic	   protein	   (MBP)	   and	   the	   proteolipid	   protein	   (PLP)	   are	   the	   two	   most	  
abundant	   myelin	   proteins	   in	   the	   CNS	   (30-­‐40%	   and	   50%,	   respectively).	   They	   are	  
involved	   into	   the	  maintenance	   of	   the	  myelin	   structural	   compactness	   and	   they	   are	  
found	   in	   significant	   quantities	   in	   both	   the	   central	   and	   peripheral	   nervous	   system	  
(Seamons	  et	  al.,	  2003).	  Their	  key	  role	  as	  inductors	  of	  the	  inflammation	  into	  the	  CNS,	  
along	  with	  other	  antigens	  candidates,	  such	  the	  myelin	  oligodendrocytes	  glycoprotein	  
(MOG),	  has	  been	  extensively	  demonstrated	  in	  the	  MS	  animal	  model	  (EAE)	  (Kennedy	  
et	  al.,	  1990;	  Mendel	  et	  al.,	  1995;	  Wekerle	  et	  al.,	  1994).	  Nevertheless,	  studies	  failed	  
to	  show	  significant	  differences	  of	  myelin	  reactivity	  between	  MS	  patients	  and	  healthy	  
donors	   (Burns	   et	   al.,	   1983).	   It	   has	   been	   hypothesized	   that,	   in	  MS	   patients,	  myelin	  
specific	   T	   cells	   are	   of	   “higher	   avidity”	   and	   skewed	   towards	   the	   pro-­‐inflammatory	  
phenotype,	   compared	   to	   healthy	   controls	   (Bielekova	   et	   al.,	   2004),	   explaining	   their	  
pathogenic	  role.	  	  
	  
1.3.1.2	  CD4+	  T	  cells	  
	  
The	   hypothesis	   that	   CD4+	   T-­‐cells	   are	   major	   players	   into	   the	   MS	   pathogenesis	   is	  
confirmed	   by	   observations	   in	   the	   experimental	   model	   of	   the	   disease	   (EAE)	  
(Goverman	   et	   al.,	   1993;	   Zamvil	   and	   Steinman,	   1990).	   EAE	   can	   be	   caused	   by	   the	  
injection	   of	   defined	   protein	   components	   of	   the	   myelin	   sheath	   into	   susceptible	  
animals,	   but	   cannot	   be	   transferred	   by	   antibodies,	   highlighting	   the	   primary	   role	  
played	  by	  T	  cell-­‐mediated	  autoimmune	  mechanisms	  (Pettinelli	  and	  McFarlin,	  1981).	  
EAE	   can	   also	   be	   transferred	   to	   naïve	   animals,	   by	   injecting	  myelin-­‐specific	   CD4+	   T-­‐
cells	   reactivated	   in	   vitro	   (Zamvil	   and	   Steinman,	   1990).	   In	   addition,	   genetic	   studies	  
demonstrate	   that	   disease	   susceptibility	   strongly	   associates	   with	   MHC	   class	   ΙΙ	  
products,	   normally	   required	   for	   presenting	   auto-­‐antigens	   to	   T	   lymphocytes	   and	  
therefore	  implicated	  into	  the	  immune	  system	  self	  tolerance	  (Watts,	  2004).	  	  
	  
CD4+	  Th1	  circulating	  cells	  are	  found	  abundant	   in	  the	  patients’	  blood	  and	  receptors	  
specific	  for	  MBP	  are	  present	  in	  MS	  human	  brains	  (Lassmann	  et	  al.,	  2001;	  Oksenberg	  
et	  al.,	  1993).	  Once	  CD4+	  T	  cells	  accumulate	  into	  the	  CNS,	  the	  macrophage-­‐mediated	  
immune	   response	   is	   amplified	   by	   pro-­‐inflammatory	   cytokines	   such	   as	   interferon	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(IFN)-­‐γ	   and	   tumour	  necrosis	   factor	   (TNF)-­‐α	   (Olsson	  et	  al.,	  1990;	  Seder	  and	  Ahmed,	  
2003).	   High	   levels	   of	   Th1	   cytokines	   are	   found	   in	   the	   MS	   patients’	   blood	   and	   the	  
disease	  activity	  seems	  to	  correlate	  with	  IFN-­‐γ	  and	  interleukin	  (IL)-­‐12	  levels	  (Balashov	  
et	  al.,	  1998).	  	  
	  
More	   recently,	  CD4+	  Th17	  cells	  have	  also	  been	  highlighted	  as	   important	  drivers	  of	  
the	  CNS	  inflammation	  (Korn	  et	  al.,	  2009;	  Tzartos	  et	  al.,	  2008).	  Through	  secretion	  of	  
IL-­‐17	  and	   IL-­‐22,	  disrupting	   the	  BBB,	   these	   cells	  penetrate	   into	   the	  brain	  and	   cause	  
the	   tissue	   damage	   (Kebir	   et	   al.,	   2007;	   Tzartos	   et	   al.,	   2008).	   Indeed,	   Th17	   cells	   are	  
found	   abundant	   in	  MS	   brain	   active	   lesions	   (Lock	   et	   al.,	   2002)	   and	   are	   in	   a	   much	  
higher	   blood	   concentration	   among	   MS	   patients,	   compared	   to	   healthy	   controls	  
(Matusevicius	   et	   al.,	   1999).	   In	   addition,	   the	   neutralization	   of	   IL-­‐17	   by	   blocking	  
antibodies	  was	  shown	  to	  have	  a	  beneficial	  effect	  in	  EAE	  (Rohn	  et	  al.,	  2006).	  
	  
Both	  Th1	  and	  Th17	  cells	  are	  therefore	  major	  players	   into	  the	  autoimmune	  cascade	  
behind	   the	   disease	   pathogenesis.	   Interestingly,	   in	   EAE,	   Th1:Th17	   ratio	   seems	   to	  
correlate	  with	  distribution	  (Stromnes	  et	  al.,	  2008)	  and	  type	  (Kroenke	  et	  al.,	  2008)	  of	  
CNS	  lesions.	  However,	  the	  extent	  of	  their	  contribution	  to	  inflammation	  in	  MS	  brains	  
remains	  to	  be	  fully	  elucidated.	  	  
	  
1.3.1.3	  CD8+	  T	  cells	  
	  
For	   many	   years	   CD4+	   T	   cells	   were	   considered	   the	   only	   player	   in	   the	   pathological	  
events	   responsible	   for	   initiating	  and	  maintaining	   the	   immune	  response	   in	  MS.	  This	  
hypothesis	   was	   challenged	   when	   depletion	   of	   CD4+	   T	   cells,	   in	   MS	   patients,	   was	  
found	  not	  to	  associate	  with	  any	  improvement	  of	  the	  disease	  activity	  parameters	  (van	  
Oosten	  et	  al.,	  1997).	   In	  contrast,	  global	  depletion	  of	  CD8+,	  as	  well	  as	  CD4+	  T	  cells,	  
with	  an	  anti-­‐CD52	  monoclonal	  antibody	  (Campath),	   led	  to	  a	  marked	  suppression	  of	  
the	  inflammatory	  component	  of	  the	  disease.	  	  Since	  then,	  the	  potential	  role	  of	  CD8+	  T	  
cells	   in	   the	   disease	   pathogenesis	   has	   received	   increasing	   attention	   (Lassmann	   and	  
Ransohoff,	  2004;	  Steinman,	  2001).	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It	  has	  been	  hypothesised	  that,	  after	  initiation	  of	  the	  autoimmune	  cascade,	  driven	  by	  
CD4+	  T	  cells,	  CD8+	  T	  cells	  predominantly	  cause	  the	  tissue	  damage	  in	  the	  CNS	  (Friese	  
and	  Fugger,	  2005).	  Indeed,	  in	  EAE,	  activated	  CD8+	  T	  cells	  are	  able	  to	  migrate	  into	  the	  
CNS,	  to	  induce	  local	  tissue	  damage,	  without	  the	  help	  of	  CD4+	  T	  cells	  (Cabarrocas	  et	  
al.,	  2003),	  and	  to	  replicate	  some	  of	  the	  MS	  features	  normally	  not	  seen	  in	  CD4+	  T	  cells	  
models	   (Sun	   et	   al.,	   2001).	   However,	   it	   remains	   unclear	   when	   and	   where	   the	  
activation	  of	  CD8+	  T	  cells	  occurs.	  Expanded	  CD8+	  T	  cells	  have	  been	  isolated	  in	  brain	  
lesions	  as	  well	  as	   in	  the	  blood	  and	   in	  the	  CSF	  of	  MS	  patients	  (Annibali	  et	  al.,	  2011;	  
Junker	  et	  al.,	  2007;	  Skulina	  et	  al.,	  2004).	  It	  has	  been	  shown	  that,	  once	  migrated	  into	  
the	   CNS,	   activated	   CD8+	   T	   cells	   can	   recognize	   their	   antigens	   on	   MHC	   class	   Ι	  
expressing	  cells,	  expand	  clonally	  and	  trigger	  the	  tissue	  damage	  (Ramakrishna	  et	  al.,	  
2004).	   Interestingly,	   the	   extent	   of	   the	   injury	   to	   axons	   and	   oligodendrocytes	   was	  
shown	   to	   be	   proportionate	   to	   the	   number	   of	   infiltrating	   cells	   (Bitsch	   et	   al.,	   2000;	  
Saxena	  et	  al.,	  2008).	  This	  can	  be	  caused	  by	  several	  mechanisms,	  including	  the	  release	  
of	  lytic	  enzymes	  (Harty	  et	  al.,	  2000)	  and	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IFN-­‐γ,	  
TNF-­‐α	  (Harty	  and	  Badovinac,	  2008)	  and	  IL-­‐17	  (Tzartos	  et	  al.,	  2008).	  	  
	  
1.3.1.4	  Regulatory	  T	  cells	  	  
	  
The	  presence	  of	  MBP-­‐reactive	  T	  cells	  in	  both	  MS	  patients	  and	  healthy	  controls	  (Burns	  
et	   al.,	   1983)	   strongly	   indicates	   that	   the	   failure	   of	   local	   regulatory	   mechanisms	  
accounts	  for	  the	  development	  of	  inflammatory	  lesions.	  Both	  CD4+	  and	  CD8	  +	  T	  cells	  
bear	   suppressor	   or	   regulatory	   properties.	   Therefore,	   a	   lack	   of	   balance	   between	  
protective	   and	   deleterious	   effects	   is	   most	   likely	   implicated	   in	   the	   disease	  
pathogenesis.	  	  
	  
The	  main	  types	  of	  regulatory	  CD4+	  T	  cells	  (Tregs),	  expressing	  the	  transcription	  factor	  
forkhead	   box	   protein	   P3	   (FoxP3)	   and	   the	   IL-­‐2	   receptor	   CD25,	   have	   been	   mostly	  
studied	   in	  mice	  (Hori	  et	  al.,	  2002;	  McGeachy	  et	  al.,	  2005).	  The	  adoptive	  transfer	  of	  
CD4+	  CD25+	  T	  was	  shown	  to	  prevent	  the	  development	  of	  spontaneous	  EAE	  (Hori	  et	  
al.,	  2002).	  In	  addition,	  the	  inactivation	  or	  the	  depletion	  of	  Tregs	  cells	  in	  mice	  results	  
in	  an	  increased	  susceptibility	  to	  EAE	  (McGeachy	  et	  al.,	  2005),	  and	  their	  accumulation	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in	  the	  CNS	  correlates	  with	  a	  recovery	  from	  EAE	  (Korn	  et	  al.,	  2007;	  McGeachy	  et	  al.,	  
2005).	   Suppressive	   CD8+	   T	   cells,	   in	   EAE,	   were	   also	   found	   to	   protect	   against	   the	  
disease	  exacerbations	  (Jiang	  et	  al.,	  1992)	  and	  to	  prevent	  the	  disease	  recurrence,	  by	  
inhibiting	  MBP-­‐activated	  CD4+	  T	  cells	  in	  the	  periphery	  (Jiang	  et	  al.,	  2003).	  Studies	  in	  
vivo	   demonstrated	   that	  MS	   patients’	   Tregs	   have	   an	   impaired	   capacity	   to	   suppress	  




The	  presence	  of	   IgG	  oligoclonal	  bands	  in	  vast	  majority	  of	  the	  patients’	  CSF	  strongly	  
suggests	   that	   B	   cells	   and	   antibodies	   are	   important	   players	   in	   the	   disease	  
pathogenesis	   (Freedman	   et	   al.,	   2005).	   Although	   their	   exact	   contribution	   remains	  
unclear,	  their	  role	  is	  supported	  by	  several	  pathology	  studies.	  	  
	  
Antibodies	  deposits	  have	  been	  observed	  in	  MS	  brains	  active	  lesions	  (Lassmann	  et	  al.,	  
2001),	   and	   B	   cells,	   producing	   anti-­‐myelin	   antibodies,	   have	   been	   detected	   in	   the	  
patients’	  CSF	  (Mancardi	  et	  al.,	  2000).	  Indeed,	  the	  number	  of	  B	  cells	  in	  the	  CSF	  seems	  
to	   correlate	  with	   the	  disease	   severity	   (Berger	   et	   al.,	   2003)	   and	  with	   the	  degree	  of	  
brain	  inflammation,	  detected	  by	  MRI	  (Kuenz	  et	  al.,	  2008).	  Plasma	  cells	  are	  observed	  
in	   large	   numbers	   in	   the	   perivascular	   spaces,	   within	   the	   demyelinated	   plaques	  
(Henderson	  et	  al.,	  2009).	  In	  addition,	  meningeal	  B	  cells	  “lymphoid-­‐like	  follicles”	  have	  
been	  recently	  identified	  in	  a	  subset	  of	  MS	  patients	  (Magliozzi	  et	  al.,	  2007;	  Serafini	  et	  
al.,	  2004),	  and	  their	  presence	  associates	  with	  a	  more	  rapid	  disease	  course	  (Howell	  et	  
al.,	   2011).	   Finally,	   therapeutic	  B	   cells	  depletion	  was	   shown	   to	   improve	   the	  disease	  
activity	  (Hauser	  et	  al.,	  2008),	  further	  highlighting	  their	  important	  contribution	  to	  the	  
demyelination.	  	  
	  
B	  cells	  participate	  to	  the	  MS	  pathology	  primarily	  by	  producing	  autoantibodies.	  These	  
accumulate	  in	  the	  brain	  demyelinated	  areas	  and	  participate	  to	  the	  BBB	  dysfunction	  
(Barnett	  et	  al.,	  2009;	  Lassmann	  et	  al.,	  2001).	  However,	  despite	  a	  variety	  of	  antibodies	  
against	   CNS	   antigens	   have	   been	   detected	   in	   MS	   patients	   (Archelos	   et	   al.,	   2000),	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these	  are	  also	  found	  in	  healthy	  controls	  (Karni	  et	  al.,	  1999),	  leaving	  their	  pathological	  
role	  controversial.	  In	  addition	  to	  the	  antibodies	  production,	  B	  cells	  might	  contribute	  
to	   the	   inflammation	   by	   acting	   as	   antigen	   presenting	   cells	   (APCs)	   (Sospedra	   and	  
Martin,	  2005),	  by	  recruiting	  auto-­‐reactive	  T	  cells	  to	  the	  CNS	  (Lou	  et	  al.,	  2000)	  and	  by	  




Cytokines	   have	   a	   primary	   role	   in	   driving	   all	   phases	   of	   the	   immune	   responses.	   To	  
maintain	   homeostasis,	   a	   balance	   between	   pro-­‐	   and	   anti-­‐inflammatory	   cytokines	   is	  
required.	   IFN-­‐γ	  and	  TNF-­‐α	  are	   the	   two	  most	   important	  pro-­‐inflammatory	  cytokines	  
and	  they	  are	  produced	  by	  both	  inflammatory	  cells	  and	  by	  tissue	  components.	  They	  
are	   known	   to	   participate	   to	   the	   pathogenesis	   of	   MS,	   by	   activating	   certain	  





TNF-­‐α	   is	   produced	   by	   a	   variety	   of	   cell	   types,	   including	   T	   cells,	   astrocytes	   and	  
microglia	   (Hanisch,	   2002;	   Locksley	   et	   al.,	   2001).	   Elevated	   serum	   (Hohnoki	   et	   al.,	  
1998)	  and	  CSF	  (Maimone	  et	  al.,	  1991)	  levels	  have	  been	  reported	  in	  MS	  patients	  and	  
its	   concentration	   was	   shown	   to	   correlate	   with	   the	   disease	   severity	   (Sharief	   and	  
Hentges,	   1991).	   In	   addition,	   TNF-­‐α	   expression	   has	   been	   detected	   in	   active	   MS	  
lesions,	  within	   the	  CNS	   (Hofman	  et	  al.,	  1989;	  Selmaj	  et	  al.,	  1991a).	  Studies	   in	  vitro	  
demonstrated	   that	   its	   pathological	   effect	   is	   primarily	   exerted	   by	   damaging	   the	  
myelin	  and	  by	  promoting	  apoptosis	  (Selmaj	  et	  al.,	  1991b;	  Selmaj	  et	  al.,	  1990).	  TNF-­‐α	  
was	  also	  shown	  to	  cause	  neurotoxicity,	  leading	  to	  the	  block	  of	  the	  axons	  conduction	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1.3.3.2	  IFN-­‐γ 	  
	  
The	   results	   of	   a	   therapeutic	   trial	   with	   IFN-­‐γ	   in	   MS	   patients	   demonstrated	   a	  
worsening	   of	   the	   disease	   course	   (Panitch	   et	   al.,	   1987).	   Therefore,	   IFN-­‐γ	   has	   a	  
pathogenic	  role	  in	  the	  disease,	  which	  is	  probably	  exerted	  by	  increasing	  MHC	  class	  II	  
expression	  and	  by	  preventing	  the	  remyelination	  (Lin	  et	  al.,	  2006).	  However,	  data	  on	  
the	   IFN-­‐γ	   blood	   concentration	   in	   MS	   patients	   are	   contradictory.	   Some	   studies	  
showed	   higher	   levels	   compared	   to	   normal	   controls	   (Hohnoki	   et	   al.,	   1998)	   others	  
found	  no	  differences	  (Nguyen	  et	  al.,	  1999).	  	  
	  
IFN-­‐γ	   expression	   in	   the	   CNS	   of	   EAE	   was	   found	   to	   increase	   during	   disease	  
exacerbations	   and	   to	   decrease	   during	   remissions	   (Begolka	   and	   Miller,	   1998).	  
Nevertheless,	  IFN-­‐γ	  knockout	  mouse	  were	  shown	  to	  develop	  a	  more	  aggressive	  form	  
of	  EAE	  (Ferber	  et	  al.,	  1996),	  suggesting	  a	  potential	  regulatory	  role	  of	  IFN-­‐γ	  on	  other	  
anti	   T	   cell	   proliferative	   cytokines	   (Badovinac	   et	   al.,	   2000)	   and	   on	   T	   cells	   apoptosis	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1.4 The	  pathology	  of	  Multiple	  Sclerosis	  
	  	  	  	  
Since	  its	  first	  description,	  MS	  has	  been	  recognized	  as	  an	  inflammatory	  disease	  of	  the	  
CNS,	   with	   focal	   destruction	   of	   myelin	   sheaths	   (Charcot,	   1880).	   The	   demyelinating	  
process,	  primarily	  driven	  by	  Th1	  cells,	  may	  occur	  at	  any	  place,	  within	  the	  CNS,	  and	  it	  
is	   accompanied	   by	   astrocytosis,	   leading	   to	   the	   formation	   of	   sclerotic	   plaques	  
(Lucchinetti	   et	   al.,	   2000).	   Although	   myelin	   represents	   the	   primary	   target	   of	   the	  
autoimmune	   reaction,	   axons,	   nerve	   cells	   and	   astrocytes	   can	   also	   be	   affected	   to	   a	  
lesser	  degree	  (Kornek	  and	  Lassmann,	  1999;	  Lassmann	  et	  al.,	  2001).	  	  
	  
The	   demyelination	   causes	   impairment	   of	   the	   physiological	   saltatory	   nerve	  
conduction,	   eventually	   leading	   to	   the	   appearance	   of	   acute	   symptoms.	  
Neurodegenerative	   processes,	   causing	   axonal	   loss,	   drive	   the	   accumulation	   of	   the	  
chronic,	  irreversible	  disability	  (Bitsch	  et	  al.,	  2000;	  Trapp	  et	  al.,	  1998).	  	  
	  
1.4.1	  The	  white	  matter	  pathology	  	  
The	   demyelinated,	   sclerotic,	   plaques	   are	   the	   pathological	   hallmark	   of	  MS.	   Lesions	  
present	  as	  areas	  of	  focal	  damage,	  involving	  the	  white	  matter,	  widely	  varying	  in	  size	  
and	   location.	   Although	   normally	   distributed	   throughout	   the	   CNS,	   inflammatory	  
lesions	   show	   a	   predilection	   for	   the	   optic	   nerves,	   the	   periventricular	   regions,	   the	  
corpus	  callosum,	  the	  cerebellum	  and	  the	  cervical	  cord	  (Lassmann	  et	  al.,	  2001).	  	  
	  
1.4.1.1	  Stage	  dependent	  features	  	  
The	   pathological	   features	   of	   demyelinating	   plaques	   are	   stage	   dependent	   and,	   to	  
some	   extent,	   reflect	   the	   evolution	   of	   the	   disease	   course	   (Frischer	   et	   al.,	   2009;	  
Lassmann	  et	  al.,	  2007).	  The	  inflammation	  dominates	  during	  the	  RR	  phase	  and	  leads	  
to	   the	   formation	   of	   new	   white	   matter	   lesions.	   When	   the	   disease	   enters	   in	   the	  
progressive	  phase,	  new	  inflammatory	   lesions	  become	  rare	  and	  the	  diffuse	  atrophy,	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accompanied	   by	   changes	   of	   the	   normal	   appearing	  white	  matter	   (NAWM),	   are	   the	  
prominent	  features	  (Lassmann	  et	  al.,	  2007).	  	  
	  
Active	   lesions	  characterize	  the	  pathology	  of	  acute	  MS	  and	  RR	  MS	  (Lassmann	  et	  al.,	  
2007).	   Their	   boundaries	   are	   irregular	   and	   ill	   defined,	   and	   the	   inflammation	   is	  
accompanied	  by	  a	  large	  disruption	  of	  the	  BBB,	  allowing	  the	  peripheral	  inflammatory	  
cells	  to	  enter	  and	  to	  target	  the	  CNS	  (Hochmeister	  et	  al.,	  2006;	  Kirk	  et	  al.,	  2003).	  High	  
numbers	  of	  lymphocytes	  and	  pro-­‐inflammatory	  cytokines	  are	  observed,	  indicating	  an	  
on	  going	  demyelination	  (Lassmann	  et	  al.,	  2007).	  The	  tissue	  damage	  results	  from	  the	  
cytotoxic	  activity	  and	  from	  the	  deposition	  of	  antibodies.	  Macrophages	  and	  microglial	  
cells	  are	   responsible	   for	   the	   removal	  of	   the	  myelin	  debris	   (Frohman	  et	  al.,	  2006b).	  
Axonal	  damage	  can	  be	  found	  within	  the	  early	  active	  lesions	  (Trapp	  et	  al.,	  1998).	  
	  
Chronic	   active	   lesions	   are	   mainly	   observed	   during	   the	   progressive	   phase	   of	   the	  
disease	  (Lassmann	  et	  al.,	  2007).	  They	  display	  a	  sharp	  edge,	  with	  perivascular	  cuffs	  of	  
infiltrating	   cells,	  macrophages,	   astrocytosis	   and	   some	  degenerating	  axons	   (Frischer	  
et	   al.,	   2009).	   In	   contrast	   with	   acute	   lesions,	   demyelination	   is	   primarily	   associated	  
with	   Ig	   deposition,	   and	   an	   increased	   number	   of	   oligodendrocytes,	   indicating	  
remyelination,	   can	  be	  observed.	  The	  centre	   is	   relatively	  hypo-­‐cellular	  and	  contains	  
naked	  axons,	  surrounded	  by	  a	  matrix	  of	  scaring	  astrocytes	  (Frohman	  et	  al.,	  2006b).	  	  
	  
Chronic	   inactive	   lesions	   are	   found	   in	   the	   latest	   stage	   of	   the	   disease.	   The	   edge	  
appears	  much	  sharper	  and	  the	  astroglial	  scar	  tissue	  is	  abundant.	  Only	  few	  microglia	  
activated	   cells	   contain	  myelin	   degradation	   products,	   suggesting	   a	   slow	   rate	   of	   on	  
going	  demyelination	  (Lassmann	  et	  al.,	  2007).	  The	  number	  of	  demyelinated	  axons	  and	  
oligodendrocytes	   is	   greatly	   reduced,	   and	   blood	   vessels	   walls	   appears	   thickened,	  
surrounded	  by	  occasional	  lymphocytes	  (Frohman	  et	  al.,	  2006b).	  	  
	  
“Shadow	   lesions”	  are	  areas	  of	  remyelination,	  commonly	  occurring	  during	  the	  early	  
stage	   of	   RR	   MS	   and	   becoming	   less	   frequent	   as	   the	   disease	   progresses	   (Franklin,	  
2002).	  These	  lesions	  are	  typified	  by	  thinner	  myelin	  sheaths,	  and	  are	  associated	  with	  
extensive	  macrophages	  infiltration	  (Prineas	  et	  al.,	  1993).	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1.4.1.2	  Active	  lesions,	  mechanisms	  dependent	  features	  
	  
The	  patterns	  of	  demyelination	  are	  different	  among	  MS	  subgroups,	  implying	  multiple	  
mechanisms,	   accounting	   for	   the	   heterogeneity	   of	   the	   lesions.	   These	   include	  
macrophages	   activation	   (Bruck	   et	   al.,	   1995;	   Ulvestad	   et	   al.,	   1994),	   involvement	   of	  
cytotoxic	  cytokines	  (Hofman	  et	  al.,	  1989)	  and	  deposition	  of	  demyelinating	  antibodies	  
or	   complement	   components	   (Mancardi	  et	  al.,	   2000;	   Serafini	   et	   al.,	   2004;	   Storch	  et	  
al.,	  1998).	  In	  addition,	  the	  pathogenesis	  of	  the	  demyelination	  is	  also	  conditioned	  by	  
other	  factors	  responsible	  for	  the	  amplification	  of	  the	  chronic	  inflammatory	  reaction	  
(Lassmann	  et	  al.,	  2001).	  	  
	  
Indeed,	   a	   profound	   heterogeneity	   characterizes	   the	   immunopathological	  
appearances	  of	  MS	  active	   lesions	  (Lucchinetti	  et	  al.,	  2000).	  An	  extensive	  work	  on	  a	  
large	  series	  of	  biopsy	  and	  autopsy	  material,	  carried	  out	  by	  Lucchinetti	  et	  al.,	  allowed	  
to	   characterize	   four	   different	   types	   of	   lesion.	   Classification	   was	   based	   on	   the	  
distribution	   and	   the	   extension	   of	   the	   myelin	   loss,	   the	   pattern	   of	   the	  
oligodendrocytes	   destruction	   and	   the	   extent	   of	   the	   Ig	   and	   of	   the	   complement	  
deposits	  distribution	  (Lucchinetti	  et	  al.,	  2000).	  	  	  	  	  
	  
Type	   I	   lesions:	   the	   demyelination	   is	   mainly	   characterized	   by	   a	   T-­‐cells	   and	  
macrophages	  infiltration,	  without	  evidence	  of	  significant	  antibodies	  or	  complement	  
deposition.	   	   Lesions	   show	   the	   typical	   perivenous	  distribution	  of	   inflammatory	   cells	  
and	  the	  extent	  of	  tissue	  damage	  correlates	  with	  the	  amount	  of	  cytokines.	  	  
	  
Type	   II	   lesions:	  the	  active	  perivenular	  demyelination	  is	  characterized	  by	  T-­‐cells	  and	  
macrophages,	  with	  an	  extensive	  antibodies	  deposition	  and	  accentuated	  Ig	  reactivity.	  
The	   large	   amount	   of	   complement	   C9	   neoantigen,	   at	   the	   sites	   of	   the	   myelin	  
destruction,	  highlights	  the	  relevant	  role	  played	  by	  antibodies	  in	  the	  development	  of	  
this	  type	  of	  lesions.	  	  
	  
Type	  III	  lesions:	  similarly	  to	  type	  I	  and	  II	  lesions,	  the	  inflammatory	  infiltrate	  is	  mainly	  
composed	  by	  T	  lymphocytes	  and	  macrophages,	  but	  Ig	  deposition	  is	  absent.	  Typically,	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the	  demyelination	  is	  not	  centred	  on	  inflamed	  blood	  vessels.	  The	  myelin	  rim	  remains	  
preserved	  around	  the	  vessels	  within	  the	  plaques,	  and	  the	  contours	  of	  the	  lesions	  are	  
well	  defined.	  	  	  
Type	  IV	  lesions:	  are	  exclusively	  present	  in	  PP	  MS	  patients.	  They	  present,	  similarly	  to	  
type	  I	  and	  II	  lesions,	  with	  a	  T	  cells	  and	  macrophages	  inflammation,	  mainly	  distributed	  
around	  blood	  vessels.	  They	  lack	  Ig	  deposition	  and	  they	  are	  typically	  characterized	  by	  
a	  large	  extent	  of	  oligodendrocytes	  damage.	  	  
	  
Interestingly,	  a	  unique	  study	  reported	  pathological	  features	  of	  12	  patients	  who	  died	  
during	   the	  RR	  phase,	   shortly	  after	   the	  onset	  of	  a	   relapse.	  These	  allowed	   to	  gather	  
important	  information	  on	  mechanisms	  leading	  to	  the	  development	  of	  inflammatory	  
lesions	   during	   the	   very	   active	   stages	   of	   the	   disease,	   and	   responsible	   of	   the	   acute	  
symptoms	   (Barnett	  and	  Prineas,	  2004).	  Some	  of	   the	   lesions	  associated	  with	  a	   fatal	  
outcome	   and,	   unlike	   what	   observed	   in	   EAE,	   were	   characterized	   by	   an	   extensive	  
oligodendrocytes	   apoptosis	   and	   microglia	   activation,	   but	   few	   or	   no	   infiltrating	  
lymphocytes	  (Barnett	  and	  Prineas,	  2004).	  	  
	  
1.4.1.3	  Axonal	  injury	  	  
	  
Within	   the	   CNS,	   oligodendrocytes-­‐myelin-­‐axon	   units	   represent	   the	   key	   functional	  
structures.	   Myelin,	   produced	   by	   the	   oligodendrocytes,	   spirally	   wraps	   the	   axons	  
(Figure	  1.6),	  creating	  periodic	  gaps	  (nodes	  of	  Ranvier).	  Its	  main	  physiological	  function	  
is	   to	  accelerate	  the	  conduction	  velocity	  of	   the	  axonal	  action	  potential,	  propagating	  
by	   a	   saltatory	  mode	   (from	   one	   node	   to	   another)	   (Hartline	   and	   Colman,	   2007).	   In	  
addition,	  oligodendrocytes	  and	  the	  myelin	  exert	  a	  protective	  and	  a	  trophic	  effect	  on	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Figure	  1.6	  A)	  The	  myelin	  sheaths	  (dark	  blue	  rings),	  surrounding	  axons	  in	  the	  normal	  white	  matter.	  The	  
arrow	  indicates	  the	  oligodendrocytes,	  producing	  the	  myelin.	  B)	  The	  myelin	  sheath	  in	  a	  cross	  section,	  
wrapping	  the	  axon	  (Frohman	  et	  al.,	  2006b).	  	  
	  
	  
Although	  the	  demyelination	  has	  been	  identified	  as	  the	  hallmark	  feature	  of	  MS	  since	  
the	  earliest	  report	  (Charcot,	  1880),	   it	   is	  now	  well	  established	  that	  the	  acute	  axonal	  
pathology	  occurs	  in	  active	  demyelinating	  lesions	  and	  the	  axonal	  density	  is	  reduced	  in	  
chronic	  plaques	  (Trapp	  et	  al.,	  1998).	  The	  axonal	  loss	  is	  considered	  the	  essential	  cause	  
of	  the	  development	  of	  unremitting	  clinical	  disability	  and	  of	  the	  disease	  progression	  
(Trapp	  and	  Nave,	  2008).	  Imaging	  studies	  with	  MRI	  (Bakshi	  et	  al.,	  2008;	  Filippi	  et	  al.,	  
2003)	  and	  with	  magnetic	  resonance	  spectroscopy	  (MRS)	  (Narayana,	  2005;	  Tartaglia	  
and	  Arnold,	  2006),	  and	  pathological	  studies	  (Bjartmar	  et	  al.,	  2000;	  Stadelmann	  and	  
Bruck,	   2008;	   Trapp	   et	   al.,	   1998)	   demonstrated	   that	   the	   axonal	   damage	   occurs	  
already	   during	   the	   early	   phase	   of	   the	   disease.	   The	   axonal	   degeneration	   takes	  
relatively	   long	   time,	   compared	   to	  myelin	   disruption,	   reflecting	   the	   variable	   axonal	  
density	   observed	   in	   inactive	   lesions,	   ranging	   from	  nearly	   normal	   to	   a	   loss	   of	   80%,	  
averaging	  60-­‐70%	  (Bjartmar	  and	  Trapp,	  2001;	  Mews	  et	  al.,	  1998).	  	  
	  
1.4.1.3.1	  Mechanisms	  of	  axonal	  loss	  
	  
Mechanisms	   causing	   the	   neurodegeneration	   and	   the	   axonal	   loss	   remain	   unclear	  
(Dutta	  and	  Trapp,	  2011).	   It	  has	  been	  hypothesized	   that	   the	  axonal	   injury	  might	  be	  
partially	   explained	   by	   the	   increased	   expression	   of	   sodium	   channels	   in	   the	  
membranes,	   attempting	   to	   re-­‐establish	   the	   normal	   conduction	   (Waxman	   et	   al.,	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2004).	  The	  sodium	  in	  excess	  slows	  the	  nerve	  conduction	  and	  triggers	  an	  intracellular	  
cascade	   of	   calcium-­‐mediated	   injury,	   eventually	   leading	   to	   the	   neurodegeneration	  
(Waxman	  et	  al.,	  2004).	  An	  excessive	  production	  of	  glutamate	  has	  also	  been	  shown	  to	  
damage	   the	   oligodendrocytes	   and	   the	   axons	   by	   promoting	   a	   toxic	   calcium	  
intracellular	   accumulation	   (Micu	   et	   al.,	   2006).	   Indeed,	   sodium-­‐channel	   blocker	  
(phenytoin)	  was	  shown	  to	  preserve	  axons	  in	  EAE	  (Lo	  et	  al.,	  2003),	  lending	  support	  to	  
this	  hypothesis.	  These	  analyses	  put	  the	  basis	  for	  the	  “mitochondrial	  theory”,	  which	  is	  
based	   on	   the	   assumption	   that	   a	   rise	   in	   the	   intracellular	   calcium	   level	   causes	   a	  
mismatch	   between	   the	   energy	   demand	   and	   the	   reduced	   supply	   of	   adenosine	  
triphosphate	   (ATP),	   ultimately	   leading	   to	   a	   mitochondrial	   dysfunction	   and	   to	   the	  
degeneration	  of	  chronically	  demyelinated	  axons	  (Dutta	  et	  al.,	  2006).	  	  	  
	  
Infiltrating	   inflammatory	   cells	   may	   also	   have	   a	   direct	   toxic	   effect	   on	   axons	   by	  
releasing	   proteolytic	   enzymes,	   cytokines	   and	   oxidative	   products	   (Trapp	   and	   Nave,	  
2008).	  An	  immunological	  attack	  on	  the	  axon	  is	  suggested	  by	  the	  correlation	  between	  
the	  inflammation	  and	  the	  axonal	  transection	  (Trapp	  and	  Nave,	  2008;	  Weiner,	  2009),	  
and	  between	  the	  number	  of	  infiltrating	  CD8+	  T	  cells	  and	  the	  extent	  of	  the	  axonal	  loss	  
(Dutta	  and	  Trapp,	  2011;	  Frischer	  et	  al.,	  2009).	  This	  might	  be	  mediated	  by	  TNF-­‐α	  and	  
by	  Interferon-­‐γ,	  both	  stimulating	  the	  release	  of	  nitric	  oxide	  (NO)	  from	  the	  astrocytes	  
and	   from	   the	   macrophages	   (Redford	   et	   al.,	   1997;	   Smith	   et	   al.,	   2001).	   However,	  
another	  study	  failed	  to	  find	  a	  correlation	  between	  the	  axonal	  damage	  and	  the	  TNF-­‐
α/NO	  expression,	  indicating	  a	  possible	  dissociation	  between	  mechanisms	  causing	  the	  
demyelination	  and	  those	  responsible	  for	  the	  axonal	  injury	  (Bitsch	  et	  al.,	  2000).	  
	  
1.4.1.3.2	  Axonal	  loss	  in	  the	  normal	  appearing	  white	  matter	  (NAWM)	  
	  
Whether	   inflammatory	  mechanisms	  are	  essential	   for	   the	  axonal	  damage	  remains	  a	  
matter	   of	   large	   debate.	   Some	   studies	   reported	   a	   strong	   correlation	   between	   the	  
number	  of	   inflammatory	   cells	   and	   the	   axonal	   damage,	   even	   in	   the	  NAWM,	  during	  
both	  the	  early	  and	  the	  late	  stage	  of	  the	  disease	  (Frischer	  et	  al.,	  2009;	  Howell	  et	  al.,	  
2011).	   However,	   extensive	   axonal	   loss	   can	   also	   occurs	   within	   the	   NAWM,	   in	   the	  
absence	  of	  inflammation	  (Bjartmar	  et	  al.,	  2001;	  DeLuca	  et	  al.,	  2006;	  Evangelou	  et	  al.,	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2000;	  Frischer	  et	  al.,	  2009;	  Trapp	  et	  al.,	  1998),	  suggesting	  that	  axons	  can	  degenerate	  
independently	  of	  the	  active	  demyelination	  (Bitsch	  et	  al.,	  2000).	  	  
	  
Trapp	   and	   colleagues	   demonstrated	   axonal	   transection	   in	   the	   demyelinated	  white	  
matter	  and	  in	  the	  NAWM	  of	  patients	  with	  variable	  disease	  duration,	  ranging	  from	  2	  
weeks	   to	  27	   years	   (Trapp	  et	   al.,	   1998).	   Similarly,	   Bitsch	  et	   al.,	   by	   analysing	   a	   large	  
group	  of	  brain	  biopsies	   from	  MS	  patients,	   reported	  axonal	  damage	   in	  areas	  of	   the	  
NAWM	  and	  within	  remyelinated	   lesions,	  during	  all	   the	  disease	  stages	  (Bitsch	  et	  al.,	  
2000).	  Furthermore,	  Evangelou	  et	  al.	  demonstrated	  a	  substantial	  (50%)	  loss	  of	  both	  
axonal	  density	  and	  volume	  in	  the	  NAWM	  of	  the	  corpus	  callosum,	  among	  8	  patients	  
with	  21	  years	  mean	  disease	  duration	  (Evangelou	  et	  al.,	  2000).	  Axons	  degeneration	  in	  
the	  NAWM,	  distal	   to	  a	   fatal	  brainstem	   lesion,	  was	  also	  described	   in	  a	  patient	  with	  
very	  aggressive	  and	  short	  disease	  course	  (Bjartmar	  et	  al.,	  2001).	  Finally,	   the	  axonal	  
injury	   in	   the	   NAWM	   appears	   to	   be	   more	   diffused	   among	   progressive	   patients,	  
compared	  to	  patients	  with	  acute	  or	  relapsing	  disease	  (Kutzelnigg	  et	  al.,	  2005).	  	  
	  
Spinal	   cord	   pathological	   analyses	   offered	   further	   evidences.	   Lovas	   et	   al.	   studied	  
samples	   from	   the	   spinal	   cord	   of	   SP	   MS	   patients’,	   where	   one	   side	   contained	   a	  
completely	   demyelinated	   plaque	   and	   the	   contralateral	   corresponding	   area	   had	  
NAWM.	  This	  approach	  allowed	  to	  compare	  the	  axon	  density,	  which	  was	  found	  to	  be	  
similarly	   reduced	   in	  both	  the	  demyelinated	  and	  the	  normal	  white	  matter	   (Lovas	  et	  
al.,	  2000).	   	  A	  much	   larger	  study	   (n	  =	  55)	  showed	  a	   lack	  of	  correlation	  between	  the	  
plaques	  (active	  and	  inactive)	  load	  both,	  in	  the	  cerebral	  hemispheres	  and	  in	  the	  spinal	  
cord,	  and	  the	  extent	  of	  the	  axonal	  loss	  at	  any	  level	  of	  the	  cortico-­‐spinal	  tract	  (DeLuca	  
et	  al.,	  2006).	  In	  addition,	  this	  study	  confirmed	  a	  similar	  extent	  of	  the	  axonal	  damage	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1.4.2	  Grey	  matter	  pathology	  	  
	  
The	   cortical	   demyelination	   in	   MS	   has	   been	   described	   for	   decades	   (Brownell	   and	  
Hughes,	  1962),	  however	  its	  importance	  was	  initially	  underestimated.	  This	  is	  because	  
grey	  matter	   lesions	  are	  not	  easily	  detectable	   in	  autopsy	  studies,	  due	  to	  their	  hypo-­‐
cellularity	   (Dutta	  and	  Trapp,	  2007),	  or	  by	  routine	  MRI	  procedures,	  due	  to	   the	  poor	  
contrast	  resolution	  and	  the	  relatively	  lack	  of	  BBB	  disruption	  (Kidd	  et	  al.,	  1999).	  	  
	  
Although	   they	   can	   be	   detected	   throughout	   the	   CNS,	   grey	  matter	   lesions	   seem	   to	  
have	  a	  predilection	  for	  the	  cingulate	  gyrus	  and	  for	  the	  temporal	  and	  frontal	  lobes	  (Bo	  
et	  al.,	  2003;	  Gilmore	  et	  al.,	  2009).	  The	  extent	  of	  the	  grey	  matter	  pathology	  does	  not	  
appear	   to	   correlate	  with	   the	   extent	   of	   the	  white	  matter	   demyelination	   (Bo	   et	   al.,	  
2007;	   Kutzelnigg	   et	   al.,	   2005),	   suggesting	   that	   the	   two	   processes	   might	   occur	  
independently.	  	  
	  
Following	   a	   study	  on	  autopsy	   tissues,	   from	  50	  MS	  patients,	   three	   types	  of	   cortical	  
lesions	  have	  been	  described,	  based	  on	   their	   localization	   in	   the	   cortex	   (Peterson	  et	  
al.,	  2001):	  	  
-­‐ Type	   I	   lesions	   accounted	   for	   34%	   of	   the	   cortical	   lesions.	   They	   typically	  
encompass	  both	  the	  white	  matter	  and	  the	  cortex	  and	  they	  can	  be	  rather	  extensive.	  	  
-­‐ Type	   II	   lesions	   accounted	   for	   16%	   of	   the	   cortical	   lesions.	   They	   are	   much	  
smaller	  and	  reside	  entirely	  within	  the	  grey	  matter.	  	  
-­‐ Type	   III	   lesions	   are	   the	  most	   abundant,	   accounting	   for	   50%	   of	   the	   cortical	  
lesions.	   They	   extend	   from	   the	   pial	   surface	   into	   the	   cortex	   and	   they	   are	   large,	  
sometimes	  involving	  all	  cortical	  layers.	  	  
	  
The	  grey	  matter	  pathology	  occurs	  in	  the	  absence	  of	  BBB	  disruption	  (Bo	  et	  al.,	  2003;	  
Kidd	   et	   al.,	   1999;	   van	   Horssen	   et	   al.,	   2007)	   and,	   compared	   to	   the	   white	   matter	  
pathology,	  it	  associates	  with	  much	  lower	  inflammatory	  infiltrating	  cells	  and	  very	  few	  
perivascular	   cuffs	   (Peterson	   et	   al.,	   2001).	   In	   addition,	   in	   the	   grey	  matter	   damaged	  
areas	   there	   is	   extensive	   axonal	   loss	   (Peterson	   et	   al.,	   2001),	  which	   is	   though	   to	   be	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driven	  by	  activated	  microglia	  (Bo	  et	  al.,	  2003;	  Peterson	  et	  al.,	  2001)	  and	  it	  was	  found	  
in	  increased	  density	  at	  the	  leading	  edge	  of	  active	  type	  I	  cortical	  lesions	  (Peterson	  et	  
al.,	  2001).	  	  
	  
The	  cortical	  demyelination	  was	  reported	  to	  be	  strikingly	  different	   in	  relation	  to	  the	  
type	  of	  the	  disease	  course	  (Kutzelnigg	  et	  al.,	  2005).	  It	  was	  rare	  or	  absent	  in	  patients	  
with	  acute	  or	  RR	  MS,	  but	  was	  described	  as	  a	  prominent	  feature	  in	  patients	  with	  SP	  
and	   PP	  MS,	  where	   it	   was	   associated	  with	   high	   degree	   of	  meningeal	   inflammation	  
(Howell	  et	  al.,	  2011;	  Kutzelnigg	  et	  al.,	  2005).	  These	  results	  suggested	  that	  the	  cortical	  
pathology	   might	   be	   the	   main	   driver	   of	   the	   disability	   accumulation,	   among	  
progressive	  patients	  (Howell	  et	  al.,	  2011;	  Kutzelnigg	  et	  al.,	  2005).	  	  
	  
However,	   a	   recent	   large	   biopsy	   study	   demonstrated	   variable	   degree	   of	   cortical	  
demyelination,	  with	  diffuse	  inflammatory	  infiltrates,	  in	  nearly	  40%	  of	  patients	  during	  
the	   early	   stage	   of	   the	   disease	   (Lucchinetti	   et	   al.,	   2011),	   implying	   that	   the	   cortex	  
might	  be	  an	  early	  target	  of	  the	  MS	  pathogenic	  mechanisms.	  Indeed,	  cortical	  lesions	  
and	  atrophy	  are	  detected	  by	  the	  MRI	  in	  early	  disease	  (Amato	  et	  al.,	  2004a;	  Calabrese	  
and	   Gallo,	   2009),	   and	   might	   represent	   the	   pathological	   substrate	   of	   the	   early	  
cognitive	  impairment	  (Calabrese	  et	  al.,	  2009a).	  
	  
1.4.2.1	  Meningeal	  inflammation	  	  
	  
Since	   B-­‐cell	   follicle-­‐like	   structures	   have	   been	   described	   in	   the	   meninges	   of	   a	  
significant	   number	   of	   SPMS	   patients	   (Howell	   et	   al.,	   2011;	   Magliozzi	   et	   al.,	   2007;	  
Magliozzi	   et	   al.,	   2010;	   Serafini	   et	   al.,	   2004),	   the	   meningeal	   inflammation	   has	  
gathered	  increasing	  attention	  as	  important	  player	  in	  the	  induction	  and	  propagation	  
of	  the	  cortical	  pathology	  (Lassmann,	  2012).	  	  
	  
Follicles	   were	   mainly	   found	   in	   the	   frontal,	   temporal,	   parietal	   lobes	   and	   in	   the	  
cingulate	   gyrus.	   They	   contained	   prominent	   inflammatory	   cells,	   comprising	   CD3+	   T	  
cells,	  CD20+	  B	  cells,	  plasma	  cells	  and	  large	  perivascular	  B-­‐cells	  aggregates	  (Magliozzi	  
et	  al.,	  2007).	   Importantly,	   follicles	  positive	  patients,	  compared	  to	   follicles	  negative,	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were	   younger	   at	   the	   clinical	   onset,	   were	   younger	   at	   the	   time	   they	   became	  
wheelchair	  bound	  and	  were	  younger	  at	  death	  (Magliozzi	  et	  al.,	  2007),	  indicating	  that	  
the	   presence	   of	   follicles	   associates	   with	   a	   worse	   clinical	   outcome.	   In	   addition,	  
follicles	  were	  also	  accompanied	  by	  a	  significantly	   increased	  number	  of	  grey	  matter	  
lesions	   and	   by	   a	   larger	   extension	   of	   grey	   matter	   demyelination	   (Magliozzi	   et	   al.,	  
2007;	  Magliozzi	   et	   al.,	   2010).	   Furthermore,	   activated	  microglia	   and	   the	  axonal	   loss	  
were	  significantly	  increased	  in	  cortical	  lesions	  of	  follicles	  positive	  patients	  (Magliozzi	  
et	  al.,	  2010).	  These	  results	  were	   lately	  expanded	  and	  confirmed	  by	  assessing	  more	  
cases	  from	  the	  same	  series	  (Howell	  et	  al.,	  2011).	  The	  analysis	  was	  also	  repeated	  in	  a	  
subgroup	  of	  PP	  cases	  only,	  where	  follicles	  were	  not	  found,	  but	  the	  diffuse	  meningeal	  
inflammation	   correlated	  with	   the	   degree	   of	   the	   cortical	   demyelination	   and	   of	   the	  
axonal	   loss	  (Choi	  et	  al.,	  2012).	  Similarly,	  a	  separate	  analysis	  from	  Lassmann’s	  group	  
confirmed	  that	  the	  diffuse	  inflammation	  in	  the	  meninges	  strongly	  associates	  with	  the	  
extent	  of	  the	  grey	  matter	  pathology,	  in	  progressive	  MS	  (Frischer	  et	  al.,	  2009).	  	  
	  
Overall,	  these	  data	  indicate	  that	  the	  meningeal	  inflammation	  is	  the	  key	  driver	  of	  the	  
cortical	  demyelination.	  By	  the	  time	  the	  disease	  enters	  in	  the	  progressive	  phase,	  the	  
inflammation	   becomes	   increasingly	   compartmentalised	   in	   the	   perivascular	   and	  
subarachnoid	   spaces,	  behind	  a	   relatively	   intact	  BBB	   (Frischer	  et	  al.,	   2009;	  Meinl	  et	  
al.,	   2008).	   In	   addition,	   the	   inflamed	   meninges,	   by	   diffusing	   proinflammatory	   and	  
cytotoxic	   factors,	   activate	   the	   microglia,	   which	   participate	   to	   sustain	   the	   cortical	  
damage	  (Frischer	  et	  al.,	  2009;	  Magliozzi	  et	  al.,	  2007).	  
	  
However,	  this	  conclusion	  was	   lately	  challenged	  by	  results	  from	  a	  Dutch	  study	  (Kooi	  
et	  al.,	  2009).	  Among	  28	  patients	  with	  progressive	  disease,	   the	  percentage	  areas	  of	  
subpial	   demyelination	   did	   not	   correlate	   with	   the	   extension	   of	   the	   meningeal	  
inflammation.	   In	   addition,	   authors	   failed	   to	   demonstrate	   a	   significant	   increase	   of	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1.4.3	  Primary	  versus	  secondary	  progression	  
	  
The	   axonal	   loss	   is	   considered	   the	   pathological	   substrate	   of	   the	   progressive	  
accumulation	  of	  disability	   (Trapp	  and	  Nave,	   2008).	   It	  was	  described	  at	   the	   sites	  of	  
white	  matter	  demyelination	   (Frischer	  et	   al.,	   2009;	   Trapp	  et	   al.,	   1998)	  but	   it	   is	   also	  
known	  to	  occur	  within	  the	  NAWM	  (Bitsch	  et	  al.,	  2000;	  Bjartmar	  et	  al.,	  2001;	  DeLuca	  
et	   al.,	   2006;	   Evangelou	   et	   al.,	   2000).	   The	   controversial	   relationship	   between	  
inflammation	   and	   neurodegeneration	   has	   been	   largely	   debated	   (Lassmann,	   2012;	  
Trapp	   and	   Nave,	   2008).	   Within	   this	   context,	   whether	   PP	   MS	   shares	   the	   same	  
pathological	  features	  of	  SP	  MS	  becomes	  particularly	  relevant.	  	  
	  
Pathology	  assessments	  confirmed	  that	  brain	  inflammatory	  lesions	  characterize	  both	  
subtypes,	  indicating	  that	  also	  PP	  MS	  is	  an	  inflammatory	  disease	  (Revesz	  et	  al.,	  1994).	  	  
The	  pattern	  of	  tissue	  injury	  observed	  in	  the	  progressive	  subtypes	  is	  generally	  similar	  
and	   it	   is	   characterized	   by	   demyelination,	   loss	   of	   oligodendrocytes	   and	   axons,	  
remyelination	  and	  gliosis	  (Frischer	  et	  al.,	  2009;	  Prineas	  et	  al.,	  2001).	  A	  recent	  study	  
directly	  compared	  pathological	  features	  of	  PP	  and	  SP	  MS,	  by	  assessing	  the	  extension	  
of	  the	  axonal	  loss	  in	  the	  cervical	  cord’s	  cortico-­‐spinal	  tracts	  of	  47	  patients,	  who	  had	  
reached	   similar	   levels	   of	   disability	   before	   death	   (Tallantyre	   et	   al.,	   2009).	   Patients	  
with	   SP	   MS	   were	   found	   to	   have	   a	   larger	   extent	   of	   the	   white	   and	   grey	   matter	  
demyelination,	  however	   the	  extent	  of	   the	  axonal	  damage	  within	   the	  demyelinated	  
areas	  was	  larger	  in	  PP	  MS	  patients.	  Interestingly,	  the	  degree	  of	  the	  axonal	  loss	  within	  
the	  NAWM	  was	  similar	  between	  the	  two	  subtypes	  (Tallantyre	  et	  al.,	  2009).	  	  
	  
In	   contrast,	   by	   comparing	   35	   SP	   and	   13	   PP	   brains,	   Lassmann’s	   group	   found	   no	  
differences	  in	  the	  extent	  of	  axonal	  damage	  within	  demyelinated	  areas	  and	  within	  the	  
NAWM	  (Frischer	  et	  al.,	  2009).	  More	  importantly,	  this	  study	  established	  a	  correlation	  
between	   the	   number	   of	   inflammatory	   cells	   and	   the	   acute	   axonal	   damage,	   in	   both	  
progressive	  subtypes,	  suggesting	  that	  the	  inflammation,	  compartmentalized	  behind	  
a	   repaired	  BBB,	   is	   the	  driver	  of	   the	  disability	   accumulation	  during	   the	   late	  disease	  
stage	  (Frischer	  et	  al.,	  2009).	  Finally,	  a	  large	  biopsy	  study,	  analysing	  samples	  from	  45	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patients	   at	   different	   stages	   of	   the	   disease	   course,	   found	  more	   pronounced	   axonal	  
damage	   within	   the	   demyelinated	   areas	   among	   SP	   MS	   patients	   and	   very	   limited	  
among	  PP	  MS	  patients	   (Bitsch	  et	  al.,	  2000).	   In	  addition,	  authors	  observed	  a	  partial	  
dissociation	   between	   the	   extent	   of	   inflammatory	   infiltrates	   and	   the	   axonal	   loss,	  
suggesting	  that	  the	  two	  processes	  might	  be	  driven	  by	  different	  mechanisms	  (Bitsch	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1.5	  The	  MRI	  
	  
	  
The	  use	  of	   conventional	  magnetic	   resonance	   imaging	   (MRI)	   has	   revolutionized	   the	  
management	  of	  MS.	  It	  is	  sensible	  to	  MS-­‐related	  abnormalities,	  it	  is	  non-­‐invasive	  and	  
it	   is	   reproducible.	   Therefore,	   this	   technique	  now	  plays	   a	   pivotal	   role	   in	   diagnosing	  
the	   disease,	   and	   in	   monitoring	   the	   disease	   progression	   and	   the	   efficacy	   of	  
treatments.	  	  
	  
1.5.1	  MRI	  and	  the	  MS	  pathology	  
	  
Although	   the	   MRI	   allows	   to	   estimate	   the	   extent	   of	   the	   focal	   and	   diffuse	   CNS	  
involvement	   in	   MS	   patients,	   it	   does	   not	   specifically	   mirror	   the	   pathological	  
substrates	   of	   the	   disease	   (Filippi	   et	   al.,	   2012).	   The	   T2-­‐weighted	   scans	   can	   easily	  
detect	  the	  white	  matter	  demyelinated	  areas,	  which	  appear	  as	  foci	  of	  hyper-­‐intensity,	  
however	  they	  lack	  specificity	  for	  the	  changes	  in	  the	  axonal	  density	  (van	  Waesberghe	  
et	   al.,	   1999).	   In	   addition,	   the	   focal	   white	  matter	   lesions	   have	   limited	   pathological	  
specificity	  and	  can	  be	  seen	   in	  other	  diseases	   (Barkhof	  and	  van	  Walderveen,	  1999).	  
Any	   alteration	   of	   the	   tissue	   composition,	   due	   to	   inflammation	   or	   to	   axonal	   injury,	  
causes	  an	  increased	  T2	  signal	  (Barkhof	  and	  van	  Walderveen,	  1999).	  Therefore,	  when	  
assessing	  the	  radiological	  features	  of	  MS,	  complementary	  information	  on	  the	  lesions	  
shape,	  location,	  and	  size	  has	  to	  be	  considered	  (Fazekas	  et	  al.,	  1999).	  MS	  lesions	  are	  
commonly	  round	  or	  ovoid	  shaped	  and	  their	  size	  ranges	  from	  few	  mm	  to	  more	  than	  1	  
cm.	   They	   typically	   locate	   in	   the	   brainstem,	   the	   cerebellum,	   around	   the	   corpus	  
callosum	   and	   in	   the	   periventricular	   white	   matter.	   The	   confluence	   of	   peri-­‐venular	  
lesions	   results	   in	   irregular	   extensive	   areas	   of	   signal	   abnormality	   (Fazekas	   et	   al.,	  
1999).	  
	  
In	   contrast	   to	   the	   T2-­‐weighted	   scan,	   the	   T1-­‐weighted	   scans	   allow	   to	   identify	   the	  
axonal	   damage	   and	   the	   areas	   of	   severe	   tissue	   destruction	   with	   higher	   reliability	  
(Bruck	  et	  al.,	  1997;	  van	  Waesberghe	  et	  al.,	  1999;	  van	  Walderveen	  et	  al.,	  1998).	  These	  
appear	  as	  hypo-­‐intense	   foci,	  also	  known	  as	  persisting	  “black	  holes”	   (Fazekas	  et	  al.,	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1999).	  Biopsy	  (Bruck	  et	  al.,	  1997)	  and	  autopsy	  (van	  Walderveen	  et	  al.,	  1998)	  studies	  
showed	  that	  the	  degree	  of	  hypo	  density	  correlates	  with	  the	  degree	  of	  loss	  of	  axons.	  	  
However,	  the	  T1	  hypo-­‐intensities	  have	  variable	  duration:	  a	  third	  lasts	  for	  more	  than	  
4	  years,	  while	  half	  disappear	  within	  1	  year	  (Bagnato	  et	  al.,	  2003).	  In	  addition,	  it	  has	  
been	   demonstrated	   that	   at	   least	   25%	   of	   gadolinium	   (GAD)-­‐enhancing	   lesions	   will	  
eventually	   resolve	   to	   become	   a	   T1	   lesion	   (Bagnato	   et	   al.,	   2003).	   Different	   factors	  
contribute	   to	   the	   increase	   of	   extracellular	   free	   water	   and,	   consequently,	   to	   the	  
increase	  of	  the	  T1	  hypo-­‐intensity:	  active	  demyelination,	  cellular	  infiltration,	  oedema	  
and	  astrogliosis	  (Bruck	  et	  al.,	  1997).	  Therefore	  only	  “black	  holes”	  that	  stay	  persistent	  
over	   time	   reflect	   an	   irreversible	   tissue	   destruction	   (Bitsch	   et	   al.,	   2001).	   	   The	  
magnetization	  transfer	  ratio	   (MTR)	   is	  also	  highly	  sensitive	  to	  changes	  of	  the	  axonal	  
density	  and	  is	  a	  reliable	  marker	  of	  the	  tissue	  damage	  (Barkhof	  and	  van	  Walderveen,	  
1999;	  Schmierer	  et	  al.,	  2007;	  van	  Waesberghe	  et	  al.,	  1999)	   
	  
On	  the	  T1-­‐weighted	  images	  the	  acute	  and	  chronic	  lesions	  can	  be	  differentiated,	  after	  
the	   administration	   of	   GAD.	   Following	   the	   BBB	   breakdown,	   resulting	   from	   the	  
inflammatory	  process,	   the	  GAD	  penetrates	   the	  CNS	  and	   is	   enhanced	  by	   the	   active	  
lesions	   (Barkhof	   and	   van	   Walderveen,	   1999;	   Filippi	   et	   al.,	   2012).	   Many	  
methodological	  factors	  can	  potentially	  affect	  the	  gadolinium	  enhancement:	  the	  dose	  
of	  GAD,	  the	  timing	  of	  the	  scan	  and	  the	  slices	  thickness	   (Filippi,	  2000;	  Thompson	  et	  
al.,	  1992).	  The	  pattern	  of	  the	  enhancement	  depends	  on	  the	  size	  and	  on	  the	  intensity	  
of	   the	   inflammation.	   It	   can	   be	   nodular	   or	   ring-­‐like,	   it	   can	   persist	   for	   2	   to	   6	  weeks	  
(Filippi,	   2000;	   Thompson	  et	   al.,	   1992)	   and	   it	   can	   change	   in	   the	   same	   lesion	  within	  
short	  time	  (Filippi	  et	  al.,	  2012).	  Active	  lesions	  predominate	  in	  the	  RR	  phase	  and	  are	  
the	   pathological	   substrate	   of	   the	   clinical	   attacks	   (Frank	   et	   al.,	   1994;	   Kappos	   et	   al.,	  
1999;	   Weiner	   et	   al.,	   2000),	   while	   chronic	   slowly	   expanding	   lesions	   are	   typical	  
features	   of	   the	   progressive	   phase,	   and	   do	   not	   show	   any	   contrast	   enhancement	  
(Filippi,	  2000).	  During	  the	  late	  stages	  of	  the	  disease,	  when	  the	  BBB	  damage	  is	  missing	  
or	   less	   prominent	   and	   the	   GAD	   cannot	   penetrate	   the	   CNS,	   the	  MRI	   becomes	   less	  
able	  to	  detect	  any	  active	  inflammation	  (Filippi	  et	  al.,	  2012).	  In	  addition,	  conventional	  
MRI	  has	  limited	  power	  to	  detect	  the	  demyelination	  occurring	  in	  the	  grey	  matter,	  as	  
the	  focal	  cortical	  demyelinating	  lesions	  are	  difficult	  to	  be	  visualized	  on	  scans	  because	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of	  their	  poor	  contrast	  with	  the	  surrounding	  normal	  grey	  matter	  (Geurts	  et	  al.,	  2012;	  
Seewann	   et	   al.,	   2011).	   However,	   the	   use	   of	   double	   inversion	   recovery	   (DIR)	  
sequences	   allows	   to	   better	   characterize	   the	   extension	   of	   the	   cortical	   damage	  
(Calabrese	  et	  al.,	  2007b;	  Geurts	  et	  al.,	  2011).	  	  
	  
1.5.2	  MRI	  and	  the	  diagnosis	  of	  MS	  
	  
The	   MS	   inflammatory	   lesions	   develop	   at	   different	   times	   and	   involve	   different	  
anatomic	   locations	  within	  the	  CNS.	  Therefore,	   the	  dissemination	   in	  time	  and	  space	  
of	   the	   demyelinating	   processes,	   and	   the	   exclusions	   of	   other	   conditions	   potentially	  
mimicking	  MS,	  are	  the	  three	  essential	  requirements	  for	  the	  diagnosis	  of	  the	  disease.	  	  
	  
Before	  the	  advent	  of	  the	  MRI,	  Schumacher	  was	  the	  first	  to	  formulate	  internationally	  
accepted	  criteria	  for	  diagnosing	  MS	  (Schumacher	  et	  al.,	  1965).	  Clinically	  definite	  MS	  
was	   defined	   by	   objective	   signs	   of	   CNS	   dysfunction,	   evidence	   of	   two	   or	   more	  
neurological	   sites	   involvement	   and	   at	   least	   2	   distinct	   (separated	   by	   at	   least	   6	  
months)	  inflammatory	  episodes	  or	  slow	  progression	  over	  6	  months	  (Schumacher	  et	  
al.,	  1965).	  Following	  the	  increasing	  availability	  of	  the	  neuroimaging	  in	  the	  late	  1970s,	  
the	  MRI	  was	  recognized	  as	  important	  tool	  for	  assessing	  the	  disease	  burden	  (Young	  et	  
al.,	   1981)	   and,	   for	   the	   first	   time,	   it	  was	   introduced	   into	   the	   diagnostic	   process	   by	  
Poser	  (Poser	  et	  al.,	  1983).	  The	  MRI	  was	  considered	  a	  “paraclinical”	  test,	  which	  could	  
be	  used	   in	   support	  of	   the	  diagnoses	  of	   clinically	  definite	  MS,	   laboratory	   supported	  
definite	  MS	  and	  clinically	  probable	  MS	  (Poser	  et	  al.,	  1983)	  
	  
1.5.2.1	  The	  McDonald	  criteria	  
	  
The	   rapid	   recognition	   of	   the	   MRI	   as	   important	   diagnostic	   tool	   led	   to	   the	  
development	   of	   the	   first	   radiological	   diagnostic	   criteria.	   The	   fulfilment	   of	   these	  
criteria	  required	  the	  presence	  of	  at	  least	  3	  lesions	  located	  in	  the	  periventricular	  and	  
infratentorial	  regions,	  within	  the	  CNS	  white	  matter	  (Fazekas	  et	  al.,	  1988;	  Paty	  et	  al.,	  
1988).	   In	   1997,	   Barkhof	   et	   al.,	   by	   conducting	   a	   3	   years	   prospective	   study	   on	   CIS	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patients,	   identified	   the	   MRI	   features	   which	   associated	   with	   an	   increased	   risk	   of	  
conversion	  to	  clinically	  definite	  MS:	  at	  least	  one	  GAD	  enhancing	  lesion,	  at	  least	  one	  
infratentorial	  lesion,	  at	  least	  one	  subcortical	  lesion	  and	  three	  or	  more	  periventricular	  
lesions	  (Barkhof	  et	  al.,	  1997).	  These	  criteria	  were	  lately	  modified	  by	  Tintore’	  et	  al.	  It	  
was	   concluded	   that,	   if	   GAD	   enhancing	   lesions	   are	   not	   present	   on	   the	   scan,	   the	  
occurrence	  of	  at	  least	  9	  T2	  lesions	  would	  have	  the	  same	  predictive	  value.	  In	  addition,	  
it	   was	   proposed	   that	   the	   fulfilment	   of	   at	   least	   3	   of	   the	   4	   Barkhof’s	   parameters	  
allowed	  an	  accurate	  prediction	  of	  the	  conversion	  to	  clinically	  defined	  MS	  (Tintore	  et	  
al.,	   2000).	   These	   guidelines	   put	   the	   basis	   for	   the	   development	   of	   the	   McDonald	  
criteria	  (McDonald	  et	  al.,	  2001),	  which	  dramatically	  redefined	  the	  diagnostic	  process.	  
The	  widespread	  use	  of	  DMTs,	  exerting	  most	  of	  their	  efficacy	  in	  the	  early	  stage	  of	  the	  
disease,	  brought	  attention	  to	  the	  need	  of	  an	  early	  diagnosis,	  among	  those	  patients	  
without	  a	  second	  clinical	  attack	  (CIS).	  According	  to	  the	  new	  diagnostic	  guidelines,	  the	  
Barkhof	  and	  Tintore’	  MRI	  criteria	  (Barkhof	  et	  al.,	  1997;	  Tintore	  et	  al.,	  2000)	  could	  be	  
used	  for	  demonstrating	  that	  the	  demyelinating	  process	  involved	  at	  least	  two	  distinct	  
anatomic	   locations	   and	   occurred	   in	   two	   separate	   times,	   at	   least	   3	   months	   apart	  
(McDonald	  et	  al.,	  2001)	  (Table	  1.1).	  	  
	  
The	  incorporation,	  in	  the	  diagnostic	  algorithm,	  of	  the	  MRI	  criteria	  was	  welcomed	  but	  
also	   received	   some	   criticisms.	   The	   radiological	   criteria	   had	   poor	   specificity	   for	  
making	   a	   correct	   differentiation	   from	   other	   diseases	   (Poser	   and	   Brinar,	   2004).	  
Furthermore,	   they	   were	   derived	   from	   patients	   with	   CIS,	   and	   therefore	   were	  
predictive	   of	   the	   risk	   of	   having	  MS	  but	   not	   truly	   diagnostic.	   The	   lack	   of	   specificity	  
about	   the	   qualitative	   description	   of	   the	   lesions	   and	   the	   lack	   of	   systematic	  
consideration	  of	  MRI	   findings	  at	   the	   spinal	   level	   represented	  additional	  drawbacks	  
(Poser	  and	  Brinar,	  2004).	  Indeed,	  when	  retrospectively	  applied	  to	  other	  CIS	  cohorts,	  
the	   2001	   McDonald	   criteria	   showed	   a	   high	   specificity	   for	   conversion	   to	   clinically	  
definite	  MS	  but	  a	  modest	  sensitivity	  for	  detecting	  and	  treating	  most	  of	  those	  at	  risk	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Table	  1.1	  MRI	  criteria	  for	  dissemination	  in	  time	  and	  in	  space	  incorporated	  in	  the	  McDonald	  diagnostic	  
criteria	  2001	  (McDonald	  et	  al.,	  2001).	  
	  
	  
Based	  on	  this	  concerns,	  the	  McDonald	  criteria	  were	  revised	  in	  2005.	  The	  spinal	  cord	  
lesions	  were	  included	  among	  the	  parameters	  that	  could	  be	  used	  for	  confirming	  the	  
dissemination	   in	   space	   (Polman	   et	   al.,	   2005b).	   In	   addition,	   less	   restrictive	   criteria	  
were	  applied	  for	  demonstrating	  the	  dissemination	  in	  time,	  which	  could	  be	  confirmed	  
by	  the	  appearance,	  after	  at	  least	  30	  days,	  of	  new	  T2	  lesions	  (Polman	  et	  al.,	  2005b).	  
The	  2005	  McDonald	  criteria	  had	  an	   improved	  sensitivity,	  while	  maintaining	  a	  good	  
specificity	  (Swanton	  et	  al.,	  2007).	  	  	  
	  
1.5.2.2	  The	  current	  guidelines	  	  
	  
The	  key	  to	  all	  diagnostic	  criteria	  remains	  the	  absence	  of	  an	  alternative	  diagnosis	   in	  
the	   context	   of	   an	   appropriate	   clinical	   presentation.	   The	   MAGNIMS	   (European	  
Network	  for	  Magnetic	  Resonance	  Research	  in	  MS)	  criteria	  were	  recently	  developed	  
with	   the	   aim	   of	   simplifying	   the	   diagnostic	   process,	  without	   reducing	   its	   specificity	  
(Montalban	   et	   al.,	   2010).	   According	   to	   the	   new	   guidelines,	   for	   demonstrating	   the	  
dissemination	   in	   space	  only	  one	  parameter	   is	   sufficient:	   the	  occurrence	  of	  at	   least	  
one	   T2	   lesion	   in	   more	   than	   two	   of	   the	   four	   typical	   locations	   (periventricular,	  
subcortical,	   infratentorial	   and	   spinal	   cord).	   For	  demonstrating	   the	  dissemination	   in	  
time	   two	   criteria	   can	   be	   applied:	   a)	   the	   simultaneous	   presence	   of	   gadolinium	  
enhancing	  and	  non	  enhancing	  lesions	  at	  any	  time	  from	  the	  clinical	  onset;	  b)	  one	  new	  
T2	   lesion	   and/or	   new	   gadolinium	   enhancing	   lesion	   on	   follow	   up	  MRI	   at	   any	   time	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After	  the	  publication	  of	  the	  2005	  McDonald	  criteria,	  further	  studies	  emphasized	  the	  
importance	  of	  a	  new	  T2	  lesion,	   irrespective	  of	  whether	  this	  was	  detected	  within	  or	  
after	  30	  days	   from	  the	  onset	  attack,	   to	  predict	   the	  conversion	   to	  clinically	  definite	  
MS	  (Swanton	  et	  al.,	  2007;	  Tur	  et	  al.,	  2008).	  For	  this	  reason,	  the	  MAGNIMS	  diagnostic	  
criteria	  were	  developed	  for	  allowing	  to	  gather	  evidence	  of	  the	  dissemination	  in	  time	  
and	  space	  on	  a	  MRI	  scan	  performed	  at	  any	  time	  after	  the	  clinical	  onset	  (Montalban	  
et	   al.,	   2010).	   The	   new	   criteria	   could	   be	   applied	   even	  when	   a	   new	  GAD	   enhancing	  
lesion	  was	  considered	  a	  proof	  of	  the	  dissemination	  in	  time,	  with	  important	  practical	  
implications	   for	   the	   diagnosis	   of	  MS	   in	   CIS	   patients	   (Montalban	   et	   al.,	   2010).	   The	  
simultaneous	   presence	   of	   GAD	   enhancing	   and	   non	   enhancing	   lesions,	   on	   the	   first	  
MRI	  scan,	  can	  substitute	   for	  a	   follow	  up	  scan	  to	  confirm	  the	  dissemination	   in	   time	  
and	  to	  make	  the	  diagnosis.	  Based	  on	  these	  new	  MRI	  parameters	  (Table	  1.2),	  in	  2010	  
the	  McDonald	   criteria	   were	  modified	   again	   and	   now	   represent	   the	  most	   updated	  
guidelines	  for	  diagnosing	  the	  disease	  (Polman	  et	  al.,	  2011).	  	  
	  
Table	  1.2	  MRI	  criteria	  for	  dissemination	  in	  time	  and	  in	  space	  incorporated	  in	  the	  McDonald	  diagnostic	  
criteria	  2010	  (Polman	  et	  al.,	  2011).	  
	  
	  
1.5.3	  Monitoring	  the	  treatment	  response	  
	  
There	  are	  no	   internationally	  accepted	  guidelines	  on	   the	  use	  of	  MRI	   for	  monitoring	  
the	   disease	   activity.	   It	   is	   common	   practice	   in	   some	  medical	   systems	   to	   arrange	   a	  
brain	  MRI	   scan	   in	   patients	   who	   are	   to	   start	   a	   new	   therapy	   or	   to	   change	   therapy	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treatment	   and	   the	   definition	   of	   treatment	   failure	   vary	   among	   practitioners	  
(Giacomini	   et	   al.,	   2009).	   Some	   consider	   the	   worsening	   of	   the	   MRI	   activity	   not	  
relevant	   to	   the	   decision	   to	   change	   therapy,	   when	   it	   occurs	   in	   the	   context	   of	   a	  
clinically	  stable	  disease.	  Others	  argue	  that	  even	  a	  single	  new	  MRI	  lesion	  indicates	  an	  
active	  disease	  and	  therefore	  a	  poor	  response	  to	  the	  therapy.	  	  
	  
Indeed,	  the	  response	  to	  IFN	  beta,	  based	  on	  MRI	  inflammatory	  parameters,	  is	  highly	  
heterogeneous	  (Kappos	  et	  al.,	  2006c;	  Rio	  et	  al.,	  2008;	  Rudick	  et	  al.,	  2004;	  Sormani	  et	  
al.,	   2005),	   reflecting	   the	   variable	   definitions	   of	   “responders”.	   Among	   patients	  
enrolled	  in	  the	  original	  IFN	  beta-­‐1a	  trial	  (Jacobs	  et	  al.,	  1996a),	  the	  presence	  of	  more	  
than	   1	   new	   gadolinium	   enhancing	   lesion	   or	   more	   than	   3	   new	   T2	   lesions	   was	  
associated	  with	  a	  higher	  risk	  of	  experiencing	  disability	  progression	  over	  a	  period	  of	  2	  
years	  (Rudick	  et	  al.,	  2004).	  These	  data	  were	  lately	  extended	  and	  confirmed	  after	  15	  
years	  follow	  up	  (Bermel	  et	  al.,	  2013).	  Similar	  result	  were	  obtained	  by	  analysing	  data	  
from	  the	  PRISMS	  trial	  (1998a).	  The	  median	  number	  of	  T2	  lesions	  accumulated	  over	  8	  
years	  from	  the	  commencement	  of	  the	  therapy	  was	  found	  to	  be	  an	   indicator	  of	  the	  
EDSS	  worsening	  (Kappos	  et	  al.,	  2006c).	  Another	  study	  demonstrated	  that	  the	  risk	  of	  
poor	  response	  to	  the	  treatment	  (increased	  disability	  after	  2	  years	  of	  treatment)	  was	  
higher	   among	   those	   with	   3	   or	   more	   new	   lesions	   within	   12	   months	   from	   the	  
commencement	  of	  IFN	  beta	  (Rio	  et	  al.,	  2008).	  Chiu	  et	  al.	  longitudinally	  assessed,	  with	  
monthly	   scans	   for	   3	   years,	   15	   patients	   treated	   with	   IFN	   beta-­‐1b,	   highlighting	   the	  
difficulties	   of	   measuring	   the	   disease	   activity	   with	   conventional	   MRI.	   The	   study	  
confirmed	   the	   expected	   large	   heterogeneity	   of	   the	   response	   to	   the	   therapy	   at	  
individual	   level.	   Only	   half	   of	   the	   patients	   experienced	   a	   reduction	   of	   the	   total	  
number	   of	   GAD	   enhancing	   lesions	   (Chiu	   et	   al.,	   2009).	   In	   addition,	   the	   MRI	  
responsiveness	  to	  the	  treatment	  changed	  over	  time.	  In	  some	  cases,	  the	  suppression	  
of	   the	   active	   lesions	  was	  not	   sustained	   for	   long	   time,	  while	   in	   other	   patients	  with	  
initial	  MRI	  activity	  it	  occurred	  after	  months	  from	  the	  commencement	  of	  the	  therapy	  
(Chiu	  et	  al.,	  2009).	  	  
	  
Among	   222	   RR	   patients	   treated	   with	   IFN	   beta-­‐1b,	   Rio	   et	   al.	   assessed	   the	   MRI	  
variables,	  which	  could	  predict	  the	  risk	  of	  experiencing	  a	  clinical	  worsening.	  Within	  1	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year	   from	  the	  commencement	  of	   the	   therapy,	   the	  presence	  of	   two	  or	  more	  active	  
lesions	  (new	  or	  enlarging	  T2	  lesions,	  or	  contrast	  enhancing	  lesions)	  associated	  with	  a	  
higher	  probability	  of	  experiencing	  a	  new	  relapse	  and/or	  an	  accumulation	  of	  disability	  
(Rio	   et	   al.,	   2009a).	   Based	   on	   these	   data,	   it	   was	   developed	   a	   decision	   making	  
algorithm	   for	   the	   individual	   therapeutic	   management	   (Rio	   et	   al.,	   2009b).	   Patients	  
should	  undergo	  neuroimaging	  assessments	  at	  the	  beginning	  of	  the	  treatment	  and	  at	  
6	  and	  12	  months	  follow	  up.	  According	  to	  the	  algorithm,	  a	  change	   in	  the	  treatment	  
strategy	  is	  recommended	  in	  patients	  developing	  three	  or	  more	  active	  lesions	  and/or	  
experiencing	  a	  clinical	  deterioration	   (new	  relapses	  and/or	  disability	  progression).	  A	  
worsening	   of	   the	   MRI	   parameters,	   in	   patients	   free	   of	   clinical	   activity,	   warrants	   a	  
closely	  monitoring	  over	  time	  (Rio	  et	  al.,	  2009b).	  	  
	  
1.5.4	  The	  association	  between	  clinical	  and	  MRI	  activity	  	  
	  
Among	  MS	   patients,	   the	   severity	   of	   the	   clinical	   picture	   does	   not	   always	   correlate	  
with	   the	   extent	   of	   the	   CNS	   radiological	   involvement	   (Barkhof,	   2002;	  Miller	   et	   al.,	  
1996).	   New	   T2	   lesions	   are	   known	   to	   occur	   5-­‐10	   times	   more	   frequently	   than	   the	  
clinically	  evident	   inflammatory	  attacks	  (Willoughby	  et	  al.,	  1989),	   indicating	  that	  the	  
MRI	   inflammatory	  activity	  does	  not	  necessarily	  mirror	   the	  clinical	  activity	   (Barkhof,	  
2002;	  McDonald	  et	  al.,	  1994;	  Miller	  et	  al.,	  1996).	  This	  discrepancy	  became	  apparent	  
in	  the	  early	  MRI	  studies	  (Thompson	  et	  al.,	  1990)	  	  and	  was	  then	  confirmed	  during	  the	  
first	  trial	  of	  the	  IFN	  beta-­‐1b,	  which	  profoundly	  reduced	  the	  MRI	  outcome	  measures	  
but	  only	  modestly	  the	  relapse	  rate	  (Paty	  and	  Li,	  1993).	   In	  addition,	  with	  the	  recent	  
widespread	  use	  of	  the	  MRI	  in	  clinical	  practice,	  MRI	  abnormalities,	  highly	  suggestive	  
of	  demyelinating	  disease,	  are	  often	  incidentally	  identified	  among	  subjects	  who	  never	  
experienced	  clinical	  symptoms	  (radiologically	  isolated	  syndrome	  [RIS])	  (Okuda	  et	  al.,	  
2009).	   For	   these	   reasons,	   the	   prognostic	   relevance	   of	   an	   increased	   MRI	  
inflammatory	  activity	  and	  the	  use	  of	  MRI	  for	  evaluating	  the	  disease	  course	  and	  the	  
treatments	  efficacy	  is	  still	  debated	  among	  some	  researchers	  (Daumer	  et	  al.,	  2009).	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Despite	   this,	   in	   the	  context	  of	   clinical	   trials,	  MRI	   remains	  widely	  used	  as	   surrogate	  
marker	  for	  monitoring	  the	  disease	  activity	  (Cohen	  et	  al.,	  2012b)	  and	  for	  assessing	  the	  
progression	   of	   disability	   (Sormani	   et	   al.,	   2011).	   By	   detecting	   the	   asymptomatic	  
pathological	   changes	  of	   the	  disease,	   the	  MRI	  gives	   the	  opportunity	   to	  monitor	   the	  
subtle	   degenerative	   process,	  much	   before	   it	   becomes	   clinically	   evident.	   The	   brain	  
atrophy	  is	  considered	  a	  measure	  of	  tissue	  damage	  and	  it	  was	  consistently	  shown	  to	  
occur	   at	   significantly	   faster	   rate	   among	   MS	   patients,	   compared	   to	   the	   healthy	  
population	  (Luks	  et	  al.,	  2000;	  Rudick	  et	  al.,	  1999;	  Simon	  et	  al.,	  1999).	   Interestingly,	  
the	   grey	   matter	   atrophy	   develops	   during	   the	   very	   early	   stage	   of	   the	   disease,	  
independent	   of	   the	   enhancing	   lesions	   load	   (Calabrese	   et	   al.,	   2007a;	   Chard	   et	   al.,	  
2002).	   Similarly,	   a	   significant	   cord	   atrophy	   was	   found	   in	   a	   large	   percentage	   of	  
patients	   presenting	  with	   CIS	   (Brex	   et	   al.,	   2001)	   and	   significant	   grey	  matter	   lesions	  
were	  found	  even	  in	  subjects	  with	  RIS	  (Giorgio	  et	  al.,	  2011).	  	  
	  
The	  proton	  magnetic	  resonance	  spectroscopy	  allows	  the	  quantification	  of	  the	  extent	  
of	   the	   axonal	   loss,	   by	   measuring	   the	   changes	   in	   the	   signal	   intensity	   of	   N-­‐
acetylaspartate	   (NAA),	   which	   decreases	   proportionally	   to	   the	   axonal	   damage	   (De	  
Stefano	  et	  al.,	  1995).	  This	  technique	  allowed	  to	  confirm	  that	  the	  axonal	  pathology	  is	  
an	  early	  event	  in	  the	  course	  of	  the	  disease	  (Trapp	  et	  al.,	  1998)	  and	  does	  not	  correlate	  
with	  the	  baseline	  inflammatory	  lesions	  volume	  (De	  Stefano	  et	  al.,	  2003;	  Filippi	  et	  al.,	  
2003).	  In	  addition,	  a	  decrease	  of	  brain	  NAA	  level	  was	  recently	  shown	  also	  in	  a	  group	  
of	   subject	  with	  RIS,	   suggesting	   that	   axonal	  damage	   can	  be	  evident	  even	  when	   the	  
disease	  has	  not	  clinically	  manifested	  yet	  (Stromillo	  et	  al.,	  2013).	  Taken	  together,	  this	  
evidence	   strongly	   indicates	   that	   the	  degenerative	  process	   starts	  much	  before	   than	  
its	  clinical	  counterpart	  and	  highlights	   the	   important	   role	  of	   the	  MRI	   for	  monitoring	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1.5.5	  MRI	  and	  long-­‐term	  prognosis	  	  
	  
1.5.5.1	  The	  T2	  lesions	  
	  
Although	   the	   baseline	   MRI	   T2	   lesions	   load	   is	   a	   good	   predictor	   of	   the	   risk	   of	  
conversion	   to	   CD	  MS	   (Barkhof	   et	   al.,	   1997),	   the	  MRI	   inflammatory	  measures	   only	  
modestly	  correlate	  with	  the	  development	  of	  severe	  disability	  in	  the	  long	  term.	  	  
	  
The	  predictive	  values	  of	  the	  number	  and	  the	  volume	  of	  T2	  lesions	  were	  assessed	  in	  
several	  studies.	  Among	  30	  patients	  originally	  enrolled	  in	  the	  IFN	  beta-­‐1a	  trial	  (Jacobs	  
et	   al.,	   1996a),	   an	   increased	   T2	   lesion	   volume,	   over	   2	   years	   from	   onset,	   was	  
associated	  with	  a	  more	  severe	  disability	  measured	  by	  the	  MSFC	  at	  13	  years	  follow	  up	  
(Rudick	   et	   al.,	   2006a).	   In	   a	   cohort	   of	   140	   CIS	   patients,	   who	   never	   received	   DMT	  
(Ormerod	  et	  al.,	  1987),	  clinical	  and	  MRI	  follow-­‐ups	  were	  performed	  at	  different	  time	  
points.	   The	   EDSS	   score	   at	   14	   years	   was	   available	   for	   71	   patients	   and	   it	   modestly	  
correlated	  with	  the	  baseline	  lesions	  volume	  (r	  =	  0.48)	  and	  number	  (r	  =	  0.47)	  (Brex	  et	  
al.,	   2002).	   From	   the	   same	   cohort	   (Ormerod	   et	   al.,	   1987)	   107	   patients	   were	  
reassessed	   after	   20	   years,	   which	   represented	   the	   longest	   observation	   period	   ever	  
reported	   in	   a	   CIS	   population	  with	  MRI	   examinations	   (Fisniku	   et	   al.,	   2008a).	   At	   the	  
end	   of	   the	   follow	   up,	   82%	   patients	   with	   abnormal	   baseline	   brain	   MRI	   scan	   had	  
developed	   CD	   MS.	   Within	   this	   group,	   the	   spectrum	   of	   disability	   and	   the	   clinical	  
course	   at	   year	   20	   largely	   varied:	   42%	   had	   converted	   to	   SP	   MS	   and	   39%	   had	  
accumulated	  minimal	  disability	  (EDSS	  ≤	  3).	   	  The	  study	  demonstrated	  only	  a	  modest	  
correlation	  between	  the	  number	  of	  T2	  lesions	  at	  baseline	  and	  the	  EDSS	  score.	  There	  
was	   a	   trend	   indicating	   that	   patients	   with	   a	   higher	   number	   of	   T2	   lesions	   were	  
somewhat	  more	  likely	  to	  be	  disabled	  after	  20	  years	  (18%	  with	  1-­‐3	  lesions	  versus	  45%	  
with	  ≥	  10	   lesions	  were	   scored	  at	  EDSS	  6	  or	  more),	   suggesting	   that	   lesions	  number	  
has	   some	   predictive	   effect	   for	   late	   disability.	   However,	   35%	   of	   those	   with	   ≥	   10	  
lesions	  accumulated	  not	  more	  than	  moderate	  disability	  and	  18%	  had	  not	  developed	  
CD	   MS,	   indicating	   that	   the	   predictive	   effect	   of	   MRI	   T2	   lesions	   number	   at	   CIS	  
presentation	   remains	   limited	   in	   the	   long	   term.	   The	   rate	   of	   lesions	   volume	   growth	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was	  found	  to	  be	  a	  more	  reliable	  indicator	  of	  disease	  activity;	  those	  developing	  SP	  MS	  
had	  a	  greater	  increase	  of	  lesions	  size,	  compared	  to	  patients	  who	  remained	  in	  the	  RR	  
phase,	   and	   this	   difference	  was	   already	   evident	   5	   years	   after	   the	   CIS	   presentation.	  
Data	   therefore	   suggested	   that	   slowing	   the	   lesions	   volume	   increase	  might	   delay	   or	  
prevent	  the	  conversion	  to	  SP	  MS	  (Fisniku	  et	  al.,	  2008a).	  The	  15	  years	  follow	  up	  study	  
of	   the	   patients	   enrolled	   in	   the	   Optic	   Neuritis	   Treatment	   Trial	   (ONTT)	   (Beck	   and	  
Cleary,	  1993)	   reported	  similar	   results.	  The	  EDSS	  was	  available	   for	  113	  subjects	  and	  
the	   degree	   of	   disability	   was	   found	   to	   be	   unrelated	   to	   the	   number	   of	   baseline	   T2	  
lesions	  (r	  =	  0.07).	  	  	  
	  
The	   location	   of	   the	   MRI	   lesions	   was	   shown	   to	   influence	   the	   short-­‐term	   disease	  
evolution.	   Two	   separate	   studies	   found	   a	   correlation	   between	   the	   presence	   of	   T2	  
lesions	  in	  the	  infratentorial	  region	  on	  the	  baseline	  scan	  an	  the	  EDSS	  score	  at	  5	  years	  
(Filippi	   et	   al.,	   1994)	   and	   at	   10	   years	   (Sailer	   et	   al.,	   1999)	   follow	   ups.	   Similarly,	   in	   a	  
cohort	  of	  42	  patients	  followed	  up	  for	  8	  years,	  the	  risk	  of	  reaching	  moderate	  disability	  
was	   significantly	   higher	   among	   those	   with	   at	   least	   two	   T2	   infratentorial	   lesions	  
(Minneboo	  et	  al.,	  2004).	  	  
	  
1.5.5.2	  The	  T1	  lesions	  
	  
The	   poor	   correlation	   between	   the	   long	   term	   disability	   accumulation	   and	   the	   T2	  
lesions	  is	  probably	  explained	  by	  their	  lack	  of	  pathological	  specificity	  (Barkhof,	  2002;	  
Filippi	   et	   al.,	   2012).	   In	   contrast,	   the	   T1	   hypo-­‐intense	   lesions	   have	   much	   higher	  
sensitivity	  and	  specificity	  for	  the	  axonal	  damage	  (Bruck	  et	  al.,	  1997;	  van	  Waesberghe	  
et	  al.,	  1999;	  van	  Walderveen	  et	  al.,	  1998)	  and	  were	  found	  to	  correlate	  more	  strongly	  
with	  the	  development	  of	  disability.	  In	  a	  small	  group	  of	  24	  patients,	  the	  total	  number	  
of	  T1	  lesions	  was	  found	  to	  be	  associated	  significantly	  with	  the	  EDSS	  score	  (r	  =	  0.65).	  
The	   level	   of	   disability	  was	   higher	   among	   those	  with	   a	   larger	   “black	   holes”	   volume	  
(Parry	  et	  al.,	   2002).	   Similarly,	   in	  a	   cohort	  of	  46	  patients,	  a	  higher	  T1	   lesion	   load	  at	  
baseline	  and	  a	  faster	  accumulation	  of	  hypo-­‐intense	  lesions	  predicted	  a	  higher	  EDSS	  
score	  at	  40	  months	  follow	  up	  (Truyen	  et	  al.,	  1996).	  However,	  the	  same	  authors	  failed	  
to	  demonstrate	  a	  significant	  association	  between	  the	  T1	  lesion	  volume	  and	  the	  EDSS	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score	   in	   a	   separate	   study	   involving	   a	   larger	   number	   (n	   =	   138)	   of	   patients	   (van	  
Walderveen	  et	  al.,	  2001).	  	  
	  
1.5.5.3	  The	  grey	  matter	  pathology	  	  
	  
The	   grey	   matter	   pathology	   is	   considered	   an	   important	   determinant	   of	   the	  
irreversible	   disability	   (Geurts	   et	   al.,	   2012;	   Pirko	   et	   al.,	   2007).	   Several	   studies	   have	  
demonstrated	  that	  the	  grey	  matter	  damage	  (Calabrese	  et	  al.,	  2007b;	  Calabrese	  et	  al.,	  
2009b;	  Calabrese	  et	  al.,	  2013;	  Roosendaal	  et	  al.,	  2009)	  and	  the	  grey	  matter	  atrophy	  
(Bakshi	  et	  al.,	  2001;	  De	  Stefano	  et	  al.,	  2003;	  Fisniku	  et	  al.,	  2008b;	  Roosendaal	  et	  al.,	  
2011;	   Tedeschi	   et	   al.,	   2005)	   have	   a	   good	   correlation	   with	   the	   clinical	   outcome.	  
Among	   203	   patients	   observed	   for	   5	   years,	   an	   increased	   number	   and	   volume	   of	  
cortical	   lesions	   at	   baseline	   associated	   with	   a	   significantly	   higher	   EDSS	   score	  
(Calabrese	  et	  al.,	  2012).	  Authors	  noted	  that,	  among	  those	  with	  worse	  outcome,	  the	  
cortical	   involvement	   increased	  significantly	  more	  quickly	  over	  time,	  suggesting	  that	  
the	   evolution	   of	   the	   cortical	   lesions	   might	   be	   used	   for	   monitoring	   the	   disease	  
evolution	   (Calabrese	   et	   al.,	   2012).	   Indeed,	   a	   separate	   study	   from	   the	   same	   group	  
demonstrated	   that,	  patients	  with	  a	  benign	  disease	  course	   (EDSS	  ≤	  3	  after	  15	  years	  
from	  onset)	  had	  a	   significantly	   lower	  number	  and	  volume	  of	   cortical	   lesions	  and	  a	  
slower	   accumulation	  of	   the	   cortical	   damage	  over	   time,	   compared	   to	  patients	  with	  
similar	   degree	   of	   disability	   but	   much	   shorter	   disease	   duration	   (Calabrese	   et	   al.,	  
2009b).	  More	  recently,	  in	  a	  5	  years	  longitudinal	  study	  of	  334	  RR	  MS	  patients,	  those	  
who	   entered	   the	   SP	   phase	   during	   the	   observation	   period	   were	   shown	   to	   have	   a	  
significantly	   higher	   number	   of	   cortical	   lesions	   and	   a	   significantly	   lower	   cortical	  
volume	  (Calabrese	  et	  al.,	  2013).	  The	  authors	  hypothesized	  that	  during	  the	  RR	  phase	  
the	  grey	  matter	  pathology	  remains	  clinically	  silent	  and,	  after	  a	  threshold	  is	  reached,	  
it	   determines	   the	   changing	   course	   of	   the	   disease	   (Calabrese	   et	   al.,	   2013).	   Similar	  
conclusions	  were	  reached	  by	  analysing	  a	  group	  of	  CIS	  patients	  observed	  for	  20	  years	  
after	   the	   first	   attack.	   A	   significantly	   greater	   grey	   matter	   atrophy	   predicted	   the	  
conversion	  to	  SP	  MS	  and	  the	  development	  of	  severe	  disability	  (Fisniku	  et	  al.,	  2008b).	  
These	  results	  strongly	  suggested	  that	  grey	  matter	  atrophy	  is	  a	  good	  indicator	  of	  the	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1.6	  Measures	  of	  disability	  	  	  	  
	  
1.6.1	  The	  expanded	  disability	  status	  scale	  	  
	  
The	   disability	   status	   scale	   (DSS)	  was	   introduced	  more	   than	   50	   years	   ago	   (Kurtzke,	  
1955)	  and	  its	  expanded	  version	  (EDSS)	  was	  created	  30	  years	  ago	  (Kurtzke,	  1983).	   It	  
remains	   the	  most	  widely	   used	   tool	   for	   assessing	   disability,	   among	  MS	   patients,	   in	  
both	  clinical	  practice	  and	  clinical	  trials.	  The	  score	  is	  calculated	  by	  taking	  into	  account	  
dysfunctions	   in	   a	   wide	   range	   of	   neurological	   functional	   systems	   (FS):	   pyramidal,	  
cerebellar,	  brainstem,	  visual,	  cerebral,	  bladder/bowel	  (Table	  1.3)	  (Kurtzke,	  1983).	  
	  
Table	  1.3	  Functional	  systems	  score	  in	  the	  EDSS	  (Kurtzke,	  1983).	  
	  
	  
The	  function	  score	  in	  each	  system	  is	  calculated	  according	  to	  the	  clinical	  findings	  from	  
the	   neurological	   examination.	   Pyramidal,	   cerebellar	   and	   brainstem	   functions	   are	  
rated	   from	   0	   to	   5,	   based	   on	   the	   degree	   of	   weakness,	   ataxia,	   ocular	   movements	  
abnormalities	   and	   speech/swallowing	   difficulties,	   respectively.	   Sensory,	   visual	   and	  
bowel/bladder	  functions	  are	  rated	  from	  0	  to	  6,	  based	  on	  the	  degree	  of	  sensory	  and	  
visual	  impairment,	  and	  sphincter	  dysfunction	  (Table	  1.3).	  The	  combination	  of	  scores	  
in	  each	  functional	  system	  allows	  to	  calculate	  the	  final	  disability	  score,	  which	  ranges	  
from	  0	  (normal)	   to	  10	  (dead)	   (Figure	  1.7),	  with	  0.5	  steps	   increments.	  Death	  due	  to	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MS	   (EDSS	   =	   10)	   is	   defined	   as	   “…due	   to	   brainstem	   involvement	   or	   to	   respiratory	  
failure,	   or	   consequent	   to	   the	   chronic	   bedridden	   state	   with	   terminal	   pneumonia,	  
sepsis,	  uremia,	  cardio-­‐respiratory	  failure.	  Antemortem,	  the	  patient	  will	  ordinarily	  be	  
scored	  EDSS	  9,	  sometimes	  8…”	  (Kurtzke,	  1983).	  
	  
The	   EDSS	   is	   familiar	   to	   virtually	   all	   MS	   clinicians,	   it	   allows	   making	   comparisons	  
between	  patients	  and	  within	  a	   single	  patient	  over	   time,	  and	   it	   is	   relatively	  easy	   to	  
administer.	  However,	   it	   is	  disadvantaged	  by	  several	  shortcomings	  and	  has	  received	  
large	   critiques	   (Cohen	   et	   al.,	   2012b;	   Whitaker	   et	   al.,	   1995;	   Willoughby	   and	   Paty,	  
1988).	   It	   is	   based	   on	   the	   standard	   neurological	   examination,	   which	   is	   inevitably	  
subjective.	   It	   relies	   heavily	   on	   the	   ambulation	   and	   it	   has	   poor	   assessment	   of	   the	  
upper	   limbs	   function.	   In	   addition,	   the	   scoring	   of	   the	   FS	   dysfunctions	   is	   rather	  
ambiguous	  (Table	  1.3),	  making	  difficult	  to	  determine	  the	  overall	  score.	  	  
	  
Figure	  1.7	  The	  EDSS	  score.	  Adapted	  from	  (Kurtzke,	  1983)	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1.6.1.1	  Limitations	  of	  the	  EDSS	  	  
	  
Several	   studies	   highlighted	   the	   poor	   reliability	   of	   the	   scale	   by	   demonstrating	   that	  
both	  the	  FS	  and	  EDSS	  are	  often	  affected	  by	  high	  inter-­‐examiner	  and	  intra-­‐examiner	  
variability,	  (Amato	  et	  al.,	  1987;	  Amato	  et	  al.,	  1988;	  Goodkin	  et	  al.,	  1992;	  Noseworthy	  
et	  al.,	  1990).	   In	  a	  small	  study	  involving	  4	  MS	  physicians,	  examining	  24	  patients,	  the	  
degree	   of	   inter-­‐examiners	   agreement	   was	   reported	   to	   be	   unacceptably	   low	   (30-­‐
50%),	   demonstrating	   that	   a	   single	   point	   change	   on	   the	   EDSS	   was	   not	   a	   sufficient	  
evidence	   of	   the	   disease	   progression	   (Amato	   et	   al.,	   1988).	   These	   findings	   were	  
confirmed	  by	  the	  Canadian	  Cooperative	  Study	  group,	  showing	  a	  considerable	  inter-­‐
examiners	   variability	   of	   the	   disability	   scores,	   even	   when	   2	   experienced	   clinicians	  
examined	   the	   patient	   consecutively	   (Noseworthy	   et	   al.,	   1989).	   The	   authors	  
concluded	  that	  the	  poor	  agreement	  among	  clinicians	  may	  often	  account	  for	  changes	  
of	  a	  single	  EDSS	  step	  (Noseworthy	  et	  al.,	  1990).	  This	  was	  shown	  to	  be	  mainly	  evident	  
in	   the	   lower	   scores	   of	   the	   scale	   (EDSS	   1-­‐3.5),	  where	   the	   inter-­‐examiners	   variation	  
occurred	   in	  up	   to	  40%	  of	  assessments	   (Goodkin	  et	  al.,	  1992).	  The	   low	  EDSS	  scores	  
are	   more	   difficult	   to	   be	   calculated	   because	   definitions	   of	   the	   FS	   dysfunction	   are	  
particularly	  ambiguous.	   In	  contrast,	  the	  scoring	  from	  4	  to	  7.5	   is	  based	  on	  the	  more	  
objective	   ambulatory	   endurance	   (distance	   the	   patient	   can	   walk	   with	   or	   without	  
assistance).	  	  
	  
More	  than	  20	  years	  ago,	  it	  was	  recommended	  that	  a	  change	  of	  at	  least	  1	  EDSS	  point,	  
preferably	  validated	  by	  a	  second	  confirmatory	  examination,	   is	   required	  to	  detect	  a	  
significant	   clinical	   change	   in	   the	   context	   of	   a	   trial	   (Noseworthy	   et	   al.,	   1989).	   The	  
unremitting	  disability,	  defined	  by	  0.5	  or	  1	  EDSS	  point	   increase,	  confirmed	  at	  3	  or	  6	  
months,	  has	  become	  the	  key	  therapeutic	  target	  in	  modern	  MS	  trials.	  The	  validity	  of	  
these	  definitions	  of	  disability	   accumulation	  was	  assessed	   in	  a	   large	   study	   involving	  
1344	  patients	  from	  several	  randomized	  controlled	  trials	  (RCTs)	  placebo	  arms,	  pooled	  
together.	   Not	   even	   the	   most	   stringent	   1	   EDDS	   point	   increase,	   confirmed	   at	   6	  
months,	  was	  found	  to	  be	  a	  valid	  surrogate	  marker	  for	  late	  disability.	  The	  worsening	  
on	  the	  EDSS	  scale	  was	  shown	  to	  occur	  as	   frequently	  as	  the	   improvement	  (Ebers	  et	  
al.,	  2008).	  These	  data	  suggested	  that	  the	  variation	  of	  the	  disability,	  and	  therefore	  the	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treatment	   failure,	  observed	   in	  placebo	  arms	   is	   likely	   to	  be	  strongly	  affected	  by	  the	  
random	  variation	  of	  the	  EDSS	  score	  (Ebers	  et	  al.,	  2008).	  Authors	  recommended	  that	  
the	  confirmation	  at	  1	  year,	  of	  at	  least	  1-­‐2	  EDSS	  point	  change,	  is	  needed	  for	  detecting	  
a	  meaningful	  disability	  (Ebers	  et	  al.,	  2008).	  During	  the	  last	  International	  Conference	  
on	   Disability	   Outcomes	   in	   MS	   (May	   2011),	   it	   was	   finally	   agreed	   that	   3	   months	  
confirmation	  of	  EDSS	  increase	  is	  not	  a	  reliable	  indicator	  that	  disability	  worsening	  has	  
occurred	  and	   it	  was	   recommended	   to	  use	  a	   confirmatory	  assessment	  at	  6	  months	  
(Cohen	  et	  al.,	  2012b).	  	  
	  
An	  additional	  drawback	  of	  the	  EDSS	  is	  the	  lack	  of	  linearity,	  as	  the	  clinical	  importance	  
of	   a	   1-­‐point	   change	   varies	   according	   to	   the	   starting	   score.	   Indeed,	   the	   rate	   of	  
progression	  experienced	  by	  an	  individual	  patient	  through	  the	  scale	  varies	  over	  time.	  
For	  instance,	  among	  the	  London	  Ontario	  database	  population,	  the	  distribution	  of	  the	  
DSS	   scores	   was	   bimodal,	   with	   peaks	   at	   levels	   3-­‐4	   and	   6-­‐7	   (Weinshenker	   et	   al.,	  
1991b).	   These	   factors	   greatly	   complicate	   the	   interpretation	   of	   score	   changes	   over	  
time,	  especially	  within	  the	  context	  of	  clinical	  trials.	  	  	  
	  
1.6.1.2	  Possible	  improvements	  of	  the	  EDSS	  	  
	  
The	   EDSS	   remains	   widely	   used	   in	   RCTs,	   mainly	   because	   of	   its	   acceptance	   by	  
regulatory	  agencies	  (Cohen	  et	  al.,	  2012b).	  Almost	  20	  years	  ago	  the	  EDSS	  was	  already	  
considered	   inadequate	   for	   reliably	   assessing	   the	   disease	   progression.	   Following	   an	  
international	  workshop	  on	  outcome	  measures	   in	  clinical	   trials,	   large	   improvements	  
of	  the	  scale	  were	  suggested	  (Whitaker	  et	  al.,	  1995),	  however,	  since	  then,	  only	  small	  
changes	   have	   occurred.	   A	  modern	   version	   is	   now	   available,	   on	   CD-­‐ROM	  or	   online	  
from	  Neurostatus.	  The	   reliability	   of	   the	   scale	  was	   improved	   by	   using	   standardized	  
neurological	   examinations	   and	   scoring	   rules,	   and	   by	   also	   questioning	   the	   patients	  
when	   calculating	   the	   scores	   (Cohen	   et	   al.,	   2012b).	   During	   the	   last	   International	  
Conference	   on	   Disability	   Outcomes	   in	   MS	   (May	   2011),	   it	   was	   advised	   that	  
modifications	  should	  be	  implemented	  to	  improve	  the	  linearity	  of	  the	  measurement,	  
although	  it	  remains	  unclear	  how	  this	  refinement	  can	  be	  accomplished	  (Cohen	  et	  al.,	  
2012b).	  	  
	   87	  
1.6.2	  Multiple	  Sclerosis	  functional	  composite	  	  
	  
The	  Multiple	  Sclerosis	  Functional	  Composite	  (MSFC)	  was	  developed	  as	  an	  alternative	  
disability	  assessment	  scale,	  able	  to	  overcome	  the	  EDSS	  shortcomings	  (Cutter	  et	  al.,	  
1999;	  Rudick	  et	  al.,	  1997).	  It	  is	  simple	  to	  administer,	  as	  it	  is	  not	  based	  on	  neurological	  
examination,	   but	   implies	   the	   use	   of	   3	   separate	   quantitative	   tests	   (Cutter	   et	   al.,	  
1999).	   1)	   The	   9-­‐Hole	   Peg	   Test	   (9HPT)	   assesses	   arms	   and	   hands	   functions,	   by	  
measuring	   the	   time	   needed	   for	   inserting	   and	   removing	   9	   pegs	   from	   a	   board;	   the	  
mean	  time	  for	  both	  hands	  represents	   the	   final	  score	   (Goodkin	  et	  al.,	  1988).	  2)	  The	  
Timed	  25-­‐Foot	  Walk	  (T25FW)	  evaluates	  changes	   in	  ambulatory	  functions;	  at	   least	  a	  
20%	  time	  increase	  indicates	  a	  clinically	  relevant	  ambulatory	  impairment	  (Kaufman	  et	  
al.,	  2000).	  3)	  The	  Paced	  Auditory	  Serial	  Addition	  Test	  (PASAT)	  measures	  the	  cognitive	  
function	   by	   asking	   the	   patient,	   while	   listening	   61	   spoken	   numbers	   at	   2-­‐3	   seconds	  
interval,	  to	  add	  each	  number	  to	  the	  previous	  one;	  the	  number	  of	  correct	  addictions	  
defines	  the	  final	  score	  (Gronwall,	  1977).	  The	  final	  MSFC	  composite	  score,	  combining	  
the	   score	   from	   the	   three	   tests,	   is	   computed	   as	   Z-­‐score	   (the	   number	   of	   standard	  
deviation	   units	   a	   patient’s	   score	   is	   below	   or	   above	   the	   average	   score).	   Therefore	  
lower	   scores,	   compared	   to	   baseline	  or	   to	   previous	   assessment,	   is	   interpreted	   as	   a	  
neurological	   deterioration	   (Cutter	   et	   al.,	   1999).	   The	   calculation	   of	   the	   Z-­‐score	   is	  
based	  on	  the	  comparison	  with	  a	  reference	  population	  (e.g.	  a	  standard	  MS	  population	  
or	  healthy	  controls),	  which	  influences	  the	  weighting	  of	  the	  individual	  components.	  	  
	  
The	  overall	  MSFC	   score,	   as	  well	   as	   the	  performance	   in	   the	   individual	   components,	  
were	  found	  to	  decline	  with	  disease	  duration	  and	  to	  correlate	  well	  with	  the	  EDSS	  and	  
its	  changes	  (Cutter	  et	  al.,	  1999).	  Not	  unexpectedly,	  the	  correlation	  of	  the	  MSFC	  with	  
the	  EDSS	  derives	  mainly	   from	  the	  T25FW	  test	   (Hoogervorst	  et	  al.,	  2002;	  Kalkers	  et	  
al.,	   2000),	  with	   the	   additional	   advantage	   of	   taking	   into	   account	   the	   arms	   and	   the	  
cognitive	   functions	   (Polman	   and	  Rudick,	   2010).	   A	  modest	   correlation	   between	   the	  
MSFC	   and	  MRI	  measures	  was	   also	   reported	   (Kalkers	   et	   al.,	   2001).	   In	   addition,	   the	  
MSFC	  was	   shown	   to	  have	  excellent	   intra-­‐examiner	   and	   inter-­‐	   examiners	   reliability,	  
especially	   when	   examiners	   were	   previously	   trained	   (Cohen	   et	   al.,	   2000).	   This	   was	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also	  confirmed	  when	  it	  was	  used	  as	  primary	  clinical	  endpoint	  in	  a	  RCT	  (Cohen	  et	  al.,	  
2001).	  
	  
However,	  the	  MSFC	  is	  not	  free	  of	  limitations.	  It	  does	  not	  include	  assessment	  of	  the	  
visual	   function	   and	   changes,	   in	   both	   the	   composite	   Z-­‐score	   and	   in	   the	   individual	  
domains	  Z-­‐scores,	  are	  difficult	   to	   interpret	   (Polman	  and	  Rudick,	  2010).	   In	  addition,	  
both	  the	  9-­‐HPT	  and	  the	  PASAT	  are	  affected	  by	  a	  practice	  effect;	  therefore	  improved	  
scores	   can	   be	   wrongly	   interpreted	   as	   a	   clinical	   improvement	   (Solari	   et	   al.,	   2005).	  
Finally,	  the	  choice	  of	  the	  reference	  population	  influences	  the	  weighting	  to	  different	  
tests,	   limiting	   the	   comparison	   among	   different	   studies	   (Uitdehaag	   et	   al.,	   2002).	  
Overall	  the	  MSFC	  cannot	  be	  easily	  clinically	   interpreted	  and	  for	  this	  reason	  has	  not	  
been	  accepted	  by	  regulatory	  agencies	  as	  an	  alternative	  to	  the	  EDSS	  in	  RCTs.	  	  
	  
1.6.3	  Surrogate	  markers	  	  
	  
Surrogate	  markers	  are	  defined	  by	  the	  FDA	  as	  “…laboratory	  measurement	  or	  physical	  
signs	  that	  can	  be	  used	  in	  therapeutic	  trials	  as	  a	  substitute	  for	  a	  clinically	  meaningful	  
endpoint	  that	  is	  expected	  to	  predict	  the	  effect	  of	  the	  therapy…”	  (Katz,	  2004;	  Temple,	  
1999).	   As	   MS	   generally	   evolves	   over	   30-­‐40	   years,	   with	   an	   unpredictable	   clinical	  
course,	  validated	  surrogate	  markers,	  predicting	  the	  clinical	  changes	  in	  the	  long	  term	  
and	  able	  to	  detect	  a	  treatment	  effect	  during	  the	  short	  duration	  of	  a	  clinical	  trial,	  are	  
desperately	  needed.	  	  
	  
1.6.3.1	  MRI	  	  
	  
The	   use	   of	   MRI,	   as	   marker	   of	   disease	   activity,	   is	   mainly	   based	   on	   its	   ability	   of	  
detecting	   the	   subclinical	   inflammatory	   activity	   (McDonald	   et	   al.,	   1994).	   Imaging	  
outcomes	  are	  currently	  well	  accepted	  as	  secondary	  endpoints	  in	  RCTs.	  Some	  authors	  
claimed	  to	  have	  validated	  the	  individual-­‐level	  surrogacy	  of	  MRI	  lesions	  for	  the	  EDSS	  
worsening	   at	   trial	   level,	   among	   patients	   under	   immunomodulatory	   treatments	  
(Sormani	   et	   al.,	   2011).	  However,	   the	   	  modest	   correlation	  between	   the	   clinical	   and	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the	  radiological	  activity	   (Barkhof,	  2002;	  Miller	  et	  al.,	  1996)	   limits	  the	  use	  of	  MRI	  as	  
para-­‐clinical	  outcome	  measure	  of	  the	  inflammatory	  activity.	  One	  strategically	  placed	  
lesion	  (e.g.	   in	  the	  lower	  medulla)	  can	  make	  a	  patient	  quadriplegic,	  whereas	  several	  
lesions	  distributed	  periventricularly	  can	  remain	  completely	  asymptomatic	   (Barkhof,	  
2002).	   In	   addition,	   MRI	   inflammatory	   lesions	   number	   was	   shown	   to	   predict	  
conversion	   from	   CIS	   to	   clinically	   defined	   MS	   (Fisniku	   et	   al.,	   2008a)	   however,	  
correlated	  only	  modestly	  with	  the	  disability	  development	  in	  the	  long	  term	  (Fisniku	  et	  
al.,	   2008a;	  Khoury	  et	   al.,	   1994).	  Although	   the	  MRI	   inflammatory	   activity	   appears	   a	  
strong	  surrogate	  endpoint	  for	  clinical	  relapses,	  it	  remains	  largely	  unclear	  which	  MRI	  
features	   can	   be	   predictive	   of	   the	   disease	   progression	   and	   of	   disability	   changes	  
(Cohen	   et	   al.,	   2012b).	   In	   contrast,	   both	   the	   grey	  matter	   damage	   (Calabrese	   et	   al.,	  
2007b;	  Calabrese	  et	  al.,	  2009b;	  Calabrese	  et	  al.,	  2013;	  Roosendaal	  et	  al.,	  2009)	  and	  
the	  grey	  matter	  atrophy	  (Bakshi	  et	  al.,	  2001;	  De	  Stefano	  et	  al.,	  2003;	  Fisniku	  et	  al.,	  
2008b;	  Roosendaal	  et	  al.,	  2011;	  Tedeschi	  et	  al.,	  2005)	  correlate	  reasonably	  well	  with	  
the	  clinical	  outcome,	  and	  might	  be	  used	  as	  surrogate	  markers	  for	  late	  disability.	  
	  
1.6.3.2	  Optical	  coherence	  tomography	  	  
	  
Optical	  coherence	  tomography	  (OCT)	   is	  a	  non-­‐invasive	  procedure,	  able	  to	  generate	  
high	   resolution	   retinal	   images	   (Huang	   et	   al.,	   1991).	   Because	   of	   its	   ability	   of	  
quantifying	   the	   retinal	   nerve	   fibre	   layer	   (RNFL),	   it	   has	   recently	   gained	   interest,	  
among	  MS	  experts,	  as	  marker	  of	  neurodegeneration	  and	  for	  monitoring	  the	  axonal	  
loss	  (Petzold	  et	  al.,	  2010).	  	  
	  
Following	  an	  optic	  neuritis	   (ON),	   the	  RFNL	  thickness	   is	  significantly	   lost	   (Costello	  et	  
al.,	  2006).	  However,	  the	  RNFL	  loss	  can	  also	  be	  a	  consequence	  of	  other	  causes	  (Choi	  
et	  al.,	  2008),	  representing	  a	  limitation	  of	  the	  technique.	  An	  association	  between	  the	  
RNFL	  thinning	  and	  the	  MS	  pathology	  is	  supported	  by	  several	  studies,	  demonstrating	  
a	  significant	  RNFL	  loss	  in	  MS	  patients	  with	  no	  evidence	  of	  ON,	  compared	  to	  healthy	  
controls	   (Albrecht	   et	   al.,	   2007;	   Bock	   et	   al.,	   2010;	   Fisher	   et	   al.,	   2006;	   Siger	   et	   al.,	  
2008).	  In	  addition,	  the	  RNFL	  thickness	  was	  reported	  to	  decrease	  with	  the	  increasing	  
EDSS	  score	  (Sepulcre	  et	  al.,	  2007;	  Siger	  et	  al.,	  2008)	  and	  with	  the	  increasing	  cognitive	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disability	   (Gordon-­‐Lipkin	  et	  al.,	  2007;	  Toledo	  et	  al.,	  2008),	  and	  to	  associate	  directly	  
with	  the	  brain	  atrophy	  (Grazioli	  et	  al.,	  2008;	  Siger	  et	  al.,	  2008).	  
	  
Furthermore,	  the	  RNFL	  loss	  in	  MS	  patients	  worsens	  with	  the	  disease	  duration	  (Pueyo	  
et	   al.,	   2008;	   Siger	   et	   al.,	   2008),	   although	   some	   studies	   could	   not	   confirm	   this	  
observation	   (Henderson	   et	   al.,	   2008;	   Klistorner	   et	   al.,	   2008).	   These	   discrepancies	  
might	   be	   accounted	   for	   by	   ascertainment	   differences.	   Indeed,	   a	   large	   longitudinal	  
study	  described	  an	  average	  2-­‐μm	  RNFL	  thinning	  for	  each	  year	  of	  follow	  up,	  totalling	  
3.2%	  loss	  after	  2-­‐3	  years	  (Talman	  et	  al.,	  2010).	  These	  data	  suggested	  that	  a	  minimum	  
2	   years	   follow	  up	  would	  be	   required	   for	   detecting	   significant	   changes,	  making	   the	  
OCT	  still	  not	  a	  reliable	  outcome	  measure	  during	  the	  phase	  2	  trials,	  normally	  lasting	  4-­‐
6	  months	  (Petzold	  et	  al.,	  2010).	  Overall,	  the	  OCT	  holds	  great	  potential	  for	  monitoring	  
the	   treatment	  effect	   in	   trials	   testing	   the	  efficacy	  of	  neuroprotective	  agents	  and	   its	  
role	   in	   the	  MS	   research	   will	   receive	   increasing	   attention	   in	   future	   (Petzold	   et	   al.,	  
2010).	  	  
	  
1.6.3.3	  CSF	  markers	  	  	  
	  
Degenerating	  axons	  release	   in	  the	  extracellular	  space	  their	  protein	  contents,	  which	  
accumulate	   in	   the	   cerebrospinal	   fluid	   (CSF),	   where	   they	   can	   be	   detected.	  
Neurofilaments	   (NFs)	   are	   the	  major	   structural	   protein	   component	  of	   neurons,	   and	  
are	   particularly	   abundant	   in	   long	   projection	   axons	   (Gresle	   et	   al.,	   2011).	   Such	  
components,	   especially	   the	   subunits	   light	   (NFs-­‐L)	   and	   heavy	   (NFs-­‐H),	   can	   be	  
potentially	   used	   as	   biomarkers	   of	   the	   axonal	   degeneration,	   for	   monitoring	   the	  
disease	   progression	   and	   for	   assessing	   the	   efficacy	   of	   drugs	   with	   neuroprotective	  
effect.	  	  
	  
The	  utility	  of	  NFs-­‐L	  as	  marker	  of	  the	  disease	  activity	  was	  first	  suggested	  15	  years	  ago,	  
following	   a	   study	  demonstrating	   increase	  CSF	   levels	   among	  RR	  MS	  patients,	   and	  a	  
moderate	   correlation	   with	   the	   disability	   (Lycke	   et	   al.,	   1998).	   Since	   then,	   findings	  
were	  confirmed,	  both	  in	  RR	  and	  progressive	  MS	  (Haghighi	  et	  al.,	  2004;	  Kuhle	  et	  al.,	  
2011;	  Malmestrom	  et	  al.,	   2003;	   Semra	  et	  al.,	   2002),	  by	  a	   large	  number	  of	   studies.	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Some	   observed	   higher	   levels	   of	   NFs-­‐L	   during	   acute	   relapses,	   decreasing	   within	   3	  
months	  from	  the	  acute	  attack	  (Kuhle	  et	  al.,	  2011;	  Lycke	  et	  al.,	  1998;	  Malmestrom	  et	  
al.,	   2003).	   In	   addition,	   elevated	   CSF	   NFs-­‐L	   levels	   were	   found	   to	   correlate	   with	   a	  
significantly	  higher	  risk	  of	  experiencing	  a	  severe	  disease	  course	  and	  of	  converting	  to	  
SP	  MS,	  suggesting	  a	  potential	  role	  as	  prognostic	  markers	  (Norgren	  et	  al.,	  2004;	  Salzer	  
et	  al.,	  2010).	  Recently,	  NFs-­‐L	  levels	  were	  used	  for	  assessing	  the	  effect	  of	  Natalizumab	  
on	   the	   tissue	   damage.	   The	   analysis	   showed	   a	   three	   folds	   reduction	   of	   CFS	   NFs-­‐L	  
levels	  after	  treatment,	  highlighting	  a	  potential	  neuroprotective	  effect	  of	  Natalizumab	  
(Gunnarsson	  et	  al.,	  2011).	  NFs-­‐H	  levels	  are	  also	  considered	  a	  useful	  measure	  of	  the	  
neurodegenerative	   activity,	   because	   high	   levels	   were	   found	   to	   associate	   with	   a	  
progressive	  disease	  course	   (Petzold	  et	  al.,	   2005).	  Overall,	   the	  measurement	  of	  CSF	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1.7	  Disease	  modifying	  treatments	  
	  	  
With	  the	  approval	  of	   the	   first	  disease	  modifying	  treatment	   (DMT)	   in	  1993	  the	  new	  
treatment	  era	   in	  MS	  began,	  marking	  a	  milestone	   in	   the	  history	  of	   the	  disease.	  The	  
therapeutic	   management,	   which	   until	   then	   was	   only	   based	   on	   treating	   acute	  
exacerbations,	   dramatically	   changed.	   Currently	   there	   are	   5	   approved	   therapies	   for	  
MS:	  interferons	  beta,	  galtiramer	  acetate,	  mitoxantrone,	  natalizumab	  and	  fingolimod.	  
These	  agents	  have	  been	  shown	  to	  suppress	  the	  relapse	  frequency	  and	  to	  reduce	  the	  
inflammatory	   load	   detected	   by	   the	   MRI.	   However,	   their	   impact	   on	   the	   severe	  
disability	  accumulation	  in	  the	  long	  term	  remains	  largely	  unknown.	  	  
	  
1.7.1	  Interferon	  beta	  
	  
Interferon	   (IFN)	   beta,	   along	  with	   other	   subtypes,	   belongs	   to	   the	   type	   I	   IFN	   family	  
with	  immune-­‐modulatory	  and	  anti-­‐infectious	  effects	  (Gonzalez-­‐Navajas	  et	  al.,	  2012).	  
Its	  efficacy	   is	  exerted	  by	  contrasting	  many	  of	  the	  pathological	  processes	  underlying	  
the	  MS	  pathogenesis,	  reflecting	  different	  possible	  mechanisms	  of	  actions,	  still	  to	  be	  
clarified.	  IFN	  beta	  is	  believed	  to	  favour	  the	  Th2	  migration,	  to	  block	  the	  Th1	  migration	  
and	   to	   shift	   the	   balance	   pro/anti-­‐inflammatory	   cytokines	   towards	   the	   latter,	  
preventing	   the	   release	   of	   IL-­‐12,	   IL-­‐17,	   IL-­‐23	   as	   well	   as	   of	   IFN	   gamma	   and	   TNF	  
(Kieseier,	  2011).	   In	  addition,	   IFN	  beta	   increases	  the	  serum	  concentration	  of	  soluble	  
vascular	   cell	   adhesion	   molecule-­‐1	   (sVCAM).	   This	   increase	   probably	   inhibits	   the	  
leukocytes	   migration	   into	   the	   CNS	   by	   blocking	   their	   adhesion	   to	   the	   cerebral	  
endothelial	  surface	  (Prat	  et	  al.,	  2005).	  
	  
1.7.1.1	  Interferon	  beta	  in	  RR	  MS	  
	  
IFN	   beta-­‐1b	   was	   approved	   by	   the	   food	   and	   drug	   administration	   (FDA)	   in	   1993,	  
following	   the	  positive	   results	   from	  a	   large	   randomized,	   placebo	   controlled,	   double	  
blind	   trial,	   testing	   its	   efficacy	   in	   RRMS	   patients	   (1993;	   Paty	   and	   Li,	   1993).	   Among	  
patients	   treated	  with	   subcutaneous	   (SC)	   injections	  of	   IFN	  beta-­‐1b	  every	  other	  day,	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compared	   to	   placebo,	   there	   was	   statistically	   significant	   34%	   reduction	   of	   the	  
annualized	  relapse	  rate	   (ARR)	  and	  a	  significantly	   lower	  disease	  activity	  detected	  by	  
the	  MRI.	   In	  1996,	  weekly	   injections	  of	   intramuscular	  (IM)	  IFN	  beta-­‐1a	  received	  FDA	  
approval	   for	   treating	  RRMS	  patients.	  Decision	  was	   taken	   in	   view	  of	   a	   randomized,	  
placebo	   controlled,	   trial	   results,	   showing	   a	   significant	   ARR	   reduction	   (32%)	   among	  
treated	   patients,	   compared	   to	   placebo	   (Jacobs	   et	   al.,	   1996a).	   Finally,	   the	   PRISM	  
(prevention	   of	   relapses	   and	   disability	   by	   IFN	   beta-­‐1a	   subcutaneously	   in	  MS	   study	  
group),	  a	  randomized,	  placebo	  controlled	  trial,	  testing	  the	  efficacy	  of	  SC	  injections	  of	  
IFN	  beta-­‐1a	  (22	  µg	  and	  44	  µg)	  three	  times	  a	  week,	  demonstrated	  a	  27%	  and	  a	  33%	  
reduction	   of	   the	   ARR,	   among	   patients	   treated	   with	   22	   and	   44	   µg,	   respectively,	  
compared	   to	   placebo	   (1998a).	   In	   2002	   SC	   both	   doses	   of	   IFN	   beta-­‐1a	   received	  
approval	  from	  the	  FDA	  for	  the	  treatment	  of	  RRMS.	  	  
	  
Since	   then,	   IFN	   beta	   preparations	   have	   been	   successfully	   used	   for	   treating	   RRMS	  
worldwide.	  Although	  results	  of	  the	  pivotal	  trials	  indicated	  that	  the	  magnitude	  of	  the	  
therapeutic	  effect	   is	   similar,	   among	   the	   three	   formulations,	  methodological	   issues,	  
complicating	   the	   interpretation	   of	   results,	   do	   not	   allow	   to	   draw	   definitive	  
conclusions	   on	   which	   compound	   exerts	   the	   largest	   effect	   (McGraw	   and	   Lublin,	  
2012).	  However,	  it	  clearly	  emerged	  that	  the	  efficacy	  of	  the	  IFN	  is	  dose	  dependent.	  A	  
comparative	   study	   demonstrated	   that	   IFN	   beta-­‐1a	   SC	   44	   µg	   three	   times	   a	   week	  
associates	   with	   a	   90%	   increased	   probability	   (OR	   =	   1.9;	   p	   =	   0.0005)	   of	   remaining	  
relapse	  free,	  compared	  to	  IFN	  beta-­‐1a	  IM	  30	  µg	  once	  a	  week	  (Panitch	  et	  al.,	  2002).	  
Similarly,	  another	  study	  demonstrated	  superiority	  (larger	  proportion	  of	  patients	  free	  
from	  relapses)	  of	  the	  IFN	  beta-­‐1b	  250	  µg	  every	  other	  day	  on	  the	  IFN	  beta-­‐1a	  IM	  30	  
µg	  once	  a	  week	  (Durelli	  et	  al.,	  2002).	  
	  
1.7.1.2	  Interferon	  beta	  in	  CIS	  
	  
Following	  the	  IFNs	  pivotal	  trials,	  further	  study	  were	  undertaken	  in	  order	  to	  test	  their	  
effect	  early	  in	  the	  disease	  course,	  among	  patients	  with	  CIS.	  The	  CHAMPS	  (controlled	  
high	  risk	  subjects	  Avonex	  MS	  prevention	  study)	  evaluated	  the	  efficacy	  of	  weekly	  IM	  
injections	  of	  IFN	  beta-­‐1a	  in	  patients	  with	  a	  first,	  single	  demyelinating	  attack	  and	  MRI	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features	   suggesting	  MS.	   A	   significantly	   lower	   percentage	   (35%)	   of	   patients	   in	   the	  
treated	   group,	   compared	   to	   the	  placebo	  group	   (50%),	   developed	   clinically	   definite	  
MS	  (CDMS),	  defined	  by	  the	  occurrence	  of	  a	  new	  acute	  attack	   (Jacobs	  et	  al.,	  2000).	  
Similar	   results	   were	   obtained	   by	   the	   ETOMS	   (early	   treatment	   of	  MS	   study	   group)	  
study,	   demonstrating	   a	   9%	  difference	   in	   the	  proportion	  of	   patients	   experiencing	   a	  
second	   attack,	   between	   the	   group	   treated	   with	   SC	   IFN	   beta-­‐1a	   injections	   (three	  
times	   a	  week)	   and	   the	   placebo	   group	   (34%	   versus	   45%,	   respectively)	   (Comi	   et	   al.,	  
2001a).	   Finally,	   SC	   IFN	  beta-­‐1a	   every	   other	   day	  was	   also	   proven	   to	   be	   effective	   in	  
delaying	  the	  conversion	  to	  CDMS	  (28%	  versus	  45%	  experiencing	  a	  second	  attack	   in	  
the	   treated	   and	   placebo	   groups,	   respectively)	   in	   the	   BENEFIT	   (Betaferon	   in	   Newly	  
Emerging	  MS	  For	  Initial	  Treatment)	  study	  (Kappos	  et	  al.,	  2006b).	  
	  
Overall,	  results	  from	  CIS	  trials	  demonstrate	  a	  beneficial	  impact	  of	  IFNs	  beta	  early	  in	  
the	   disease	   course.	   However,	   large	   controversy	   still	   exists	   on	   whether	   patients	  
should	  start	  treatment	  at	  the	  time	  of	  diagnosis	  (Frohman	  et	  al.,	  2006a;	  Pittock	  et	  al.,	  
2006;	  Pittock,	  2007).	  Given	  that	  a	  considerable	  proportion	  might	  remain	  progression	  
free	   for	  decades	  without	   treatment	   (Skoog	  et	  al.,	  2012),	  and	  given	  the	  difficulty	  of	  
adhering	  to	  an	  injectable	  drug	  for	  a	  long	  time	  (Giovannoni	  et	  al.,	  2012),	  the	  potential	  
clinical	   benefit	   should	   be	   carefully	   evaluated.	   One	   of	   the	   main	   limitations	   of	  
CHAMPS,	  ETOMS	  and	  BENEFIT	  trials	   is	   the	   limited	  observation	  period	  (2	  years).	  No	  
clear	  evidence	  support	  the	  assumption	  that	  delaying	  the	  second	  attack	  by	  6	  months	  
prevents	  the	  long-­‐term	  disability	  accumulation	  (Pittock	  et	  al.,	  2006).	  More	  than	  half	  
of	  patients	  in	  the	  placebo	  groups	  of	  both	  CHAMPS	  and	  ETOMS	  studies	  did	  not	  have	  a	  
second	   attack	   during	   the	   observation	   period.	   In	   addition,	   even	   in	   the	   BENEFIT	  
extension	   study	   (5	   years),	   the	   effect	   of	   early	   versus	   delayed	   treatment	   on	   the	  
probability	   of	   converting	   to	   CDMS	   (46%	   versus	   57%)	   and	   on	   the	   disability	  
progression	  (25%	  versus	  29%)	  was	  clinically	  rather	  small;	  it	  was	  calculated	  that	  9	  and	  
25	   patients	   needed	   to	   be	   treated	   early,	   to	   avoid	   one	   additional	   patient	   to	   have	   a	  
second	   attack	   and	   to	   experience	   disease	   progression	   (increase	   of	   1	   EDSS	   score),	  
respectively	   (Kappos	   et	   al.,	   2009).	   Similarly,	   in	   the	   CHAMPS	   extension	   study	   the	  
effect	  of	  early	  initiation	  versus	  delayed	  treatment	  on	  the	  probability	  of	  converting	  to	  
CDMS	  remained	  small	  at	  10	  years	  (58%	  versus	  69%)	  (Kinkel	  et	  al.,	  2012).	  The	  limited	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impact	   of	   delayed	   conversion	   to	   CDMS	   on	   the	   long-­‐term	   disability	   accumulation	  
leaves	   the	   question	   whether	   patients	   should	   start	   treatment	   early	   in	   the	   disease	  
course	  still	  open	  (Pittock,	  2007;	  Pittock,	  2009).	  	  
	  
1.7.1.3	  Interferon	  beta	  in	  progressive	  MS	  
	  
In	   1998,	   for	   the	   first	   time,	   The	   European	   Study	   Group	   of	   IFN	   beta-­‐1b	   in	   SP	   MS	  
assessed	  the	  effect	  of	  SC	  IFN	  beta-­‐1b	  every	  other	  day	  in	  SPMS.	  Patients	  recruited	  in	  
the	  study	  had	  had	  6	  months	  of	  neurological	  deterioration,	  independent	  of	  relapses,	  
and	  a	  previous	  history	  of	  RR	  MS.	  Treatment	  efficacy	  was	  tested	  by	  using	  the	  time	  to	  
3	  months	  confirmed	  disability,	  defined	  as	  a	  sustained	  increase	  of	  1	  EDSS	  point	  (or	  0.5	  
point	  if	  baseline	  EDSS	  was	  6	  to	  6.5),	  as	  outcome	  measure.	  At	  the	  end	  of	  the	  3	  years	  
observation	   period,	   the	   study	   demonstrated	   a	   significantly	   smaller	   number	   of	  
treated	  patients	   (38.9%)	  experiencing	   sustained	  disability,	   as	   compared	   to	  placebo	  
(49.8%)	  (1998b).	  These	  results	  led	  to	  the	  approval	  of	  SC	  IFN	  beta-­‐1b	  every	  other	  day	  
for	  the	  treatment	  of	  SP	  MS.	  	  
	  
However,	  a	  subsequent	   trial	   in	  North	  America	   failed	  to	  replicate	  these	  results,	  and	  
demonstrated	  no	  significant	  effect	  exerted	  by	  SC	  IFN	  beta-­‐1b	  every	  other	  day	  in	  SP	  
patients.	   In	   this	   study,	   it	   was	   used	   a	   slightly	   different	   definition	   of	   disease	  
progression	  (time	  to	  6	  months	  sustained	  disability,	  defined	  as	  an	  increase	  of	  1	  EDSS	  
point,	   or	   0.5	   point	   if	   baseline	   EDSS	   was	   6	   to	   6.5)	   (Panitch	   et	   al.,	   2004).	   It	   was	  
concluded	  that	  the	  differences	  in	  outcome	  measures	  and	  the	  recruitment	  of	  patients	  
with	   earlier	   SPMS,	   and	   therefore	   more	   active	   disease,	   in	   the	   European	   study	  
(1998b),	  accounted	  for	  the	  different	  results	  observed	  in	  the	  two	  trials	  (Kappos	  et	  al.,	  
2004).	  	  
	  
In	  addition,	  another	   study	   (SPECTRIMS:	  The	  Secondary	  Progressive	  Efficacy	  Trial	  of	  
Recombinant	  Interferonbeta-­‐1a	  in	  MS)	  compared	  two	  different	  doses	  (22	  µg	  and	  44	  
µg)	  of	   SC	   IFN	  beta-­‐1a	   three	   times	   a	  week	   versus	  placebo,	   among	  patients	  with	   SP	  
MS.	  No	  significant	  differences	  were	  observed	  between	  groups,	  in	  the	  proportion	  of	  
patients	   experiencing	   a	   3	   months	   confirmed	   disability	   progression,	   defined	   as	   an	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increase	  of	  1	  EDSS	  point	  (or	  0.5	  point	  if	  baseline	  EDSS	  was	  6	  to	  6.5)	  (2001a).	  Similar	  
results	  were	  obtained	  in	  The	  Nordic	  SPMS	  group	  study,	  which	  showed	  no	  significant	  
impact	  of	  IFN	  beta-­‐1a	  SC	  22	  µg	  once	  a	  week	  on	  disease	  progression	  (6	  months	  time	  
of	  sustained	  disability)	  (Andersen	  et	  al.,	  2004).	  	  
	  
Finally,	   The	   International	   MS	   Secondary	   Progressive	   Avonex	   Controlled	   Trial	  
(IMPACT)	  assessed	  the	  effect	  of	  IM	  IFN	  beta-­‐1a	  in	  SPMS	  patients	  by	  using	  the	  MSFC	  
as	   primary	   outcome	  measure.	   Although	   in	   the	   treatment	   group	   there	  was	   a	   large	  
(40%)	  reduction	  in	  the	  MSFC	  worsening,	  the	  study	  failed	  to	  demonstrate	  significant	  
differences	  in	  the	  proportion	  of	  patients	  experiencing	  EDSS	  progression	  confirmed	  at	  
3	  months	   (Cohen	  et	   al.,	   2002).	   For	   this	   reason	   IM	   IFN	  beta-­‐1a	  never	   received	  FDA	  
approval	  for	  treating	  SPMS.	  
	  
Based	  on	  the	  results	  of	  the	  European	  study	  (1998b),	  IFN	  beta-­‐1b	  SC	  every	  other	  day	  
remains	   the	   only	   IFN	   approved	   for	   SPMS.	   Interestingly,	   a	   recent	   Cochrane	   review	  
pooled	   together	   data	   from	   the	   5	   trials,	   totalling	   3082	   SPMS	   patients	   treated	  with	  
IFNs	  or	  placebo;	   IFN	  beta-­‐1b	   (1998b;	  Panitch	  et	  al.,	  2004)	  and	   IFN	  beta-­‐1a	   (2001a;	  
Andersen	  et	  al.,	  2004;	  Cohen	  et	  al.,	  2002).	  The	  risk	  of	  6	  months	  sustained	  disability	  
accumulation	  was	  found	  to	  be	  not	  significantly	  different	  between	  the	  treatment	  and	  
the	   placebo	   group	   (65%	   and	   67%	   of	   patients	   experienced	   disease	   progression,	  
respectively).	  Same	  results	  were	  obtained	  when	  considering	  number	  of	  patients	  with	  
progression	   confirmed	   at	   3	   months.	   Overall,	   results	   showed	   that	   IFNs	   are	   not	  
effective	  in	  reducing	  the	  risk	  of	  disease	  progression	  in	  SPMS	  (La	  Mantia	  et	  al.,	  2012).	  	  
	  
1.7.1.4	  Interferon	  beta	  long-­‐term	  follow	  up	  studies	  
	  
The	   impact	   of	   IFN	   on	   the	   disability	   development	   in	   the	   long	   term	   remains	   largely	  
unclear.	  The	  validity	  of	  the	  findings	  from	  clinical	  trials,	   typically	   lasting	  2	  years,	  has	  
been	  questioned	  (Gout,	  2008;	  Koch	  et	  al.,	  2008).	  The	  debate	  has	  mainly	  focused	  on	  
trials	  methodological	  issues,	  including	  immortal	  time	  bias	  (Renoux	  and	  Suissa,	  2008;	  
Suissa,	  2008),	  selection	  bias	  (Dimick	  and	  Livingston,	  2010;	  Trojano	  et	  al.,	  2007),	  small	  
sample	   sizes	   (Coppola	   et	   al.,	   2006;	   Pozzilli	   et	   al.,	   2005),	   insufficient	   follow	   up	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(Coppola	  et	  al.,	  2006;	  Milanese	  et	  al.,	  2003)	  and	  outcome	  measures	  (Daumer	  et	  al.,	  
2009;	  Ebers	  et	  al.,	  2008;	  Ebers	  et	  al.,	  2011;	  Ebers	  et	  al.,	  2012).	  Long	  term	  follow	  up	  
(LTF)	   studies	   have	   recently	   gained	   increasing	   attention	   as	   potential	   tool	   for	  
addressing	   the	   controversial	   point	   of	   the	   effect	   of	   DMTs	   on	   the	   accumulation	   of	  
severe	  disability	  (Freedman,	  2011).	  	  
	  
The	   longest	   study	   so	   far	   published,	   reported	   results	   from	   the	   original	   cohort	   of	  
patients	  treated	  with	  SC	  IFN	  beta-­‐1b	  every	  other	  day	  (1993),	  which	  was	  followed	  up	  
for	  16	  years	   (Ebers	  et	  al.,	   2009)	  and	   subsequently	   for	  21	  years	   (Ebers	  et	  al.,	   2010;	  
Goodin	   et	   al.,	   2012).	   Although	   patients	   treated	   with	   IFN	   continued	   to	   show	   a	  
sustained	   reduction	   of	   the	   AAR	   and	   a	   slower	   disease	   progression,	   no	   statically	  
significant	  differences	  were	  observed	  between	  the	  treated	  and	  the	  untreated	  group	  
in	   the	   proportions	   reaching	   SP	   and	   EDSS	   6,	   after	   16	   years	   (Ebers	   et	   al.,	   2009).	  
However,	   the	   21	   years	   follow	   up	   study,	   with	   nearly	   complete	   ascertainment	   (366	  
patients	  identified	  from	  the	  original	  372),	  demonstrated	  a	  significant	  reduction	  of	  all	  
cause	  mortality,	  among	  those	  treated	  with	  IFN,	  compared	  to	  placebo	  (Goodin	  et	  al.,	  
2012).	  Nevertheless,	  the	  missing	  data	  between	  when	  patients	  were	  last	  observed	  in	  
the	   trial	   and	   their	   time	   to	   death	   represents	   a	   main	   limitation,	   especially	   for	  
characterizing	  the	  clinical	  course	  over	  time	  before	  demise.	  	  
	  
From	  the	  original	  cohort	  treated	  with	  IM	  IFN	  beta-­‐1a	  weekly	  (Jacobs	  et	  al.,	  1996a),	  
70%	  of	  patients	  were	   followed	  up	  for	  15	  years	   (Bermel	  et	  al.,	  2010).	  At	   the	  end	  of	  
the	   observation	  period,	   those	  who	  had	   chosen	   to	   continue	   staying	   on	   IM	   IFN	  had	  
lower	  EDSS	  score	  and	  experienced	  slower	  disease	  progression,	  as	  compared	  to	  those	  
who	  had	  switched	  to	  other	  drugs	  (Bermel	  et	  al.,	  2010).	  However,	  these	  results	  might	  
be	   biased	  by	   the	   better	   adherence	   to	   therapy	   and	  by	   the	   better	   disease	   outcome	  
among	  those	  who	  had	  remained	  on	  treatment.	  	  
	  
The	  original	   2	   years	   study,	   evaluating	   the	   efficacy	  of	   SC	   IFN	  beta-­‐1a	   three	   times	   a	  
week	   (1998a),	  was	   extended	   initially	   to	   4	   years	   (2001b)	   and	   eventually	   to	   6	   years	  
(Kappos	   et	   al.,	   2006c).	   The	   study	   confirmed	   a	   dose	   dependent	   effect,	   showing	   a	  
slower	  disease	  progression,	  among	  patients	  treated	  with	  44	  µg	  versus	  those	  treated	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with	  22	  µg.	   In	  addition,	  the	  early	  treatment	  associated	  with	  a	  delayed	  onset	  of	  the	  
progressive	   phase	   and	   a	   delayed	   attainment	   of	   EDSS	   6	   (Kappos	   et	   al.,	   2006c).	  
However,	   the	   frequency	   and	   the	   timing	   of	   assessments	   were	   not	   consistent	   over	  
time	   and	  many	  patients	   had	   a	   single	   examination	  during	   the	   follow	  up,	   increasing	  
the	   chance	   of	   false	   positive	   when	   assessing	   the	   disability	   progression	   (Freedman,	  
2011).	  	  
	  
A	   large	   study	   carried	   out	   by	   the	   British	   Columbia	   group	   evaluated	   the	   long	   term	  
clinical	  benefit	  of	  IFN	  therapy	  by	  comparing	  the	  disease	  evolution	  of	  treated	  patients	  
and	  two	  untreated	  natural	  history	  cohorts.	  The	  exposure	  to	  IFN	  beta	  was	  found	  not	  
to	  influence	  the	  risk	  of	  requiring	  walking	  assistance	  (EDSS	  6),	  and	  authors	  concluded	  
that	   the	   administration	   of	   IFN	   beta	   was	   not	   associated	   with	   a	   reduction	   of	   the	  
disability	  progression	  (Shirani	  et	  al.,	  2012).	  However,	  methodology	  of	  this	  study	  has	  
been	  largely	  criticized,	  leaving	  the	  debate	  still	  open	  (Derfuss	  and	  Kappos,	  2012).	  	  
	  
1.7.1.5	  Interferon	  beta	  safety	  
	  
The	  occurrence	  of	  adverse	  events	  represents	  an	  important	  factor,	  which	  affects	  the	  
adherence	  to	  the	  therapy,	  and	  it	  is	  the	  reason	  most	  commonly	  reported	  by	  patients	  
for	   discontinuing	   IFN.	   The	   rate	   of	   discontinuation	   largely	   varies	   among	   studies,	  
averaging	  from	  22%	  in	  SC	  IFN	  beta-­‐1a	  trials	  to	  30%	  and	  34%	  in	  IM	  IFN	  beta-­‐1a	  and	  SC	  
IFN	  beta-­‐1b	  trials,	  respectively	  (Giovannoni	  et	  al.,	  2012).	  	  
	  
Flu-­‐like	   syndrome	   (FLS)	   and	   injection	   site	   reaction	   (ISR)	   are	   the	   side	   effects	  more	  
frequently	  observed.	  In	  a	  large	  review,	  including	  151	  studies,	  it	  has	  been	  calculated	  
that	  FLS	  was	  reported	  in	  57%,	  40%	  and	  32%	  of	  patients	  receiving	  IM	  IFN	  beta-­‐1a,	  SC	  
IFN	   beta-­‐1a	   and	   SC	   IFN	   beta-­‐1b,	   respectively	   (Giovannoni	   et	   al.,	   2012).	   ISRs	   were	  
more	   frequently	  observed	  among	  patients	   treated	  with	  SC	   IFN	  beta-­‐1a	   (65%)	   than	  
patients	   treated	   with	   IM	   IFN	   beta-­‐1a	   (22%)	   and	   with	   SC	   IFN	   beta-­‐1b	   (33%)	  
(Giovannoni	   et	   al.,	   2012).	   The	   incidence	  of	   both	   FLS	   and	   ISR	   does	   not	   seem	   to	   be	  
affected	   by	   the	   treatment	   duration	   and	   does	   not	   diminish	   with	   the	   extended	  
administration	   of	   the	   drugs.	   Headaches,	   myalgia	   and	   fatigue	   are	   often	   reported,	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more	   frequently	   among	  patients	   receiving	   IM/SC	   IFN	  beta-­‐1a,	   than	  patients	   on	   SC	  
IFN	  beta-­‐1b	  (Giovannoni	  et	  al.,	  2012).	  
	  
1.7.2	  Glatiramer	  acetate	  
	  
Despite	   glatiramer	   acetate	   (GA)	   was	   first	   described	   more	   than	   40	   years	   ago	  
(Abramsky	  et	  al.,	  1977),	   its	  mechanisms	  of	  action	  remain	  poorly	  understood.	   It	  has	  
been	   hypothesized	   that	   GA	   exerts	   its	   therapeutic	   effect	   by	   promoting	   the	   T	   cells	  
shifting	   from	  pro-­‐inflammatory	   (Th1)	   to	   anti-­‐inflammatory	   state	   	   (Th2)	   (Blanchette	  
and	  Neuhaus,	  2008).	  In	  addition,	  GA	  may	  restore	  the	  function	  of	  Treg	  and	  therefore	  
increase	  the	  suppression	  of	  auto-­‐reactive	  lymphocytes	  (Hong	  et	  al.,	  2005).	  Beside	  its	  
anti-­‐inflammatory	  properties,	  GA	  may	  also	  have	  neuro-­‐protective	  effect.	   Indeed,	   in	  
animal	  model	  it	  was	  shown	  to	  stimulate	  the	  release	  of	  neurotrophic	  factors	  (Aharoni	  
et	  al.,	  2005).	  
	  
1.7.2.1	  Glatiramer	  acetate	  in	  RR	  MS	  
	  
GA	  was	  approved	  in	  1996	  for	  the	  treatment	  of	  RR	  MS	  following	  results	  of	  a	  2	  years,	  
double	   blind,	   placebo	   controlled	   trial.	   In	   the	   group	   treated	   with	   GA	   20	   mg	   SC	  
injections	  daily,	  compared	  to	  placebo,	  a	  significantly	  lower	  (29%)	  ARR	  was	  observed,	  
however,	  no	  effect	  on	  the	  disability	  progression	  was	  detected	  (Johnson	  et	  al.,	  1995).	  
Results	  were	  confirmed	  in	  the	  extension	  study,	  reporting	  32%	  reduction	  of	  the	  ARR	  
after	  2	  more	  years	  of	  observation	  (Johnson	  et	  al.,	  1998).	  To	  address	  the	  GA	  effect	  on	  
MRI	   parameters,	   a	   larger	   study	   assessing	   239	  RR	  MS	  patients	   over	   9	  months	  with	  
monthly	  MRIs	  was	  undertaken.	  Patients	  treated	  with	  GA	  had	  a	  significant	  reduction	  
(29%)	  of	  MRI	  gadolinium	  enhancing	  lesions	  (Comi	  et	  al.,	  2001b).	  	  
	  
GA	   was	   also	   shown	   to	   delay	   the	   time	   to	   the	   second	   attack	   and	   therefore	   the	  
conversion	   to	  CDMS,	   among	  patients	  with	  CIS	   (Comi	  et	   al.,	   2009).	  Although	   it	  was	  
originally	   planned	   to	   last	   for	   3	   years,	   given	   the	   clear	   efficacy	   demonstrated	   in	   the	  
group	  treated	  with	  GA	  (45%	  reduction	  of	  the	  risk	  of	  converting	  to	  CDMS,)	  the	  study	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was	  interrupted	  after	  2.3	  years,	  and	  patients	  in	  the	  placebo	  group	  were	  offered	  the	  
possibility	  of	  starting	  the	  active	  treatment.	  	  
	  
1.7.2.2	  Glatiramer	  acetate	  in	  progressive	  MS	  
	  
The	   efficacy	   of	   GA	   was	   tested	   among	   patients	   showing	   evidence	   of	   a	   chronic	  
progressive	  course	  over	  at	  least	  18	  months	  (Bornstein	  et	  al.,	  1991).	   	  No	  statistically	  
significant	  differences	  were	  observed	  between	  the	  treated	  and	  the	  placebo	  group	  in	  
the	   proportion	   of	   patients	   experiencing	   3	  months	   sustained	   increased	   disability	   (1	  
EDSS	  point,	  if	  baseline	  was	  5	  or	  greater,	  or	  1.5	  EDSS	  point,	  if	  baseline	  was	  less	  than	  
5)	   (Bornstein	   et	   al.,	   1991).	   In	   addition,	   GA	   was	   shown	   to	   exert	   no	   effect	   on	   the	  
disability	  progression	  among	  PPMS	  patients	  (Wolinsky	  et	  al.,	  2007).	  
	  
1.7.2.3	  Glatiramer	  acetate	  long-­‐term	  follow-­‐up	  studies	  
	  
The	   cohort	   recruited	   in	   the	  GA	   pivotal	   study	   (Johnson	   et	   al.,	   1995)	  was	   given	   the	  
opportunity	  to	  remain	  in	  an	  open	  label	  long	  term-­‐follow	  up	  study	  and	  was	  observed	  
for	  up	  to	  15	  years	  (Ford	  et	  al.,	  2010).	  The	  GA	  treated	  group	  appeared	  to	  maintain	  a	  
lower	  ARR	  and	  to	  experience	  a	  slower	  disease	  progression.	  However,	  131	  patients,	  
from	  the	  251	  included	  in	  the	  original	  study,	  had	  discontinued	  the	  treatment,	  most	  of	  
them	  because	  of	  “perception	  of	  disease	  worsening”,	  strongly	  biasing	  results.	  	  
	  
1.7.2.4	  IFN	  versus	  GA	  
	  
Trials	   comparing	   the	   efficacy	   of	   high	   dose	   IFN	   versus	   GA,	   showed	   no	   large	  
differences	   between	   the	   two	   products.	   The	   time	   to	   the	   first	   attack	   was	   similar	  
between	  the	  two	  groups	  treated	  with	  IFN	  beta-­‐1a	  SC	  44	  µg	  three	  times	  a	  week	  and	  
with	  GA	  SC	  20	  mg	  daily	  (Mikol	  et	  al.,	  2008).	  Similar	  efficacy	  of	  the	  two	  compounds	  
was	   also	   demonstrated	   with	   regards	   to	   MRI	   active	   lesions	   (Cadavid	   et	   al.,	   2009),	  
relapse	  free	  risk	  and	  changes	  in	  the	  EDSS	  score	  (O'Connor	  et	  al.,	  2009).	  Interestingly,	  
the	   combination	   of	   IFN	   beta-­‐1a	   IM	   30	  weekly	   and	  GA	   daily	  was	   shown	   not	   to	   be	  
superior	   to	  GA	  alone,	  but	   to	  provide	  a	   larger	   reduction	  of	   the	   risk	  of	  experiencing	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relapses	  than	  the	  IFN	  alone,	  possibly	  indicating	  a	  higher	  efficacy	  of	  GA	  (McGraw	  and	  
Lublin,	  2012).	  	  
	  
1.7.2.5	  Glatiramer	  acetate	  safety	  
	  
GA	  is	  probably	  better	  tolerated	  than	  IFNs,	  although	  the	  adherence	  remains	  similar,	  
as	   the	  average	   rate	  of	  discontinuation	  was	   reported	   to	  be	  36%	   (Giovannoni	   et	   al.,	  
2012).	  Patients	  on	  GA	  only	  rarely	  report	  FLS	  but	   in	   large	  percentage	  (61%)	  develop	  
ISR.	   In	  addition,	  a	  significantly	  higher	  proportion	  of	  patients,	  compared	  to	  placebo,	  
experience	  a	  short	  lasting,	  harmless,	  but	  rather	  frightening,	  sensation	  of	  flushing	  and	  




Natalizumab	  (NTZ)	  is	  a	  humanized	  monoclonal	  antibody	  antagonist	  to	  the	  α4-­‐subunit	  
of	   α4β1-­‐integrin,	   expressed	   on	   the	   surface	   of	   all	   leukocytes.	   By	   binding	   to	   α4-­‐
integrin,	  it	  inhibits	  the	  adhesion	  of	  leukocytes	  to	  vascular	  cells	  receptors,	  preventing	  
their	  migration	  across	  the	  BBB	  to	  the	  inflammatory	  sites,	  within	  the	  CNS.	  In	  addition,	  
it	  was	  shown	  to	  have	  a	  down	  regulating	  effect	  on	  activated	  lymphocytes	  (Khademi	  et	  
al.,	  2009;	  Rice	  et	  al.,	  2005).	  	  
	  
1.7.3.1	  Natalizumab	  efficacy	  	  
	  
The	   efficacy	   and	   the	   safety	   of	   NTZ	   in	   MS	   was	   tested	   in	   two	   2-­‐year	   studies,	   the	  
AFFIRM	   (Natalizumab	   Safety	   and	   Efficacy	   in	   RR	  MS)	   (Polman	   et	   al.,	   2006)	   and	   the	  
SENTINEL	  (Safety	  and	  Efficacy	  of	  Natalizumab	  in	  Combination	  with	   Interferon	  beta-­‐
1a	  in	  Patients	  with	  RR	  MS)	  (Rudick	  et	  al.,	  2006b).	  Results	  from	  the	  two	  trials	   led	  to	  
the	  approval	  of	  NTZ	  for	  treating	  active	  forms	  of	  RRMS	  (Kappos	  et	  al.,	  2011).	   In	  the	  
AFFIRM	   study	   patients	   received	   intravenous	   (IV)	   infusions	   of	   NTZ	   300	  mg	   every	   4	  
weeks,	   up	   to	   116	   weeks,	   and	   were	   compared	   to	   placebo.	   In	   the	   SENTINEL	   study	  
patients	   had	   received,	   for	   at	   least	   12	   months	   before	   randomization,	   weekly	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injections	  of	  IM	  IFN	  beta-­‐1a	  and	  were	  randomized	  to	  receive	  NTZ	  (300	  mg	  IV	  every	  4	  
weeks,	   up	   to	   116	   weeks)	   in	   addition	   to	   IFN	   or	   IFN	   alone.	   Both	   studies	   used	   the	  
relapse	  rate	  at	  1	  years	  and	  the	  3	  months	  sustained	  disability	  progression	  (increase	  of	  
1	  EDSS	  point,	   if	  baseline	  score	  ≥	  1,	  or	  of	  1.5	  EDSS	  point,	   if	  baseline	  score	  =	  0)	  over	  
two	   years,	   as	   primary	   clinical	   outcome	   measures.	   MRI	   measures	   (number	   of	   T2	  
lesions	   and	   number	   of	   gadolinium-­‐enhancing	   lesions)	   were	   used	   as	   secondary	  
endpoints.	  	  
	  
The	   relapse	   suppression	   exerted	  by	  NTZ	  was	  much	   greater	   than	  what	  observed	   in	  
patients	   treated	   with	   IFNs.	   In	   the	   AFFIRM	   study	   NTZ	   mono-­‐therapy	   significantly	  
decreased	  the	  ARR	  at	  1	  year	  by	  68%,	  compared	  with	  placebo	  (ARR	  0.26	  versus	  0.81),	  
maintaining	   similar	   effect	   at	   2	   years	   (ARR	   0.23	   versus	   0.73).	   In	   addition,	   the	  
proportion	   of	   patients	   free	   from	   attacks	   was	   significantly	   larger	   in	   the	   treatment	  
group	   (77%	   versus	   56%).	   The	   therapy	   with	   NTZ	   was	   also	   associated	   with	   a	   42%	  
reduction	   of	   the	   risk	   of	   disability	   progression	   sustained	   for	   3	  months;	   17%	   versus	  
29%	   of	   the	   treatment	   and	   the	   placebo	   group,	   respectively,	   experienced	   disease	  
progression.	  A	  post-­‐hoc	  analysis	  showed	  a	  significant	  reduction	  (64%)	  of	  the	  risk	  of	  6	  
months	  sustained	  progression,	  among	  treated	  patients	  with	  highly	  active	  RRMS	  (≥	  2	  
attacks	   1	   year	   before	   study	   entry	   and	   ≥	   1	   gadolinium-­‐enhancing	   lesion	   at	   MRI)	  
(Hutchinson	  et	  al.,	  2009).	  NTZ	  also	  exerted	  a	  large	  (83%)	  suppression	  of	  MRI	  lesions	  
(new	   T2	   lesions	   at	   2	   years:	   treatment	   group	   =	   1.9	   versus	   placebo	   group	   =	   11.0)	  
(Polman	  et	  al.,	  2006).	  	  
	  
The	   SENTINEL	   study	   showed	   similar	   results.	   Patients	   treated	   with	   NTZ	   +	   IM	   IFN,	  
compared	  with	  those	  treated	  with	  IM	  IFN	  alone,	  had	  54%	  and	  55%	  reduction	  of	  the	  
ARR	  at	  1	  and	  2	  years,	  respectively.	  NTZ	  +	  IM	  IFN	  also	  reduced	  the	  risk	  of	  3	  months	  
sustained	   disability	   progression	   by	   24%	  however,	   no	   differences	   between	   the	   two	  
groups	   were	   observed	   in	   the	   risk	   of	   6	   months	   sustained	   disability.	   In	   addition,	  
patient	  receiving	  NTZ	  had	  significantly	  lower	  number	  of	  T2	  MRI	  lesions,	  which	  were	  
reduced	  by	  83%	  over	  2	  years	  (Rudick	  et	  al.,	  2006b).	  Similarly	  to	  what	  observed	  in	  the	  
AFFIRM	   study,	   a	   post-­‐hoc	   analysis	   in	   treated	   patients	   with	   highly	   active	   disease,	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showed	  a	  58%	  reduced	  risk	  of	  6	  months	  sustained	  disability	  progression	  (Hutchinson	  
et	  al.,	  2009).	  	  
	  
1.7.3.2	  Natalizumab	  safety	  	  	  
	  
Overall,	  NTZ	  was	  well	   tolerated	   in	   both	   studies.	   Infusion	   reactions	   (within	   2	   hours	  
from	   the	   infusion)	   were	   reported	   in	   24%	   of	   treated	   patients.	   The	   most	   common	  
complaints	  were	   headache	   and	   hypersensitivity	   reactions	   (allergic	   or	   anaphylactic)	  
(Polman	  et	  al.,	  2006;	  Rudick	  et	  al.,	  2006b).	  Adverse	  events	  were	  generally	  mild	  and	  
included	  headache,	  fatigue,	  and	  urinary	  tract	  infections.	  	  
	  
In	  February	  2005,	  the	  clinical	  trials	  were	  temporarily	  suspended,	  following	  reports	  of	  
3	  cases	  of	  progressive	  multifocal	  leukoenchephalopathy	  (PML)	  in	  2	  MS	  patients	  from	  
the	   SENTINEL	   study	   (Kleinschmidt-­‐DeMasters	   and	   Tyler,	   2005;	   Langer-­‐Gould	   et	   al.,	  
2005)	  and	  in	  1	  patient	  affected	  by	  Crohn’s	  disease	  (Van	  Assche	  et	  al.,	  2005),	  treated	  
with	  NTZ.	  PML	  is	  a	  serious,	  and	  potentially	  fatal,	  demyelinating	  disease	  of	  the	  CNS,	  
normally	   occurring	   among	   immune-­‐compromised	   patients,	   which	   is	   caused	   by	  
reactivation	   of	   the	   latent	   JC	   virus	   (Major	   et	   al.,	   1992).	   Following	   the	   temporary	  
withdrawal,	   an	   extensive	   safety	   report	   showed	   no	   additional	   PML	   cases,	   among	  
3116	  patients	  treated	  with	  NTZ	  (Yousry	  et	  al.,	  2006),	  leading	  to	  the	  reintroduction	  of	  
the	  drug	  in	  the	  market	  in	  2006.	  Since	  then,	  as	  of	  June	  2011,	  133	  new	  cases	  of	  PML	  
(24	   [18%]	  deaths)	  have	  been	  reported,	  among	  MS	  patients,	  who	  had	  received	  NTZ	  
mono-­‐therapy	   for	   more	   than	   1	   year,	   with	   a	   2	   mean	   years	   exposure	   to	   the	   drug.	  
Accordingly,	   the	   estimated	   risk	   of	   PML	   is	   1.51/1000	   patients.	   This	   appears	   to	   be	  
higher	   among	   those	   who	   had	   previous	   immunosuppression.	   PML	   incidence	   was	  
reported	  to	  be	   low	  in	  the	  first	  12	  months	  of	  treatment	  and	  to	  reach	   its	  peak	  at	  36	  
months	  (Kappos	  et	  al.,	  2011).	  
	  
NTZ	  is	  currently	  recommended	  for	  patients	  with	  RRMS,	  responding	  poorly	  to,	  or	  not	  
tolerating,	  an	  alternative	  MS	  treatment.	  However,	  its	  use	  is	  also	  allowed	  as	  first	  line	  
treatment	   in	  US	   (Kappos	  et	  al.,	  2011).	   In	   the	  UK,	  according	   to	   the	  NICE	  guidelines,	  
NTZ	  can	  be	  administered	  as	  first	  line	  therapy	  to	  patients	  with	  rapidly	  evolving	  severe	  
	   104	  
RR	  MS,	  defined	  as	   two	  or	  more	  disabling	   relapses	   in	  1	  year,	  and	  one	  or	  more	  MRI	  
GAD-­‐enhancing	  lesions	  or	  a	  significant	  increase	  in	  the	  T2	  lesions	  load,	  compared	  with	  




Fingolimod,	  also	  known	  as	  FTY720,	  is	  the	  first	  oral	  drug	  approved	  by	  the	  FDA	  in	  2010	  
as	  first	  line	  treatment	  for	  RRMS,	  and	  by	  the	  European	  Medical	  Agency	  (EMA)	  in	  2011	  
as	  second	  line	  therapy	  for	  patients	  with	  high	  disease	  activity,	  not	  responding	  to	  IFN	  
treatments.	   It	   is	   structurally	   similar	   to	   sphingosine-­‐1-­‐phosphate	   (S1P)	   receptors,	  
which	   are	   present	   on	   the	   surface	   of	   lymphocytes	   and,	   because	   of	   its	   lipophilic	  
structure,	   it	   can	   easily	   enter	   the	   CNS.	   By	   binding	   to	   S1P	   receptors,	   Fingolimod	  
prevents	   the	   migration	   of	   T	   and	   B	   cells	   from	   the	   lymph	   nodes	   to	   the	   circulation	  
(Conway	   and	   Cohen,	   2010).	   This	   ultimately	   results	   in	   a	   dramatic	   reduction	   (more	  
than	  90%)	  of	  circulating	  lymphocytes,	  including	  IL-­‐17	  producing	  T	  cells,	  known	  to	  be	  
key	   players	   in	   the	   inflammatory	  mechanisms	   underlying	   the	   disease	   pathogenesis	  
(Mehling	  et	  al.,	  2010).	  
	  
1.7.4.1	  Fingolimod	  efficacy	  	  
	  
The	  initial	  trial	  assessing	  the	  efficacy	  of	  Fingolimod	  was	  a	  phase	  2,	  6	  months	  study,	  in	  
281	  patients,	  which	  were	  randomized	  to	  1.25	  mg,	  5	  mg,	  or	  placebo	   (Kappos	  et	  al.,	  
2006a).	   The	   primary	   outcome	  measure	  was	   the	   cumulative	   number	   of	   gadolinium	  
enhancing	  lesions	  and	  the	  new	  T2	  lesions,	  which	  were	  both	  shown	  to	  be	  significantly	  
reduced	  in	  the	  treatment	  group	  versus	  placebo	  (Kappos	  et	  al.,	  2006a).	  	  
	  
The	  FREEDOMS	  (FTY720	  Research	  Evaluating	  Effects	  of	  Daily	  Oral	  Therapy	  in	  MS)	  was	  
the	   first	   phase	   3,	   double	   blind,	   randomized,	   placebo-­‐controlled	   trial	   assessing	   the	  
effect	  of	  Fingolimod	  in	  RRMS:	  1272	  patients	  were	  randomized	  to	  receive	  Fingolimod	  
1.25	  mg	  or	  0.5	  mg	  daily	  for	  2	  years	  (Kappos	  et	  al.,	  2010).	  The	  ARR	  was	  significantly	  
reduced	  by	  60%	  in	  the	  1.25	  mg	  group	  and	  by	  54%	  in	  the	  0.5	  mg	  group,	  compared	  to	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placebo	   (ARR	   =	   0.16,	   0.18	   and	   0.40	   respectively).	   A	   beneficial	   effect	   was	   also	  
observed	  in	  the	  time	  to	  3	  months	  sustained	  disability	  accumulation	  (1	  EDSS	  point	  or	  
0.5,	   if	   the	  EDSS	  baseline	  was	  5.5).	  The	  percentage	  of	  patients	  experiencing	  disease	  
progression	  was	  significantly	  lower	  in	  the	  high	  (16.6%)	  and	  low	  (17.7%)	  dose	  groups,	  
compared	   to	   placebo	   (24.1%).	   Finally,	   the	   number	   of	   new	   T2	   MRI	   lesions	   was	  
significantly	   reduced	   among	   treated	   patients,	   and	   almost	   90%	   were	   free	   of	  
gadolinium	  enhancing	  lesions	  at	  the	  end	  of	  the	  24	  months	  follow	  up.	  	  
	  
The	   TRANSFORMS	   	   (Trial	   Assessing	   Injectable	   Interferon	   Versus	   FTY720	  Oral	   in	   RR	  
MS)	  study	  compared	  the	  two	  Fingolimod	  doses	  (1.25	  mg	  and	  0.5	  mg)	  to	  IM	  IFN	  beta-­‐
1a,	  over	  12	  months	  (Cohen	  et	  al.,	  2010).	  The	  AAR	  was	  significantly	  lower	  in	  the	  two	  
Fingolimod	  doses	  groups	  (1.25	  mg	  =	  0.20,	  0.5	  mg	  =	  0.26),	  compared	  to	  the	  IFN	  group	  
(0.33);	   this	   resulted	   in	   a	   52%	   and	   38%	   AAR	   reduction,	   respectively.	   However,	   the	  
time	  to	  sustained	  disability	  was	  not	  significantly	  different	   in	  the	  3	  groups.	   In	  the	  1-­‐
year	  extension	  study,	  totalling	  24	  months	  of	  follow	  up,	  the	  larger	  effect	  on	  the	  AAR	  
exerted	  by	  Fingolimod	  was	  confirmed	  (Khatri	  et	  al.,	  2011).	  
	  
1.7.4.2	  Fingolimod	  safety	  
	  
The	   safety	   of	   Fingolimod	   in	   the	   long	   term	   remains	   unclear	   due	   to	   limited	   data	  
available.	   During	   the	   TRANSFORM	   trial	   two	   deaths	  were	   reported	   among	   patients	  
treated	  with	  high	  dose;	  one	  for	  herpes	  zoster	   infection	  and	  one	  for	  herpes	  simplex	  
encephalitis.	   The	   role	   of	   Fingolimod	   in	   the	   two	   deaths	   remains	   unclear	   however,	  
given	   its	  mechanism	  of	  action,	   it	   is	  plausible	   to	  suspect	  a	   link	   (Pelletier	  and	  Hafler,	  
2012).	  	  
	  
The	   most	   commonly	   reported	   adverse	   effects	   were	   cardiovascular	   events	  
(bradycardia	   and	   1st	   degree	   atrio-­‐ventricular	   block),	   which	   occurred	   in	   1-­‐3	   %	   of	  
patients.	   Most	   of	   these	   events	   are	   normally	   observed	   during	   the	   first	   dose	   and	  
resolved	   within	   the	   first	   24	   hours.	   In	   addition,	   less	   than	   1%	   developed	   macular	  
oedema.	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1.7.5	  Mitoxantrone	  
	  
Mitoxantrone	   is	   an	   antineoplastic	   agent	   currently	   approved	   for	   the	   treatment	   of	  
acute	  myeloid	   leukaemia	  and	  of	  hormone-­‐refractory	  prostate	  cancer	   (Shenkenberg	  
and	   Von	   Hoff,	   1986).	   The	   rationale	   for	   its	   use	   in	   MS	   is	   based	   on	   its	  
immunosuppressive	  effect,	  leading	  to	  the	  inhibition	  of	  T	  and	  B	  cell	  and	  macrophage	  
proliferation	  (Chan	  et	  al.,	  2005;	  Lublin	  et	  al.,	  1987).	  	  
	  
1.7.5.1	  Mitoxantrone	  efficacy	  
	  
The	  drug	  was	  approved	  for	  treating	  aggressive	  RRMS	  and	  SPMS	  by	  the	  FDA	  in	  2000,	  
following	  results	  from	  a	  phase	  III	  double	  blind,	  placebo-­‐controlled	  multicentre	  study	  
(MIMS)	  (Hartung	  et	  al.,	  2002).	  	  A	  total	  of	  124	  patients,	  with	  a	  1	  EDSS	  point	  worsening	  
over	  the	  previous	  18	  months,	  received	  Mitoxantrone	  at	  low	  (5	  mg/m2)	  and	  high	  (12	  
mg/m2)	  doses,	  every	  3	  months	  for	  2	  years,	  and	  were	  compared	  to	  patients	  treated	  
with	  placebo.	  In	  the	  high	  dose	  group	  there	  was	  a	  significant	  reduction	  of	  the	  disease	  
progression,	   measured	   using	   a	   composite	   score,	   which	   included	   the	   EDSS	  
assessment,	  the	  ambulatory	   index,	  the	  number	  of	  treated	  relapses	  and	  the	  time	  to	  
first	   relapse.	   Furthermore,	   among	   patients	   treated	   with	   12	   mg/m2,	   compared	   to	  
placebo,	   a	   lower	   percentage	   (8%	   versus	   25%;	   p	   =	   0.013)	   had	   a	   one	   point	   EDSS	  
worsening	  and	   their	   annualized	   relapse	   rate	  was	  66%	   lower	   (0.35	  versus	  1.02;	  p	  =	  
0.001).	  Nevertheless,	  because	  of	  the	  lack	  of	  blinding	  amongst	  the	  physicians	  carrying	  
out	   the	   clinical	   assessments,	   information	   on	   the	   primary	   and	   secondary	   outcomes	  
was	   rated	   as	   only	   Class	   III	   evidence	   of	   efficacy	   by	   the	   Therapeutic	   Technology	  
Assessment	   (TTA)	   Subcommittee	   of	   the	   American	   Academy	   of	   Neurology	   (AAN)	  
(Goodin	   et	   al.,	   2003;	   Marriott	   et	   al.,	   2010).	   In	   addition,	   the	   strength	   of	   evidence	  
supporting	   its	  beneficial	  effect	   in	  SPMS	  was	  considered	  very	  weak,	  questioning	  the	  
validity	  of	   the	  rationale	  use	  of	  Mitoxantrone	   in	  progressive	  patients	   (Goodin	  et	  al.,	  
2003).	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Following	   its	  approval	  by	  the	  FDA,	  Mitoxantrone	  was	  tested	   in	  specific	  sub-­‐cohorts	  
of	  patients	  with	  aggressive	  disease	  course.	  A	  large	  open	  study,	  involving	  100	  patients	  
with	   aggressive	   RRMS	   (3	   mean	   relapses	   and	   one	   point	   worsening	   at	   EDSS	   in	   the	  
previous	  12	  months)	   from	  the	  Rennes	  EDMUS	  database	  (Confavreux	  et	  al.,	  1992b),	  
tested	   the	   effect	   of	   monthly	   doses	   of	   Mitoxantrone	   (20	   mg	   +	   1	   g	   of	  
methylprednisolone)	   for	   six	   months	   (Le	   Page	   et	   al.,	   2008).	   At	   12	   months	   it	   was	  
observed	  a	  marked	  reduction	  of	  the	  relapse	  rate	  (91%)	  and	  of	  the	  MRI	  activity	  (78%).	  
In	  addition,	  78%	  of	  patients	  had	  been	  free	  of	  attacks	  and	  64%	  of	  cases	  had	  had	  an	  
improvement	  of	  1	  point	  or	  more	  on	  the	  EDSS.	  More	   importantly,	  the	  effect	  on	  the	  
relapse	  rate	  and	  on	  the	  disability	  accumulation	  was	  prolonged	  up	  to	  5	  years	  from	  the	  
start	  of	  the	  study	  (Le	  Page	  et	  al.,	  2008).	  
	  
1.7.5.2	  Mitoxantrone	  safety	  	  	  
	  
Unfortunately,	   the	   use	   of	   Mitoxantrone	   is	   limited	   by	   its	   cardiac	   toxicity,	   causing	  
cardiomyopathy	  (De	  Castro	  et	  al.,	  1995;	  Strotmann	  et	  al.,	  2002).	  Because	  of	  this,	  it	  is	  
recommended	  a	  cumulative	  dose	  of	  not	  more	  than	  140	  mg/m2.	  This	  implies	  that	  the	  
therapy,	  at	   the	   standard	  dose	  of	  12	  mg/m2	  every	  3	  months,	   should	   last	  no	   longer	  
than	   2-­‐3	   years	   (Marriott	   et	   al.,	   2010).	   In	   addition,	   the	   potential	   risk	   of	   late	  
malignancy	   should	   be	   considered.	   An	   increasing	   number	   of	   studies	   have	  
documented	  cases	  of	  treatment	  related	  acute	  leukaemia	  (TRAL)	  and	  it	  was	  reported	  
that	  at	   least	  29%	  of	  MS	  patients	  who	  developed	  TRAL	  died	   (Marriott	  et	  al.,	  2010).	  
The	   overall	   incidence	   of	   TRAL	   is	   now	   estimated	   as	   0.8%	  of	   treated	   cases,	   and	   the	  
number	   needed	   to	   harm	   (NNH)	   as	   123	   patients	   (Marriott	   et	   al.,	   2010).	   Given	   the	  
potential	   serious	   adverse	   effects,	   the	   Therapeutics	   and	   Technology	   Assessment	  
Subcommittee	  of	   the	  American	  Academy	  of	  Neurology	  has	   recommended	   that	   the	  
use	  Mitoxantrone	  should	  not	  be	  preferred	  to	  other	   immunomodulatory	  drugs,	  and	  
should	   be	   limited	   to	   those	   patients	   with	   a	   rapidly	   advancing	   disease	   course,	   who	  
have	  failed	  other	  therapies	  (Marriott	  et	  al.,	  2010).	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1.7.6	  Teriflunomide	  	  
	  
Leflunomide,	   the	   prodrug	   of	   teriflunomide,	   is	   approved	   for	   the	   treatment	   of	  
rheumatoid	   arthritis	   (Schattenkirchner,	   2000).	   It	   is	   an	   oral	   drug	   that	   is	   rapidly	  
converted	  into	  its	  active	  metabolite	  (teriflunomide)	  in	  the	  intestinal	  mucosa	  (Fox	  et	  
al.,	  1999).	  The	  actions	  of	  teriflunomide	  are	  wide:	  it	  inhibits	  the	  migratory	  capacity	  of	  
T	   cells,	   it	   prevents	   the	   switch	   of	   B	   cells	   to	   IgG1	   (Korn	   et	   al.,	   2004)	   and	   it	   targets	  
neutrophils	  and	  macrophages	  by	  modulating	  their	  cytokines	  secretion	  (Claussen	  and	  
Korn,	  2012).	  	  	  
	  
The	   first	  phase	   II	   trial	   testing	   the	  efficacy	  and	  safety	  of	  oral	   teriflunomide	   involved	  
179	  relapsing	  onset	  MS	  patients	  (157	  RR	  and	  22	  SP).	  Two	  doses	  (7	  mg	  and	  14	  mg	  per	  
day)	  were	  tested	  against	  placebo,	  and	  were	  shown	  to	  reduce	  by	  more	  than	  61%	  the	  
MRI	  activity	  (O'Connor	  et	  al.,	  2006).	   In	  addition,	  Teriflunomide	  in	  combination	  with	  
IFN-­‐beta	  was	  associated	  with	  a	  significant	   reduction	  of	   the	  GAD	  enhancing	   lesions,	  
compared	   to	   the	   IFN	   alone	   (Freedman	   et	   al.,	   2012).	   The	   Teriflunomide	   MS	   Oral	  
(TEMSO)	   trial	   was	   a	   large	   phase	   III	   study,	   involving	   1088	   relapsing	   MS	   patients,	  
treated	  with	  the	  two	  doses.	  Compared	  to	  placebo,	  the	  ARR	  was	  significantly	  reduced	  
in	   both	   treated	   arms	   (31%	   relative	   risk	   reduction),	   and	   the	   risk	   of	   sustained	  
progression	  was	  significantly	  reduced	  by	  30%	  in	  the	  14	  mg	  group	  only	  (O'Connor	  et	  
al.,	  2011).	  The	  trial	  also	  confirmed	  the	  positive	  effect	  on	  the	  formation	  of	  new	  GAD	  
enhancing	  lesions	  (O'Connor	  et	  al.,	  2011),	  detected	  in	  the	  previous	  study	  (O'Connor	  
et	  al.,	  2006).	  	  
	  
A	   separate	   phase	   III	   trial	   (TOWER:	   Teriflunomide	   Oral	   in	   People	   With	   RR	   MS)	  
involved	  1169,	  randomized	  for	  receiving	  the	  two	  doses	  of	  teriflunomide	  or	  placebo.	  
The	  group	  receiving	  14	  mg	  teriflunomide	  had	  a	  36.3%	  (p	  <	  0.001)	  reduction	   in	  ARR	  
and	  31.5%	  (p	  =	  0.044)	   reduction	   in	   the	  risk	  of	  12	  weeks	  sustained	  accumulation	  of	  
disability	  compared	  to	  placebo	  (results	  presented	  at	  ECTRIMS	  2012).	  	  
	  
Data	   on	   safety	   are	   rather	   extensive,	   as	   leflunomide	   has	   been	   licensed	   for	  
rheumatoid	   arthritis.	   Common	   adverse	   event	   are	   predominantly	   gastrointestinal,	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skin	   rashes	   and	   hypertension	   (Schattenkirchner,	   2000).	   Serious	   adverse	   event	  
included	   elevated	   liver	   enzymes	   and	   neutropenia	   (Mladenovic	   et	   al.,	   1995).	  
Teriflunomide	   (14	   mg)	   was	   approved	   for	   the	   treatment	   of	   MS	   by	   the	   FDA	   in	  
September	  2012.	  	  
	  
1.7.7	  BG-­‐12	  	  
	  
BG-­‐12	  is	  a	  oral	  dimethyl	  fumaric	  acid	  (DMF)	  ester	  (FAE)	  compound	  already	  licensed	  
as	   second	   line	   therapy	   for	   psoriasis	   (Mrowietz	   et	   al.,	   1999).	   	   It	   has	   been	   recently	  
(March	  2013)	  approved	  by	  the	  FDA	  for	  its	  use	  in	  MS.	  Its	  exact	  mechanism	  of	  action	  is	  
poorly	   understood.	   Experimental	   studies	   have	   suggested	   anti-­‐inflammatory	   effects	  
on	  the	  immune	  system:	  increase	  production	  of	  anti-­‐inflmmatory	  cytokines	  IL-­‐10	  and	  
IL-­‐1	  (Asadullah	  et	  al.,	  1997)	  and	  reduction	  of	  TNF	  production	  (Lee	  et	  al.,	  2008).	  	  
	  
Its	  efficacy	   in	  MS	  was	  assessed	   in	  a	  24	  week	  phase	   II	   trial,	   randomizing	  257	  RR	  MS	  
patients	   into	  4	  groups:	  BG-­‐12	  120	  mg	  daily,	  BG-­‐12	  120	  mg	   three	   times	  daily	   (total	  
dose	  360	  mg),	  BG-­‐12	  240	  mg	  three	  times	  daily	  (total	  dose	  720	  mg)	  or	  placebo.	  The	  
treatment	  with	   the	  higher	  dose	   (720	  mg)	  associated	  with	  a	  70%	   reduction	  of	  GAD	  
enhancing	  lesions,	  but	  no	  differences	  were	  found	  in	  the	  other	  two	  treatment	  groups	  
(Kappos	   et	   al.,	   2008;	   Kappos	   et	   al.,	   2012).	   Subsequently,	   two	   phase-­‐III	   trials	  were	  
carried	  out.	  The	  DEFINE	  (Determination	  of	  the	  Efficacy	  and	  Safety	  of	  Oral	  Fumarate	  
in	  RR	  MS)	   involved	  1237	  RR	  MS	  patients,	   randomized	  for	  receiving	  240	  mg	  twice	  a	  
day,	   240	   mg	   three	   times	   a	   day	   or	   placebo	   (Gold	   et	   al.,	   2012).	   Both	   doses	   were	  
superior	   to	   placebo	   in	   reducing	   the	   ARR	   (53%	   and	   48%	   for	   the	   lower	   and	   higher	  
dose,	   respectively)	   and	   in	   reducing	   the	   number	   of	   GAD	   enhancing	   lesions.	   In	  
addition,	  BG-­‐12	   reduced	   the	  disability	  progression	  at	  12	  weeks,	  by	  38%	   (low	  dose)	  
and	  by	  34%	  (high	  dose).	  In	  the	  second	  phase-­‐III	  trial,	  CONFIRM	  (Comparator	  and	  an	  
Oral	  Fumarate	  in	  RR	  MS),	  1430	  RR	  MS	  patients	  were	  randomized	  for	  receiving	  BG-­‐12	  
(480	  mg	  daily	  or	  720	  mg	  daily),	  GA	  or	  placebo	  (Fox	  et	  al.,	  2012).	  In	  both	  BG-­‐12	  doses	  
arms	  there	  was	  a	  significant	  reduction	  of	  the	  ARR	  (51%	  and	  41%,	  respectively)	  and	  of	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the	  number	  of	  new	  T2	  lesions	  (73%	  and	  71%,	  respectively),	  compared	  to	  GA	  (Fox	  et	  
al.,	  2012).	  	  
	  
Adverse	   events	   more	   frequently	   occurring	   in	   BG-­‐12	   treated	   patients	   were	  
gastrointestinal	   symptoms	   and	   flushing	   (typically	   within	   30	   minutes	   from	   the	  
administration).	  	  
	  
1.7.8	  Treatments	  in	  advance	  clinical	  development	  	  	  
	  
1.7.8.1	  Alemtuzumab	  	  
	  
Alemtuzumab	  is	  a	  monoclonal	  antibody	  targeting	  the	  CD52	  antigen	  on	  the	  surface	  of	  
more	   than	   95%	   of	   T	   and	   B	   cells,	   monocytes	   and	   macrophages,	   and	   causing	  
leukopenia	   (Flynn	   and	   Byrd,	   2000).	   In	   US	   and	   Europe	   is	   approved	   as	   first	   line	  
treatment	  for	  B	  cell	  lymphoma.	  	  
	  
Its	  therapeutic	  effect	  in	  MS	  has	  been	  tested	  in	  several	  trials.	  In	  an	  open	  label	  study,	  
25	  SPMS	  patients	  received	  a	  single	  dose	  of	  Alemtuzumab	  and	  were	  followed	  up	  for	  
18	   months.	   Although	   there	   was	   a	   significant	   decrease	   of	   relapses	   rate	   and	  
inflammatory	   activity	   detected	   by	   the	  MRI,	   most	   of	   patients	   experienced	   disease	  
progression	  and	  an	  increase	   in	  brain	  atrophy	  (Paolillo	  et	  al.,	  1999).	  However,	  when	  
tested	   in	   active	  RRMS	   (high	   relapse	   rate),	   along	  with	   a	   strong	   relapse	   suppression	  
(90%),	   patients	   also	   experienced	   disability	   improvement,	   suggesting	   different	  
mechanisms	  driving	  disease	  evolution	  before	  and	  after	  the	  onset	  of	  the	  progressive	  
phase	   (Coles	   et	   al.,	   1999).	   Recently,	   a	   phase	   II	   trial	   (CAMMS223)	   compared	   the	  
efficacy	  of	  Alemtuzumab	  (annual	  infusions	  12	  mg	  or	  24	  mg)	  versus	  SC	  IFN	  beta-­‐1a	  in	  
patients	  with	  early	  RRMS	  (disease	  duration	  <	  3	  years),	  followed	  up	  for	  36	  months.	  It	  
was	   observed	   a	   significant	   reduction	   of	   ARR	   (74%)	   and	   of	   sustained	   disability	  
accumulation	  (71%),	  compared	  to	  IFN.	  In	  addition,	  the	  EDSS	  score	  improved	  by	  0.39	  
points	   in	   Alemtuzumab	   treated	   patients,	   whereas	   worsened	   by	   0.38	   points	   in	  
patients	  treated	  with	  IFN	  (Coles	  et	  al.,	  2008).	  These	  finding	  were	  partially	  confirmed	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by	  the	  2	  subsequent	  phase	  III	  trials.	  Comparison	  of	  Alemtuzumab	  with	  SC	  IFN	  beta-­‐
1a	   	   (CARE-­‐MS1)	   did	   not	   shown	   any	   significant	   difference	   in	   the	   progression	   of	  
disability,	  between	  the	  two	  compounds	  (8%	  of	  Alemtuzumab	  group	  and	  11%	  of	  the	  
IFN-­‐beta	   group	   experienced	   sustained	   increase	   in	   the	   EDSS	   score).	   However,	   the	  
study	   confirmed	   the	   Alemtuzumab	   superiority	   in	   reducing	   the	   relapse	   frequency	  
(Cohen	  et	  al.,	  2012a).	  Results	  from	  the	  second	  phase	  III	  trial	  (CARE-­‐MS2)	  were	  more	  
encouraging:	  Alemtuzumab,	  compared	   to	  SC	   IFN	  beta-­‐1a,	   reduced	  the	   relapse	   rate	  
by	   49%	   (p<0.001)	   and	   the	   risk	   of	   a	   6-­‐month	   sustained	   accumulation	   of	   disability	  
(increase	  of	  1	  EDSS	  point	  from	  the	  baseline,	  or	  at	  least	  1.5	  point	  if	  the	  baseline	  was	  
0)	   by	   42%	   (p	   =	   0.008).	   In	   addition,	   29%	   of	   Alemtuzumab	   treated	   patients	  
experienced	  an	  improvement	  of	  the	  EDSS	  score	  (Coles	  et	  al.,	  2012a)	  
	  
The	  principal	  adverse	  effect	  was	  autoimmunity	  caused	  by	   lymphopenia,	  presenting	  
months	   or	   even	   years	   after	   treatment.	   About	   20-­‐30%	   developed	   hyperthyroidism	  
and	  about	  3%	  developed	  idiopathic	  thrombocytopenia	  purpura	  (ITP).	  	  	  
	  
1.7.8.2	  Autologous	  haematopoietic	  stem	  cell	  transplantation	  
	  
Immune	   ablation	   followed	   by	   autologous	   hematopoietic	   stem	   cell	   transplantation	  
(HSCT)	  is	  under	  evaluation	  as	  an	  experimental	  therapeutic	  approach	  in	  MS	  and	  other	  
autoimmune	   diseases.	   The	   rationale	   of	   HSCT	   in	   MS	   is	   to	   eliminate	   the	   existing	  
immune	   system	   that	   harbours	   disease-­‐associated	   cells	   and	   regenerate	   a	   new	   and	  
healthy	   immune	   system	   (Muraro	   et	   al.,	   2003).	   Heterogeneous	   patient	   populations	  
and	   transplantation	   regimens,	   small	  number	  of	  patients,	  and	   lack	  of	  a	   control	  arm	  
makes	  difficult	  to	  draw	  definitive	  conclusions	  about	  its	  efficacy	  in	  MS	  (Mancardi	  and	  
Saccardi,	  2008).	  	  
	  
HSCT	   clearly	   exerts	   a	   suppression	   of	   relapses	   and	   of	   Gadolinium-­‐enhancing	   MRI	  
lesions	  (Mancardi	  et	  al.,	  2001;	  Saccardi	  et	  al.,	  2005;	  Saiz	  et	  al.,	  2001),	  much	  stronger	  
than	  other	  treatments	  (Mancardi	  and	  Saccardi,	  2008).	  The	  largest	  data	  set	  currently	  
available	  is	  a	  retrospective	  analysis	  from	  the	  European	  Group	  for	  Blood	  and	  Marrow	  
Transplantation	   (EBMT),	   last	   updated	   in	   2006	   (Saccardi	   et	   al.,	   2006).	   The	   analysis	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reported	  a	  progression-­‐free	  survival	  in	  60-­‐70%	  of	  patients	  after	  3	  years	  and	  50-­‐60%	  
after	  6-­‐8	  years.	  In	  addition,	  Burt	  et	  al.	  recently	  treated	  21	  RRMS	  patients	  with	  mild	  to	  
moderate	   disability	   (EDSS	   2.0-­‐5.5)	   with	   a	   reduced-­‐intensity	   conditioning	   HSCT	  
regimen	   and	   reported	   100%	   progression-­‐free	   survival	   and	   81%	   showing	   an	  
improvement	  of	  neurological	  function	  after	  a	  median	  of	  3	  years	  of	  follow-­‐up	  (Burt	  et	  
al.,	   2009b).	  However,	   25%	  of	   patients	   had	   a	   relapse	   post-­‐therapy;	   this	  was	   higher	  
than	  what	  was	  previously	  observed	  in	  intermediate-­‐	  and	  high-­‐intensity	  regimes.	  	  
	  
A	  group	  that	  seems	  to	  especially	  benefit	   from	  HSCT	  are	  young	  patients	  with	  highly	  
aggressive,	  rapidly	  evolving	  forms	  of	  MS	  (Fagius	  et	  al.,	  2009;	  Kimiskidis	  et	  al.,	  2008).	  
Case	   reports	   have	   described	   dramatic	   clinical	   improvement,	   stabilisation	   of	   lesion	  
burden,	   and	   suppression	   of	   relapses	   among	   patients	   with	   highly	   active	   RRMS,	  
experiencing	  high	  numbers	  of	  relapses	  (Portaccio	  et	  al.,	  2007).	  	  
	  
Unfortunately,	   the	   use	   of	   HSCT	   remains	   limited	   by	   its	   potential	   severe	   adverse	  
effects,	   including	   death.	   However,	   data	   from	   EBMT	   database	   showed	   a	   treatment	  
related	  mortality	  that	  has	  decreased	  consistently	  over	  time	  and	  has	  dropped	  to	  1.3%	  
in	  2001-­‐2007	  (Mancardi	  and	  Saccardi,	  2008).	  	  
	  
1.7.8.3	  Laquinimod	  	  
	  
Laquinimod	   is	   a	   novel	   oral	   immunomodulator	   with	   both	   anti-­‐inflammatory	   and	  
neuroprotective	   effects	   (Bruck	   and	   Wegner,	   2011).	   It	   inhibits	   the	   leukocytes	  
migration	   into	  the	  CNS	  and	  the	  production	  of	  pro-­‐inflammatory	  cytokines	   (Wegner	  
et	  al.,	  2010).	  In	  EAE	  it	  was	  shown	  to	  reduce	  the	  axonal	  damage	  (Thone	  et	  al.,	  2012).	  	  
	  
Laquinimod	  was	   initially	  assessed	   in	  a	  phase	   II	   trial,	   comparing	   two	  doses	   (0.1	  and	  
0.3	  mg)	  to	  placebo,	  in	  209	  RR	  MS	  patients.	  There	  was	  a	  significant	  reduction	  by	  44%	  
of	  GAD	  enhancing	   lesions	   in	   the	  higher	  dose	  arm,	  but	  no	  effect	  on	   the	  number	  of	  
relapses	  (Polman	  et	  al.,	  2005a).	  The	  results	  of	  the	  phase	  III	  ALLEGRO	  (Assessment	  of	  
Oral	   Laquinimod	   in	   Preventing	   Progression	   in	   MS)	   study	   were	   recently	   published	  
(Comi	  et	  al.,	  2012).	  Patients	  (n	  =	  1106)	  were	  randomized	  for	  receiving	  0.6	  mg/day	  of	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Laquinimod	  or	  placebo.	  In	  the	  treatment	  group	  there	  was	  a	  modest	  reduction	  (23%)	  
of	   the	  ARR	  and	  of	   the	  risk	  of	  disability	  progression	  (23%),	  compared	  to	  placebo.	   In	  
addition,	  Laquinimod	  reduced	  the	  number	  of	  new	  T2	  lesions	  and	  the	  number	  of	  GAD	  
enhancing	  lesions	  (Comi	  et	  al.,	  2012)	  and	  more	  importantly,	   it	  reduced	  significantly	  
(p	   =	   0.	   004)	   the	   rate	   of	   grey	  matter	   atrophy,	   indicating	   a	   neuro-­‐protective	   effect	  
(Filippi	   et	   al.,	   2013).	   Laquinimod	   is	   currently	   being	   reviewed	   by	   the	   European	  






1.8	  Aims	  of	  this	  thesis	  	  
	  
This	   thesis	   aimed	   to	   analyse	   the	   long-­‐term	   disease	   evolution	   and	   the	   survival	  
probability	   of	   the	   London	   Ontario	   (LO)	   database	   patients.	   We	   hypothesized	   that	  
early	   features	   of	   the	   disease	   allow	   estimating	   the	   risk,	   for	   individual	   subjects,	   of	  
developing	   severe	   disability.	   Models	   predicting	   the	   attainment	   of	   hard	   outcomes	  
were	  developed.	  	  
	  
The	  specific	  aims	  of	  the	  analyses	  were:	  	  
-­‐ Aim	  1:	  To	  carry	  out	  a	  descriptive	  analysis	  of	  the	  LO	  database	  population	  and	  
to	  compare	  the	  disease	  progression	  among	  patients	  stratified	  by	  the	  clinical	  
phenotype.	   To	   assess	   the	   survival,	   the	   causes	   of	   death	   and	   the	   factors	  
affecting	  mortality.	  	  
-­‐ Aim	  2:	  To	   investigate	  the	  prognostic	  value	  of	  relapses	  and	  to	  examine	  their	  
relationship	  with	  the	  long-­‐term	  disease	  evolution.	  
-­‐ Aim	   3:	   To	   assess	   the	   effect	   of	   age	   on	   the	   disease	   progression	   and	   the	  
disability	  accumulation.	  
-­‐ Aim	   4:	   To	   identify	   clinical	   and	   demographic	   features	   predicting	   the	  
attainment	  of	  the	  SP	  phase.	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2.1	  The	  London	  Ontario	  database	  
	  
	  
2.1.1	  Methodology	  of	  the	  LO	  database	  
	  
2.1.1.1	  Data	  collection	  1972-­‐1984	  (1st	  systematic	  data	  review)	  
	  
The	  LO	  MS	  clinic	  was	  established	  in	  1972	  to	  provide	  care	  for	  patients	  in	  the	  referral	  
area	  of	   southern	  Ontario.	  Patients	  were	  accrued	  between	  1972	  and	  1984.	  Records	  
were	  reviewed	  between	  1979	  and	  1984,	  leading	  to	  the	  creation	  of	  the	  first	  database.	  
This	  was	   the	   subject	   of	   several	   analyses,	   published	   in	   4	   scientific	   papers	   between	  
1989	  and	  1991	  (Weinshenker	  et	  al.,	  1989b;	  Weinshenker	  et	  al.,	  1989c;	  Weinshenker	  
et	  al.,	  1991a;	  Weinshenker	  et	  al.,	  1991b).	  	  
	  
The	   cohort	   consisted	   of	   patients	   attending	   the	   tertiary	   referral	   centre	   for	   the	  
province	   of	   Ontario	   and	   the	   geographically	   based	   clinic	   for	   residents	   in	   the	  
Middlesex	  County	  (MC);	  90	  %	  of	  MS	  patients	  from	  MC	  were	  followed	  at	  the	  LO	  clinic	  
(Hader	   et	   al.,	   1988),	   providing	   the	   clinic	   a	   geographically	   based	   character.	   The	  
ascertainment	   of	   MS	   patients	   in	   the	   MC	   area	   was	   virtually	   complete,	   as	   all	  
neurologists	   worked	   in	   five	   hospitals	   affiliated	   to	   the	   university	   department	   and	  
agreed	  to	  refer	  their	  patients	  to	  the	  MS	  clinic.	  All	  individuals	  in	  the	  community	  were	  
within	  30-­‐60	  km	  distance	  from	  the	  MS	  clinic.	  During	  the	  period	  from	  1973	  to	  1984,	  
with	  the	  help	  of	  the	  Home	  care	  program	  and	  of	  the	  MS	  Society,	  the	  research	  team	  in	  
LO	   reviewed	   the	  medical	   records	   from	   all	   teaching	   and	   non-­‐teaching	   hospitals,	   all	  
extended	  care	  facilities,	  community	  health	  services	  and	  nursing	  homes	  in	  the	  county.	  
As	  of	  January	  1984	  the	  prevalence	  of	  MS,	  among	  residents	  in	  MC	  for	  at	  least	  1	  year,	  
was	  91/100000	  and	  the	  incidence	  was	  3.4/100000	  between	  1975	  and	  1979	  (Hader	  et	  
al.,	   1988).	   The	   diagnosis	   of	  MS	  was	   retrospectively	   confirmed,	   according	   to	   Poser	  
criteria,	   using	   clinical	   and	   para-­‐clinical	   (evoked	   response	   studies	   and	   CSF	   analysis)	  
information	  (Poser	  et	  al.,	  1983).	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In	   the	  MS	   clinic	   patients	  were	  evaluated	  by	  4	  MS	  neurologists	   and	  never	   received	  
DMTs,	  but	  only	   steroid	   for	   treating	   relapses,	  as	  per	   standard	  protocol.	  Clinical	  and	  
demographic	  information	  were	  recorded,	  and	  the	  disability	  outcome	  was	  measured	  
using	   the	  DSS	   (Kurtzke,	  1955).	   For	   those	  patients	  with	  disease	  onset	  prior	   to	  1972	  
data	  were	  gathered	   retrospectively,	  based	  on	  patients’	   interview	  and	  on	   review	  of	  
their	  record,	  and	  then	  longitudinally	  collected.	  Clinical	  evaluations	  were	  carried	  out	  
annually	   or	   semi-­‐annually,	   regardless	   of	   the	   patients’	   clinical	   course.	   Information	  
were	   stored	   in	   research	   charts,	   separated	   from	   patients’	   hospital	   records,	   and	  
completed	   at	   each	   patient	   visit.	   Data	   were	   recorded	   on	   standardized	   forms	   and	  
entered	  on	  a	  mainframe	  computer.	  At	  each	  visit	  new	  information	  was	  collected	  and	  
data	   previously	   recorded	   were	   confirmed.	   The	   frequent	   clinical	   assessments	   and	  
patients’	   interviews	  allowed	  to	  check	  the	  reliability	  of	  both	  the	  retrospectively	  and	  
prospectively	   collected	   data	   on	   the	   disability	   outcome.	   Particularly,	   those	  
information	   gathered	   retrospectively	   were	   inserted	   in	   the	   database	   only	   when	  
confirmed	  in	  serial	  evaluations	  and	  therefore	  considered	  indisputable.	  	  
	  
At	   the	   end	   of	   accrual	   (1984),	   1099	   patients,	   with	   mean	   disease	   duration	   of	   11.9	  
years,	  were	  identified.	  A	  subgroup	  of	  “seen	  from	  onset”	  (SO)	  patients	  (n	  =	  197)	  was	  
seen	  within	  12	  months	  of	  their	   first	  symptoms,	  and	   information	  was	  collected	  only	  
prospectively.	  By	  comparison	  against	  the	  total	  population,	  the	  MC	  (n	  =	  196)	  and	  the	  
SO	   subgroups	  were	  used	  as	   control	   for	   assessing	   the	   impact	  of	   ascertainment	  and	  
referral	  biases	  on	  data.	  The	  disease	  course	  was	  classified	  as	  RR	  in	  65.8%	  (n	  =	  722),	  or	  
progressive	   from	   onset,	   with	   (relapsing	   progressive	   [RP]:	   n	   =	   162	   [14.8%])	   and	  
without	   (chronically	   progressive	   [CP]:	   n	   =	   205	   [18.7%])	   superimposed	   acute	  
episodes.	  The	  criterion	  for	  progressive	  disease	  was	  continuing	  deterioration	  without	  
remission,	  regardless	  of	  the	  rate	  of	  progression.	  	  	  
	  
2.1.1.2	  Data	  collection	  1984-­‐1997	  (2nd	  systematic	  data	  review)	  
	  
The	   original	   database	   was	   extended,	   as	   the	   data	   collection	   of	   surviving	   patients	  
continued	  with	  annual	  or	  bi-­‐annual	  examinations	  until	  1997.	  After	  25	  years	  of	  follow	  
up,	  the	  second	  systematic	  data	  review	  was	  carried	  out;	  data	  analyses’	  results	  were	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published	   in	   5	   scientific	   papers	   between	   1999	   and	   2006	   (Cottrell	   et	   al.,	   1999a;	  
Cottrell	   et	   al.,	   1999b;	   Ebers	   et	   al.,	   2000;	   Kremenchutzky	   et	   al.,	   1999a;	  
Kremenchutzky	  et	  al.,	  2006a).	  	  
	  
Patients	  categorized	  into	  disease	  course	  subgroups	  (RR,	  RP	  and	  CP)	  from	  the	  original	  
natural	   history	   cohort	   were	   reclassified	   according	   to	   the	   internationally	   accepted,	  
standardized	   definitions	   of	   the	   clinical	   phenotype	   (Lublin	   and	   Reingold,	   1996).	  
Information	  on	  previously	   recorded	  DSS	  scores	  was	  revised.	  For	   local	  patients	  who	  
have	  become	  institutionalized,	  information	  on	  the	  physical	  status	  was	  derived	  from	  
telephone	   follow	   up	   with	   physicians,	   family	   and,	   as	   much	   as	   possible,	   from	   the	  
patients	  themselves.	  This	  has	  included	  visit	  to	  patients	  in	  local	  nursing	  home.	  	  
	  
Extensive	  efforts	  were	  made	  to	  trace	   lost	  to	  follow	  up.	  These	   included	  attempts	  to	  
contact	   the	   patients,	   their	   family	   doctors,	   their	   relatives	   and	  neighbours	   and	   local	  
MS	  society	  chapters.	  The	  assistance	  from	  the	  government	  of	  Ontario	  and	  its	  Ministry	  
of	  Health	  provided	  access	  to	  the	  provincial	  registry	  of	  deaths,	  allowing	  to	  identify	  the	  
final	   outcome	   in	   the	  majority	   of	   patient	   lost	   to	   follow	   up.	   From	   the	   original	   1099	  
patients	   cohort	   55	  were	   excluded:	   41	   turned	   out	   to	   have	  wrong	   diagnosis	   and	   15	  
were	   either	   duplicates,	   not	   originally	   recognized	   because	   of	   name	   change,	   or	   had	  
follow	  up	  shorter	  than	  2	  years,	  or	  had	  been	  lost	  to	  follow	  up.	  Consequently,	  the	  total	  
sample	  size	  reduced	  to	  1043	  cases	  (Ebers	  et	  al.,	  2000;	  Kremenchutzky	  et	  al.,	  2006a).	  	  
	  
2.1.1.3	  Definitions	  	  
	  
2.1.1.3.1	  Clinical	  and	  demographic	  features	  
	  
Information	   included	   in	   the	   clinical	   notes	   concerning	   the	   symptoms	   characterizing	  
the	  onset	  of	  the	  disease	  was	  used	  to	  determine	  the	  neurological	  systems	  involved	  at	  
onset.	  For	  patients	  recruited	  when	  the	  disease	  had	  already	  started,	  findings	  on	  the	  
initial	  examination	  were	  used	  to	  confirm	  data	  suggested	  by	  the	  history.	  Symptoms	  at	  
onset	  were	  grouped	   into	  balance	   impairment,	  bladder	  symptoms,	  gait	   impairment,	  
diplopia,	   limbs	   ataxia,	   Lhermitte	   sign,	  motor	   symptoms	   (acute	   or	   slow),	   pain,	   and	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sensory	   symptoms	   (face	   or	   body)	   (Weinshenker	   et	   al.,	   1989a;	  Weinshenker	   et	   al.,	  
1989c).	   Neurological	   systems	   involved	   at	   onset	   were	   categorized	   into	   motor,	  
sensory,	   cerebellar,	   brainstem,	   optic	   and	   bladder/bowel	   (Cottrell	   et	   al.,	   1999b).	  
Exacerbations	  were	  defined	  as	  acute	  development	  of	  new	  symptoms	  or	  worsening	  
of	  existing	  symptoms	  lasting	  more	  than	  24	  hours	  (Poser	  et	  al.,	  1983).	  	  
	  
2.1.1.3.2	  Disability	  outcomes	  	  
	  
Among	   LO	   database	   patients,	   disability	  was	   scored	   using	   the	   DSS	   (Kurtzke,	   1955).	  
The	  analyses	  presented	  in	  this	  thesis	  focused	  on	  the	  attainment	  of	  hard	  outcomes:	  	  
-­‐ DSS	  3:	  moderate	  disability	  
-­‐ DSS	  6:	  ambulatory	  but	  unilateral	  assistance	  required	  to	  walk	  short	  distance	  
-­‐ DSS	  8:	  restricted	  to	  bed	  with	  preserved	  use	  of	  arms	  	  
	  
2.1.1.3.3	  The	  progressive	  course	  	  
	  
In	   the	  original	  natural	  history	   series,	   accrued	  between	  1972	  and	  1984,	  progressive	  
disease	  was	  defined	  by	  a	  continuous	  deterioration	  without	  remission,	  regardless	  the	  
rate	  of	  deterioration	  (Weinshenker	  et	  al.,	  1989b).	  During	  the	  second	  data	  collection	  
(1984-­‐1997)	   the	   criterion	   for	   a	   progressive	   course	   was	   redefined	   more	   strictly.	  
Patients	   with	   progressive	   MS	   had	   to	   show	   at	   least	   1-­‐year	   of	   continuous	  
deterioration,	  without	   substantial	   remission,	   regardless	  of	   the	   rate	  of	  worsening.	  
In	  many	  patients	  the	  disease	  course	  appeared	  stable	  for	  extended	  periods	  however,	  
subjective	   worsening	   was	   often	   described	   even	   if	   it	   was	   not	   clinically	   obvious.	  
Therefore,	   transitory	   plateaus	   and	   trivial	   improvements	   in	   the	   relentlessly	  
progressive	   course	   were	   allowed	   in	   the	   long	   term,	   although	   steady	   progression	  
was	  the	  rule.	  The	  onset	  of	  the	  progressive	  course	  was	  predominantly	  characterized	  
by	   a	   distal	   central	   motor	   dysfunction	   and	   the	   progressive	   deficit	   was	   almost	  
exclusively	   localized	   to	   the	   distal	   lower	   extremity	   corticospinal	   tract	   fibres,	   and	  
manifested	  with	  ambulation	  impairment	  (Kremenchutzky	  et	  al.,	  2006a).	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During	   the	   second	   systematic	   data	   review	   (1997),	   researchers	   in	   LO	   focused	   on	  
information	  on	  the	  onset	  of	  SP.	  Special	  attention	  was	  paid	  to	  patients	  with	  a	  single	  
attack	   before	   progression	   (SAP	   MS)	   and	   to	   those	   entering	   the	   progressive	   phase	  
when	   permanent	   motor	   disability	   had	   not	   developed	   yet	   (Kremenchutzky	   et	   al.,	  
2006a).	   This	   aimed	   specifically	   at	   addressing	   the	   problem	   of	   the	   overlapping	  
between	   the	   relapsing	   and	   the	   progressive	   phase.	   Those	  who	   started	   to	   progress	  
when	   DSS	   2	   was	   reached,	   were	   identified.	   Such	   patients	   may	   have	   had	   multiple	  
relapses	   but	   with	   complete	   recovery,	  making	   the	   insidious	   onset	   of	   the	   SP	   phase	  
identifiable	   at	   an	   early	   stage,	   when	   they	   typically	   complained	   of	   exercise-­‐induced	  
impairment	   of	   the	   ambulation.	   With	   the	   advantage	   of	   frequent	   neurological	  
evaluations,	  in	  few	  cases	  the	  onset	  of	  progression	  could	  be	  even	  identified	  at	  DSS	  1,	  
by	  documenting	  the	  asymptomatic	  emergence	  of	   long	  tract	  signs.	  Overall,	  majority	  
of	  SP	  patients	  attained	   the	  progressive	  course	  at	  or	  before	  DSS	  3	   (Figure	  4.9),	  and	  
the	  great	  majority	  (84.8%)	  of	  SAP	  patients	  at	  or	  before	  DSS	  2	  (Kremenchutzky	  et	  al.,	  
2006a).	  Among	  those	  who	  had	  multiple	  relapses,	  mostly	  with	  partial	   recovery,	  and	  
converted	  to	  SP	  MS	  at	  higher	  DSS	  levels,	  it	  was	  particularly	  difficult	  to	  separate	  the	  
relapsing	  phase	  from	  the	  progressive	  phase	  	  (personal	  communication	  from	  George	  
Ebers).	  	  	  	  
	  
2.1.1.3.4	  The	  disease	  phenotype	  	  
	  
Following	  the	  1996	  international	  consensus	  on	  the	  classification	  of	  clinical	  subtypes	  
(Lublin	   and	   Reingold,	   1996),	   patients	   were	   reassigned	   to	   the	   new	   standardized	  
definitions	  (Cottrell	  et	  al.,	  1999a;	  Cottrell	  et	  al.,	  1999b;	  Kremenchutzky	  et	  al.,	  1999a).	  
During	  the	   long-­‐term	  follow	  up,	  some	  PP	  patients	   (n	  =	  21),	  questioned	  about	  early	  
symptoms,	   recalled	   early	   exacerbation	   initially	   forgotten	   and	   were	   therefore	  
reclassified	   as	   SP	   MS.	   (Cottrell	   et	   al.,	   1999b).	   In	   addition,	   the	   second	   systematic	  
review	   of	   data	   focused	   on	   those	   367	   cases	   originally	   identified	   as	   progressive	  
patients	   (Weinshenker	   et	   al.,	   1989b)	   with	   or	   without	   superimposed	   relapses	  
(chronically	  progressive	  and	  relapsing	  progressive	  MS),	  attempting	  to	  justify	  the	  use	  
of	  this	  terminology,	  based	  on	  the	  long	  term	  outcome	  (Kremenchutzky	  et	  al.,	  1999a).	  
The	   original	   group	   of	   relapsing	   progressive	   MS	   was	   reclassified	   as	   one	   of	   the	   3	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different	  progressive	  clinical	  phenotypes,	  according	  to	  the	  last	  consensus	  (Lublin	  and	  
Reingold,	  1996):	  	  
-­‐ PP	   MS:	   disease	   progression	   from	   onset,	   with	   occasional	   plateaux	   and	  
temporary	  minor	  improvements	  allowed,	  but	  not	  distinct	  relapses.	  	  
-­‐ SP	   MS:	   initial	   RR	   disease	   course,	   followed	   by	   progression	   with	   or	   without	  
occasional	  relapses,	  minor	  remission	  and	  plateaux.	  
-­‐ PR	   MS:	   progressive	   disease	   from	   onset,	   with	   clear	   acute	   relapses,	   with	   or	  
without	  full	  recovery.	  	  
	  
In	   view	   of	   the	   identical	   survival	   curves,	   between	   PP	   and	   PR	   patients,	   it	   was	  
concluded	  that	  superimposed	  relapses	  did	  not	  affect	  the	  outcome	  in	  PP	  MS	  and	  the	  
term	   “progressive-­‐relapsing”	   could	   be	   abandoned.	   Accordingly,	   PR	   patients	   were	  
merged	  in	  the	  PP	  subgroup	  (Kremenchutzky	  et	  al.,	  1999a).	  	  
	  
Eventually,	  among	  the	  total	  population	  of	  1043	  patients,	  219	  were	  deemed	  to	  have	  a	  
PP	  course	  and	  824	  a	  relapsing	  onset	  course,	  of	  whom	  551	  had	  converted	  to	  SP	  MS	  
(Kremenchutzky	  et	  al.,	  2006a).	  	  
	  
2.1.2	  Data	  quality	  check	  procedures	  
	  
Following	   the	   second	  systematic	   review	   (1997),	   the	  data	  collection	  continued	  until	  
2000,	  totalling	  28	  years	  follow	  up	  (1972-­‐2000).	  In	  2006	  Prof	  George	  Ebers	  gave	  to	  me	  
and	   to	   the	  Sylvia	   Lawry	  Centre	   (Munich,	  Germany)	   the	  database,	   in	  order	   to	   carry	  
out	  further	  analyses	  on	  the	  LO	  cohort.	  
	  
The	   Sylvia	   Lawry	   Centre	   (SLC)	   (http://www.slcmsr.net/en/about/start.html)	   was	  
established	   in	   2001	   to	   support	   the	   research	   in	   MS	   and	   to	   accelerate	   the	  
development	   of	   effective	   therapies,	   by	   using	   innovative	   statistical	   methods	   and	  
computer	   technology,	   combined	   with	   medical	   expertise.	   To	   facilitate	   the	  
accomplishment	   of	   these	   aims	   the	   centre	  was	   donated	   44	  data	   sets	   from	  placebo	  
arms	  of	  many	  MS	  RCTs	  and	  many	  other	  natural	  history	   registries	   from	  around	   the	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world.	   The	   team	   of	   statisticians	   has	   gained	   extensive	   experience	   in	   MS	   data	  
management	  and	  has	  offered	  me	  statistical	  support	  for	  the	  analyses	  reported	  in	  this	  
thesis.	  I	  initially	  attended	  the	  centre	  in	  two	  separate	  4-­‐weeks	  periods,	  during	  which	  I	  
learnt	   the	   correct	   methodology	   for	   managing	   data,	   planning	   and	   carrying	   out	  
statistical	  analyses.	   I	   then	  attended	  the	  centre	   in	  several	  other	  short-­‐term	  periods,	  
when	   a	   closer	   collaboration	   with	   the	   statisticians	   was	   needed.	   Otherwise,	   we	  
communicated	   through	  emails	  and	   telephone	  conferences	  and	  we	  exchanged	  data	  
and	  analyses	  results	  by	  uploading	  word	  documents	  on	  the	  SLC	  intranet.	  In	  particular,	  
I	   strictly	   collaborated	  with	  Dr	  Anneke	  Neuhaus	  and	  Dr	  Martin	  Daumer	   (director	  of	  
the	  centre).	  	  
	  
The	   data	   from	   the	   LO	   database	   were	   available	   on	   a	   CD-­‐rom,	   containing	   several	  
datasets	  in	  SAS,	  SPSS	  and	  Excel	  format.	  These	  were	  created	  by	  the	  LO	  research	  team,	  
following	  the	  continuous	  update	  of	   information,	  correction	  of	  data	  and	  creation	  of	  
new	  variables.	  Each	  dataset	  was	  named	  with	  the	  date	  of	  creation,	  allowing	  to	  trace	  
how	  data	  changed	  over	  time.	  Thanks	  to	  the	  information	  contained	  the	  “Data	  History	  
doc”	  (found	  in	  the	  CD-­‐rom),	  we	  could	  decode	  meaning	  of	  variables	  in	  the	  database.	  
The	   file	   also	   helped	   us	   to	   figure	   out	   that	   the	   most	   updated	   dataset,	   called	  
MS0200_1,	  had	  been	  created	  by	  merging	  the	  information	  on	  SP	  patients	  contained	  
in	   the	   dataset	   FINAL.SPMS.DATABASE.012100,	   which	   was	   used	   to	   carry	   out	   the	  
latest	   analysis	   of	   the	   database	   (Kremenchutzky	   et	   al.,	   2006a),	   to	   the	   information	  
contained	  in	  the	  dataset	  called	  MS0999_1.	  	  
	  
Before	   carrying	   out	   the	   statistical	   analyses	   we	   decided	   to	   check	   the	   reliability	   of	  
data,	   by	   performing	   independent	   verifications	   in	   parallel,	   and	   by	   comparing	   the	  
results	  obtained.	  For	  each	  patient,	   identified	   through	  an	  “ID	  number”,	  we	  checked	  
and	   compared	   data	   contained	   in	  MS0999_1	   and	   in	  MS0200_1.	   Datasets.	   This	  was	  
done	  manually	  by	  me,	  and	  using	  the	  software	  R	  by	  the	  SLC.	  Very	  few	  inconsistencies	  
were	  detected	  and	  some	  arbitrary	  decisions	  had	   to	  be	   taken	  with	   regard	   to	  which	  
information	   could	  be	   trusted.	  We	   concluded	   that	   the	   overall	   quality	   of	   data	  was	  
highly	   trustworthy.	   In	  order	  to	  solve	  the	  few	  inconsistencies	  detected,	  we	  decided	  
to	   rely	   on	   the	   two	   datasets,	   containing	   the	   most	   updated	   information:	   1)	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FINAL.SPMS.DATABASE.012100	  for	  data	  on	  SP	  patients;	  2)	  MS0200_1	  for	  data	  on	  RR	  
and	  PP	  patients.	  	  
	  
2.1.2.1	  Inconsistencies	  and	  methods	  to	  handle	  it	  	  
	  
1. Duplicate	  or	  wrong	  diagnosis:	  	  
Patients	  (n	  =	  56)	  identified	  using	  the	  variable	  NSTATUS1,	  indicating	  N	  or	  DUP,	  
meaning	   that	   they	   had	   wrong	   diagnosis	   or	   were	   duplicates,	   not	   initially	  
recognized	  because	  of	  name	  change	  (Ebers	  et	  al.,	  2000),	  were	  deleted.	  
	  
2. Information	  on	  times	  to	  DSS	  levels,	  indicated	  by	  the	  variable	  TK1	  to	  TK10:	  
A) Type	  I	  inconsistency:	  
For	   some	   patients	   values	   of	   the	   times	   to	   disability	   endpoints	   increased	  
and	  then	  decreased,	  creating	  not	  continuous	  patterns:	  e.g.	  time	  to	  DSS	  3	  




Times	  to	  DSS	  3-­‐6-­‐8-­‐10	  (the	  outcomes	  analysed	  in	  this	  study)	  
	  
The	  DSS	  (Kurtzke,	  1955)	   is	  an	  ordinal	  scale	  and	  the	  attainment	  of	  motor	  
disability	   (≥	   DSS	   3)	   is	   meant	   to	   be	   irreversible,	   unless	   the	   patient	   is	  
experiencing	   an	   acute	   exacerbation.	   Minor	   improvements	   on	   the	   EDSS	  
can	   occur.	   However,	   they	   are	   mostly	   not	   sustained	   for	   more	   than	   6	  
months	  and	  they	  are	  mainly	  observed	  among	  patients	  with	  short	  disease	  
duration	  and	  still	   in	  the	  lower	   intervals	  of	  the	  scale	  (EDSS	  1-­‐3)	  (Tremlett	  
et	  al.,	  2012).	   In	   the	  LO	  database,	  with	   the	  advantage	  of	   the	   long	   follow	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up,	  information	  on	  previously	  recorded	  DSS	  scores,	  especially	  DSS	  3-­‐6-­‐8-­‐
10,	   have	   been	   repeatedly	   checked	   and	   confirmed.	   We	   eventually	  
concluded	   that,	   when	   generating	   the	   last	   dataset	   (MS0200_1),	   the	  
research	  team	  in	  LO	  updated	  information	  only	  on	  the	  times	  to	  DSS	  3-­‐6-­‐8-­‐
10,	   which	   were	   the	   focus	   of	   the	   latest	   publications	   and	   were	   not	  
subjected	   to	   fluctuations	   (Cottrell	   et	   al.,	   1999a;	   Cottrell	   et	   al.,	   1999b;	  
Ebers	   et	   al.,	   2000;	   Kremenchutzky	   et	   al.,	   1999a;	   Kremenchutzky	   et	   al.,	  
2006a).	   The	   information	   on	   the	   times	   to	   the	   other	   DSS	   levels	   was	   not	  
updated,	   creating	   the	   inconsistent	  TK	   patterns.	  We	   therefore	   choose	   to	  
trust	  only	  the	  most	  updated	  (from	  MS0200_1)	   information	  on	  the	  times	  
to	  hard	  endpoints	  (DSS	  3-­‐6-­‐8-­‐10)	  and	  to	  purge	  the	  unreliable	  information	  
about	  the	  times	  to	  the	  other	  DSS	  levels.	  	  
	  
Times	  to	  DSS	  1-­‐2-­‐4-­‐5-­‐7-­‐9	  (the	  outcomes	  NOT	  analysed	  in	  this	  study)	  
	  
Subsequently,	   by	   checking	   a	   previous	   dataset,	   named	   MS1197,	   we	  
identified	   variables	   providing	   information	   on	   the	   DSS	   levels	   attained	   at	  
each	   year	   from	   the	   disease	   onset	   (variable	   name	   was	   K1-­‐n).	   After	  
comparison	  with	   the	  most	   updated	   data	   on	   the	   times	   to	   DSS	   3-­‐6-­‐8-­‐10,	  
from	  the	  dataset	  MS0200_1,	  this	  information	  appeared	  reliable	  and	  more	  
accurate	  than	  those	  given	  by	  the	  variables	  TK-­‐n.	  We	  therefore	  decided	  to	  
trust	   it	   and	   to	   use	   it	   in	   order	   to	   calculate	   the	   times	   to	   DSS	   1-­‐2-­‐4-­‐5-­‐7-­‐9	  
levels,	   which	   nevertheless	   were	   not	   used	   as	   outcomes	   in	   this	   study.	  	  
Information	   were	   accepted	   only	   when	   the	   following	   conditions	   were	  
respected:	  
	  
-­‐	  Time	  to	  DSS	  1	  and	  to	  DSS	  2	  <	  Time	  to	  DSS	  3	  	  
-­‐	  Time	  to	  DSS	  4	  and	  to	  DSS	  5	  <	  Time	  to	  DSS	  6	  
-­‐	  Time	  to	  DSS	  7	  <	  Time	  to	  DSS	  8	  	  
-­‐	  Time	  to	  DSS	  9	  <	  Time	  to	  DSS	  10	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This	  long	  process	  finally	  led	  to	  obtain	  reliable	  information	  on	  the	  times	  to	  
all	  DSS	  levels,	  for	  the	  vast	  majority	  of	  patients.	  	  
	  
B) Type	  II	  inconsistency:	  
For	   some	   patients	   information	   on	   the	   times	   to	   different	   disability	  
endpoints	  had	  the	  same	  value	  (e.g.	  time	  to	  DSS	  6	  =	  31	  years;	  time	  to	  DSS	  




In	   previous	   datasets,	   censoring	   indicators	   were	   created	   (variable	  
TKXCENS:	  0	   =	  DSS	   level	   not	   reached,	  1	   =	  DSS	   level	   reached).	  When	   the	  
censoring	   value	   was	   0,	   the	   time	   to	   the	   corresponding	   DSS	   level	   was	  
scored	   equal	   to	   the	   disease	   duration	   (procedure	   required	   in	   order	   to	  
perform	   survival	   analysis).	   By	   comparing	   information	   on	   times	   to	   DSS	  
level,	   censoring	   indicators	   and	   disease	   duration,	   we	   figured	   out	   that,	  
during	   previous	   data	   updates,	   occasionally,	   information	   on	   the	   time	   to	  
disability	   levels,	  among	  patients	  with	   the	  corresponding	  censoring	  value	  
equal	   to	   0	   (indicating	   that	   the	   level	   had	   not	   been	   reached),	   actually	  
indicated	  the	  disease	  duration,	  thus	  generating	  confusion.	  We	  decided	  to	  
accept	   the	   value	   on	   the	   times	   to	   DSS	   levels	   only	   when	   the	   censoring	  
indicator	  was	  =	  1.	  
	  
3. Information	  on	  censoring	  levels,	  indicated	  by	  the	  variable	  TKXCENS:	  
Some	  patients	  had	  non-­‐linear	  censoring	  values	  (e.g.	  censoring	  for	  DSS	  3	  =	  1,	  
censoring	  for	  DSS	  6	  =	  0,	  censoring	  for	  DSS	  8	  =	  1;	  or	  censoring	  for	  DSS	  3	  =	  0,	  
censoring	  for	  DSS	  6	  =	  1,	  censoring	  for	  DSS	  8	  =	  1).	  	  




We	   concluded	   that	   the	   censoring	   value	   =	   0	   was	   also	   incorrectly	   used	   for	  
indicating	  that	  the	  specific	  disability	  level	  had	  been	  reached,	  but	  the	  time	  to	  
the	   DSS	   level	  was	   unknown	   (left	   censoring).	   Subsequent	   levels	   of	   disability	  
were	   then	   recorded	   years	   later.	   Therefore,	   to	   obtain	   consistent	   censoring	  
values	  we	  used	  a	  backward	  algorithm.	  Starting	  from	  information	  whether	  DSS	  
level	  10	  was	  reached	  or	  not,	  along	  with	  information	  on	  the	  time	  to	  the	  next	  
lower	  disability	   level	  and	  the	  censoring	   information,	  we	  were	  able	  to	  assign	  
consistent	  censoring	  values.	  
	  
When	   the	   information	   on	   the	   time	   to	   DSS	   10	   (TK10)	   was	   available	   the	  
censoring	  information	  for	  DSS	  10	  (TKCENS10)	  was	  scored	  1,	  otherwise	  it	  was	  
scored	   0.	   In	   addition,	   the	   information	   on	   the	   attainment	   of	   DSS	   10	  
(TKCENS10)	  was	  checked	  by	  comparison	  with	  the	  variable	  SURVIVAL,	  which	  
contained	   the	  most	   updated	   data	   on	   dead	   patients.	   In	   point	   8	   (below)	   are	  
provided	  details	  on	  how	  we	  assigned	  the	  status	  “death	  due	  to	  MS”	  (DSS	  10	  
reached).	   Once	   the	   checking	   was	   carried	   out,	   the	   following	   algorithm	   was	  
applied.	  	  
• Censoring	  information	  for	  DSS	  8:	  
A)	   If	   information	   on	   the	   time	   to	   DSS	   8	   (TK8)	   was	   available,	   the	  
censoring	  information	  for	  DSS	  8	  (TKCENS8)	  was	  scored	  1.	  	  
B)	   If	   information	  on	   the	   time	   to	  DSS	  8	   (TK8)	  was	  NOT	   available	  and	  
the	   censoring	   information	   for	  DSS	  10	   (TKCENS10)	  was	   scored	  0,	   the	  
censoring	  information	  for	  DSS	  8	  (TKCENS8)	  was	  scored	  0.	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C)	   If	   information	  on	   the	   time	   to	  DSS	  8	   (TK8)	  was	  NOT	   available	  and	  
the	   censoring	   information	   for	  DSS	  10	   (TKCENS10)	  was	   scored	  1,	   the	  
censoring	  information	  for	  DSS	  8	  (TKCENS8)	  was	  scored	  3.	  	  	  	  
• Censoring	  information	  for	  DSS	  6:	  
A)	   If	   information	   on	   the	   time	   to	   DSS	   6	   (TK6)	   was	   available,	   the	  
censoring	  information	  for	  DSS	  6	  (TKCENS6)	  was	  scored	  1.	  
B)	   If	   information	  on	   the	   time	   to	  DSS	  6	   (TK6)	  was	  NOT	   available	  and	  
the	   censoring	   information	   for	   DSS	   8	   (TKCENS8)	   was	   scored	   0,	   the	  
censoring	  information	  for	  DSS	  6	  (TKCENS6)	  was	  scored	  0.	  
C)	   If	   information	  on	   the	   time	   to	  DSS	  6	   (TK6)	  was	  NOT	   available	  and	  
the	   censoring	   information	   for	   DSS	   8	   (TKCENS8)	   was	   scored	   1,	   the	  
censoring	  information	  for	  DSS	  6	  (TKCENS6)	  was	  scored	  3.	  	  	  
• Censoring	  information	  for	  DSS	  3:	  
A)	   If	   information	   on	   the	   time	   to	   DSS	   3	   (TK3)	   was	   available,	   the	  
censoring	  information	  for	  DSS	  3	  (TKCENS3)	  was	  scored	  1.	  	  
B)	   If	   information	  on	   the	   time	   to	  DSS	  3	   (TK3)	  was	  NOT	   available	  and	  
the	   censoring	   information	   for	   DSS	   6	   (TKCENS6)	   was	   scored	   0,	   the	  
censoring	  information	  for	  DSS	  3	  (TKCENS3)	  was	  scored	  0.	  
C)	   If	   information	  on	   the	   time	   to	  DSS	  3	   (TK3)	  was	  NOT	   available	  and	  
the	   censoring	   information	   for	   DSS	   6	   (TKCENS6)	   was	   scored	   1,	   the	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When	   this	   process	   was	   finalized,	   the	   censoring	   information	   (TKCENS)	   was	  
labelled	  as	  follow:	  	  
	  
-­‐	  1	  =	  disability	  level	  was	  reached	  and	  point	  in	  time	  was	  documented	  
-­‐	  3	  =	  disability	  level	  was	  reached	  but	  point	  in	  time	  was	  not	  documented	  (left	  
censoring).	  	  
-­‐	   0	   =	   disability	   was	   not	   reached	   during	   the	   observation	   time	   (right	  
censoring).	  	  
	  
4. Information	  on	  the	  disease	  duration:	  
Two	   variables	   indicated	   the	   disease	   duration:	  DUR	   and	   DUR1.	   The	   variable	  
DUR	   appeared	   inconsistent,	   as	   it	   often	   indicated	   different	   values	   between	  
the	  two	  most	  update	  datasets	  (MS0200_1	  and	  MS0999_1).	  However,	  DUR1	  
seemed	  more	  consistent.	  In	  order	  to	  check	  its	  accuracy	  we	  decided	  to	  apply	  
the	  following	  rules:	  
-­‐ DUR1	  had	  to	  be	  equal	  to	  time	  to	  DSS	  10	  (when	  DSS	  10	  was	  reached).	  
-­‐ DUR1	  had	  always	  to	  be	  ≥	  the	  time	  to	  the	  last	  DSS	  level	  recorded.	  
	  
Six	   patients	   did	   not	  meet	   the	   second	   condition	   and	   therefore	   the	   variable	  
was	  deemed	  to	  be	  unreliable.	  For	  the	  remaining	  patients,	  the	  information	  on	  the	  
length	  of	  the	  disease	  course	  was	  considered	  reliable.	  
	  
5. Information	  on	  the	  year	  of	  last	  visit:	  
The	  year	  of	  the	  last	  visit	  was	  indicated	  by	  the	  variable	  YRLV.	  This	  turned	  out	  
to	  be	  unreliable,	  as	  some	  patients	  seemed	  to	  have	  been	  examined	  after	  the	  
year	   of	   death.	  We	   decided	   to	   calculate	   the	   year	   of	   last	   visit	   by	   adding	   the	  
value	  of	  the	  disease	  duration	  (DUR1)	  to	  the	  value	  of	  the	  year	  of	  the	  onset	  of	  
the	  disease,	  creating	  a	  new	  variable	  (YRLVcalc).	  	  
	  
6. Information	  on	  the	  type	  of	  the	  disease	  course:	  
The	   type	   of	   the	   disease	   course	   was	   indicated	   by	   the	   variable	   NSTATUS.	  
According	   to	   Data	   History	   doc,	   during	   the	   last	   data	   update,	   20	   patients	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turned	  out	   to	  be	  wrongly	   labelled	  as	   SP	  and	  were	   reclassified	  as	  RR.	   There	  
were	   identified,	   by	   using	   the	   dataset	   FINAL.SPMS.DATABASE.012100	  
(containing	  the	  final	  list	  of	  SP	  patients),	  and	  labelled	  correctly.	  	  
	  
7. Information	  on	  number	  of	  relapses:	  
The	   number	   of	   relapses	   was	   indicated	   by	   the	   variables	   RELY1	   (number	   of	  
attacks	   in	   the	   first	   year),	   RELY12	   (number	   of	   attacks	   during	   the	   first	   two	  
years)	  and	  PREREL	  (number	  of	  attacks	  during	  the	  RR	  phase,	  before	  the	  onset	  
of	  progression).	  The	  accuracy	  of	  the	  three	  variables	  was	  checked	  by	  applying	  
the	  following	  rules:	  
-­‐ RELY12	  had	  to	  be	  ≥	  to	  RELY1	  	  
-­‐ RELY12	  had	  be	  ≤	  PREREL	  
	  
Two	  patients	  were	   found	   to	   have	  RELY12	   >	  PREREL;	   therefore	   the	   variable	  
PREREL	   was	   deemed	   to	   be	   unreliable.	   For	   the	   remaining	   patients,	  
information	  of	  number	  of	  relapses	  during	  the	  first	  two	  years	  and	  during	  the	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8. Information	  on	  survival,	  causes	  of	  death	  and	  death	  due	  to	  MS	  (DSS	  10):	  
According	   to	  Data	   History	   doc,	   the	   variable	  SURVIVAL	   contained	   the	  most	  
updated	   information	   on	   those	   patients	   who	   had	   died,	   by	   the	   end	   of	   the	  
observation	   period.	   Information	   on	   causes	   of	   death	  were	   indicated	   by	   two	  
variables:	   IMMCAUSE	   (primary	   cause	   of	   death)	   and	   SECAUSE	   (secondary	  
cause	   of	   death).	   Among	   dead	   patients,	   as	   indicated	   by	   the	   variable	  
SURVIVAL,	   the	   patients	   who	   died	   from	  MS	   and	   therefore	   reached	   DSS	   10	  
were	  identified	  by	  applying	  the	  following	  rules	  (Figure	  2.1):	  	  
	  
A) Primary	   causes	   of	   death	   recorded	   as	   aspiration,	   cachexia,	   dehydration,	  
“Multiple	   Sclerosis”,	   pneumonia,	   pulmonary	   oedema,	   pulmonary	  
embolism,	  septicaemia	  and	  suicide,	  were	  considered	  attributable	  to	  MS.	  
B) Primary	  causes	  of	  death	  recorded	  as	  G-­‐I	  bleeding,	  accidental	  pulmonary	  
oedema,	  accident,	  cancer,	  heart	  disease,	  chronic	  bronchitis,	  chronic	  renal	  
failure,	   head	   injury,	   intestinal	   obstruction,	   pyelonephritis,	   renal	   failure	  
and	  stroke,	  were	  considered	  NOT	  attributable	  to	  MS.	  
C) For	   those	   patients	   who	   died	   from	   unknown	   causes,	   respiratory	  
failure/arrest	   or	   cardiac	   failure/arrest,	   an	   arbitrary	   decision	   had	   to	   be	  
taken,	   regarding	  whether	   the	   death	  was	   attributable	   to	  MS	  or	   not.	  We	  
applied	  a	  composite	  criterion,	  which	  was	  based	  on	  the	  information	  about	  
the	  secondary	  cause	  of	  death	  and	  on	  whether	  a	  bedridden	  status	  (DSS	  8)	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9. Information	  on	  clinical	  and	  demographic	  features:	  
Information	   on	   clinical	   and	   demographic	   features	   was	   checked	   by	  
comparison	   among	   the	   3	   datasets.	   When	   inconsistencies	   were	   detected	   it	  
was	  agreed	  to	  trust	  only	  information	  contained	  in	  the	  most	  updated	  dataset	  
(MS0200_1).	  	  	  
	  
2.1.2.2	  The	  creation	  of	  variables	  	  
	  
Variables	  for	  carrying	  out	  the	  analyses	  were	  created	  from	  the	  raw	  data	  or	  computed	  
from	   existing	   variables.	   In	   addition,	  when	   needed,	   categorical	   variables	   (grouping)	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2.1.2.3	  The	  final	  dataset	  	  
	  
Utilization	   of	   specific	   and	   objective	   rules	   has	   prevented	   the	   statistical	   bias	   that	  
occurs	  when	  data	  are	  manually	  corrected	  or	  censored.	  The	  systematic	  data	  clean-­‐up	  
and	   the	   quality	   check	   resolved	   the	   inconsistencies,	   which	   were	   caused	   by	   the	  
stratification	  of	  data	  updates	  over	  a	  number	  of	  years,	  and	   led	   to	   the	  creation	  of	  a	  
final	  dataset,	  containing	  the	  most	  reliable	  information	  (Figure	  2.2).	  	  
	  





The	  dataset	  now	  contains,	   for	   each	  patient,	   the	   following	   information:	   ID,	   gender,	  
time	   (years)	   to	   DSS	   1-­‐2-­‐3-­‐4-­‐5-­‐6-­‐7-­‐8-­‐9-­‐10	   and	   corresponding	   censoring	   indicators,	  
time	  (years)	  from	  DSS	  3	  to	  6,	  8	  and	  10;	  times	  from	  DSS	  6	  to	  8	  and	  10;	  time	  from	  DSS	  
8	  to	  10	  and	  corresponding	  censoring	  indicators,	  duration	  of	  the	  disease	  (years),	  age	  
at	  disease	  onset,	  year	  of	  onset	  of	   the	  disease,	  clinical	  subtype	  of	   the	  disease,	   time	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of	   the	  progressive	  phase,	  DSS	  at	  onset	  of	   the	  progressive	  phase,	   time	   (years)	   from	  
the	   onset	   of	   the	   progressive	   phase	   to	   DSS	   3-­‐6-­‐8-­‐10	   and	   corresponding	   censoring	  
indicators,	   symptoms	   at	   the	   disease	   onset,	   neurological	   systems	   involved	   at	   the	  
disease	  onset,	  neurological	  systems	  involved	  at	  the	  onset	  of	  progressive	  phase,	  	  the	  
number	  of	  relapses	  in	  the	  1st	  and	  2nd	  year	  of	  the	  disease	  and	  corresponding	  relapse	  
rate,	  the	  number	  of	  relapses	  before	  and	  after	  the	  onset	  of	  the	  progressive	  phase	  and	  
corresponding	  relapse	  rate,	  number	  of	  relapses	  after	  the	  second	  year	  of	  the	  disease	  
up	  to	  the	  onset	  of	  progressive	  phase	  and	  corresponding	  relapse	  rate,	  total	  number	  
of	   relapses	   and	   corresponding	   relapse	   rate,	   functional	   systems	   score	   at	   last	   DSS	  
assessment,	   diagnostic	   certainty	   according	   to	   Poser	   criteria	   (Poser	   et	   al.,	   1983),	  
primary	  and	  secondary	  cause	  of	  death,	  year	  of	  last	  visit	  (Figure	  2.3).	  	  
	  
Figure	   2.3	   Information	   contained	   in	   the	   LO	   database.	   The	   boxes	   list	   the	   groups	   of	   variables	   that	  
passed	   the	  quality	   check	  procedures	  and	   constitute	   the	   final	  data	   set.	   In	   the	   top	   row	   the	  variables	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2.2	  Statistical	  analyses	  	  
	  
A	  standardized	  approach	  for	  carrying	  out	  analyses	  was	  mutually	  agreed	  with	  the	  SLC.	  
This	   consisted,	   firstly	   of	   setting	   up	   a	   statistical	   plan	   for	   each	   aim	   of	   the	   project.	  
Subsequently,	   statistical	  analyses	  were	  performed	  by	  me,	  using	   the	  SPSS	  software,	  
and	  independently	  by	  the	  SLC	  statisticians,	  using	  R	  software.	  Eventually,	  results	  from	  
the	   two	  analyses	  were	   compared.	   If	   differences	  were	  detected,	   the	   analyses	  were	  
repeated	  after	  revising	  together	  the	  statistical	  methods,	  until	  results	  matched.	  This	  
approach	  guaranteed	  high	  reliability	  to	  our	  conclusions.	  	  	  
	  
2.2.1	  Survival	  analysis	  	  
	  
Due	  to	  the	  lack	  of	  information	  on	  the	  disease	  evolution,	  in	  the	  entire	  natural	  history	  
cohort,	  from	  the	  onset	  of	  the	  disease	  until	  death,	  we	  need	  to	  rely	  on	  estimates.	  With	  
respect	  to	  a	  given	  endpoint	  (e.g.	  the	  attainment	  of	  a	  level	  of	  disability,	  the	  onset	  of	  
progression)	   for	   every	   patient,	   at	   the	   end	  of	   the	   study,	   fit	   in	   one	   of	   the	   following	  
categories:	  
• The	  endpoint	  was	  reached.	  
• The	  endpoint	  was	  not	  reached	  and	  the	  patient	  was	  observed	  until	  the	  
end	  of	  the	  study.	  
• The	  endpoint	  was	  not	  reached	  and	  the	  patient	  was	   lost	  to	  follow	  up	  
during	  the	  study	  period.	  	  
	  
The	   last	   two	   categories	   form	   the	   group	   of	   censored	   patients.	   Analysing	   only	  
observed	   data,	   without	   taking	   in	   account	   censored	   information,	   is	   easier	   but	  
invariably	  leads	  to	  underestimate	  the	  time	  to	  reach	  the	  endpoint,	  and	  consequently	  
to	  overestimate	  the	  disease	  severity.	  	  
	  
Survival	   analyses	   (Cox	   Regression	   and	   Kaplan	   Meier)	   allow	   me	   to	   assess	   a	  
dichotomized	  outcome	  (that	  has	  or	  has	  not	  happened)	  as	  a	  function	  of	  the	  time	  until	  
the	   event	   (endpoint)	   occurs	   (Singh	   and	  Mukhopadhyay,	   2011).	   By	   calculating	   the	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number	  and	  the	  proportion	  of	  subjects	  failing	  to	  attain	  the	  endpoint,	  at	  certain	  time	  
intervals,	   survival	   analyses	   assess	   the	   estimated	   time	   to	   and	   the	   probability	   of	  
experiencing	   the	   event	   in	   specific	   subgroups.	   In	   addition,	   when	   estimating	   the	  
cumulative	  probability,	  these	  techniques	  include	  in	  the	  analysis	  each	  subject	  who	  did	  
not	  experience	   the	  event	   for	   the	  period,	  up	   to	   the	   time	  he/she	  became	  censored.	  
The	  biggest	  limitation	  is	  related	  to	  the	  proportion	  of	  censored	  patients,	  which	  tends	  
to	  increase	  with	  the	  time	  needed	  to	  attain	  the	  endpoint	  and	  affects	  the	  accuracy	  of	  
the	   estimated	   time	   intervals.	   The	   larger	   the	   number	   of	   censored	   information,	   the	  
longer	   will	   be	   the	   estimated	   time	   to	   the	   endpoint.	   However,	   long	   follow-­‐up	   of	  
natural	  history	  cohorts	  guarantees	   lower	  proportion	  of	   censored	  data	   (Clark	  et	  al.,	  
2003).	   Therefore,	   although	   they	   might	   provide	   longer	   and	   not	   necessarily	   more	  
accurate	   estimates,	   these	   techniques	   are	   preferable	   to	   analyses	   strictly	   based	   on	  
observational	  data.	  	  
	  
The	   survival	   analyses	   can	   be	   potentially	   affected	   by	   bias	   from	   the	   immortal	   time.	  
This	   is	  the	  period	  of	   follow	  up,	  during	  which,	  by	  design,	  the	  outcome	  cannot	  occur	  
(Suissa,	  2008).	  For	  instance,	  when	  assessing	  the	  effect	  of	  a	  variable	  occurring	  during	  
the	   first	   five	   year	   of	   the	   disease	   (e.g.	   relapses),	   the	   endpoint	   must	   necessarily	  
happen	  at	  least	  after	  five	  years	  from	  onset.	  	  
	  
2.2.1.1	  Kaplan	  Meier	  analysis	  	  
	  
The	   Kaplan	   Meier	   technique	   maximizes	   the	   use	   of	   information	   available.	   Each	  
patient	  included	  in	  the	  analysis	  contributes	  to	  calculate	  the	  estimated	  probability	  of	  
an	   event,	   for	   as	   long	   as	   he/she	   is	   known	   to	   be	   event-­‐free.	   With	   the	   increasing	  
number	   of	   subjects	   experiencing	   the	   event,	   at	   certain	   time	  points,	   the	   cumulative	  
risk	  of	  attaining	  the	  endpoint	  becomes	   lower	  or,	   in	  other	  words,	   the	  probability	  of	  
surviving	   (remaining	   event	   free)	   becomes	   greater	   (Clark	   et	   al.,	   2003).	   The	   Kaplan	  
Meier	   survival	   curve	   represents	   a	   plot	   of	   the	   survival	   probability	   against	   the	   time	  
(disease	  duration)	  and	   it	   is	  used	  to	  estimate	  the	  median	  survival	   time	  to	  the	  event	  
(time	  at	  which,	  in	  50%	  of	  cases,	  the	  event	  occurred).	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Survival	   curves	  of	   two	  or	  more	  groups	  of	  patients	   can	  be	  compared	  using	   the	   log-­‐
rank	   test.	   This	   allows	   one	   to	   assessing	   the	   null	   hypothesis,	   where	   there	   is	   no	  
difference	  among	  groups,	  in	  the	  probability	  of	  an	  event	  (Peto	  et	  al.,	  1977).	  The	  log-­‐
rank	  test	  is	  based	  on	  the	  assumption	  that	  the	  survival	  probabilities	  are	  the	  same	  for	  
subjects	  early	  and	  late	  in	  the	  study.	  It	  calculates,	  in	  each	  group,	  at	  each	  time	  point,	  
the	  number	  of	  events	  observed	  and	  those	  expected	  since	  the	  occurrence	  of	  the	  last	  
event.	  The	  number	  of	  expected	  events	  is	  obtained	  by	  multiplying	  the	  proportion	  of	  
subjects	  at	  risk	  by	  the	  number	  of	  events	  observed	  at	  specific	  time	  point.	  The	  values	  
are	  used	   for	   computing	  a	   total	   expected	  number	  of	   events	   in	   each	  group,	   and	   for	  
making	   the	   comparison	   (Singh	   and	   Mukhopadhyay,	   2011).	   P-­‐values	   express	   the	  
statistical	  significance	  of	  the	  difference	  observed	  between	  the	  groups.	  The	  log-­‐rank	  
test	   can	  also	  be	  used	   for	   assessing	   the	  prognostic	   value	  of	   specific	  patient	   related	  
features,	  potentially	  affecting	  the	  survival	  time.	  	  
	  
However,	   Kaplan	   Meier	   analysis	   remains	   of	   limited	   value	   when	   assessing	   the	  
influence	  of	  multiple	   factors	  occurring	   simultaneously	   (multivariate	   analysis)	   (Clark	  
et	  al.,	  2003).	  	  
	  
2.2.1.2	  Cox	  regression	  analysis	  	  
	  
The	   Cox	   (proportional	   hazard	   [PH])	   linear	   regression	   model	   is	   widely	   used	   for	  
performing	  multivariate	  survival	  analyses	  (Bradburn	  et	  al.,	  2003a).	  By	  stratifying	  the	  
cohort	   into	   smaller	   subgroups,	   the	   Cox	   regression	   analysis	   allows	   to	   assess	   the	  
relationship	  between	  a	  set	  of	  covariates	  and	  the	  time	  to	  a	  particular	  event.	  	  
	  
Covariates	  in	  the	  model	  can	  be	  either	  categorical	  or	  numerical.	  The	  size	  of	  the	  risk	  of	  
reaching	   the	   endpoint,	   at	   specific	   times,	   for	   each	   covariate,	   is	   expressed	   by	   the	  
hazard	   ratio	   (HR).	   This	   is	   calculated	   from	   the	   regression	   coefficient,	   which	   can	   be	  
either	   negative	   (associated	   with	   a	   reduced	   risk)	   or	   positive	   (associated	   with	   an	  
increased	   risk).	   Therefore,	   an	   HR	   above	   1	   indicates	   that	   the	   covariate	   associates	  
positively	  with	  the	  event,	  and	  increases	  the	  risk	  proportionally.	  When	  the	  covariate	  
correlates	  with	   the	  event	  conversely,	   so	   that	  higher	  values	   reduce	   the	   risk,	   the	  HR	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value	  is	  below	  1.	  When	  analysing	  numerical	  covariates,	  HR	  expresses	  the	  risk	  of	  the	  
event	   due	   to	   a	   single	   unit	   value	   (e.g.	   1	   year	   of	   age).	   By	   using	   the	   regression	  
coefficient,	  the	  HR	  indicating	  the	  risk	  due	  to	  specific	  values	  (e.g.	  the	  risk	  when	  aged	  
30)	  can	  be	  calculated.	  	  
	  
2.2.1.3	  Cox	  regression	  analysis:	  multivariate	  models	  	  
	  
The	   great	   strength	   of	   the	   Cox	   regression	   analysis	   is	   the	   possibility	   to	   weight	   the	  
effect	   of	   each	   covariate	   on	   the	   outcome	   over	   time,	   and	   to	   assess	   the	   degree	   of	  
interdependency	   with	   the	   other	   variables.	   A	   covariate	   exerting	   a	   statistically	  
significant	  effect	  on	   the	   risk	  of	  experiencing	  an	  event,	   in	  a	  univariate	  analysis,	   can	  
become	   statistically	   NOT	   significant	  when	   tested	   along	  with	   other	   covariates,	   in	   a	  
multivariate	   analysis.	   For	   this	   reason,	   multivariate	   models	   are	   useful	   tools	   when	  
needing	   to	   estimate	   the	   risk	   of	   an	   event	   according	   to	   the	   concomitant	   effect	   of	  
several	  variables.	  A	  standard	  approach	  for	  building	  up	  multivariate	  models	  implies	  to	  
first	   test	   all	   variables	   of	   interest	   in	   the	   multivariate	   model.	   Subsequently,	   those	  
covariates	   found	   to	   have	   no	   statistically	   significant	   relevance	   (p	   >	   0.05)	   can	   be	  
excluded	  stepwise,	  until	  the	  model	  contains	  only	  variable	  impacting	  significantly	  (p	  <	  
0.05)	  on	  the	  risk.	  	  
	  
Finally,	   by	   combining	   the	   HRs	   from	   each	   covariate,	   impairing	   survival	   to	   varying	  
degree,	  we	  can	  obtain	  a	  single	  HR	  value,	  expressing	  the	  overall	  risk	  of	  attaining	  the	  
endpoint	  in	  a	  specific	  model.	  By	  combining	  the	  effect	  of	  all	  variables,	  specific	  clinical	  
scenarios	  can	  be	  simulated.	  	  
	  
2.2.1.4	  Cox	  regression	  analysis:	  adequacy	  of	  the	  model	  (goodness	  to	  fit)	  	  
	  
It	  is	  important	  to	  evaluate	  how	  well	  the	  model	  represent	  the	  data.	  The	  adequacy	  of	  a	  
survival	  model	  depends	  on	  whether	  it	  represents	  the	  survival	  patterns	  in	  the	  data	  to	  
an	  acceptable	  degree	  (Bradburn	  et	  al.,	  2003b).	  The	  key	  assumption	  of	  the	  PH	  model	  
is	  that	  the	  hazards	  of	  the	  event	   in	  any	  group	  are	  proportional	  (constant	  over	  time)	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and	   not	   overlapping	   at	   any	   time	   point.	   Adequate	   models	   do	   not	   violate	   the	   PH	  
assumption.	  To	  verify	   the	  PH	  assumption,	   the	  hazard	   in	  each	  group	  can	  be	  plotted	  
(Schoenfeld	   residual	   plot).	   If	   the	  model	   is	   valid,	   the	   hazard	   curves	   for	   the	   groups	  
should	  be	  parallel	  and	  should	  not	  cross,	  as	  shown	  in	  the	  plots	  below	  (Figure	  2.4).	  	  
	  
Figure	   2.4	  Cox	   regression	  analysis.	  Schoenfeld	   residual	  plots	   for	  checking	   the	  assumption	  of	   the	  PH	  
model.	  Hazard	  of	  attaining	  SP	  (A)	  and	  DSS	  6	   (B)	  over	  time	  (x-­‐axis)	  according	  to	  the	  number	  of	  early	  
relapses	  (y-­‐axis).	  Analysis	  of	  the	  LO	  database.	  	  
	  
	  
2.2.2	  Binary	  logistic	  regression	  analysis	  	  	  
	  
The	   binary	   logistic	   regression	   analysis	   can	   be	   used	   when	   assessing	   the	   effect	   of	  
covariates	  on	  the	  probability	  of	  a	  dichotomized	  event,	  occurring	  during	  some	  fixed	  
interval	  of	   follow	  up	   (Abbott,	   1985).	   The	  odds	   ratio	   (OR)	  expresses	   the	   size	  of	   the	  
effect	  exerted	  by	  the	  covariate.	  Similarly	  to	  Cox	  regression	  analysis,	  OR	  is	  calculated	  
from	   the	   regression	   coefficient,	  which	   can	  be	  negative	   (associated	  with	   a	   reduced	  
risk)	   or	   positive	   (associated	  with	   an	   increased	   risk).	   An	  OR	   of	   1	   indicates	   that	   the	  
odds	  of	  an	  outcome	  are	  equally	  likely	  for	  both	  groups	  under	  comparison.	  The	  higher	  
the	   value	   above	  1,	   the	   stronger	   is	   the	   relationship	  between	   the	   covariate	   and	   the	  
outcome.	   OR	   below	   1	   indicates	   a	   converse	   relationship	   with	   the	   outcome	   (the	  
covariate	  associates	  with	  a	  lower	  risk).	  	  
	  
Although	   the	   logistic	   regression	   often	   leads	   to	   similar	   conclusions,	   compared	   to	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progression	   (Green	   and	   Symons,	   1983),	   the	   Cox	   regression	   analysis	   remains	  more	  
attractive	  because	  of	   its	  ability	  of	  considering	   the	   time	  to	   the	  event.	  However,	   the	  
binary	  the	  logistic	  regression	  analysis	  can	  be	  useful	  when	  the	  Cox	  regression	  model	  
violates	   the	  PH	  assumption.	   In	   addition,	   the	   logistic	   regression	   analysis,	   unlike	   the	  
survival	   analyses,	   allows	   to	   assess	   the	   effect	   of	   time-­‐dependent	   covariates	   (e.g.	  
disease	  duration)	  on	  the	  outcome.	  	  
	  
2.2.2.1	  Binary	  logistic	  regression	  analysis:	  multivariate	  models	  	  
	  
Similarly	  to	  the	  Cox	  regression	  analysis,	  the	  binary	  logistic	  regression	  analysis	  can	  be	  
used	   for	  building	  up	  models,	   taking	   into	  account	   the	  concomitant	  effect	  of	   several	  
covariates.	  The	  ORs	  from	  each	  covariate,	  generated	  in	  the	  model,	  can	  then	  be	  used	  
for	  computing	  a	  single	  OR,	  expressing	  the	  overall	  probability	  of	  the	  event	  to	  occur,	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Chapter	  3	  	  
	  
	  
The	  long-­‐term	  disability	  accumulation	  and	  






























Over	  the	  past	  60	  years,	  a	  great	  wealth	  of	   information	  on	  the	  natural	  history	  of	  the	  
disease	  has	  been	  collected.	  Despite	  this,	  MS	  prognosis	  keeps	  puzzling	  clinicians	  and	  
remains	   largely	   unpredictable,	   especially	   at	   individual	   level.	   Clinical	   features	   are	  
heterogeneous	   and	   the	   disease	   severity	   ranges	   from	   benign	   forms	   to	   malignant	  
cases	  (Lublin	  and	  Reingold,	  1996).	  	  
	  
Familiarity	   with	   the	   natural	   history	   of	   MS	   is	   crucial	   to	   the	   understanding	   of	   the	  
health,	  social	  and	  economic	   impact	  of	  the	  disease	  on	  the	  patients,	  their	  family	  and	  
careers	   as	   a	   whole.	   A	   detailed	   knowledge	   of	   the	   overall	   disease	   course	   helps	  
physicians	  managing	  patients	  and	  it	  also	  gives	  reasonable	  expectations	  for	  the	  long	  
term	   outcome	   to	   the	   individual	   patient,	   facing	   decisions	   on	   his/her	   personal	   and	  
professional	  life.	  MS	  registries	  are	  a	  valuable	  source	  of	  information	  for	  improving	  our	  
understanding	   of	   the	   disease	   prognosis.	   They	   can	   serve	   as	   important	   guide	   for	  
clinical	  and	  therapeutic	  decisions,	  and	  ultimately	  for	  optimizing	  the	  use	  of	  currently	  
available	   DMTs.	   By	   Identifying	   risk	   factors,	   we	   can	   rationalize	   the	   therapeutic	  
approach,	  in	  order	  to	  treat	  timely	  and	  aggressively	  those	  at	  higher	  risk	  of	  developing	  
severe	   disability,	   and	   to	   avoid	   exposing	   non	   disabled	   young	   adults	   to	   potentially	  
toxic	  drugs.	   In	  addition,	   information	  on	   the	  disease	  course	  enables	   to	   improve	   the	  
RCTs	  methodology,	   by	   refining	   inclusion	   criteria	   and	  by	   calculating,	  within	   defined	  
limits,	  the	  sample	  size	  and	  the	  follow	  up	  required	  for	  detecting	  a	  beneficial	  effect	  of	  
therapies.	   Finally,	   natural	   history	   studies	   can	   offer	   important	   clues	   on	   possible	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3.1.1	  The	  methodology	  of	  natural	  history	  studies	  	  
	  
To	  obtain	  reliable	  information	  on	  the	  natural	  course,	  data	  should	  be	  gathered	  from	  a	  
population	   that	   can	   be	   representative	   of	   the	   disease	   as	   a	   whole.	   This	   can	   be	  
achieved	   in	  geographically	  based	   studies,	   including	  all	   cases	  of	  MS	   living	   in	  a	  well-­‐
defined	  geographical	  area	  (Confavreux	  et	  al.,	  1980;	  Runmarker	  and	  Andersen,	  1993;	  
Tremlett	   et	   al.,	   2006;	   Weinshenker	   et	   al.,	   1989b).	   A	   large	   number	   of	   patients	   is	  
needed	   and,	   as	   the	   disease	   course	   normally	   spans	   over	   40-­‐50	   years,	   decades	   of	  
follow	  up	  are	  necessary.	  Collecting	  data	  over	  the	  long	  term	  is	  extremely	  challenging	  
and	   requires	   huge	   efforts,	   especially	   for	   systematically	   following	   up	   each	   patients	  
and	  minimizing	  missing	  information	  (Ebers,	  2001).	  	  
	  
Unfortunately,	   longitudinal	   studies	   are	   often	   affected	   by	   different	   sources	   of	   bias	  
(Table	   3.1).	   Ideally,	   all	   cases	   should	   be	   identified	   at	   the	   disease	   onset	   and	   data	  
should	  be	  collected	  prospectively	  until	  death	  (inception	  cohort).	  However,	  inception	  
cohorts	  of	  MS	  patients	  are	  virtually	   impossible	  to	  obtain,	  as	  the	  clinical	  onset	  does	  
not	  correspond	  to	  the	  biological	  onset	  of	   the	  disease.	   In	  addition,	   the	   long	  disease	  
course	   often	   prevents	   physicians	   from	  maintaining	   longitudinal	   assessments	   of	   all	  
patients.	  When	  high	  levels	  of	  disability	  are	  reached	  extra	  efforts	  should	  be	  made	  to	  
follow	  up	  home	  bound	  or	   institutionalized	  patients,	   in	  order	   to	  maximize	   the	  data	  
collection.	   When	   gathered	   retrospectively,	   data	   might	   be	   inaccurate,	   owing	   to	  
limited	  information	  in	  medical	  records	  and	  to	   imprecision	  of	  patients	  recall	   (“recall	  
bias”).	  	  
	  
Furthermore,	   the	   accessibility	   to	   neurologists,	   the	   varying	   medical	   care	   standards	  
and	  the	  cultural	  differences,	  with	  regards	  to	  seeking	  for	  medical	  attention,	  represent	  
potential	   sources	   of	   “ascertainment	   bias”.	   Hospital-­‐based	   and	   clinic-­‐based	   studies	  
are	   often	   biased	   by	   a	   predominance	   of	   more	   severe	   cases.	   Consequently,	   the	  
number	   of	   patients	   with	   benign	   forms,	   who	   tend	   not	   to	   attend	   the	   specialized	  
clinics,	   might	   be	   artificially	   low,	   and	   the	   study	   might	   ultimately	   overestimate	   the	  
disease	   severity.	  However,	   some	   tertiary	  centres	  can	  see	  virtually	  all	   cases	   in	   their	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area,	  especially	  when	  they	  benefit	  from	  epidemiological	  studies,	  which	  minimize	  the	  
ascertainment	   bias	   (Runmarker	   and	   Andersen,	   1993;	   Weinshenker	   et	   al.,	   1989b),	  
other	  see	  only	  the	  majority	  of	  cases	  (Confavreux	  et	  al.,	  1980;	  Tremlett	  et	  al.,	  2006).	  
In	   population-­‐based	   cohorts,	   patients’	   migration	   can	   also	   influence	   the	   quality	   of	  
data	   (“migration	   bias”)	   (Miller	   et	   al.,	   1992;	   Sumelahti	   et	   al.,	   2002).	   In	   addition,	  
during	   the	   study,	   the	   frequency	   of	   assessments	   and	   the	   “compliance	   bias”	   (when	  
patients	  expectations	  alter	  the	  examination	  findings)	  can	  affect	  the	  accuracy	  of	  the	  
disability	  scores.	  This	  can	  be	  minimized	  by	  sufficiently	  long	  follow	  ups	  and	  frequent	  
clinical	  evaluations,	  carried	  out	  at	  fixed	  intervals	  (Degenhardt	  et	  al.,	  2009).	  	  
	  
Table	  3.1	  Sources	  of	  bias	  potentially	  affecting	  the	  quality	  of	  natural	  history	  data,	  and	  ideal	  features	  of	  
a	  natural	  history	  cohort.	  	  
	  
	  
3.1.2	  MS	  registries	  	  
	  
Muller	  was	  the	  first	  to	  describe	  the	  evolution	  of	  MS	  over	  time	  (Muller,	  1949).	  Since	  
then,	  our	  knowledge	  on	  the	  natural	  history	  of	  the	  disease	  has	  been	  mainly	  based	  on	  
long-­‐term	  cohort	  studies,	  spanning	  over	  the	  past	  60	  years.	  Table	  3.2	  summarizes	  the	  
methodological	   features	   of	   the	   most	   important	   MS	   registries	   from	   US	   veterans	  
(Kurtzke	  et	  al.,	  1977;	  Kurtzke	  et	  al.,	  1979),	  Los	  Angeles	  (US)	  (Clark	  et	  al.,	  1982;	  Detels	  
et	  al.,	  1982;	  Visscher	  et	  al.,	  1984),	  Europe	  (multicentre)	  (Riise	  et	  al.,	  1992),	  Denmark	  
(Bronnum-­‐Hansen	  et	  al.,	  1994;	  Bronnum-­‐Hansen	  et	  al.,	  2004),	  Sweden	   (Eriksson	  et	  
al.,	  2003;	  Runmarker	  and	  Andersen,	  1993;	  Skoog	  et	  al.,	  2012),	  Norway	  (Myhr	  et	  al.,	  
2001),	  Germany	   (Poser	  et	  al.,	  1982a),	  Groningen	   (The	  Netherland)	   (Minderhoud	  et	  
al.,	   1988b),	   Turkey	   (Kantarci	   et	   al.,	   1998),	   Scotland	   (UK)	   (Phadke,	   1987;	   Phadke,	  
1990),	  Lyon	  (France)	  (Confavreux	  et	  al.,	  1980;	  Confavreux	  et	  al.,	  2000;	  Confavreux	  et	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(France)	  (Leray	  et	  al.,	  2010),	  British	  Columbia	  (Canada)	  (Kingwell	  et	  al.,	  2012;	  Koch	  et	  
al.,	  2009;	  Koch	  et	  al.,	  2010;	  Sayao	  et	  al.,	  2007;	  Tremlett	  et	  al.,	   2005;	  Tremlett	  and	  
Devonshire,	   2006;	   Tremlett	   et	   al.,	   2006;	   Tremlett	   et	   al.,	   2008a;	   Tremlett	   et	   al.,	  
2008b;	  Tremlett	  et	  al.,	  2009a;	  Tremlett	  et	  al.,	  2009b)	  and	  London	  Ontario	  (Canada)	  
(Cottrell	  et	  al.,	  1999a;	  Cottrell	  et	  al.,	  1999b;	  Ebers	  et	  al.,	  2000;	  Kremenchutzky	  et	  al.,	  
1999a;	  Kremenchutzky	  et	  al.,	  2006a;	  Weinshenker	  et	  al.,	  1989b;	  Weinshenker	  et	  al.,	  
1989c;	  Weinshenker	  et	  al.,	  1991a;	  Weinshenker	  et	  al.,	  1991b).	  	  
	  
General	   findings	   from	   natural	   history	   studies	   allow	   to	   draw	  meaningful	   and	   often	  
cohering	  overall	   conclusions,	  however	  methodologies,	  demographics	  and	  choice	  of	  
endpoints	   largely	   vary,	   making	   comparison	   not	   always	   simple	   (Degenhardt	   et	   al.,	  
2009).	   The	   majority	   of	   studies	   gathered	   information	   retrospectively	   and	   partially	  
prospectively	   and	   few	   studies	   collected	   data	   only	   longitudinally.	   Although	   the	  
completeness	  of	  data	  acquisition	  is	  a	  cardinal	  feature,	  the	  percentage	  of	  cases	  lost	  to	  
follow	   up	   is	   often	   not	   clearly	   addressed.	   In	   addition,	   ascertainment	  might	   remain	  
incomplete,	  despite	  the	  use	  of	  prevalence	  material	  (geographically	  based	  studies).	  	  
	  
Each	   study	   has	   contributed	   to	   our	   understanding	   of	   the	   disease	   course	   and	   the	  
prognosis.	   However,	   here	   I	   analysed	   the	   methodology	   of	   those	   databases	  
advantaged	  by	  a	  large	  sample	  size,	  long	  duration	  of	  follow	  up	  and	  high	  accuracy	  and	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3.1.2.1	  The	  Lyon	  database	  	  	  
	  
Confavreux	   has	   been	   one	   of	   the	   pioneers	   of	   modern	   natural	   history	   studies	  
(Confavreux	  et	  al.,	  1980;	  Confavreux	  et	  al.,	  2000;	  Confavreux	  et	  al.,	  2003;	  Confavreux	  
and	   Vukusic,	   2006a;	   Confavreux	   and	   Vukusic,	   2006b).	   The	   Lyon	   cohort	   was	  
established	   in	   1957	   and	   included	   all	   patients	  with	   a	   diagnosis	   of	  MS,	   according	   to	  
Poser’s	  classification	  (Poser	  et	  al.,	  1983),	  attending	  the	  only	  referral	  centre	  in	  the	  city	  
of	  Lyon	  and	  the	  region	  of	  Rhone-­‐Alpes.	  Data	  were	  computerized	  in	  1990,	  using	  the	  
EDMUS	   software	   (Confavreux	   et	   al.,	   1992a).	   This	   helped	   to	   standardize	   clinical	  
evaluations,	   as	   the	   regional	   network	   of	   neurologists	   received	   regular	   EDMUS	  
training.	  	  
	  
The	   database	   is	   therefore	   advantaged	   by	   a	   geographically	   based	   ascertainment,	  
which	   led	   to	   the	   recruitment	   of	   1844	   patients.	   These	   were	   followed	   up	  
longitudinally,	  with	   yearly	   assessments,	   until	   1997,	  when	   the	   database	  was	   closed	  
for	  research	  purpose.	  By	  the	  end	  of	  the	  observation	  period,	  the	  total	  population	  had	  
a	  mean	  disease	  duration	  of	  11	  years:	  1066	   (57.8%)	  were	  still	   in	   the	  RR	  phase,	  496	  
(26.8%)	   had	   converted	   to	   SP	   MS	   and	   282	   (15.2%)	   had	   PP	   course.	   Disability	   was	  
assessed	  using	  the	  DSS	  (Kurtzke,	  1955),	  and	  focused	  was	  placed	  on	  irreversible	  (for	  
at	   least	  6	  months)	  scores	  of	  4	   (limited	  walking	  ability,	  but	  without	  aid	  or	   rest	   for	  
more	  than	  500	  meters),	  which	  was	  attained	  by	  56%	  (n	  =	  1026),	  score	  of	  6	  (ability	  to	  
walk	  with	   unilateral	   support	   no	  more	   than	   100	  meters	  without	   rest),	  which	  was	  
attained	   by	   32%	   (595)	   and	   score	   of	   7	   (ability	   to	   walk	   no	   more	   than	   10	   meters	  
without	   rest	  while	   leaning	   against	   a	  wall	   or	   holding	   onto	   furniture	   for	   support),	  
which	   was	   attained	   by	   21%	   (n	   =	   380).	   Almost	   half	   (n	   =	   804)	   of	   the	   population	  
received	  Azathioprine	  at	  some	  point	  during	  the	  disease	  course.	  	  
	  
3.1.2.2	  The	  Rennes	  database	  	  	  
	  
Patients	   in	   the	   Rennes	   database	   were	   identified	   through	   the	   Rennes	  MS	   Clinic,	   a	  
regional	  centre	   for	  MS	   in	  west	  France,	   serving	  Britanny,	  Pays	  de	  Loire	  and	  borders	  
regions	  (Leray	  et	  al.,	  2010).	  The	  ascertainment	  was	  therefore	  mainly	  geographically	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based	   and	   started	   in	   1976.	   Data	  were	   collected	   retrospectively	   for	   those	   patients	  
with	   disease	   onset	   prior	   to	   this,	   and	   then	   longitudinally	   collected	   up	   to	   2004.	  
Information	  were	  computerized	   in	  1996	  using	   the	  EDMUS	  software	   (Confavreux	  et	  
al.,	  1992a).	  	  
	  
By	   the	   end	   of	   the	   study	   (2004),	   2054	   patients	   diagnosed	   with	   MS,	   according	   to	  
Poser’s	  criteria	  (Poser	  et	  al.,	  1983),	  were	  recruited.	  In	  the	  total	  population	  the	  mean	  
disease	  duration	  was	  12	  years	  and	  the	  disability	  was	  scored	  using	  the	  EDSS	  (Kurtzke,	  
1983).	   However,	   for	   data	   analysis	   authors	   preferred	   to	   use	   the	   10	   step	   scale	  
(Kurtzke,	  1955)	  and	  focused	  on	  irreversible	  (sustained	  for	  at	  least	  6	  months)	  score	  of	  
3	   (moderate	  disability)	  and	  score	  of	  6	   (unilateral	   assistance	   required	   to	  walk	  100	  
meters).	  In	  the	  total	  population,	  445	  patients	  (21.7%)	  had	  progressive	  onset	  (PP	  MS)	  
and	   1609	   patients	   (78.3%)	   had	   relapsing	   onset.	   Among	   those,	   618	   (38.4%)	   had	  
converted	  to	  SP	  MS.	  	  During	  the	  follow	  up	  period,	  68.9%	  reached	  DSS	  3	  and	  35%	  DSS	  
6.	  A	  total	  of	  1154	  (56.2%)	  received	  DMTs	  for	  at	  least	  6	  months.	  	  
	  
3.1.2.3	  The	  Gothenburg	  database	  	  	  
	  
The	   Gothenburg	   MS	   clinic	   served	   all	   patients	   diagnosed	   with	   MS,	   according	   to	  
Poser’s	   criteria	   (Poser	  et	  al.,	  1983),	   living	   in	  Gothenburg	   from	  1950	   to	  1964	  at	   the	  
time	   of	   the	   disease	   onset	   (Eriksson	   et	   al.,	   2003;	   Runmarker	   and	   Andersen,	   1993;	  
Skoog	  et	  al.,	   2012).	  Data	  were	  collected	   longitudinally	   for	  more	   than	  25	  years	  and	  
follow	  up	  was	  extended	  up	  to	  2009	  (Skoog	  et	  al.,	  2012).	  At	  that	  point	  the	  database	  
comprised	  255	  patients;	  44	  (17.2%)	  had	  PP	  course,	  40	  (15.6%)	  had	  remained	  in	  the	  
RR	  phase	  and	  162	  	  (63.5%)	  had	  converted	  to	  SP	  MS.	  For	  9	  patients,	  the	  type	  of	  the	  
disease	   course	   could	   not	   be	   established	   (Skoog	   et	   al.,	   2012).	   The	   disability	   was	  
scored	  using	  the	  DSS	  (Kurtzke,	  1955),	  and	  the	  analyses	  focused	  on	  DSS	  6	  (unilateral	  
support	   needed	   for	   short	   distance	   to	   walk),	   DSS	   7	   (essentially	   wheelchair	  
dependent)	  and	  DSS	  10	  (death	  due	  to	  MS).	  No	  patient	  received	  any	  DMTs.	  Despite	  
the	  small	  sample	  size,	  the	  database	  is	  advantaged	  by	  high	  geographic	  ascertainment,	  
by	   the	  minimal	   number	   of	   patients	   (n	   =	   3)	   loss	   of	   follow	  up	   and	   by	   the	   extended	  
longitudinal	  assessments.	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3.1.2.4	  The	  British	  Columbia	  database	  	  	  
	  
The	  university	  of	  British	  Columbia’s	  MS	  clinic	  was	  established	  in	  1980	  and	  incudes	  4	  
clinics,	  covering	  80%	  of	  the	  MS	  population	  in	  British	  Columbia	  (Sweeney	  et	  al.,	  1986).	  
Data	  were	   collected	   retrospectively	   for	   those	   patients	  with	   disease	   onset	   prior	   to	  
this,	   and	   then	   longitudinally,	   up	   to	   2003.	   By	   the	   end	   of	   observation	   period,	   5727	  
patients	   with	   definite	   MS	   according	   to	   Poser’s	   criteria	   (Poser	   et	   al.,	   1983),	   were	  
identified.	  However,	  analyses	   included	  only	  patients	  with	  minimum	  15	  years	  follow	  
up.	  Therefore,	  the	  cohort	  consisted	  of	  2837	  patients	  with	  a	  mean	  disease	  duration	  of	  
20	  years;	  353	  (12.4	  %)	  had	  PP	  MS	  and	  2484	  (87.6%)	  had	  initial	  RR	  course,	  of	  whom	  
1445	  (50.9%	  of	  the	  total	  population)	  had	  entered	  the	  SP	  phase	  (Tremlett	  et	  al.,	  2005;	  
Tremlett	   and	   Devonshire,	   2006;	   Tremlett	   et	   al.,	   2006;	   Tremlett	   et	   al.,	   2008a;	  
Tremlett	  et	  al.,	   2009a).	  Disability	  was	  assessed	  using	   the	  EDSS	   (Kurtzke,	  1983)	  and	  
analyses	   focused	   on	   irreversible	   (sustained	   for	   >	   150	   days)	   score	   of	   3,	   (moderate	  
disability),	   of	   6	   (cane	   requirement)	   and	   of	   8	   (wheelchair	   bound).	   A	   total	   of	   439	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3.1.3	  Clinical	  and	  demographic	  features	  of	  MS	  
	  
	  
Natural	   history	   cohorts	   provide	   a	   comprehensive	   amount	   of	   data	   about	  
demographic	  and	  clinical	  characteristics	  of	  the	  disease.	  Information,	  to	  large	  extent,	  
appears	  consistent	  among	  studies	  (Table	  3.4),	  however	  some	  discrepancies	  exist	  and	  
are	  probably	  due	  to	  methodological	  differences.	  
	  
Table	  3.4	  Female/male	  ratio	  in	  natural	  history	  cohorts.	  	  
	  
	  
3.1.3.1	  Sex	  ratio	  
	  
	  
The	  Female/Male	  (F/M)	  ratio	  has	  gained	  increasing	  interest	  during	  recent	  years.	  It	  is	  
considered	   a	   robust	   epidemiological	   marker	   and	   can	   be	   used	   as	   internal	   control,	  
within	  the	  same	  group,	  for	  testing	  the	  potential	  impact	  of	  ascertainment	  bias	  (Orton	  
et	  al.,	  2006;	  Trojano	  et	  al.,	  2012).	  	  
	  
Interestingly,	  at	  the	  beginning	  of	  last	  century	  MS	  was	  thought	  to	  be	  a	  predominantly	  
male	   disease	   (Brain,	   1930),	   and	   in	   the	   late	   70s	   it	   was	   first	   described	   a	   female	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preponderance	   (Acheson,	  1977).	  There	   is	  now	  consensus	   that	  women	  are	   twice	  as	  
likely	  than	  men	  to	  be	  affected	  by	  MS	  (Compston	  and	  Coles,	  2008).	  However,	  the	  F/M	  
ratio	  largely	  varies	  among	  natural	  history	  cohorts	  (Table	  3.4).	  The	  highest	  proportion	  
of	   MS	   women	   was	   reported	   in	   the	   Lorraine	   cohort	   (72%;	   F/M	   ratio	   =	   2.6)	   from	  
France	  (Debouverie	  et	  al.,	  2008),	  and	  the	  smallest	  proportion	  (60%;	  F/M	  ratio	  =	  1.5)	  
was	   observed	   in	   Danish	   and	   Swedish	   studies,	   advantaged	   by	   a	   large	   sample	   size	  
(Bronnum-­‐Hansen	   et	   al.,	   2004)	   and	   by	   a	   geographically	   based	   ascertainment	  
(Runmarker	  and	  Andersen,	  1993).	  	  
	  
It	  is	  now	  well	  established	  that	  the	  proportion	  of	  women	  affected	  by	  the	  disease	  has	  
increased	  over	  time.	  This	  was	  observed	  in	  Canada	  (Sadovnick,	  2009),	  Japan	  (Houzen	  
et	  al.,	  2003;	  Osoegawa	  et	  al.,	  2009),	  Denmark	  (Bentzen	  et	  al.,	  2010),	  Iran	  (Maghzi	  et	  
al.,	  2010),	  France	  (Debouverie	  et	  al.,	  2007),	  Norway	  (Celius	  and	  Smestad,	  2009),	  US	  
(Wallin	   et	   al.,	   2004)	   and	   Australia	   (Barnett	   et	   al.,	   2003).	   A	   more	   sophisticated	  
approach,	  using	  stratification	  by	  year	  of	  birth,	  which	  minimizes	  the	  artefact	  related	  
to	   the	  ascertainment,	   confirmed	   this	   trend.	   In	  a	   sample	  of	  more	   than	  27000	  cases	  
from	  Canada,	  the	  F/M	  ratio	  for	  the	  entire	  cohort	  increased	  over	  50	  years,	  from	  1.33	  
to	  3.96	  (Orton	  et	  al.,	  2006).	  Similar	  results	  were	  reported	  in	  two	  smaller	  studies	  from	  
Iran	   (about	   8000	   cases)	   and	   from	   the	  MSbase	   registry	   (about	   15000	   cases),	   both	  
using	   the	   year	   of	   birth	   approach	   (Sahraian	   et	   al.,	   2010;	   Trojano	   et	   al.,	   2012).	  
Interestingly,	   among	   patients	   from	   the	   Msbase	   registry,	   the	   increased	   F/M	   ratio	  
(from	   2.35	   to	   2.73	   over	   60	   years)	   was	   paralleled	   by	   an	   increased	   proportion	   of	  
women	  with	  RR	  disease	  (Trojano	  et	  al.,	  2012).	  Furthermore,	  a	  recent	  study	  from	  the	  
Canadian	   Collaborative	   Project	   demonstrated	   a	   gradual	   increase	   of	   the	   F/M	   ratio	  
over	   time	   in	   RR	   MS	   only,	   and	   no	   significant	   changes	   in	   the	   PP	   MS	   group	  
(Ramagopalan	  et	  al.,	  2010)	   (Figure	  3.1).	  The	  magnitude	  of	   the	   increasing	  F/M	  ratio	  
was	  also	  shown	  to	  be	  highest	  in	  northern	  latitudes	  and	  lowest	  in	  southern	  latitudes	  
(Figure	  3.1).	  The	  authors	  concluded	  that	  the	  global	  increase	  of	  the	  MS	  incidence	  and	  
the	  “gradient	  effect”	  might	  be	  partially	  driven	  by	  females	  with	  RR	  course	  (Trojano	  et	  
al.,	  2012).	  However,	  a	  recent	  Norwegian	  study	  could	  not	  replicate	  these	  results,	  and	  
found	  no	  association	  between	  sex	  ratio	  changes	  and	  the	   latitude	   (Kampman	  et	  al.,	  
2013).	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Figure	  3.1	  Mean	  sex	  ratio	  change	  (y-­‐axis)	  over	  time,	  in	  patients	  grouped	  by	  year	  of	  birth	  (x-­‐axis)	  and	  




The	  factors	  accounting	  for	  the	  increasing	  number	  of	  women	  affected	  by	  MS	  remain	  
unclear.	   Given	   the	   relatively	   short	   time	   over	   which	   this	   was	   observed,	   this	   trend	  
cannot	   be	   attributed	   to	   genetic	   changes	   but	   more	   likely	   to	   gene-­‐environment	  
interactions	   (Orton	  et	  al.,	   2006).	  Other	  possible	   candidates	  are	   smoking,	   known	   to	  
affect	   the	   risk	   of	  MS	   (Hernan	   et	   al.,	   2001)	   and	   to	   have	   increased	   in	   women	   over	  
time,	  and	  changes	  in	  lifestyle	  (Sellner	  et	  al.,	  2011).	  
	  
3.1.3.2	  Age	  at	  onset	  	  
	  
It	   is	   not	   always	   easy	   to	   determine	   when	   the	   first	   clinical	   presentation	   occurred,	  
especially	  if	  the	  onset	  is	  characterized	  by	  vague,	  sensory	  symptoms.	  The	  oldest	  age	  
disease	   onset	   (35	   years)	   was	   reported	   among	   patients	   from	   the	   Danish	   database	  
(Bronnum-­‐Hansen	   et	   al.,	   2004),	   and	   the	   youngest	   age	   (27	   years)	   among	   Turkish	  
patients	   (Kantarci	   et	   al.,	   1998).	   This	   variability	   among	   studies	   probably	   reflects	  
differences	  in	  the	  proportion	  of	  retrospectively	  collected	  information.	  Nevertheless,	  
there	  is	  a	  general	  consensus	  that	  disease	  starts	  on	  average	  at	  around	  the	  age	  of	  30	  
(Compston	  and	  Coles,	  2008).	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3.1.3.3	  Presenting	  symptoms	  	  
	  
	  
Table	   3.5	  Symptoms	  at	   the	  disease	  onset	   in	  natural	  history	  cohorts.	   Patients	   can	   experience	  more	  
than	  one	  symptom	  at	  onset.	  	  
	  
	  
Similarly	   to	   age,	   the	   retrospective	   ascertainment	   of	   symptoms	   occurring	   at	   the	  
disease	   onset	   might	   be	   difficult.	   In	   addition,	   attributing	   symptoms	   to	   specific	  
anatomic	  locations	  it	  is	  not	  always	  straightforward.	  Therefore,	  the	  categorization	  of	  
neurological	   disturbances	   varies	   among	   studies	   (Table	   3.5).	   For	   instance,	   in	   the	  
cohorts	   from	   the	   EDMUS	   databases	   (Confavreux	   et	   al.,	   2003;	   Debouverie	   et	   al.,	  
2008;	   Leray	   et	   al.,	   2010),	   motor,	   sensory,	   cerebellar	   and	   sphincter	   symptoms	   are	  
pooled	   together,	   and	   categorized	   as	   “long	   tracts	   dysfunction”.	   However,	   there	   is	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general	   agreement,	   among	   MS	   registries,	   that	   sensory	   disturbances	   are	   the	  
commonest	  presenting	  symptoms,	  followed	  by	  motor	  dysfunctions	  (Table	  3.5).	  	  
	  
3.1.4	  The	  type	  of	  the	  disease	  course	  
	  
It	   is	   well	   established	   that	   the	   majority	   of	   MS	   patients	   present	   with	   an	   initial	   RR	  
course,	  and	  only	  a	  minority	  experience	  a	  progressive	  course	  from	  onset.	  However,	  in	  
some	   cases,	   categorizing	   correctly	   the	   disease	   course	   might	   be	   complicated.	   The	  
diagnosis	   of	   PP	  MS	   has	   intrinsic	   difficulties,	   as	   it	   can	   only	   be	   made	   in	   retrospect	  
(Lublin	  and	  Reingold,	  1996).	  In	  addition,	  especially	  when	  not	  seen	  at	  onset,	  patients	  
might	  forget	  previous	  attacks,	  which	  occurred	  years	  before	  the	  assessment.	  This	  can	  
result	   in	   an	   overestimation	   of	   the	   number	   of	   cases	   with	   a	   true	   PP	   course	  
(Kremenchutzky	   et	   al.,	   1999a).	   These	   factors	   probably	   account	   for	   the	   variable	  
proportion	  of	  PP	  MS,	  among	  natural	  history	   cohorts	   (Figure	  3.2),	   ranging	   from	   the	  
excessively	   high	   37%	   in	   Netherland	   (Minderhoud	   et	   al.,	   1988a),	   which	   probably	  
reflects	   the	   study	   methodology	   focused	   on	   the	   assessment	   of	   the	   onset	   of	  
progression,	   to	   the	  very	   low	  9%	  reported	   in	  Scotland	  (Phadke,	  1987).	   	  On	  average,	  
15%	  of	  cases	  with	  a	  PP	  course	   is	  considered	  a	  reasonable	  estimate	  (Compston	  and	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Figure	  3.2	  Percentage	  of	  patients	  (x-­‐axis)	  with	  PP	  MS,	  among	  natural	  history	  cohorts:	  the	  exact	  value	  




3.1.4.1	  Clinical	  and	  demographic	  features	  according	  to	  the	  type	  of	  the	  disease	  
course	  
	  
The	   disease	   phenotypes	   are	   distinguished	   by	   different	   clinical	   and	   demographic	  
features.	   Since	   the	   early	   studies	   it	   has	   been	   described	   a	   higher	   incidence	   of	   a	   PP	  
course	   among	   men,	   compared	   to	   women	   (Muller,	   1951).	   The	   F/M	   ratio	   remains	  
shifted	  towards	  a	  female’s	  preponderance	  in	  RR	  MS,	  but	  it	  becomes	  much	  closer	  to	  
unity	  in	  PP	  MS:	  1.3	  (Confavreux	  and	  Vukusic,	  2006a),	  1.4	  (Leray	  et	  al.,	  2010)	  and	  1.06	  
(Tremlett	  et	  al.,	  2005).	  	  
	  
In	  addition,	  initial	  symptoms	  vary	  in	  relation	  to	  the	  type	  of	  the	  disease	  course.	  Motor	  
disturbances	  are	  the	  most	  common	  symptoms	  at	  the	  onset	  of	  the	  PP	  and	  of	  the	  SP	  
courses	  (Cottrell	  et	  al.,	  1999b;	  Kremenchutzky	  et	  al.,	  2006a),	  whereas	  optic	  neuritis	  
and	   sensory	   problems	   are	  more	   likely	   to	   occur	   as	   presenting	   symptoms	  of	   the	  RR	  
course	  (Confavreux	  and	  Vukusic,	  2006a;	  Leray	  et	  al.,	  2010;	  Riise	  et	  al.,	  1992;	  Tremlett	  
et	   al.,	   2009b).	   Relapsing	   onset	   and	   progressive	   onset	   patients	   are	   also	   strikingly	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years	   later	   than	   RR	   MS,	   however	   the	   age	   at	   the	   onset	   of	   progression	   has	   been	  
reported	  very	  similar,	  between	  PP	  and	  SP	  patients	  (Confavreux	  and	  Vukusic,	  2006a;	  
Koch	  et	  al.,	  2007;	  Leray	  et	  al.,	  2010;	  Tutuncu	  et	  al.,	  2013).	  The	  only	  study	  that	  failed	  
to	  replicate	  this	  observation	  was	  from	  the	  British	  Columbia	  database	  (Tremlett	  et	  al.,	  
2009b).	  	  
	  
Table	  3.6	  Mean	  age	  at	  onset	  of	  RR,	  SP	  and	  PP	  MS	  reported	  in	  natural	  history	  cohorts.	  	  
	   	  
	  
3.1.5	  Accumulation	  of	  disability	  	  
	  
Among	  natural	  history	  cohorts,	  the	  accumulation	  of	  disability	  has	  been	  assessed	  with	  
the	   Kaplan	   Meier	   survival	   analysis,	   estimating	   the	   mean	   and	   median	   times	   to	  
DSS/EDSS	   landmarks	   levels.	  As	  discussed	   in	  methods	  (Chapter	  2),	   the	  Kaplan	  Meier	  
estimate	   is	   affected	   by	   the	   number	   of	   patients	   reaching	   the	   endpoint	   (censored	  
information),	   which	   is	   a	   direct	   function	   of	   the	   duration	   of	   the	   follow	   up.	   This	  
probably	  accounts	  for	  the	  differences	  observed	  among	  studies	  (Figure	  3.3).	  I	  choose	  
the	   attainment	   of	   DSS/EDSS	   levels	   of	   6	   for	   comparing	   the	   outcome	   among	  
databases,	   as	   it	   is	   the	  most	   commonly	   used	   endpoint	   and	   its	   definition	   (need	   for	  
unilateral	  support	  to	  walk	  ≤	  100	  meters	  without	  rest)	  does	  not	  vary	  among	  cohorts	  
(Confavreux	  et	  al.,	  2003;	  Debouverie	  et	  al.,	  2008;	  Kantarci	  et	  al.,	  1998;	  Leray	  et	  al.,	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Figure	  3.3	  Kaplan	  Meier	  median	  times	  (x-­‐axis)	  to	  EDSS/DSS	  6	  in	  natural	  history	  cohorts.	  Percentages	  
of	  patients	  reaching	  the	  endpoint,	  when	  available,	  are	  indicated	  in	  brackets	  next	  to	  each	  bar.	  On	  the	  
y-­‐axis	  are	  listed	  the	  geographic	  location	  of	  natural	  history	  studies,	  the	  sample	  size	  (in	  bracket)	  and	  the	  





Unfortunately,	  the	  number	  of	  lost	  to	  follow	  up	  and	  the	  censored	  information	  remain	  
unmentioned	  in	  most	  of	  studies.	  The	  estimated	  median	  time	  to	  EDSS/DSS	  6	  mainly	  
ranged	  between	  18	  and	  20	  years.	  The	  British	  Columbia	  cohort	  again	  stands	  out	  as	  an	  
outlier,	   showing	   a	   remarkably	   slow	   rate	   of	   disability	   accumulation	   (27.9	   years)	  
(Tremlett	  et	  al.,	  2006),	  which	  might	  be	  partially	  accounted	  for	  by	  the	  relatively	  small	  
percentages	  of	  patients	  with	  PP	  course	  (Figure	  3.2).	  	  
	  
3.1.5.1	  The	  onset	  of	  secondary	  progression	  	  
	  
As	  largely	  discussed	  in	  chapter	  1	  (paragraph	  1.2),	  defining	  the	  onset	  of	  the	  SP	  phase	  
remains	   difficult,	   especially	   when	   it	   is	   clouded	   by	   concomitant	   relapses	  
(Kremenchutzky	   et	   al.,	   2006a).	   For	   this	   reason,	   among	   natural	   history	   studies,	   the	  
onset	   of	   progression	   has	   not	   been	   explored	   as	   often	   as	   the	   attainment	   of	   severe	  
disability.	   In	   early	   studies	   the	   time	   to	   SP	  was	   calculated	  without	   using	   the	   Kaplan	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Meier	  analysis,	  and	  varied	  between	  9	  (Runmarker	  and	  Andersen,	  1993)	  to	  11	  years	  
(Confavreux	  et	  al.,	  1980).	  	  
	  
However,	   the	   rate	   of	   conversion	   to	   SP	   MS	   is	   known	   to	   increase	   over	   time	  
(Confavreux	   et	   al.,	   1980;	   Mc	   and	   Compston,	   1952;	   Weinshenker	   et	   al.,	   1989b).	  
Therefore,	   the	   survival	   analysis	   allows	   a	   more	   reliable	   estimate	   of	   the	   risk	   of	  
developing	  a	  progressive	  course	  and	  of	   the	   latency	  to	  progression,	  among	  patients	  
with	   an	   initial	   RR	   course	   (Eriksson	   et	   al.,	   2003;	   Leray	   et	   al.,	   2010;	   Tremlett	   et	   al.,	  
2008a;	   Vukusic	   and	   Confavreux,	   2003).	   Although	   the	   proportion	   of	   censored	  
information	   varied,	   data	   from	   natural	   history	   cohorts	   appear	   consistent.	   Overall,	  
studies	   converge	  on	  19	  median	  years,	   as	  an	  estimated	   time	   to	  enter	   the	  SP	  phase	  
(Figure	  3.4).	  It	  is	  important	  to	  note	  that	  data	  from	  British	  Columbia	  have	  been	  lately	  
reported	  differently.	  A	   second	  analysis,	   including	  a	   larger	   sample	   (n	  =	  5162)	  and	  a	  
lower	  percentage	  of	  patients	  converting	  to	  SP	  MS	  (35%),	  showed	  a	  median	  time	  to	  
SP	  of	  21.4	  years	  (Koch	  et	  al.,	  2010).	  The	  differences	  between	  the	  two	  studies	  were	  
not	  addressed	  by	  the	  authors.	  	  
	  
Figure	  3.4	  Kaplan	  Meier	  median	  times	  (x-­‐axis)	  to	  SP	  in	  natural	  history	  cohorts.	  Percentages	  of	  patients	  
reaching	   the	   endpoint	   are	   indicated	   in	   brackets	   next	   to	   each	   bar.	   On	   the	   y-­‐axis	   are	   listed	   the	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3.1.5.2	  The	  evolution	  of	  secondary	  progression	  	  
	  
The	   evolution	   of	   the	   SP	   phase	   was	   described	   only	   in	   the	   Lyon	   and	   in	   the	   British	  
Columbia	  cohorts.	  The	  two	  studies	  reported	  discordant	  results;	  median	  time	  to	  DSS	  
6	   from	  onset	  of	  SP	  was	  4	  years	  and	  8.2	  years,	   respectively	   (Tremlett	  et	  al.,	  2008a;	  
Vukusic	   and	   Confavreux,	   2003).	   In	   addition,	   median	   times	   to	   DSS	   7	   (Vukusic	   and	  
Confavreux,	  2003)	  and	  to	  DSS	  8	  (Tremlett	  et	  al.,	  2008a),	   from	  conversion	  to	  SP	  MS	  
were	  8	  and	  15.9	  years,	  respectively.	  	  	  	  
	  
3.1.5.3	  Relapsing	  onset	  versus	  progressive	  onset	  
	  
The	   rate	   of	   disability	   accumulation	   is	   affected	   by	   the	   clinical	   phenotype.	   It	   is	  well	  
established	  that	  a	  PP	  course	  associates	  with	  a	  significantly	  faster	  attainment	  of	  hard	  
outcomes,	   from	   the	   disease	   onset	   (Figure	   3.5)	   (Confavreux	   and	   Vukusic,	   2006a;	  
Debouverie	  et	  al.,	  2008;	  Kantarci	  et	  al.,	  1998;	  Leray	  et	  al.,	  2010;	  Myhr	  et	  al.,	  2001;	  
Phadke,	  1990;	  Runmarker	  and	  Andersen,	  1993;	  Tremlett	  et	  al.,	  2006).	  However,	  once	  
established	  disability	  occurs,	  further	  disease	  progression	  is	  largely	  unaffected	  by	  the	  
type	   of	   the	   disease	   course.	   In	   the	   French	   cohorts,	   times	   from	  DSS	   3	   (Leray	   et	   al.,	  
2010)	  and	  from	  DSS	  4	  (Confavreux	  and	  Vukusic,	  2006a;	  Debouverie	  et	  al.,	  2008)	  to	  
higher	   disability	   levels	  were	   shown	   to	   be	   remarkably	   similar,	   between	  progressive	  
onset	  and	  relapsing	  onset	  patients.	  In	  contrast,	  in	  the	  British	  Columbia	  database	  the	  
attainment	   of	   DSS	   6	   and	   of	   DSS	   8	   from	   the	   onset	   of	   progression	   was	   reported	  
significantly	  shorter	  in	  SP	  MS	  (8.2	  and	  15.9	  median	  years,	  respectively)	  than	  in	  PP	  MS	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Figure	   3.5	   Comparison	   of	   Kaplan	  Meier	  median	   times	   (x-­‐axis)	   to	   EDSS/DSS	   6	   between	   progressive	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3.1.6	  Mortality	  in	  MS	  
	  
Survival	  in	  MS	  has	  been	  studied	  in	  several	  epidemiological	  cohorts,	  gathering	  a	  large	  
amount	   of	   data.	   However,	   the	   comparison	   among	   datasets	   is	   difficult,	   because	   of	  
the	   increasing	   incidence	   of	   MS	   in	   many	   countries	   and	   because	   of	   the	   variable	  
duration	   of	   studies,	   which	   affect	   the	  mortality	   estimates	   (Bronnum-­‐Hansen	   et	   al.,	  
2004;	  Grytten	  Torkildsen	  et	  al.,	  2008;	  Hader,	  2010;	  Hirst	  et	  al.,	  2008b;	  Kingwell	  et	  al.,	  
2012;	  Koch-­‐Henriksen	  et	  al.,	  1998;	  Leray	  et	  al.,	  2007;	  Midgard	  et	  al.,	  1995;	  Phadke,	  
1987;	  Ragonese	  et	  al.,	  2010;	  Redelings	  et	  al.,	  2006;	  Sadovnick	  et	  al.,	  1991b;	  Smestad	  
et	  al.,	  2009;	  Sumelahti	  et	  al.,	  2010;	  Wallin	  et	  al.,	  2000)	  (Table	  3.7).	  	  
	  
Table	  3.7	  Studies	  assessing	  the	  mortality	  in	  MS.	  	  
	  
	  
Although	   the	   accumulation	   of	   severe	   disability	   in	   the	   long-­‐term	   is	   not	   strictly	   the	  
immediate	  cause	  of	  death,	  patients	  with	  MS	  have	  a	  statistically	  significant	  increase	  in	  
mortality,	  compared	  to	  the	  general	  population	  (Figure	  3.6),	  with	  a	  reduction	  of	   life	  
expectancy	  of	  7	  to	  14	  years	  (Bronnum-­‐Hansen	  et	  al.,	  2004;	  Grytten	  Torkildsen	  et	  al.,	  
2008;	   Hader,	   2010;	   Hirst	   et	   al.,	   2008b;	   Kingwell	   et	   al.,	   2012;	   Leray	   et	   al.,	   2007;	  
Ragonese	  et	  al.,	  2008;	  Smestad	  et	  al.,	  2009;	  Sumelahti	  et	  al.,	  2010).	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Figure	  3.6	  Life	  expectancy	  in	  MS	  patients:	  comparison	  of	  survival	  probability	  between	  Norwegian	  RR	  
MS	   patients	   and	   the	   total	   population	   (Hordaland	   County,	   Western	   Norway,	   1953-­‐2003).	   The	  




Table	  3.8	  Mean	  age	  at	  death	  in	  MS	  patients.	  1range.	  	  
	  
	  
Survival	   analyses	   can	   be	   used	   for	   calculating	   the	   time	   to	   death	   from	  birth	   (age	   at	  
death)	  (Ekestern	  and	  Lebhart,	  2004;	  Hirst	  et	  al.,	  2008b;	  Kingwell	  et	  al.,	  2012;	  Koch-­‐
Henriksen	   et	   al.,	   1998;	   Leray	   et	   al.,	   2007;	   Phadke,	   1987;	   Ragonese	   et	   al.,	   2010;	  
Redelings	   et	   al.,	   2006;	   Smestad	   et	   al.,	   2009)	   (Table	   3.8).	   This	   approach	   allows	   to	  
compare	   the	   MS	   related	   mortality	   with	   the	   expected	   mortality	   in	   matched	  
population-­‐based	   controls,	   however	   it	   does	   not	   take	   into	   account	   the	   disease	  
duration	  and	  severity.	  	  	  
	  
MS and Mortality:
Survival in MS Patients Is Shortened by 7 to 14 Years
Survival probability of Norwegian patients with relapsing-remitting MS (Hordaland
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In	  contrast,	  when	  estimating	  the	  time	  from	  the	  disease	  onset	  to	  death,	  the	  rate	  of	  
disability	  accumulation	  can	  be	  better	  typified	  (Bronnum-­‐Hansen	  et	  al.,	  2004;	  Grytten	  
Torkildsen	   et	   al.,	   2008;	   Hader,	   2010;	   Leibowitz	   et	   al.,	   1969;	  Midgard	   et	   al.,	   1995;	  
Ragonese	   et	   al.,	   2010;	   Riise	   et	   al.,	   1988;	   Smestad	   et	   al.,	   2009;	  Wallin	   et	   al.,	   2000;	  
Wynn	  et	  al.,	  1990)	  (Table	  3.9).	  As	  outlined	  in	  table	  3.6,	  survival	  is	  extremely	  variable	  
among	  cohorts,	   ranging	   from	  the	  shortest	  17	  years,	   reported	   in	  a	  early	  study	   from	  
Israel	  (Leibowitz	  et	  al.,	  1969),	  to	  47.5	  years	  recently	  described	  among	  patients	  from	  
the	   British	   Columbia	   database	   (Kingwell	   et	   al.,	   2012).	   Differences	   in	   follow-­‐up	  
duration	  and	  sample	  size,	  and	  the	  improvement	  of	  the	  diagnostic	  criteria,	  affect	  the	  
survival	   estimates	   and	   partially	   accounted	   for	   this	   large	   variability.	   In	   addition,	  
among	  recent	  studies,	  the	  reported	  longer	  time	  to	  death	  is	  likely	  to	  be	  explained	  by	  
the	   better	   ascertainment	   and	   by	   the	   improvement	   of	   the	   care	   provided	   to	   the	  
chronically	   disabled.	   An	   overall	   average	   survival	   from	   MS	   onset	   of	   35	   years	   is	  
considered	  a	  reasonable	  estimate	  (Degenhardt	  et	  al.,	  2009).	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A	   more	   sophisticated	   approach	   for	   assessing	   mortality	   in	   MS	   is	   the	   use	   of	  
standardised	  mortality	   ratios	   (SMRs)	   (the	  ratio	  of	  observed	  to	  expected	  number	  of	  
deaths,	   using	  mortality	   in	   the	   general	   population).	   The	  directly	   age-­‐adjusted	   SMRs	  
allow	   the	   comparison	   of	   mortality	   with	   respect	   to	   the	   general	   population,	  
eliminating	   effects	   of	   differing	   age	   distributions.	   Although	   advantaged	   by	   the	  
possibility	  of	  adjusting	  the	  analysis	  according	  to	  several	  factors	  (such	  as	  race	  or	  sex),	  
directly	  age-­‐adjusted	  SMRs	  are	  relatively	  unstable	  when	  based	  on	  small	  numbers	  of	  
deaths.	   The	   mortality	   varies	   among	   studies	   even	   when	   using	   SMRs	   (Figure	   3.7)	  
(Bronnum-­‐Hansen	   et	   al.,	   2004;	  Grytten	   Torkildsen	   et	   al.,	   2008;	  Hirst	   et	   al.,	   2008b;	  
Kingwell	  et	  al.,	  2012;	  Leray	  et	  al.,	  2007;	  Smestad	  et	  al.,	  2009;	  Sumelahti	  et	  al.,	  2010).	  
This	  is	  due	  to	  the	  declining	  pattern	  of	  SMR	  when	  the	  duration	  of	  follow-­‐up	  increases,	  
resulting	   into	   a	   higher	   number	   of	   expected	   and	   observed	   deaths	   (Smestad	   et	   al.,	  
2009).	   A	   clarifying	   example	   is	   the	   study	   from	   Finland,	  where	   the	   overall	  mortality	  
rate	   remained	   stable	  during	   the	   first	  2	   years	  after	  diagnosis	   (SMR	  0.8),	  however	   it	  
became	   significantly	   higher	   (2.4)	   between	   2	   and	   9.9	   years,	   and	   increased	   further	  
(3.1)	  after	  10	  years	  (Sumelahti	  et	  al.,	  2010).	  	  
	  
Figure	  3.7	  Standardized	  mortality	  ratios	  (y-­‐axis)	  for	  all	  cause	  of	  mortality:	  the	  exact	  values	  [95%	  C.I.]	  
are	   indicated	   on	   top	   of	   each	   column.	   On	   the	   x-­‐axis	   are	   listed	   studies	   (sample	   size/number	   of	  







































































	   164	  
3.1.6.1	  Factors	  affecting	  mortality	  
	  
Several	  factors	  have	  been	  reported	  to	  affect	  survival.	  It	  is	  well	  established	  that	  a	  PP	  
course	  associates	  with	  a	  faster	  time	  to	  death	  from	  disease	  onset	  (Grytten	  Torkildsen	  
et	   al.,	   2008;	   Hader,	   2010;	   Kantarci	   et	   al.,	   1998;	   Kingwell	   et	   al.,	   2012;	   Leray	   et	   al.,	  
2007;	  Midgard	   et	   al.,	   1995;	   Phadke,	   1987;	   Smestad	   et	   al.,	   2009;	   Sumelahti	   et	   al.,	  
2002).	  However,	  the	  survival	  from	  birth	  (age	  at	  death)	  is	  not	  significantly	  affected	  by	  
the	   type	   of	   the	   disease	   course.	   Similar	   median/mean	   ages	   at	   death	   have	   been	  
reported	   between	   patients	   with	   a	   PP	   course	   and	   with	   a	   RR	   onset:	   68	   versus	   66	  
median	   years	   in	   Norway	   (Smestad	   et	   al.,	   2009),	   76.3	   versus	   76.9	   mean	   years	   in	  
British	  Columbia	  (Kingwell	  et	  al.,	  2012).	  	  
	  
Most	   of	   the	   studies	   found	   an	   association	   between	   a	   younger	   age	   at	   onset	   and	   a	  
longer	  survival	  or	  a	  lower	  risk	  of	  death	  (Grytten	  Torkildsen	  et	  al.,	  2008;	  Hader,	  2010;	  
Kingwell	  et	  al.,	  2012;	  Leray	  et	  al.,	  2007;	  Smestad	  et	  al.,	  2009;	  Sumelahti	  et	  al.,	  2002).	  
Data	   on	   the	   prognostic	   effect	   of	   the	   type	   of	   initial	   symptoms	   do	   not	   seem	  
homogenous.	   Groups	   with	   brainstem/cerebellar	   involvement	   at	   onset	   have	   been	  
reported	   to	   have	   shorter	   (Midgard	   et	   al.,	   1995;	   Phadke,	   1987)	   or	   even	   longer	  
(Smestad	  et	  al.,	  2009)	  survival.	  Others	  found	  no	  impact	  of	  the	  initial	  presentation	  on	  
the	   time	   to	   and	   the	   probability	   of	   death	   (Leray	   et	   al.,	   2007).	   Data	   about	   the	  
relationship	   between	   gender	   and	  mortality	   are	   also	   contradicting.	   Although	  many	  
studies	   found	   a	   longer	   survival	   in	   females	   groups	   (Grytten	   Torkildsen	   et	   al.,	   2008;	  
Hader,	  2010;	  Kingwell	  et	  al.,	  2012;	  Leray	  et	  al.,	  2007;	  Midgard	  et	  al.,	  1995;	  Phadke,	  
1987),	   others	   reported	   no	   difference	   between	   men	   and	   women	   (Hader,	   2010;	  
Smestad	   et	   al.,	   2009;	   Sumelahti	   et	   al.,	   2002)	   or	   even	   an	   higher	   risk	   of	   mortality	  
among	   females	   (Ekestern	   and	   Lebhart,	   2004;	   Ragonese	   et	   al.,	   2010).	   The	   lack	   of	  
homogeneity	   could	   be	   partially	   attributed	   to	   changes	   of	   MS	   sex	   ratio	   over	   time	  
(Orton	  et	  al.,	  2006).	  	  
	  
3.1.6.2	  Causes	  of	  death	  	  
	  
Although	  MS	  is	  essentially	  a	  chronic	  and	  disabling	  disease,	  the	  long-­‐term	  disability	  is	  
not	  necessarily	  the	  immediate	  cause	  of	  death.	  However,	  MS,	  in	  the	  advanced	  stages,	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does	  carry	  the	  risk	  of	  systemic	  complications,	  which	  may	  lead	  to	  death.	  The	  record	  of	  
“MS”,	   as	   the	   main	   cause	   of	   death,	   marks	   the	   attainment	   of	   the	   last	   step	   of	   the	  
expanded	  disability	  status	  scale	  (EDSS	  10),	  This	  is	  defined	  as	  “...an	  acute	  death	  due	  to	  
brainstem	   involvement	  or	   to	   respiratory	   failure	  or	  death	   consequent	   to	   the	   chronic	  
bedridden	  state	  with	  terminal	  pneumonia,	  sepsis,	  uremia,	  cardiorespiratory	  failure.	  It	  
excludes	  intercurrent	  causes	  of	  death.	  Antemortem,	  the	  patient	  will	  ordinary	  be	  DSS	  
9,	   sometimes	   8”	   (Kurtzke,	   1983).	   This	   definition	   can	   be	   variably	   interpreted	   by	  
doctors	  and	  be	  entirely	  unknown	  for	  those	  not	  familiar	  with	  MS,	   leading	  to	  a	   large	  
variation	   of	   the	   proportion	   of	   “deaths	   due	   to	  MS”,	   among	   databases.	   This	   ranges	  
from	  the	  lowest	  50%	  in	  the	  Norwegian	  cohort	  (Smestad	  et	  al.,	  2009)	  and	  47%	  in	  the	  
Canadian	  cohort	  (Sadovnick	  et	  al.,	  1991b)	  to	  the	  highest	  75%	  recorded	  in	  the	  French	  
cohort	  (Leray	  et	  al.,	  2007)	  (Figure	  3.8).	  	  
	  
Figure	  3.8	  Percentages	  of	  deaths	  due	  (blue)	  and	  NOT	  due	  (grey)	  to	  MS	  among	  studies.	  On	  top	  and	  on	  
the	   left	   of	   each	   bar	   the	   total	   number	   of	   deaths	   and	   studies	   from	   which	   data	   were	   taken,	   are	  













































	   166	  
Deaths	  not	  related	  to	  MS	  are	  mainly	  attributable	  to	  the	  common	  causes	  of	  death	  in	  
the	   non-­‐MS	   population:	   cardiovascular	   disease,	   cancer,	   infectious	   and	   respiratory	  
disease,	  and	  accidents	  or	  suicide	  (Bronnum-­‐Hansen	  et	  al.,	  2004;	  Grytten	  Torkildsen	  
et	  al.,	  2008;	  Hirst	  et	  al.,	  2008b;	  Koch-­‐Henriksen	  et	  al.,	  1998;	  Phadke,	  1987;	  Redelings	  
et	  al.,	   2006;	   Sadovnick	  et	  al.,	   1991b;	   Smestad	  et	  al.,	   2009;	   Sumelahti	  et	  al.,	   2002).	  
The	  incidence	  of	  these	  causes	  of	  death	  varies	  greatly	  among	  studies	  (Table	  3.10).	  	  
	  
	  
Table	  3.10	  Causes	  of	  death	  among	  MS	  patients,	  from	  epidemiological	  studies.	  
	  
	  
3.1.7	  Aim	  of	  the	  study	  presented	  in	  this	  chapter	  
	  
This	  study	  aimed	  at	  describing	  clinical	  and	  demographic	  features	  of	  the	  LO	  database	  
following	   the	   data	   quality	   check	   procedures	   (chapter	   2).	   In	   addition,	   the	   disability	  
accumulation	   over	   time	   was	   estimated	   in	   the	   total	   population	   and	   in	   patients	  
grouped	  by	  clinical	  phenotypes.	  Finally	  survival,	   factors	  affecting	  the	  time	  to	  death	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3.2	  Methods	  
	  
The	  clinical	  and	  demographic	  features	  of	  the	  LO	  database	  total	  population	  and	  of	  the	  
two	   subpopulations,	   the	   highly	   ascertained	   subgroup	   from	  Middlesex	   County	   and	  
the	   subgroup	   with	   information	   collected	   only	   prospectively	   (from	   disease	   onset),	  
were	  described.	  Disease	  features	  were	  compared	  between	  patients	  grouped	  by	  the	  
initial	   disease	   course	   (progressive	   onset	   and	   relapsing	   onset).	   The	   Chi	   square	   test	  
and	  the	  Student	  T-­‐test	  were	  used	  for	  the	  comparison	  of	  categorical	  and	  quantitative	  
data,	  respectively.	  The	  Kaplan	  Meier	  survival	  analysis	  was	  used	  for	  estimating	  mean	  
and	  median	  times	  to	  disability	  levels	  from	  the	  disease	  onset	  and	  from	  DSS	  3.	  The	  Log	  
Rank	   test	   investigated	   differences	   between	   survival	   curves.	   The	   Distribution	   of	  
disability	  (number	  of	  patients	  at	  disability	  levels)	  at	  last	  follow	  up	  and	  the	  disability	  
progression	  (percentages	  of	  patients	  attaining	  disability	  levels	  at	  specific	  time	  points)	  
were	  examined.	  	  
	  
Finally,	   the	   clinical	   and	   demographic	   features,	   causes	   of	   death	   and	   disability	  
accumulation	   over	   time,	   among	   patients	   who	   had	   died,	   by	   the	   end	   of	   the	  
observation	  period,	  were	  assessed.	  Patients	  were	  grouped	  and	  compared	  according	  
to	   whether	   death	   was	   attributed	   to	   MS	   or	   not.	   Deaths	   due	   to	   MS	   were	   defined	  
according	   to	   a	   composite	   criterion,	   as	   described	   in	   methods	   (Chapter	   2).	   Kaplan	  
Meier	   and	   Cox	   regression	   analyses	  were	   used	   to	   estimate	   the	   survival	   probability	  
and	   the	   time	   to	   death,	   among	   patients	   grouped	   by	   clinical	   and	   demographic	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3.3	  Results	  
	  
3.3.1	  Clinical	  and	  demographic	  features	  	  
	  
3.3.1.1	  Total	  population	  	  
	  
The	  LO	  database	  now	  comprises	  1023	  patients.	  Table	  3.11	  shows	  general	  features	  of	  
total	   population	   (TOT)	   and	   the	   two	   subgroups:	   1)	   those	   from	   Middlesex	   County	  
(MC):	  n	  =	  196	  (19.1%	  of	  TOT	  population);	  2)	  those	  exclusively	  seen	  from	  onset	  (SO);	  
n	  =	  181	  (17.6%	  of	  TOT	  population).	  	  
	  
Table	  3.11	  General	  features	  of	  total	  population	  and	  the	  two	  MC	  and	  SO	  subgroups.	  	  
	  
	  
During	   the	   data	   quality	   check	   (Chapter	   2),	   20	   patients	   (17	   SP;	   2	   PP;	   1	   RR)	   were	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sample	   size	   has	   slightly	   decreased,	   compared	   to	   the	   last	   published	   data	  
(Kremenchutzky	  et	  al.,	  2006a).	  After	  28	  years	  of	  follow	  up,	  the	  diagnostic	  accuracy,	  
according	   to	   Posers’	   criteria	   (Poser	   et	   al.,	   1983),	   was	   almost	   complete	   (97.7%).	  
Women	  almost	   doubled	   the	  number	  of	  men	   (F/M	   ratio	   =	   1.96),	   the	  mean	  disease	  
duration	  was	  24.2	  years	  and	  the	  mean	  age	  at	  the	  disease	  onset	  was	  30.6	  years,	  with	  
no	  difference	  between	  males	  and	  females	  (31.1	  years	  vs.	  30.1	  years	  respectively;	  p	  =	  
0.10).	   The	   PP	   course	   was	   reported	   in	   21.7	   %	   and	   by	   the	   end	   of	   the	   observation	  
period,	   among	   806	   patients	   with	   relapsing	   remitting	   course	   (78.3%	   of	   total	  
population),	   more	   than	   half	   (n	   =	   534;	   66.2	   %	   of	   relapsing	   onset	   population)	   had	  
converted	  to	  SP	  MS.	  The	  highly	  ascertained	  subgroup	  from	  Middlesex	  County	  (MC)	  
(Hader	  et	  al.,	  1988)	  and	  the	  subgroup	  exclusively	  seen	  from	  onset	  (SO)	  resemble	  the	  
total	  population	  in	  the	  age	  at	  onset,	  the	  sex	  ratio,	  the	  clinical	  presentation	  and	  the	  
diagnostic	  certainty,	  allowing	  unbiased	  comparisons.	  The	  SO	  subgroup	  had	  obviously	  
a	   shorter	   mean	   disease	   duration,	   explaining	   the	   larger	   percentage	   (49.7%)	   of	  
patients	  still	  in	  the	  RR	  phase.	  Compared	  to	  the	  total	  population,	  the	  proportion	  of	  PP	  
MS	   was	   slightly	   smaller	   in	   the	   MC	   subgroup,	   but	   substantially	   smaller	   in	   the	   SO	  
subgroup.	   The	   number	   of	   patients	  with	   a	   PP	   course	   increased	   proportionally	  with	  
the	  age	  at	  the	  disease	  onset	  and	  reached	  its	  peak	  among	  those	  aged	  more	  than	  50	  at	  
first	  symptom;	  similar	  trend	  is	  observed	  in	  the	  two	  subgroups	  (Figure	  3.9).	  
Figure	   3.9	   Percentages	  of	  patients	  with	  PP	  course	   (x-­‐axis)	   in	  each	  age	  at	  onset	  group	   (y-­‐axis):	   total	  
population	  (blue),	  seen	  from	  onset	  subgroup	  (yellow)	  and	  Middlesex	  County	  subgroup	  (red).	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Figure	   3.10	   Percentage	   of	   patients	   (y-­‐axis)	   with	   different	   neurological	   systems	   involved	   at	   disease	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In	  Table	  3.12	  are	  listed	  presenting	  symptoms	  in	  the	  total	  population,	  and	  Figure	  3.10	  
shows	  percentages	  of	  patients	   grouped	  by	  neurological	   systems	   involved	  at	  onset.	  
Most	   of	   patients	   (43%)	   presented	   with	   sensory	   impairment,	   followed	   by	   optic	  
neuritis	  (17.6%),	  gait	  impairment	  (13.5%)	  and	  insidious	  motor	  deficit	  (13.2%)	  (Table	  
3.12).	  Accordingly,	  the	  commonest	  neurological	  system	  involved	  at	  first	  presentation	  
was	  the	  sensory	  one	  (50.6%),	  followed	  by	  the	  motor	  one	  (23.7%)	  (Figure	  3.10).	  More	  
than	   60%	   of	   patients	   (n	   =	   677)	   in	   the	   total	   population	   had	   a	   mono-­‐symptomatic	  
onset,	  23%	  (n	  =	  236)	  presented	  with	  two	  symptoms	  and	  very	  few	  (n	  =	  19)	  with	  3	  or	  
more	  symptoms.	  
3.3.1.2	  Relapsing	  onset	  and	  progressive	  onset	  patients	  	  
	  
Table	  3.13	  Clinical	  and	  demographic	  features	  of	  progressive	  onset	  and	  relapsing	  onset	  subgroups.	  	  
*	  Chi-­‐square	  test;	  **	  Student’s	  T-­‐test	  
	  
 
In	  Table	  3.13	  patients	  were	  grouped	  according	  to	  the	  initial	  disease	  course	  (PP	  and	  
RR/SP),	  and	  compared.	  The	  PP	  group	  had	  larger	  percentage	  of	  males	  (42.9%	  versus	  
31.2%;	   p	   =	   0.001),	   bringing	   the	   F/M	   ratio	   much	   closer	   to	   unity	   (1.3);	   this	   is	  
particularly	   seen	   in	   the	   younger	   age	   at	   onset	   groups	   (Cottrell	   et	   al.,	   1999b).	   No	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differences	  were	  observed	   in	   the	  mean	  disease	  duration.	  The	   two	  subgroups	  were	  
distinguished	  by	  the	  different	  age	  at	  first	  symptom.	  This	  occurred	  between	  the	  age	  
of	  20	  and	  40	  years	  for	  most	  of	  the	  relapsing	  onset	  patients	  (75%),	  and	  between	  the	  
age	  of	   30	   and	   50	   for	  most	   of	   the	   PP	  patients	   (65%)	   (Figure	   3.11).	   In	   addition,	   the	  
clinical	   onset	   differed	   according	   to	   the	   type	   of	   the	   disease	   course.	   A	   motor	  
involvement	   was	   more	   commonly	   observed	   within	   the	   progressive	   onset	   group	  
(44.7%	  versus	  17.9%;	  p	  <	  0.001),	  whereas	  relapsing	  onset	  patients	  presented	  more	  
frequently	   with	   sensory	   symptoms	   (54.3%	   versus	   36.8%;	   p	   <	   0.001).	   Most	   of	   the	  
patients	  in	  both	  groups	  had	  mono-­‐symptomatic	  onset,	  (Figure	  3.12).	  
	  
Figure	   3.11	   Percentages	   of	   patients	   (y-­‐axis)	   in	   different	   age	   at	   disease	   onset	   categories	   (x-­‐axis):	  
comparison	  between	  progressive	  onset	  (red)	  and	  relapsing	  onset	  (blue)	  MS.	  
	  
	  
Figure	  3.12	  Percentages	  of	  patients	  (y-­‐axis)	  with	  different	  numbers	  of	  neurological	  systems	  involved	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3.3.2	  Analysis	  of	  disability	  	  
	  
3.3.2.1	  The	  distribution	  of	  disability	  	  	  
Figure	  3.13	  Percentages	  of	  patients	  (y-­‐axis)	  at	  disability	  levels	  (x-­‐axis),	  by	  the	  end	  of	  the	  observation	  
period.	  A)	  Total	  population	   (TOT	  =	  1023),	  Middlesex	  County	   (MC	  =	  196)	  and	  seen	   from	  onset	   (SO	  =	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The	   analysis	   of	   disability	   focused	  on	   the	   attainment	   of	   hard	   outcomes	   (DSS	   3-­‐6-­‐8-­‐
10).	  By	   the	  end	  of	   the	  observation	  period,	  at	   last	  assessment,	  more	  than	  50%	  (n	  =	  
561)	  of	  the	  total	  population	  had	  disability	  rated	  between	  DSS	  8	  and	  DSS	  10.	  Similar	  
distribution	  was	  observed	   in	   the	  MC	  subgroup,	  whereas	  a	   larger	  percentage	  of	  SO	  
patients	   were	   still	   at	   lower	   levels	   of	   disability,	   due	   to	   the	   shorter	   mean	   disease	  
duration	  (Figure	  3.13	  A).	  Almost	  half	  (n	  =	  390;	  48.3%)	  of	  the	  relapsing	  onset	  patients	  
and	  most	  of	   the	  PP	  patients	   (n	   =	   171,	   78.7%)	  were	   scored	  between	  DSS	  8	   and	  10	  
(Figure	  3.13	  B).	  	  
3.3.2.2	  The	  progression	  of	  disability	  	  	  
	  
Figures	   3.14	   shows,	   in	   the	   total	   population	   (Figure	  3.14	  A)	   and	   in	   the	   two	  disease	  
course	   subgroups	   (Figure	   3.14	   B),	   the	   number	   of	   patients,	   reaching	   each	   DSS	  
hallmark	  level	  during	  the	  observation	  period,	  the	  proportion	  that	  progressed	  to	  the	  
following	  disability	  level,	  and	  the	  mean	  time	  patients	  stayed	  in	  between	  DSS	  levels.	  	  
	  
As	  expected,	  the	  percentages	  advancing	  to	  the	  higher	  DSS	   levels	  slightly	  decreased	  
along	   the	   DSS	   scale.	   However,	   no	   substantial	   variations	   were	   observed	   for	  
progressing	   up	   to	   DSS	   8,	  where	   the	   number	   of	   patients	   reaching	   DSS	   10	   dropped	  
dramatically,	   as	   a	   consequence	  of	   the	   deaths	   not	   due	   to	  MS	   (35.1%	  of	   total	   dead	  
patients).	  In	  the	  total	  population	  (Figure	  3.14	  A)	  and	  in	  the	  relapsing	  onset	  subgroup	  
(Figure	   3.14	  B),	   the	   average	   time	   in	   between	  DSS	   levels	  was	  unevenly	   distributed,	  
with	  the	  highest	  peak	  in	  between	  DSS	  0	  and	  3,	  and	  the	  lowest	  peak	  in	  between	  DSS	  3	  
and	   6,	   partially	   explained	   by	   the	   lack	   of	   linearity	   of	   the	   DSS	   scale.	   Primary	  
progressive	   patients	   took	  much	   shorter	   time	   to	   reach	   DSS	   3	   than	   relapsing	   onset	  
patients,	  however	  the	  average	  times	  for	  progressing	  to	  higher	  disability	  levels	  were	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Figure	   3.14	   Number	   of	   patients	   reaching	   each	   DSS	   hallmark	   level,	   percentages	   progressing	   to	   the	  
following	  disability	  level	  and	  the	  mean	  time	  spent	  in	  between	  DSS	  levels.	  The	  number	  of	  patients	  who	  
did	  not	  advance	  to	  the	  higher	  disability	  level	  and	  their	  mean	  disease	  duration	  are	  also	  indicated	  (for	  
the	  total	  population	  only)	  in	  rectangles.	  A)	  Total	  population	  (n	  =	  1023).	  B)	  Relapsing	  onset	  (n	  =	  806)	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3.3.2.3	  Survival	  analysis	  of	  disability	  	  	  
	  
3.3.2.3.1	  The	  disability	  accumulation	  over	  time	  in	  the	  total	  population	  	  
The	  number	   of	   patients	   reaching	   each	  DSS	   level	   increased	   proportionally	  with	   the	  
disease	  duration,	  and	  at	  different	   rates	  among	  patients	   (Figure	  3.15	  A).	  At	  5	   years	  
from	  onset,	  2.5%	  had	  already	  reached	  DSS	  8,	   rising	   to	  10	  %	  at	  10	   years.	  However,	  
after	  15	   years,	  more	   than	  30	  %	  of	  patients	  had	  not	   reached	  DSS	  3	  yet,	  half	  of	   the	  
population	  had	  reached	  DSS	  6	  and	  20%	  had	  reached	  DSS	  8.	  By	  25	  years	  these	  values	  
increased	   to	   62.1%	   of	   patients	   at	   DSS	   6	   and	   37.7%	   at	   DSS	   8.	   By	   the	   end	   of	   the	  
observation	  period,	  85.2%,	  73.7%,	  54.8%	  and	  20.6%	  had	  reached	  DSS	  3,	  6,	  8	  and	  10,	  
respectively	  (Figure	  3.13	  A).	  	  
	  
In	  the	  total	  population,	  the	  Kaplan	  Meier	  survival	  analysis	  estimated	  7	  years	  (95%	  C.I.	  
6.1-­‐7.8),	  15	   years	   (95%	   C.I.	   14.0-­‐15.9),	  26	   years	   (95%	   C.I.	   24.5-­‐27.4)	   and	  46	   years	  
(95%	  C.I.	  40.0-­‐49.9)	  as	  the	  median	  time	  from	  the	  disease	  onset	  to	  reach	  DSS	  3,	  6,	  8	  
and	  10,	  respectively	  (Figure	  3.15	  B).	  
	  
The	  comparison	  of	  survival	  curves,	  between	  the	  total	  population	  and	  the	  MC	  and	  SO	  
subgroups,	  allowed	  to	  assess	  the	  impact	  of	  ascertainment	  and	  referral	  biases	  on	  the	  
disability	  data	  (Figure	  3.16	  A	  and	  B).	  The	  overlapping	  survival	  curves	  demonstrated	  
remarkably	   similar	   times	   to	   DSS	   6	   and	   to	   DSS	   8	   (total	   population	   versus	   MC	  
subgroup:	  p	  =	  0.23,	  p	  =	  0.59;	  total	  population	  versus	  SO	  subgroup	  p=	  0.42,	  p	  =	  0.37,	  
respectively),	   indicating	   that	   only	   little	   bias	   affected	   the	   estimates	   of	   the	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Figure	   3.15	   Kaplan	   Meier	   survival	   analysis	   of	   disability	   in	   the	   total	   population	   (TOT	   =	   1023).	   A)	  
Percentage	  of	  patients	  (y-­‐axis)	  reaching	  each	  DSS	  level	  at	  specific	  time	  points	  from	  the	  disease	  onset	  
(x-­‐axis).	  The	  analysis	  of	  each	  disability	  level	  is	  independent	  from	  the	  others.	  B)	  Kaplan	  Meier	  survival	  
curves	  to	  DSS	  3,	  6,	  8	  and	  10.	  The	  mean	  and	  median	  times	  from	  disease	  onset	  to	  DSS	   levels	  and	  the	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Figure	   3.16	  Kaplan	  Meier	   survival	  analysis	  of	  disability.	  Comparison	  of	  Kaplan	  Meier	   survival	   curves	  
from	  disease	  onset	  to	  DSS	  6	  (A)	  and	  to	  DSS	  8	  (B)	  between	  the	  total	  population,	  the	  seen	  from	  onset	  
(SO	  n	  =	  181)	  and	  the	  Middlesex	  County	  (MC	  n	  =	  196)	  subgroups.	  The	  mean	  and	  median	  times	  from	  
disease	  onset	  to	  DSS	  levels	  and	  the	  percentages	  of	  censored	  information	  contributing	  to	  the	  survival	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3.3.2.3.2	  The	  disability	  accumulation	  among	  relapsing	  onset	  patients	  	  
Figure	  3.17	  Kaplan	  Meier	  survival	  analysis	  of	  disability	  in	  the	  relapsing	  onset	  population	  (n	  =	  806).	  A)	  
Percentage	  of	  patients	  (y-­‐axis)	  reaching	  each	  DSS	  level	  at	  specific	  time	  points	  from	  the	  disease	  onset	  
(x-­‐axis).	   The	   analysis	   of	   each	   disability	   level	   is	   independent	   from	   the	   others.	  B)	   Estimated	  median	  
times	  from	  onset	  to	  DSS	  3,	  6,	  8	  and	  10.	  The	  mean	  times	  to	  endpoints	  and	  the	  percentages	  of	  censored	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Within	  the	  relapsing	  onset	  group	  (n	  =	  806),	  at	  5	  years	  from	  onset,	  87	  (10.7%)	  and	  18	  
(2.2%)	  patients	  already	  reached	  DSS	  6	  and	  8,	  respectively.	  These	  percentages	  rose	  to	  
38.4%	  (n	  =	  310)	  and	  16.3%	  (n	  =	  132)	  at	  15	  years,	  to	  49.5%	  (n	  =	  399)	  and	  24.9%	  (n	  =	  
201)	   at	   20	   years,	   and	   to	   54.4%	   (n	   =	   439)	   and	   32.1%	   (n	   =	   259)	   at	   25	   years,	  
respectively	   (Figure	   3.17	   A).	   However,	   by	   15	   years	   from	   the	   disease	   onset,	   304	  
patients	   (37.8%)	  had	  not	  reached	  DSS	  3	  yet.	  By	  the	  end	  of	   the	  observation	  period,	  
81.5%	  (n	  =	  657),	  67.4%	  (n	  =	  543),	  48.4%	  (n	  =	  390)	  and	  17.1%	  (n	  =	  138)	  were	  scored	  at	  
DSS	  3,	  6,	  8	  and	  10,	   respectively	   (Figure	  3.13	  B).	   	   Estimated	  median	   times	   to	   reach	  
DSS	  3,	  6,	  8	  and	  10,	   from	  disease	  onset,	  were	  10,	  18,	  28	  and	  54	   years,	   respectively	  
(Figure	  3.17	  B).	  	  
	  
The	  time	  to	  DSS	  6	  was	  known	  for	  506	  relapsing	  onset	  patients,	  and	  it	  ranged	  from	  1	  
to	  44	  years.	  The	  quickest	  25%	  required	  a	  walking	  aid	  within	  8	  years	  from	  onset,	  and	  
the	   slowest	   25	   %	   in	   more	   than	   19	   years.	   In	   Figure	   3.18	   are	   presented	   the	  
percentages	  of	  patients	  grouped	  by	  the	  time	  interval	  between	  the	  disease	  onset	  and	  
DSS	  6,	  highlighting	  the	  large	  variability	  of	  the	  clinical	  outcome.	  	  	  	  
	  
Figure	   3.18	   Distribution	   of	   the	   time	   to	   DSS	   6	   in	   the	   relapsing	   onset	   group:	   percentages	   (y-­‐axis)	   of	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3.3.2.3.3	  The	  disability	  accumulation	  among	  progressive	  onset	  patients	  	  
	  
Progressive	  onset	  patients	  were	  distinguished	  by	  a	  faster	  accumulation	  of	  disability	  
over	  time.	  After	  5	  years	  from	  disease	  onset,	  only	  a	  minority	  (n	  =	  84;	  24.9%)	  was	  left	  
without	   moderate	   disability	   (DSS	   3),	   and	   more	   than	   1/3	   (n	   =	   75;	   35.5%)	   already	  
reached	  DSS	  6.	  By	  15	   years,	   the	  majority	   (n	  =	  166;	  77.4%)	  had	   required	  an	  aid	   for	  
walking	   (DSS	   6)	   and	   33.6%	   (n	   =	   73)	   had	   become	   bedbound	   (DSS	   8).	   These	  
percentages	  rose	  dramatically	  25	  years	  after	  the	  disease	  onset,	  when	  only	  few	  (n	  =	  
20;	   9.2%)	   have	   not	   reached	  DSS	   6	   yet,	   and	  more	   than	   half	   (n	   =	   127;	   58.5%)	   have	  
reached	  DSS	  8	   (Figure	  3.20	  A).	  By	   the	  end	  of	   the	  observation	  period,	  215	   (99.1%),	  
211	  (97%),	  171	  (78.9%)	  and	  72	  (33.1%)	  patients	  had	  been	  scored	  at	  DSS	  3,	  6,	  8	  and	  
10,	   respectively	   (Figure	   3.13	   B).	   Estimated	   Kaplan	   Meier	   median	   times	   from	   the	  
disease	  onset	  to	  DSS	  3,	  6,	  8,	  and	  10	  were	  3,	  8,	  18	  and	  34	  years,	  respectively	  (Figure	  
3.20	  B).	  	  
	  
The	  time	  to	  DSS	  6	  was	  known	  for	  208	  progressive	  onset	  patients,	  and	  it	  ranged	  from	  
1	  to	  49	  years.	  The	  quickest	  25%	  required	  a	  walking	  aid	  within	  4	  years	  from	  onset	  and	  
the	   slowest	   25	   %	   in	   more	   than	   13	   years.	   In	   Figure	   3.19	   are	   presented	   the	  
percentages	  of	  patients	  grouped	  by	  the	  time	  interval	  between	  the	  disease	  onset	  and	  
DSS	  6.	  	  	  	  
	  
Figure	  3.19	  Distribution	  of	  time	  to	  DSS	  6	  in	  the	  PP	  group:	  percentages	  (y-­‐axis)	  of	  patients	  grouped	  by	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Figure	  3.20	  Kaplan	  Meier	  survival	  analysis	  of	  disability	  in	  the	  progressive	  onset	  population	  (n	  =	  217).	  
A)	   Percentage	   (y-­‐axis)	   of	   patients	   reaching	   each	   DSS	   level	   at	   specific	   time	   points	   from	   the	   disease	  
onset	   (x-­‐axis).	   The	   analysis	   of	   each	   disability	   level	   is	   independent	   from	   the	   others.	   B)	   Estimated	  
median	  times	  from	  onset	  to	  DSS	  3,	  6,	  8	  and	  10.	  The	  mean	  times	  to	  endpoints	  and	  the	  percentages	  of	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3.3.2.3.4	  Progressive	  onset	  versus	  relapsing	  onset	  MS	  
	  
The	   analysis	   confirmed	   the	  well-­‐established	  notion	   that	   a	   progressive	   course	   from	  
onset	   associates	   with	   a	   worse	   prognosis.	   The	   comparison	   of	   the	   Kaplan	   Meier	  
survival	   curves,	   estimating	   the	   disability	   accumulation	   from	   the	   disease	   onset,	  
demonstrated	   significantly	   shorter	   times	   (approximately	   10	   years	   earlier)	   to	  DSS	   6	  
and	   to	   DSS	   8,	   among	   PP	   MS	   patients	   compared	   to	   RR	   and	   SP	   patients	   pooled	  
together	  (DSS	  6	  =	  9.5	  versus	  21.3	  years;	  DSS	  8	  =	  20.5	  versus	  30.9	  years,	  respectively)	  
(Figure	   3.21	   A-­‐B).	   However,	   the	   2	   groups	  matched	  much	  more	   closely	   when	   they	  
reached	   the	   endpoints	   from	   moderate	   disability.	   Although	   still	   statistically	  
significant,	  there	  was	  less	  than	  3	  mean	  years	  difference	  for	  advancing	  from	  DSS	  3	  to	  
higher	  disability	   levels	  (from	  DSS	  3	  to	  DSS	  6	  =	  5.1	  versus	  7.9	  years,	  p	  <	  0.001;	  from	  
DSS	  3	  to	  DSS	  8	  =	  15.3	  versus	  17.6	  years,	  p	  =	  0.03,	  respectively)	  (Figure	  3.21	  C-­‐D).	  	  
The	  comparison	  between	  PP	  and	  SP	  MS	  yielded	  similar	  results.	  The	  disease	  evolution	  
from	  onset	  was	   significantly	   faster,	   among	  PP	  patients	   (Figure	  3.22).	  However,	   the	  
differences	  between	   the	   two	   groups	  were	  much	   smaller	   compared	   to	   the	   analysis	  
including	  also	  RR	  patients	  (Figure	  3.21).	  The	  PP	  MS	  group	  attained	  DSS	  6	  and	  DSS	  8	  
approximately	  6	  mean	  years	  earlier	  than	  the	  SP	  MS	  group	  (DSS	  6	  =	  9.5	  versus	  15.7	  
years,	  p	  <	  0.001;	  DSS	  8	  =	  20.5	  versus	  26.5,	  p	  <	  0.001,	  respectively)	  (Figure	  3.22	  A-­‐B).	  
In	  addition,	  once	  again,	   the	  disease	  progression	  from	  DSS	  3	  was	   largely	  unaffected	  
by	  the	  type	  of	  disease	  course.	  Times	  from	  moderate	  disability	  to	  DSS	  6	  and	  to	  DSS	  8	  
differed	   little	  between	  PP	  and	  SP	  patients	  (DSS	  6	  =	  5.1	  versus	  6.4	  years,	  p	  =	  0.006;	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Figure	   3.21	  Kaplan	  Meier	   survival	  analysis	  of	  disability.	  Comparison	  of	   times	   to	  DSS	  6	  and	   to	  DSS	  8	  
from	   disease	   onset	   (A-­‐B)	   and	   from	  DSS	   3	   (C-­‐D)	   between	   relapsing	   onset	   (RR/SP	   n=	   806,	   blue)	   and	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Figure	   3.22	  Kaplan	  Meier	   survival	  analysis	  of	  disability.	  Comparison	  of	   times	   to	  DSS	  6	  and	   to	  DSS	  8	  
from	  disease	  onset	  (A-­‐B)	  and	  from	  DSS	  3	  (C-­‐D)	  between	  secondary	  progressive	  (SP	  n=	  534,	  blue)	  and	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  3.3.3	  Mortality	  and	  causes	  of	  death	  	  	  
	  
During	   the	   last	   review	  of	   the	   LO	  database	   (1996),	   extensive	   efforts	  were	  made	   to	  
trace	  patients	  who	  had	  been	  lost	  to	  follow	  up	  (Cottrell	  et	  al.,	  1999b).	  With	  the	  help	  
of	   the	   Government	   of	   Ontario	   and	   its	  Ministry	   of	   Health,	   providing	   access	   to	   the	  
provincial	  registry	  of	  all	  deaths	  and	  to	  copies	  of	  death	  certificates,	  the	  final	  outcome	  
and	   the	  causes	  of	  death	  were	  ascertained	   in	   the	  majority	  of	  patients.	  This	  process	  
led	  to	  the	  identification	  of	  286	  dead	  patients	  (101	  PP	  MS,	  185	  RR/SP	  MS).	  With	  the	  
extended	   follow	   up	   (2000),	   the	   sample	   increased	   to	   324	   (31.6%	   of	   the	   total	  
population).	   A	   similar	   percentage	   of	   dead	   patients	   (n=	   65;	   33.1%)	   was	   observed	  
within	  the	  MC	  subgroup.	  
3.3.3.1	  Clinical	  and	  demographic	  features	  of	  dead	  patients	  
By	  the	  end	  of	  the	  observation	  period,	  51.5%	  (n	  =	  111)	  of	  the	  progressive	  onset	  group	  
and	   26.4%	   (n	   =	   213)	   of	   the	   relapsing	   onset	   group	   had	   died.	   Among	   the	   324	   dead	  
patients,	  34.2%	  had	  a	  primary	  progressive	  course	  and	  75.8%	  experienced	  a	  relapsing	  
onset	   course;	   the	   two	   subgroups	   were	   distinguished	   by	   different	   clinical	   and	  
demographic	   features	   (Table	   3.14),	   resembling	   what	   observed	   in	   the	   general	  
population	  (Table	  3.13).	  	  
	  
Among	  the	  total	  dead	  patients,	  females	  predominated	  in	  the	  relapsing	  onset	  group	  
and	  the	  F/M	  ratio	  in	  the	  PP	  group	  was	  close	  to	  unity	  (F/M	  ratios:	  1.5	  versus	  0.9;	  p	  <	  
0.001).	  Although	  an	   initial	  RR	  course	  associated	  with	  a	  significantly	  younger	  age	  at	  
the	  disease	  onset	  (31.5	  versus	  39.8	  mean	  years;	  p	  <	  0.001),	  the	  age	  at	  the	  onset	  of	  
progression	  was	   remarkably	   similar	   between	   the	   two	   subgroups	   (41.4	   versus	   39.8	  
mean	   years;	   p	   =	   0.21)	   and	   not	   affected	   by	   the	   clinical	   phenotype.	   The	   clinical	  
presentation	   varied	   according	   to	   the	   type	   of	   the	   disease	   course.	   The	   progressive	  
onset	   group	   more	   commonly	   presented	   with	   a	   motor	   involvement	   (43.2%	   versus	  
23.9%;	   p	   <	   0.001)	   and	   the	   relapsing	   onset	   group	   with	   sensory	   symptoms	   (46.0%	  
versus	  34.2%;	  p	  <	  0.042)	  (Table	  3.14).	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Table	  3.14	  Clinical	  and	  demographic	  features	  of	  dead	  patients	  (n	  =	  324),	  grouped	  by	  the	  initial	  disease	  




3.3.3.2	  Disease	  progression	  and	  time	  to	  death	  	  
	  
Among	   all	   324	   dead	   patients,	   the	   disease	   progression	   from	   onset	   to	   death	   was	  
assessed.	  The	  analysis	  did	  not	  include	  censored	  information.	  The	  time	  to	  death	  was	  
not	  known	  for	  2	  patients	  (one	  with	  PP	  and	  one	  with	  SP	  course),	  and	  it	  widely	  varied,	  
from	   1	   to	   63	   years:	   the	   quickest	   and	   the	   slowest	   25%	   (25	   and	   75	   percentiles)	  
reached	  death	  within	  17	  years	  and	   in	  more	   than	  30	  years,	   respectively.	  Among	  all	  
dead	  patients,	  at	  20	  years	  from	  onset,	  36.7%	  (n	  =	  119)	  had	  died,	  increasing	  to	  55.5	  %	  
(n	  =	  180),	  75.3%	  (n	  =	  244)	  and	  84.8%	  (n	  =	  275)	  at	  25,	  30	  and	  35	  years,	  respectively	  
(Figure	  3.26).	   The	  median	   time	   to	  death	   from	  onset	  was	  24	  years	  and	   the	  median	  
age	  at	  death	  was	  60	  years.	  Survival	  was	  not	  significantly	  different	  between	  the	  total	  
population	  and	   the	  MC	  subgroup	   (time	   to	  death	  24.1	  versus	  26.9	  mean	  years;	  p	  =	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The	  relapsing	  and	  progressive	  onset	  dead	  patients	  were	  compared.	  Patients	  with	  a	  
PP	   course	   took	   significantly	   shorter	   times	   to	   DSS	   levels,	   indicating	   a	   faster	  
accumulation	  of	  disability.	  However,	   the	  proportion	  dying	  over	   time	  was	   similar	   in	  
the	  two	  subgroups	  (Figure	  3.24).	  Among	  dead	  patients,	  by	  20	  years	  from	  the	  disease	  
onset,	   41.4%	   (n	   =	   46)	  with	   a	   PP	   course	   and	  34.2%	   (n	   =	   73)	  with	   a	   relapsing	  onset	  
course	  had	  already	  died.	  At	  35	  years,	  these	  percentages	  increased	  to	  91.8%	  (n	  =	  102)	  
and	   to	   81.2%	   (n	   =	   173),	   respectively	   (Figure	   3.24).	   Indeed,	   despite	   the	   faster	  
attainment	  of	  DSS	  levels,	  PP	  patients	  reached	  death	  only	  3	  mean	  years	  earlier	  (22.7	  
versus	   25.7	   mean	   years;	   p	   =	   0.005)	   and	   the	   disease	   progression	   from	   DSS	   3	   was	  
remarkably	  similar	  between	  the	  two	  subgroups.	  In	  addition,	  relapsing	  onset	  patients	  
died	   at	   significantly	   younger	   age	   (57.2	   versus	   62.4	  mean	   years;	   p	   <	   0.001)	   (Table	  
3.15),	   secondary	   to	   their	   younger	   age	   at	   onset	   (31.5	   versus	   39.8	  mean	   years;	   p	   <	  
0.001)	  (Table	  3.14).	  	  	  
	  
Figure	  3.23	  Time	  to	  death	  from	  disease	  onset:	  comparison	  of	  Kaplan	  Meier	  survival	  curves	  between	  
the	  total	  population	   (TOT)	  and	  he	  Middlesex	  County	   (MC)	  subgroup.	  Censored	   information	  was	  not	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Figure	  3.24	  Percentages	  (y-­‐axis),	  among	  dead	  patients	  (n	  =	  324),	  dying	  at	  specific	  time	  points	  (x-­‐axis)	  
from	  disease	  onset	  in	  the	  total	  population	  and	  in	  the	  two	  disease	  course	  subgroups:	  RR/SP	  (n	  =	  213)	  
and	  PP	  (n	  =	  111).	  	  
	  
Table	  3.15	  Disease	  progression	  (from	  onset	  and	  from	  DSS	  3)	  and	  time	  to	  death	  (from	  onset	  and	  from	  
birth)	   among	   dead	   patients	   (n	   =	   324)	   grouped	   by	   the	   initial	   disease	   course	   (progressive	   onset	   and	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3.3.3.3	  Causes	  of	  death	  	  
	  
Table	   3.16	   Causes	   of	   death	   among	   324	   dead	   patients.	   Patients	   are	   grouped	   by	   the	   initial	   disease	  




Information	   on	   causes	   of	   death	   was	   available	   for	   311	   patients	   (95.9%	   of	   dead	  
patients).	  The	  criteria	  used	  for	  defining	  death	  due	  to	  MS	  (attainment	  of	  DSS	  10)	  were	  
outlined	   in	  methods	   (Chapter	   2).	   Primary	   causes	   of	   death	   described	   as	   aspiration,	  
cachexia,	   dehydration,	  MS,	   pneumonia,	   pulmonary	   oedema,	   pulmonary	   embolism,	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and	  septicaemia,	  were	  considered	  a	  direct	  consequence	  of	  MS.	  For	  those	  who	  died	  
from	  gastro-­‐intestinal	   (G-­‐I)	  bleeding,	  pulmonary	  oedema	   from	  aspiration,	  accident,	  
cancer,	  chronic	  bronchitis,	  chronic	  renal	  failure,	  heart	  disease,	  head	  injury,	  intestinal	  
obstruction,	  pyelonephritis,	  renal	  failure	  and	  stroke	  death	  was	  considered	  unrelated	  
to	  MS.	   For	   44	   patients,	   who	   died	   from	   respiratory	   failure/arrest	   (n	   =	   17),	   cardiac	  
failure/arrest	   (n	  =	  14)	  or	  unknown	  causes	   (n	  =	  13),	  an	  arbitrary	  decision	  had	  to	  be	  
taken,	   regarding	   whether	   the	   death	   was	   attributable	   to	   MS	   or	   not.	   By	   using	   a	  
composite	  criterion,	  based	  on	  information	  on	  the	  secondary	  cause	  of	  death	  and	  on	  
whether	  a	  bedridden	  status	   (DSS	  8)	  had	  been	  reached	  and	  sustained	   for	  at	   least	  3	  
years,	   26	   patients	  were	   deemed	   to	   have	   died	   from	  MS	   and	   18	   to	   have	   died	   from	  
unrelated	  causes	  (Table	  3.16).	  	  
	  
3.3.3.3.1	  Comparative	  analysis:	  deaths	  due	  to	  MS	  versus	  deaths	  NOT	  due	  to	  MS	  	  
	  
In	  the	  total	  dead	  population,	  210	  (64.8%)	  patients	  died	  from	  causes	  directly	  related	  
to	   MS,	   including	   6	   who	   committed	   suicide,	   and	   114	   (35.2%)	   died	   from	   causes	  
unrelated	  to	  MS	  (Table	  3.16).	  Comparison	  of	  clinical	  and	  demographic	  features,	  and	  
of	  the	  disease	  progression	  revealed	  differences	  and	  similarities	  (Table	  3.17).	  Times	  to	  
disability	   endpoints	   and	   to	   death	   were	   calculated	   in	   the	   dead	   population	   only,	  
without	  including	  censored	  information	  in	  the	  analysis.	  	  
	  
Figure	  3.25	  DSS	  score	  at	  last	  assessment	  before	  death.	  Percentages	  (y-­‐axis)	  of	  dead	  due	  and	  NOT	  due	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In	  both	   subgroups,	   of	   dead	  due	  and	  not	  due	   to	  MS,	   the	  disease	  phenotypes	  were	  
equally	  distributed	  (relapsing	  onset	  patients:	  65.7%	  versus	  65.8%;	  p	  =	  0.98),	  and	  the	  
F/M	  ratio	  and	  the	  clinical	  presentation	  were	  remarkably	  similar.	  However,	  those	  who	  
died	   from	  causes	   related	   to	  MS	  were	  almost	  4	  mean	  years	  younger	  at	   the	  disease	  
onset	  (33.0	  versus	  36.7	  mean	  years;	  p	  =	  0.03).	  The	  binary	  logistic	  regression	  analysis	  
confirmed	   that	   being	   older	   at	   the	   disease	   onset	   significantly	   associated	   with	   a	  
modestly	  lower	  probability	  of	  dying	  from	  MS	  (OR	  =	  0.96;	  p	  =	  0.004).	  In	  addition,	  the	  
dead	  due	   to	  MS	  were	  much	  younger	  at	   the	  onset	  of	  progression	   (38.7	  versus	  45.0	  
mean	   years;	   p	   <	   0.001),	   secondary	   to	   the	   shorter	   duration	   of	   the	   RR	   phase	   (8.8	  
versus	  12.3	  mean	  years;	  p	  =	  0.002).	  	  
	  
Interestingly,	  patients	  who	  died	  from	  MS	  took	  slightly	  shorter	  times	  to	  all	  disability	  
endpoints	  (Table	  3.17).	  Nevertheless,	  they	  attained	  death	  only	  2.1	  years	  earlier	  than	  
those	   who	   died	   from	   causes	   unrelated	   to	   MS	   (23.9	   versus	   26.0	   mean	   years,	  
respectively;	  p	  =	  0.075).	  Consequently,	  given	  the	  similar	  time	  to	  death	  between	  the	  
two	  groups,	  the	  younger	  age	  at	  death	  among	  the	  dead	  due	  to	  MS	  (57.0	  versus	  62.7	  
mean	  years;	  p	  <	  0.001)	  was	  mainly	  accounted	  for	  by	  their	  younger	  age	  at	  the	  disease	  
onset	  (Table	  3.17).	  The	  DSS	  scores,	  at	  last	  assessment,	  are	  presented	  in	  figure	  3.25.	  
Most	  of	  the	  patients	  in	  both	  subgroups	  were	  followed	  up	  to	  the	  latest	  stage	  of	  the	  
disease,	  before	  dying;	  91.8%	  of	  dead	  due	  to	  MS	  and	  61.5%	  of	  dead	  NOT	  due	  to	  MS	  
were	  scored	  between	  DSS	  7	  and	  9	  (Figure	  3.25).	  
	  
Causes	   of	   death	   were	   grouped	   in	   categories	   as	   follows:	   cachexia,	   cardiovascular	  
(heart	   disease,	   cardiac	   arrest/failure/arrhythmia),	   cerebrovascular	   (stroke),	  
infections	   (septicaemia),	   malignancy,	   miscellaneous	   (intestinal	   obstruction,	   head	  
injury,	   internal	   bleed,	   bowel	   infarction,	   accident),	   MS,	   pulmonary	   (respiratory	  
arrest/failure,	   pulmonary	   embolism,	   pneumonia,	   chronic	   bronchitis,	   aspiration),	  
renal	   (renal	   failure,	   pyelonephritis),	   suicides	   and	   unknown	   (Table	   3.18).	   Factors	  
affecting	  the	  time	  to	  death	  were	  assessed	  among	  the	  dead	  due	  to	  MS	  (Table	  3.19)	  
and	  among	  the	  dead	  from	  causes	  unrelated	  to	  MS	  (Table	  3.20).	  	  
	  
	  
	   193	  
Table	  3.17	  Clinical	  and	  demographic	  features	  of	  dead	  patients	  (n	  =	  324),	  grouped	  by	  causes	  of	  death:	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3.3.3.3.2	  Deaths	  due	  to	  MS	  	  
	  
Among	  the	  dead	  due	  to	  MS,	  the	  time	  to	  death	  was	  not	  affected	  either	  by	  the	  type	  of	  
the	   disease	   course,	   or	   by	   the	   age	   at	   onset	   or	   by	   the	   type	   of	   symptoms	   at	   clinical	  
presentation	   (Table	   3.19).	   Consequently,	   being	   younger	   at	   onset	   and	   having	   a	  
relapsing	   onset	   course	   predicted	   a	   younger	   age	   at	   death	   and	   therefore	   worse	  
prognosis.	   Those	   younger	   at	   disease	   onset	   died	   at	   younger	   age	   (age	   ≤	   20	   =	   42.6	  
versus	  age	  >	  30	  =	  63.2	  mean	  years,	  p	  <	  0.001;	  age	  21-­‐30	  =	  50.5	  versus	  age	  >	  30	  =	  63.2	  
mean	   years,	   p	   <	   0.001).	   Similarly,	   relapsing	   onset,	   compared	   to	   progressive	   onset	  
patients,	   took	   almost	   the	   same	   time	   to	   death	   (24.3	   versus	   23.1	   mean	   years,	   p	   =	  
0.36),	  but	  were	  significantly	  younger	  when	  they	  died	  (RR/SP	  =	  55.0	  versus	  PP	  =	  60.7	  
mean	   years;	   p	   =	   0.01),	   secondary	   to	   their	   younger	   age	   at	   onset	   (30.7	   versus	   35.1	  
mean	   years,	   p	   <	   0.001).	   Males	   compared	   to	   females	   had	   similar	   age	   at	   first	  
symptoms	   (32.7	   versus	   33.1	  mean	   years,	   p	   =	   0.71),	   took	   a	   slightly	   shorter	   time	   to	  
death	  (22.4	  versus	  25.0	  mean	  years,	  p	  =	  0.10)	  and	  were	  slightly	  younger	  when	  they	  
died	  (males	  =	  55.2	  versus	  females	  =	  58.3	  mean	  years;	  p	  =	  0.003)	  (Table	  3.19).	  	  	  	  
	  
Respiratory	  diseases	  (n	  =	  116;	  55.2%),	  MS	  (n	  =	  48;	  22.8%)	  and	  infections	  (n	  =	  19;	  9%)	  
were	   the	  commonest	   immediate	   causes	  of	  death	   (Table	  3.18).	   In	   the	  3	   subgroups,	  
the	   mean	   age	   at	   onset	   was	   approximately	   33	   years,	   females	   and	   relapsing	   onset	  
disease	   course	   predominated,	   however	   the	   F/M	   ratio,	   among	   the	   dead	   due	   to	  
pulmonary	   diseases,	   was	   close	   to	   unity.	   In	   addition,	   the	   mean	   DSS	   score	   before	  
death,	  the	  average	  time	  to	  death	  and	  the	  mean	  age	  at	  death	  were	  similar.	  	  
	  
Six	  patients	  (2.8%)	  committed	  suicide	  (3	  females/3	  males).	  These	  were	  significantly	  
younger	  at	  the	  disease	  onset	  (26.5	  mean	  years),	  and	  were	  younger	  (47.8	  years)	  and	  
less	  disabled	  at	  death	  (mean	  DSS	  =	  5.3),	  secondary	  to	  the	  shorter	  survival	  (21.3	  mean	  
years)	  (Table	  3.18).	  	  
	  
Patients	   who	   died	   from	   cardiovascular	   causes	   (9	   from	   cardiac	   arrest	   and	   1	   from	  
cardiac	  failure)	  (n	  =	  10;	  4.7%)	  and	  spent	  at	  least	  3	  years	  bedbound,	  were	  the	  oldest	  
at	  onset	  (34.2	  mean	  years)	  and	  at	  death	  (66.1	  mean	  years),	  were	  the	  most	  disabled	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before	  dying	  (mean	  DSS	  =	  8.2),	  and	  took	  the	  longest	  time	  to	  death	  (31.9	  mean	  years)	  
(Table	  3.18).	  	  
	  
For	  6	  patients	  (2.8%)	  the	  cause	  of	  death	  was	  unknown,	  however	  they	  were	  deemed	  
to	  have	  died	  from	  MS,	  as	  they	  had	  been	  bedbound	  for	  at	  least	  3	  years	  before	  dying	  
(3	  patients	  stayed	  15	  years	  at	  DSS	  8	  and	  the	  remaining	  3	  stayed	  6,	  7	  and	  9	  years).	  	  
	  
	  Table	  3.19	  Factors	  affecting	  the	  time	  to	  death	  from	  the	  disease	  onset	  and	  from	  birth	  (age	  at	  death)	  
among	  patients	  who	  died	  from	  MS	  related	  causes	  (n	  =	  210).	  Censored	  information	  was	  not	  included	  in	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3.3.3.3.3	  Deaths	  NOT	  due	  to	  MS	  	  
	  
Among	  the	  dead	  NOT	  due	  to	  MS,	  males	  had	  a	  shorter	  survival	  (males	  =	  23.3	  versus	  
females	  =	  28.1	  mean	  years;	  p	  =	  0.03)	  and	  were	  younger	  (males	  =	  60.8	  versus	  females	  
=	  64.2	  mean	  years;	  p	  =	  0.06)	  at	  death.	  In	  contrast	  to	  the	  dead	  due	  to	  MS,	  a	  PP	  course	  
associated	  with	  a	  significantly	  shorter	  time	  to	  death	  (PP	  =	  21.9	  versus	  RR/SP	  =	  28.2	  
mean	   years;	   p	   =	   0.02).	   However,	   again,	   a	   younger	   age	   at	   onset	   and	   an	   initial	   RR	  
course	   associated	   with	   a	   younger	   age	   at	   death.	   Relapsing	   onset	   patients	   died	   at	  
slightly	  younger	  age	  (RR/SP	  =	  61.2	  versus	  PP	  =	  65.7	  mean	  years;	  p	  =	  0.53),	  secondary	  
to	   their	   younger	   age	   at	   clinical	   presentation	   (33.0	   versus	   41.5	   mean	   years,	   p	   <	  
0.001).	  Those	  older	  at	  the	  disease	  onset	  reached	  death	  more	  rapidly	  (age	  ≤	  20	  =	  30.7	  
versus	  age	  >	  30	  =	  23.9	  mean	  years,	  p	  =	  0.02;	   age	  21-­‐30	  =	  31.0	   versus	  >	  30	  =	  23.9	  
mean	  years,	  p	  =	  0.06),	  although	  at	  significantly	  older	  age	  (age	  ≤	  20	  =	  48.6	  versus	  age	  
>	  30	  =	  67.0	  mean	  years,	  p	  <	  0.001;	  age	  21-­‐30	  =	  55.5	  versus	  age	  >	  30	  =	  67.0	  mean	  
years,	  p	  <	  0.001)	  (Table	  3.20).	  	  
	  
Deaths	   not	   related	   to	   MS	   were	   mainly	   attributed	   to	   causes	   of	   death	   normally	  
observed	   in	   the	   general	   population	   (Table	   3.18).	   Most	   of	   the	   patients	   died	   from	  
malignancies	   (n	   =	   42;	   36.8%),	   cardiovascular	   diseases	   (n	   =	   31;	   27.1%)	   and	  
cerebrovascular	  diseases	  (n	  =	  15;	  13.1%).	  The	  dead	  due	  to	  malignancies	  were	  mainly	  
women	  (F/M	  ratio	  =	  2.2),	  with	  relapsing	  onset	  disease	  course	  (74%).	  In	  this	  subgroup	  
patients	   took	   longer	   time	   to	   die	   (25.7	  mean	   years)	   and	  were	   older	   at	   death	   (62.4	  
mean	  years),	  compared	  to	  most	  of	  the	  dead	  due	  to	  MS.	  However,	  few	  (n	  =	  8)	  were	  
still	  in	  the	  RR	  phase	  when	  they	  died,	  which	  probably	  explains	  the	  relatively	  low	  level	  
of	  disability	  (mean	  DSS	  =	  6.0)	  at	  the	  last	  assessment.	  The	  primary	  malignancy	  could	  
be	  determined	  for	  37	  patients	  (88%	  of	  dead	  from	  cancer).	  Lung	  (n	  =	  9)	  and	  breast	  (n	  
=	  8)	  carcinomas	  predominated,	  and	  were	  followed	  by	  pancreas	  (n	  =	  4),	  bowel	  (n	  =	  3),	  
gastric	  (n	  =	  2),	  cervix	  (n	  =	  2)	  cancers,	  Hodgkin’s	  lymphoma	  (n	  =	  2),	  sarcoma	  (n	  =	  2),	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Table	  3.20	  Factors	  affecting	  the	  time	  to	  death	  from	  the	  disease	  onset	  and	  from	  birth	  (age	  at	  death)	  
among	  patients	  who	  died	   from	  causes	  NOT	  related	   to	  MS	   (n	  =	  114).	  Censored	   information	  was	  not	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Patients	   who	   died	   from	   cardiovascular	   diseases	   (26	   from	   heart	   disease,	   4	   from	  
cardiac	   arrest,	   1	   from	   cardiac	   arrhythmia)	   (n	   =	   31;	   27.1%)	   and	   patients	   who	   died	  
from	   cerebrovascular	   diseases	   (stroke)	   (n	   =	   15;	   13.1%)	   were	   distinguished	   by	   the	  
opposite	   F/M	   ratio	   (0.7	   versus	   1.5),	   although	   the	   age	   at	   the	   disease	   onset	   (37.8	  
versus	   38.2	  mean	   years)	   and	   the	   type	   of	  MS	   phenotype	   (relapsing	   onset	   course	   =	  
61%	  versus	  60%)	  were	  alike.	  In	  addition,	  both	  subgroups	  took	  similar	  time	  to	  death	  
(29.4	  versus	  27.7	  mean	  years)	  and	  died	  at	  similar	  age	  (67.2	  versus	  65.9	  mean	  years).	  	  
	  
Miscellaneous	   causes	   included:	   accidents	   (n	   =	   3),	   bowel	   infarction	   (n	   =	   1),	   gastro-­‐
intestinal	  bleeding	  (n	  =	  2),	  intestinal	  obstruction	  (n	  =	  1)	  and	  head	  injury	  (n	  =	  1).	  The	  
few	   (n	   =	   8;	   7%)	   dead	   from	  pulmonary	   diseases	   (6	   from	   respiratory	   failure,	   1	   from	  
respiratory	  arrest	  and	  1	  from	  chronic	  bronchitis)	  who	  were	  deemed	  to	  have	  not	  died	  
from	  MS,	  had	  spent	  less	  than	  3	  years	  bedbound	  (n	  =	  4)	  or	  were	  never	  recorded	  (n	  =	  
4)	  at	  DSS	  8.	  Those	  patients	  (n	  =	  7;	  6.1%),	  whose	  cause	  of	  death	  was	  unknown,	  stand	  
out	   for	   their	   very	   young	   age	   at	   onset	   (26.2	  mean	   years)	   and	   at	   death	   (42.2	  mean	  
years)	  and	  the	  very	  short	  time	  to	  death	  (16.0	  mean	  years):	  two	  of	  them	  stayed	  less	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3.3.3.4	  Survival	  in	  the	  total	  population	  	  	  
 
Figure	   3.26	   Proportions	   of	   patients	   (y-­‐axis)	   in	   the	   total	   population	   (n	   =	   1023)	   and	   in	   the	   relapsing	  
onset	  (n	  =	  806)	  and	  progressive	  onset	  (n	  =	  217)	  subgroups	  dying	  at	  specific	  time	  points	  from	  disease	  
onset	  (x-­‐axis).	  	  
	  
	  
In	   the	   total	   population	   (n	   =	   1023),	   the	   survival	   analysis	   allowed	   to	   calculate	   the	  
probability	   of	   surviving	   and	   to	   estimate	   the	   time	   to	   death,	   taking	   into	   account	  
censored	   information.	  Twenty-­‐five	   years	   after	   onset,	   17.5%	   (n	   =	   180)	   of	   the	   total	  
population	  had	  died,	  rising	  to	  26.8%	  (n	  =	  275)	  at	  35	  years	  (Figure	  3.26)	  and	  to	  31.6%	  
(n	  =	  324),	  by	  the	  end	  of	  the	  observation	  period.	  The	  Kaplan	  Meier	  estimated	  mean	  
time	   to	  death	   from	  onset	  was	  37.5	  years	   (median	   time	  =	  38	  years)	  and	   from	  birth	  
(age	  at	  death)	  was	  69.4	  years	  (median	  age	  =	  71	  years).	  The	  probability	  of	  surviving	  
over	  time	  was	  higher	  in	  the	  relapsing	  onset	  group,	  compared	  to	  the	  PP	  group:	  at	  25	  
years	  from	  onset,	  86.2%	  (n	  =	  694)	  of	  RR/SP	  and	  68.7%	  (n	  =	  149)	  of	  PP	  patients	  were	  
still	  alive,	  decreasing	  to	  78.6%	  (n	  =	  633)	  and	  53%	  (n	  =	  115)	  at	  35	  years	  (Figure	  3.26)	  
and	  to	  73.5%	  (n	  =	  593)	  and	  48.8%	  (n	  =	  106)	  by	   the	  end	  of	   the	  observation	  period,	  
respectively.	  	  
	  
Factors	  affecting	  survival	  in	  the	  total	  population	  were	  assessed	  (Table	  3.21).	  The	  PP	  
group,	  compared	  to	  relapsing	  onset	  group,	  took	  a	  much	  shorter	  time	  to	  death	  (30.3	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RR/SP	  HR	  =	  1.60;	  p	  <	  0.001)	  (Table	  3.18).	  However,	  the	  estimated	  age	  at	  death	  was	  
not	  influenced	  by	  the	  type	  of	  the	  disease	  course	  (RR/SP	  =	  69.6	  versus	  PP	  =	  69.3	  mean	  
years;	   p	   =	   0.86).	   In	   addition,	   the	   probability	   of	   surviving	   was	   lower	   among	  males	  
(time	  to	  death:	  males	  =	  33.0	  versus	   females	  =	  39.5	  mean	  years;	   risk	  of	  death	  HR	  =	  
1.49;	  p	  <	  0.001)	  and	  among	  those	  older	  at	  disease	  onset	  (time	  to	  death:	  age	  ≤	  20	  =	  
47.2	  versus	  age	  >	  30	  =	  31.9	  mean	  years;	  risk	  of	  death	  HR	  =	  0.38,	  p	  <	  0.001;	  time	  to	  
death:	  age	  21-­‐30	  =	  39.6	  versus	  age	  >	  30	  =	  31.9	  mean	  years;	  risk	  of	  death	  HR	  =	  0.58,	  p	  
<	  0.001).	  Patients	  presenting	  with	  motor	  and	  cerebellar	  symptoms	  took	  significantly	  
shorter	   time	   to	   death	   however,	   this	   was	   not	   confirmed	   by	   the	   multivariate	   cox	  
regression	  analysis	  (Table	  3.21).	  	  
	  
Table	  3.21	  Kaplan	  Meier	  survival	  analysis:	  estimated	  time	  to	  death.	  Multiple	  Cox	  regression	  analysis:	  
risk	   (HR)	  of	  death	   in	   total	  population	   (n	  =	  1023)	  according	   to	   the	  concomitant	  effect	  of	  clinical	  and	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3.3.3.4.1	  Dying	  from	  MS	  (the	  attainment	  of	  DSS	  10)	  	  	  	  
	  
Among	  210	  patients	  (20.5%	  of	  the	  total	  population),	  who	  had	  attained	  DSS	  10	  by	  the	  
end	  of	  the	  observation	  period,	  72	  (33.1%	  of	  PP	  population)	  had	  a	  progressive	  onset	  
and	  138	  (17.1%	  of	  RR/SP	  population)	  had	  an	  initial	  relapsing	  course.	  The	  number	  of	  
patients	  dying	  from	  MS	  over	  time	  increased	  in	  greater	  percentages	  in	  the	  PP	  group	  
(Figure	   3.29).	   Twenty	   years	   after	   onset,	   within	   the	   PP	   group,	   13.8%	   (n	   =	   30)	   had	  
attained	  DSS	   10	   versus	   only	   6.3%	   (n	   =	   51)	   of	   the	  RR/SP	   group.	   These	  percentages	  
increased	   to	   19.3%	   (n=	   42)	   and	   9.1%	   (n	   =	   74)	   at	  25	   years,	   to	   26.2%	   (n	   =	   57)	   and	  
13.1%	  (n	  =	  106)	  at	  30	  years,	  and	  to	  29.9%	  (n	  =	  65)	  and	  14.8%	  (n	  =	  120)	  at	  35	  years,	  
respectively	  (Figure	  3.27).	  	  
	  
In	   the	   total	   population,	   the	   Kaplan	   Meier	   estimated	   mean	   and	   median	   times	   for	  
reaching	  DSS	  10	  were	  44.5	  (95%	  CI	  42.2-­‐46.8)	  and	  45	  years	  from	  the	  disease	  onset,	  
and	  74.7	  (95%	  CI	  72.9-­‐76.5)	  and	  78	  years	  from	  birth	  (age	  at	  death	  from	  MS).	  Primary	  
progressive	  patients	  attained	  DSS	  10	  from	  the	  disease	  onset	  in	  a	  significantly	  shorter	  
time	  compared	  to	  relapsing	  onset	  patients	   (12.3	  mean	  years	  difference).	  However,	  
the	  type	  of	  the	  disease	  course	  did	  not	  affect	  the	  estimated	  age	  at	  DSS	  10,	  which	  was	  
remarkably	  similar	  in	  the	  two	  subgroups	  (PP	  =	  73.8	  versus	  76.1	  mean	  years,	  p	  =	  0.63)	  
(Figure	  3.28)	  
 
Figure	   3.27	   Proportions	   of	   patients	   (y-­‐axis)	   in	   the	   total	   population	   (n	   =	   1023)	   and	   in	   the	   relapsing	  
onset	   (n	   =	   806)	   and	  progressive	  onset	   (n	   =	   217)	   subgroups	   reaching	  DSS	   10	   at	   specific	   time	  points	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Figure	   3.28	  Kaplan	  Meier	  analysis:	   comparison	  of	   survival	   curves	   to	  DSS	  10	   from	  disease	  onset	  and	  
from	  birth	  (age	  at	  DSS	  10)	  between	  PP	  and	  RR/SP	  patients.	  P	  values	  were	  obtained	  with	  Log	  Rank	  test.	  




3.3.3.4.2	  Factors	  affecting	  the	  attainment	  of	  DSS	  10.	  	  	  	  
	  
Within	   the	   total	  population,	  being	  male	   (males	  =	  37.9	  versus	   females	  =	  46.3	  mean	  
years,	  HR	  =	  1.48,	  p	  =	  0.002)	  and	  being	  older	  at	   the	  disease	  onset	   (age	  ≤	  20	  =	  30.7	  
versus	  age	  >	  30	  =	  23.9	  mean	  years,	  HR	  0.39,	  p	  =	  0.02;	  age	  21-­‐30	  =	  31.0	  versus	  age	  >	  
30	  =	  23.9	  mean	  years,	  HR	  0.71,	  p	  =	  0.06)	  associated	  with	  a	  significantly	  higher	  risk	  of	  
dying	   from	  MS	   and	   with	   a	   significantly	   shorter	   time	   to	   DSS	   10	   (Table	   3.22).	   The	  
multivariate	   cox	   regression	   model,	   assessing	   the	   effect	   of	   all	   variables	  
simultaneously,	  confirmed	  these	  associations.	  The	  type	  of	  symptoms	  at	   the	  clinical	  
presentation	  did	  not	  affect	  the	  time	  to	  and	  the	  risk	  of	  death	  due	  to	  MS	  (Table	  3.22).	  
	  
Similarly,	   within	   the	   relapsing	   onset	   group,	  males	   (males	   =	   40.1	   versus	   females	   =	  
48.3	  mean	   years,	   p	   =	   0.04)	   and	   those	  older	   at	   the	   disease	   onset	   (age	   ≤	   20	   =	   56.0	  
versus	  age	  >	  30	  =	  39.5	  mean	  years,	  HR	  0.38,	  p	  <	  0.001;	  age	  21-­‐30	  =	  44.4	  versus	  age	  >	  
30	  =	  39.5	  mean	  years,	  HR	  0.73,	  p	  <	  0.001)	  took	  significantly	  shorter	  times	  to	  die	  from	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among	  males	   (Table	  3.23).	   In	  addition,	   the	  type	  of	  symptoms	  at	  disease	  onset	  was	  
shown	  not	  to	  exert	  any	  predictive	  effect	  (Table	  3.23).	  	  
	  
In	  the	  PP	  group,	  beside	  a	  modestly	  increased	  risk	  of	  death	  due	  to	  MS	  (HR	  1.63,	  p	  =	  
0.04)	   among	   males,	   none	   of	   the	   variables	   analysed	   significantly	   affected	   the	  
probability	  and	  the	  time	  to	  DSS	  10	  (Table	  3.24).	  	  	  
	  
	  
Table	   3.22	  Kaplan	  Meier	   survival	   analysis:	   time	   to	  DSS	   10.	  Multiple	   Cox	   regression	   analysis:	   risk	   of	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Table	   3.23	  Kaplan	  Meier	   survival	   analysis:	   time	   to	  DSS	   10.	  Multiple	   Cox	   regression	   analysis:	   risk	  of	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Table	   3.24	  Kaplan	  Meier	   survival	   analysis:	   time	   to	  DSS	   10.	  Multiple	   Cox	   regression	   analysis:	   risk	   of	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3.4	  Discussion	  	  
	  
	  
3.4.1	  The	  ideal	  natural	  history	  database	  	  
	  	  
The	  astonishingly	  high	  number	  of	  studies	  carried	  out	  over	  the	  past	  60	  years	  proves	  
the	  natural	   history	  of	  MS	  as	   probably	   one	  of	   the	  most	   scrutinized,	   among	   chronic	  
diseases.	   Despite	   the	   huge	   efforts	   for	   collecting	   reliable	   information	   during	   the	  
disease	  course,	  normally	  spanning	  over	  40-­‐50	  years,	  none	  of	  the	  MS	  registries	  can	  be	  
considered	   representative	   of	   the	  whole	   disease.	   Indeed,	   information	   on	   prognosis	  
can	  be	  only	  applied	  to	  large	  groups	  of	  patients	  and	  the	  long-­‐term	  outcome	  remains	  
widely	  unpredictable	  at	  individual	  level.	  	  
	  
The	   ideal	   inception	   cohort,	   whereby	   all	   information	   are	   identified	   at	   the	   disease	  
onset	  and	  then	  collected	  until	  death,	  is	  virtually	  impossible	  to	  obtain.	  Inevitably,	  data	  
are	   affected	   by	   several	   sources	   of	   bias	   (Table	   3.1).	   Although	   all	   the	   studies	   have	  
valuably	  contributed	  to	  our	  current	  knowledge	  of	  the	  natural	  history	  of	  the	  disease,	  
only	   few	   of	   them	   were	   carried	   out	   with	   rigorous	   methodology.	   Some	   strategies	  
should	   be	   implemented	   for	   minimizing	   bias	   (Weinshenker	   and	   Ebers,	   1987).	   The	  
accuracy	   of	   data	   collection	   can	   be	   improved	   when	   studies	   benefit	   from	   a	  
geographically	  based	  survey,	  ascertaining	  all	  MS	  cases	  in	  the	  community	  and	  serving	  
as	  comparator.	  This	  happened	  in	  Sweden	  (Runmarker	  and	  Andersen,	  1993),	  Europe	  
(Riise	   et	   al.,	   1988),	  Germany	   (Poser	   et	   al.,	   1982a)	   and	   Scotland	   (Phadke,	   1987).	   In	  
principle,	  ascertainment	  bias	  is	  generally	  low	  among	  cohorts	  from	  small	  geographic	  
areas,	   where	   all	   cases	   in	   the	   area	   are	   referred	   to	   a	   single	   tertiary	   clinic	   and	   few	  
neurologists	  only	  examine	  the	  patients.	  This	  allows	  a	  geographically	  based	  collection	  
of	   data	   and	   standardized	   clinical	   assessments.	   Good	   examples	   are	   the	   French	  
databases	   from	   the	   EDMUS	   network	   (Confavreux	   et	   al.,	   2003;	   Debouverie	   et	   al.,	  
2008;	   Leray	   et	   al.,	   2010)	   and	   the	   Swedish	   database	   from	  Gothenburg	   (Runmarker	  
and	   Andersen,	   1993).	   In	   contrast,	   cohorts	   of	   patients	   from	   several	   clinics	   are	  
advantaged	  by	  a	   large	  sample	  size,	  although	  they	  are	  often	  affected	  by	   incomplete	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ascertainment.	   This	   is	   the	   case	   of	   the	   British	   Columbia	   database,	   including	   5727	  
patients,	  of	  which	  2837	  were	  followed	  up	  for	  at	   least	  15	  years,	  but	  covering	  “only”	  
80%	   of	   the	   MS	   population	   in	   the	   area	   (Tremlett	   et	   al.,	   2006).	   The	   use	   of	   DMTs,	  
altering	  the	  natural	  history	  of	  the	  disease,	  can	  represent	  an	  additional	  drawback	  and	  
it	   varies	   among	   cohorts:	   15%	   of	   patients	   (439	   of	   2837)	   in	   the	   British	   Columbia’s	  
cohort	  (Tremlett	  et	  al.,	  2006),	  56.2%	  (1154	  of	  2054)	  in	  the	  Rennes’	  cohort	  (Leray	  et	  
al.,	  2010),	  and	  an	  unspecified	  proportion	  in	  the	  Lorraine’s	  cohort	  (Debouverie	  et	  al.,	  
2008)	  were	  treated	  with	  IFN	  or	  Copaxone.	  Almost	  half	  (n	  =	  804)	  of	  the	  Lyon	  database	  
population	   received	  Azathioprine	   (Confavreux	   et	   al.,	   2003).	   This	  might	   have	   had	   a	  
significant	   impact	   when	   assessing	   the	   relationship	   between	   inflammatory	   attacks	  
and	  late	  outcomes.	  	  
	  
Information	   collected	   retrospectively	   can	   be	   affected	   by	   recall	   bias,	   however	   very	  
few	  modern	  natural	  history	  cohorts,	  such	  as	  the	  Lyon	  (Confavreux	  et	  al.,	  2003)	  and	  
the	   Gothenburg	   databases	   (Runmarker	   and	   Andersen,	   1993),	   contain	   only	  
longitudinal	  data.	  The	  proportion	  of	  retrospective	  data	  largely	  varies	  among	  studies	  
and	   remains	   one	   of	   the	   least	   detailed	   information	   provided	   by	   the	   authors.	   A	  
separate	  group	  of	  patients	  seen	  from	  disease	  onset	  only	  can	  be	  used	  as	  comparator,	  
in	   order	   to	   assess	   the	   potential	   impact	   of	   referral	   bias	   (Weinshenker	   and	   Ebers,	  
1987).	  Equally	   relevant	   is	   the	  number	  of	   lost	   to	   follow	  up,	  which	  tends	  to	   increase	  
among	  the	  most	  disabled	  patients,	  normally	  not	  attending	  the	  clinics	  (Weinshenker	  
and	   Ebers,	   1987).	   This	   methodological	   aspect,	   along	   with	   the	   frequency	   of	   the	  
assessments,	   is	  often	  poorly	  and	  not	   clearly	  addressed	   in	  most	  of	   the	   studies.	  The	  
completeness	  of	  data	  acquisition	  is	  a	  cardinal	  feature,	  especially	  when	  carrying	  out	  
survival	   analyses	   (Chapter	   2),	   as	   it	   strongly	   affects	   the	   estimates	   of	   the	   disability	  
accumulation	  over	  time.	  The	  large	  efforts	  for	  maintaining	  long	  follow	  up	  are	  voided	  
when	  patients	  with	   the	  most	   severe	  outcome	  are	  not	   traced,	   in	  order	   to	  minimize	  
the	   rate	   of	   drop	   out.	   For	   instance,	   in	   the	   Lyon	   and	   Rennes	   cohorts,	   despite	   the	  
observation	  period	  lasted	  40	  (from	  1957	  to	  1997)	  and	  28	  (from	  1976	  to	  2004)	  years,	  
respectively,	   the	   mean	   disease	   duration	   was	   only	   11	   and	   12	   years,	   and	   the	  
proportion	  attaining	  DSS	  6	  was	  rather	  low	  (32%	  and	  35%),	  suggesting	  a	  high	  rate	  of	  
lost	  to	  follow	  up.	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3.4.2	  The	  London	  Ontario	  database	  	  
	  
Among	   natural	   history	   cohorts,	   the	   LO	   database	   represents	   one	   of	   the	   most	  
comprehensive	  and	  detailed	  collection	  of	  information	  on	  the	  disease	  course	  up	  to	  its	  
latest	  stage.	   Its	  methodology	  was	  advantaged	  by	  two	  subgroups	  of	  patients,	  highly	  
ascertained	   and	   with	   exclusively	   longitudinal	   data,	   which	   allowed	   internal	  
comparisons	  for	  assessing	  the	  potential	  impact	  of	  ascertainment	  and	  referral	  biases.	  
Data	  collection	  benefited	   from	  annual	  or	   semi-­‐annual	  assessments	   for	  most	  of	   the	  
patients,	   28	   years	   of	   follow	   up	   and	   special	   efforts	   for	   minimizing	   the	   rate	   of	  
dropouts.	   In	   addition,	   none	   of	   the	   patients	   was	   exposed	   to	   DMTs.	   The	   database	  
went	   through	   rigorous	  data	  quality	   check	  procedures,	  which	   further	   improved	   the	  
accuracy	  of	  the	  information	  (Chapter	  2).	  	  	  
	  
3.4.2.1	  The	  clinical	  and	  demographic	  features	  	  
	  
With	  the	  advantage	  of	  the	  long	  follow	  up,	  among	  the	  1023	  total	  patients,	  diagnostic	  
accuracy,	   according	   to	   Posers’	   criteria	   (Poser	   et	   al.,	   1983),	   was	   almost	   complete	  
(97.7%).	  The	  long	  mean	  disease	  duration	  (24.2	  years)	  in	  the	  total	  population	  reflects	  
the	   low	   proportion	   of	   lost	   to	   follow	   up,	   occurring	   over	   28	   years	   of	   observation	  
period.	  The	  mean	  age	  at	  the	  disease	  onset	  (30.6	  years)	  and	  the	  clinical	  presentation,	  
were	  in	  line	  with	  what	  observed	  in	  most	  of	  MS	  registries	  (Tables	  3.3	  and	  3.4).	  	  
	  
The	  number	  of	  women	  almost	  doubled	  the	  number	  of	  men,	  confirming	  the	  female	  
prevalence	   in	   the	  MS	   population.	   The	   F/M	   ratio	   (1.96)	   in	   the	   LO	   database	   lays	   in	  
between	   the	   lowest	   values	   (1.5)	   reported	   in	   Denmark	   and	   Sweden	   (Bronnum-­‐
Hansen	   et	   al.,	   2004;	   Runmarker	   and	   Andersen,	   1993)	   and	   the	   highest	   values	  
reported	   in	  France,	  Lorraine	  (2.6)	   (Debouverie	  et	  al.,	  2008)	  and	   in	  British	  Columbia	  
(2.3)	   (Tremlett	   et	   al.,	   2006)	   (Table	   3.4).	   The	   geographic	   area	   was	   shown	   to	  
potentially	  influence	  MS	  females’	  proportions	  (Figure	  3.1),	  however,	  it	  is	  unlikely	  to	  
explain	  these	  differences,	  as	  studies	  from	  Canada	  and	  north	  Europe	  were	  carried	  out	  
at	   similar	   latitudes.	   The	   different	   methodology	   and	   the	   variable	   proportion	   of	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relapsing	   onset	   disease,	   more	   frequently	   affecting	   women,	   might	   reasonably	  
account	  for	  this	  variation	  among	  cohorts.	  It	  remains	  possible	  that	  the	  larger	  number	  
of	  females	  observed	  in	  the	  British	  Columbia	  and	  Lorraine	  studies,	  which	  started	  data	  
collection	   more	   recently,	   is	   due	   to	   the	   increased	   F/M	   ratio	   over	   the	   past	   years	  
(Figure	  3.1).	  	  
	  
The	  proportion	  of	   PP	  patients	   in	   the	   LO	  database	   (21.7%)	   is	   similar	   to	   the	  Rennes	  
(Leray	   et	   al.,	   2010)	   and	   the	   European	   databases	   (Riise	   et	   al.,	   1992),	   although	   it	   is	  
higher	  than	  the	  average	  15%	  observed	  among	  most	  of	  the	  studies	  (Figure	  3.2).	  The	  
large	   female	   preponderance	   in	   cohorts	   reporting	   low	   percentages	   of	   PP	  MS	   cases	  
might	   partially	   explain	   the	   clinical	   phenotype	   distribution:	   British	   Columbia	   (F/M	  
ratio	  =	  2.3),	  Lorraine	  (F/M	  ratio	  =	  2.3)	  and	  Germany	  (F/M	  ratio	  =	  1.9).	  Most	  likely,	  the	  
completeness	   of	   the	   ascertainment	   and	   the	   recall	   bias	   drive	   these	   discrepancies.	  
However,	   it	  remains	  unclear	   if	   the	  number	  of	  LO	  patients	  with	  PP	  course	  was	  truly	  
above	  average	  or	  the	  estimates	  from	  other	  studies	  are	  less	  accurate.	  Among	  the	  LO	  
database	  patients,	   the	  clinical	  phenotypes	  was	   redefined	   (Chapter	  2)	   following	   the	  
latest	   consensus	  on	   the	  definitions	  of	   the	  MS	  disease	  course	   (Lublin	  and	  Reingold,	  
1996).	   Unlike	   other	   databases,	   this	   reclassification	   of	   the	   clinical	   phenotype	   was	  
extensively	  addressed	  in	  detail	  (Cottrell	  et	  al.,	  1999b;	  Kremenchutzky	  et	  al.,	  1999a).	  
A	   primary	   progressive	   course	   had	   to	   be	   characterized	   by	   at	   least	   1	   year	   of	  
continuous	  deterioration,	  with	  temporary	  plateaux	  allowed,	  during	  which	  worsening	  
occurs,	  even	   if	  not	   clinically	  obvious	   (Cottrell	   et	  al.,	   1999b).	  Repeated	  questioning,	  
over	   yearly	   assessments,	   about	   early	   symptoms	   led	   some	   patients,	   initially	  
categorized	   as	   PP	   MS,	   to	   recall	   an	   early	   single	   exacerbation	   (n	   =	   21)	   or	   multiple	  
attacks	  (=	  8),	  and	  therefore	  to	  be	  reclassified	  as	  single	  attack	  progressive	  (SAP)	  or	  RR	  
MS,	   respectively	   (Cottrell	   et	   al.,	   1999b;	   Kremenchutzky	   et	   al.,	   1999a).	   Given	   the	  
same	   long-­‐term	   outcome,	   the	   progressive	   patients	   from	   onset	   with	   (PR	   MS)	   or	  
without	   (PP	  MS)	   superimposed	   relapses	  were	  merged	   together	   and	   constitute	   the	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3.4.2.1.1	  The	  MC	  and	  SO	  subgroups	  
	  
The	  total	  population	  was	  compared	  to	  the	  geographically	  ascertained	  subgroup	  from	  
Middlesex	   County	   (MC),	   including	   90%	   of	   MS	   patients	   in	   the	   area	   (Hader	   et	   al.,	  
1988),	  and	  to	  the	  subgroup	  exclusively	  seen	  from	  disease	  onset	  (SO).	  This	  allowed	  to	  
assess	  the	  potential	  impact	  of	  ascertainment	  and	  referral	  biases	  on	  the	  LO	  database.	  
The	  two	  subgroups	  resemble	  the	  total	  population	  in	  age	  at	  onset,	  F/M	  ratio,	  clinical	  
presentation	  and	  diagnostic	  certainty	  (Table	  3.8).	  	  
	  
The	  lack	  of	  retrospective	  data	  in	  the	  SO	  subgroup	  explains	  the	  shorter	  mean	  disease	  
duration	  (Table	  3.8)	  and	  the	  lower	  percentages	  of	  severely	  disabled	  patients	  (Figure	  
3.15	  A).	  In	  addition,	  among	  those	  seen	  from	  onset,	  the	  proportion	  of	  PP	  MS	  is	  much	  
smaller	   (8.3%).	   This	   might	   be	   due	   to	   the	   exclusion	   from	   this	   subgroup	   of	   those	  
patients	   presenting	   with	   progressive	   insidious	   symptoms,	   seeking	   for	   medical	  
attention	   only	   years	   after	   disease	   onset.	   However,	   this	   disparity	   might	   also	   have	  
resulted	   from	  recall	  bias,	   as	   those	   first	   seen	  at	  a	   later	  point	   in	   their	  disease	  might	  
have	  forgotten	  early	  remitting	  symptoms	  (Weinshenker	  et	  al.,	  1989b).	  	  
	  
3.4.2.2	  The	  long	  term	  outcome	  
	  
The	   survival	   estimates	   in	   the	   LO	  database	  were	   advantaged	  by	   the	   long	   follow	  up	  
and	   the	   low	   rate	   of	   dropouts,	   allowing	   to	   observe	   a	   large	   percentage	   of	   patients	  
progressing	   up	   to	   the	   latest	   stage	   of	   the	   disease.	   By	   the	   end	   of	   the	   observation	  
period,	   85.2%	   (n	   =	   872),	   73.7%	   (n	   =	   754),	   54.8%	   (n	   =	   561)	   and	   20.6%	   (n	   =	   210)	  
reached	  DSS	  3,	  6,	  8	  and	  10,	  respectively	  (Figure	  3.14	  A).	  More	  than	  50%	  of	  the	  total	  
population	  was	   scored	   between	  DSS	   8	   and	   10,	  with	   similar	   distribution	   in	   the	  MC	  
subgroup	   (Figure	   3.13	   A).	   This	   is	   the	   largest	   proportion	   of	   patients	   reaching	   high	  
disability	  levels	  among	  MS	  registries,	  although	  data	  available	  from	  other	  cohorts	  for	  
comparison	  are	  very	  limited.	  	  
	  
The	  analysis	  of	  the	  disability	  accumulation	  over	  time	  (Figure	  3.14	  A)	  highlighted	  the	  
lack	  of	   linearity	  of	   the	  DSS	   (paragraph	  1.6).	  The	  average	  time	   in	  between	  disability	  
	   212	  
levels	  was	  unevenly	  distributed,	  with	  the	  highest	  peak	  (8.1	  mean	  years)	  in	  between	  
DSS	   0	   and	   3,	   and	   the	   lowest	   peak	   (5.4	  mean	   years)	   in	   between	  DSS	   3	   and	   6.	   The	  
disability	   accumulated	   proportionally	   with	   the	   disease	   duration	   but	   at	   different	  
rates:	  at	  15	  years	  from	  onset	  more	  than	  30%	  of	  patients	  had	  not	  reached	  moderate	  
disability	  (DSS	  3),	  half	  (50%)	  had	  required	  walking	  stick	  (DSS	  6)	  and	  20%	  had	  already	  
become	  bedbound	  (Figure	  3.15	  A).	  The	  Kaplan	  Meier	  estimated	  median	  times	  to	  DSS	  
3,	  DSS	  6,	  DSS	  8	  and	  DSS	  10	  were	  7,	  15,	  26	  and	  46	  years,	  respectively.	  The	  MC	  and	  SO	  
subgroups	  attained	  disability	  endpoints	  in	  remarkably	  similar	  times,	  compared	  to	  the	  
total	   population,	   reassuringly	   demonstrating	   that	   only	   little	   bias	   affected	   the	  
estimates	  of	  the	  disability	  accumulation	  (Figure	  3.16).	  	  
	  
However,	   among	  MS	   registries,	   the	   LO	  population	   stands	  out	   for	   its	   faster	  disease	  
progression.	   The	   median	   time	   to	   DSS	   6	   (15	   years)	   was	   slightly	   shorter	   than	   the	  
average	  estimate	  (18-­‐20	  years)	  from	  the	  other	  cohorts	  (Figure	  3.3).	  This	  could	  be	  due	  
to	  the	  larger	  proportion	  of	  PP	  MS	  cases	   in	  the	  LO	  database.	  Nevertheless,	   it	  seems	  
improbable	  as	  progressive	  onset	  patients	  attained	  disability	  endpoints	  (median	  time	  
to	  DSS	  6	  =	  8	  years)	  (Figure	  3.20)	  in	  similar	  times,	  compared	  to	  other	  MS	  populations	  
(Figure	   3.5).	   On	   the	   contrary,	   LO	   relapsing	   onset	   patients	   had	   the	   fastest	   disease	  
progression	  (median	  time	  to	  DSS	  6	  =	  18	  years)	  (Figure	  3.17),	  among	  cohorts	  (Figure	  
3.5).	  Most	  likely,	  the	  variable	  proportion	  of	  censored	  information	  accounts	  for	  these	  
differences.	  The	  Kaplan	  Meier	  estimated	  times	  to	  disability	  endpoints	  shorten	  with	  
the	   increasing	   number	   of	   patients	   attaining	   the	   endpoint.	   Indeed,	   in	   the	   Lorraine,	  
Rennes	  and	  Lyon	  databases	  the	  percentages	  of	  censored	  data,	  when	  estimating	  the	  
time	  to	  DSS	  6,	  were	  72%,	  65%	  and	  68%,	  respectively	  (Figure	  3.3),	  much	  higher	  than	  
the	   LO	   database	   (26.2%).	   It	   can	   be	   speculated	   that,	   among	   LO	   patients,	   the	  more	  
severe	   outcome	   was	   driven	   by	   genetic	   and	   environmental	   factors.	   However,	   this	  
would	   not	   explain	   why	   there	   was	   such	   a	   large	   different	   outcome	   between	   MS	  
patients	   from	   LO	   and	   from	   the	   neighbour	   area	   of	   British	   Columbia,	   where	   MS	  
patients	  experienced	  an	  unusually	   slow	  disease	  evolution	   (median	   time	   to	  DSS	  6	  =	  
27.9	  years)	  (Tremlett	  et	  al.,	  2006)	  (Figure	  3.3).	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3.4.2.3	  The	  relapsing	  onset	  and	  the	  progressive	  onset	  patients	  
	  
The	   analysis	   confirmed	   the	   well-­‐known	   clinical	   and	   demographic	   differences	  
between	   relapsing	   onset	   and	   progressive	   onset	   patients	   (Table	   3.13).	   As	   seen	   in	  
other	  large	  cohorts	  from	  Lyon	  (Confavreux	  and	  Vukusic,	  2006a),	  Rennes	  (Leray	  et	  al.,	  
2010)	   and	   British	   Columbia	   (Tremlett	   et	   al.,	   2005),	   men	   were	   more	   likely	   to	  
experience	   a	   progressive	   course	   at	   disease	   onset.	   The	   F/M	   ratio	   in	   the	   LO	   PP	  MS	  
group	  (1.3)	  was	  close	  to	  unity,	  in	  contrast	  to	  the	  RR	  group,	  which	  was	  featured	  by	  a	  
large	  female	  preponderance	  (2.1).	  In	  addition,	  the	  two	  groups	  were	  distinguished	  by	  
strikingly	  different	  age	  at	  onset,	  with	  PP	  MS	  staring	  on	  average	  10	  years	   later	  than	  
RR	  MS.	  However,	  primary	  and	  secondary	  progressive	  patients	  started	  to	  progress	  at	  
remarkably	  similar	  age	  (Table	  3.13),	  confirming	  that	  the	  type	  of	  the	  disease	  course	  
does	   not	   affect	   the	   age	   at	   the	   onset	   of	   progression	   (Table	   3.6).	   In	   line	  with	   other	  
studies,	   the	  presenting	   clinical	   pattern	   varied	   according	   to	   the	  disease	  phenotype.	  
Motor	  symptoms	  at	  onset	  were	  observed	  in	  most	  of	  the	  PP	  cases,	  sensory	  and	  visual	  
disturbances	   were	   more	   likely	   to	   occur	   at	   presentation	   of	   the	   relapsing	   disease	  
(Table	  3.10).	  	  
	  
The	   disability	   accumulated	  more	   rapidly	   in	   the	   progressive	   onset	   group:	   20	   years	  
after	  disease	  onset	  half	  of	  PP	  patients	  became	  bed	  bound	  (Figure	  3.20	  A)	  and	  half	  of	  
RR/SP	  patients	  required	  walking	  assistance	  (Figure	  3.17	  A).	  However,	  in	  both	  groups	  
the	   clinical	   outcome	   largely	   varied,	   further	   confirming	   the	   unpredictability	   of	   the	  
prognosis	  at	  individual	  level,	  regardless	  of	  the	  clinical	  phenotype.	  The	  time	  to	  DSS	  6	  
widely	  spanned	  from	  1	  to	  49	  years	  among	  progressive	  onset	  patients	  (25	  percentiles	  
≤	   4	   years,	   75	   percentiles	   >	   13	   years)	   (Figure	   3.19)	   and	   from	   1	   to	   44	   years	   among	  
relapsing	  onset	  patients	  (25	  percentiles	  ≤	  8	  years,	  75	  percentiles	  >	  19	  years)	  	  (Figure	  
3.18).	  	  	  
	  
The	   proportion	   reaching	   disability	   levels	   increased	  with	   the	   disease	   duration,	   and	  
was	   larger	   among	   PP	   patients.	   More	   than	   60%	   of	   the	   PP	   population	   had	   already	  
reached	  DSS	  6	  at	  10	  years	   from	  disease	  onset,	   increasing	   to	  77%	  at	  15	  years;	  50%	  
had	   become	   bedbound	   (DSS	   8),	   at	   20	   years	   (Figure	   3.20	   A).	   In	   contrast,	   among	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relapsing	   onset	   patients,	   at	   15	   years,	   38%	   and	   16%	   reached	   DSS	   6	   and	   DSS	   8,	  
respectively.	   These	   percentages	   increased	   to	   50%	   and	   to	   25%	   at	   20	   years	   (Figure	  
3.17	  A).	  By	  the	  end	  of	  the	  observation	  period,	  the	  vast	  majority	  (79%)	  of	  PP	  patients	  
and	  almost	  half	   (48%)	  of	   relapsing	  onset	  patients	  were	  distributed	  between	  DSS	  8	  
and	  10	  (Figure	  3.13	  B).	  	  
	  
3.4.2.4	  The	  amnestic	  nature	  of	  the	  disease	  course.	  	  
	  
Among	  natural	  history	   studies,	   there	   is	   large	  agreement	   that	  PP	  course	   represents	  
the	   strongest	   negative	   prognostic	   factor	   (Figure	   3.5).	   The	  Kaplan	  Meier	   analysis	   in	  
the	  LO	  population	  confirmed	  that	  PP	  patients	   took	  significantly	  shorter	   times	   from	  
the	   disease	   onset	   to	   disability	   endpoints,	   both	  when	   compared	   to	   relapsing	   onset	  
(RR/SP)	  and	  to	  SP	  patients	  (Figures	  3.21	  and	  3.22).	  However,	  controversy	  remains	  on	  
whether	   PP	  MS	   is	   a	   separate	   clinical	   entity	   (Confavreux	   and	   Vukusic,	   2006a)	   and	  
whether,	   among	   all	   MS	   subtypes,	   the	   progressive	   phase	   is	   driven	   by	   common	  
mechanisms	  (Kremenchutzky	  et	  al.,	  2006a;	  Lassmann,	  2010).	  In	  the	  Lyon	  (Confavreux	  
and	  Vukusic,	  2006a),	  the	  Rennes	  (Leray	  et	  al.,	  2010)	  and	  the	  Lorraine	  (Debouverie	  et	  
al.,	   2008)	   databases	   the	   disease	   evolution	   from	   moderate	   disability	   was	   not	  
influenced	   by	   the	   clinical	   phenotype.	   Times	   from	  DSS	   3	   and	   from	  DSS	   4	   to	   higher	  
disability	   levels	  were	   similar	  between	  PP	  and	  RR/SP	  patients.	   In	   addition,	  previous	  
analysis	   of	   the	   LO	   database	   demonstrated	   that	   the	   rate	   of	   the	   disability	  
accumulation	  was	  homogeneous	  among	  progressive	  subtypes.	  Those	  with	  one	  (SAP	  
MS),	  many	  (SP	  MS)	  and	  no	  (PP	  MS)	  relapses	  before	  the	  onset	  of	  progression	  started	  
to	   progress	   at	   similar	   age	   and	   attained	   DSS	   6,	   8	   and	   10,	   from	   the	   onset	   of	  
progression,	  in	  remarkably	  similar	  times	  (Kremenchutzky	  et	  al.,	  2006a).	  	  
	  
The	  analyses	   in	   this	   study	   confirmed	   that	  progressive	  and	   relapsing	  onset	  patients	  
share	  much	  more	  than	  they	  differ	  and	  supported	  a	  unifying	  concept	  of	  the	  disease	  
course	   (Confavreux	   and	   Vukusic,	   2006a).	   Once	   established	   disability	   occurred,	  
further	   disease	   progression	   was	   only	   marginally	   influenced	   by	   the	   type	   of	   the	  
disease	   course.	   With	   the	   exception	   of	   the	   time	   from	   DSS	   0	   to	   DSS	   3,	   the	   two	  
subgroups	   took	   similar	   average	   times	   to	   advance	   from	   one	   DSS	   landmark	   to	   the	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following	  (Figure	  3.14	  B).	  In	  addition,	  the	  estimated	  Kaplan	  Meier	  times	  from	  DSS	  3	  
to	  DSS	  6	  and	   to	  DSS	  8	  were	  only	  3	  mean	  years	   shorter	   in	   the	  PP	  group	  versus	   the	  
relapsing	  onset	  group	  (Figure	  3.21),	  and	  were	  almost	  equal	  when	  compared	  to	  the	  
SP	  group	  (Figure	  3.22).	  The	  narrower	  differences	  between	  PP	  and	  SP	  MS	  reflect	  the	  
larger	   number	   of	   patients	   attaining	   the	   endpoints,	   following	   the	   exclusion	   of	   RR	  
patients	  from	  the	  analysis.	  	  
	  
In	   the	   LO	  database	  more	   than	  70%	  of	  RR	  patients	   converted	   to	   SP	  MS	  when	   they	  
were	   scored	   at	   ≤	   DSS	   3	   (Chapter	   4),	   implying	   that	   the	   disease	   progression	   from	  
moderate	  disability	  heralded	  the	  SP	  phase.	  Therefore,	  the	  similar	  times	  from	  DSS	  3	  
to	   the	   endpoints,	   between	   RR/SP	   and	   PP	   patients,	   further	   proved	   that	   the	  
progressive	  phase	   is	   largely	   unaffected	  by	   the	   type	  of	   the	   initial	   disease	   course.	   It	  
remains	  unclear	  and	  hard	  to	  explain	  why	  the	  progressive	  disease	  can	  be	  preceded	  or	  
not	   by	   the	   relapsing	   remitting	   phase.	   However,	   these	   data,	   in	   agreement	   with	  
previous	  analyses	  from	  the	  Rennes	  database	  (Leray	  et	  al.,	  2010),	  highlighted	  DSS	  3	  as	  
the	  hallmark	  status,	  separating	  two	  disease	  stages	  apparently	   independent	  of	  each	  
other.	  Once	  established	  disability	  occurs	  (DSS	  3	  or	  4),	  further	  disability	  accumulation	  
becomes	   a	   self-­‐perpetuating	   process,	   amnesic	   to	   the	   previous	   clinical	   history	  
(Confavreux	  and	  Vukusic,	  2006a;	  Kremenchutzky	  et	  al.,	  2006a;	  Leray	  et	  al.,	  2010).	  It	  
is	   reasonable	   to	   conclude	   that	   the	   outcome	   is	   largely	   determined	   before	   the	  
attainment	   of	   moderate	   disability.	   Therefore	   the	   most	   relevant	   window	   of	  
therapeutic	  opportunity	  probably	  terminates,	  once	  the	  cascade	  of	  events	  leading	  to	  
the	  permanent	  damage	  occurs.	   In	  addition,	  the	  similar	  disease	  evolution	  among	  all	  
MS	  progressive	  subtypes	  suggests	  common	  mechanisms	  driving	  the	  accumulation	  of	  
severe	   disability	   and	   question	   the	   contribution	   of	   the	   inflammatory	   attacks,	  
featuring	  the	  RR	  phase,	  to	  the	  evolution	  of	  the	  progressive	  phase.	  This	  will	  be	  more	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3.4.3	  Mortality	  in	  MS	  
	  
Mortality	  in	  MS	  has	  been	  largely	  addressed	  by	  several	  epidemiological	  studies,	  most	  
of	   them	   advantaged	   by	   a	   very	   large	   sample,	   long	   follow	   up	   (Table	   3.7)	   and	   the	  
possibility	  of	  comparing	  data	  with	   the	  general	  population	   (Figure	  3.6).	  The	  survival	  
estimates	   are	   difficult	   to	   compare	   because	   of	  methodological	   differences	   and	   the	  
variable	   incidence	  of	  MS	  among	  countries.	  The	  LO	  database,	  unlike	  other	  datasets,	  
offered	   the	   possibility	   of	   addressing	   the	   mortality	   in	   a	   well	   ascertained	   MS	  
population,	  with	  detailed	  clinical	  assessments	  up	  to	  the	  latest	  disease	  stages	  before	  
death	  for	  most	  of	  the	  patients.	  However,	  the	  lack	  of	  data	  on	  mortality	  in	  the	  general	  
population,	  at	   the	   time	   the	  study	  was	  undertaken,	  did	  not	  allow	  assessing	  survival	  
more	  sophisticatedly,	  by	  calculating	  SMRs.	  	  	  
	  
3.4.3.1	  Dead	  in	  the	  LO	  database	  
	  
Following	   extensive	   efforts	   for	   tracing	   all	   patients	   lost	   to	   follow	   up	   and	   for	  
ascertaining	   their	   cause	  of	  death,	  324	  dead	  were	   identified,	   representing	  31.6%	  of	  
the	   total	   population.	   Similar	   percentage	   (33.1%)	  of	   dead	  patients	  was	  observed	   in	  
the	  MC	  subgroup,	  supporting	  the	  accuracy	  of	  the	  estimate.	  	  
	  
Among	   the	   324	   dead	   patients,	   the	   median	   time	   to	   death	   was	   24	   years	   and	   the	  
median	  age	  at	  death	  was	  60	  years,	  however	  survival	  largely	  varied.	  The	  quickest	  25%	  
died	  within	  17	  years	  and	  the	  slowest	  25%	  in	  more	  than	  30	  years.	  Comparison	  with	  
the	   MC	   group	   showed	   no	   significantly	   different	   time	   to	   death	   (Figure	   3.23),	  
demonstrating	   that	  minimal	   ascertainment	   bias	   affected	  data	   on	  mortality.	   By	   the	  
end	  of	  the	  observation	  period,	  51%	  of	  the	  progressive	  onset	  group	  and	  26%	  of	  the	  
relapsing	   group	   had	   died,	   confirming	   that	   PP	   course	   associated	   with	   a	   worse	  
outcome.	   However,	   among	   all	   dead,	   the	   type	   of	   disease	   course	   only	   marginally	  
affected	   the	   time	   to	   death.	   Although	   they	   died	   in	   larger	   proportion,	   progressive	  
onset	  patients	  attained	  death	  only	  3	  years	  earlier	  than	  relapsing	  onset	  patients	  (22.7	  
versus	  25.7	  mean	  years,	  p	  =	  0.005)	  (Table	  3.15).	  Indeed,	  relapsing	  onset	  patients	  had	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worse	   outcome,	   as	   they	   died	   younger	   (6	   median	   years	   difference),	   secondary	   to	  
their	  younger	  age	  at	  the	  disease	  onset	  (9	  median	  years	  difference)	  (Table	  3.15).	  	  
	  
3.4.3.2	  Causes	  of	  death	  
	  
Among	  MS	  patients,	  the	  severe	  disability	   is	  not	  necessarily	  the	   immediate	  cause	  of	  
death.	   The	   definition	   of	   death	   due	   to	  MS	   (DSS	   10),	   according	   to	   Kurtzke	   (Kurtzke,	  
1983),	   remains	  somehow	  ambiguous	  and	  can	  be	  variably	   interpreted.	  The	  problem	  
of	  defining	   causes	  of	  death	  directly	   attributed	   to	  MS	  has	  never	  been	  addressed	   in	  
details.	  Indeed,	  most	  of	  the	  studies	  relied	  exclusively	  on	  information	  from	  the	  death	  
certificates,	  without	  correlating	  it	  with	  the	  level	  of	  disability	  reached	  by	  the	  patient	  
before	  dying.	  	  
	  
In	   the	  LO	  database	   information	  on	  causes	  of	  death	  were	  available	   for	   the	  majority	  
(96%)	   of	   dead	   patients.	   Deaths	   from	   aspiration,	   cachexia,	   dehydration,	   MS,	  
pneumonia,	  pulmonary	  oedema,	  pulmonary	  embolism,	  septicemia	  and	  suicide	  were	  
considered	  attributable	  to	  MS	  (Cottrell	  et	  al.,	  1999b).	  For	  those	  patients	  (n	  =	  44)	  who	  
died	   from	   respiratory	   disease	   (n	   =	   17),	   cardiac	   dysfunctions	   (n	   =	   14)	   or	   unknown	  
causes	   (n=	   13),	   attributing	   the	   death	   to	   MS	   was	   particularly	   challenging	   and,	   to	  
reduce	  the	  ambiguity,	  a	  composite	  criterion	  was	  applied.	  This	  was	  primarily	  based	  on	  
the	   attainment	   of	   DSS	   8,	   as	   death	   due	   to	   MS	   is	   normally	   a	   consequence	   of	   the	  
chronic	   bedridden	   state	   (Kurtzke,	   1983),	   and	  was	   supported	  by	   pathophysiological	  
considerations.	   Respiratory	   muscle	   weakness,	   bulbar	   function	   impairment	   and	  
abnormalities	   of	   breathing	   control	   represent	   the	   respiratory	   problems	   most	  
commonly	  observed	  in	  the	  MS	  population	  (Carter	  et	  al.,	  1950;	  Gosselink	  et	  al.,	  1999).	  
Both	   inspiratory	  and	  expiratory	  activities	  and	  the	  general	  pulmonary	  function	  were	  
found	   to	  be	   significantly	  decreased	  even	  among	  MS	  patients	   still	   fully	   ambulatory,	  
during	   the	  early	  stage	  of	   the	  disease	   (Mutluay	  et	  al.,	  2005).	  More	   importantly,	   the	  
degree	  of	  the	  respiratory	   impairment	  was	  found	  to	  correlate	  strongly	  with	  the	  DSS	  
score,	   and	   to	   increase	   proportionally	   with	   the	   level	   of	   disability	   (Gosselink	   et	   al.,	  
2000;	  Mutluay	  et	  al.,	  2005).	  The	  bedridden	  status	  (DSS	  8),	  which	  exposes	  patients	  to	  
respiratory	   infections	   and	   aspiration	   pneumonia,	   plays	   an	   important	   role	   in	   the	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worsening	   of	   the	   pre-­‐existing	   respiratory	   dysfunctions	   (Gosselink	   et	   al.,	   2000).	  
Similarly,	  MS	  patients	  can	  loose	  the	  parasympathetic	  and	  sympathetic	  control	  of	  the	  
cardiovascular	   system,	   secondary	   to	   brainstem	   demyelinating	   lesions	   (Acevedo	   et	  
al.,	  2000;	  Vita	  et	  al.,	  1993).	  In	  addition,	  the	  degree	  of	  cardiac	  dysfunctions	  correlates	  
with	  the	  EDSS	  score,	  and	  becomes	  more	  severe	  among	  the	  most	  disabled	  (Acevedo	  
et	  al.,	  2000;	  Sterman	  et	  al.,	  1985).	  According	   to	   these	  data,	   in	  agreement	  with	  my	  
supervisor,	   I	   considered	   a	   chronic	   bedridden	   state	   sustained	   for	   at	   least	   3	   years	   a	  
sufficient	  criterion	  for	  assuming	  that	  the	  respiratory	  and	  cardiac	  dysfunctions,	  which	  
led	  to	  patients’	  death,	  were	  a	  direct	  consequence	  of	  MS	  related	  disability.	  The	  same	  
assumption	  was	  made	  for	  the	  dead	  from	  unknown	  causes.	  However,	  the	  choice	  of	  at	  
least	  3	  years	  time	  frame	  was	  purely	  arbitrary,	  and	  it	  remains	  possible	  that,	  for	  some	  
patients,	   being	   bedridden	   for	   such	   a	   short	   time	   did	   not	   actually	   directly	   lead	   to	  
death.	   The	   composite	   criterion	  was	   applied	   to	   44	  dead	  patients:	   26	  patients	  were	  
deemed	   to	   have	   died	   from	  MS	   and,	   among	   these,	   vast	   majority	   had	   spent	   much	  
longer	  than	  3	  years	  bedbound	  (the	  time	  varied	  from	  3	  to	  23	  years).	  For	  18	  patients	  
DSS	  8	  was	  never	  recorded	  or	  was	  sustained	  for	  less	  than	  3	  years.	  	  
	  
This	  led	  to	  a	  final	  estimate,	  among	  the	  total	  324	  dead,	  of	  210	  (64.8%)	  dead	  from	  MS	  
(Table	  3.16),	  representing	  one	  of	  the	  highest	  percentages	  compared	  to	  other	  studies	  
(Figure	   3.8).	   Indeed,	   the	   proportion	   of	   deaths	   due	   to	   MS	   ranged	   widely	   among	  
cohorts.	   The	   differences	   among	   recorded	   causes	   of	   death	   can	   be	   attributed	   to	  
methodological	  differences,	  but	  there	  are	  other	  potential	  factors.	  The	  assessment	  of	  
causes	  of	  death,	  among	  MS	  patients,	   is	   inevitably	   incomplete	  and	  rarely	  confirmed	  
by	  autopsy.	  The	  variable	  accuracy	  of	  the	  ascertainment	  depends	  on	  the	  possibility	  of	  
accessing	   to	   death	   certificates	   or	   to	   death	   registries	   and	   on	   the	   quality	   of	   the	  
information.	   Deaths	   may	   lack	   clear	   documentation	   as	   they	   often	   occur	   outside	  
hospital	   settings.	   In	   addition,	   the	   interpretation	   of	   “death	   related	   to	  MS”	   can	   be	  
ambiguous.	  Therefore,	   the	  distribution	  of	  causes	  of	  death	   is	  strongly	   influenced	  by	  
the	  coding	  practice	  (Smestad	  et	  al.,	  2009).	  All	  these	  factors	  are	  particularly	  relevant	  
when	   information	   on	   the	   cause	   of	   death	   is	   sought	   years	   after	   the	   last	   clinical	  
assessment.	   In	   the	   LO	  database,	  most	   of	   the	   dead	  were	   followed	  up	   to	   the	   latest	  
clinical	   stages	   (median	   DSS	   at	   last	   assessment	   =	   8),	   reflecting	   the	   low	   rate	   of	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dropouts	  (Figure	  3.25).	  Compared	  to	  other	  cohorts,	  the	  detailed	  clinical	  information	  
probably	  allowed	  estimating	  more	  reliably	  the	  proportion	  of	  dead	  due	  to	  MS	  (Table	  
3.18).	  	  
	  
For	   the	   majority	   of	   dead	   due	   to	   MS	   primary	   causes	   of	   death	   were	   respiratory	  
diseases	   (including	   10	   patients	   who	   died	   from	   respiratory	   failure/arrest	   and	   had	  
been	  bedbound	  for	  at	  least	  3	  years),	  MS	  and	  infections.	  The	  3	  subgroups	  had	  similar	  
baseline	  features	  and	  similar	  survival	  (Table	  3.18).	  Dead	  from	  cardiovascular	  causes,	  
deemed	   to	   be	  MS	   related	   (n	   =	   10),	   took	   significantly	   longer	   time	   to	   die	   and	  were	  
older	   at	   death,	   compared	   to	   the	   other	   dead	   due	   to	   MS	   (Table	   3.18).	   This	   was	  
expected	  as	  the	  risk	  of	  cardiovascular	  diseases	  increases	  with	  age.	  Among	  dead	  not	  
due	  to	  MS,	  cancers,	  cardiovascular	  diseases	  and	  cerebrovascular	  diseases	  were	  the	  3	  
most	  common	  causes	  of	  death	  (Table	  3.18).	  It	  is	  worth	  noticing	  that,	  those	  who	  died	  
from	   unknown	   causes	   (n	   =	   7)	   and	   did	   not	   fulfil	   the	   composite	   criterion,	   had	   the	  
shortest	   survival	   (16	   mean	   years).	   This	   might	   indicate	   that	   their	   death	   was	  
attributable	  to	  MS,	  as	  they	  experienced	  a	  particularly	  aggressive	  disease	  course,	  with	  
rapid	   accumulation	   of	   disability.	   Alternatively	   this	   small	   subgroup	   died	   from	  
accidental	  causes	  or	  from	  rapid	  illness.	  	  
	  
The	  comparative	  analysis	  revealed	  differences	  and	  similarities	  between	  the	  dead	  due	  
to	  MS	  or	  not	  (Table	  3.17).	  Baseline	  features	  were	  similar	  and	  the	  clinical	  phenotype	  
was	  equally	   distributed	   (65%	  of	  RR/SP	  MS	   in	  both	   subgroups),	   demonstrating	   that	  
the	  type	  of	  the	  disease	  course	  did	  not	  influence	  the	  probability	  of	  dying	  from	  causes	  
related	   to	  MS.	   In	   addition,	   although	   those	  who	  died	   from	  MS	  had	  a	   slightly	   faster	  
attainment	  of	  DSS	  levels,	  the	  two	  subgroups	  took	  similar	  times	  to	  die	  (23	  versus	  24	  
median	  years,	  p	  =	  0.07)	  (Table	  3.17),	  and	  had	  accumulated	  similar	  disability	  (median	  
DSS	  =	  8)	  before	  death	  (Table	  3.18).	  This	  was	  unexpected	  and	  contradicted	  the	  notion	  
that	  the	  dead	  due	  to	  MS	  die	  more	  rapidly	  and	  are	  more	  disabled	  at	  death.	  However,	  
the	   two	   groups	   differed	   by	   the	   age	   at	   disease	   onset	   and	   at	   death.	   Therefore,	   the	  
dead	  due	  to	  MS,	  compared	  to	  the	  dead	  not	  due	  to	  MS,	  were	  significantly	  younger	  at	  
clinical	   presentation	   (33.0	   versus	   36.7	  mean	   years,	   p	   =	   0.03),	   took	   similar	   time	   to	  
death,	   and	   consequently	   died	   at	   significantly	   younger	   age	   (57.0	   versus	   62.7	  mean	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years,	   p	   <	   0.001)	   (Table	   3.17).	   	   In	   contrast,	   patients	   older	   at	   clinical	   presentation	  
reached	   older	   age	   and,	   therefore,	   were	   exposed	   to	   a	   higher	   risk	   of	   pathological	  
conditions	  such	  as	  malignancies,	  cardiovascular	  and	  cerebrovascular	  diseases.	  	  
	  
This	   indicated	   that	   the	   probability	   of	   dying	   from	   MS	   related	   causes	   was	   mainly	  
influenced	  by	  the	  age	  at	  the	  disease	  onset,	  which	  affected	  the	  age	  at	  death,	  and	  not	  
by	  the	  severity	  of	  the	  disease	  course.	  Indeed,	  the	  binary	  logistic	  regression	  analysis	  
confirmed	  that	  being	  older	  at	  first	  symptom	  modestly	  but	  significantly	  decreased	  the	  
probability	  of	   dying	   from	  MS	   (OR	  =	  0.96;	   p	   =	  0.004).	   There	  was	  no	   indication	   that	  
those	   who	   died	   from	   MS	   accumulated	   more	   severe	   disability	   and	   had	   a	   worse	  
outcome,	   except	   for	   a	   slightly	   faster	   disease	   evolution.	   These	   data	   question	   the	  
validity	   of	   differentiating	   whether	   death	   is	   directly	   related	   to	  MS	   or	   not,	   and	   the	  




Six	  patients	   (1.8%	  of	  dead)	  committed	  suicide.	  These	  were	   the	  youngest	  at	   clinical	  
onset	   and	   at	   death	   and	   had	   the	   shortest	   survival	   (Table	   3.18).	   The	   risk	   of	   suicide	  
among	  MS	   patients	   has	   been	   reported	   to	   be	   increased,	   compared	   to	   the	   general	  
population:	  SMR	  =	  2.3	  (Fredrikson	  et	  al.,	  2003),	  SMR	  =	  2.1	  (Bronnum-­‐Hansen	  et	  al.,	  
2005),	   SMR	   =	   1.62	   (Koch-­‐Henriksen	   et	   al.,	   1998),	   7.5x	   (Sadovnick	   et	   al.,	   1991b).	  
However,	   assessing	   its	   prevalence	   is	   particularly	   challenging,	   and	   widely	   varying	  
incidence	   rates	   are	   found	   in	   the	   literature	   (Table	  3.7),	   exemplifying	   cultural	   biases	  
existing	   in	  different	  populations:	  28.6%	  (Sadovnick	  et	  al.,	  1991b),	  5%	  (Sumelahti	  et	  
al.,	   2002),	   5.3%	   (Smestad	   et	   al.,	   2009),	   4.5%	   (Bronnum-­‐Hansen	   et	   al.,	   2004),	   3.8%	  
(Koch-­‐Henriksen	   et	   al.,	   1998),	   2.5%	   (Grytten	   Torkildsen	   et	   al.,	   2008).	   Part	   of	   this	  
variation	  results	  from	  the	  referral	  bias,	  due	  to	  the	  fact	  that	  clinic-­‐based	  cohorts	  tend	  
to	  include	  more	  severely	  affected	  individuals,	  with	  higher	  rates	  of	  affective	  disorders	  
(Hirst	  et	  al.,	  2008b).	  It	  is	  also	  plausible	  that	  the	  cause	  of	  death	  recorded	  on	  the	  death	  
certificate	  may	   be	   influenced	   by	   cultural	   taboos	   such	   as	   the	   right	   to	   be	   buried	   in	  
certain	   cemeteries	   (cultural	   bias),	   making	   suicide	   underreported	   to	   avoid	   social	  
stigma.	   In	  Finland,	  where	  the	  suicide	  rates	   in	  the	  general	  population	  are	  very	  high,	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suicides	   are	   not	   typically	   disguised	   or	   recorded	   as	   ‘accidents’,	   and	   there	   are	   no	  
obvious	  cultural	  or	  religious	  factors	  that	  would	  lead	  to	  under-­‐reporting	  (Sumelahti	  et	  
al.,	   2010).	   Indeed,	   the	   SMR	   for	   suicides	   (1.7)	   in	   Finnish	   MS	   patients	   was	   not	  
significantly	  increased	  compared	  to	  the	  general	  population	  (Sumelahti	  et	  al.,	  2010).	  
On	   the	   contrary,	   substantially	   higher	   (7.5x)	   incidence	   is	   seen	   in	   longitudinally	  
followed	  patients	  from	  Canada	  where	  suicide	  tends	  to	  be	  underreported	  (Sadovnick	  
et	  al.,	  1991b).	  There	  is	  no	  reasonable	  doubt	  that	  suicide	  is	  substantially	  increased	  in	  
MS	  and	   it	   should	  be	   included	  as	  an	  “MS-­‐related	  cause	  of	  death”,	  unless	   there	   is	  a	  
case-­‐specific	  reason	  to	  think	  otherwise.	  	  
	  
3.4.3.2.2	  Malignancies	  	  
	  
Those	  who	  died	   from	  cancer	   represented	  12.9%	  of	   dead	   and	  were	  mainly	  women	  
with	   relapsing	   onset	   disease	   course.	   The	   subgroup	   was	   distinguished	   by	   a	   more	  
benign	  disease	  evolution	  (8	  patients	  were	  still	  in	  the	  RR	  phase	  when	  they	  died)	  and	  
less	   disability	   at	   death	   (median	  DSS	   =	   7).	   Compared	   to	   the	   dead	   due	   to	  MS,	   they	  
were	  older	  at	  death	  (age	  at	  death	  =	  62.4	  mean	  years),	  secondary	  to	  their	  older	  age	  at	  
onset	  (38	  median	  years),	  and	  were	  therefore	  exposed	  to	  a	  higher	  risk	  of	  malignancy.	  	  
	  
The	   incidence	   of	   cancer	   in	   MS	   largely	   varies	   among	   studies.	   One	   of	   the	   highest	  
proportion	  of	  deaths	  related	  to	  cancer,	  among	  MS	  patients,	  was	  reported	  in	  Finland	  
(35%)	  (Sumelahti	  et	  al.,	  2002),	  compared	  to	  cohorts	  from	  Denmark	  (8.6%	  and	  10.1%)	  
(Bronnum-­‐Hansen	  et	  al.,	  2004;	  Koch-­‐Henriksen	  et	  al.,	  1998),	  Wales	   (9.5%)	   (Hirst	  et	  
al.,	  2008b)	  and	  Norway	  (9.8%	  and	  10.6%)	  (Grytten	  Torkildsen	  et	  al.,	  2008;	  Smestad	  
et	   al.,	   2009).	   Indeed,	   there	   seems	   to	   be	   contradicting	   data	   on	   the	   frequency	   of	  
cancer	   among	  MS	   patients.	   A	   lower	   incidence,	   compared	   to	   the	  matched	   general	  
population,	  was	  observed	   in	  Denmark	   (SMR	  =	  0.85	  and	  0.79)	   (Bronnum-­‐Hansen	  et	  
al.,	   2004;	   Koch-­‐Henriksen	   et	   al.,	   1998)	   and	   in	   Canada	   (0.67x)	   (Sadovnick	   et	   al.,	  
1991b).	   In	   contrast,	   a	   higher	   incidence	   was	   observed	   in	   Finland	   (35%	   vs	   20%)	  
(Sumelahti	  et	  al.,	  2002)	  and	  in	  Norway	  (SMR	  =	  2.25)	  (Grytten	  Torkildsen	  et	  al.,	  2008).	  
Other	   studies,	   aimed	   at	   addressing	   this	   specific	   question,	   could	   not	   find	   cohering	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results,	  demonstrating	  similar	  (Fois	  et	  al.,	  2010;	  Nielsen	  et	  al.,	  2006)	  or	  a	  lower	  risk	  
(Achiron	   et	   al.,	   2005;	   Bahmanyar	   et	   al.,	   2009)	   of	   cancer,	   among	   MS	   patients.	   A	  
recent	  meta-­‐analysis	  pooled	  data	  from	  several	  cohorts,	  gathering	   information	  from	  
more	  than	  45000	  patients,	  and	  reported	  a	  significantly	  decreased	  risk	  (OR	  =	  0.92;	  p	  =	  
0.004)	   of	   all	   cancers	   in	   the	   MS	   population,	   relative	   to	   controls	   (Handel	   and	  
Ramagopalan,	  2010).	  The	  authors	  concluded	  that	  this	  could	  be	  due	  to	  earlier	  death	  
among	  MS	  patients,	  since	  the	  risk	  of	  cancer	  rises	  with	  age,	  further	  supporting	  data	  
presented	  in	  this	  thesis.	  	  
	  
3.4.3.2.3	  Cardiovascular	  and	  cerebrovascular	  diseases	  
	  
Those	  who	  died	  from	  cardiovascular	  and	  cerebrovascular	  diseases	  represented	  9.5%	  
and	  4.6%	  of	  the	  dead	  population,	  respectively.	  Patients	  in	  both	  subgroups	  were	  the	  
oldest	   at	   death	   (69	   and	   68	   median	   years,	   respectively)	   (Table	   3.18),	   therefore	  
exposed	  to	  a	  higher	   incidence	  of	  vascular	  risk	  factors.	  The	  F/M	  ratio	  resembles	  the	  
general	   population.	   As	   expected,	   among	   dead	   from	   cardiac	   diseases,	   men	  
predominated.	   The	  mortality	   from	   heart	   diseases	   is	  markedly	   higher	   among	  men,	  
secondary	  to	  a	  higher	  incidence	  of	  cardiovascular	  risk	  factors	  (Jousilahti	  et	  al.,	  1999).	  	  
In	  contrast,	  among	  dead	  from	  cerebrovascular	  accidents,	  there	  was	  a	  preponderance	  
of	  women.	  Interestingly,	  although	  the	  incidence	  of	  cerebrovascular	  disease	  is	  higher	  
among	  men	   (Prencipe	   et	   al.,	   1997)	  women	   have	   been	   reported	   to	   be	   older	  when	  
experiencing	  a	  stroke	  (Roquer	  et	  al.,	  2003).	  This	  might	  explain	  why,	  among	  patients	  
who	   died	   at	   similar	   age,	   there	   was	   a	   larger	   percentage	   of	   women	   suffering	   from	  
cerebrovascular	  events.	  	  
	  
The	  incidence	  of	  cardiovascular	  diseases,	  observed	  in	  the	  LO	  database,	  is	  lower	  than	  
what	   reported	   in	   other	   MS	   populations.	   However,	   deaths	   due	   to	   cardiovascular	  
disease	   depend	   heavily	   on	   the	   age	   distribution	   of	   those	   at	   risk,	   and	   on	   lifestyle	  
factors.	   Cardiac	   problems	   were	   responsible	   for	   14.4%	   (Smestad	   et	   al.,	   2009)	   and	  
13.1%	   (Grytten	   Torkildsen	   et	   al.,	   2008)	   of	   mortality	   cases	   in	   two	   Norwegian	   MS	  
cohorts,	  but	  for	  as	  many	  as	  26%	  in	  a	  Finnish	  MS	  population	  (Sumelahti	  et	  al.,	  2002)	  
and	   18.9%	   in	   Scotland	   (Phadke,	   1987).	   Deaths	   due	   to	   cerebrovascular	   disease	   are	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underreported	  among	  studies.	  These	  accounted	  for	  5.3%	  of	  cases	  in	  US	  (Redelings	  et	  
al.,	  2006),	  however	  no	  other	  data	  are	  available	  for	  comparison.	  	  
	  
3.4.3.2.4	  Respiratory	  diseases	  
	  
Respiratory	   diseases	   not	   attributed	   to	   MS	   related	   disability	   accounted	   for	   a	   low	  
percentage	   of	   deaths	   (2.4%	   of	   dead).	   This	   is	   line	   with	   results	   from	   other	   studies	  
where	  the	   incidence	  ranged	  from	  1.5%	  among	  Norwegian	  patients	   (Smestad	  et	  al.,	  
2009)	   to	   4.7%	   in	   Danish	   (Bronnum-­‐Hansen	   et	   al.,	   2004)	   and	   5.4%	   in	   Finnish	  
(Sumelahti	   et	   al.,	   2010)	  patients,	   respectively.	   In	   striking	   contrast	  with	   the	  general	  
trend,	   47.5%	   of	   deaths	   in	   Welsh	   patients	   were	   attributed	   to	   respiratory	   diseases	  
(infections	  included)	  (Hirst	  et	  al.,	  2008b).	  	  
	  
3.4.3.3	  Factors	  affecting	  the	  time	  to	  death	  and	  the	  age	  at	  death	  	  
	  
Factors	   affecting	   survival	   were	   assessed	   among	   dead	   patients	   only	   (not	   including	  
censored	   information).	   Interestingly,	   among	   all	   dead,	   progressive	   onset	   and	  
relapsing	  onset	  patients	  died	  in	  similar	  time	  (22.7	  versus	  25.7	  mean	  years;	  p	  =	  0.005)	  
(Table	  3.15),	  indicating	  that	  the	  time	  to	  death	  was	  largely	  unaffected	  by	  the	  clinical	  
phenotype.	  Same	  results	  were	  observed	  when	  the	  analysis	  was	  limited	  to	  the	  dead	  
due	  to	  MS	  (PP	  group	  =	  23.1	  versus	  RR/SP	  group	  =	  24.3	  mean	  years,	  p	  =	  0.36)	  (Table	  
3.19).	   In	   addition,	   in	   both	   analyses,	   relapsing	   onset	   patients,	   compared	   to	  
progressive	  onset	  patients,	  had	  worse	  outcome	  as	  they	  died	  at	  younger	  age	  	  (Tables	  
3.15	  and	  3.19).	   In	  striking	  contrast,	  among	  dead	  not	  due	  to	  MS,	   the	   time	  to	  death	  
was	  much	  shorter	   in	  the	  PP	  group,	  compared	  to	  the	  RR/SP	  group	  (21.9	  versus	  28.2	  
mean	  years,	  p	  =	  0.02)	   (Table	  3.20).	  This	  was	  explained	  by	   the	  different	   survival,	   in	  
each	   clinical	   phenotype	   group,	   between	   dead	   due	   to	  MS	   or	   not.	   In	   the	   relapsing	  
onset	  group,	  patients	  who	  died	   from	  causes	  unrelated	   to	  MS	  had	  a	   longer	   time	  to	  
death	   (28.2	   mean	   years),	   compared	   to	   patients	   who	   died	   from	   MS	   (24.3	   mean	  
years).	   This	   was	   probably	   accounted	   for	   by	   the	   dead	   due	   to	   malignancies,	  
cardiovascular	   and	   cerebrovascular	   diseases,	   who	   had	   long	   disease	   duration	   and	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large	  proportion	  of	  RR	  cases.	  On	  the	  contrary,	  PP	  dead	  from	  MS	  and	  from	  unrelated	  
causes	  had	  similar	  survival	  (23.1	  versus	  21.9	  mean	  years).	  
	  
In	  addition,	  males	  compared	  to	  females,	  took	  slightly	  shorter	  time	  to	  die	  and	  were	  
younger	  at	  death,	  in	  both	  groups	  of	  dead	  due	  to	  MS	  or	  not	  (Tables	  3.19	  and	  3.20).	  	  
	  
3.4.3.4	  Survival	  analysis	  	  
	  
The	  Kaplan	  Meier	  analysis	  allowed	  estimating	  the	  probability	  of	  surviving	  among	  all	  
MS	   patients.	   The	   survival	   probability	   reduced	   proportionally	   with	   the	   disease	  
duration,	  from	  82.5%	  of	  patients	  still	  alive	  at	  25	  years	  from	  onset,	  to	  68.4%	  10	  years	  
later	   (Figure	   3.26).	   The	   number	   of	   patients	   dying	   over	   time	   was	   larger	   in	   the	   PP	  
group,	   compared	   to	   relapsing	   onset	   group,	   reflecting	   their	   faster	   disease	  
progression.	  At	  35	  years	   from	  the	  disease	  onset	  only	  half	   (53%)	  of	  PP	  patients	  and	  
majority	  (78.6%)	  of	  RR/SP	  patients	  were	  still	  alive	  (Figure	  3.26).	  	  
	  
Among	   the	   total	   population	   (n	   =	   1023	  patients)	   the	   estimated	  mean	   survival	   time	  
was	  37.5	  years	   from	  disease	  onset	  and	  69.4	  years	   from	  birth	  (age	  at	  death),	  which	  
cohere	  with	  results	   from	  other	   large	  registries	   (Tables	  3.8	  and	  3.9).	  Patients	  with	  a	  
PP	  course	  had	  an	  increased	  risk	  of	  death	  (HR	  =	  1.60;	  p	  <	  0.001)	  and	  took	  on	  average	  
10	  years	  less	  to	  die,	  compared	  to	  the	  relapsing	  onset	  group	  (30.3	  versus	  39.6	  mean	  
years).	  However,	  age	  at	  death	  was	  remarkably	  similar	  in	  the	  two	  subgroups	  (RR/SP	  =	  
69.6	  versus	  PP	  =	  69.3	  mean	  years;	  p	  =	  0.86)	  and	  therefore	  not	  influenced	  by	  the	  type	  
of	   disease	   course,	   as	   already	   reported	   in	   other	   studies	   (Kingwell	   et	   al.,	   2012;	  
Smestad	   et	   al.,	   2009).	   In	   addition,	   the	   probability	   of	   surviving	   was	   lower	   among	  
males	   and	   among	   those	   older	   at	   disease	   onset	   (Table	   3.21),	   confirming	   the	   trend	  
observed	  among	  dead	  patients	  without	  including	  censored	  information.	  	  
	  
3.4.3.4.1	  The	  attainment	  of	  DSS	  10	  
	  
The	  analysis	  restricted	  to	  patients	  reaching	  DSS	  10	  (dead	  due	  to	  MS)	  yielded	  similar	  
results.	  By	  the	  end	  of	  the	  observation	  period,	  among	  the	  total	  population,	  20.5%	  had	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attained	   DSS	   10	   in	   an	   estimated	   mean	   time	   from	   onset	   of	   44	   years	   and	   at	   an	  
estimated	  mean	  age	  of	  74	  years.	  The	  proportion	  of	  dead	  from	  MS	  was	  larger	  in	  the	  
progressive	  onset	  group	  (33.1%	  of	  PP	  population)	  than	  in	  the	  relapsing	  onset	  group	  
(17.1%	  of	  RR/SP	  population).	  In	  line	  with	  previous	  studies	  (Grytten	  Torkildsen	  et	  al.,	  
2008;	   Hader,	   2010;	   Kantarci	   et	   al.,	   1998;	   Kingwell	   et	   al.,	   2012;	   Leray	   et	   al.,	   2007;	  
Midgard	  et	  al.,	  1995;	  Phadke,	  1987;	  Smestad	  et	  al.,	  2009;	  Sumelahti	  et	  al.,	  2002),	  the	  
analysis	   confirmed	   that	   PP	   patients	   took	   significantly	   shorter	   time	   from	   onset	   to	  
death	   (12	   mean	   years	   difference),	   however	   the	   estimated	   age	   at	   death	   was	   not	  
affected	  by	  the	  type	  of	  disease	  course	  (PP	  =	  73.8	  versus	  RR/SP	  =	  76.1	  mean	  years,	  p	  
=	  0.63)	  (Figure	  3.30).	  The	  type	  of	  symptoms	  at	  clinical	  presentation	  did	  not	  affect	  the	  
time	  to	  and	  the	  risk	  of	  death	  due	  to	  MS	  (Table	  3.19).	  These	  associations	  were	  also	  
seen	  among	  the	  relapsing	  onset	  patients	  (Table	  3.20).	  In	  contrast,	  among	  PP	  patient	  
none	  of	   the	  clinical	  and	  demographic	  baseline	  variables	  affected	   the	  probability	  of	  
surviving	  (Table	  3.21).	  	  	  	  
	  
3.4.4	  Conclusions	  	  
	  
The	  clinical	  and	  demographic	  features	  of	  the	  LO	  database	  population	  resemble	  the	  
other	   MS	   cohorts.	   Survival	   estimates	   were	   advantaged	   by	   the	   large	   number	   of	  
patients	  reaching	  the	  disability	  levels	  analysed.	  It	  can	  be	  reliably	  concluded	  that	  half	  
of	   relapsing	   onset	   patients	   and	   half	   of	   progressive	   onset	   patients	   are	   expected	   to	  
require	  a	  walking	  aid	  by	  18	  and	  8	  years	  from	  onset,	  respectively.	  The	  slightly	  faster	  
disease	   progression	   in	   the	   LO	  database,	   compared	   to	   other	   cohorts,	   is	  most	   likely	  
explained	  by	  the	  smaller	  proportion	  of	  censored	  information,	  shortening	  the	  survival	  
estimates.	   The	   comparison	   with	   the	   highly	   ascertained	   subgroup	   from	   Middlesex	  
County	  and	  with	  the	  subgroup	  seen	  from	  onset	  demonstrated	  that	  data	  are	  affected	  
by	  little	  bias.	  	  
	  
The	  results	  from	  the	  comparative	  analyses,	  between	  relapsing	  onset	  and	  progressive	  
onset	   patients,	   lent	   support	   to	   the	   amnestic	   nature	   of	   disease	   evolution	   and	  
highlighted	  the	  attainment	  of	  moderate	  disability	  (DSS	  3),	  heralding	  for	  most	  of	  the	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patients	  the	  SP	  phase,	  as	  the	  clinical	  watershed	  separating	  two	  independent	  stages.	  
Once	   established	   disability	   occurred,	   disease	   evolution	   was	   similar	   between	  
relapsing	   onset	   and	   progressive	   onset	   groups	   and	   therefore	   largely	   unaffected	   by	  
type	   of	   disease	   course,	   implying	   common	  mechanisms	   driving	   progression	   among	  
patients.	  The	  outcome	  is	  largely	  determined	  before	  entering	  this	  common	  pathway,	  
leading	  to	  the	  accumulation	  of	  severe	  disability.	  
	  
The	   analysis	   of	   mortality	   confirmed	   that	   life	   expectancy	   in	   the	   MS	   population	   is	  
slightly	   shortened.	  Half	   of	   the	   patients	  were	   dead	  by	   the	   age	   of	   71.	   Among	   those	  
who	  died	  from	  MS	  related	  causes,	  50%	  were	  dead	  within	  45	  years	  from	  onset	  and	  by	  
the	  age	  of	  78.	  The	  PP	  course	  associated	  with	  a	  higher	  risk	  of	  death	  and	  with	  shorter	  
survival	  however,	  the	  type	  of	  the	  disease	  course	  did	  not	  affect	  the	  estimated	  age	  at	  
death.	  This	  was	  observed	  both	  when	  analysing	  all	  dead	  patients	  or	  only	  those	  who	  
died	  from	  MS.	  The	  comparative	  analysis	  demonstrated	  that	  survival	  is	  not	  influenced	  
by	   causes	   of	   death.	   The	   probability	   of	   dying	   from	  MS	   related	   causes	   is	   primarily	  
driven	   by	   the	   age	   at	   the	   disease	   onset,	   affecting	   the	   age	   at	   death.	   These	   data	  
question	  the	  validity	  of	  differentiating	  whether	  the	  death	  resulted	  from	  the	  disability	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4.1	  Introduction	  	  
	  
Relapses	  are	  the	  most	   florid	  clinical	   feature	  of	   the	  RR	  phase	  and	  they	  can	  produce	  
temporary	   or	   even	   permanent	   disability	   (Hirst	   et	   al.,	   2008a;	   Lublin	   et	   al.,	   2003).	  
Typical	   inflammatory	   attacks	   in	   appropriate	   anatomic	   locations	   are	   sufficient	   for	  
experienced	   clinicians	   to	   diagnose	   MS	   with	   high	   reliability.	   However,	   their	  
relationship	   with	   the	   progressive	   unremitting	   disability,	   which	   is	   the	   heart	   of	   the	  
medical,	   social	   and	   economic	   impact	   of	   the	   disease,	   remains	   largely	   unclear.	   This	  
represents	   one	   of	   the	   most	   controversial	   aspects	   of	   the	   disease	   (Edan,	   2012;	  
Hutchinson,	  2011;	   Lublin,	   2011)	   and	   it	   is	   highly	   relevant	   to	   the	   clinical	   practice,	   to	  
the	  patients’	  therapeutic	  management,	  and	  to	  the	  RCTs	  design.	  The	  relapse	  number	  
is	  used	  for	  monitoring	  the	  disease	  activity	  (Cohen	  et	  al.,	  2004)	  and	  as	  indicator	  of	  the	  
response	   to	   treatments	   (Sormani	   et	   al.,	   2012).	   In	   addition,	   the	   ARR	   is	   the	   most	  
common	   primary	   clinical	   endpoint	   in	   RCTs	   (paragraph	   1.7,	   Chapter	   1)	   and	   it	   is	  
considered	  a	  valid	  surrogate	  marker	  for	  the	  short-­‐term	  disease	  evolution	  (Sormani	  et	  
al.,	  2011).	  	  
	  
Among	   relapsing	   onset	   patients,	   the	   attainment	   of	   the	   SP	   phase	   and	   the	  
accumulation	   of	   long-­‐term	   disability	   might	   result	   from	   serial,	   cumulative	  
exacerbations	   over	   time,	   each	   contributing	   to	   the	   permanent	   deficit.	   However,	  
evidence	   from	   radiological,	   pathological	   and	   clinical	   studies,	   on	   the	   relationship	  
between	   relapses	   and	   late	   outcomes,	   remains	   ambiguous.	   The	   baseline	   MRI	  
inflammatory	   lesions	   load,	   which	   is	   a	   surrogate	   of	   the	   relapses	   frequency,	   was	  
shown	  to	  predict	   the	  conversion	  from	  CIS	  to	  clinically	  defined	  MS,	  but	   to	  correlate	  
poorly	  with	  the	  long	  term	  disease	  evolution	  (2008;	  Calabrese	  et	  al.,	  2013;	  Fisniku	  et	  
al.,	   2008a).	   Mechanisms	   determining	   the	   axonal	   loss,	   which	   is	   considered	   the	  
essential	   cause	   of	   the	   permanent	   disability	   (Trapp	   and	   Nave,	   2008),	   are	   unclear	  
(Dutta	   and	   Trapp,	   2011;	   Lassmann	   et	   al.,	   2012).	   The	   axonal	   damage	   is	   known	   to	  
occur	   in	   the	   early	   stage	   of	   the	   disease,	   within	   active	   demyelinating	   lesions	  
(Kuhlmann	   et	   al.,	   2002;	   Trapp	   et	   al.,	   1998),	   but	   it	   was	   also	   found	   in	   the	   NAWM	  
(Bitsch	  et	  al.,	  2000;	  Bjartmar	  et	  al.,	  2001;	  DeLuca	  et	  al.,	  2006;	  Evangelou	  et	  al.,	  2000;	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Frischer	  et	  al.,	  2009;	  Trapp	  et	  al.,	  1998).	  It	  has	  been	  suggested	  that	  the	  inflammation	  
is	   the	  essential	  driver	  of	   the	  neurodegenerative	  process,	  up	   to	   the	   latest	   stages	  of	  
the	  disease	  (Frischer	  et	  al.,	  2009).	  Nevertheless,	  the	  inflammatory	  lesions	  load	  in	  the	  
spinal	   cord,	   was	   found	   to	   correlate	   poorly	   with	   the	   extent	   of	   the	   axonal	   damage	  
(DeLuca	   et	   al.,	   2006;	   Lovas	   et	   al.,	   2000).	   Indeed,	  DMTs	   seem	   to	   have	   only	   limited	  
effect	   on	   the	   disability	   accumulation	   during	   the	   progressive	   phase	   (paragraph	   1.7,	  
Chapter	  1).	  This	  suggests	  that	  biological	  mechanisms	  underlying	  acute	  attacks	  might	  
be	  different	   from	  those	  driving	  the	  disease	  evolution	   (Chaudhuri	  and	  Behan,	  2004;	  
Trapp	  and	  Nave,	  2008).	  	  
	  
Natural	   history	   studies	   offer	   the	   possibility	   to	   better	   define	   the	   role	   of	   the	  
inflammatory	  attacks	  on	  the	  development	  of	  severe	  disability.	  	  This	  allows	  to	  test	  the	  
validity	   of	   prognostic	   models,	   predicting	   late	   disability	   based	   on	   the	   number	   of	  
relapses,	  to	  assess	  the	  reliability	  of	  the	  attacks	  frequency	  as	  indicator	  of	  the	  disease	  
activity	   and	   to	   elucidate	   the	   complex	   interaction	   between	  mechanisms	   underlying	  
the	  inflammatory	  attacks	  and	  those	  driving	  the	  disease	  progression.	  	  
	  
	  
4.1.1	  The	  natural	  history	  of	  relapses	  
	  
	  
4.1.1.1	  The	  type	  of	  symptoms	  	  
	  
Inflammatory	  attacks	  can	  virtually	  present	  with	  any	  kind	  of	  neurological	  disturbance.	  
The	   clinical	   features	   of	   the	   onset	   attack	   have	   been	   widely	   described	   (Table	   3.2,	  
Chapter	   3)	   and	   are	   known	   to	   influence	   the	   long-­‐term	   disease	   evolution.	   Analyses	  
from	   Lyon,	   Lorraine,	   British	   Columbia,	   and	   Gothenburg	   cohorts	   demonstrated	   a	  
faster	  disease	  progression,	  among	  patients	  with	  multiple	  symptoms	  and	  with	  motor	  
involvement	  at	  clinical	  onset,	  and	  better	  prognosis,	  among	  patients	  presenting	  with	  
optic	  neuritis	  (Confavreux	  et	  al.,	  2003;	  Debouverie	  et	  al.,	  2008;	  Eriksson	  et	  al.,	  2003;	  
Tremlett	  et	  al.,	  2006).	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4.1.1.2	  The	  recovery	  from	  relapses	  	  
	  
The	  percentage	  of	  patients	  experiencing	  residual	  deficit	  from	  the	  onset	  attack	  varies	  
among	  databases,	  probably	  due	  to	  the	  different	  definitions	  of	  incomplete	  remission	  
(Table	  4.1).	  A	  partial	   recovery	   from	   the	   first	   attack	  was	   shown	   to	  associate	  with	  a	  
significantly	  shorter	  times	  from	  the	  disease	  onset	  to	  EDSS/DSS	  levels	  (Table	  4.1),	  but	  
not	   to	   affect	   the	   disease	   progression	   from	   established	   disability	   (DSS3	   or	   DSS	   4)	  
(Confavreux	  et	  al.,	  2003;	  Debouverie	  et	  al.,	  2008;	  Leray	  et	  al.,	  2010).	   In	  addition,	   in	  
the	  LO	  database,	  the	  time	  to	  SP	  was	  similar,	  among	  SAP	  patients	  with	  full,	  partial	  and	  
no	  recovery	  from	  the	  first	  attack	  (Kremenchutzky	  et	  al.,	  2006a)	  (Table	  4.1).	  	  	  
	  
Table	  4.1	  The	  percentage	  of	  patients	  with	  different	  degree	  of	  recovery	  from	  the	  onset	  attack,	  and	  the	  
predictive	  effect	  of	  incomplete	  recovery	  from	  the	  first	  relapse:	  data	  from	  MS	  registries.	  *	  Single	  attack	  
progressive	  (SAP)	  patients	  only.	  
	  
	  
The	   degree	   of	   recovery	   from	   inflammatory	   attacks	   after	   the	   clinical	   onset	   and	   its	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studies,	  which	  were	  limited	  by	  their	  relatively	  short	  duration.	  Lublin	  et	  al.	  examined	  
224	  patients	   from	  placebo	   arms,	  with	   a	  mean	   EDSS	   score	   of	   2.5,	   and	   reported,	   in	  
42%	   of	   cases,	   a	   residual	   deficit	   (0.5	   or	   ≥	   1	   EDSS	   point	   increase),	   occurring	   after	   a	  
mean	  time	  of	  64	  days	  from	  exacerbations	  (Lublin	  et	  al.,	  2003).	  Similarly,	  Hirst	  et	  al.	  
described,	  among	  182	  patients	  (mean	  EDSS	  score	  =	  3.7),	  attending	  an	  MS	  clinic	  and	  
experiencing	   279	   relapses,	   in	   49.4%	   a	   residual	   increase	   of	   ≥	   0.5	   EDSS	   point,	   127	  
mean	  days	  after	  an	  inflammatory	  attack	  (Hirst	  et	  al.,	  2008a).	  	  
However,	  these	  results	  could	  not	  be	  replicated	  in	  a	  separate	  study	  assessing	  patients	  
from	  2	  placebo	  arms	  (n	  =	  256	  and	  n	  =	  320	  both	  with	  mean	  EDSS	  of	  2.8)	  (Young	  et	  al.,	  
2006).	  The	  analysis	  showed	  no	  consistent	  effect	  of	  relapses,	  after	  200	  days,	  on	  the	  
development	  of	  sustained	  EDSS	  score	  (Young	  et	  al.,	  2006).	  In	  addition,	  among	  1078	  
patients,	  experiencing	  2578	  relapses	  over	  a	  period	  of	  15	  years,	  only	  7	  attacks	  were	  
reported	  to	  cause	  permanent	  severe	  disability	  (EDSS	  6	  or	  more,	  sustained	  for	  at	  least	  
6	  months)	  (Bejaoui	  and	  Rolak,	  2010).	  	  
	  
4.1.1.3	  The	  frequency	  of	  relapses	  	  
	  
The	   frequency	   of	   relapses	   varies	   among	   MS	   cohorts.	   The	   recall	   bias	   most	   likely	  
explains	   the	   lower	   estimates	   reported	   by	   retrospective	   studies	   (Leibowitz	   et	   al.,	  
1964;	   Mc	   and	   Compston,	   1952;	   Myhr	   et	   al.,	   2001;	   Panelius,	   1969),	   compared	   to	  
longitudinal	  studies	  (Confavreux	  et	  al.,	  1980;	  Fog	  and	  Linnemann,	  1970;	  Goodkin	  and	  
Hertsgaard,	  1989;	  Patzold	  and	  Pocklington,	  1982)	  (Figure	  4.1).	  The	  number	  of	  attacks	  
is	  known	  to	  decrease	  over	  time	  (Mc	  and	  Compston,	  1952;	  Patzold	  and	  Pocklington,	  
1982;	  Tremlett	  et	  al.,	  2008b),	  partially	  due	  to	  the	  regression	  to	  the	  mean	  (Martinez-­‐
Yelamos	   et	   al.,	   2006).	   This	   is	   the	   tendency	   for	   a	   group	   to	   return	   to	   the	   average,	  
rather	  than	  sustaining	  an	  increase	  above	  average	  (Goodin,	  2004;	  Weinshenker	  et	  al.,	  
1996).	  In	  the	  British	  Columbia	  database	  the	  annualized	  relapse	  rate	  reduced	  by	  17%	  
every	  5	  years	  of	  disease	  duration	  (Figure	  4.2	  A).	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Figure	  4.2	  Annualized	  relapse	  rate	  according	  to	  disease	  duration	  (A)	  and	  according	  
to	  patients’	  age	  (B),	  among	  patients	  from	  the	  British	  Columbia	  database	  (Tremlett	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The	   decrease	   of	   the	   attacks	   frequency	   was	   also	   shown	   to	   be	   proportional	   to	   the	  
patients’	   age	   and	   to	   become	   more	   evident	   by	   growing	   older	   (Figure	   4.2	   B).	   In	  
addition,	  more	  than	  70%	  of	  patients	  experienced	  at	  least	  5	  years	  relapse-­‐free	  period,	  
highlighting	  the	  largely	  variable	  presenting	  pattern	  of	  inflammatory	  attacks	  (Tremlett	  
et	  al.,	  2008b).	  	  
	  
This	   is	   particularly	   relevant	   to	   RCTs	   using	   relapse	   related	   outcome	   measures	   for	  
testing	  the	  efficacy	  of	   therapies.	  At	   least	  40%	  of	   the	  relapse	  reduction	  observed	   in	  
the	  placebo	  groups	  might	  be	  actually	  due	  to	  the	  regression	  to	  the	  mean	  (Martinez-­‐
Yelamos	   et	   al.,	   2006).	   In	   addition,	   the	   ARR	   in	   trials	   populations	   has	   reduced	   over	  
time,	  making	  the	  comparison	  of	  data	  from	  different	  studies	  problematic	  (Nicholas	  et	  
al.,	  2011).	  Two	  large	  meta-­‐analyses,	  pooling	  data	  from	  several	  trials,	  estimated,	  over	  
a	  10	  years	  period,	  a	  decline	  of	  0.37	  relapses	  per	  year,	  in	  both	  the	  treatment	  and	  the	  
placebo	  group	  (Inusah	  et	  al.,	  2010;	  Nicholas	  et	  al.,	  2011).	  This	  might	  be	  due	  to	  the	  
inclusion	   in	   early	   studies	   of	  more	   active	   patients,	   or	   to	   the	   exclusion	   from	   recent	  
studies	  of	  patients	  requiring	  treatment	  because	  of	  a	  more	  aggressive	  disease	  course	  
(Inusah	  et	  al.,	  2010).	  Finally,	  the	  changes	  of	  the	  ARR	  during	  trials,	  observed	  over	  the	  
last	  30	  years,	  have	  also	  been	  accompanied	  by	  a	  2%/year	   reduction	  of	   the	  pre-­‐trial	  
ARR	  (Steinvorth	  et	  al.,	  2013).	  	  
	  
4.1.2	  The	  predictive	  effect	  of	  relapses	  
	  
	  
4.1.2.1	  Early	  relapses	  and	  the	  disease	  evolution	  
	  
It	   is	   widely	   agreed	   that	   early	   relapses	   are	   predictors	   of	   the	   long-­‐term	   disease	  
evolution	   and	   affect	   adversely	   the	   prognosis.	   This	   information	   has	   been	   strongly	  
validated	  by	  several	  analyses,	  which	  were	  carried	  out	  with	  different	  methodologies	  
and	  in	  databases	  from	  different	  geographic	  areas.	  A	  large	  number	  of	  attacks	  during	  
the	  first	  two	  (Leray	  et	  al.,	  2010;	  Weinshenker	  et	  al.,	  1989c)	  and	  five	  (Confavreux	  et	  
al.,	   2003;	   Debouverie	   et	   al.,	   2008;	   Eriksson	   et	   al.,	   2003;	   Kantarci	   et	   al.,	   1998;	  
Tremlett	   et	   al.,	   2009a)	   years,	   was	   shown	   to	   be	   associated	   with	   a	   faster	   disease	  
evolution	  (Table	  4.2).	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In	  the	  Lyon	  database,	  patients	  with	  a	  higher	  number	  of	  relapses	  occurring	  during	  the	  
first	  5	  years	  attained	  DSS	  4,	  DSS	  6	  and	  DSS	  7,	  from	  the	  disease	  onset,	  in	  significantly	  
shorter	   time.	   Nevertheless,	   results	   were	   affected	   by	   the	   large	   proportion	   of	  
censored	  information	  (68%	  did	  not	  reach	  DSS	  6).	  For	  instance,	  the	  time	  for	  requiring	  
a	   walking	   aid	   was	   only	   slightly	   different	   among	   those	   grouped	   by	   early	   attacks	  
frequency	   (1	   attack	   =	   25.3	   years,	   2	   attacks	   =	   21.9	   years,	   ≥	   3	   attacks	   =	   24.7	  mean	  
years),	  however	  differences	   reached	  statistical	   significance	   (p	  =	  0.001)	   (Confavreux	  
et	  al.,	  2003).	  
	  
Table	   4.2	   The	   relationship	   between	   early	   relapses	   and	   late	   outcomes:	   results	   from	   the	   analyses	  




In	  the	  Lorraine	  database,	  patients	  with	  2,	  3	  and	  >	  3	  attacks,	  during	  the	  first	  5	  years,	  
compared	   to	   those	   with	   1	   attack,	   took	   significantly	   shorter	   times	   to	   SP	   and	   to	  
disability	  endpoints	  (EDSS	  3,	  EDSS	  4,	  and	  EDSS	  6)	  (Debouverie	  et	  al.,	  2008).	  However,	  
the	  differences	  between	  those	  with	  >	  3	  and	  2	  relapses	  were	  relatively	  small	   (mean	  
difference	  =	  4.8	  years	  for	  reaching	  EDSS	  6	  and	  1	  year	  for	  reaching	  SP)	  and,	  again,	  the	  
large	  percentage	  of	  censored	  information	  (72%	  did	  not	  reach	  EDSS	  6)	  represented	  an	  
important	   limitation	   (Debouverie	   et	   al.,	   2008).	   In	   both	   the	   French	   cohorts,	   the	  
number	   of	   inflammatory	   attacks	   experienced	   during	   the	   first	   5	   years	   did	   not	  
influence	   times	   for	   advancing	   from	   DSS	   4	   to	   DSS	   6	   (Confavreux	   et	   al.,	   2003;	  
Debouverie	  et	  al.,	  2008)	  and	  to	  DSS	  7	  (Confavreux	  et	  al.,	  2003).	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The	   analysis	   of	   the	   relatively	   small	   population	   from	   the	   Goteborg	   database	  
confirmed	   the	   association	   between	   a	   larger	   number	   of	   attacks	   during	   the	   first	   5	  
years	  and	  a	  worse	  outcome	  (Eriksson	  et	  al.,	  2003).	  The	  group	  with	  5	  or	  more	  attacks,	  
compared	  to	  those	  with	  2-­‐4	  attacks,	  had	  a	  higher	  risk	  of	  and	  a	  shorter	  time	  to	  SP	  (7	  
median	   years	   difference)	   (Figure	   4.3)	   and	   to	   EDSS	   7.	   However,	   the	   comparison	   of	  
patients	   with	   2	   versus	   3	   or	   more	   attacks	   did	   not	   demonstrate	   any	   significant	  
difference	   (Eriksson	   et	   al.,	   2003).	   In	   addition,	   early	   relapses	   did	   not	   influence	   the	  
attainment	  of	  EDSS	  7	  from	  the	  onset	  of	  SP.	  	  
	  
Figure	   4.3	   Analysis	   from	   the	   Goteborg	   database:	   time	   to	   SP	   in	   patients	   grouped	   by	   number	   of	  




In	   the	   British	   Columbia	   database,	   patients	  were	   grouped	   according	   to	   the	   relapse	  
rate	   during	   the	   first	   5	   years.	   A	   higher	   attacks	   frequency	   predicted	   significantly	  
shorter	  times	  to	  EDSS	  6	  and	  to	  SP.	  The	  group	  with	  a	  high	  rate	  (≥	  0.4)	  was	  the	  main	  
driver	   of	   this	   association,	   as	   differences	   between	   those	   with	   low	   (<	   0.2)	   and	  
intermediate	  (0.2-­‐<0.4)	  rate	  were	  small	   (0.2	  median	  years	  to	  attain	  EDSS	  6	  and	  2.1	  
median	  years	  to	  attain	  SP)	   (Figure	  4.4).	  By	  using	  the	  Cox	  Regression	  analysis	   it	  was	  
estimated	  that	  one	  attack,	  within	  5	  years	  post	  onset,	   increased	  the	  risk	  of	  reaching	  
EDSS	  6	  (HR	  =	  1.48)	  and	  SP	  (HR	  =	  1.29)	  during	  this	  time	  period.	  This	  effect	  diminished	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from	  onset	  (HRs	  =	  1.25	  and	  1.11,	  respectively)	  or	  after	  10	  years	  (HRs	  =	  1.10	  and	  1.02,	  
respectively).	   The	   relatively	   large	   proportion	   of	   censored	   information	   (72%	   for	  
reaching	  EDSS	  6	  and	  45%	  for	  reaching	  SP)	  had	  a	  potential	   impact	  on	  these	  findings	  
(Tremlett	  et	  al.,	  2009a).	  	  
	  
Figure	  4.4	  Analysis	  from	  the	  British	  Columbia	  database:	  time	  to	  EDSS	  6	  and	  to	  SP	  in	  patients	  grouped	  





Previous	  analysis	  of	  the	  LO	  database	  demonstrated	  an	  association	  between	  a	  larger	  
number	   of	   attacks	   during	   the	   first	   two	   years	   and	   a	   shorter	   times	   to	   DSS	   6	  
(Weinshenker	   et	   al.,	   1989c)	   (Figure	   4.5).	   This	   was	   also	   confirmed	   more	   recently	  
among	   patients	   from	   the	   Rennes	   database:	   the	   group	  with	   ≥	   2	   attacks	   during	   the	  
first	  two	  years	  attained	  DSS	  3	  and	  DSS	  6,	  4.5	  years	  and	  2	  mean	  years	  earlier	  than	  the	  
group	  with	  1	  attack	  (Leray	  et	  al.,	  2010).	  However,	  the	  time	  for	  advancing	  from	  DSS	  3	  
to	  DSS	  6	  was	  not	  affected	  by	  the	  number	  of	  early	  relapses	  (7	  median	  years	  in	  both	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Figure	  4.5	  Analysis	  from	  the	  LO	  database:	  time	  to	  DSS	  6	  grouped	  by	  number	  of	  relapse	  during	  the	  first	  




4.1.2.2	  Late	  relapses	  and	  the	  disease	  evolution	  
	  
The	  predictive	  effect	  of	   late	  relapses	  has	  been	  poorly	   investigated.	  This	   is	  probably	  
due	   to	   the	  difficulties	  of	   collecting	   information	  on	   inflammatory	   attacks,	   occurring	  
later	   in	   the	   disease	   course.	   In	   the	   British	   Columbia	   database,	   similarly	   to	   early	  
relapses,	  the	  effect	  of	  late	  relapses	  on	  the	  outcome	  diminished	  with	  time	  (Tremlett	  
et	   al.,	   2009a).	  One	   attack,	   occurring	   between	   5	   to	   10	   years	   after	   onset,	   increased	  
significantly	  the	  hazard	  of	  reaching	  EDSS	  6	  (HR	  =	  1.31)	  and	  SP	  (HR	  =	  1.23),	  within	  this	  
period	  of	  time,	  however	  it	  impacted	  less	  significantly	  on	  the	  risk	  of	  attaining	  the	  two	  
endpoints	  after	  10	  years	  from	  onset	  (HR	  =	  1.07	  and	  1.06,	  respectively).	   In	  addition,	  
relapses	   occurring	   more	   than	   10	   years	   post	   onset,	   only	   marginally	   increased	   the	  
probability	  of	  reaching	  DSS	  6	  (HR	  =	  1.12)	  and	  SP	  (HR	  =	  1.08).	  	  
	  
The	   predictive	   effect	   of	   relapses	   occurring	   after	   the	   attainment	   of	   DSS	   3,	   among	  
patients	   still	   experiencing	   the	  RR	  phase,	  was	   investigated	   in	   the	  Rennes	   database.	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disability,	   compared	   to	   group	   with	   relapses,	   however	   the	   differences	   were	   not	  
statistically	  significant	  (12	  versus	  9	  median	  years;	  p	  =	  0.67)	  (Leray	  et	  al.,	  2010).	  	  
	  
4.1.2.3	  Total	  relapses	  and	  the	  disease	  evolution	  
	  
The	   effect	   of	   total	   relapses	   during	   the	   RR	   phase	   on	   late	   outcome	   has	   never	   been	  
directly	   investigated.	  Previous	  analyses	  of	  the	  LO	  database	  compared	  the	  evolution	  
of	  the	  progressive	  phase,	  among	  progressive	  subtypes.	  Patients	  with	  no	  (PP	  MS),	  one	  
(SAP	  MS)	  and	  many	  (SP	  MS)	  attacks	  before	  progression	  took	  equal	  times	  for	  reaching	  
DSS	   6	   and	   DSS	   8,	   from	   the	   onset	   of	   progression	   (Figure	   4.6).	   These	   results	  
demonstrated	   that	   the	   disability	   accumulation	   during	   the	   progressive	   phase	   was	  
largely	   unaffected	   by	   inflammatory	   attacks	   preceding	   its	   onset	   (Kremenchutzky	   et	  
al.,	  2006a).	  	  
	  
Figure	   4.6	  Analyses	   from	   the	   LO	  database:	   times	   to	  DSS	  6	   and	   to	  DSS	  8	   from	  onset	  of	   progression	  





4.1.2.4	  Superimposed	  relapses	  and	  the	  disease	  evolution	  
	  
	  
The	  effect	  of	  relapses	  occurring	  during	  the	  progressive	  phase	  on	  late	  outcomes	  has	  
been	   extensively	   investigated.	   Among	   PP	   patients	   from	   the	   LO	   database,	   28%	  
experienced	   superimposed	   relapses.	   These	   occurred	   in	   50%	   within	   10	   years	   from	  
onset,	   in	   40%	   between	   10	   and	   20	   years	   and	   in	   10%	   even	   after	   20	   years.	   These	  
attacks	  were	  generally	  very	  discrete,	  followed	  by	  good	  recovery	  and	  usually	  affecting	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extra-­‐spinal	   locations	   (Kremenchutzky	   et	   al.,	   1999a).	   The	   analysis	   showed	   almost	  
identical	   survival	   curves	  between	  PP	  and	  PR	  patients,	  demonstrating	  no	   significant	  
effect	  of	  superimposed	  relapses	  on	  the	  disease	  evolution	  (Figure	  4.7).	  Same	  results	  
were	  obtained	  in	  a	  small	  dataset	  from	  California	  (US);	  83	  PP	  and	  12	  PR	  MS	  patients	  
took	  equal	  times	  to	  reach	  EDSS	  6	  (Andersson	  et	  al.,	  1999).	  	  
	  
In	   the	   Lyon	   database,	   the	   predictive	   effect	   of	   relapses	   occurring	   during	   the	  
progressive	   phase	   was	   assessed	   in	   both	   primary	   and	   secondary	   progressive	   MS	  
(Confavreux	   et	   al.,	   2000).	   The	   analysis	   confirmed	   the	   same	   rate	   of	   disability	  
accumulation,	  between	  PP	  and	  PR	  patients	  (Figure	  4.8).	  In	  addition,	  SP	  patients,	  with	  
or	  without	   superimposed	   attacks,	   took	   equal	   times	   from	  DSS	  4	   (Confavreux	   et	   al.,	  
2000)	  (Figure	  4.8)	  and	  from	  the	  onset	  of	  progression	  (Vukusic	  and	  Confavreux,	  2003)	  
to	   DSS	   6.	   Similarly,	   among	   patients	   in	   the	   British	   Columbia	   database,	   relapses	  
occurring	   during	   the	   SP	   phase	   did	   not	   affect	   the	   attainment	   of	   late	   outcomes	  
(Tremlett	  et	  al.,	  2009a).	  
	  
Overall,	  this	  data	  consistently	  demonstrated	  that	  the	  rate	  of	  disability	  accumulation	  
during	  the	  progressive	  phase,	  preceded	  or	  not	  by	  the	  RR	  phase,	  is	  not	  influenced	  by	  
superimposed	  relapses.	  	  
	  
Figure	  4.7	  Analysis	  from	  the	  LO	  database:	  comparison	  of	  times	  to	  DSS	  6	  and	  to	  DSS	  8	  from	  the	  disease	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Figure	  4.8	  Analysis	  from	  the	  Lyon	  database:	  comparison	  of	  times	  from	  DSS	  4	  to	  DSS	  6,	  among	  primary	  








4.1.3	  The	  predictive	  effect	  of	  the	  first	  inter-­‐attack	  interval	  
	  
It	   is	   largely	   agreed	   that	   a	   shorter	   first	   inter-­‐attack	   interval	   associates	  with	   a	  more	  
rapid	   disease	   progression.	   Previous	   analysis	   of	   the	   LO	   database	   demonstrated	   a	  
faster	   attainment	   of	   DSS	   6,	   among	   patients	   with	   short	   (0-­‐2	   years),	   compared	   to	  
those	  with	  intermediate	  (3-­‐5	  years)	  or	  long	  (≥	  6	  years)	  interval	  (Weinshenker	  et	  al.,	  
1989c).	  In	  the	  Lyon	  and	  Lorraine	  databases,	  the	  outcome	  was	  worse	  among	  patients	  
experiencing	   the	   second	   attack	   in	   less	   than	   2	   years	   (Confavreux	   et	   al.,	   2003;	  
Debouverie	  et	  al.,	  2008).	  However,	   the	  analysis	   from	  the	  Goteborg	  database	  could	  
not	  confirm	  the	  association	  between	  a	  short	   first	   inter-­‐attack	   interval	  and	  a	  worse	  
prognosis	  (Runmarker	  and	  Andersen,	  1993).	  	  
	  
Only	   few	  studies	  have	  evaluated	   factors	  predicting	   time	  to	   the	  second	  attack.	  First	  
attack	   severity	   and	   location	   were	   shown	   to	   strongly	   influence	   the	   severity	   and	  
location	  of	   the	   subsequent	   relapse	   (Mowry	  et	   al.,	   2009a;	  Mowry	  et	   al.,	   2009b).	   In	  
addition,	   the	  probability	  of	  experiencing	  a	   second	  attack	  within	  one	  year	   from	  the	  
clinical	  onset	  was	  significantly	  higher	  among	  younger	  patients,	  presenting	  with	  poly-­‐
regional	  symptoms	  (Mowry	  et	  al.,	  2009c).	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4.1.4	  Aim	  of	  the	  study	  presented	  in	  this	  chapter	  
	  
	  
This	   study	   aimed	   at	   assessing	   the	   relationship	   between	   relapses,	   occurring	   during	  
the	  RR	  phase,	  and	  the	  attainment	  of	  SP	  and	  of	  hard	  disability	  outcomes	  (DSS	  6	  and	  
DSS	  8).	  Inflammatory	  attacks	  during	  the	  early	  and	  late	  stages	  of	  the	  disease,	  before	  
entering	   the	   progressive	   phase,	  were	   examined	   separately.	   This	   allowed	   to	   assess	  
the	  validity	  of	  attacks	  number	  as	  clinical	  indicator	  of	  the	  disease	  activity,	  to	  test	  the	  
reliability	   of	   the	   relapse	   frequency	   as	   surrogate	  marker	   for	   late	   outcomes,	   and	   to	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4.2	  Methods	  	  
	  
	  
Among	  806	   relapsing	  onset	   patients,	   the	   relationship	  between	  disability	   outcomes	  
and	   the	   following	   variables	   was	   investigated:	   A)	   the	   number	   and	   the	   type	   of	  
neurological	  systems	  involved	  at	  disease	  onset;	  B)	  the	  number	  of	  relapses	  during	  the	  
first	   2	   years	  of	   the	  disease	   (early	   relapses);	   C)	   the	   time	  between	   the	   first	   and	   the	  
second	  attack;	  D)	   the	   time	   from	   the	  disease	  onset	   to	   the	   attainment	  of	  moderate	  
disability	  (DSS	  3);	  E)	  the	  number	  of	  relapses	  from	  year	  3	  up	  to	  the	  onset	  of	  secondary	  
progression	   (late	   relapses);	   F)	   the	   total	   number	   of	   relapses	   during	   the	   RR	   phase	  
(total	  relapses).	  	  
	  
Kaplan	  Meier	  analysis	  was	  used	  to	  estimate	   the	   time	  to	  SP	  and	  the	   times	   to	   reach	  
DSS	  6	  and	   to	  DSS	  8	   from	  the	  disease	  onset,	   from	  DSS	  3	  and	   from	  the	  onset	  of	  SP,	  
among	   patients	   grouped	   according	   to	   the	   variables	   listed	   above.	   Groups	   were	  
computed	   in	   order	   to	   maintain,	   to	   the	   possible	   extent,	   similar	   numbers	   in	   each	  
category	   (Table	   4.3).	  However,	   the	   analyses	  were	   also	   carried	   out	   among	  patients	  
with	  different	  stratifications,	  for	  confirming	  results.	  The	  Log	  rank	  test,	  with	  p	  values	  
level	   of	   significance	   <	   0.05,	   was	   used	   to	   assess	   differences	   among	   groups.	   To	  
eliminate	   bias	   from	   the	   immortal	   time	   (Suissa,	   2008),	   the	   following	   criteria	   were	  
applied	   for	   excluding	   patients	   from	   the	   analyses;	   A)	   relapsing	   onset	   patients	  
attaining	  the	  endpoints	  in	  <	  2	  years	  	  (SP	  =	  24,	  DSS	  6	  =	  10,	  DSS	  8	  =	  1)	  when	  assessing	  
the	  effect	  of	  early	  attacks;	  B)	  SP	  patients	  attaining	  the	  endpoints	  before	  entering	  the	  
progressive	  phase	  (DSS	  6	  =	  16,	  DSS	  8	  =	  0)	  when	  assessing	  the	  effect	  of	  late	  and	  total	  
relapses.	  	  
	  
The	   Cox	   proportional	   hazard	   analysis	   was	   used	   to	   investigate	   relapses,	   first	   inter-­‐
attack	   interval	   and	   time	   to	  DSS	   3	   as	   continuous	   variables.	   The	   analysis	   allowed	   to	  
calculate	   the	   risk	   of	   attaining	   the	   endpoints	   according	   to	   increasing	   number	   of	  
attacks,	   the	   increasing	   time	  between	   the	   first	   two	  attacks	   and	   the	   increasing	   time	  
from	  the	  disease	  onset	  to	  accumulation	  of	  moderate	  disability	  (DSS	  3).	  Hazard	  ratios	  
(HR),	   expressing	   the	   size	   of	   the	   risk	   of	   reaching	   the	   endpoints,	   were	   obtained	  
through	  comparison	  versus	  0	  relapses	  and	  versus	  0	  years	  interval	  between	  the	  first	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two	   attacks	   and	   between	   the	   disease	   onset	   and	   DSS	   3.	   Proportional	   hazards	  
assumption	   was	   checked	   by	   visual	   inspections	   of	   Schoenfeld	   residual	   plots	   and	  
corresponding	   statistical	   tests.	   The	   predictive	   effect	   of	   the	   variables	   was	   also	  
analysed	   in	  multivariate	  models	  of	  disability,	  allowing	   to	  simulate	  clinical	   scenarios	  
according	  to	  specific	  number	  of	  relapses	  and	  first	  inter-­‐attack	  interval.	  Models	  were	  
also	   compared	   to	   assess	   the	   difference	   in	   the	   hazard	   of	   reaching	   the	   endpoints	  
between	  different	  scenarios.	  	  
	  
Information	  on	  the	   time	  to	  endpoints	   (Chapter	  3)	  and	  on	  variables	   (Table	  4.3)	  was	  
not	  always	  available,	  resulting	  in	  slightly	  different	  numbers	  of	  patients	  contributing	  
to	   each	   analysis.	   Patients	   not	   reaching	   given	   endpoints,	   but	   followed	   for	   known	  
period,	  were	  right	  censored.	  	  
	  
Table	   4.3	  Grouping,	   according	   to	   variables,	   used	  when	  estimating	   the	   times	   to	  disability	   endpoints	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The	   analysis	   focused	   on	   806	   patients	  with	   relapsing	   remitting	   onset.	   Their	   clinical	  
and	  demographic	  features	  (Table	  4.4)	  were	  extensively	  described	   in	  chapter	  3,	  and	  
here	  are	  summarized.	  Most	  of	  the	  patients	  were	  females	  (68.8%),	  the	  mean	  age	  at	  
onset	  was	  28.5	  years	  and	  the	  mean	  disease	  duration	  was	  24.4	  years,	  reflecting	  the	  
long	  observation	  period	  and	  the	  low	  rate	  of	  lost	  to	  follow	  up.	  A	  mono-­‐symptomatic	  
onset,	   characterized	   by	   sensory	   disturbances,	   was	   the	   most	   commonly	   observed	  
clinical	  presentation.	  The	  mean	  age	  at	  onset	  of	  progression	  was	  40.2	  years,	  and	  most	  
of	  the	  patients	  entered	  the	  progressive	  phase	  when	  they	  were	  scored	  between	  DSS	  
2	  and	  DSS	  4;	  more	  than	  70%	  within	  DSS	  3	  (Figure	  4.9).	  By	  the	  end	  of	  the	  observation	  
period,	  the	  majority	  of	  patients	  had	  converted	  to	  SP	  MS	  (n	  =	  534;	  66.2%)	  and	  in	  large	  
percentages	  had	  attained	  DSS	  3	  (n	  =	  657;	  81.5%),	  DSS	  6	  (n	  =	  543;	  67.4%)	  and	  DSS	  8	  (n	  
=	  390;	  48.4%),	  in	  15,	  10,	  18	  and	  28	  median	  years	  respectively	  (Table	  4.4).	  	  
	  
Figure	  4.9	  DSS	  scores	  (x-­‐axis)	  recorded	  when	  patients	  converted	  to	  SP	  MS.	  On	  the	  y-­‐axis	  is	  indicated	  
the	  percentage	  of	  patients,	  at	  each	  DSS	  score	  category,	  when	  the	  SP	  phase	  occurred.	  Below	  the	  x-­‐axis	  
it	  is	  indicated	  the	  cumulative	  percentage	  of	  patients	  entering	  the	  SP	  phase	  within	  each	  DSS	  score:	  this	  
was	  obtained	  by	  adding	  the	  percentages	  of	  patients	  in	  each	  DSS	  score	  category	  up	  to	  the	  specific	  DSS	  








$# %# &# '# (# )#
'*$"# &!*("# +%*!"# ,%*,"# ,)*+"# ,-*)"#
!""#$%#&''#
	   246	  
4.3.1	  Early	  relapses	  	  
	  
Information	  on	   the	   frequency	  of	   relapses	  during	   the	   first	  2	  years	  was	  available	   for	  
730	  patients,	  who	  experienced	  1363	  relapses.	  The	  number	  of	  attacks	  ranged	  from	  1	  
to	  8,	   and	   the	  mean	   relapse	   rate	  was	  0.93	  attack/year.	  At	  2	   years	   from	   the	   clinical	  
presentation,	  more	  than	  half	  of	  patients	  (n	  =	  389)	  experienced	  the	  onset	  attack	  only,	  
25%	  (n	  =	  183)	  had	  2	  relapses	  and	  20%	  (n	  =	  158)	  had	  3	  or	  more	  relapses	  (Table	  4.3).	  
	  
The	   analysis	   confirmed	   (Weinshenker	   et	   al.,	   1989c)	   that	   the	   number	   of	   attacks	  
during	  the	  first	  2	  years	  predicted	  the	   long-­‐term	  disease	  evolution.	  The	  groups	  with	  
higher	   early	   relapses	   frequency	   attained	   the	   disability	   endpoints	   from	   the	   disease	  
onset	   in	   significantly	   shorter	   times	   (Table	   4.5	   and	   Figure	   4.10).	   Between	   patients	  
with	  1	  and	  ≥	  3	  attacks,	  there	  was	  a	  mean	  difference	  of	  7.6	  years	  and	  of	  4.3	  years	  for	  
reaching	  DSS	  6	  and	  DSS	  8,	  respectively.	  The	  Cox	  regression	  analysis	  demonstrated	  a	  
strong	   association	  between	   the	   attacks	   during	   the	   first	   2	   years	   and	   late	  outcomes	  
(HR	  =	  1.23	   for	  DSS	  6;	  HR	  =	  1.32	   for	  DSS	  8).	  The	  risk	  of	  developing	  severe	  disability	  
increased	  proportionally	  with	  the	  number	  of	  attacks	  (Figure	  4.10	  B-­‐C).	  Patients	  with	  
3	  relapses,	  compared	  to	  those	  with	  1	  attack,	  had	  approximately	  50%	  and	  90%	  higher	  
hazard	  of	  reaching	  DSS	  6	  and	  DSS	  8,	  respectively	  (Figure	  4.10).	  	  
	  
Table	   4.5	   Kaplan	  Meier	   estimated	   times	   to	   SP,	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   the	   disease	   onset	   in	  
patients	  grouped	  by	  the	  number	  of	  early	  relapses.	  P	  values	  were	  obtained	  using	  the	  Log	  Rank	  test	  by	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Figure	   4.10	   Kaplan	  Meier	   analysis	   (left):	   estimated	   times	   to	   SP	   (A),	   to	   DSS	   6	   (B)	   and	   to	   DSS	   8	   (C),	  
among	  groups	  with	  low	  (1	  attack),	  intermediate	  (2	  attacks)	  and	  high	  (≥	  3	  attacks)	  number	  of	  relapses	  
during	   the	   first	   two	   years.	   Cox	   regression	   analysis	   (right):	   variation	   of	   the	   risk	   (HRs	   on	   y-­‐axis)	   of	  
attaining	  the	  endpoints	  according	  to	  the	   increasing	  number	  of	  early	  relapses	  (x-­‐axis).	  The	  exact	  HRs	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The	   effect	   of	   early	   relapses	  was	   primarily	   exerted	   by	   increasing	   the	   probability	   of	  
entering	  the	  SP	  phase	  and	  by	  shortening	  the	  latency	  to	  SP	  (Table	  4.5	  and	  Figure	  4.10	  
A).	  A	  higher	  number	  of	  attacks	  during	  the	  first	  2	  years	  predicted	  a	  higher	  risk	  (HR	  =	  
1.11)	   of	   converting	   to	   SP	  MS	   and	   a	   shorter	   time	   to	   the	  onset	   of	   progression.	   This	  
association	  was	  mainly	  driven	  by	  the	  group	  with	  ≥	  3	  attacks,	  which	  attained	  SP	  4.8	  
mean	   years	   earlier	   than	   the	   group	   with	   1	   attack	   (p	   =	   0.014).	   The	   comparison	  
between	   the	   patients	  with	   low	   and	   intermediate	   early	   relapses	   frequency	   did	   not	  
demonstrate	  any	  statistically	  significant	  (p	  =	  0.38)	  difference	  (Table	  4.5).	  	  
	  
Additional	  analyses	  further	  demonstrated	  that	  the	  conversion	  to	  SP	  MS	  was	  the	  key	  
determinant	  of	  the	  early	  relapses’	  predictive	  effect.	  The	  risk	  of	  reaching	  DSS	  3	  and	  
DSS	  6	   from	   the	  disease	  onset,	   according	   to	   the	  number	  of	   attacks	   during	   the	   first	  
two	   years,	   became	   much	   larger	   when	   it	   was	   assessed	   in	   the	   SP	   group	   only:	   3	  
relapses	  yielded	  HRs	  1.59	  and	  2.87	   for	  attaining	  moderate	  disability,	   and	  HRs	  1.84	  
and	  2.45	  for	  requiring	  a	  walking	  aid,	  in	  RR	  and	  SP	  patients,	  respectively	  (Table	  4.6).	  
Moreover,	   among	   those	   who	   converted	   to	   SP	   MS,	   the	   predictive	   effect	   of	   early	  
relapses	   decreased	   proportionally	   with	   the	   duration	   of	   the	   RR	   phase	   (Table	   4.7).	  
Three	  attacks	  yielded	  HRs	  3.03,	  2.27	  and	  2.02	  for	  reaching	  DSS	  6	   in	  the	  group	  with	  
short	   (1-­‐5	   years),	   intermediate	   (6-­‐12	   years)	   and	   long	   (≥	   13	   years)	   latency	   to	  
progression,	  respectively	  (Table	  4.7).	  	  	  
	  
The	  number	  of	  early	  relapses	  also	  significantly	  influenced	  the	  times	  to	  the	  endpoints	  
and	  the	  probability	  of	  developing	  severe	  disability	  from	  DSS	  3	  (Table	  4.8),	  however	  
the	  impact	  was	  much	  smaller	  than	  from	  the	  disease	  onset	  (Table	  4.9).	  Patients	  with	  
high	  early	  relapse	  frequency,	  compared	  to	  those	  with	  low	  frequency,	  reached	  DSS	  6,	  
from	  onset,	  10	  median	  years	  earlier	  (Table	  4.5),	  but	  the	  two	  groups	  differed	  by	  only	  
2	  median	  years	  when	  attaining	  the	  endpoint	  from	  DSS	  3	  (Table	  4.8).	  Accordingly,	  the	  
effect	   of	   early	   relapses	   on	   the	   risk	   of	   requiring	   a	  walking	   aid	  was	   larger	   from	   the	  
disease	   onset	   than	   from	  DSS	   3	   (3	   attacks	  HR	   =	   1.84	   and	   1.39,	   respectively)	   (Table	  
4.9).	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Finally,	  the	  number	  of	  attacks	  during	  the	  first	  two	  years	  also	  affected	  the	  evolution	  
of	  the	  SP	  phase.	  Among	  SP	  patients,	  those	  with	  higher	  early	  relapse	  frequency	  had	  
significantly	   shorter	   times	   to	   DSS	   levels	   and	   a	   higher	   probability	   of	   attaining	   the	  
endpoints	   from	   the	  onset	  of	   SP	   (Tables	  4.8	  and	  4.9).	   The	  predictive	  effect	  of	  early	  
attacks	  was	  much	  larger	  from	  the	  onset	  of	  progression	  than	  from	  the	  disease	  onset	  
and	  from	  DSS	  3	  (Table	  4.9),	  further	  emphasizing	  the	  importance	  of	  the	  conversion	  to	  





Table	  4.6	  Cox	  regression	  analysis:	  risk	  (HR)	  of	  attaining	  DSS	  3	  and	  DSS	  6	  according	  to	  the	  number	  of	  




Table	  4.7	  Cox	  regression	  analysis	  in	  SP	  patients:	  risk	  (HR)	  of	  attaining	  DSS	  6	  according	  to	  the	  number	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Table	   4.8	   Kaplan	  Meier	   analysis:	   times	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   DSS	   3	   and	   from	   the	   onset	   of	  
secondary	  progression,	  in	  patients	  grouped	  by	  the	  number	  of	  early	  relapses.	  P	  values	  were	  obtained	  




Table	  4.9	  Cox	  regression	  analysis:	  risk	  (HR)	  of	  attaining	  DSS	  6	  from	  the	  disease	  onset,	  from	  DSS	  3	  and	  

















!"#$%&'($ )*!"+,*-.)*/0"123 4"5*55! 2*!"+6*-.2*)0"173 4"5*55!






!"#$%&'($ !)*-"+!2*7.!/*/0"1!23 5*55! !2*7"+!7*6.!)*-0"1!73 4"5*55!










) )(+, )()+ )(,-
+ )(.' )(+. )(-+




	   251	  
4.3.1.1	  Frequent	  early	  relapses	  	  	  
	  
In	  table	  4.10	  are	  compared	  the	  clinical	  and	  demographic	  features,	  between	  patients	  
with	   low	   (1-­‐2	   attacks;	   n	   =	   572)	   and	   high	   (≥	   3	   attacks;	   n	   =	   158)	   early	   relapse	  
frequency.	   In	   both	   subgroups	   women	   predominated,	   and	   the	   mean	   age	   at	   the	  
disease	  onset	  differed	  very	  little	  (28.8	  versus	  27.4	  mean	  years;	  p	  =	  0.11).	  However,	  
patients	  with	  frequent	  early	  relapses	  (≥	  3	  attacks)	  were	  significantly	  younger	  at	  the	  
onset	   of	   the	   SP	  phase	   (35.3	   versus	   41.5	  mean	   years;	   p	   <	   0.001),	   secondary	   to	   the	  
shorter	  duration	  of	  the	  RR	  phase	  (6.9	  versus	  11.7	  mean	  years;	  p	  <	  0.001).	  By	  the	  end	  
of	  the	  observation	  period,	  among	  patients	  with	  low	  attacks	  frequency	  (1-­‐2	  attacks),	  
84.2%	  had	  attained	  DSS	  3,	  70.6%	  had	  attained	  DSS	  6	  and	  46.3%	  had	  attained	  DSS	  8	  in	  
11,	   19	   and	   31	   estimated	   median	   years,	   respectively.	   This	   was	   significantly	   longer	  
than	  patients	  with	  frequent	  early	  relapses	  (Table	  4.10).	  	  
	  
The	   group	  with	   ≥	   3	   attacks	   during	   the	   first	   two	   years	   (“frequent	   early	   relapsers”)	  
represented	   20%	   (n	   =	   158)	   of	   the	   total	   relapsing	   onset	   population	   and	   drove	   the	  
association	   between	   early	   relapses	   and	   late	   outcomes.	   Among	   frequent	   early	  
relapsers,	  the	  Kaplan	  Meier	  estimated	  time	  to	  the	  onset	  of	  SP	  was	  15.1	  mean	  years	  
(95%	  C.I.	  12.8-­‐17.4):	  50%	  (n	  =	  79)	  of	  patients	  entered	  the	  SP	  phase	  after	  9	  years	  from	  
the	  disease	  onset	  (median	  time),	  increasing	  to	  65.2%	  (n	  =	  103)	  after	  24	  years	  (Figure	  
4.12).	   The	   remaining	   34.8%	   (n	   =	   55),	   despite	   the	   high	   early	   relapses	   frequency,	  
stayed	  in	  the	  RR	  phase	  (Figure	  4.11).	  	  
	  
Among	  patients	  who	  had	  converted	  to	  SP	  MS	  by	  the	  end	  of	  the	  observation	  period	  
(n	  =	  103),	  50%	  attained	  the	  progressive	  phase	  in	  5	  years	  and	  75%	  in	  9	  years	  (Figure	  
4.11).	   In	   this	   subgroup,	  patients	  experienced	  a	   rapid	  disease	  evolution;	  all	  of	   them	  
reached	  DSS	  3,	  94%	  (n	  =	  97)	  reached	  DSS	  6	  and	  75%	  (n	  =	  77)	  reached	  DSS	  8	  in	  4.5,	  
9.1	   and	   17.2	   estimated	   mean	   years,	   respectively	   (Table	   4.11).	   On	   the	   contrary,	  
within	   the	   RR	   subgroup,	   less	   than	   half	   (n	   =	   24;	   43%)	   attained	  moderate	   disability	  
(DSS	   3)	   in	   estimated	   16.2	   mean	   years	   and	   very	   few	   (n	   =	   8;	   14%)	   attained	   DSS	   6	  
through	   relapses	   (Table	   4.11).	   There	   was	   a	   difference	   of	   11.7	   mean	   years	   for	  
reaching	  DSS	  3	  between	  the	  RR	  and	  the	  SP	  patients	  (Figure	  4.12).	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Table	  4.10	  Comparison	  of	  clinical	  and	  demographic	  features	  between	  patients	  with	  low	  (1-­‐2)	  and	  high	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Figure	  4.11	  Kaplan	  Meier	  analysis	  of	  time	  to	  SP,	  among	  158	  patients	  with	  ≥	  3	  attacks	  during	  the	  first	  
two	   years:	   cumulative	  percentage	  of	   patients	   converting	   to	   SP	  MS.	   The	  median	   time	   to	   SP	   (dotted	  






Figure	   4.12	   Kaplan	  Meier	   analysis	   of	   time	   to	   DSS	   3	   from	   the	   disease	   onset,	   among	   patients	   with	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Figure	   4.13	   Cumulative	   percentage	   (y-­‐axis)	   of	   patients	   with	   frequent	   early	   relapses	   (≥	   3	   attacks),	  
stratified	  by	  type	  of	  disease	  course	  (RR	  =	  55;	  SP=	  103),	  reaching	  each	  DSS	  level	  at	  specific	  time	  points	  
(x-­‐axis)	   from	  the	  disease	  onset.	  The	  analysis	  of	  each	  disability	   level	   is	   independent	  from	  the	  others.	  




The	   rate	   of	   disability	   accumulation	   was	   widely	   different	   in	   the	   two	   subgroups,	  
sharing	   the	   same	   high	   early	   relapse	   frequency	   (Figure	   4.13).	   At	   5	   years	   from	   the	  
disease	  onset	  72%	  and	  41%	  of	  the	  SP	  subgroup	  already	  reached	  moderate	  disability	  
(DSS	   3)	   and	   required	   a	   walking	   aid	   (DSS	   6),	   respectively.	   By	   10	   years,	   23%	   of	   RR	  
patients	  had	  attained	  DSS	  3	  and	  28%	  of	  SP	  patients	  had	  already	  become	  bedbound	  
(DSS	  8).	  At	  20	  years,	  these	  percentages	  increased	  to	  38.1%	  and	  53.3%,	  respectively.	  
	  
Clinical	  and	  demographic	  features	  were	  compared	  between	  RR	  (n	  =	  55)	  and	  SP	  (n	  =	  
103)	  patients	  with	   frequent	  early	  relapses.	   In	  both	  subgroups,	   the	  number	  of	  early	  
attacks	  was	   similar	   (Table	   4.12),	   and	  most	   of	   the	   patients	   presented	  with	   sensory	  
symptoms	   and	   had	   a	   mono-­‐symptomatic	   onset	   attack	   (Table	   4.11).	   Among	   those	  
who	   remained	   in	   the	   RR	   phase	   there	   was	   a	   larger	   percentage	   of	   women	   (81.8%	  
versus	  63.1%;	  p	  =	  0.02)	  and	  the	  age	  at	  the	  disease	  onset	  was	  slightly	  younger	  (25.5	  
versus	   28.4	   mean	   years;	   p	   =	   0.01)	   (Table	   4.11).	   The	   mean	   disease	   duration	   was	  
slightly	  (p	  =	  0.003)	  shorter	  in	  the	  RR	  subgroup	  (17.2	  mean	  years	  [95%	  C.I.	  15.4-­‐18.8])	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than	  80%	  of	  RR	  patients	  were	  observed	  for	  longer	  than	  10	  years	  and	  more	  than	  70%	  
for	  longer	  than	  15	  years	  (Figure	  4.14).	  	  
	  
Table	   4.11	   Clinical	   and	   demographic	   features	   of	   patients	   with	   high	   (≥	   3)	   early	   relapse	   frequency,	  
stratified	  by	  the	  type	  of	  the	  disease	  course	  (RR	  and	  SP)	  at	  the	  end	  of	  the	  observation	  period.	  *	  Chi-­‐
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Table	  4.12	  Number	  of	  attacks	  experienced	  during	  the	  first	  two	  years	  among	  frequent	  early	  relapsers,	  











Figure	   4.14	   Distribution	   of	   the	   disease	   duration,	   expressed	   as	   cumulative	   percentages,	   among	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4.3.2	  First	  inter-­‐attack	  interval	  	  
	  
The	  First	  inter-­‐attack	  interval	  was	  known	  for	  684	  patients	  and	  it	  spanned	  from	  1	  to	  
34	  years	   (median	  time	  =	  2	  years).	  More	  than	  half	   (n	  =	  388)	  of	  patients	  had	  second	  
attack	  within	  2	  years,	  20%	  (n	  =	  141)	  after	  3-­‐5	  years	  and	  22%	  (n	  =	  155)	  after	  6	  years	  or	  
more.	   The	   analysis	   confirmed	   (Weinshenker	   et	   al.,	   1989c)	   that	   a	   shorter	   time	  
between	  the	  first	  two	  attacks	  associated	  with	  significantly	  shorter	  times	  to	  disability	  
endpoints	   and	  with	   a	   greater	   risk	   of	   developing	   severe	   disability	   (Figure	   4.15	   and	  
Table	  4.13).	  	  
	  
There	   was	   a	   difference	   of	   4.9,	   7.7	   and	   10.4	  mean	   years	   between	   the	   group	   with	  
short	  (0-­‐2	  years)	  and	  long	  (≥	  6	  years)	  first	  inter-­‐attack	  interval	  when	  attaining	  SP,	  DSS	  
6	   and	   DSS	   8,	   respectively	   (Table	   4.13).	   Accordingly,	   a	   longer	   time	   to	   the	   second	  
attack	   associated	   with	   a	   proportionally	   lower	   hazard	   of	   SP	   (HR	   =	   0.97)	   and	   of	  
becoming	  disabled	  (HR	  for	  DSS	  6	  =	  0.95;	  HR	  for	  DSS	  8	  =	  0.93).	  Although	  significant,	  
the	  size	  of	  this	  effect	  was	  relatively	  small;	  the	  probability	  of	  reaching	  SP,	  DSS	  6	  and	  
DSS	  8	  decreased	  by	  approximately	  13%	  (HR	  =	  0.87),	  23%	  (HR	  =	  0.77)	  and	  28%	  (HR	  =	  
0.72),	   respectively,	  when	  the	  second	  attack	  occurred	  after	  5	  years	   (Figure	  4.15).	   In	  
addition,	   the	   first	   inter-­‐attack	   interval	   did	   not	   significantly	   affect	   the	   disease	  
evolution	  from	  DSS	  3,	  and	  only	  marginally	  impacted	  on	  the	  evolution	  of	  the	  SP	  phase	  
(times	  to	  endpoints	  from	  onset	  of	  SP)	  (Table	  4.14	  and	  4.15).	  	  
	  
Table	   4.13	   Kaplan	  Meier	   estimated	   times	   to	   SP,	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   the	   disease	   onset	   in	  
patients	  grouped	  by	  the	  interval	  between	  the	  first	  two	  attacks.	  P	  values	  were	  obtained	  using	  the	  Log	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Figure	   4.15	   Kaplan	  Meier	   analysis	   (left):	   estimated	   times	   to	   SP	   (A),	   to	   DSS	   6	   (B)	   and	   to	   DSS	   8	   (C)	  
among	  groups	  with	  short	  (0-­‐2	  years),	   intermediate	  (3-­‐5	  years)	  and	  long	  (≥	  6	  years)	   interval	  between	  
the	  first	  two	  attacks.	  Cox	  regression	  analysis	   (right):	  variation	  of	  the	  risk	  (HRs	  on	  y-­‐axis)	  of	  attaining	  
the	  endpoints	  according	  to	  increasing	  years	  between	  the	  first	  two	  attacks	  (x-­‐axis).	  The	  exact	  HRs	  are	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Table	   4.14	   Kaplan	   Meier	   analysis:	   times	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   DSS	   3	   and	   from	   onset	   of	  
progression	   (SP)	   in	   patients	   grouped	   by	   the	   interval	   between	   the	   first	   two	   attacks.	   P	   values	   were	  





Table	  4.15	  Cox	  regression	  analysis:	  risk	  of	  attaining	  DSS	  6	  from	  disease	  onset,	   from	  DSS	  3	  and	  from	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4.3.3	  Late	  relapses	  	  	  
	  
Within	   the	   SP	  population	   (n	   =	   534),	   the	  number	  of	   relapses	   experienced	   from	   the	  
third	  year	  up	  to	  onset	  of	  progression	  was	  known	  for	  436	  patients	  and	  it	  ranged	  from	  
0	  to	  17	  attacks.	  A	   total	  of	  1038	  attacks	  was	  recorded,	  with	  a	  mean	  relapse	  rate	  of	  
0.41	   attacks/year;	   107	  patients	   had	  no	   attack	   after	   year	   2,	   before	   entering	   the	   SP	  
phase.	  	  	  
	  
The	   number	   of	   late	   relapses	   did	   not	   affect	   negatively	   the	   attainment	   of	   late	  
outcomes.	   Indeed,	   the	   analysis	   highlighted	   a	   proportional	   relationship	   with	   the	  
disease	   evolution.	   A	   higher	   late	   relapses	   frequency	   associated	   with	   significantly	  
longer	  times	  to	  disability	  endpoints	  and	  with	  a	  significantly	  lower	  risk	  of	  developing	  
severe	  disability	  (Figure	  4.16	  and	  Table	  4.16).	  Patients	  with	  no	  attacks,	  compared	  to	  
patients	  with	  ≥	  3,	  took	  significantly	  shorter	  times	  to	  SP	  (5.4	  mean	  years	  difference;	  p	  
<	  0.001)	  and	  to	  DSS	  6	   (4.3	  mean	  years	  difference;	  p	  =	  0.003).	  The	  same	  trend	  was	  
observed	  for	  the	  attainment	  of	  DSS	  8,	  although	  differences	  did	  not	  reach	  statistical	  
significance	   (p	   =	   0.07)	   (Table	   4.16).	   Late	   relapses	   yielded	   a	   negative	   regression	  
coefficient	  for	  reaching	  SP	  (-­‐	  0.0956;	  HR	  =	  0.90;	  p	  <	  0.001)	  and	  DSS	  6	  (-­‐	  0.0531;	  HR	  =	  
0.94;	   p	   =	   0.015),	   indicating	   that	   the	   hazard	   of	   accumulating	   severe	   disability	  
decreased	  proportionally	  to	  the	  number	  of	  attacks.	  The	  size	  of	  this	  effect	  was	  larger	  
on	   the	   probability	   of	   entering	   the	   SP	   phase	   (5	   attacks	   reduced	   the	   risk	   by	  
approximately	  38%;	  HR	  =	  0.62)	  than	  on	  the	  probability	  of	  attaining	  DSS	  6	  (5	  attacks	  
reduced	   the	   risk	   by	   approximately	   24%;	   HR	   =	   0.76).	   Similar	   impact,	   although	   not	  
statistically	   significant,	  was	   exerted	   on	   the	   risk	   of	   DSS	   8	   (-­‐	   0.0489;	  HR	   =	   0.95;	   p	   =	  
0.063).	  The	  predictive	  effect	  of	  late	  relapses	  was	  also	  tested	  within	  the	  subgroup	  (n	  =	  
165)	  with	  frequent	  late	  attacks	  (≥	  3).	  The	  times	  to	  SP,	  to	  DSS	  6	  and	  to	  DSS	  8	  were	  not	  
significantly	  different	  among	  those	  with	  3-­‐4	  (n	  =	  93),	  5-­‐6	  (n	  =	  44)	  or	  ≥	  7	  attacks	  (n	  =	  
28)	  (Figure	  4.17).	  Finally,	  the	  number	  of	  late	  relapses	  did	  not	  significantly	  affect	  the	  
times	  to	  disability	  endpoints	  from	  DSS	  3	  and	  from	  the	  onset	  of	  SP	  (Table	  4.17).	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Table	   4.16	   Kaplan	  Meier	   estimated	   times	   to	   SP,	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   the	   disease	   onset	   in	  
patients	  grouped	  by	  the	  number	  of	  relapses	  from	  years	  3	  to	  the	  onset	  of	  SP.	  P	  values	  were	  obtained	  







Table	   4.17	   Kaplan	   Meier	   analysis:	   times	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   DSS	   3	   and	   from	   onset	   of	  
progression	   (SP)	   in	   patients	   grouped	  by	  number	  of	   attacks	   from	  year	   3	   to	   SP	  onset.	   P	   values	  were	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Figure	   4.16	   Kaplan	  Meier	   analysis	   (left):	   estimated	   times	   to	   SP	   (A),	   to	   DSS	   6	   (B)	   and	   to	   DSS	   8	   (C)	  
among	   groups	   with	   low	   (0	   attacks),	   intermediate	   (1-­‐2	   attacks)	   and	   high	   (≥	   3	   attacks)	   number	   of	  
relapses	   from	  year	  3	   to	  SP	  onset	   (late	  relapses).	  Cox	  regression	  analysis	   (right):	  variation	  of	   the	  risk	  
(HRs	  on	  y-­‐axis)	  of	  attaining	  the	  endpoints	  according	  to	  the	  increasing	  number	  of	  relapses	  from	  year	  3	  


















































:-H;" :-H:" :-7." :-7+" :-I7"
J"
	   263	  
Figure	  4.17	  Kaplan	  Meier	  analysis	  and	  Cox	  regression	  analysis:	  estimated	  times	  to	  SP	  (A),	  to	  DSS	  6	  (B)	  
and	   to	   DSS	   8	   (C)	   among	   groups	  with	   frequent	   late	   relapses	   (n	   =	   165;	   ≥	   3	   attacks).	   Comparison	   of	  
survival	  curves	  among	  those	  with	  low	  (3-­‐4	  attacks),	  intermediate	  (5-­‐6	  attacks)	  and	  high	  (≥	  7	  attacks)	  
frequency.	   HRs	   (risk	   of	   attaining	   the	   endpoints)	   and	   p	   values	   were	   obtained	   with	   Cox	   Regression	  












!"#$%&'()*&* +#,!$-+#. /,01 /,!0











!"#$%&'()*&* +,-!$.+/0 1-,# 1-#2
















!"#$%&'()*&* +,-.$/+01 2-,. 2-.3




	   264	  
Late	  relapses	  were	  recorded	  during	  a	  necessarily	  variable	  time,	  from	  year	  3	  up	  to	  SP	  
onset.	   This	   makes	   problematic	   the	   comparison	   with	   early	   relapses,	   which	   were	  
counted	  in	  the	  fixed	  time	  of	  2	  years	  from	  the	  disease	  onset.	  The	  predictive	  effect	  of	  
late	  relapses	  was	  therefore	  tested	  among	  patients	  matched	  by	  the	  duration	  of	   the	  
year	   3-­‐SP	   period.	   In	   order	   to	   make	   a	   more	   appropriate	   comparison	   with	   early	  
relapses,	   the	   association	   between	   late	   relapses	   and	   the	   disease	   evolution	   was	  
analysed	  in	  small	  subgroups,	  divided	  by	  serial	  2-­‐year	  intervals	  of	  the	  time	  from	  year	  
3	  to	  SP.	  For	  each	  2-­‐years	   interval,	  past	  year	  2	  no	  significant	   impact	  of	   late	  relapses	  
on	   the	   times	   to	   DSS	   6	   and	   to	   DSS	   8	   was	   found	   (Figure	   4.18).	   In	   addition,	   the	  
predictive	  effect	  of	  relapses	  after	  year	  2	  was	  assessed	  in	  two	  subgroups	  of	  patients	  
matched	   by	   the	   duration	   of	   the	   RR	   phase	   (short	   =	   1-­‐13	   years,	   n	   =	   270;	   long	   ≥	   14	  
years,	   n	   =	   145).	   This	   allowed	   ruling	   out	   the	   independent	   impact	   of	   the	   latency	   to	  
progression	   on	   the	   outcomes.	   Again,	   the	   time	   to	   disability	   endpoints	   remained	  
largely	  unaffected	  by	  the	  late	  relapses	  frequency	  (Figure	  4.19).	  	  
	  
	  
Figure	  4.18	  Kaplan	  Meier	  analysis:	  time	  to	  DSS	  6	  and	  to	  DSS	  8	  in	  subgroups	  of	  patients	  stratified	  by	  
the	  number	  of	  late	  relapses	  and	  by	  the	  duration	  of	  the	  period	  from	  year	  3	  to	  SP	  onset.	  P	  values	  were	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Figure	  4.19	  Kaplan	  Meier	  and	  Cox	  regression	  analyses:	  time	  to	  DSS	  6	  and	  risk	  (HRs)	  of	  reaching	  DSS	  6	  
in	  two	  subgroups	  of	  patients	  stratified	  by	  the	  duration	  of	  the	  RR	  phase	  (short	  1-­‐13	  years,	   long	  ≥	  14	  
years).	  Comparison	  of	  survival	  curves	  among	  patients	  grouped	  by	  the	  number	  of	  late	  relapses	  (0;	  1-­‐2;	  





4.3.4	  Total	  relapses	  	  	  
	  
Within	  the	  SP	  group	  (n	  =	  534),	  information	  on	  the	  total	  number	  of	  attacks	  during	  the	  
RR	  phase	  was	  available	  for	  459	  patients,	  who	  experienced	  a	  total	  of	  1882	  relapses.	  
The	  frequency	  spanned	  from	  1	  to	  18	  attacks,	  with	  a	  mean	  relapse	  rate	  before	  SP	  of	  
0.65	  relapses/year.	  	  
	  
Total	   relapses	   exerted	   no	   significant	   impact	   on	   the	   disease	   evolution	   (Figure	   4.21	  
and	   Table	   4.18).	  More	   attacks	   during	   the	   RR	   phase	  were	   associated	  with	   a	   longer	  
time	  to	  SP	  onset	  (3.4	  mean	  years	  difference	  between	  those	  with	  1-­‐2	  attacks	  versus	  
those	  with	  ≥	  5	   attacks,	   p	  <	  0.001)	   and	  with	  a	   lower	   risk	   (regression	   coefficient	  =	   -­‐
0.0417;	  HR	  =	   0.96,	   p	   =	   0.02)	   of	   entering	   the	   SP	  phase.	  Although	   small	   in	   size,	   this	  
effect	  was	   statistically	   significant,	   and	   it	  was	  unlikely	   to	  be	  an	  artefact	  of	  how	   the	  
onset	   of	   progression	   was	   defined.	   Indeed,	   a	   larger	   number	   of	   total	   relapses	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0.001),	  secondary	  to	  the	  longer	  latency	  to	  progression.	  The	  mean	  DSS	  score	  was	  2.4	  
(median	  =	  2),	  2.8	  (median	  =	  3)	  and	  3.4	  (median	  =	  3)	  among	  patients	  with	  1-­‐2,	  3-­‐4	  and	  
≥	  5	  attacks,	  respectively	  (Figure	  4.20).	  In	  addition,	  the	  analysis	  in	  subgroups	  starting	  
to	  progress	  at	  DSS	  ≤	  2	  and	  at	  DSS	  ≤	  3,	  where	  the	  onset	  of	  the	  progressive	  phase	  was	  
not	   clouded	   by	   concomitant	   relapses	   and	   therefore	   more	   easily	   pinpointed	  
(Kremenchutzky	   et	   al.,	   2006a),	   yielded	   the	   same	   results,	   demonstrating	   a	   shorter	  
time	  to	  SP	  among	  patients	  with	  fewer	  relapses	  (Table	  4.19).	  	  
	  
The	   times	   to	   disability	   endpoints	   from	   the	   disease	   onset	   were	   remarkably	   similar	  
among	  the	  groups	  with	  low	  (1-­‐2),	  intermediate	  (3-­‐4)	  or	  large	  (≥	  5)	  number	  of	  attacks	  
during	   the	   RR	   phase.	   The	   3	   groups	   required	   a	   walking	   aid	   (DSS	   6)	   and	   become	  
bedbound	   (DSS	   8)	   in	   15	   and	   25-­‐26	  mean	   years,	   respectively	   (Table	   4.18).	   Among	  
patients	   seen	   from	   onset	   only	   (SO	   subgroup)	   the	   analysis	   confirmed	   no	   effect	   of	  
total	  relapses	  on	  times	  to	  disability	  endpoints	  (mean	  years	  to	  DSS	  6:	  1-­‐2	  relapses	  =	  
9.5,	  3-­‐4	  relapses	  =	  10.8,	  ≥	  5	  relapses	  =	  8.8;	  p	  =	  0.65),	  demonstrating	  that	  recollection	  
bias	  did	  not	  affect	   the	  results.	   In	  addition,	   total	   relapses	  did	  not	  affect	   the	  disease	  
evolution	  from	  DSS	  3,	  and	  only	  modestly	  impacted	  on	  the	  evolution	  of	  the	  SP	  phase	  
(Table	   4.19).	   Finally,	   the	   comparison	  of	   the	   two	   subgroups	   at	   the	   extremes	  of	   the	  
total	   relapse	   frequency	   (1	   attack	   n	   =	   68	   versus	   ≥	   7	   attacks	   n	   =	   70)	   further	  
demonstrated	  no	  significant	  impact	  of	  the	  attacks	  during	  the	  RR	  phase	  on	  the	  long-­‐
term	  outcome.	  The	   latency	  to	  progression	  was	  shorter	  among	  those	  with	  1	  attack,	  
and	  the	  times	  to	  DSS	  6	  and	  to	  DSS	  8	  were	  almost	  the	  same	  between	  two	  subgroups	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Figure	  4.20	  DSS	  score	  (y-­‐axis)	  at	  conversion	  to	  SP	  MS,	  among	  patients	  grouped	  by	  the	  number	  of	  total	  






Table	   4.18	   Kaplan	  Meier	   estimated	   times	   to	   SP,	   to	   DSS	   6	   and	   to	   DSS	   8	   from	   the	   disease	   onset	   in	  
patients	  grouped	  by	  the	  number	  of	  total	  relapses	  during	  the	  RR	  phase.	  P	  values	  were	  obtained	  with	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Table	  4.19	  Kaplan	  Meier	  estimated	  times	  to	  SP	  in	  patients	  grouped	  by	  the	  number	  of	  total	  relapses	  
during	   the	   RR	   phase,	   and	   differentiated	   by	   the	   DSS	   score	   at	   conversion	   to	   SP	  MS.	   P	   values	   were	  





Table	   4.20	   Kaplan	  Meier	   analysis:	   times	   to	  DSS	   6	   and	   to	  DSS	   8	   from	  DSS	   3	   and	   from	   the	   onset	   of	  
progression	   (SP)	   in	  patients	  grouped	  by	   the	  total	  number	  of	   relapses	  during	   the	  RR	  phase.	  P	  values	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Figure	   4.21	   Kaplan	  Meier	   analysis	   (left):	   estimated	   times	   to	   SP	   (A),	   to	   DSS	   6	   (B)	   and	   to	   DSS	   8	   (C)	  
among	   groups	  with	   low	   (1-­‐2	   attacks),	   intermediate	   (3-­‐4	   attacks)	   and	   high	   (≥	   5	   attacks)	   number	   of	  
relapses	  during	  the	  RR	  phase	  (total	  relapses).	  Cox	  regression	  analysis	  (right):	  variation	  of	  the	  risk	  (HRs	  
on	   y-­‐axis)	   of	   attaining	   the	  endpoints	   according	   to	   the	   increasing	  number	  of	   relapses	  during	   the	  RR	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Figure	  4.22	  Kaplan	  Meier	  analysis	  and	  Cox	  regression	  analysis:	  estimated	  times	  to	  SP	  (A),	  to	  DSS	  6	  (B)	  
and	   to	  DSS	  8	   (C)	  among	  groups	  with	  very	   low	   (n	  =	  68,	  1	  attack)	  and	  very	  high	   (n	  =	  70,	  ≥	  7	  attacks)	  
number	  of	   total	   relapses.	  HRs	   (risk	  of	  attaining	   the	  endpoint)	  and	  p	  values	  were	  obtained	  with	  Cox	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4.3.5	  Multivariate	  models	  of	  disability	  	  	  	  
	  
The	  concomitant	  effect	  of	  the	  variables	  on	  the	  outcomes	  was	  tested	  in	  multivariate	  
models	  of	  disability.	  	  
	  
4.3.5.1	  Early	  relapses	  and	  the	  type	  of	  clinical	  onset	  	  	  
	  
The	  type	  and	  the	  number	  of	  neurological	  systems	  involved	  at	  clinical	  onset	  did	  not	  
exert	  any	  significant	   impact	  on	  the	   long-­‐term	  outcome.	  Polysymptomatic	  onset	  did	  
not	  affect	  times	  to	  SP	  (HR	  =	  1.02,	  p	  =	  0.76),	  to	  DSS	  6	  (HR	  =	  1.03,	  p	  =	  0.58)	  and	  to	  DSS	  
8	  (HR	  =	  1.12,	  p	  =	  0.12).	  In	  addition,	  among	  the	  types	  of	  symptoms	  characterizing	  the	  
first	   attack,	   only	   brainstem	   presentation	   associated	  with	   a	   higher	   risk	   of	   reaching	  
DSS	  6	  (HR	  =	  1.31,	  p	  =	  0.02)	  and	  DSS	  8	  (HR	  =	  1.59,	  p	  =	  0.001).	  	  The	  predictive	  effect	  of	  
early	   relapses	   remained	   unchanged	   when	   tested	   in	   the	   multivariate	   model	   along	  
with	  type	  and	  number	  of	  symptoms	  at	  onset	  (Table	  4.21).	  	  
	  
Table	   4.21	  Cox	  Regression	  multiple	   analysis:	   risk	  of	   attaining	   SP,	  DSS	  6	  and	  DSS	  8	  according	   to	   the	  
concomitant	  effect	  of	  the	  number	  of	  early	  relapses,	  the	  type	  and	  the	  number	  of	  neurological	  systems	  
involved	  at	  the	  clinical	  onset.	  	  
	  
	  
4.3.5.2	  Early	  relapses	  and	  the	  first	  inter-­‐attack	  interval	  	  
	  
When	   assessed	   simultaneously,	   early	   relapses	   and	   the	   first	   inter-­‐attack	   interval	  
exerted	  the	  same	   impact	  on	  the	  risk	  of	  entering	  the	  SP	  phase	   (HR	  =	  1.10,	  p	  =	  0.02	  
and	  HR	  =	  0.98,	  p	  =	  0.05,	  respectively)	  and	  of	  attaining	  DSS	  6	  (HR	  =	  1.18,	  p	  <	  0.001	  and	  
HR	  =	  0.96,	  p	  <	  0.001,	  respectively)	  and	  DSS	  8	  (HR	  =	  1.28,	  p	  <	  0.001	  and	  HR	  =	  0.96,	  p	  <	  
0.001,	  respectively),	  compared	  to	  when	  assessed	  separately	  (univariate	  analysis).	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4.3.5.3	  Early	  relapses	  and	  late	  relapses	  	  	  
	  
In	  the	  multivariate	  model,	  the	  size	  of	  the	  predictive	  effect	  exerted	  by	  early	  relapses	  
increased,	  while	  the	  impact	  of	  late	  relapses	  on	  the	  outcomes	  remained	  unchanged.	  
The	   analysis	   confirmed	   that,	   among	   SP	   patients,	   the	   hazard	   of	   entering	   the	  
progressive	  phase,	   and	  of	   reaching	  DSS	  6	   and	  DSS	  8	   increased	  proportionally	  with	  
the	  number	  of	  attacks	  during	  the	  first	  2	  years	  (HRs	  1.34,	  p	  <	  0.001;	  1.34,	  p	  <	  0.001;	  
1.34.	  p	  <	  0.001,	  respectively)	  and	  decreased	  proportionally	  to	  the	  number	  of	  attacks	  
from	  year	  3	  up	   to	  SP	  onset	   (HRs	  0.90,	  p	  <	  0.001;	  0.93,	  p	  =	  0.003;	  0.94,	  p	  =	  0.020,	  
respectively).	  	  
	  
The	  Multiple	  Cox	  regression	  analysis	  allowed	  calculating	  the	  probability	  of	  attaining	  
DSS	   6,	   according	   to	   the	   concomitant	   effect	   of	   early	   and	   late	   relapses.	   Among	   SP	  
patients,	  grouped	  by	  the	  number	  of	  early	  relapses,	  the	  hazard	  of	  reaching	  DSS	  6	  (1	  
attack	  HR	  =	  1.34,	  2	  attacks	  HR	  =	  1.80,	  3	  attacks	  HR	  =	  2.43)	   in	  each	  group	   reduced	  
with	   the	   increasing	   number	   of	   attacks	   after	   year	   2,	   and	   become	   about	   30-­‐40%	  
smaller	   if	   3	   relapses	   occurred	   during	   the	   year	   3-­‐SP	   period	   (HRs	   1.10,	   1.48,	   2.00,	  
respectively)	  (Figure	  4.23).	  The	  Kaplan	  Meier	  analysis	  was	  used	  to	  estimate	  the	  times	  
to	   the	   endpoint,	   in	   subgroups	   of	   patients	   selected	   according	   to	   the	   early	   and	   late	  
relapses	   frequencies,	   and	   confirmed	   the	   results	   from	   the	   Cox	   regression	   multiple	  
analysis.	  Among	  patients	  with	  1,	  2	  or	  3	  attacks	  during	  the	  first	  two	  years,	  the	  times	  
to	   DSS	   6	   increased	   proportionally	   to	   the	   number	   of	   late	   relapses	   (Table	   4.22).	   In	  
addition,	   the	  multivariate	  model	   further	  highlighted	  year	  2	  as	   the	  watershed,	  after	  
which	   the	   predictive	   effect	   of	   relapses	   reversed.	   Two	   hypothetical	   patients,	  
experiencing	   3	   relapses	   at	   different	   timing	   before	   entering	   the	   progressive	   phase,	  
were	  compared.	  The	   time	   to	  DSS	  6	  was	  much	  shorter	  and	   the	   risk	  of	   reaching	   the	  
endpoint	  was	  much	  higher	  when	  the	  onset	  attacks	  was	  followed	  by	  two	  additional	  
relapses	  occurring	  during	  the	  first	  two	  years	  (3	  attacks	  in	  y1-­‐y2	  +	  0	  attacks	  in	  y3-­‐SP:	  
time	   to	  DSS	   6	   =	   7.4	   years,	  HR	   =	   2.43),	   compared	   to	  when	   two	   additional	   relapses	  
occurred	  during	  the	  year	  3-­‐SP	  period	  (1	  attack	  in	  y1-­‐y2	  +	  2	  attacks	  in	  y3-­‐SP:	  time	  to	  
DSS	  6	  =	  22.7	  years,	  HR	  =	  1.18)	  (Figure	  4.23	  and	  Table	  4.22).	  The	  comparison	  of	  these	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two	   clinical	   scenarios	   demonstrated	   a	   difference	   of	   almost	   50%	   less	   probability	   of	  
reaching	  the	  endpoint	  (HR	  =	  0.48),	  among	  those	  with	  2	  relapses	  after	  year	  2.	  	  
	  
Figure	  4.23	  Multiple	  Cox	  regression	  analysis	  in	  SP	  patients:	  calculated	  risk	  (HR)	  of	  attaining	  DSS	  6	  from	  
the	   disease	   onset	   according	   to	   the	   concomitant	   effect	   of	   early	   and	   late	   relapses.	   On	   the	   y-­‐axis	   is	  
shown	  the	  variation	  of	  the	  HRs	  (on	  top	  of	  each	  column)	  among	  patients	  with	  1,	  2,	  3	  attacks	  during	  the	  




Table	   4.22	  Kaplan	  Meier	  analysis	   in	  SP	  patients.	  Estimated	   times	   to	  DSS	  6	  based	  on	   the	  number	  of	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4.3.5.4	  Early	  relapses,	  first	  inter-­‐attack	  interval	  and	  late	  relapses	  	  	  
 
When	   the	   first	   inter-­‐attack	   interval	   (HR	   =	   0.92)	   was	   included	   in	   the	   multivariate	  
analysis,	   calculating	   the	   probability	   of	   reaching	   DSS	   6	   from	   the	   disease	   onset,	   the	  
impact	   of	   early	   relapses	   slightly	   decreased	   (HR	   =	   1.23),	   while	   the	   effect	   of	   late	  
relapses	   remained	   unchanged	   (HR	   =	   0.91)	   (Table	   4.23).	   The	   multivariate	   model	  
allowed	  assessing	  more	  precisely	  the	  influence	  of	  the	  timing	  of	  the	  second	  attack	  on	  
the	   outcome,	   by	   simulating	   different	   hypothetical	   clinical	   scenarios	   (Table	   4.24).	  
Model	  A	  refers	  to	  a	  patient	  experiencing	  2	  relapses	  before	  converting	  to	  SP	  MS.	  Two	  
attacks	  within	   2	   years	   from	   the	  disease	  onset	   (first	   inter-­‐attack	   interval	   =	   1	   years)	  
yielded	  HR	  1.42	   for	   reaching	  DSS	  6.	  However,	  when	   the	  second	  attack	  occurred	  at	  
year	  3	   (first	   inter-­‐attack	   interval	   =	  2	   years)	   the	  hazard	   reversed	   (HR	  =	  0.97)	   (Table	  
4.24	   model	   A)	   and	   became	   about	   32%	   lower	   (comparison	   of	   the	   two	   scenarios	  
yielded	  HR	  =	  0.68).	  These	  results	  indicated	  that	  the	  predictive	  effect	  of	  the	  first	  inter-­‐
attack	   interval	   largely	   depended	   on	   whether	   or	   not	   the	   second	   attack	   occurred	  
within	  the	  first	   two	  years.	   In	  addition,	   the	  risk	  of	  attaining	  the	  endpoint	  decreased	  
modestly	   and	   proportionally	   to	   the	   duration	   of	   the	   interval	   between	   the	   first	   two	  
attacks	   (Table	   4.24	  model	   A).	   Finally,	  model	   B	   confirmed	   that	   the	   number	   of	   late	  
relapses	   associated	   with	   a	   proportionally	   lower	   probability	   of	   developing	   severe	  
disability	  even	  when	  it	  was	  adjusted	  to	  the	  first	  inter-­‐attack	  interval	  (Table	  4.24).	  	  
	  
	  
Table	  4.23	  Cox	  regression	  multivariate	  analysis.	  Risk	  (HR)	  of	  attaining	  DSS	  6	  from	  the	  disease	  onset,	  
from	   the	   onset	   of	   progression	   (SP)	   and	   from	   DSS	   3,	   according	   to	   the	   concomitant	   effect	   of	   early	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Table	  4.24	  Cox	  regression	  multivariate	  analysis.	  Risk	  of	  attaining	  DSS	  6	  calculated	  by	  combining	  the	  





4.3.5.5	  Early	  relapses	  and	  time	  to	  moderate	  disability	  	  
	  
The	  interval	  between	  the	  disease	  onset	  and	  moderate	  disability	  (DSS	  3)	  was	  known	  
for	  634	  patients	  and	   ranged	   from	  1	   to	  40	  years.	  Among	  patients	  who	   reached	   the	  
endpoint,	  the	  mean	  time	  to	  DSS	  3	  was	  9.5	  years	  (95%	  C.I.	  8.9-­‐10.1)	  and	  the	  median	  
time	  was	  8	  years.	  The	  analysis	  demonstrated	   that	   the	   time	   to	  DSS	  3	  predicted	   the	  
long-­‐term	   disease	   evolution.	   A	   longer	   interval	   associated	   with	   modestly,	   but	  
significantly	  longer	  times	  from	  DSS	  3	  to	  DSS	  6	  and	  to	  DSS	  8	  (Table	  4.25)	  and	  with	  a	  
lower	  risk	  of	  attaining	  the	  endpoints	  (DSS	  6,	  HR	  =	  0.97,	  p	  <	  0.001;	  DSS	  8	  HR	  =	  0.96,	  p	  
<	   0.001)	   (Table	   4.26).	   In	   addition,	   the	   predictive	   effect	   of	   the	   time	   to	   DSS	   3	   was	  
independent	  of	  the	  number	  of	  early	  relapses	  and	  of	  the	  first	  inter-­‐attack	  interval,	  as	  
it	   remained	  unchanged	   in	   the	  multivariate	   analysis	   (Table	   4.26).	   In	   contrast,	  when	  
adjusted	  for	  the	  time	  to	  reach	  DSS	  3,	   the	  effect	  of	  total	  attack	  during	  the	  first	   two	  
years	   on	   the	   outcomes	   became	   smaller	   (Table	   4.26)	   than	   the	   univariate	   analysis	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Table	   4.25	   Kaplan	  Meier	   analysis:	   times	   from	  DSS	   3	   to	  DSS	   6	   and	   to	  DSS	   8	   in	   patients	   grouped	  by	  
interval	   from	  disease	  onset	   to	  moderate	  disability	   (DSS	  3).	   P	   values	  obtained	  with	   Log	  Rank	   test.	   *	  





Table	  4.26	  Cox	  regression	  multiple	  analysis.	  Risk	  of	  attaining	  DSS	  6	  calculated	  by	  combining	  the	  effect	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The	   relationship	   between	   relapses	   and	   the	   accumulation	   of	   severe	   disability	   is	  
perhaps	  the	  most	  controversial	  topic	  in	  MS.	  It	  keeps	  fuelling	  discussions	  and	  debates	  
among	  clinicians	  and	  scientists	  around	   the	  world.	  The	  inflammatory	  attacks	  can	  be	  
sufficient	  for	  the	  experienced	  physicians	  when	  making	  the	  diagnosis,	  yet	  they	  are	  the	  
most	   puzzling	   clinical	   feature	   of	   the	   disease.	   Because	   of	   their	   random	   presenting	  
pattern	   and	   because	   they	   can	   unpredictably	   determine	   a	   residual	   deficit,	   relapses	  
contribute	   not	   only	   to	   the	   physical	   but	   also	   to	   the	   psychological	   burden	   of	   the	  
disease.	  
	  
Since	   the	   earliest	   reports	   (Charcot,	   1880),	   MS	   has	   been	   described	   as	   an	  
inflammatory	   disease,	   which	   primary	   targets	   the	   myelin	   sheaths	   in	   the	   CNS	   and	  
causes	  the	  formation	  of	  the	  demyelinated	  plaques.	  As	  permanent	  disability	  develops	  
over	  time,	  it	  is	  reasonable	  to	  assume	  that	  the	  axonal	  damage,	  which	  is	  the	  essential	  
cause	  of	  disease	  progression	  (Trapp	  and	  Nave,	  2008),	  is	  a	  consequence	  of	  successive	  
exacerbations.	  The	   frequency	  of	   inflammatory	  attacks	   is	   therefore	   commonly	  used	  
for	  monitoring	  the	  disease	  activity	  (Cohen	  et	  al.,	  2004),	  as	  indicator	  of	  the	  treatment	  
response	   (Sormani	  et	  al.,	  2012)	  and	  as	  surrogate	  marker	  of	   the	  short	   term	  disease	  
evolution	  (Sormani	  et	  al.,	  2011).	  In	  addition,	  the	  efficacy	  of	  MS	  therapies	  in	  RCTs	  is	  
normally	  measured	  by	  assessing	  their	  impact	  on	  relapse	  related	  endpoints.	  	  
	  
However,	   the	   contribution	   of	   inflammatory	   attacks	   to	   the	  mechanisms	   driving	   the	  
evolution	  of	  the	  progressive	  course,	  and	  leading	  to	  the	  development	  of	  permanent	  
disability,	   remains	   ambiguous.	   The	   therapeutic	   relapse	   suppression	   was	   shown	   to	  
prevent	   the	   EDSS	   worsening	   within	   the	   short	   observation	   period	   of	   clinical	   trials	  
(1993;	  1998a;	  Coles	  et	  al.,	  1999;	  Jacobs	  et	  al.,	  1996a;	  Johnson	  et	  al.,	  1995;	  Kappos	  et	  
al.,	   2006a;	   Polman	   et	   al.,	   2006),	   but	   its	   impact	   on	   the	   hard	   outcomes	   in	   the	   long	  
term	  is	  unclear	  (Bermel	  et	  al.,	  2010;	  Ebers	  et	  al.,	  2010;	  Goodin	  et	  al.,	  2012;	  Kappos	  et	  
al.,	   2006c;	   Shirani	   et	   al.,	   2012).	   This	   highlighted	   a	   possible	   dissociation	   between	  
exacerbations	   and	   the	   pathological	   processes	   responsible	   for	   the	   disease	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progression.	   The	   axonal	   damage	   is	   known	   to	   occur	   in	   the	   context	   of	   acute	  myelin	  
disruption	  (Kuhlmann	  et	  al.,	  2002;	  Trapp	  et	  al.,	  1998)	  and,	  to	  variable	  extent,	  within	  
chronic	   demyelinated	   lesions	   (Bjartmar	   and	   Trapp,	   2001;	  Mews	   et	   al.,	   1998).	   The	  
mechanisms	   causing	   the	   axonal	   loss	   have	   never	   been	   fully	   elucidated	   (Dutta	   and	  
Trapp,	  2011).	  The	  infiltrating	  inflammatory	  cells	  might	  exert	  a	  direct	  toxic	  effect	  on	  
the	  axons,	  by	  releasing	  proteolytic	  enzymes,	  cytokines	  and	  oxidative	  products	  (Smith	  
et	   al.,	   2001;	   Trapp	   and	   Nave,	   2008;	   Weiner,	   2009).	   Nevertheless,	   the	  
neurodegeneration	   could	   also	   be	   a	   consequence	   of	   sodium	   and	   calcium	  mediated	  
injuries	  (Craner	  and	  Fugger,	  2011;	  Micu	  et	  al.,	  2006;	  Waxman	  et	  al.,	  2004),	  and	  could	  
be	  unrelated	  to	  the	   inflammation	  (Chaudhuri	  and	  Behan,	  2004).	  The	  controversy	   is	  
further	   fuelled	   by	   pathological	   studies	   describing	   extensive	   axonal	   damage	   within	  
the	   NAWM	   (Bjartmar	   et	   al.,	   2001;	   DeLuca	   et	   al.,	   2006;	   Evangelou	   et	   al.,	   2000;	  
Frischer	  et	  al.,	  2009;	  Lovas	  et	  al.,	  2000;	  Trapp	  et	  al.,	  1998),	  and	  suggesting	  that	  the	  
neurodegeneration	  might	  occur	  independently	  of	  active	  demyelination	  (Bitsch	  et	  al.,	  
2000).	  More	  recently,	  the	  cortical	  demyelination,	  which	  does	  not	  correlate	  with	  the	  
white	   matter	   demyelination	   (Bo	   et	   al.,	   2007)	   and	   it	   is	   possibly	   caused	   by	  
compartmentalized	  inflammation	  (Frischer	  et	  al.,	  2009),	  was	  suggested	  as	  a	  potential	  
pathological	  driver	  of	   the	  disease	  progression	  (Kutzelnigg	  et	  al.,	  2005).	  MRI	  studies	  
have	   also	   contributed	   to	   the	   debate.	   The	   inflammatory	   lesions	   load	   associates	  
weakly	  with	  the	  clinical	  activity	  (Bakshi	  et	  al.,	  2008;	  McDonald	  et	  al.,	  1994)	  and	  was	  
shown	  to	  predict	  only	  modestly	  the	  disability	  accumulation	  in	  the	  long	  term	  (2008;	  
Calabrese	  et	  al.,	  2013;	  Fisniku	  et	  al.,	  2008a).	  In	  contrast	  to	  the	  white	  matter	  changes,	  
the	  grey	  matter	  atrophy,	  which	  is	  an	  expression	  of	  the	  axonal	  pathology,	  correlates	  
strongly	   with	   the	   disease	   severity	   (Calabrese	   et	   al.,	   2013;	   Fisniku	   et	   al.,	   2008b;	  
Rudick	  et	  al.,	  2009).	  
	  
Within	  this	  complicated	  picture,	  natural	  history	  studies	  can	  help	  to	  solve	  this	  endless	  
debate,	   although	   they	   are	   not	   free	   of	   potential	   limitations.	   The	   collection	   of	  
information	   on	   relapses	  might	   be	   affected	   by	   recollection	   bias.	   Overcoming	   these	  
difficulties	   in	   the	   long	   term	   is	   particularly	   challenging,	   as	   demonstrated	   by	   the	  
paucity	   of	   data	   on	   the	   relationship	   between	   late	   relapses	   and	   hard	   outcomes.	   In	  
addition,	   the	   clinical	  manifestations	   partially	   dissociate	   from	   the	   biological	   events,	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limiting	  the	  possibility	  of	  drawing	  conclusions	  on	  the	  disease	  pathogenesis.	  Episodic	  
relapses	   are	   just	   a	   “filtered”	   expression	   of	   an	   underlying,	   constantly	   active	  
inflammatory	  process.	  The	  MRI	  inflammatory	  lesions	  are	  known	  to	  occur	  5-­‐10	  times	  
more	   frequently	   than	   the	   clinically	   evident	   attacks	   (Barkhof,	   2002).	  Moreover,	   the	  
axonal	  damage	  (Trapp	  et	  al.,	  1998)	  and	  the	  brain	  atrophy	   (Filippi	  et	  al.,	  2003)	   take	  
place	   already	   during	   the	   early	   stage	   of	   the	   disease,	  when	   the	   patients	   are	   free	   of	  
permanent	  disability.	  Notwithstanding	  these	   limitations,	   the	  natural	  history	  studies	  
can	   offer	   important	   clues	   to	   further	   elucidate	   the	   complex	   interaction	   between	  
inflammation,	   unremitting	   disability	   and	   the	   mechanisms	   driving	   the	   disease	  
progression.	   The	   data	   from	   large	   sample	   of	   patients,	   observed	   for	   a	   long	   period,	  
gives	  a	  unique	  picture	  of	  the	  variable	  clinical	  outcome	  over	  time.	  	  
	  
Among	   MS	   registries,	   the	   LO	   database	   contains	   the	   most	   extensive	   collection	   of	  
information	  on	  relapses	   from	  a	  well-­‐ascertained,	  untreated	  population,	   reaching	   in	  
large	  percentages	  high	  disability	  levels.	  This	  offered	  the	  possibility	  to	  test	  the	  validity	  
of	   the	   relapses	  number	  as	   clinical	   indicator	  of	   the	  disease	  activity	  and	   to	  estimate	  
the	   impact	   of	   inflammatory	   attacks	   on	   unambiguous,	   meaningful	   disability	  
outcomes,	  representing	  the	  heart	  of	  the	  medical,	  social	  and	  economic	  burden	  of	  MS.	  	  	  
	  
4.4.1	  The	  frequency	  of	  relapses	  	  
The	  average	  attacks	  number	  shows	  marked	  variation	  within	  and	  between	  individuals	  
over	  time	  (Weinshenker	  and	  Ebers,	  1987).	  Longitudinal	  assessments	  (Confavreux	  et	  
al.,	   1980;	   Fog	   and	   Linnemann,	   1970;	   Goodkin	   and	   Hertsgaard,	   1989;	   Patzold	   and	  
Pocklington,	   1982)	   yielded	   greater	   frequencies	   compared	   to	   the	   retrospective	  
studies	  (Leibowitz	  et	  al.,	  1964;	  Mc	  and	  Compston,	  1952;	  Myhr	  et	  al.,	  2001;	  Panelius,	  
1969)	   (Figure	   4.1).	   This	  was	  most	   likely	   due	   to	   the	   recollection	   bias.	   As	   previously	  
reported	  in	  other	  cohorts	  (Mc	  and	  Compston,	  1952;	  Patzold	  and	  Pocklington,	  1982;	  
Tremlett	   et	   al.,	   2008b),	   in	   the	   LO	   database	   the	   relapse	   rate	   lessened	   with	   time,	  
mostly	  due	   to	   the	   regression	   to	   the	  mean.	  The	  number	  of	  attacks	   recorded	  during	  
the	   first	   two	   years	   (0.93	  mean	   attacks/year)	   decreased	   with	   the	   disease	   duration	  
(mean	  0.41	  attacks/year	  from	  year	  3	  up	  to	  SP	  onset)	  and	  averaged	  0.65	  attacks/year	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during	   the	  RR	  phase.	   This	   figure	   coheres	  with	  other	  natural	  history	   studies	   (Figure	  
4.1)	  and	  also	  conforms	  to	  the	  rates	  seen	   in	  placebo	  arms	  from	  RCTs	   (Inusah	  et	  al.,	  
2010)	  
	  
4.4.2	  Relapses	  and	  the	  evolution	  of	  the	  RR	  phase	  (the	  latency	  to	  SP)	  
	  
The	   probability	   of	   entering	   the	   progressive	   phase	   and	   the	   time	   to	   progression	  
remain	   relatively	   unexplored	   outcomes,	   with	   a	   profound	   clinical	   relevance	  
(Kremenchutzky	   et	   al.,	   2006a).	   It	   has	   been	   previously	   demonstrated	   that	   early	  
relapses	  are	  predictors	  of	  SP	  (Table	  4.2).	  However,	  the	  independent	  role	  of	  late	  and	  
total	  relapses	  before	  the	  onset	  of	  progression,	  on	  the	  evolution	  of	  the	  RR	  phase	  has	  
never	  been	  assessed.	  
	  
4.4.2.1	  Early	  relapses	  
	  
Only	   few	   studies	   examined	   the	   relationship	   between	   early	   relapses	   and	   the	  
attainment	   of	   SP.	   In	   the	   Lorraine	   database,	   the	   time	   to	   convert	   to	   SP	   MS	   was	  
significantly	   longer	   between	   those	  with	   1	   and	   >	   1	   attacks	   during	   the	   first	   5	   years	  
(Debouverie	  et	  al.,	  2008).	  Similarly,	  in	  the	  Gothenburg	  database	  5	  or	  more	  relapses	  
during	  the	  first	  5	  years	  associated	  with	  a	  significantly	  shorter	  time	  to	  SP,	  compared	  
to	   2-­‐4	   attacks	   (7	  median	   years	   difference)	   (Figure	   4.3)	   (Eriksson	   et	   al.,	   2003).	   The	  
British	   Columbia’s	   group	   used	   a	   different	   methodology	   and	   offered	   the	   most	  
extensive	  analysis.	  A	  higher	  attack	  rate	  within	  5	  years	  from	  onset	  associated	  with	  a	  
higher	  hazard	  of	  and	  with	  a	  shorter	  time	  to	  SP	  (Figure	  4.4).	  One	  attack	  increased	  the	  
risk	  of	   reaching	  SP	  within	  5	  years	   (HR	  =	  1.29)	  and	   the	  size	  of	   this	  effect	  decreased	  
proportionally	  to	  the	  disease	  duration	  (HR	  =	  1.11	  and	  1.02	  for	  SP	  reached	  in	  >	  5	  to	  10	  
years	  or	  in	  >	  10	  years,	  respectively)	  (Tremlett	  et	  al.,	  2009a).	  	  
	  
The	  LO	  database	  is	  advantaged	  by	  a	  large	  proportion	  (66.2%)	  of	  patients	  attaining	  SP	  
at	   the	   end	   of	   the	   observation	   period.	   In	   line	   with	   previous	   studies,	   the	   analysis	  
confirmed	  that	  early	  relapses	  are	  a	  good	  predictor	  of	  the	  evolution	  of	  the	  RR	  phase.	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A	  higher	  number	  of	  attacks	  during	  the	  first	  2	  years	  associated	  with	  an	  increased	  risk	  
of	  converting	  to	  SP	  MS	  and	  with	  a	  shorter	   latency	  to	  progression	  (Table	  4.5,	  Figure	  
4.10).	   The	  probability	  of	   reaching	  SP	  was	   significantly	  affected	  by	  early	   relapses	   (1	  
attack	  yielded	  HR	  =	  1.11)	  and	  increased	  proportionally	  with	  the	  frequency	  of	  attacks,	  
becoming	  26%	  higher	  among	  patients	  with	  3	  attacks	  (HR	  =	  1.37).	  The	  Kaplan	  Meier	  
analysis	   highlighted	   the	   patients	   with	   high	   (≥	   3)	   early	   relapse	   frequency	   as	   the	  
outliers	  driving	  this	  association.	  This	  subgroup	  attained	  SP	  4.8	  mean	  years	  earlier	  (p	  
<	  0.001)	  than	  those	  with	  1	  relapse,	  but	  only	  1.6	  mean	  years	  earlier	   (p	  =	  0.38)	  than	  
those	  with	  2	  relapses	  (Table	  4.5).	  	  
	  
4.4.2.2	  Late	  and	  total	  relapses	  
	  
In	  contrast	  with	  early	  relapses,	  the	  attacks	  after	  year	  2	  and	  the	  total	  attacks	  during	  
the	  RR	  phase	  did	  not	  predict	  the	  time	  to	  SP.	  However,	   late	  and	  total	  relapses	  were	  
collected	  among	  SP	  patients	  only.	  Therefore,	   the	  Cox	   regression	  analysis	  could	  not	  
assess	   the	   risk	   of	   converting	   to	   SP	  MS,	   but	   it	   rather	   estimated	   the	   probability	   of	  
attaining	  the	  endpoint	  in	  short	  or	  long	  times.	  The	  two	  variables	  yielded	  HRs	  below	  1,	  
which	   indicated	   that	   fewer	   late	   and	   total	   relapses	   associated	   with	   a	   significantly	  
higher	   probability	   of	   entering	   the	   SP	   phase	   more	   rapidly	   (HR	   =	   0.90	   and	   0.96,	  
respectively)	  (Figures	  4.16	  A	  and	  4.21	  A).	  The	  Kaplan	  Meier	  analyses	  confirmed	  that	  
the	  latency	  to	  progression	  was	  longer	  among	  those	  with	  a	  higher	  attacks	  frequency	  
(Tables	   4.16	   and	  4.18).	   SP	  patients	  with	   ≥	   3	   late	   relapses	   attained	  progression	  2.8	  
mean	   years	   and	   5.4	  mean	   years	   later	   than	   those	  with	   1-­‐2	   (p	   =	   0.003)	   and	  with	   0	  
attacks	   (p	  <	  0.001),	   respectively	   (Figure	  4.16).	  The	  subgroup	  analysis,	  among	  those	  
with	  high	  late	  relapses	  frequency	  (3-­‐4,	  5-­‐6	  and	  ≥	  7	  attacks),	  further	  demonstrated	  no	  
influence	  exerted	  by	  late	  attacks	  on	  the	  time	  to	  progression	  (Figure	  4.17	  A).	  
	  
Therefore,	   neither	   the	   number	   of	   relapses	   after	   year	   2	   nor	   the	   number	   of	   total	  
attacks	  was	  a	  good	   indicator	  of	   the	  evolution	  of	   the	  RR	  phase.	  A	   larger	  number	  of	  
total	   relapses	   associated	   with	   a	   longer	   latency	   to	   SP.	   This	   was	   demonstrated	   by	  
comparing	  patients	  with	  ≥	  5	  versus	  1-­‐2	  attacks	  (3.4	  mean	  years	  difference;	  p	  <	  0.001)	  
(Figure	   4.21	   A),	   by	   comparing	   patients	   with	   ≥	   7	   versus	   1	   attack	   (3.1	   mean	   years	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difference;	   p	   =	   0.06)	   (Figure	   4.22	   A)	   and	   by	   including	   in	   the	   analysis	   only	   those	  
patients	  who	  started	  to	  progress	  at	  DSS	  ≤	  2	  and	  at	  DSS	  ≤	  3	   (Table	  4.19),	   indicating	  
that	   the	   difficulty	   in	   defining	   the	   onset	   of	   progression	   did	   not	   affect	   the	   results.	  
Indeed,	  previous	  analysis	  of	  the	  LO	  database	  reported	  a	  shorter	  duration	  of	  the	  RR	  
phase	   among	   SAP	   (1	   attack	   before	   progression)	   compared	   to	   SP	   (multiple	   attacks	  
before	   progression)	   patients	   (time	   to	   SP	   =	   7.6	   versus	   10.3	   mean	   years)	  
(Kremenchutzky	  et	  al.,	  2006a),	  highlighting	  a	  proportional	  relationship	  between	  total	  
attacks	  and	  the	  latency	  to	  progression.	  Given	  the	  association	  between	  early	  relapses	  
and	   the	   onset	   of	   SP,	   these	   results	   came	   unexpected	   and	   suggested	   that,	   after	   an	  
early	   watershed	   is	   reached,	   mechanisms	   leading	   to	   the	   onset	   of	   the	   progressive	  
phase	   dissociate	   from	   the	   focal	   inflammatory	   pathology.	   This	   will	   be	   more	  
extensively	  addressed	  in	  Chapter	  7.	  	  
	  
The	  relationship	  between	  late	  relapses	  and	  the	  onset	  of	  SP	  was	  previously	  assessed	  
only	  in	  the	  British	  Columbia	  database	  (Tremlett	  et	  al.,	  2009a).	  One	  attack,	  occurring	  
between	  5	  to	  10	  years	  from	  onset,	  increased	  the	  risk	  of	  SP	  (HR	  =	  1.23),	  but	  this	  effect	  
decreased	   over	   time	   (HR	   =	   1.08	   for	   1	   attack	   occurring	   after	   10	   years).	   This	  
methodological	  approach	  aimed	  at	  exploring	  the	  impact	  of	  relapses	  in	  the	  long	  term.	  
However,	   performing	   separate	   analyses	   in	   patients	   categorized	   according	   to	   the	  
disease	   duration	   (0-­‐5;	   >5	   to	   10;	   >10	   years)	   limited	   the	   meaningfulness	   of	  
conclusions.	  The	  selection	  bias	  explains,	  at	   least	  partially,	  the	  decreasing	  predictive	  
effect	  of	  relapses,	  as	  the	  groups	  observed	  for	  longer	  time	  are	  necessarily	  more	  likely	  
to	   reach	   the	   endpoint	   less	   rapidly.	   In	   addition,	   the	   different	   definition	   of	   late	  
relapses	   and	   the	   inclusion	   in	   the	   LO	   analysis	   of	   only	   SP	   patients	   make	   further	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4.4.3	  Relapses	  and	  the	  attainment	  of	  hard	  disability	  endpoints	  	  
	  
4.4.3.1	  Early	  relapses	  and	  late	  outcomes	  
	  
Natural	   history	   studies	   consistently	   demonstrated	   that	   the	   number	   of	   early	  
inflammatory	   attacks	   predicts	   the	   long-­‐term	   disease	   evolution	   (Table	   4.2).	   A	   high	  
early	   relapses	   frequency	   associates	   not	   only	  with	   a	   shorter	   latency	   to	   progression	  
but	  also	  with	  a	   faster	  attainment	  of	  disability	  endpoints.	  Overall,	   the	  effect	  on	   the	  
times	  to	  DSS	  levels	  appears	  larger	  than	  the	  effect	  on	  the	  time	  to	  SP.	  Interestingly,	  in	  
the	  majority	  of	  the	  studies,	  the	  times	  to	  DSS	  6,	  according	  to	  the	  number	  of	  attacks	  
during	   the	   first	  5	   (Confavreux	  et	  al.,	   2003;	  Debouverie	  et	  al.,	   2008;	  Eriksson	  et	  al.,	  
2003)	  and	  2	  (Leray	  et	  al.,	  2010)	  years	  differed	  significantly	  but	  little,	  among	  groups.	  
The	   analysis	   from	   the	   British	   Columbia	   database	   again	   stands	   out	   as	   the	   most	  
comprehensive,	   although	   the	   survival	   estimates	  were	   affected,	   at	   least	   in	   part,	   by	  
the	   large	  proportion	   (72%)	  of	   censored	   information.	  The	  number	  of	  attacks	  during	  
the	  first	  5	  years	  increased	  significantly	  (HR	  =	  1.48)	  the	  probability	  of	  reaching	  EDSS	  6,	  
and	  this	  effect	  decreased	  over	  time.	  The	  group	  with	  a	  high	  attack	  rate	  (≥	  0.4),	  which	  
attained	   the	  endpoint	  9	  years	  earlier	   than	   the	  other	   two	  groups	  with	  a	   lower	   rate	  
(<0.2	  and	  0.2-­‐<0.4),	  was	   the	  main	  driver	  of	   the	  association	  between	  early	   relapses	  
and	  late	  outcomes	  (Figure	  4.4).	  	  	  
	  
With	  the	  extended	  follow	  up,	  the	  analysis	  here	  presented	  confirmed	  (Weinshenker	  
et	  al.,	  1989c)	  that,	  among	  LO	  patients,	  a	  larger	  number	  of	  attacks	  during	  the	  first	  two	  
years	   associated	   with	   a	   faster	   attainment	   of	   hard	   disability	   outcomes	   from	   the	  
disease	  onset,	   from	  the	  onset	  of	  SP	  and	   from	  DSS	  3.	  Times	   to	  DSS	  6	  and	   to	  DSS	  8	  
from	   onset	  where	   significantly	   shorter	   among	   those	  with	   ≥	   3,	   compared	   to	   those	  
with	  2	   (3.6	  and	  8.5	  mean	  years	  differences,	   respectively)	  and	  with	  1	   (7.6	  and	  12.8	  
mean	   years	   difference,	   respectively)	   early	   relapse	   (Table	   4.5).	   The	   risk	   of	  
accumulating	  disability	  increased	  proportionally	  with	  the	  number	  of	  attacks	  and	  the	  
impact	  on	  the	  two	  endpoints	  was	  slightly	  different	  (HRs	  yielded	  by	  3	  attacks:	  DSS	  6	  =	  
1.84	  and	  DSS	  8	  =	  2.32)	  (Figure	  4.10).	  This	  predictive	  effect	  was	  primarily	  exerted	  by	  
	   284	  
increasing	  the	  probability	  of	  entering	  the	  SP	  phase	  and	  by	  shortening	  the	  latency	  to	  
progression.	  Among	  patients	  with	  a	  large	  number	  of	  attacks	  during	  the	  first	  2	  years,	  
the	  faster	  attainment	  of	  DSS	   levels	  was	  secondary	  to	  the	  more	  rapid	  conversion	  to	  
SP	  MS	  (Table	  4.5).	  The	  onset	  of	  the	  SP	  phase	  was	  the	  key	  determinant	  of	  the	  effect	  
of	   early	   relapses	  on	   the	  outcomes.	   In	   support	  of	   this,	  when	  only	   SP	  patients	  were	  
included	  in	  the	  analysis	  the	  predictive	  effect	  of	  relapses	  became	  larger	  (Table	  4.6).	  In	  
addition,	   in	   the	   SP	   group,	   the	   impact	   exerted	   by	   early	   relapses	   on	   the	   outcome	  
decreased	   proportionally	  with	   the	   latency	   to	   progression,	   and	   become	   almost	   not	  
significant	  when	  it	  was	  tested	  among	  patients	  with	  a	  long	  duration	  of	  the	  RR	  phase	  
(Table	  4.7).	  	  
	  
4.4.3.2	  Late	  relapses	  and	  late	  outcomes	  	  
As	  seen	  for	  the	  attainment	  of	  progression,	  the	  analysis	  demonstrated	  that	  after	  year	  
2	  a	  reversal	  seems	  to	  take	  place.	  The	  number	  of	  late	  relapses	  did	  not	  affect	  the	  long-­‐
term	   disease	   evolution.	   Indeed,	   the	   probability	   of	   developing	   severe	   disability	  
decreased	  proportionally	  to	  the	  number	  of	  attacks.	  This	  might	  indicate	  that	  different	  
biological	  mechanisms	  underly	   early	   and	   late	   inflammatory	   attacks.	  More	   relapses	  
from	   year	   3	   up	   to	   the	   onset	   of	   progression	   predicted	   a	   significantly	   lower	   risk	   of	  
attaining	  the	  endpoints;	  5	  attacks	  reduced	  the	  hazard	  of	  reaching	  DSS	  6	  by	  24	  %	  (HR	  
=	  0.76)	  and	  DSS	  8	  by	  22%	  (HR	  0.78)	  (Figure	  4.16).	  This	  effect	  was	  also	  demonstrated	  
by	  the	  Kaplan	  Meier	  analysis.	  The	  group	  with	  ≥	  3	  attacks	  reached	  the	  endpoints	   in	  
significantly	   longer	   times	   compared	   to	   the	   group	  with	   no	   relapse	   (4.3	  mean	   years	  
difference	   for	   attaining	  DSS	   6)	   (Table	   4.16).	   In	   addition,	   the	   similar	   survival	   times,	  
among	  patients	  with	  3-­‐4,	  5-­‐6	  or	  ≥	  7	  attacks	  (Figure	  4.17),	  further	  confirmed	  the	  lack	  
of	   impact	   of	   late	   relapses	   on	   the	   long	   term	   disease	   evolution.	   The	   proportional	  
relationship	   between	   the	   attacks	   after	   year	   2	   and	   the	   latency	   to	   SP	   explains	   the	  
longer	   times	   to	   disability	   endpoints,	   among	   groups	   with	   a	   higher	   number	   of	   late	  
relapses	   (Figure	   4.16).	   In	   support	   of	   this,	   when	   patients	   were	   matched	   by	   the	  
duration	  of	  the	  RR	  phase	  (1-­‐13	  or	  ≥	  14	  years),	  the	  groups	  with	  low,	  intermediate	  and	  
high	   late	   relapses	   frequency	   had	   very	   similar	   survival	   curves	   and	   the	   same	   risk	   of	  
developing	  disability	  (Figure	  4.19).	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4.4.3.3	  Total	  relapses	  and	  late	  outcomes	  
	  
Importantly,	  the	  number	  of	  attacks	  during	  the	  RR	  phase	  exerted	  no	  significant	  effect	  
on	   the	   attainment	   of	   the	   disability	   outcomes.	   The	   times	   to	   the	   endpoints	   from	  
disease	   onset	   were	   remarkably	   equal	   among	   patients	   with	   small	   (1-­‐2	   attacks),	  
intermediate	   (3-­‐4	   attacks)	   and	   high	   (≥	   5	   attacks)	   number	   of	   total	   relapses.	   The	   3	  
groups	  reached	  DSS	  6	  in	  15.6,	  15.7	  and	  15.9	  mean	  years,	  respectively,	  and	  DSS	  8	  in	  
26.2,	   25.8	   and	   26.2	  mean	   years,	   respectively	   (Table	   4.18).	   Accordingly,	   the	   risk	   of	  
developing	  severe	  disability	  remained	  unchanged,	  despite	  the	  increasing	  number	  of	  
attacks	  (4.21	  B	  and	  C).	  Even	  when	  the	  two	  subgroups	  of	  patients	  at	  the	  extremes	  of	  
the	  total	  relapse	  frequency	  (1	  versus	  ≥	  7	  attacks)	  were	  compared,	  the	  total	  number	  
of	   attacks	   before	   progression	   exerted	   no	   impact	   on	   the	   disease	   evolution	   (Figure	  
4.23	   B	   and	   C).	   Same	   results	   were	   obtained	   when	   the	   SO	   subgroup	   was	   assessed	  
separately,	  demonstrating	  that	  the	  retrospectively	  collected	  information	  on	  relapses	  
did	  not	  bias	  the	  analysis.	  	  
	  
4.4.4	  Relapses	  and	  the	  evolution	  of	  the	  SP	  phase	  	  
	  
The	   relationship	   between	   relapses	   and	   the	   evolution	   of	   SP	   MS	   remains	   partially	  
unexplored.	   It	   is	   well	   established	   that	   superimposed	   relapses	   do	   not	   affect	   the	  
evolution	  of	  the	  progressive	  phase	  in	  both	  SP	  (Confavreux	  et	  al.,	  2000;	  Vukusic	  and	  
Confavreux,	  2003)	  (Figure	  4.8)	  and	  PP	  patients	  (Kremenchutzky	  et	  al.,	  1999a)	  (Figure	  
4.7).	  Less	  is	  known	  about	  the	  effect	  exerted	  by	  relapses	  during	  the	  RR	  phase	  on	  the	  
slope	   of	   the	   SP	   phase.	   Previous	   analysis	   of	   the	   LO	   database	   reported	   remarkably	  
similar	   times	   from	   the	   onset	   of	   progression	   to	   DSS	   levels	   among	   SAP,	   SP	   and	   PP	  
patients	   (Figure	   4.6),	   indicating	   that	   the	   disability	   accumulation	   during	   the	  
progressive	  phase	  was	  largely	  independent	  of	  attacks	  preceding	  its	  onset.	  The	  group	  
from	  Gothenburg	  demonstrated	  no	  predictive	  effect	  exerted	  by	   the	  attacks	  during	  
the	  first	  5	  years	  on	  the	  time	  from	  SP	  to	  EDSS	  7	  (Eriksson	  et	  al.,	  2003).	  In	  the	  3	  French	  
cohorts	  from	  the	  EDMUS	  network	  early	  relapses	  did	  not	  significantly	  affect	  the	  times	  
from	  DSS	  3	  (Leray	  et	  al.,	  2010)	  and	  from	  DSS	  4	  (Confavreux	  et	  al.,	  2003;	  Debouverie	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et	  al.,	   2008)	   to	  higher	  DSS	   levels.	  However,	   it	  was	  not	   reported	   the	  percentage	  of	  
patients	  still	  in	  the	  RR	  phase	  at	  the	  time	  when	  moderate	  disability	  occurred.	  	  	  
	  
In	  this	  study	  the	  effect	  of	  relapses	  on	  the	  evolution	  of	  the	  SP	  phase	  was	  explored	  by	  
assessing	  the	  times	  to	  the	  endpoints	  and	  the	  risk	  of	  developing	  disability	  both	  from	  
DSS	  3	  and	   from	  SP,	  however	   the	   two	  approaches	  were	  methodologically	  different.	  
The	   analysis	   of	   the	   disease	   evolution	   from	   moderate	   disability	   (DSS	   3)	   included	  
approximately	  30%	  of	  patients	  who	  had	  reached	  this	   level	  through	  relapses	  (Figure	  
4.9),	  remained	  stable	  and	  free	  of	  progression	  for	  long	  time,	  or	  never	  entered	  the	  SP	  
phase.	   In	   contrast,	   the	   analysis	   from	   the	   onset	   of	   progression	   included	   only	   SP	  
patients,	  who	  were	  therefore	  at	  higher	  risk	  of	  developing	  severe	  disability.	  	  
	  
4.4.4.1	  Early	  relapses	  and	  the	  progressive	  phase	  
	  
In	  mild	   contrast	  with	   previous	   reports	   (Confavreux	   et	   al.,	   2003;	  Debouverie	   et	   al.,	  
2008;	  Leray	  et	  al.,	  2010),	  among	  the	  LO	  patients,	  the	  evolution	  of	  the	  SP	  phase	  was	  
affected	   by	   early	   relapses.	   A	   larger	   number	   of	   attacks	   during	   the	   first	   two	   years	  
associated	  with	   significantly	   shorter	   times	   from	   the	   onset	   of	   SP	   to	   the	   endpoints.	  
This	  was	  primarily	  driven	  by	  the	  group	  with	   frequent	  early	  relapses	   (≥	  3),	  attaining	  
very	   rapidly	  DSS	  6	   (2.5	  mean	  years)	  and	  DSS	  8	   (9.6	  mean	  years)	   from	  the	  onset	  of	  
progression	  (Table	  4.8).	  The	  size	  of	  the	  predictive	  effect	  exerted	  by	  y1-­‐y2	  attacks	  on	  
the	   probability	   of	   developing	   severe	   disability	   was	   larger	   from	   the	   onset	   of	  
progression	  than	  from	  disease	  onset	  (3	  attacks	  for	  reaching	  DSS	  6	  yielded	  HRs	  2.67	  
and	  1.84,	  respectively)	  (Table	  4.9).	  This	  was	  explained	  by	  the	  selection	  bias,	  as	  only	  
SP	  patients	  were	   included	   in	   the	   analysis	   from	  progression,	   and	   again	   emphasized	  
the	  conversion	   to	  SP	  MS	  as	   the	  key	  determinant	  of	   the	  effect	  of	  early	   relapses	  on	  
late	  outcomes.	  	  
	  
The	  times	  to	  disability	  levels	  from	  DSS	  3	  were	  significantly	  affected	  by	  the	  number	  of	  
early	  relapses,	  however	  the	  differences	  among	  groups	  were	  very	  small	  (Table	  4.8).	  In	  
addition,	  the	  probability	  of	  reaching	  the	  endpoints,	  according	  to	  the	  number	  of	  early	  
attacks,	   was	   much	   lower	   from	   DSS	   3	   than	   from	   the	   onset	   of	   SP	   (3	   attacks	   for	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reaching	   DSS	   6	   yielded	   HRs	   1.39	   from	   DSS	   3	   and	   2.67	   from	   SP)	   (Tables	   4.9).	   The	  
inclusion	  in	  the	  analysis	  of	  those	  patients	  who	  reached	  moderate	  disability	  through	  
relapses	   and	   never	   entered	   progression,	   explains	   why	   the	   disease	   evolution	   from	  
DSS	  3	  was	  only	  modestly	  impacted	  by	  early	  relapses.	  Moreover,	  the	  predictive	  effect	  
of	  y1-­‐y2	  attacks	  from	  DSS	  3	  was	  also	  smaller	  than	  from	  disease	  onset	  (3	  attacks	  for	  
reaching	  DSS	  6	  yielded	  HR	  1.39	  and	  1.84,	  respectively)	  (Table	  4.9).	  This	  importantly	  
confirmed	  that	  early	  relapses	   influenced	  the	  attainment	  of	   late	  outcomes	  primarily	  
by	  shortening	  the	  time	  to	  DSS	  3,	  which	  for	  most	  of	  the	  patients	  implied	  the	  latency	  
to	  progression.	  	  
	  
It	  has	  been	  suggested	  that	  the	  disease	  progresses	  in	  2	  stages,	   independent	  of	  each	  
other,	  and	  separated	  by	  a	  clinical	  watershed	  of	  irreversible	  disability.	  In	  the	  Rennes	  
and	   the	   Lyon	   databases,	   the	   times	   to	   DSS	   3	   (Leray	   et	   al.,	   2010)	   and	   to	   DSS	   4	  
(Confavreux	  et	  al.,	  2003)	  did	  not	  affect	  the	  subsequent	  disease	  evolution	  from	  these	  
disability	  landmarks.	  This	  supported	  the	  notion	  that	  the	  disease	  evolution	  in	  the	  late	  
stages	   is	   amnesic	   to	   the	   previous	   clinical	   history	   (Confavreux	   et	   al.,	   2003).	   In	  mild	  
contrast,	   the	   analysis	   in	   this	   study	   confirmed	   (Weinshenker	   et	   al.,	   1989c)	   that	   a	  
longer	  time	  to	  DSS	  3	  modestly,	  but	  significantly,	  predicted	  a	   lower	  risk	  of	  disability	  
(DSS	  6,	  HR	  =	  0.97,	  p	  <	  0.001;	  DSS	  8	  HR	  =	  0.96,	  p	  <	  0.001)	  (Table	  4.26)	  and	  associated	  
with	   longer	   times	   to	   the	  endpoints	   (Table	  4.25).	   The	  differences	  with	   the	  analyses	  
from	  the	  French	  cohorts	  might	  be	  explained	  by	  the	  different	  percentages	  of	  patients	  
reaching	  the	  endpoints	  (61.8%	  at	  DSS	  3	  and	  48.3%	  at	  DSS	  4	  in	  the	  Lyon	  and	  Rennes	  
databases,	  respectively,	  and	  81.5%	  at	  DSS	  3	  in	  the	  LO	  database),	  which	  affected	  the	  
survival	  estimates.	  Nevertheless,	  this	  study	  supported	  the	  notion	  that	  the	  outcome	  
is	  mainly	  determined	  before	  the	  attainment	  of	  moderate	  disability.	  Past	   this	  point,	  
the	   disease	   progression	   seems	   to	   enter	   a	   common	   final	   pathway,	  which	   is	   largely	  
independent	  of	  the	  previous	  evolution.	  Indeed,	  in	  the	  multivariate	  analysis,	  the	  time	  
to	  DSS	  3,	  probably	  by	  heralding	   the	  progressive	  course,	  accounted	   for	  most	  of	   the	  
predictive	  effect	  of	  early	  relapses,	  which	  remained	  only	  modestly	  significant	  (DSS	  6:	  
HR	   =	   1.08,	   p	   =	   0.04)	   (Table	   4.26).	   On	   the	   contrary,	   the	   impact	   of	   the	   time	   to	  
moderate	   disability	   on	   the	   disease	   progression	   remained	   unchanged	   when	   it	   was	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adjusted	  for	  the	  number	  of	  y1-­‐y2	  attacks	  (Table	  4.26),	  suggesting	  that	  it	   influenced	  
the	  outcome’s	  severity	  independently	  of	  the	  number	  of	  relapses.	  	  
	  
4.4.4.2	  Late	  relapses	  and	  the	  progressive	  phase	  
	  
The	   attacks	   from	   year	   3	   to	   SP	   onset	   had	   no	   impact	   on	   the	   evolution	   of	   the	  
progressive	  phase.	  The	  times	   to	  disability	  endpoints	   from	  DSS	  3	  and	   from	  onset	  of	  
progression	  were	   similar	   among	   patients	   grouped	   by	   the	   number	   of	   late	   relapses	  
(Table	  4.17).	  
	  
4.4.5	  The	  different	  predictive	  effect	  of	  early	  and	  late	  relapses	  	  
	  
The	   analyses	   unexpectedly	   highlighted	   a	   dichotomy,	   among	   SP	   patients,	   between	  
early	   and	   late	   relapses,	   which	   related	   to	   the	   outcomes	   in	   an	   opposite	   way.	   The	  
attacks	  from	  year	  3	  to	  the	  onset	  of	  SP	  seem	  to	  counterbalance	  the	  negative	  impact	  
of	   y1-­‐y2	   relapses	   on	   the	   long-­‐term	   disease	   evolution.	   This	   might	   imply	   a	   yet	  
undetermined	  interaction	  between	  the	  development	  of	  the	  progressive	  course	  and	  
the	  suppression	  of	  clinically	  evident	  attacks,	  possibly	  analogous	  to	  what	  occurs	  in	  PP	  
MS.	   A	   higher	   number	   of	   attacks	   during	   the	   first	   2	   years	   associated	   with	   what	   is	  
destined	  to	  be	  a	  more	  rapid	  clinical	  course.	  Among	  patients	  with	  a	  poor	  prognosis,	  
the	   faster	   attainment	   of	   the	   SP	   phase	   probably	   suppresses	   or	   masks	   attacks	  
occurring	   after	   year	   2,	   explaining	   the	   converse	   relationship	   between	   late	   relapses	  
and	  the	  times	  to	  progression	  and	  to	  disability	  endpoints.	  This	  disconnection	  between	  
the	  relapse	  rate	  and	  the	  disease	  evolution	  seems	  to	  occur	  after	  an	  early	  watershed	  is	  
reached.	  The	  biological	  explanations	  of	  this	  discrepancy	  remain	  unclear,	  but	  analyses	  
suggest	   that	   mechanisms	   driving	   the	   disease	   evolution	   dissociate	   from	   the	   focal	  
inflammatory	   pathology	   early	   in	   the	   disease	   course.	   Early	   and	   late	   relapses	   are	  
difficult	   to	   compare	   because	   of	   methodological	   differences.	   Early	   relapses	   were	  
counted	   in	   the	   fixed	   first	   2	   years	   interval	   and	  were	   collected,	   among	   all	   relapsing	  
onset	   patients.	   On	   the	   contrary,	   late	   relapses	   were	   collected	   during	   the	   variable	  
interval	  from	  year	  3	  to	  the	  onset	  of	  progression,	  among	  SP	  patients	  only.	  Inevitably,	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the	   latency	   to	   SP	   affected	   the	   results	   from	   the	   analyses	   of	   late	   relapses.	   Indeed,	  
when	  patients	  were	   stratified	  by	   the	  duration	  of	   the	  RR	  phase,	   the	   survival	   curves	  
according	  to	  the	  number	  of	  attacks	  after	  year	  2	  were	  similar	  (Figure	  4.19).	  For	  these	  
reasons,	  the	  effect	  of	  late	  relapses	  on	  the	  times	  to	  DSS	  6	  and	  to	  DSS	  8	  was	  assessed	  
in	  small	  subgroups	  of	  serial	  2-­‐years	   intervals	  from	  year	  3	  to	  SP,	  allowing	  to	  make	  a	  
more	  appropriate	  comparison	  with	  early	  relapses.	  In	  each	  subgroup,	  patients	  sharing	  
the	   same	   duration	   of	   the	   y3-­‐SP	   period	   attained	   the	   endpoints	   in	   similar	   times,	  
despite	  the	  different	  number	  of	  late	  attacks	  (Figure	  4.18).	  Notwithstanding	  the	  small	  
samples	  size,	  these	  sub-­‐analyses	  further	  confirmed	  no	  impact	  of	  relapses	  after	  year	  2	  
on	  the	  disease	  evolution.	  	  	  
	  
The	  concomitant	  effect	  of	  early	  and	   late	   relapses	  on	   the	  outcome	  was	  assessed	   in	  
multivariate	   analysis	   (Figure	   4.23).	   The	   model	   confirmed	   that	   the	   two	   variables	  
affected	   the	   disease	   evolution	   in	   an	   opposite	   way.	   The	   probability	   of	   developing	  
severe	  disability	  increased	  proportionally	  with	  the	  number	  of	  attacks	  during	  the	  first	  
2	   years	   and	   inversely	   with	   the	   number	   of	   attacks	   after	   year	   2	   (Figure	   4.23).	   This	  
allowed	  to	  calculate	  the	  risk	  of	  attaining	  DSS	  6	  according	  to	  clinical	  scenarios,	  based	  
on	   specific	   relapses	   numbers.	   For	   instance,	   the	   hazard	   of	   requiring	   a	   walking	   aid,	  
among	   those	   with	   3	   attacks	   during	   the	   fist	   two	   years	   (HR	   =	   2.43),	   decreased	   by	  
approximately	   40%	   (HR	   =	   2.00)	   if	   3	   more	   attacks	   occurred	   during	   the	   year	   3-­‐SP	  
period.	   The	   Kaplan	   Meier	   analysis	   confirmed	   results	   from	   the	   Cox	   regression	  
multivariate	  model	  (Table	  4.22).	  	  
	  
In	  addition,	  the	  model	  further	  emphasized	  year	  2	  as	  the	  watershed	  after	  which	  the	  
predictive	   effect	   of	   relapses	   reversed.	   Two	   hypothetical	   patients,	   experiencing	   3	  
relapses	  before	  entering	  the	  SP	  phase,	  were	  compared.	  The	  hazard	  of	  reaching	  DSS	  6	  
was	  much	  higher	  when	   the	  3	  attacks	  occurred	  during	   the	   first	   2	   years	   (HR	  =	  2.43)	  
rather	   than	   before	   and	   after	   year	   2	   (1	   early	   relapse	   +	   2	   late	   relapses:	  HR	   =	   1.18),	  
highlighting	   the	   relevance	   of	   the	   timing	   of	   relapses	   on	   the	   outcome	   and	   further	  
emphasizing	  the	  influence	  of	  early	  attacks	  on	  late	  outcomes.	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4.4.6	  Frequent	  early	  relapses	  	  
	  
The	   groups	   with	   a	   larger	   number	   of	   early	   attacks	   attained	   SP	   and	   DSS	   levels	   in	  
significantly	  shorter	  times,	  however	  a	  causal	  relationship	  with	  the	  severe	  disability,	  
occurring	  15-­‐20	  years	   later,	   cannot	  be	  assumed.	  The	  possibility	   that	  a	  higher	  early	  
relapse	   frequency	   is	   simply	   a	   concomitant	   to	   a	   predestined,	   more	   rapid	   clinical	  
course	   remains	   open.	   Indeed,	   in	   all	   databases	   analyses,	   the	   association	   between	  
early	  relapses	  and	  late	  outcomes	  was	  mainly	  driven	  by	  the	  subgroup	  with	  very	  high	  
attack	   frequency,	   experiencing	   an	   aggressive	   disease	   course.	   In	   the	   LO	   database	  
those	  patients	  with	  ≥	  3	  early	  relapses	  were	  outliers	  and	  exhibited	  an	  unusually	  fast	  
disability	   accumulation.	   They	   attained	   progression	   in	   9	   median	   years,	   and	   they	  
reached	  DSS	  6	  and	  DSS	  8	  from	  disease	  onset	  in	  10	  and	  21	  median	  years,	  respectively,	  
and	  from	  onset	  of	  SP	  in	  1	  and	  9	  median	  years,	  respectively.	  It	  remains	  unclear	  if	  this	  
exceptionally	   bad	  disease	   course	   can	  be	  merely	   explained	  by	   a	   causal	   relationship	  
between	   the	   frequent	   early	   inflammatory	   attacks	   and	   the	   late	   disability	   or	   other	  
factors	  are	  implicated	  in	  determining	  the	  outcome’s	  severity.	  	  
	  
This	   hypothesis	   drove	   the	   analysis	   of	   the	   frequent	   early	   relapses	   subgroup	   (≥	   3	  
attacks),	  which	  represented	  20%	  (n	  =	  158)	  of	  the	  RR	  onset	  population.	  Although	  the	  
disease	   evolution	   is	   unpredictable	   at	   individual	   level,	   this	   subpopulation	   was	  
expected	   to	   have	   homogeneously	   a	   poor	   prognosis.	   However,	   at	   the	   end	   of	   the	  
observation	  period,	  patients	  sharing	  the	  same	  adverse	  features	  of	  high	  early	  relapses	  
frequency	   were	   distributed	   from	   one	   extreme	   of	   the	   disability	   spectrum	   to	   the	  
opposite.	   During	   the	   first	   9	   years	   from	   onset	   (median	   time	   to	   SP),	   about	   5.5%	   of	  
“frequent	   early	   relapsers”	   every	   year	   had	   become	   progressive,	   and	   the	   subgroup	  
equally	   split	   according	   to	   the	   type	  of	   disease	   course	   (79	   SP	  MS/79	  RR	  MS).	   In	   the	  
following	   15	   years	   an	   additional	   15.2%	   entered	   the	   SP	   phase,	   leaving	   55	   patients	  
(34.8%)	  progression	  free	  (Figure	  4.11).	  Those	  who	  remained	   in	  the	  RR	  phase	  had	  a	  
remarkable	   benign	   disease	   course.	   Less	   than	   half	   (43.6%)	   accumulated	   moderate	  
disability	   (DSS	   3)	   in	   16.2	  mean	   years,	   which	  was	   11	   years	   slower	   than	   those	  who	  
entered	  the	  SP	  phase.	  The	  RR	  subgroup	  was	  observed	  for	  17	  median	  years	  (70%	  for	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longer	   than	  15	   years)	   (Figure	   4.14)	   and	   their	   lack	  of	   progression	   cannot	  be	   simply	  
attributable	   to	   the	   insufficiently	   long	   observation	   time.	   This	   is	   because	   the	  mean	  
duration	  of	   the	  RR	  phase	   in	   the	   total	   SP	  population	  was	   10	   years	   (Chapter	   6)	   and	  
75%	  of	   SP	   “frequent	   early	   relapsers”	  became	  progressive	  by	  9	   years	   (Figure	  4.11).	  
The	  remaining	  103	  (65.2%)	  “frequent	  early	  relapsers”	  rapidly	  attained	  progression	  (5	  
median	  years)	  and	  accumulated	   severe	  disability	   in	   large	  percentages.	  Comparison	  
of	  the	  baseline	  features	  demonstrated	  that	  RR	  and	  SP	  subgroups	  differed	  little	  (Table	  
4.11).	  The	  slightly	  younger	  age	  at	  onset	  (25.5	  versus	  28.4	  mean	  years,	  p	  =	  0.001)	  and	  
the	  larger	  percentages	  of	  females	  (82%	  versus	  63%,	  p	  =	  0.02),	  among	  patients	  who	  
remained	   in	   the	   RR	   phase,	   cannot	   explain	   the	   largely	   different	   final	   outcome	  
between	  the	  two	  subgroups.	  	  
	  
This	  study	  for	  the	  first	  time	  analysed	  the	  long-­‐term	  evolution	  among	  a	  very	  specific	  
subgroup	  of	  patients,	  selected	  for	  the	  adverse	  clinical	  features	  of	  high	  early	  relapses	  
frequencies.	   The	   results	   need	   confirmation	   from	   other	   databases.	   The	   analysis	  
further	  highlighted	   the	  onset	  of	   the	  SP	  phase	  as	   the	  key	  determinant	  of	   long-­‐term	  
prognosis.	   The	   conversion	   to	   SP	   MS	   represented	   the	   clinical	   watershed	  
differentiating	  the	  severity	  of	  the	  disease	  course	  among	  “frequent	  early	  relapsers”,	  
partially	   independently	   of	   inflammatory	   attacks.	   A	   subgroup	   of	   patients	   with	   an	  
exceptionally	  severe	  disease	  course	  was	   identified.	  This	  might	   represent	   the	  target	  
for	  a	  very	  aggressive	  therapeutic	  approach	  early	  in	  the	  disease	  course.	  	  
	  
In	   addition,	   such	   a	   large	   variability	   of	   the	   clinical	   phenotype,	   within	   a	   population	  
sharing	   the	   same	   adverse	   clinical	   features,	   also	   suggests	   that	   individuals	  
susceptibility	   to	   inflammation	   might	   be	   controlled	   by	   other	   independent	   factors,	  
which	   promote	   a	   more	   aggressive	   outcome	   by	   facilitating	   the	   onset	   of	   the	  
progressive	  course.	  The	  axonal	  vulnerability	  or	   its	  resistance	  to	  degeneration	  might	  
be	  genetically	  influenced,	  however	  this	  fascinating	  hypothesis	  needs	  to	  be	  tested	  in	  
other	  suitable	  populations.	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4.4.7	  The	  first	  inter-­‐attack	  interval	  	  	  
	  
Previous	   analyses	  of	   the	   LO	  database	   (Weinshenker	  et	   al.,	   1989c),	   in	   line	  with	   the	  
reports	   from	   the	   Lyon	   and	   the	   Lorraine	   databases	   (Confavreux	   et	   al.,	   2003;	  
Debouverie	   et	   al.,	   2008),	   demonstrated	   an	   association	   between	   short	   first	   inter-­‐
attack	  interval	  and	  worse	  outcome.	  	  
	  
This	   study	   confirmed	   that	   patients	  with	   a	   short	   interval	   between	   the	   first	   and	   the	  
second	   attack	   attained	   SP	   and	   the	   DSS	   levels	   in	   significantly	   shorter	   times	   (Table	  
4.12).	  The	  risk	  of	  entering	  the	  progressive	  phase	  and	  of	  developing	  severe	  disability	  
decreased	  proportionally	  with	  the	  duration	  of	  the	  interval.	  The	  predictive	  effect	  was	  
modest	  but	  significant:	  the	  hazard	  of	  reaching	  SP	  (HR	  =	  0.97),	  DSS	  6	  (HR	  =	  0.95)	  and	  
DSS	  8	  (HR	  =	  0.93)	  decreased	  by	  13%	  (HR	  =	  0.87),	  by	  23%	  (HR	  =	  0.77)	  and	  by	  28%	  (HR	  
=	   0.72),	   among	  patients	   experiencing	   the	   second	   attack	   after	   5	   years,	   respectively	  
(Figure	   4.16).	   This	   effect	   remained	   unchanged	   in	   the	  multivariate	   analysis	  when	   it	  
was	  adjusted	  to	  the	  effect	  of	  early	  relapses.	  However,	  the	  first	   inter-­‐attack	   interval	  
did	   not	   significantly	   impact	   on	   disease	   evolution	   from	   DSS	   3	   and	   only	   marginally	  
affected	  the	  evolution	  of	  the	  SP	  phase	  (Table	  4.13).	  	  
	  
The	   concomitant	   impact	  of	  early	   relapses,	   interval	  between	   the	   first	  2	  attacks	  and	  
late	  relapses	  on	  the	  probability	  of	  attaining	  DSS	  6	  was	  assessed	   in	  the	  multivariate	  
analysis.	   In	  a	  hypothetical	  patient	  experiencing	  2	  relapses	  in	  the	  first	  two	  years	  the	  
risk	   of	   requiring	   a	   walking	   aid	   (HR	   =	   1.42)	   reversed	   if	   the	   second	   exacerbation	  
occurred	  3	  years	  after	  onset	  (2	  years	  first	  inter-­‐attack	  interval	  HR	  =	  0.97)	  (Table	  4.24	  
A).	   In	  addition,	   the	  hazard	   further	  decreased	  with	   the	   longer	   interval	  between	   the	  
first	   two	   attacks.	   The	   model	   highlighted	   the	   timing	   of	   the	   second	   attack	   as	   an	  
important	   determinant	   of	   the	   probability	   of	   developing	   severe	   disability	   and	  
suggested	  that	  the	  predictive	  effect	  of	  the	  first	  inter-­‐attack	  interval	  largely	  depended	  
on	  whether	  or	  not	  a	  second	  relapse	  occurred	  within	  the	  first	  2	  years.	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4.4.8	  Clinical	  presentation	  and	  residual	  deficit	  from	  relapses	  
	  
Previous	   analysis	   of	   the	   LO	   database	   reported	   that	   polysymptomatic	   presentation	  
was	  strongly	  associated	  with	  worse	  prognosis	  in	  PP	  patients	  (Cottrell	  et	  al.,	  1999b).	  
In	   contrast,	   this	   study	   demonstrated	   that,	   among	   RR	   patients,	   the	   number	   of	  
neurological	  systems	  involved	  at	  onset	  did	  not	  influence	  the	  risk	  of	  converting	  to	  SP	  
MS	  (HR	  =	  1.02,	  p	  =	  0.76)	  and	  to	  attain	  disability	  endpoints	  (DSS	  6	  H	  =	  1.03,	  p	  =	  0.58;	  
DSS	   8	   HR	   1.12,	   p	   =	   0.12).	   In	   addition,	   the	   type	   of	   symptoms	   at	   clinical	   onset	  was	  
found	  not	  to	  affect	  the	  disease	  evolution,	  beside	  a	  modest	  predictive	  effect	  exerted	  
by	   the	   brainstem	  presentation	   (Table	   4.21).	   This	   data	   does	   not	   cohere	  with	   other	  
studies,	   showing	   worse	   outcome	   in	   patients	   presenting	   with	   motor	   disturbances	  
(Confavreux	  et	  al.,	  2003;	  Debouverie	  et	  al.,	  2008;	  Eriksson	  et	  al.,	  2003;	  Tremlett	  et	  
al.,	  2006).	  However,	  the	  comparison	  among	  studies	  remains	  difficult	  because	  of	  the	  
different	   criteria	   and	   terminology	   used	  when	   attributing	   the	   symptoms	   to	   specific	  
anatomic	  locations	  (Table	  3.2).	  	  
	  
Previous	   analyses	   from	   the	   other	   cohorts	   consistently	   showed	   that	   an	   incomplete	  
recovery	   from	   the	   onset	   attack	   associated	   with	   a	   faster	   attainment	   of	   disability	  
endpoints	   (Table	   4.1),	   but	   it	   did	   not	   affect	   the	   disease	   evolution	   from	   established	  
disability	  (Confavreux	  et	  al.,	  2003;	  Debouverie	  et	  al.,	  2008;	  Leray	  et	  al.,	  2010).	  One	  of	  
the	  shortcomings	  of	  this	  study	  is	  the	  lack	  of	  data	  on	  the	  residual	  deficit	  from	  the	  first	  
relapse,	  which	  did	  not	  allow	  to	  test	  the	  predictive	  effect	  of	   the	  degree	  of	  recovery	  
from	  the	  onset	  attack,	  among	  the	  LO	  patients.	  More	  importantly,	  the	  evaluation	  of	  
only	   the	   number	   of	   relapses,	   but	   not	   of	   the	   type	   of	   symptoms	   characterizing	   the	  
attacks,	  represents	  the	  biggest	   limitation,	  which	   is	  shared	  by	  all	   the	  natural	  history	  
studies.	  The	  available	  data	  on	  the	  development	  of	  disability	  as	  a	  direct	  consequence	  
of	   an	   inflammatory	   attack	   were	   obtained	   during	   short	   observation	   times,	   from	  
patients	   who	   had	   already	   reached	   EDSS	   2.5-­‐3.5	   (Hirst	   et	   al.,	   2008a;	   Lublin	   et	   al.,	  
2003;	  Young	  et	  al.,	  2006)	  and	  possibly,	  at	   least	   in	  part,	  had	  already	  entered	  the	  SP	  
phase.	   Indeed,	   conclusions	  were	   contradicting.	  A	   residual	   deficit	   (0.5-­‐1	   EDSS	  point	  
worsening)	   from	  exacerbations	  was	   reported	   in	   42%	  of	   224	  patients	   from	  placebo	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groups	  (Lublin	  et	  al.,	  2003)	  and	  in	  49%	  of	  182	  patients	  attending	  an	  MS	  clinic	  (Hirst	  
et	   al.,	   2008a).	   These	   results	   could	   not	   be	   replicated	   by	   a	   separate	   analysis	   of	   576	  
placebo	   patients,	   showing	   no	   consistent	   effect	   of	   relapses	   on	   the	   development	   of	  
sustained	  EDSS	  score	  (Young	  et	  al.,	  2006).	  In	  addition,	  among	  2578	  attacks	  observed	  
in	  a	  MS	  clinic	  over	  15	  years,	  only	  7	  exacerbations	  caused	  the	  attainment	  of	  EDSS	  6	  
sustained	  for	  at	  least	  6	  months	  (Bejaoui	  and	  Rolak,	  2010).	  	  	  
	  
This	  study	  could	  not	  address	  the	  important	  question	  whether	  unremitting	  disability	  
can	  be	  directly	  caused	  by	  inflammatory	  attacks.	  However,	  most	  of	  patients	  in	  the	  LO	  
database	  converted	  to	  SP	  MS	  at	  or	  before	  DSS	  3;	  more	  than	  80%	  within	  DSS	  4	  (Figure	  
4.9).	  This	  indicates	  that,	  in	  most	  of	  the	  patients,	  the	  accumulation	  of	  severe	  disability	  
(requiring	  a	  walking	  cane	  or	  worse)	  did	  not	  occur	  during	   the	  RR	  phase,	  but	  almost	  
invariably	   resulted	   from	   the	   steady	   evolution	   of	   the	   progressive	   phase.	   It	   remains	  
possible	  that,	  among	  some	  patients,	  a	  residual	  deficit	  from	  relapses	  accelerated	  the	  
attainment	   of	   DSS	   3	   and	   therefore	   promoted	   a	   faster	   accumulation	   of	   severe	  
disability.	   However,	   given	   the	   proportional	   relationship	   between	   late	   relapses	   and	  
the	   time	   to	   DSS	   levels,	   this	   appears	   improbable.	   Groups	   with	   high	   late	   relapse	  
frequency	  would	  be	  expected	   to	  experience	  more	   likely	  a	  partial	   recover	   from	  the	  




The	  data	   from	   this	   study	   indicated	   that	   the	   relapse	   frequency	  during	   the	   first	   two	  
years	   is	   a	   good	   predictor	   of	   the	   late	   disability	   accumulation	   and	   influenced	   the	  
outcome	  primarily	  by	  affecting	  the	  probability	  of	  entering	  the	  SP	  phase.	  The	  results	  
suggest	   that	  mechanisms	   responsible	   for	   the	  development	  of	   a	  progressive	   course	  
are	  probably	  already	  active	  during	   the	  early	   stage	  of	   the	  disease,	   representing	   the	  
only	  plausible	  window	  of	  therapeutic	  opportunity.	  The	  number	  of	  early	  attacks	  can	  
be	  potentially	   used	   for	   selecting	  patients	   at	   high	   risk	  of	   a	   fast	   disease	  progression	  
and	   therefore	   needing	   more	   aggressive	   treatments.	   This	   information	   is	   available	  
early	   in	   the	   disease	   course	   and	   therefore	   is	   extremely	   useful	   for	   optimizing	   an	  
aggressive	   therapeutic	   approach.	   In	   addition,	   in	   view	   of	   their	   exceptionally	   severe	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disease	  course,	  patients	  with	   frequent	  early	  attacks	   (≥	  3)	  appear	  a	  good	  candidate	  
for	  an	  induction	  therapy	  with	  strong	  immunosuppression.	  
	  
However,	   the	   analyses	   did	   not	   provide	   any	   evidence	   that	   relapse	   frequency	   after	  
year	  2	  is	  a	  reliable	  indicator	  of	  the	  disease	  evolution	  and	  a	  valid	  surrogate	  marker	  for	  
late	   outcomes.	   There	  was	   no	   indication	   that	   LO	   database	   patients	  with	  more	   late	  
and	  total	  attacks	  accumulated	  disability	  more	  rapidly,	  even	  in	  groups	  with	  very	  high	  
number	  of	  attacks.	  In	  addition,	  the	  proportional	  relationship	  between	  the	  number	  of	  
attacks	   from	  year	  3	  up	  to	   the	  onset	  of	  progression,	  which	  are	  normally	  counted	   in	  
RCTs,	  and	  the	  disease	  evolution	  questions	  the	  validity	  of	  measuring	  the	  treatments	  
efficacy	  by	  using	  relapse	  related	  endpoints.	  It	  remains	  possible	  that,	  among	  patients	  
under	  treatment,	  inflammatory	  attacks	  have	  different	  biological	  meaning	  and	  relate	  
differently	   to	   the	   outcome.	   Models	   predicting	   disability	   based	   exclusively	   on	   the	  
relapses	   number	   cannot	   sufficiently	   explain	   the	   large	   variability	   of	   the	   disease	  
evolution	  among	  patients.	  The	  data	  consistently	   indicated	  that	   the	  onset	  of	   the	  SP	  
phase	   is	   the	   key	  determinant	   of	   the	   long-­‐term	  prognosis	   and	   is	   a	   robust	   outcome	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Chapter	  5	  	  
	  
	  
Age	  and	  the	  long-­‐term	  disability	  
accumulation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




Relapses	  and	   the	  steady	  accumulation	  of	  disability	   (progression)	  can	  present	  alone	  
or	  in	  combination	  and	  define	  the	  MS	  clinical	  phenotypes	  (Lublin	  and	  Reingold,	  1996),	  
however	   their	   interaction	   remains	   uncertain.	   It	   has	   been	   suggested	   that	   common	  
pathophysiological	   mechanisms	   might	   drive	   the	   disease	   evolution	   among	  
progressive	  patients	  (Revesz	  et	  al.,	  1994),	   independent	  of	  the	  occurrence	  of	  clinical	  
inflammatory	   attacks	   (Confavreux	   and	   Vukusic,	   2006a).	   Indeed,	   a	   large	   body	   of	  
evidence,	   from	   natural	   history	   studies,	   indicates	   that	  MS	   subtypes	   share	   a	   similar	  
rate	   of	   disability	   accumulation	   during	   the	   progressive	   phase.	   In	   the	   LO	   database,	  
SAP,	  SP	  and	  PP	  patients	  attained	  disability	  endpoints	  from	  the	  onset	  of	  progression	  
in	   remarkably	   similar	   times	   (Kremenchutzky	  et	   al.,	   2006a).	   In	  addition,	   the	  disease	  
evolution	  from	  established	  disability	  was	  shown	  to	  be	  unaffected	  by	  the	  type	  of	  the	  
initial	  disease	  course.	  In	  the	  EDMUS	  French	  cohorts,	  progressive	  onset	  and	  relapsing	  
onset	  patients	  took	  the	  same	  times	  to	  progress	  from	  DSS	  3	  (Leray	  et	  al.,	  2010)	  and	  
from	  DSS	  4	  (Confavreux	  and	  Vukusic,	  2006a;	  Debouverie	  et	  al.,	  2008)	  to	  higher	  DSS	  
levels.	  This	  was	  also	  observed	  among	  LO	  patients	  (Chapter	  3).	  The	  accumulation	  of	  
disability	   from	  DSS	  3	  differed	   little	  between	   the	  RR/SP	  and	   the	  PP	  group,	  and	  was	  
almost	  equal	  between	  the	  SP	  and	  the	  PP	  group	  (Figures	  3.21	  and	  3.22).	  These	  results	  
lent	  support	  to	  the	  unifying	  concept	  of	  the	  disease	  course	  and	  further	  confirmed	  the	  
amnestic	  nature	  of	  the	  disease	  evolution,	  characterized	  by	  two	  independent	  stages	  
(Confavreux	   and	   Vukusic,	   2006a;	   Leray	   et	   al.,	   2010).	   The	   attainment	   of	  moderate	  
disability	   (DSS	   3/DSS	   4)	   represents	   the	   clinical	   watershed,	   after	   which	   a	   common	  
final	   pathway,	   not	   influenced	   by	   the	   previous	   clinical	   history,	   drives	   the	   disease	  
progression.	  	  
	  
The	  predictive	  effect	  of	  relapses	  was	  shown	  to	  be	  limited	  to	  the	  first	  2	  years	  of	  the	  
disease	  (early	  relapses)	  (Chapter	  4).	  This	  suggested	  that,	  after	  an	  early	  watershed	  is	  
reached,	   a	   disconnection	   occurs	   between	   biological	   mechanisms	   underlying	  
inflammatory	   attacks	   and	   those	   driving	   the	   disease	   evolution.	   The	   progressive,	  
steady	   accumulation	   of	   permanent	   disability	   gradually	   prevails	   and	   possibly	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suppresses	   or	   masks	   relapses.	   However,	   it	   remains	   largely	   unclear	   which	   factors	  
cause	   the	   changes	   in	   this	   complex	   interaction	   between	   inflammation	   and	  
degeneration,	  and	  shifts	  the	  balance	  in	  favour	  of	  the	  latter.	  	  	  
	  
Age	  has	  often	  been	  indicated	  as	  an	  important	  prognostic	  factor	  in	  MS.	  In	  view	  of	  the	  
similar	  outcome	  (Kremenchutzky	  et	  al.,	  2006a)	  and	  of	  the	  strikingly	  similar	  age	  at	  the	  
onset	   of	   progression,	   among	   all	   progressive	   subtypes	   (Table	   3.3)	   (Confavreux	   and	  
Vukusic,	   2006a;	   Koch	   et	   al.,	   2007;	   Tutuncu	   et	   al.,	   2013),	   it	   has	   been	   hypothesized	  
that	  age-­‐related	  neurodegenerative	  mechanisms	  might	  determine	  the	  emergence	  of	  
the	   progressive	   phase	   and	   drive	   its	   evolution	   (Confavreux	   and	   Vukusic,	   2006b;	  
Kremenchutzky	   et	   al.,	   2006a).	   The	   disease	   course	   among	  MS	   subgroups	   could	   be	  
mainly	   a	   function	   of	   the	   different	   ages	   at	   which	   pathological	   process	   become	  
clinically	  evident.	  	  
	  
5.1.1	  Age	  at	  disease	  onset	  and	  disability	  outcomes	  
	  
It	   has	   been	   overwhelmingly	   demonstrated	   that	   an	   older	   age	   at	   disease	   onset	  
associates	  with	  a	  worse	  outcome.	  This	  was	  consistently	  shown	  by	  early	  (Bonduelle,	  
1967;	  Leibowitz	  et	  al.,	  1964;	  McAlpine,	  1961;	  Panelius,	  1969)	  and	  late	  (Confavreux	  et	  
al.,	   1980;	   Confavreux	   et	   al.,	   2003;	   Debouverie	   et	   al.,	   2008;	   Eriksson	   et	   al.,	   2003;	  
Kantarci	  et	  al.,	  1998;	  Koch	  et	  al.,	  2007;	  Leray	  et	  al.,	  2010;	  Myhr	  et	  al.,	  2001;	  Phadke,	  
1990;	   Poser	   et	   al.,	   1982b;	   Riise	   et	   al.,	   1992;	   Tremlett	   et	   al.,	   2006;	   Trojano	   et	   al.,	  
1995;	  Visscher	  et	  al.,	  1984)	  natural	  history	  studies,	  using	  different	  age	  grouping	  and	  
methodologies	   (Table	   5.1).	   Being	   older	   at	   first	   symptoms	  unequivocally	   associated	  
with	  shorter	  times	  from	  disease	  onset	  to	  EDSS/DSS	  levels.	  	  
	  
In	  the	  three	  French	  EDMUS	  cohorts,	  the	  age	  at	  onset	  was	  investigated	  by	  analysing	  
the	   total	   population,	   grouped	   in	   5	   age	   categories.	   An	   older	   age	   at	   first	   symptoms	  
predicted	  shorter	  times	  from	  the	  disease	  onset	  to	  the	  endpoints	  (Confavreux	  et	  al.,	  
2003;	  Debouverie	  et	  al.,	  2008;	  Leray	  et	  al.,	  2010).	  However,	  the	  age	  at	  onset	  did	  not	  
affect	  the	  disease	  evolution	  from	  DSS	  3	  (Leray	  et	  al.,	  2010),	  from	  DSS	  4	  (Confavreux	  
et	  al.,	  2003;	  Debouverie	  et	  al.,	  2008)	  and	  from	  SP	  (Vukusic	  and	  Confavreux,	  2003).	  In	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addition,	   patients	   older	   at	   onset	   were	   significantly	   older	   when	   attaining	   the	   DSS	  
levels	  (Confavreux	  and	  Vukusic,	  2006b;	  Leray	  et	  al.,	  2010),	  highlighting	  the	  complex	  
interaction	  between	  age	  and	  prognosis.	  
	  
Table	  5.1	  The	  association	  between	  age	  at	  onset	  and	  the	  attainment	  of	  disability	  endpoints,	  among	  MS	  




Tremlett	  et	  al.	  reached	  similar	  conclusions	  by	  analysing	  the	  total	  population	  from	  the	  
British	   Columbia	   database,	   stratified	   in	   5	   age	   categories.	   The	   groups	   younger	   at	  
onset	   took	   longer	   times	   to	   EDSS	   6,	   and	   the	   risk	   of	   developing	   disability	   increased	  
proportionally	  with	  the	  age,	  becoming	  double	  (HR	  for	  EDSS	  6	  =	  2.22)	  among	  patients	  
aged	  >	  50.	  However,	  patients	  younger	  at	  onset	  were	  also	  significantly	  younger	  when	  
attaining	   the	   endpoint	   (Tremlett	   et	   al.,	   2006).	   The	   analyses	   from	   the	   Gothenburg	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database	   yielded	   partially	   contradicting	   results.	   Among	   relapsing	   onset	   patients,	  
being	  older	  was	  associated	  with	  significantly	  shorter	  times	  to	  DSS	  6	  (Runmarker	  and	  
Andersen,	  1993)	  but	  did	  not	  affect	  the	  risk	  of	  attaining	  DSS	  7	  (Eriksson	  et	  al.,	  2003).	  
	  
5.1.2	  Age	  at	  disease	  onset	  and	  the	  onset	  of	  the	  progressive	  phase	  	  
	  
The	  effect	  of	  the	  age	  at	  disease	  onset	  on	  the	  risk	  of	  conversion	  to	  SP	  MS	  has	  been	  
extensively	   investigated.	   Two	   separate	   analyses	   from	   the	   British	   Columbia	   group	  
demonstrated	  that	  patients	  older	  at	  first	  symptoms	  attained	  secondary	  progression	  
in	  a	  significantly	  shorter	  time,	  but	  were	  also	  older	  at	  the	  onset	  of	  SP	  MS	  (Koch	  et	  al.,	  
2010;	   Tremlett	   et	   al.,	   2008a).	   The	   risk	   of	   entering	   the	   SP	  phase	   rose	  by	   27.1%	   for	  
every	  5	  years	  increase	  of	  the	  age	  at	  onset	  (HR	  for	  1	  year	  =	  1.05)	  (Koch	  et	  al.,	  2010).	  
Controversially,	  patients	  older	  at	  the	  onset	  of	  the	  RR	  phase	  had	  a	  shorter	  latency	  to	  
progression	  and	  exhibited	  a	  slower	  evolution	  of	  the	  SP	  phase.	  There	  was	  a	  8.8	  mean	  
years	   difference	   for	   reaching	   EDSS	   8	   from	   the	   onset	   of	   progression,	   between	   the	  
group	  aged	  <	  20	  and	  the	  group	  aged	  >	  40	  (Tremlett	  et	  al.,	  2008a).	  The	  authors	  did	  
not	  address	  the	  possible	  explanations	  of	  these	  results,	  which	  are	  largely	  in	  contrast	  
with	   the	   faster	   disability	   accumulation	   from	   the	   disease	   onset	   observed	   among	  
patients	  older	  at	  onset.	  	  
	  
The	  association	  between	  older	  age	  at	  onset	  and	  a	  greater	  risk	  of	  conversion	  to	  SP	  MS	  
was	   confirmed	   in	   the	   Gothenburg	   database	   (Eriksson	   et	   al.,	   2003),	   in	   the	   Lyon	  
database	  (Vukusic	  and	  Confavreux,	  2003)	  and	  in	  a	  small	  dataset	  (n	  =	  249)	  from	  Italy	  
(Trojano	  et	  al.,	  1995).	  In	  addition,	  shorter	  times	  to	  SP,	  in	  groups	  older	  at	  onset,	  were	  
reported	  in	  several	  cohorts,	  from	  Lorraine	  (Debouverie	  et	  al.,	  2008),	  from	  Groningen	  
(n	  =	  228)	   (Koch	  et	  al.,	  2007)	  and	   from	  Salpetriere	   (n	  =	  844)	   (Stankoff	  et	  al.,	  2007).	  
These	   results	   strongly	   indicate	   that,	   by	   growing	   older,	   relapsing	   onset	   patients	  
become	  more	   likely	   to	   experience	   the	   SP	   course.	   Similarly,	   the	   risk	  of	   having	   a	  PP	  
course	  was	  shown	  to	  increase	  proportionally	  with	  the	  age	  at	  the	  disease	  onset	  (OR	  =	  
1.13	  per	  additional	  year	  at	  onset)	  (Stankoff	  et	  al.,	  2007).	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5.1.3	  Age	  at	  onset	  of	  progression	  	  
	  
The	   age	   at	   onset	   of	   progression	   is	   largely	   unaffected	   by	   the	   type	   of	   the	   disease	  
course.	   This	   was	   first	   reported	   more	   than	   40	   years	   ago	   by	   Fog	   et	   al.,	   who	  
demonstrated	  exactly	  the	  same	  age	  (36.3	  years)	  at	  conversion	  to	  SP	  MS	  and	  at	  onset	  
of	   PP	   MS	   (Fog	   and	   Linnemann,	   1970).	   Same	   results	   were	   lately	   yielded	   by	   the	  
analysis	  of	  a	  Dutch	  MS	  cohort	  (n	  =	  342),	  which	  showed	  very	  similar	  age	  at	  the	  onset	  
of	   the	  progressive	  phase	  between	  SP	   (37.5	  mean	  years)	   and	  PP	   (35.7	  mean	  years)	  
patients	  (Minderhoud	  et	  al.,	  1988b).	  More	  recently,	  natural	  history	  studies	  used	  the	  
Kaplan	   Meier	   analysis	   from	   birth	   to	   compare	   the	   age	   at	   onset	   of	   primary	   and	  
secondary	  progressive	  MS.	   This	  was	   reported	   strikingly	   similar	  between	  PP	  and	  SP	  
patients	   from	   the	   Lyon	   database	   (mean	   years:	   SP	   =	   39.5,	   PP	   =	   39.3;	   p	   =	   0.47)	  
(Confavreux	  and	  Vukusic,	  2006a)	  and	  from	  the	  Groningen	  database	  (mean	  years:	  SP	  
=	  39.5,	  PP	  =	  39.1;	  p	  =	  0.95)	  (Koch	  et	  al.,	  2007).	  	  
	  
Interestingly,	   same	   conclusions	  were	   reached	  when	   analysing	   progressive	   patients	  
stratified	  by	   the	  number	  of	   relapses	  before	   the	  onset	  of	  progression.	  The	  analyses	  
from	  the	  LO	  database	  (Table	  5.2)	  (Kremenchutzky	  et	  al.,	  2006a)	  and	  from	  the	  Mayo	  
Clinic	  database	  (Figure	  5.1)	  (Tutuncu	  et	  al.,	  2013)	  demonstrated	  a	  remarkably	  similar	  
age	  at	  the	  onset	  of	  progression	  among	  those	  with	  one	  (SAP	  MS),	  many	  (SP	  MS)	  and	  
no	  (PP	  MS)	  attacks	  before	  the	  progressive	  phase.	  
	  
The	  only	   study	   that	   failed	   to	   replicate	   these	   results	  was	   from	  the	  British	  Columbia	  
database.	  All	  relapsing	  onset	  patients	  at	  risk	  of	  SP	  were	  included	  in	  the	  Kaplan	  Meier	  
analysis.	   The	   median	   age	   at	   the	   onset	   of	   secondary	   progression	   was	   significantly	  
older	   than	   the	  median	   age	   at	   the	   onset	   of	   primary	   progression	   (49.0	   versus	   41.0	  
years;	   p	   <	   0.005)	   (Tremlett	   et	   al.,	   2009b).	   However,	   when	   only	   SP	   patients	   were	  
analysed,	   the	   age	   differences	  with	   the	   PP	   group	   became	   narrower,	   although	   they	  
remained	   statistically	   significant	   (43.1	   versus	   41.0;	   p	   <	   0.005).	   The	   authors	  
commented	  that	   the	  exclusion	   from	  the	  analysis	  of	  patients	  still	  at	   risk	  of	  entering	  
the	  SP	  phase	   represents	  a	  methodological	   caveat,	  which	  explains	  why	   in	   the	  other	  
cohorts	   the	  age	  at	  onset	  of	  primary	  and	   secondary	  progression	  did	  not	  differ.	   It	   is	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worth	  noticing	  that	  a	  separate	  analysis	  from	  the	  British	  Columbia	  database,	  including	  
a	  larger	  sample,	  reported	  a	  different	  estimate	  of	  the	  median	  age	  at	  onset	  of	  SP	  (53.7	  




Table	  5.2	  Mean	  age	  at	  the	  disease	  onset	  and	  at	  the	  onset	  of	  progression,	  among	  progressive	  subtypes	  
in	   the	   LO	   database:	   SP	   (excluding	   SAP),	   SP	   (all),	   SP	   starting	   to	   progress	   at	   DSS	   ≤	   2-­‐3,	   SAP	   and	   PP	  







Figure	   5.1	   Kaplan	  Meier	   analysis	   from	   birth	   to	   the	   disease	   onset	   and	   to	   the	   onset	   of	   progression:	  





















	   303	  
5.1.3.1	  Age	  at	  onset	  of	  progression	  and	  prognosis	  	  
	  
Only	  few	  studies	  have	  investigated	  the	  relationship	  between	  the	  age	  at	  the	  onset	  of	  
progression	   and	   prognosis.	   Among	   patients	   from	   the	   LO	   database	   (Cottrell	   et	   al.,	  
1999b)	  and	  from	  the	  Lorraine	  database	  (Leray	  et	  al.,	  2010),	  the	  evolution	  of	  the	  PP	  
phase	  was	  shown	  to	  be	  unaffected	  by	  the	  age	  at	  its	  onset.	  	  
	  
Two	   separate	   analyses	   from	   the	   British	   Columbia	   database,	   including	   different	  
samples	  (n	  =	  352	  and	  424),	  reported	  significantly	   longer	  times	  to	  EDSS	  6	  among	  PP	  
patients	  aged	  <	  30,	  but	  very	  similar	  outcome	  in	  the	  others	  age	  groups	  (Koch	  et	  al.,	  
2009;	   Tremlett	   et	   al.,	   2005).	   In	   addition,	   the	   age	   at	   the	   onset	   of	   progression	  was	  
found	  to	  affect	  the	  evolution	  of	  the	  SP	  phase.	  Times	  from	  the	  onset	  of	  SP	  to	  EDSS	  8	  
were	  significantly	   longer	  among	  patients	  older	  at	  conversion	  to	  SP	  MS	  (Tremlett	  et	  
al.,	  2008a).	  	  	  
	  
5.1.4	  Current	  age	  
	  
The	   effect	   of	   current	   age	   on	   the	   disability	   accumulation	   has	   been	   extensively	  
investigated	  by	  Trojano	  et	  al.	  (Liguori	  et	  al.,	  2000;	  Trojano	  et	  al.,	  2002).	  Among	  1463	  
patients	   from	   two	   separate	   datasets,	   the	   EDSS	   score	   increased	   significantly	   by	  
growing	  older	  (Liguori	  et	  al.,	  2000)	  (Figure	  5.2	  A),	  even	  when	  patients	  were	  stratified	  
by	  the	  duration	  of	  the	  disease.	  (Figure	  5.2	  B)	  (Trojano	  et	  al.,	  2002).	  	  
	  
Figure	  5.2	  Current	  age	  and	  disability	  accumulation	  among	  1463	  patients	  from	  two	  Italian	  databases.	  
A)	  Mean	  EDSS	  score	   (y-­‐axis)	  among	  current	  age	  groups	   (x-­‐axis)	   (Liguori	  et	  al.,	  2000);	  B)	  Mean	  EDSS	  
score	   (y-­‐axis)	   among	   patients	   stratified	   by	   current	   age	   (dotted	   lines)	   and	   disease	   duration	   (x-­‐axis)	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5.1.5	  Age	  and	  relapses	  
	  
Only	   few	   studies	  have	  examined	   the	   relationship	  between	  age	  and	   the	  number	  of	  
relapses.	   Overall,	   results	   indicate	   that	   the	   relapse	   rate	   reduces	   by	   growing	   older.	  
Tremlett	   et	   al.	   reported	   a	   gradual	   decrease	   of	   the	   attacks	   frequency	   over	   time,	  
proportional	  to	  the	  patients’	  age	  (Figure	  4.2	  B,	  Chapter	  4).	  Similarly,	  in	  the	  database	  
from	  Salpetriere,	  the	  median	  number	  of	  relapses	  before	  the	  onset	  of	  SP	  diminished	  
with	   the	   increasing	  age	  at	  onset	   (Stankoff	  et	  al.,	  2007).	   In	  addition,	   in	  both	   the	  LO	  
and	  in	  the	  Mayo	  Clinic	  databases,	  patients	  with	  many	  attacks	  (SP)	  were	  younger	  at	  
disease	  onset,	  compared	  to	  patients	  with	  only	  one	  attack	  (SAP)	  before	  progression	  
(Kremenchutzky	  et	  al.,	  2006a;	  Tutuncu	  et	  al.,	  2013)	   (Table	  5.2	  and	  Figure	  5.5).	  This	  
further	   demonstrated	   that	   the	   relapses	   frequency	   during	   the	   RR	   phase	   reduces	  
proportionally	  with	  an	  older	  age.	  Interestingly,	  among	  patients	  from	  the	  Mayo	  Clinic	  
database,	  the	  age	  at	  the	  last	  relapse,	  over	  the	  entire	  disease	  course,	  was	  shown	  to	  
be	  unaffected	  by	  the	  type	  of	  the	  disease	  course	  (mean	  years:	  SP	  =	  48.1,	  SAP	  =	  49.6,	  
PP	  =	  47.8;	  p	  >	  0.05)	  (Tutuncu	  et	  al.,	  2013).	  
	  
5.1.6	  Age	  at	  disability	  milestones	  	  
	  
Confavreux	  et	  al.	  offered	  the	  most	  extensive	  analysis	  of	  factors	  affecting	  the	  age	  at	  
the	   attainment	   of	   disability	  milestones	   (DSS	   4,	   6	   and	   7)	   (Confavreux	   and	   Vukusic,	  
2006b).	   For	   the	   total	   population	   of	   1844	   patients,	  median	   age	   at	   DSS	   6	  was	   54.7	  
years	   (95%	   CI	   53.5-­‐55.8).	   Factors	   that	   associated	   with	   a	   younger	   age	   at	   disability	  
levels	   were	  male	   sex	   and	   young	   age	   at	   the	   disease	   onset.	   Interestingly,	   relapsing	  
onset	  and	  progressive	  onset	  patients	  differed	   little	   in	   the	  age	  at	   the	  attainment	  of	  
DSS	   4	   (44.8	   versus	   42.2	  median	   years;	   p	   <	   0.001)	   and	   of	   DSS	   6	   (55.3	   versus	   53.0	  
median	  years;	  p	  =	  0.002).	  In	  addition,	  the	  two	  subgroups	  reached	  DSS	  7	  (62.8	  versus	  
63.1	  median	  years;	  p	  =	  0.24)	  at	  the	  same	  age.	  	  
	  
The	   analysis	   from	   the	   Rennes’	   database	   confirmed	   that	   the	   age	   at	   disability	  
milestones	  was	  not	  affected	  by	  the	  type	  of	  the	  disease	  course.	  The	  median	  ages	  at	  
DSS	  3	  were	  41.9	  and	  42.4	  years	  (p	  =	  0.23),	  and	  at	  DSS	  6	  were	  52.1	  and	  51.1	  years	  (p	  =	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0.91)	  between	  progressive	  onset	  and	  relapsing	  onset	  patients,	  respectively	  (Leray	  et	  
al.,	   2010).	   In	   addition,	   men	   attained	   DSS	   levels	   at	   significant	   younger	   age	   than	  
women,	  in	  both	  disease	  phenotype	  subgroups	  (Leray	  et	  al.,	  2010).	  	  
	  
Factors	   affecting	   the	   age	   at	   EDSS	   6	   were	   also	   assessed	   among	   patients	   from	   the	  
British	   Columbia	   database.	   The	   analysis	   confirmed	   a	   slightly	   younger	   age	   among	  
men,	   compared	   to	  women,	  when	   reaching	   severe	   disability.	   In	   addition,	   relapsing	  
onset	   patients	   were	   significantly	   (p	   <	   0.005)	   older	   (61.4	   mean	   years)	   at	   EDSS	   6,	  
compared	  to	  progressive	  onset	  patients	  (57.3	  mean	  years)	  (Tremlett	  et	  al.,	  2006).	  	  	  	  
	  
5.1.7	  Aim	  of	  the	  study	  presented	  in	  this	  chapter	  
	  
The	  overall	  aim	  of	  this	  study	  was	  to	  assess	  the	  effect	  of	  age	  on	  the	  disease	  evolution	  
before	  and	  after	  the	  onset	  of	  the	  progressive	  phase.	  This	  allowed	  to	  investigate	  the	  
contribution	  of	   age	   related	   factors	   to	   the	   accumulation	  of	   severe	   disability	   and	   to	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5.2	  Methods	  
	  
The	  analyses	  were	  carried	  out	  in	  the	  total	  population,	   in	  the	  relapsing	  onset	  and	  in	  
the	  progressive	  onset	   groups,	   and	   in	   all	   progressive	  patients	   pooled	   together.	   The	  
relationships	  between	  the	  disability	  accumulation	  and	  1)	  the	  age	  at	  disease	  onset,	  2)	  
the	   age	   at	   onset	   of	   progression	   and	   3)	   current	   age	   were	   investigated.	   Variables	  
were	   assessed	   both	   as	   categorical	   (Table	   5.3)	   and	   as	   continuous.	   Groups	   were	  
computed	   in	   order	   to	   maintain,	   to	   the	   possible	   extent,	   similar	   numbers	   in	   each	  
category.	  However,	  the	  analyses	  were	  also	  carried	  out	  among	  patients	  with	  different	  
stratifications,	  for	  confirming	  results.	  
	  
The	  binary	  logistic	  regression	  analysis	  was	  used	  to	  assess	  1)	  the	  risk	  of	  experiencing	  a	  
PP	   course	   according	   to	   the	   increasing	   age	   at	   onset;	   2)	   the	   risk	   of	   entering	   the	   SP	  
phase	  and	  of	   attaining	  DSS	   levels,	   according	   to	   the	   increasing	  age	  at	  onset,	   to	   the	  
increasing	  current	  age	   (“growing	  older”)	  and	   to	   the	   increasing	  disease	  duration;	  3)	  
the	   risk	   of	   attaining	   DSS	   levels,	   according	   to	   the	   increasing	   age	   at	   onset	   of	  
progression.	  The	  Kaplan	  Meier	  analysis	  was	  used	  for	  estimating,	  among	  age	  groups,	  
the	   time	   from	  birth	   to	   the	  onset	  of	   the	  disease,	   the	   times	   to	  conversion	   to	  SP	  MS	  
from	  the	  disease	  onset	  and	  from	  birth	  (age	  at),	  and	  the	  times	  to	  DSS	  6-­‐8	  from	  birth	  
(age	  at),	  from	  the	  disease	  onset,	  from	  DSS	  3	  and	  from	  the	  onset	  of	  progression.	  The	  
Log	  Rank	  test	  investigated	  the	  differences	  among	  groups.	  When	  testing	  the	  effect	  of	  
age	  at	  onset	  of	  SP	  on	  the	  attainment	  of	  disability	  outcomes	  from	  the	  disease	  onset,	  
to	   eliminate	   bias	   from	   immortal	   time	   (Suissa,	   2008),	   SP	   patients	   attaining	   the	  
endpoints	   before	   entering	   the	   progressive	   phase	   (DSS	   6	   =	   16,	   DSS	   8	   =	   0)	   were	  
excluded	  from	  the	  analysis.	  The	  Cox	  regression	  multiple	  analysis	  was	  used	  to	  assess	  
the	   risk	   of	   attaining	   the	   endpoints	   among	   age	   categories,	   to	   investigate	   the	  
concomitant	  effect	  of	  the	  age	  and	  of	  the	  number	  of	  relapses	  on	  the	  outcomes,	  and	  
for	   validating	   results	   from	   binary	   logistic	   regression	   analysis.	   Spearman	   rank	  








Table	  5.3	  Stratification	  by	  the	  age	  at	  the	  disease	  onset	  and	  by	  the	  age	  at	  the	  onset	  of	  progression	  in	  
the	   total	   population	   (n	   =	   1023),	   the	   RR/SP	   group	   (n	   =	   806),	   the	   PP	   group	   (n	   =	   217)	   and	   the	   PP/SP	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5.3.1	  The	  age	  at	  the	  disease	  onset	  
	  
Information	  on	  the	  age	  at	  disease	  onset	  was	  available	  for	  all	  but	  6	  patients	  (5	  SP	  and	  
1	  PP	  MS)	   (Table	  5.3).	   In	   the	  total	  population,	   the	  binary	   logistic	   regression	  analysis	  
was	  used	   to	  calculate	   the	  probability	  of	  experiencing	   the	  PP	  course,	  among	  age	  at	  
onset	   categories.	   The	   relative	   risk	   (OR)	   increased	  proportionally	  with	   the	   age	   and,	  
compared	  to	  patients	  aged	  <	  20,	  was	  1.4	  (p	  =	  0.34)	  for	  the	  group	  aged	  20-­‐30,	  4.9	  (p	  <	  
0.001)	  for	  the	  group	  aged	  31-­‐40,	  16.5	  for	  the	  group	  aged	  41-­‐50	  (p	  <	  0.001)	  and	  25.0	  
(p	  <	  0.001)	  for	  the	  group	  aged	  >	  50	  (Figure	  5.3	  A).	  By	  assessing	  the	  effect	  of	  the	  age	  
at	   onset	   as	   continuous	   variable,	   the	   risk	   of	   experiencing	   the	   PP	   course	   at	   specific	  
ages	  was	  also	  calculated	  (regression	  coefficient	  0.103,	  OR	  =	  1.10	  per	  additional	  year	  
at	  onset;	  p	  <	  0.001)	  (Figure	  5.3	  B).	  In	  both	  analyses,	  the	  probability	  of	  having	  PP	  MS	  
increased	   dramatically	   past	   the	   age	   of	   40	   (Figure	   5.3	   A	   and	   B).	   This	   reflected	   the	  
large	   percentage	   (65%)	   of	   PP	   cases	   between	   the	   ages	   30	   and	   50	   at	   onset	   (Figure	  
3.11,	  Chapter	  3).	  	  	  
	  
Figure	  5.3	  Binary	  logistic	  regression	  analysis	  in	  the	  total	  population:	  relative	  risk	  of	  experiencing	  the	  
PP	  course	  according	  to	  the	  age	  at	  disease	  onset.	  A)	  Risk	  (OR)	  of	  PP	  (y-­‐axis)	   in	  different	  age	  at	  onset	  
groups	   (x-­‐axis),	   compared	   to	   the	   group	   aged	   <	   20;	   B)	   Risk	   (OR)	   of	   PP	   (y-­‐axis)	   according	   to	   the	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The	  total	  population	  was	  stratified	  in	  5	  age	  categories	  (Table	  5.3),	  in	  order	  to	  assess	  
the	  relationship	  between	  the	  age	  at	   the	  disease	  onset	  and	   late	  outcomes.	  Patients	  
older	   attained	  DSS	   levels	   from	  onset	   in	   significantly	   shorter	   times,	   and	   the	   risk	   of	  
accumulating	  disability	   increased	  proportionally	  with	   the	  age	   (Table	  5.4	  and	  Figure	  
5.4).	   The	  disease	  progressed	  at	   remarkably	  different	   rates,	   among	  age	  groups;	   the	  
youngest	  (<	  20)	  patients	  attained	  DSS	  6,	  14	  years	  later	  than	  the	  oldest	  (>	  50)	  (Table	  
5.4).	   By	   15	   and	   18	   years	   from	   onset,	   50%	   of	   patients	   aged	   <	   20	   had	   reached	  
moderate	   disability	   and	   50%	   of	   patients	   aged	   >	   50	   had	   become	   bedbound,	  
respectively	  (Figure	  5.4).	  	  
	  
Among	   the	   age	   at	   onset	   categories,	   the	   distribution	   of	   the	   clinical	   phenotypes	  
varied;	  most	  of	  RR/SP	  patients	  had	  the	  clinical	  onset	  between	  the	  age	  <	  20	  and	  40	  
and	   most	   of	   PP	   patients	   between	   the	   age	   30	   and	   >	   50	   (Figure	   3.11,	   Chapter	   3).	  
Therefore,	   in	   the	   total	   population,	   the	   different	   outcomes,	   among	   age	   groups,	  
mainly	   reflected	   the	   different	   rate	   of	   the	   disability	   accumulation	   between	   the	  
relapsing	  onset	  and	  the	  progressive	  onset	  group.	   In	  addition,	  the	  disease	  evolution	  
from	   DSS	   3	   was	   not	   significantly	   influenced	   by	   the	   age	   at	   onset.	   Times	   from	  
moderate	  disability	  to	  DSS	  6	  and	  to	  DSS	  8	  were	  remarkably	  similar,	  among	  patients	  
stratified	  by	  the	  age	  at	  clinical	  onset	  (Table	  5.5).	  	  
	  
Table	  5.4	  Kaplan	  Meier	  analysis	  in	  the	  total	  population:	  times	  from	  onset	  to	  DSS	  6	  and	  DSS	  8	  among	  
patients	  stratified	  by	  the	  age	  at	  the	  disease	  onset.	  Cox	  regression	  analysis:	  risk	  (HR)	  of	  attaining	  the	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Table	   5.5	   Kaplan	  Meier	   analysis	   in	   the	   total	   population:	   times	   from	  DSS	   3	   to	   DSS	   6	   and	   to	   DSS	   8,	  
among	   patients	   stratified	   by	   the	   age	   at	   the	   disease	   onset.	   Cox	   regression	   analysis:	   risk	   (HR)	   of	  







Figure	  5.4	  Kaplan	  Meier	  analysis	  in	  the	  total	  population:	  median	  times	  from	  the	  disease	  onset	  to	  DSS	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5.3.1.1	  The	  age	  at	  the	  onset	  of	  the	  RR	  phase	  
	  
The	  association	  between	  an	  older	  age	  at	  onset	  and	  worse	  outcome	  was	  confirmed	  
among	   relapsing	   onset	   patients.	  Groups	   older	   at	   the	   onset	   of	   the	  RR	  phase	   had	   a	  
significantly	  higher	  risk	  of	  attaining	  DSS	  6	  (OR	  per	  additional	  year	  at	  onset	  =	  1.04,	  p	  <	  
0.001)	  and	  DSS	  8	  (OR	  per	  additional	  year	  at	  onset	  =	  1.02,	  p	  =	  0.02),	  and	  a	  significantly	  
higher	  risk	  of	  converting	  to	  SP	  MS	  (OR	  per	  additional	  year	  at	  onset	  =	  1.04,	  p	  <	  0.001).	  
Onset	   at	   age	   40	   (OR	   =	   4.22)	   and	   at	   age	   50	   (OR	   =	   6.04)	   respectively	   doubled	   and	  
tripled	  the	  probability	  of	  entering	  the	  SP	  phase,	  compared	  to	  onset	  at	  age	  20	  (OR	  =	  
2.05)	  (Figure	  5.5).	  	  
	  
When	  grouped,	  RR	  patients	  older	  at	  the	  first	  relapse	  took	  significantly	  shorter	  times	  
to	   accumulate	   severe	   disability	   from	   the	   disease	   onset,	   secondary	   to	   the	   shorter	  
latency	  to	  SP	  MS	  (Tables	  5.6	  and	  5.6).	  Patients	  aged	  >	  30,	  compared	  to	  patients	  aged	  
≤	  20,	  entered	  the	  SP	  phase	  12	  median	  years	  earlier	  (Table	  5.6),	  and	  attained	  DSS	  6	  
and	  DSS	  8	  more	  rapidly	  (11	  and	  9	  median	  years	  difference,	  respectively)	  (Table	  5.7).	  
This	  effect	  was	   limited	  to	  the	  evolution	  of	   the	  RR	  phase	  and	  disappeared	  once	  the	  
progressive	   phase	   supervened.	   Times	   to	   disability	   endpoints	   from	   the	   onset	   of	  
progression	  and	  from	  DSS	  3	  were	  remarkably	  similar,	  among	  age	  groups	  (Table	  5.8).	  
This	   demonstrated	   that	   the	   disability	   accumulation	   during	   the	   SP	   phase	   was	  
unaffected	  by	  the	  age	  at	  the	  onset	  of	  the	  RR	  phase.	  An	  older	  age	  at	  onset	  influenced	  
adversely	  the	  outcome	  by	  increasing	  the	  probability	  of	  entering	  the	  SP	  phase	  (Figure	  
5.5)	  and	  by	  shortening	  the	  latency	  to	  progression	  (Figure	  5.6).	  Indeed,	  when	  patients	  
were	  stratified	  by	  the	  duration	  of	  the	  RR	  phase	  (short	  =	  1-­‐5	  years;	  intermediate	  =	  6-­‐
12	   years;	   long	   ≥	   13	   years),	   in	   each	   group,	   times	   to	  DSS	  6	  were	   similar	   among	   age	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Figure	  5.5	  Binary	  logistic	  regression	  analysis	  in	  relapsing	  onset	  patients:	  risk	  (OR)	  of	  converting	  to	  SP	  




Table	   5.6	   Kaplan	   Meier	   analysis	   in	   relapsing	   onset	   patients:	   times	   to	   SP	   from	   the	   disease	   onset,	  
among	  patients	   stratified	  by	   the	  age	  at	  onset	  of	   the	  RR	  phase.	  Cox	   regression	  analysis:	   risk	   (HR)	  of	  




Table	  5.7	  Kaplan	  Meier	  analysis	  in	  relapsing	  onset	  patients:	  times	  from	  the	  disease	  onset	  to	  DSS	  6	  and	  
to	  DSS	   8,	   among	   age	   at	   onset	   groups.	   Cox	   regression	   analysis:	   risk	   (HR)	   of	   attaining	   the	   endpoints	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Table	  5.8	  Kaplan	  Meier	  analysis	  in	  relapsing	  onset	  patients:	  times	  from	  DSS	  3	  and	  from	  the	  onset	  of	  
SP	  to	  DSS	  6	  and	  to	  DSS	  8,	  among	  age	  at	  onset	  groups.	  Cox	  regression	  analysis:	  risk	  (HR)	  of	  attaining	  







Figure	  5.6	  Kaplan	  Meier	  analysis	  in	  RR	  patients	  stratified	  by	  the	  age	  at	  disease	  onset:	  comparison	  of	  
times	  from	  the	  disease	  onset	  to	  the	  onset	  of	  SP,	  and	  of	  times	  from	  the	  onset	  of	  SP	  to	  DSS	  6	  and	  to	  DSS	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Figure	  5.7	  Kaplan	  Meier	  analysis	  in	  relapsing	  onset	  patients	  stratified	  by	  the	  duration	  of	  the	  RR	  phase	  
(A:	   1-­‐5	   years;	  B:	   6-­‐12	   years;	  C:	   ≥	   13	   years):	   comparison	   of	   times	   from	   the	   disease	   onset	   to	  DSS	   6,	  
among	  patients	  grouped	  by	   the	  age	  at	  disease	  onset.	  Cox	   regression	  analysis:	   risk	   (HR)	  of	  attaining	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5.3.1.2	  Multiple	  analysis	  
	  
The	  rate	  of	  conversion	  to	  SP	  MS	  is	  known	  to	  increase	  proportionally	  with	  the	  disease	  
duration	   (Weinshenker	   et	   al.,	   1989b).	   The	   binary	   logistic	   regression	   analysis	  
confirmed	  that	  the	  probability	  of	  entering	  the	  SP	  phase	  became	  higher	  with	  a	  longer	  
time	  from	  the	  disease	  onset	  	  (OR	  =	  1.07	  per	  additional	  year	  of	  disease	  duration,	  p	  <	  
0.001).	  Importantly,	  in	  the	  multivariate	  analysis,	  the	  effect	  of	  the	  age	  at	  onset	  of	  the	  
RR	  phase	  on	  the	  risk	  of	  conversion	  to	  SP	  MS	  remained	  unchanged	  (OR	  =	  1.04)	  when	  
adjusted	   to	   the	   duration	   of	   the	   disease	   (OR	   =	   1.07).	   This	   indicated	   that	   the	   two	  
variables	   impacted	   on	   the	   probability	   of	   SP	   independently.	   In	   addition,	   the	   Cox	  
regression	  multivariate	   analysis	   was	   used	   to	   assess	   the	   concomitant	   effect	   of	   the	  
number	  of	  early	  relapses	  and	  the	  age	  at	  onset	  on	  the	  risk	  of	  attaining	  SP,	  DSS	  6	  and	  
DSS	  8.	  The	  impact	  of	  the	  two	  variables	  on	  the	  outcomes	  did	  not	  substantially	  change	  
between	   the	   univariate	   and	   the	   multivariate	   model,	   demonstrating	   that	   their	  





Table	  5.9	  Cox	  Regression	  univariate	  and	  multivariate	  analyses	  in	  relapsing	  onset	  patients:	  risk	  (HR)	  of	  
attaining	  SP,	  DSS	  6	  and	  DSS	  8	  according	  to	  the	  age	  at	  the	  disease	  onset	  and	  to	  the	  number	  of	  relapses	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5.3.1.3	  The	  age	  at	  onset	  and	  the	  relapse	  frequency	  	  
	  
The	   Spearman’s	   test	   was	   used	   to	   assess	   the	   correlation	   between	   the	   number	   of	  
relapses	  and	  the	  age	  at	  onset.	  The	  analysis	  demonstrated	  that	  the	  frequency	  of	  early	  
relapses	   was	   not	   affected	   by	   the	   age	   at	   the	   first	   symptom	   (r	   =	   -­‐0.05;	   p	   =	   0.13).	  
However,	   being	   older	   at	   the	   disease	   onset	   correlated	   with	   a	   significantly	   lower	  
number	  of	  late	  (r	  =	  -­‐0.26;	  p	  <	  0.001)	  and	  total	  relapses	  (r	  =	  -­‐0.24;	  p	  <	  0.001)	  (Figure	  
5.8).	   The	   longitudinal	   analysis	   confirmed	   that,	   among	   age	   at	   onset	   groups,	   the	  
frequency	  of	  total	  attacks	  during	  the	  RR	  phase	  peaked	  at	  20-­‐30	  years	  and	  gradually	  
decreased	  with	   older	   age	   (Figure	   5.9).	   Similarly,	   the	  mean	   age	   at	   onset	   of	   the	   RR	  
phase	   increased	  conversely	  with	   the	  number	  of	   total	   relapses.	  Patients	  with	  a	   low	  
attack	   frequency	   had	   the	   clinical	   onset	   at	   older	   age,	   compared	   to	   patients	  with	   a	  
high	  attack	  frequency	  (Figure	  5.10).	  	  
	  
The	  Kaplan	  Meier	  analysis	  from	  birth	  was	  used	  to	  estimate	  the	  influence	  of	  the	  total	  
number	  of	  relapses	  during	  the	  RR	  phase	  on	  the	  age	  at	  the	  disease	  onset	  and	  at	  the	  
onset	  of	  progression.	  The	  survival	  curves	  among	  patients	  with	  1	  (SAP)	  2-­‐3	  and	  4	  or	  
more	  attacks	  were	  compared.	  The	  SAP	  group	  had	  disease	  onset	  at	  significantly	  older	  
age	  (33	  median	  years),	  compared	  to	  SP	  groups	  with	  2-­‐3	  (30	  median	  years)	  and	  ≥	  4	  
(27	  median	  years)	  total	  attacks.	  However,	  the	  age	  at	  the	  onset	  of	  progression	  varied	  
by	  only	  2	  mean	  years	  among	  the	  three	  groups	  and	  was	  not	  significantly	  affected	  by	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Figure	  5.8	  Distribution	  of	  the	  number	  of	  late	  and	  total	  relapses	  according	  to	  the	  age	  at	  the	  onset	  of	  








Figure	  5.9	  Number	  of	  total	  relapses	  during	  the	  RR	  phase	  (y-­‐axis),	  among	  age	  at	  onset	  groups	  (x-­‐axis);	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Figure	  5.10	  Mean	  age	  (95%	  C.I.)	  at	  the	  onset	  of	  the	  RR	  phase	  (y-­‐axis),	  among	  patients	  grouped	  by	  the	  




Figure	   5.11	  Kaplan	  Meier	  analysis	   from	  birth	   to	   the	  disease	  onset	  and	   to	   the	  onset	  of	  progression:	  
comparison	  of	  the	  age	  at	  the	  disease	  onset	  and	  at	  the	  onset	  of	  progression,	  among	  SP	  patients	  with	  1,	  
2-­‐3,	   ≥	   4	   total	   attacks	   during	   the	   RR	   phase.	   HR	   and	   p	   values	   were	   obtained	   with	   Cox	   regression	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5.3.2	  The	  age	  at	  the	  onset	  of	  progression	  	  
	  
5.3.2.1	  The	  age	  at	  the	  onset	  of	  progression	  and	  the	  clinical	  phenotype	  	  
	  
	  
Among	  751	  progressive	  patients,	  information	  on	  the	  age	  at	  onset	  of	  progression	  was	  
not	   available	   for	   26	   cases	   (25	   SP	   and	   1	   PP	   MS)	   (Table	   5.3).	   The	   age	   at	   which	  
progression	   started	   largely	   varied,	   from	   14	   to	   83	   years	   (median	   age	   =	   39):	   the	  
youngest	   25%	   became	   progressive	   by	   33	   years	   and	   the	   oldest	   25%	   after	   47	   year	  
(Figure	  5.12).	  The	  Kaplan	  Meier	  analysis	  was	  used	  to	  compare	  the	  time	  from	  birth	  to	  
the	  disease	  onset	  and	  to	  the	  onset	  of	  progression	  between	  patients	  experiencing	  a	  
progressive	  course,	  preceded	   (SP	  MS	  =	  534)	  or	  not	   (PP	  MS	  =	  217)	  by	   the	  relapsing	  
remitting	  phase.	  The	  SP	  group	  had	  disease	  onset	  12	  median	  years	  earlier	  than	  the	  PP	  
group,	   however	   the	   progressive	   phase	   started	   at	   almost	   the	   same	   age	   in	   both	  
subpopulations	  (40	  versus	  39	  median	  years,	  respectively;	  p	  =	  0.09)	  (Figure	  5.13).	  	  
	  
The	   time	   from	   birth	   to	   the	   onset	   of	   progression	   was	   also	   compared	   among	   PP	  
patients	   and	   SP	   patients	   stratified	   by	   the	   total	   number	   of	   relapses	   during	   the	   RR	  
phase	  (1;	  2-­‐3;	  ≥	  4)	  and	  by	  the	  number	  of	  early	  relapses	  (1;	  2;	  ≥	  3).	  Groups	  with	  a	  high	  
total	  attacks	  frequency	  were	  significantly	  younger	  at	  the	  disease	  onset,	  however	  the	  
SP	  subtypes	  and	  the	  PP	  group	  started	  to	  progress	  at	  similar	  median	  ages	  (SAP	  =	  41	  
years,	  SP	  2-­‐3	  relapses	  =	  42	  years,	  SP	  ≥	  4	  =	  38	  years,	  PP	  =	  40	  years)	  (Figure	  5.14).	  In	  
contrast,	  SP	  patients	  with	  different	  number	  of	  early	  relapses	  had	  similar	  age	  at	  the	  
disease	  onset	  and,	  compared	  to	  PP	  patients,	  had	  almost	  the	  same	  age	  at	  the	  onset	  
of	  the	  progressive	  phase	  (Figure	  5.15).	  Again,	  the	  group	  with	  frequent	  early	  attacks	  	  
(≥	   3)	   diverged	   from	   the	   other	   SP	   patients	   and	   attained	   the	   progressive	   phase	   at	  
significantly	   younger	   age	   (35	  median	   years)	   (Figure	   5.15),	   secondary	   to	   the	   faster	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Figure	   5.12	  Percentages	   (y-­‐axis)	  of	  progressive	  patients	   (PP	  +	  SP)	  entering	   the	  progressive	  phase	  at	  
different	  ages	   (x-­‐axis):	  percentages	  are	  calculated	  within	  each	  age	  group,	   independently	   (10-­‐20;	  21-­‐
30;	  31-­‐40;	  41-­‐50;	  51-­‐60;	  61-­‐70;	  71-­‐80).	  Percentiles	  of	  the	  time	  from	  birth	  to	  the	  onset	  of	  progression	  




Figure	  5.13	  Kaplan	  Meier	  analysis	  in	  progressive	  patients	  (PP	  +	  SP):	  comparison	  of	  times	  from	  birth	  to	  
the	  disease	  onset	  (age	  at	  disease	  onset)	  and	  to	  the	  onset	  of	  progression	  (age	  at	  onset	  of	  progression),	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Figure	  5.14	  Kaplan	  Meier	  analysis	  in	  progressive	  patients	  (PP	  +	  SP):	  comparison	  of	  times	  from	  birth	  to	  
the	  disease	  onset	  (age	  at	  disease	  onset)	  and	  to	  the	  onset	  of	  progression	  (age	  at	  onset	  of	  progression)	  
between	   PP	   and	   SP	   MS	   (1;	   2-­‐3;	   ≥	   4	   total	   attacks).	   HR	   obtained	   with	   Cox	   regression	   analysis	   by	  




Figure	  5.15	  Kaplan	  Meier	  analysis	  in	  progressive	  patients	  (PP	  +	  SP):	  comparison	  of	  times	  from	  birth	  to	  
the	  disease	  onset	  (age	  at	  disease	  onset)	  and	  to	  the	  onset	  of	  progression	  (age	  at	  onset	  of	  progression)	  
between	   PP	   and	   SP	   MS	   (1;	   2;	   ≥	   3	   early	   attacks).	   HR	   obtained	   with	   Cox	   regression	   analysis	   by	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In	  order	  to	  estimate	  the	  probability	  of	  experiencing	  the	  SP	  course	  according	  to	  age,	  
the	   time	   from	   birth	   to	   the	   onset	   of	   the	   SP	   phase	   was	   also	   calculated	   among	   all	  
relapsing	  onset	  patients	  (n	  =	  806);	  37	  patients	  (4.5%	  or	  relapsing	  onset	  population)	  
were	   excluded	   from	   the	   analysis	   because	   of	  missing	   information	   on	   the	   age	   at	   SP	  
onset	  or	  on	  the	  duration	  of	  the	  disease.	  Among	  the	  remaining	  769	  patients,	  by	  the	  
end	   of	   the	   observation	   period,	   509	   (66.2%)	   converted	   to	   SP	  MS	   and	   260	   (33.8%)	  
remained	   free	   of	   progression.	   The	   inclusion	   of	   censored	   information	   (patients	   not	  
attaining	  the	  endpoint)	   in	  the	  analysis	  extended	  by	  8	  mean	  years	  the	  Kaplan	  Meier	  
estimated	  age	  at	   conversion	   to	   SP	  MS	   (mean	  age	  =	  48.3	   years	   [95%	  CI	   46.8-­‐49.8];	  
median	  age	  =	  45	  years)	  (Figure	  5.16).	  By	  the	  age	  of	  35,	  20%	  (n	  =	  161)	  of	  patients	  had	  
attained	  the	  SP	  phase;	  this	  percentage	  increased	  to	  46%	  (n	  =	  354),	  to	  62%	  (n	  =	  477)	  
and	  to	  65%	  (n	  =	  506)	  by	  the	  age	  of	  45,	  55	  and	  75	  years,	  respectively	   (Figure	  5.17).	  
Among	  those	  who	  did	  not	  enter	  the	  progressive	  phase	  (n	  =	  260),	  the	  mean	  disease	  
duration	  was	  20.2	  (95%	  CI	  19.1-­‐21.3)	  years	  and	  the	  mean	  age	  at	  last	  assessment	  was	  
47.0	  (95%	  CI	  45.6-­‐48.5)	  years.	  	  
	  	  
Figure	   5.16	   Kaplan	   Meier	   analysis	   from	   birth	   to	   the	   onset	   of	   progression	   among	   relapsing	   onset	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Figure	  5.17	  Cumulative	  percentage	  (y-­‐axis)	  of	  patients	  converting	  to	  SP	  MS	  according	  to	  age	  (x-­‐axis):	  
data	   were	   taken	   from	   the	   Kaplan	   Meier	   analysis	   from	   birth	   to	   the	   onset	   of	   progression,	   among	  






5.3.2.2	  The	  age	  at	  the	  onset	  of	  progression	  and	  late	  outcomes	  
	  
Information	  on	  the	  age	  at	  the	  onset	  of	  SP	  was	  known	  for	  509	  patients	  (95.3%	  of	  the	  
SP	  population)	  (Table	  5.3).	  The	  age	  at	  conversion	  to	  SP	  MS	  largely	  varied	  from	  18	  to	  
83	  years	  (median	  age	  =	  39);	  the	  youngest	  25%	  became	  progressive	  by	  33	  years	  (25	  
percentiles)	  and	  the	  oldest	  after	  47	  year	  (75	  percentiles).	  	  	  
	  
The	   age	   at	   the	   onset	   of	   secondary	   progression	   correlated	   inversely	   with	   the	  
probability	   of	   developing	   severe	   disability.	   The	   negative	   regression	   coefficient	  
yielded	  by	  the	  logistic	  regression	  analysis	  indicates	  that	  being	  older	  at	  conversion	  to	  
SP	  MS	  associated	  with	  a	  modestly,	  but	  significantly	  lower	  risk	  of	  attaining	  DSS	  6	  (OR	  
=	  0.96,	  p	  =	  0.03)	  and	  DSS	  8	  (OR	  =	  0.96,	  p	  <	  0.001).	  This	  was	  secondary	  to	  the	  shorter	  
latency	   to	  progression,	  among	  patients	  with	  poor	  prognosis	   (Chapter	  4),	  becoming	  
progressive	   at	   younger	   age.	   Accordingly,	   groups	   younger	   at	   the	   onset	   of	   the	   SP	  
phase	   attained	   disability	   endpoints	   from	   the	   disease	   onset	   in	   significantly	   shorter	  
times	  (Table	  5.10).	  However,	  the	  age	  at	  conversion	  to	  SP	  MS	  did	  not	  affect	  the	  rate	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progression	  to	  disability	  levels	  were	  remarkably	  similar,	  among	  patients	  grouped	  by	  
the	  age	  at	  SP	  onset;	  only	  those	  aged	  ≤	  30	  attained	  DSS	  8	  in	  significantly	  shorter	  time	  
(Table	  5.11).	  	  	  
	  
Table	   5.10	   Kaplan	  Meier	   analysis	   in	   SP	   patients:	   times	   from	   onset	   to	   DSS	   6	   and	   to	   DSS	   8,	   among	  
patients	   grouped	   by	   the	   age	   at	   the	   onset	   of	   SP.	   Cox	   regression	   analysis:	   risk	   (HR)	   of	   attaining	   the	  





Table	  5.11	  Kaplan	  Meier	  analysis	  in	  SP	  and	  in	  PP	  patients:	  times	  from	  the	  onset	  of	  SP	  to	  DSS	  6	  and	  to	  
DSS	  8,	  among	  patients	  grouped	  by	  the	  age	  at	  the	  onset	  of	  SP,	  and	  times	  from	  the	  onset	  of	  PP	  to	  DSS	  6	  
and	  to	  DSS	  8,	  among	  patients	  grouped	  by	  the	  age	  at	  the	  onset	  of	  PP.	  Cox	  regression	  analysis:	  risk	  (HR)	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Similarly,	   among	   PP	   MS	   patients,	   the	   logistic	   regression	   analysis	   showed	   no	  
significant	   impact	  of	   the	  age	  at	   the	  onset	  of	   the	  primary	  progressive	  phase	  on	   the	  
probability	  of	  attaining	  DSS	  6	  (OR	  =	  0.93,	  p	  =	  0.13)	  and	  DSS	  8	  (OR	  =	  0.99,	  p	  0.48).	  In	  
addition,	   the	   Kaplan	   Meier	   analysis	   demonstrated	   similar	   times	   to	   the	   endpoints	  
among	  the	  3	  age	  groups	  (Table	  5.11).	  	  
	  
All	  progressive	  patients	   (PP	  +	  SP)	  were	  pooled	   together	  and	  stratified	  according	   to	  
the	   age	   at	   start	   of	   progression,	   to	   further	   assess	   its	   effect	   on	   the	   disability	  
accumulation	  during	  the	  progressive	  phase.	  The	  closely	  matching	  survival	  curves	   in	  
the	   three	   age	   groups,	   attaining	   DSS	   levels	   from	   progression	   in	   very	   similar	   times,	  
demonstrated	   no	   significant	   impact	   of	   the	   age	   at	   the	   onset	   of	   progression	   on	   the	  
evolution	  of	  the	  progressive	  phase	  (Figure	  5.18).	  	  
	  
	  
Figure	   5.18	   Kaplan	   Meier	   analysis	   in	   progressive	   patients	   (PP	   +	   SP):	   times	   from	   the	   onset	   of	  
progression	   to	   DSS	   6	   and	   to	   DSS	   8	   in	   patients	   grouped	   by	   the	   age	   at	   onset	   of	   progression.	   Cox	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5.3.3	  The	  current	  age	  	  
	  
Current	  age	  (age	  at	  last	  visit)	  was	  known	  for	  1004	  patients	  and	  ranged	  between	  18	  
and	  94	  year.	  At	   last	  assessment,	   in	   the	   total	  population	   the	  mean	  and	   the	  median	  
age	  were	  54.9	  (95%	  CI	  54.1-­‐55.7)	  and	  55	  years,	  respectively.	  	  
	  
The	   logistic	   regression	   analysis	   demonstrated	   that	   the	   probability	   of	   accumulating	  
disability	   increased	   proportionally	   with	   ageing.	   Growing	   older	   associated	   with	   a	  
significantly	  higher	  risk	  of	  attaining	  DSS	  3	  (OR	  per	  additional	  year	  =	  1.08,	  p	  	  <	  0.001),	  
DSS	  6	  (OR	  per	  additional	  year	  =	  1.06,	  p	  	  <	  0.001)	  and	  DSS	  8	  (OR	  per	  additional	  year	  =	  
1.04,	   p	   	   <	   0.001).	   Similar	   effect	   was	   exerted	   by	   the	   length	   of	   the	   disease	   course,	  
which	   increased	   proportionally	   the	   probability	   of	   attaining	   the	   endpoints	   (OR	   per	  
additional	  year:	  DSS	  3	  =	  1.08,	  p	  <	  0.001;	  DSS	  6	  =	  1.06,	  p	  <	  0.001;	  DSS	  8	  =	  1.03,	  p	  <	  
0.001).	   However,	   when	   the	   variables	   were	   tested	   in	   the	   multivariate	   model,	   the	  
effect	  of	  current	  age	  remained	  unchanged,	  while	  the	  predictive	  effect	  of	  the	  disease	  
duration	  became	  not	  significant	  for	  all	  endpoints	  (Table	  5.12).	  In	  addition,	  the	  impact	  
of	   ageing	   on	   the	   outcomes	   was	   tested	   in	   patients	   stratified	   by	   the	   length	   of	   the	  
disease	  course	  (short	  ≤	  15	  years;	  intermediate	  16-­‐25	  years;	  long	  >	  25	  years).	  In	  each	  
subgroup,	   the	   effect	   of	   current	   age	   remained	   significant	   and	   its	   size	   did	   not	  
substantially	  vary	  (Table	  5.13).	  	  
	  
Among	   relapsing	   onset	   patients,	   growing	   older	   increased	   the	   probability	   of	  
converting	  to	  SP	  MS	  (OR	  =	  1.06,	  p	  <	  0.001)	  and	  of	  developing	  severe	  disability	  (DSS	  6	  
OR	  =	  1.06,	  p	  <	  0.001;	  DSS	  8	  OR	  =	  1.04,	  p	  <	  0.001).	  The	  multivariate	  analysis	   left	   its	  
effect	  unchanged,	  while	  the	   impact	  of	  the	  disease	  duration	  on	  the	  risk	  of	  attaining	  
DSS	  6	  and	  DSS	  8	  became	  not	   significant	   (Table	  5.14).	  Current	  age	  was	  assessed	  as	  
continuous	  variable,	   in	  order	   to	  estimate	   the	  probability	  of	   requiring	  a	  walking	  aid	  
and	  of	  attaining	  SP	  at	  specific	  ages.	  The	  relative	  risk	  for	  reaching	  both	  endpoints	  was	  
very	   low	   at	   the	   age	   of	   20	   (OR	   =	   3.1	   and	   3.3,	   respectively)	   and	   increased	  
proportionally	  with	   ageing,	   becoming	   about	   6	   folds	   higher	   at	   the	   age	   of	   50	   (OR	   =	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17.2	  and	  20.0,	  respectively),	  and	  about	  20	  times	  higher	  at	  the	  age	  of	  70	  (OR	  =	  54.0	  
and	  66.0,	  respectively)	  (Figure	  5.19).	  	  	  
	  
In	   striking	   contrast,	   current	   age	   did	   not	   exert	   any	   significant	   impact	   on	   the	  
attainment	  of	  the	  disability	  endpoints,	  among	  PP	  patients	  (DSS	  3	  OR	  =	  0.93,	  p	  =	  0.52;	  
DSS	  6	  OR	  =	  1.01,	  p	  =	  0.70;	  DSS	  8	  OR	  =	  1.01,	  p	  =	  0.27),	  and	  among	  SP	  patients	  (DSS	  3	  
OR	  =	  1.06,	  p	  =	  0.47;	  DSS	  6	  OR	  =	  1.01,	  p	  =	  0.25;	  DSS	  8	  OR	  =	  1.00,	  p	  =	  0.23)	  (Table	  5.15).	  
	  	  
Table	   5.12	   Binary	   logistic	   regression	   univariate	   and	   multivariate	   analyses	   in	   the	   total	   population:	  






Table	   5.13	   Binary	   logistic	   regression	   analysis	   in	   the	   total	   population,	   stratified	   according	   to	   the	  
disease	   duration	   (short,	   intermediate,	   long):	   probability	   (OR)	   of	   attaining	   disability	   endpoints	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Table	   5.14	   Binary	   logistic	   regression	   univariate	   and	   multivariate	   analyses	   in	   the	   relapsing	   onset	  
population:	  probability	  (OR)	  of	  attaining	  SP	  and	  disability	  endpoints	  according	  to	  the	  current	  age	  and	  





Table	   5.15	   Binary	   logistic	   regression	   analysis	   in	   the	   SP	   and	   PP	   populations	   assessed	   separately:	  






Figure	  5.19	  Binary	  Logistic	  regression	  analysis	  in	  RR	  patients.	  Probability	  of	  reaching	  DSS	  6	  (regression	  
coefficient	  =	  0.057,	  OR	  per	  additional	  year	  =	  1.05;	  p	  <	  0.001)	  and	  SP	  (regression	  coefficient	  =	  0.060,	  
OR	  per	  additional	  year	  =	  1.06;	  p	  <	  0.001)	  according	  to	  the	  current	  age:	  risk	  (ORs	  on	  y-­‐axis)	  of	  requiring	  
a	  walking	  aid	  and	  of	  converting	  to	  SP	  MS	  according	  to	  patients’	  age	  (x-­‐axis).	  ORs	  are	  indicated	  on	  top	  





'())*+,$-.* /01%$2/0134/01567$8$9$1011/ /01:$2/0134/01567$8$9$1011/ /01;$2/01<4/01:67$8$9$1011/
#=>*->*$?()-,=@+ /015$2/01:4/01A67$8$9$1011/ /01%$2$/0134/01&67$8$9$1011/ /013$2/01<4/01:67$8$9$1011/
'())*+,$-.*$ /013$2/01<4/01%67$8$9$1011/ /013$2/01<4/01%67$8$9$1011/ /01;$2/01/4/01367$8$9$1011/





''#(" )*+$#,)*-%./*/012#3#4#)*56 /*)/#,)*+0./*)&12#3#4#)*-6 /*)/#,)*+&./*)012#3#4#)*6-






















	   329	  
5.3.4	  The	  age	  at	  disability	  landmark	  	  
	  
For	  the	  total	  population	  of	  1023	  patients	  the	  mean	  age	  at	  DSS	  3	  was	  41.6	  years	  (95%	  
CI	  40.8	  -­‐	  42.4),	  at	  DSS	  6	  was	  49.0	  years	  (95%	  CI	  48.0	  -­‐	  50.0),	  at	  DSS	  8	  was	  58.7	  years	  
(95%	  CI	  57.5	  -­‐	  59.9)	  and	  at	  DSS	  10	  was	  74.9	  (95%	  CI	  72.9-­‐76.5)	  (Table	  5.16).	  By	  the	  
end	  of	  the	  observation	  period,	  among	  patients	  who	  had	  required	  a	  walking	  cane,	  the	  
age	  at	  the	  attainment	  of	  the	  endpoint	  ranged	  from	  16	  to	  85	  years	  (median	  age	  =	  48	  
years);	  the	  youngest	  25%	  reached	  DSS	  6	  by	  the	  age	  of	  37	  and	  the	  oldest	  25%	  after	  
the	  age	  of	  53.	  	  
	  
Table	  5.16	  Kaplan	  Meier	  analysis	  from	  birth	  to	  disability	  endpoints	  in	  the	  total	  population.	  Mean	  and	  
median	  ages	  at	  DSS	  3,	  6,	  8	  and	  10.	  	  
	  
	  
5.3.4.1	  Factors	  affecting	  the	  age	  at	  disability	  levels	  
	  
The	  Kaplan	  Meier	  analysis	   from	  birth	  demonstrated	  men	  attained	  the	  endpoints	  at	  
modestly	   younger	   age	   than	   women	   (3	   mean	   years	   difference)	   (Table	   5.17).	   In	  
addition,	  groups	  younger	  at	   the	  disease	  onset	   took	   longer	   times	  to	  reach	  disability	  
outcomes	   (Table	   5.4),	   however	   they	   were	   younger	   when	   attaining	   the	   DSS	   levels	  
(Table	  5.17	  and	  Figure	  5.20).	  Among	  relapsing	  onset	  and	  progressive	  onset	  patients	  
assessed	  separately,	  males	  and	  groups	  younger	  at	  onset	  became	  severely	  disabled	  at	  
younger	  age	   (Table	  5.18).	   	   In	  addition,	  patients	  older	  at	   the	  onset	  of	   the	  RR	  phase	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Table	  5.17	  Kaplan	  Meier	  analysis:	  time	  from	  birth	  to	  DSS	  6	  and	  DSS	  8	  (age	  at	  disability	  levels)	  in	  the	  
total	   population	   grouped	   by	   sex,	   age	   at	   disease	   onset	   and	   type	   of	   clinical	   presentation.	   Cox	  
regression:	  risk	  (HR)	  of	  attaining	  the	  endpoint	  from	  birth	  among	  categories.	  	  	  
	  
	  
Figure	   5.20	  Kaplan	  Meier	   analysis	   from	  birth	   (age	   at)	   and	   from	  disease	  onset	   to	  DSS	  8	   in	   the	   total	  
population,	  grouped	  by	  the	  age	  at	  the	  disease	  onset.	  	  
	  
	  
!" #$ !" #$
%&'()$#&#*)('+&,
-.,/.0




(*1+* *'23 *'**4 *'25 *'*(
+&16* *'6) 0-*'**& *'66 0-*'**&
6&14* *'+( 0-*'**& *'+4 0-*'**&
-7-4* *'&3 0-*'**& *'&5 0-*'**&
4&'&0
"8%$9: *'5+ *'62 *'3) *'(6
-,-;<$%$9:
5.,3&06
"8%$9: *'33 *'&3 *'32 *'&4
,-;<$%$9:-
7.0.8.))(0$
"8%$9: *')6 *'*2 *'45 *'**+
,-;<$%$9:
90(+,3'.:$
"8%$9: *'36 *'&+ *'23 *'**2
,-;<$%$9:-
;#'+<















































	   331	  
Table	  5.18	  Kaplan	  Meier	  analysis:	  time	  from	  birth	  to	  DSS	  6	  (age	  at	  DSS	  6)	  in	  the	  relapsing	  onset	  and	  in	  
the	  progressive	  onset	  group,	  stratified	  by	  sex	  and	  by	  the	  age	  at	  the	  disease	  onset.	  Cox	  regression:	  risk	  







Table	   5.19	   Kaplan	  Meier	   analysis:	   time	   from	   birth	   to	   SP	   (age	   at	   SP)	   in	   relapsing	  
onset	   patients	   stratified	  by	   the	   age	   at	   the	  onset	  of	   the	  RR	  phase.	   Cox	   regression	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5.3.4.2	  The	  age	  at	  disability	  and	  the	  clinical	  phenotype	  
 
The	  number	  of	  patients	   reaching	  DSS	   levels	   increased	  proportionally	  with	  age;	   the	  
rate	  at	  which	  disability	  accumulated	  while	  growing	  older	  was	  similar	  between	  PP	  and	  
SP	  groups.	  By	  the	  age	  of	  55,	  70.9%	  (n	  =	  154)	  of	  PP	  patients	  and	  74.7%	  (n	  =	  399)	  of	  SP	  
patients	  had	  reached	  DSS	  6.	  These	  percentages	  increased	  to	  89.4%	  (n	  =	  194)	  and	  to	  
85.9%	  (n	  =	  459),	  respectively,	  by	  the	  age	  of	  65	  and	  to	  92.1%	  (n	  =	  200)	  and	  to	  88.0%	  
(n	  =	  470),	  respectively,	  by	  the	  age	  of	  75	  (Figure	  5.21).	  	  
	  
The	   Kaplan	   Meier	   analysis	   from	   birth	   demonstrated	   that	   relapsing	   onset	   and	  
progressive	  onset	  patients	  attained	  DSS	  3	  (41	  versus	  43	  median	  years,	  p	  =	  0.82),	  DSS	  
6	  (48	  versus	  49	  median	  years,	  p	  =	  0.05),	  DSS	  8	  (58	  versus	  58	  median	  years,	  p	  =	  0.44)	  
and	  DSS	  10	  (77	  versus	  78	  median	  years,	  p	  =	  0.55)	  at	  remarkably	  similar	  ages	  (Figure	  
5.22).	   The	   age	   at	   disability	  milestones	   was	   unaffected	   by	   the	   type	   of	   the	   disease	  
course	   even	   among	  males	   (median	   age	   at	   DSS	   6:	   RR/SP	   =	   46	   versus	   PP	   =	   46,	   p	   =	  
0.09),	  and	  among	  females	  (median	  age	  at	  DSS	  6:	  RR/SP	  =	  49	  versus	  PP	  =	  51,	  p	  =	  0.35),	  
assessed	  separately.	  	  
	  
	  
Figure	  5.21	  SP	  and	  PP	  patients	  assessed	  separately:	  cumulative	  percentages	  (y-­‐axis)	  attaining	  DSS	  6	  at	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Figure	   5.22	   Kaplan	   Meier	   analysis	   from	   birth	   to	   DSS	   3	   (A),	   DSS	   6	   (B),	   DSS	   8	   (C)	   and	   DSS	   10	   (D):	  
comparison	  between	  relapsing	  onset	  (blue	  lines)	  and	  progressive	  onset	  (green	  lines)	  groups.	  P	  values	  
were	  obtained	  with	  Log	  Rank	  test.	  	  

















<<=7>% !"#$%&!'#()(*#+,%-!+. *#// '!#'%&'0#0)'+#$,%-''.% *#!!
>> !+#/%&!(#/)(*#0,%-!+. '0#$%&'1#*)'!#/,%-'+.






One	   of	   the	  most	   puzzling	   features	   of	  MS	   is	   its	   heterogeneous	   clinical	   course.	   The	  
disability	   accumulates	  at	  different	   rate,	   among	  patients,	   and	   the	  disease	  evolution	  
follows	   a	   variable	   pattern,	   characterized	   either	   by	   periods	   of	   acute	   worsening	  
(relapses)	   or	   by	   a	   gradual	   steady	   deterioration,	   or	   by	   a	   combination	   of	   both.	  
According	   to	   an	   international	   consensus,	   the	   classification	  of	   the	  disease	   course	   is	  
based	  of	  these	  clinical	  features,	  and	  particularly	  on	  their	  points	  of	  departure	  (Lublin	  
and	  Reingold,	  1996).	  The	  distinction	  of	  clinical	  phenotypes	  is	  convenient	  and	  allows	  
to	  better	  defining	  the	  disability	  accumulation	  over	  time.	  However,	  different	  disease	  
phases	  are	  not	   always	  discretely	   separable	  and	  do	  not	  necessarily	  mirror	  different	  
pathological	  mechanisms,	  occurring	  sequentially.	  	  
	  
It	   is	   generally	   accepted	   that	   the	   inflammation	   plays	   a	   dominant	   role	   in	   the	  
development	  of	   focal	  demyelinating	   lesions,	  but	   the	  axonal	   injury	  and	   loss	  are	   the	  
major	   determinants	   of	   the	   unremitting	   disability	   (Trapp	   and	   Nave,	   2008).	   Both	  
pathological	   processes	   are	   known	   to	   occur	   independently	   of	   their	   clinical	  
counterpart,	   highlighting	   a	   “biological-­‐clinical	   paradox”,	   which	   contributes	   to	   the	  
difficulties	   of	   understanding	  mechanisms	   driving	   the	   disease	   evolution.	   From	  MRI	  
studies,	  it	  is	  well	  established	  that	  relapses	  are	  just	  the	  “filtered”	  clinical	  expression	  of	  
an	   underlying	   inflammatory	   activity	   (Barkhof,	   2002).	   The	   axonal	   loss	   and	   the	  
degeneration	  were	   shown	   to	   take	   place	   early	   in	   the	   disease	   course	   (Filippi	   et	   al.,	  
2003;	   Trapp	   et	   al.,	   1998),	   when	   permanent	   disability	   has	   not	   developed.	   The	  
assumption	   that	   the	   pathological	   processes	   driving	   the	   RR	   and	   the	   SP	   phases	   are	  
causally	   related	  could	  be	   simply	  a	  misconception	  of	  distinguishing	   separate	  clinical	  
stages,	  and	  it	  is	  not	  easily	  applicable	  to	  PP	  MS	  patients.	  
	  
The	  reason	  why	  the	  progressive	  phase	  can	  start	  “de	  novo”	  or	  following	  inflammatory	  
attacks	   remain	   largely	  debated,	  but	   it	   is	  unlikely	   that	  PP	  MS	  represents	  a	   separate	  
	   335	  
clinical	  entity	  (Antel	  et	  al.,	  2012;	  Rice	  et	  al.,	  2013).	  Indeed,	  its	  pathological	  features	  
are	   similar	   to	   SP	  MS	   (Frischer	   et	   al.,	   2009;	   Revesz	   et	   al.,	   1994),	   implying	   that	   the	  
disability	   accumulation	   during	   the	   progressive	   phase	  might	   be	   driven	   by	   common	  
mechanisms,	   among	   all	   subtypes.	   This	   is	   also	   supported	   by	   evidence	   from	  natural	  
history	   studies,	   which	   demonstrated	   that	   the	   disease	   evolution	   from	   moderate	  
disability	  (Confavreux	  and	  Vukusic,	  2006a;	  Debouverie	  et	  al.,	  2008;	  Leray	  et	  al.,	  2010)	  
and	   from	  onset	  progression	   (Kremenchutzky	  et	  al.,	  2006a)	   is	  not	   influenced	  by	   the	  
initial	   clinical	   course.	   The	   role	   of	   the	   inflammation	   on	   the	   development	   of	   severe	  
disability	   remains	   ambiguous.	   Early	   relapses	  were	   shown	   to	   significantly	   affect	   the	  
attainment	  of	   late	  outcomes,	  however	   late	   inflammatory	  attacks	  did	  not	   influence	  
the	   latency	   to	   progression	   and	   the	   long-­‐term	   disease	   evolution	   (Chapter	   4).	   This	  
suggests	  that,	  after	  an	  early	  watershed	   is	  reached,	   focal	   inflammatory	  mechanisms	  
probably	  disconnect	  from	  those	  leading	  to	  the	  onset	  of	  the	  progressive	  phase.	  	  
	  
Age	   might	   account	   for	   this	   dissociation	   and	   might	   explain	   the	   variable	   clinical	  
phenotype,	  among	  patients.	  The	  changes	  of	   the	  disease	  course	  over	  time	  could	  be	  
determined	   by	   the	   different	   ages	   at	   which	   pathological	   mechanisms	   become	  
clinically	  evident.	   	   Indeed,	  progressive	  MS	  patients	  share	   the	  same	  age	  at	  onset	  of	  
progression	  (Confavreux	  and	  Vukusic,	  2006a;	  Koch	  et	  al.,	  2007;	  Kremenchutzky	  et	  al.,	  
2006a;	   Tutuncu	   et	   al.,	   2013),	   and	   the	   age	   at	   the	   attainment	   of	   DSS	   levels	   is	   only	  
marginally	   affected	   by	   the	   type	   of	   the	   disease	   course	   (Confavreux	   and	   Vukusic,	  
2006b;	  Leray	  et	  al.,	  2010).	  Overall	  this	  data	  lend	  support	  to	  the	  unifying	  concept	  of	  
the	  disease	  evolution	  (Confavreux	  and	  Vukusic,	  2006a)	  and	  suggest	  that	  age	  related	  
mechanisms	  might	  play	  an	  important	  role	  in	  the	  chronic	  diffuse	  neurodegeneration,	  
which	   is	   the	   likely	   pathological	   substratum	   of	   the	   clinical	   progression	   (Confavreux	  
and	   Vukusic,	   2006b).	   The	   analyses	   of	   the	   LO	   database	   presented	   in	   this	   study	  
allowed	   to	   further	   address	   the	   complex	   interaction	   between	   age,	   inflammatory	  
attacks	  and	   the	  evolution	  of	   the	  progressive	  phase,	  attempting	   to	  better	  elucidate	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5.4.1	  Age	  and	  the	  long-­‐term	  disease	  evolution	  	  
	  
5.4.1.1	  The	  total	  population	  	  
	  
As	   largely	   reported	   by	   previous	   studies	   (Table	   5.1),	   the	   analysis	   confirmed	   an	  
association	  between	  older	  age	  at	   the	  disease	  onset	   and	  a	  worse	  outcome.	  Among	  
the	  LO	  total	  population,	  patients	  older	  at	  the	  clinical	  onset	  attained	  disability	  levels	  
in	  significantly	  shorter	  times	  (Table	  5.4).	  Age	  groups	  exhibited	  a	  remarkably	  different	  
rate	  of	  disability	  accumulation	  (Figure	  5.4).	  Patients	  aged	  20-­‐30	  at	  onset,	  compared	  
to	  those	  aged	  more	  than	  50,	  required	  a	  walking	  cane	  and	  became	  bedbound	  12	  and	  
10	   median	   years	   later,	   respectively.	   These	   differences	   mainly	   reflected	   the	  
distribution	   of	   the	   clinical	   phenotypes,	   among	   age	   categories.	   Most	   of	   the	  
progressive	   onset	   patients	   had	   the	   disease	   onset	   between	   the	   age	   of	   30	   and	   50	  
(Figure	   3.11,	   Chapter	   3)	   and,	   therefore,	   their	   faster	   disease	   evolution	   largely	  
accounted	   for	   the	   worse	   outcome,	   among	   groups	   older	   at	   onset	   in	   the	   total	  
population.	  Indeed,	  the	  probability	  of	  experiencing	  the	  PP	  course	  increased	  with	  the	  
age	  at	  first	  symptoms	  (OR	  =	  1.10	  per	  additional	  year	  at	  onset)	  and	  peaked	  between	  
the	  age	  of	  40	  and	  of	  50	  (Figure	  5.3	  B).	  However,	  the	  age	  at	  the	  disease	  onset	  did	  not	  
affect	  the	  times	  from	  moderate	  disability	  (DSS	  3)	  to	  DSS	  levels	  (Table	  5.5).	  This	  is	  in	  
line	  with	  previous	  studies	  (Confavreux	  and	  Vukusic,	  2006a;	  Debouverie	  et	  al.,	  2008;	  
Leray	  et	  al.,	  2010),	   it	  further	  emphasizes	  DSS	  3	  as	  the	  clinical	  watershed	  separating	  
two	   independent	   phases,	   and	   supports	   the	   amnestic	   nature	   of	   the	   late	   disease	  
evolution,	  which	  is	  largely	  unaffected	  by	  factors	  influencing	  the	  early	  disease	  stage.	  	  
	  
The	  analysis	  of	  the	  effect	  of	  current	  age	  on	  the	  attainment	  of	  late	  outcomes	  further	  
elucidated	   the	   relationship	  between	  age	   and	   the	  disease	   course.	  Growing	  older	   in	  
the	   total	   population	  necessarily	   associated	  with	   a	   higher	   probability	   of	   developing	  
severe	  disability.	  The	  hazard	  of	  attaining	  the	  DSS	  levels	  increased	  proportionally	  with	  
the	  current	  age	  (OR	  per	  additional	  year:	  DSS	  3	  =	  1.08,	  DSS	  6	  =	  1.06,	  DSS	  8	  =	  1.04).	  
However,	  the	  disease	  duration	  also	  influenced	  the	  attainment	  of	  the	  endpoints	  (ORs	  
per	   additional	   year:	  DSS	  3	  =	  1.08,	  DSS	  6	  =	  1.06,	  DSS	  8	  =	  1.03),	   similarly	   to	   ageing.	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Importantly,	  when	   the	   two	   variables	  were	   tested	   in	   the	   same	  multivariate	  model,	  
the	  length	  of	  the	  disease	  course	  did	  not	  significantly	  affect	  the	  outcomes,	  while	  the	  
effect	  of	  current	  age	  remained	  significant	  (Table	  5.12).	  In	  addition,	  the	  probability	  of	  
developing	   unremitting	   disability	   increased	   proportionally	   by	   growing	   older	   even	  
among	  groups	  of	  patients	  with	  a	  short	  disease	  duration	   (Table	  5.13).	  These	  results	  
indicate	   that	   ageing	   is	   a	   strong	   determinant	   of	   the	   outcome	   and	   suggest	   that	   the	  
accumulation	  of	  disability	   is	  affected	  by	  age	  related	  mechanisms,	   independently	  of	  
the	  length	  of	  the	  disease	  course.	  	  
	  
5.4.1.2	  The	  relapsing	  onset	  and	  the	  progressive	  onset	  subgroups	  
	  
When	   progressive	   and	   relapsing	   onset	   patients	   were	   assessed	   separately,	   the	  
analysis	  highlighted	  a	  largely	  different	  effect	  of	  age	  on	  the	  two	  clinical	  phenotypes.	  
The	   age	   at	   the	   onset	   of	   PP	   MS	   did	   not	   impact	   on	   the	   attainment	   of	   disability	  
endpoints	   (Table	   5.11).	   In	   contrast,	   an	   older	   age	   at	   the	   onset	   of	   the	   RR	   phase	  
associated	  with	   a	   significantly	   faster	  disease	  progression.	  Groups	   aged	  >	  30	  at	   the	  
first	  attack,	  compared	  to	   those	  aged	  ≤	  20,	   reached	  much	  earlier	  DSS	  6	   (11	  median	  
years	  difference)	  and	  DSS	  8	  (9	  median	  years	  difference)	  (Table	  5.7).	  This	  effect	  was	  
limited	   to	   the	   evolution	   of	   the	   RR	   phase	   and	   disappeared	   once	   the	   SP	   phase	  
supervened.	  Times	  from	  DSS	  3	  and	  from	  SP	  to	  disability	  endpoints	  were	  remarkably	  
similar	  among	  age	  groups,	  demonstrating	  that	  the	  evolution	  of	  the	  SP	  phase	  was	  not	  
influenced	  by	   the	  age	  at	  which	   the	  RR	  phase	   started	   (Table	  5.8).	  These	   results	  are	  
not	  in	  line	  with	  previous	  analyses	  from	  the	  British	  Columbia	  database,	  which	  showed	  
a	  faster	  attainment	  of	  EDSS	  8	  from	  the	  onset	  of	  SP,	  among	  patients	  younger	  at	  the	  
onset	   of	   the	   RR	   phase	   (Tremlett	   et	   al.,	   2008a).	   Although	   the	   number	   of	   patients	  
reaching	  the	  endpoint	  was	  unmentioned,	  the	  Kaplan	  Meier	  estimate	  was	  calculated	  
only	  for	  25%	  of	  British	  Columbia	  SP	  patients	  (Tremlett	  et	  al.,	  2008a),	  indicating	  that	  
the	   proportion	   of	   censored	   information	   was	   large.	   This	   probably	   explains	   the	  
discrepancy	  between	  the	  two	  databases.	  	  
	  
Among	   LO	   patients	   older	   at	   the	   onset	   of	   the	   RR	   phase,	   the	   faster	   attainment	   of	  
disability	  endpoints	  was	  secondary	  to	  the	  higher	  probability	  of	  converting	  to	  SP	  MS	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and	   to	   the	   shorter	   latency	   to	   progression	   (Figure	   5.6).	   The	   age	   at	   onset	   strongly	  
influenced	   the	   hazard	   of	   becoming	   progressive.	   The	   risk	   of	   entering	   the	   SP	   phase	  
increased	  proportionally	  with	  the	  age	  at	  the	  first	  attack,	  and	  doubled	  and	  tripled	  for	  
onset	  at	  the	  age	  of	  40	  (OR	  =	  4.22)	  and	  of	  50	  (OR	  =	  6.04),	  respectively,	  compared	  to	  
onset	   at	   the	   age	   of	   20	   (OR	   =	   2.04)	   (Figure	   5.5).	   Accordingly,	   groups	   older	   at	   the	  
disease	   onset	   reached	   SP	  more	   rapidly	   (Table	   5.6).	   However,	   when	   patients	  were	  
matched	   by	   the	   duration	   of	   the	   RR	   phase	   (short,	   intermediate,	   long),	   in	   each	  
subgroup	  the	  age	  at	  the	  disease	  onset	  did	  not	  significantly	  affect	  the	  attainment	  of	  
DSS	  levels	  (Figure	  5.7).	  This	  further	  demonstrated	  that	  an	  older	  age	  at	  onset	  of	  the	  
RR	  phase	  affected	  the	  outcome	  mainly	  by	  increasing	  the	  probability	  of	  converting	  to	  
SP	  MS.	  Importantly,	  similarly	  to	  the	  current	  age,	  the	  effect	  of	  the	  age	  at	  first	  attack	  
on	  the	  risk	  of	  entering	  the	  SP	  phase	  was	  independent	  of	  the	  disease	  duration	  and	  of	  
the	  number	  of	  early	  relapses	  (Table	  5.9).	  
	  
Current	   age	   was	   shown	   to	   influence	   the	   disease	   evolution	   also	   among	   relapsing	  
onset	  patients.	  The	  probability	  of	  converting	  to	  SP	  MS	  (OR	  per	  additional	  year	  =	  1.06)	  
and	  to	  attain	  DSS	  6	  and	  DSS	  8	  (OR	  per	  additional	  year	  =	  1.06	  and	  1.04,	  respectively)	  
increased	   proportionally	   by	   growing	   older,	   independently	   of	   the	   disease	   duration	  
(Table	  5.14).	  The	  relative	  risk	  of	  requiring	  a	  walking	  aid	  and	  of	  entering	  the	  SP	  phase	  
changed	  dramatically	  according	  to	  age,	  over	  a	  lifetime.	  It	  was	  obviously	  very	  low	  at	  
young	  age	  (age	  20	  OR	  for	  DSS	  6	  =	  3.1	  and	  for	  SP	  =	  3.3;	  age	  30	  OR	  for	  DSS	  6	  =	  5.5	  and	  
for	  SP	  =	  6.0)	  and	  it	  became	  extremely	  high	  at	  older	  ages	  (age	  60	  OR	  for	  DSS	  6	  =	  30.5	  
and	   for	   SP	  =	  36.0;	   age	  70	  OR	   for	  DSS	  6	   =	   54.0	   and	   for	   SP	  =	  66.0)	   (Figure	  5.18).	   In	  
striking	  contrast,	   the	  effect	  of	  ageing	  on	   the	  disease	  evolution	  did	  not	  apply	   to	  PP	  
and	  SP	  MS	  (Table	  5.15).	  	  
	  
These	  results	  indicated	  that	  the	  effect	  of	  current	  age	  on	  the	  disease	  progression,	  in	  
the	  total	  population,	  was	  limited	  to	  the	  relapsing	  onset	  group.	  In	  addition,	  the	  lack	  of	  
impact	   of	   current	   age	   on	   the	   evolution	   of	   the	   PP	   and	   of	   the	   SP	   phases	   further	  
suggested	   that,	   among	   relapsing	   onset	   patients,	   growing	   older	   affected	   prognosis	  
primarily	  by	  promoting	  the	  onset	  of	  the	  progressive	  course,	  but	  did	  not	  influence	  the	  
accumulation	  of	  disability	  during	  the	  progressive	  phase.	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5.4.2	  The	  age	  at	  the	  onset	  of	  progression	  	  
	  
Being	  younger	  at	   the	  onset	  of	   the	  SP	  phase	  associated	  with	  a	  worse	  outcome.	  The	  
negative	   regression	   coefficient	   yielded	   by	   the	   logistic	   regression	   analysis	   indicated	  
that	   the	   probability	   of	   attaining	   DSS	   6	   and	   DSS	   8	   decreased	   modestly	   and	  
proportionally	  with	  the	  age	  at	  the	  onset	  of	  SP	  (for	  both	  endpoints	  OR	  per	  additional	  
year	   was	   0.96).	   Accordingly,	   groups	   younger	   at	   the	   conversion	   to	   SP	  MS	   attained	  
disability	   endpoints,	   from	   the	   disease	   onset,	   in	   significantly	   shorter	   times	   (Table	  
5.10).	  This	  was	  expected,	  and	  was	  secondary	  to	  the	  shorter	   latency	  to	  progression,	  
which	  associated	  with	  a	  faster	  disability	  accumulation	  (Chapter	  6,	  Figure	  6.7).	  	  
	  
However,	  the	  evolution	  of	  the	  progressive	  phase	  was	  largely	  unaffected	  by	  the	  age	  
at	   its	   onset.	   This	  was	   seen	   in	   both	   the	   SP	   and	   the	   PP	   subgroups.	   Times	   from	   the	  
onset	  of	  progression	  to	  disability	  levels	  were	  similar,	  among	  patients	  grouped	  by	  the	  
age	   at	   the	   onset	   of	   the	   PP	   phase,	   and	   among	   patients	   grouped	   by	   the	   age	   at	   the	  
onset	  of	  the	  SP	  phase	  (Table	  5.11).	  Although	  there	  was	  a	  pattern	  indicating	  a	  slightly	  
faster	  evolution	  of	  the	  SP	  phase,	  among	  groups	  younger	  at	  the	  onset	  of	  progression,	  
differences	  did	  not	  reach	  statistical	  significance	  (Table	  5.11).	  In	  contrast,	  Tremlett	  et	  
al.	   concluded	   that	   being	   younger	   at	   onset	   of	   SP	   associated	   with	   a	   more	   rapid	  
disability	  accumulation	  during	  the	  progressive	  phase;	  the	  group	  aged	  <	  30	  attained	  
EDSS	  8,	  from	  the	  onset	  of	  progression,	  10	  mean	  years	  earlier	  than	  the	  group	  aged	  >	  
50	   (Tremlett	   et	   al.,	   2008a).	   In	   the	   British	   Columbia	   database,	   the	   use	   of	   different	  
stratification	   (5	   age	   categories)	   and	   the	   high	   proportion	   of	   censored	   information	  
probably	  accounted	  for	  such	  a	  large	  difference	  between	  age	  groups.	  
	  
Indeed,	   when	   LO	   SP	   and	   PP	   patients	   were	   pooled	   together,	   the	   analysis	   further	  
indicated	  that	  the	  evolution	  of	  the	  progressive	  phase	  was	  largely	  unaffected	  by	  the	  
age	   at	   its	   onset.	   Progressive	   patients,	   starting	   to	   progress	   at	   young	   (≤	   35	   years),	  
intermediate	  (36-­‐45	  years)	  or	  old	  (>	  45	  years)	  age,	  attained	  disability	  endpoints	  from	  
the	  onset	  of	  progression	  in	  remarkably	  similar	  times	  (Figure	  5.17).	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5.4.3	  The	  age	  at	  disability	  milestones	  	  	  
	  
Kaplan	  Meier	  analysis	  from	  birth	  calculated	  that	  50%	  of	  the	  LO	  MS	  total	  population	  
required	  a	  walking	  aid	  by	  the	  age	  of	  48	  years	  (Table	  5.16).	  However,	  the	  age	  at	  the	  
attainment	   of	   DSS	   6	   largely	   varied	   from	   16	   to	   85	   years,	   with	   the	   youngest	   25%	  
reaching	  the	  endpoint	  by	  the	  age	  of	  37	  and	  the	  oldest	  25%	  after	  the	  age	  of	  53.	  In	  line	  
with	   analyses	   from	   other	   databases	   (Confavreux	   and	   Vukusic,	   2006b;	   Leray	   et	   al.,	  
2010;	   Tremlett	   et	   al.,	   2006),	   males	   were	   modestly	   but	   significantly	   younger	   than	  
women	  when	  reaching	  the	  endpoints	   (3	  mean	  years	  difference	   for	  both	  DSS	  6	  and	  
DSS	  8)	  and	   the	   type	  of	   the	  clinical	  presentations	  did	  not	   significantly	   influence	   the	  
age	   at	   the	   disability	   milestones	   (Table	   5.17).	   Only	   cerebellar	   and	   brainstem	  
symptoms	  at	  onset	  were	  found	  to	  be	  associated	  with	  a	  younger	  age	  at	  DSS	  8	  (Table	  
5.17).	  	  	  
	  
For	  the	  first	  time,	  this	  study	  provided	  a	  complete	  account	  of	  the	  mean/median	  ages	  
at	  all	  milestones	  disability	  levels	  in	  relapsing	  onset	  and	  progressive	  onset	  patients.	  As	  
already	   suggested	   by	   the	   analyses	   in	   the	   Lyon	   and	   Rennes	   databases	   (Confavreux	  
and	  Vukusic,	  2006b;	  Leray	  et	  al.,	  2010),	  the	  type	  of	  the	  disease	  course	  did	  not	  affect	  
the	  times	  to	  endpoints	  from	  birth.	  RR/SP	  and	  PP	  groups	  attained	  DSS	  3	  (41	  versus	  43	  
years),	  DSS	  6	  (48	  versus	  49	  years),	  DSS	  8	  (58	  versus	  58	  years)	  and	  DSS	  10	  (77	  versus	  
78)	  at	  remarkably	  similar	  median	  ages	  (Figure	  5.22).	  	  
	  
Taken	   together,	   the	   analyses	   further	   demonstrated	   a	   remarkably	   similar	   outcome,	  
among	  all	  progressive	  patients.	  Primary	  and	  secondary	  progressive	  MS	  started	  at	  the	  
same	  ages	  (Figure	  5.13).	  The	  evolution	  of	  the	  progressive	  phase	  was	  not	  influenced	  
by	  the	  age	  at	  its	  onset	  (Figure	  5.18).	  The	  disability	  accumulated	  by	  growing	  older	  at	  
similar	   rate,	   between	   the	   two	   disease	   phenotypes	   (Figure	   5.21),	   and	   patients	  
attained	  disability	  landmarks	  at	  similar	  ages	  (Figure	  5.22).	  These	  results	  question	  the	  
widespread	  belief	  that	  an	  initial	  progressive	  course	  affects	  the	  outcome	  negatively.	  
In	  addition,	  they	  further	  emphasize	  the	  primary	  role	  of	  age	  on	  the	  accumulation	  of	  
disability,	   irrespective	  of	   the	  clinical	  phenotype	  and,	   therefore,	   independent	  of	   the	  
	   341	  
focal	   inflammatory	  mechanisms	  underlying	   the	  disease	   course	  before	   the	  onset	  of	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5.4.4	  Age	  and	  prognosis	  
	  
The	  analyses	  in	  this	  study	  redefined	  age	  as	  an	  important	  prognostic	  factor,	  affecting	  
the	   attainment	   of	   late	   outcomes,	   independently	   of	   the	   disease	   duration.	   The	  
accumulation	  of	  severe	  disability	  over	  time	  is	  influenced	  by	  patient’s	  age,	  suggesting	  
that	  different	  age-­‐related	  rates	  of	  progression	  might	  be	  identified	  among	  individuals	  
and	  within	  the	  same	  patient,	  during	  the	  disease	  course.	  	  
	  
The	  effect	  of	   age	   is	  primarily	  exerted	  by	   increasing	   the	  probability	  of	  experiencing	  
the	  progressive	  course,	   further	  highlighting	  the	  onset	  of	   the	  progressive	  disease	  as	  
the	  overwhelming	  determinant	  of	  the	  long-­‐term	  prognosis.	  Older	  age	  at	  the	  disease	  
onset	  associated	  with	  a	  higher	  risk	  of	  experiencing	  a	  primary	  progressive	  course	  and,	  
among	   RR	   patients,	   influenced	   the	   disease	   evolution	   by	   increasing	   the	   hazard	   of	  
converting	   to	   SP	   MS.	   Similarly,	   growing	   older	   affected	   the	   disease	   evolution,	   in	  
relapsing	   onset	   patients	   only,	   by	   heralding	   the	   progressive	   course.	   The	   disability	  
accumulation	  during	  the	  progressive	  phase	  was	  reported	  to	  be	  homogeneous	  among	  
all	  patients	  (Kremenchutzky	  et	  al.,	  2006a)	  and	   independent	  of	   factors	  preceding	   its	  
onset	   (Confavreux	   et	   al.,	   2003;	   Leray	   et	   al.,	   2010).	   The	   analyses	   in	   this	   thesis	  
demonstrated	   that	   the	   evolution	   of	   progressive	  MS	   is	   largely	   unaffected	  by	   either	  
the	  age	  at	  onset	  of	  the	  RR	  phase	  or	  by	  the	  age	  at	  onset	  of	  progression	  or	  by	  ageing.	  
Therefore,	   the	   outcome	   is	  mainly	   determined	   before	   the	   onset	   of	   the	   progressive	  
phase,	  and	  it	  is	  strongly	  influenced	  by	  age	  related	  mechanisms,	  leading	  to	  the	  onset	  
of	  progression.	  
	  
In	   the	   context	   of	   the	   long	   term	   outcome	   at	   population	   level,	   the	   almost	   identical	  
ages	   at	   the	  onset	   of	   progression	   and	   at	   the	   attainment	   of	   disability	   levels,	   among	  
clinical	  phenotypes,	  minimizes	  the	  significance	  of	  the	  clinically	  evident	  inflammatory	  
attacks	   and	  of	   the	  duration	  of	   the	  disease	   course,	   and	  emphasizes	   the	   role	  of	   the	  
subclinical	   pathological	   processes,	   independent	   of	   their	   clinical	   counterpart.	  
Nevertheless,	   it	   would	   be	   an	   oversimplification	   to	   consider	   the	   disability	  
accumulation	  strictly	  age	  dependent.	  Patients	  older	  at	  the	  disease	  onset,	  compared	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to	  those	  younger,	  attained	  endpoints	  more	  rapidly,	  however	  they	  were	  older	  when	  
they	   became	   progressive	   (Table	   5.19)	   and	   severely	   disabled	   (Figure	   5.20).	   This	  
indicates	  that	  the	  age	  at	  disease	  onset	  also	  plays	  a	  relevant	  role,	  and	  highlights	  the	  
complexity	  of	  the	  age	  related	  mechanisms	  affecting	  the	  disease	  evolution.	  	  
	  
From	  the	  patients’	  prospective,	  the	  prognostic	  effect	  of	  age	   is	  rather	  controversial.	  
Over	   a	   lifetime,	   those	  older	   at	   onset	   had	   a	   longer	   “disease	   free”	  period	   and	  were	  
older	  when	  they	  became	  disabled.	  Therefore,	  although	  a	  younger	  age	  at	  onset	  has	  
been	  largely	  reported	  as	  a	  predictor	  of	  a	  better	  prognosis,	  reaching	  disability	  levels	  
in	  longer	  time	  but	  at	  an	  earlier	  age	  might	  be	  perceived	  as	  a	  negative	  outcome.	  	  
	  
5.4.5	  Age	  and	  the	  clinical	  phenotype	  
	  
5.4.5.1	  Age	  and	  progressive	  MS	  
	  
A	  large	  body	  of	  evidence	  suggests	  that	  progressive	  MS	  is	  an	  age	  dependent	  disease.	  
The	  PP	  course	  occurs	  very	  infrequently	  in	  children	  and,	  even	  when	  the	  disease	  starts	  
during	  childhood,	  the	  SP	  course	  develops	  in	  adult	   life	  (mean	  age	  41	  years)	  (Renoux	  
et	   al.,	   2007).	   The	   age	   at	   onset	   influences	   the	   probability	   of	   experiencing	   a	  
progressive	   course	   and,	   more	   importantly,	   the	   progressive	   phase	   starts	   at	  
remarkably	   similar	   ages,	   among	   progressive	   patients.	   This	   was	   consistently	  
demonstrated	   by	   comparing	   the	   SP	   and	   the	   PP	   groups	   (Confavreux	   and	   Vukusic,	  
2006a;	  Fog	  and	  Linnemann,	  1970;	  Koch	  et	  al.,	  2007;	  Minderhoud	  et	  al.,	  1988b),	  and	  
by	   comparing	   different	   progressive	   phenotypes	   (Table	   5.2	   and	   Figure	   5.1)	  
(Kremenchutzky	  et	  al.,	  2006a;	  Tutuncu	  et	  al.,	  2013).	  The	  almost	  identical	  ages	  when	  
the	   progressive	   phase,	   starting	   “de	   novo”	   or	   following	   the	   RR	   phase,	   becomes	  
clinically	   evident,	   further	   indicates	   that	   degenerative	   processes	   are	   already	   active	  
much	  before	   their	   clinical	   counterpart	   (De	  Stefano	  et	  al.,	  2003;	  Filippi	  et	  al.,	  2003;	  
Trapp	  et	  al.,	  1998).	  These	  observations	  have	  supported	  the	  unifying	  concept	  of	  the	  
disease	  course.	  The	  changes	  of	  the	  clinical	  phenotypes	  might	  be	  an	  effect	  of	  the	  age,	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rather	  than	  the	  effect	  of	  changing	  pathogenic	  mechanisms	  (Confavreux	  and	  Vukusic,	  
2006a).	  	  	  
	  
In	  this	  study,	  the	  Kaplan	  Meier	  analysis	  from	  birth	  confirmed	  a	  very	  similar	  age	  at	  the	  
onset	   of	   progression	   between	   534	   SP	   patients	   and	   217	   PP	   patients	   (39	   versus	   40	  
median	  years;	  p	  =	  0.09),	  despite	  a	  12	  years	  span	  in	  the	  age	  at	  the	  disease	  onset	  (28	  
versus	   40	  median	   years;	   p	   <	   0.001)	   (Figure	   5.13).	   It	   has	   been	   suggested	   that	   the	  
exclusion	   from	   the	   analysis	   of	   RR	   patients	   at	   risk	   of	   developing	   the	   SP	   course	  
represents	  a	  methodological	  caveat	  that	  might	  bias	  results	  (Tremlett	  et	  al.,	  2009b).	  
Indeed,	   among	   all	   relapsing	   onset	   patients,	   the	   estimated	   age	   at	   the	   onset	   of	  
secondary	  progression	  was	  8	  mean	  years	  older,	  compared	  to	  when	  only	  SP	  patients	  
were	   analysed	   (48.3	   versus	   40.2	   years,	   respectively)	   (Figure	   5.16).	   The	   analysis	  
calculated	  that	  50%	  of	  the	  RR/SP	  group	   is	  expected	  to	  enter	  the	  progressive	  phase	  
by	   the	   age	   of	   45,	   rising	   to	   65%	  by	   the	   age	   of	   75	   (Figure	   5.17).	   As	   reported	   in	   the	  
British	   Columbia	   database	   (Tremlett	   et	   al.,	   2009b),	   when	   censored	   information	  
(patients	  who	  did	  not	  convert	  to	  SP	  MS)	  were	  considered,	  the	  estimated	  mean	  age	  
at	  the	  onset	  of	  the	  SP	  phase	  was	  much	  older	  than	  the	  mean	  age	  at	  the	  onset	  of	  the	  
PP	  phase	  (48.3	  versus	  38.6	  years;	  p	  <	  0.001).	  However,	  comparing	  patients	  at	  risk	  of	  
progression	   (RR	   MS)	   versus	   those	   who	   are	   progressive	   already	   (PP	   MS)	   is	   also	  
methodologically	   incorrect.	   In	   the	   first	  group	  the	  analysis	  allowed	  an	  estimation	  of	  
what	  the	  age	  would	  be,	  taking	  into	  account	  those	  patients	  who	  have	  not	  reached	  the	  
endpoint,	  while	  in	  the	  second	  group	  it	  calculated	  what	  the	  actual	  age	  was.	  A	  correct	  
approach	   would	   imply	   analysing	   patients	   in	   the	   pre-­‐progressive	   course,	   at	   risk	   of	  
developing	  PP	  MS,	  which	  is	  practically	  impossible.	  In	  addition,	  although	  RR	  MS	  might	  
be	   regarded	  as	   “a	  disease	   that	  has	  not	  grown	  older	  yet”	   (Confavreux	  and	  Vukusic,	  
2006a),	   and	   most	   of	   the	   patients	   eventually	   attain	   progression	   over	   time,	   the	  
progressive	   disease	   does	   not	   necessarily	   supervene.	   In	   the	   British	   Columbia	  
population	   42%	   of	   patients	   did	   not	   convert	   to	   SP	  MS	   after	   20	   years	   of	   follow	   up	  
(Tremlett	   et	   al.,	   2009b).	   Among	   patients	   from	   the	   Mayo	   Clinic,	   45%	   had	   not	  
developed	  progression	  after	  35	  years	  from	  onset	  and	  38%	  were	  still	  in	  the	  RR	  phase	  
by	  the	  age	  of	  75	  (Tutuncu	  et	  al.,	  2013).	  Even	  after	  50	  years	  of	  disease	  course	  14%	  of	  
the	  Gothenburg	  population	  remained	  progression	  free,	  decreasing	  to	  6.5%	  after	  60	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years	   (Skoog	   et	   al.,	   2012).	   Similarly,	   in	   the	   LO	   database,	   by	   the	   end	   of	   the	  
observation	  period,	  33%	  of	  RR	  patients	  had	  not	  entered	  the	  progressive	  phase.	  This	  
subgroup	   was	   observed	   for	   20	   mean	   years:	   in	   25%	   (n	   =	   68)	   progression	   had	   not	  
occurred	   after	   ≥	   24	   years	   from	   the	   disease	   onset	   and	   for	   some	   (n	   =	   13)	   not	   even	  
after	  ≥	  40	  years.	  Those	  who	  remained	  in	  the	  RR	  phase	  had	  a	  mean	  age	  of	  47	  years	  at	  
the	   last	   assessment,	   and,	   by	   this	   age,	   75%	   of	   all	   progressive	   patients	   had	   already	  
started	  to	  progress	  (Figure	  5.12).	  In	  addition,	  during	  the	  RR	  phase	  patients	  may	  die:	  
this	  occurred	   in	  9	   cases	   from	  the	  Gothenburg	  population	   (Skoog	  et	  al.,	  2012),	   in	  9	  
cases	  from	  the	  Mayo	  Clinic	  database	  (Tutuncu	  et	  al.,	  2013)	  and	  in	  20	  cases	  from	  the	  
LO	  database	  (Chapter	  3).	  Therefore,	  it	  can	  be	  assumed	  that	  some	  of	  the	  RR	  patients	  
would	  have	  eventually	  converted	  to	  SP	  MS,	  if	  observed	  for	  longer	  time,	  but	  probably	  
not	  all	  of	  them.	  The	  comparison	  with	  the	  geographically	  ascertained	  subgroup	  from	  
Middlesex	  County	  (Figure	  3.16,	  Chapter	  3)	  demonstrated	  that	  little	  bias	  affected	  the	  
ascertainment	   of	   the	   LO	   MS	   population,	   which	   can	   be	   considered	   thoroughly	  
representative	   of	   patients	   at	   risk	   of	   both	   secondary	   and	   primary	   progressive	  MS.	  
Therefore,	  from	  the	  analysis	  presented	  in	  this	  thesis	  it	  can	  be	  reliably	  concluded	  that	  
the	   age	   at	   which	   progression	   started	   is	   not	   affected	   by	   the	   type	   of	   the	   disease	  
course.	  	  
	  
This	  was	   further	  demonstrated	  by	  comparing	  progressive	  patients	   stratified	  by	   the	  
total	   number	   of	   relapses	   during	   the	   pre-­‐progressive	   phase	   (Figure	   5.14)	   and	  
stratified	  by	  the	  number	  of	  early	  relapses	  (Figure	  5.15).	  Groups	  with	  no	  (PP	  MS),	  1	  
(SAP	  MS),	  2-­‐3	  (SP	  MS)	  and	  ≥	  4	  (SP	  MS)	  attacks	  before	  progression	  differed	  by	  the	  age	  
at	   the	   disease	   onset	   but	   shared	   very	   similar	   age	   at	   the	   onset	   of	   the	   progressive	  
phase,	  which	  ranged	  only	  by	  2.8	  mean	  years	  among	  the	  4	  subgroups	  (Figure	  5.14).	  
This	  was	   also	   observed	   among	   patients	   grouped	   by	   the	   number	   of	   early	   relapses,	  
attaining	  progression	  at	  similar	  age,	  compared	  to	  PP	  patients	  (Figure	  5.15).	  Only	  the	  
group	  with	  frequent	  early	  attacks	  (≥	  3)	  diverged	  from	  the	  other	  progressive	  subtypes	  
and	  became	  progressive	  at	  significantly	  younger	  age	  (35	  mean	  years).	  These	  resulted	  
highlighted,	  again,	  frequent	  early	  relapsers,	  as	  a	  specific	  subgroup	  of	  patients	  with	  an	  
unusually	  aggressive	  disease	  course.	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Overall,	   the	   age	   at	   which	   progression	   started	   was	   not	   influenced	   by	   the	   clinical	  
phenotype,	   but	   was	   also	   unaffected	   by	   the	   number	   of	   relapses	   before	   the	  
progressive	   phase	   started	   (Figure	   5.23).	   This	   further	   emphasizes	   the	   age	   as	   the	  
cardinal	   factor,	   which	   influences	   when	   the	   relentless	   accumulation	   of	   disability	  
becomes	  clinically	  evident,	  independently	  of	  inflammatory	  attacks.	  However,	  the	  age	  
at	  the	  onset	  of	  the	  progressive	  phase	  remains	  extremely	  unpredictable	  at	  individual	  
level.	   Among	   LO	   patients,	   it	   spanned	   from	   14	   to	   83	   years;	   50%	   of	   progressive	  
patients	  started	  to	  progress	  by	  the	  age	  of	  39	  and	  75%	  by	  the	  age	  of	  47	  (Figure	  5.12).	  
In	  addition,	  being	  older	  at	  the	  onset	  of	  the	  RR	  phase	  associated	  with	  older	  age	  at	  the	  
conversion	  to	  SP	  MS	  (Table	  5.19),	  partially	  explaining	  the	  variability	  of	  the	  long-­‐term	  
clinical	  outcome.	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5.4.5.2	  Age	  and	  relapsing	  MS	   	  
	  
The	  conspicuous	  fact	  that	  SP	  subgroups,	  stratified	  by	  the	  number	  of	  total	  relapses,	  
had	  a	  statistically	  significant	  different	  age	  at	  the	  disease	  onset	  (Figure	  5.14)	  warrants	  
further	  comments.	  Despite	  sharing	  almost	  the	  same	  age	  at	  the	  onset	  of	  progression,	  
patients	  with	  a	   larger	  number	  of	   total	  attacks	   (≥	  4)	  were	   the	  youngest	   (27.4	  mean	  
years)	   at	   clinical	   presentation,	   followed	   by	   patients	   with	   2-­‐3	   attacks	   (31.0	   mean	  
years)	  and	  by	  patients	  with	  only	  a	  single	  attack	  (32.8	  mean	  years)	  (Figure	  5.24).	  This	  
indicated	   that	   the	   age	   at	   the	   disease	   onset	   influenced	   the	   frequency	   of	   relapses.	  
Indeed,	   although	   the	  number	  of	  early	   relapses	  was	  not	  affected	  by	   the	  age	  at	   the	  
clinical	  onset	   (r	  =	   -­‐0.05;	  p	  =	  0.13),	  being	  older	  at	   the	   first	   attack	  associated	  with	  a	  
significantly	  lower	  number	  of	  late	  (r	  =	  -­‐0.26;	  p	  <	  0.001)	  and	  total	  (r	  =	  -­‐0.24;	  p	  <	  0.001)	  
relapses	   (Figure	   5.8).	   This	   was	   in	   line	   with	   previous	   reports,	   showing	   that	   the	  
annualized	  relapse	  rate	  decreases	  by	  growing	  older	   (Tremlett	  et	  al.,	  2008b)	   (Figure	  
4.2,	  Chapter	  4).	  The	  total	  number	  of	  attacks	  recorded	  during	  the	  RR	  phase	  reduced	  
proportionally	  with	  age,	  from	  1000	  attacks,	  among	  patients	  with	  onset	  between	  the	  
age	  31-­‐40,	  to	  only	  29	  attacks,	  among	  those	  with	  onset	  after	  the	  age	  50	  (Figure	  5.9).	  
The	   same	   pattern	   was	   observed	   when	   patients	   were	   stratified	   in	   small	   groups	  
according	   to	   the	   number	   of	   total	   relapses.	   Those	   with	   a	   higher	   total	   relapse	  
frequency	   were	   younger	   at	   onset	   (Figure	   5.10).	   It	   is	   worth	   noticing	   that	   women,	  
compared	  to	  men,	  were	  slightly	  younger	  at	  the	  onset	  of	  the	  RR	  phase	  (27.9	  versus	  
29.7	  mean	  years;	  p	  =	  0.01)	  and	  experienced	  a	  slightly	  higher	  number	  of	  total	  attacks	  
(4.2	  versus	  3.8	  mean	  attacks;	  p	  <	  0.001).	  However,	  these	  differences	  are	  small	  and	  
can	   only	   partially	   explain	   the	   higher	   total	   relapse	   frequency	   observed	   among	  
patients	  younger	  at	  the	  clinical	  presentation.	  	  
	  
These	  results	  cast	  further	  light	  on	  the	  evolution	  of	  the	  RR	  phase	  and	  on	  the	  complex	  
interaction	  between	  the	  age	  at	   its	  onset	  and	  the	  total	  number	  of	  attacks	  during	   its	  
course.	   The	   time	   to	   the	   onset	   of	   SP	   was	   longer	   among	   patients	   younger	   at	   the	  
disease	   onset	   (Figure	   5.6)	   and	   also	   longer	   among	   patients	   with	   a	   higher	   attacks	  
frequency	   before	   progression	   (Figures	   4.21,	   4.22,	   Chapter	   4).	   Therefore,	   groups	  
older	  at	  onset	  took	  a	  shorter	  time	  to	  enter	  the	  SP	  phase	  and	  had	  less	  relapses	  before	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progression.	  The	  converse	  relationship	  between	  the	  latency	  to	  progression	  and	  the	  
number	  of	   total	  attacks	   is	   largely	  accounted	   for	  by	   the	  age	  at	  onset,	  which	  affects	  
the	   relapse	   frequency.	   As	   already	   suggested	   by	   imaging	   studies	   (Granberg	   et	   al.,	  
2013),	  inflammatory	  mechanisms	  are	  already	  active	  before	  the	  clinical	  onset	  and	  age	  
seems	   to	   influence	   when	   they	   first	   become	   clinically	   evident.	   Alternatively,	   the	  
association	   between	   an	   older	   age	   at	   onset	   and	   a	   lower	   relapse	   frequency,	   among	  
patients	   sharing	   the	   same	   age	   at	   the	   onset	   of	   progression,	   implies	   a	   yet	  
undetermined	   interaction	  between	  age	   related	  degenerative	  processes	  and	   factors	  
determining	   the	   frequency	   of	   inflammatory	   attacks.	   With	   ageing	   the	   subtle	  
degenerative	  process	  gradually	  prevails	  over	  the	  inflammatory	  mechanisms,	  possibly	  




The	  data	  presented	  in	  this	  study	  confirmed	  that	  the	  clinical	  onset	  of	  the	  progressive	  
phase	  is	  strongly	  determined	  by	  the	  age	  rather	  than	  by	  the	  pre-­‐progression	  disease	  
course.	  Also,	  age	  affects	  the	  variable	  presenting	  pattern	  of	  inflammatory	  attacks,	  by	  
influencing	  the	  clinical	  onset	  and	  by	  affecting	  the	  evolution	  of	  the	  relapsing	  course.	  
These	   results	   further	   defined	   MS	   as	   a	   one-­‐stage	   disorder,	   where	   the	   complex	  
balance	  between	   inflammatory	  and	  neurodegenerative	  processes,	  and	  their	  clinical	  
manifestations,	   changes	   over	   time	   according	   to	   the	   age.	   Therefore,	   the	   clinical	  
phenotype	   is	   strictly	   age	   dependent	   and	   does	   not	   necessarily	   mirrors	   changes	   in	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The	   outcome’s	   severity	   in	  MS	   is	   extremely	   variable.	   The	   disease	   evolution	   ranges	  
widely,	   and	   while	   some	   patients	   remain	   without	   significant	   disability	   after	   10-­‐15	  
years	   from	   onset	   (Hawkins	   and	   McDonnell,	   1999;	   Ramsaransing	   and	   De	   Keyser,	  
2006;	  Sayao	  et	  al.,	  2007),	  others	  become	  severely	  disabled	  within	  a	  short	  period	  of	  
time	   (Lublin	   and	  Reingold,	   1996).	  Groups	   at	   risk	   of	   poor	   outcome	   can	   be	   defined,	  
however	  the	  factors	  accounting	  for	  the	  large	  variability	  of	  the	  disease	  severity	  at	  the	  
individual	  level	  are	  still	  unclear.	  The	  unpredictable	  clinical	  course	  makes	  the	  task	  of	  
monitoring	   the	   disease	   activity	   (Rio	   et	   al.,	   2009b)	   and	   of	   testing	   the	   efficacy	   of	  
treatments	  (Rieckmann,	  2008)	  particularly	  problematic.	  	  
	  
Among	  RR	  patients,	  the	  onset	  of	  the	  SP	  phase	  represents	  a	  crucial	  milestone	  in	  the	  
disease	   course.	   Inflammatory	   attacks	   during	   the	   RR	   phase	   can	   contribute	   to	   the	  
development	  of	  moderate	  disability	  (Lublin	  et	  al.,	  2003),	  but	  only	  rarely	  are	  a	  direct	  
cause	  of	  permanent	   severe	  disability	   (Bejaoui	   and	  Rolak,	  2010).	   The	  attainment	  of	  
hard	  outcomes,	   such	  as	   requiring	  a	  walking	  aid	  or	  worse,	   almost	   invariably	   results	  
from	   the	   relentless,	   steady	   accumulation	   of	   disability,	   which	   occurs	   during	   the	  
progressive	  phase	  (Kremenchutzky	  et	  al.,	  2006a;	  Tutuncu	  et	  al.,	  2013).	  Indeed,	  most	  
of	  the	  LO	  patients	  converted	  to	  SP	  MS	  when	  they	  were	  scored	  at	  DSS	  ≤	  3	  (Figure	  4.9,	  
Chapter	   4).	   Previous	   analyses	   identified	   DSS	   3/DSS	   4	   as	   the	   clinical	   watersheds	  
between	   two	   independent	   phases	   (Confavreux	   and	  Vukusic,	   2006a;	  Debouverie	   et	  
al.,	   2008;	   Leray	   et	   al.,	   2010).	   Once	   the	   moderate	   disability	   develops,	   the	   further	  
disease	  evolution	  appears	  largely	  uninfluenced	  by	  baseline	  prognostic	  factors	  and	  by	  
the	   type	   of	   the	   initial	   disease	   course	   (Confavreux	   et	   al.,	   2003;	   Confavreux	   and	  
Vukusic,	   2006a;	   Leray	   et	   al.,	   2010)	   (Figure	   3.22,	   Chapter	   3).	   Similarly	   to	   the	   LO	  
patients,	   among	   patients	   from	   the	   French	   cohorts,	   the	   attainment	   of	   moderate	  
disability	  probably	  heralded	   the	  SP	  phase	   in	  most	  of	   the	  cases.	  Overall,	   the	   results	  
support	   the	   homogeneity	   of	   the	   progressive	   course,	   among	   progressive	   patients.	  
Therefore,	  the	  conversion	  to	  SP	  MS	  is	  undoubtedly	  the	  key	  determinant	  of	  the	  long-­‐
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term	  outcome	  and	  the	  true	  clinical	  watershed	  between	  two	  disease	  phases,	  mostly	  
independent	  of	  each	  other.	  	  
	  
In	   the	   LO	   database,	   MS	   progressive	   subtypes	   shared	   almost	   the	   same	   rate	   of	  
disability	  accumulation	  during	  the	  progressive	  phase	  (Kremenchutzky	  et	  al.,	  2006a).	  
In	   addition,	   the	   evolution	   of	   the	   SP	   phase	   was	   mainly	   unaffected	   by	   relapses	  
preceding	  its	  onset	  (Figure	  4.6,	  Chapter	  4)	  or	  occurring	  during	  its	  course	  (Figures	  4.7,	  
4.8,	  Chapter	  4),	  it	  was	  similar	  among	  patients	  grouped	  by	  the	  age	  at	  the	  onset	  of	  the	  
RR	  phase	  (Figure	  5.6,	  Chapter	  5)	  and	  by	  the	  age	  at	  the	  onset	  of	  progression	  (Figure	  
5.18,	  Chapter	  5),	  and	  it	  was	  not	   influenced	  by	  the	  current	  age	  (Table	  5.15,	  Chapter	  
5).	  The	  predictive	  effect	  of	  early	  relapses	  (Figure	  4.10,	  Chapter	  4)	  and	  of	  age	  (Figure	  
5.5,	  Chapter	  5)	  was	  primarily	  exerted	  by	   increasing	  the	  probability	  of	  converting	  to	  
SP	   MS.	   Even	   among	   patients	   selected	   for	   the	   adverse	   feature	   of	   frequent	   early	  
inflammatory	  attacks,	  the	  occurrence	  of	  the	  SP	  course	  differentiated	  groups	  with	  a	  
benign	  or	  an	  aggressive	  disease	  course,	  and	  accounted	   for	   the	  severity	  of	   the	   final	  
outcome	  (Figure	  4.11,	  Chapter	  4).	  	  
	  
Taken	   together	   these	   data	   indicate	   that	   the	   severity	   of	   the	   outcome	   is	   mainly	  
accounted	  for	  by	  mechanisms	  driving	  the	  evolution	  of	  the	  RR	  phase	  and	  leading	  to	  
the	  conversion	  to	  SP	  MS.	  Therefore,	  the	  onset	  of	  the	  progressive	  phase	   is	  a	  robust	  
surrogate	  marker	  for	  late	  disability	  and	  a	  major	  therapeutic	  target.	  Factors	  affecting	  
the	  probability	  of	  entering	   the	  SP	  phase	   should	  be	  used	   to	  optimize	   the	   individual	  
therapeutic	  management	  and	  to	  improve	  the	  design	  of	  RCTs.	  	  
	  
6.1.1	  Factor	  affecting	  the	  evolution	  of	  the	  RR	  phase	  
	  
A	  relatively	  low	  number	  of	  natural	  history	  studies	  focused	  specifically	  on	  SP	  MS.	  This	  
probably	   reflects	   the	  difficulty	  of	   reliably	  pinpointing	  when	   the	  SP	  phase	  occurs.	   It	  
has	  been	  suggested	  that	  SP	  MS	  can	  be	  regarded	  as	  “RR	  MS	  that	  has	  to	  grow	  older”	  
(Confavreux	   and	   Vukusic,	   2006a).	   Indeed,	   the	   number	   of	   patients	   entering	   the	   SP	  
phase	   increases	   over	   time,	   and	   parallels	   the	   duration	   of	   the	   disease	   course	  
(Confavreux	   et	   al.,	   1980;	   Mc	   and	   Compston,	   1952;	   Weinshenker	   et	   al.,	   1989b).	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Consequently,	  among	  natural	  history	  cohorts,	  the	  time	  to	  SP	  largely	  varies,	  based	  on	  
the	   variable	   proportion	   of	   censored	   information.	   Overall,	   19	  median	   years	   can	   be	  
considered	  a	  reliable	  estimate	  of	  the	  duration	  of	  the	  RR	  phase	  (Figure	  3.4,	  Chapter	  
3).	  
	  
The	   most	   extensive	   analysis	   of	   the	   disease	   evolution	   up	   to	   the	   onset	   of	   the	  
secondary	   progression	   was	   carried	   out	   in	   the	   British	   Columbia	   database.	   Two	  
separate	  studies	  included	  2485	  patients	  (58%	  converting	  to	  SP	  MS)	  (Tremlett	  et	  al.,	  
2008a),	   and	   subsequently	   5162	   patients	   (35%	   converting	   to	   SP	   MS)	   (Koch	   et	   al.,	  
2010).	   In	   the	   first	   study,	   the	   Kaplan	  Meier	   estimated	   time	   to	   SP	  was	   18.9	  median	  
years	  from	  the	  disease	  onset,	  and	  49.0	  median	  years	  from	  birth	  (age	  at	  the	  onset	  of	  
progression)	  (Tremlett	  et	  al.,	  2008a).	  Being	  male	  and	  older	  at	  onset	  associated	  with	  a	  
shorter	  time	  to	  SP.	  Among	  SP	  patients	  (n	  =	  1415),	  the	  information	  on	  the	  EDSS	  score	  
at	  the	  onset	  of	  progression	  was	  available	  for	  913	  (64.5%);	  24%	  reached	  SP	  at	  ≤	  EDSS	  
3,	  80%	  at	  ≤	  EDSS	  6	  and	  99%	  at	  ≤	  EDSS	  8	  (Tremlett	  et	  al.,	  2008a).	  This	  was	  in	  contrast	  
with	   the	   LO	   population,	   where	   only	   approximately	   30%	   of	   patients	   attained	  
progression	  after	  DSS	  3	  (Figure	  4.9,	  Chapter	  4).	  	  	  
	  
In	  the	  Lyon	  and	  Lorraine	  databases,	  males,	  groups	  older	  at	  onset	  and	  with	  a	  longer	  
first	   inter-­‐attack	   interval	   had	   a	   higher	   probability	   of	   entering	   the	   SP	   phase	   and	   a	  
shorter	   latency	   to	   progression	   (Debouverie	   et	   al.,	   2008;	   Vukusic	   and	   Confavreux,	  
2003).	   Interestingly,	   in	   the	   Gothenburg	   database,	   men	   and	   women	   exhibited	   the	  
same	  risk	  of	  converting	   to	  SP	  MS	   (Eriksson	  et	  al.,	  2003).	  Bergamaschi	  et	  al.	  used	  a	  
different	   statistical	   approach	   and	   developed	   a	   Bayesian	   model,	   which	   confirmed	  
older	  age	  at	  onset,	  and	  male	  sex	  as	  unfavourable	  prognostic	  factors	  (Bergamaschi	  et	  
al.,	   2001).	   Other	   studies	   reported	   a	   higher	   probability	   of	   becoming	   SP,	   among	  
patients	   with	   multiple	   symptoms	   at	   the	   clinical	   onset	   (Amato	   et	   al.,	   1999;	  
Debouverie	   et	   al.,	   2008;	   Phadke,	   1990).	   However,	   the	   type	   of	   the	   initial	   clinical	  
manifestations	  has	  little	  effect	  on	  the	  time	  to	  SP	  (Tremlett	  et	  al.,	  2008a;	  Trojano	  et	  
al.,	  1995;	  Vukusic	  and	  Confavreux,	  2003).	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6.1.2	  Factor	  affecting	  the	  evolution	  of	  the	  SP	  phase	  
	  
Results	   from	   MS	   cohorts	   converge	   in	   demonstrating	   that	   most	   of	   the	   factors,	  
affecting	  the	  evolution	  of	  the	  RR	  phase,	  do	  not	  exert	  any	  impact	  on	  the	  slope	  of	  the	  
SP	  phase.	  In	  the	  Lyon	  (Vukusic	  and	  Confavreux,	  2003),	  the	  British	  Columbia	  (Tremlett	  
et	  al.,	  2008a)	  and	  the	  Gothenburg	  (Eriksson	  et	  al.,	  2003)	  databases,	  gender	  and	  the	  
type	  of	  symptoms	  at	  the	  clinical	  presentation	  were	  found	  not	  to	  influence	  the	  times	  
from	  the	  onset	  of	  SP	  to	  disability	  endpoints.	  In	  the	  LO	  database,	  the	  age	  at	  the	  onset	  
of	   the	   RR	   phase	   and	   the	   age	   at	   the	   onset	   of	   progression	   did	   not	   impact	   on	   the	  
evolution	  of	  the	  SP	  phase	  (Figures	  5.6,	  5.18,	  Chapter	  5).	  In	  contrast,	  among	  patients	  
from	  British	  Columbia,	  a	  younger	  age	  at	  the	  onset	  of	  the	  RR	  phase	  and	  an	  older	  age	  
at	  the	  onset	  of	  the	  SP	  phase	  associated	  with	  a	  slower	  rate	  of	  disability	  accumulation	  
during	  the	  progressive	  phase	  (Tremlett	  et	  al.,	  2008a).	  	  
	  
6.1.3	  Latency	  to	  SP	  and	  the	  evolution	  of	  the	  SP	  phase	  
	  
Only	   three	   studies	  assessed	   the	   time	   to	   SP	  as	   a	  predictor	  of	   the	  disease	  evolution	  
during	   the	   SP	   phase.	   In	   the	   Gothenburg	   database,	   a	   latency	   to	   progression	   ≤	   10	  
years,	  compared	  to	  >	  10	  years,	  associated	  with	  an	  increased	  risk	  (2.4	  time	  higher)	  of	  
attaining	   EDSS	   7	   from	   the	   onset	   of	   SP	   (Eriksson	   et	   al.,	   2003).	   In	   the	   Lyon	   cohort,	  
patients	  who	  converted	  to	  SP	  MS	  within	  or	  after	  8	  years	  were	  compared.	  A	   longer	  
duration	  of	  the	  RR	  phase	  predicted	  slightly	  longer	  times	  from	  SP	  to	  DSS	  6	  (1.4	  mean	  
years	   difference)	   and	   to	  DSS	   7	   (1	  mean	   year	   difference)	   (Vukusic	   and	   Confavreux,	  
2003).	  The	  British	  Columbia	  patients	  were	  stratified	  in	  3	  categories,	  according	  to	  the	  
latency	  to	  progression	  (short	  <	  10;	  intermediate	  10	  to	  <	  20;	  long	  ≥	  20).	  The	  analysis	  
demonstrated	  that	  the	  group	  with	  short,	  compared	  to	  the	  groups	  with	  intermediate	  
and	   long	   time	  to	  SP,	   reached	  EDSS	  8	   from	  the	  onset	  of	  progression	   in	   faster	   times	  
(2.8	  and	  5.5	  mean	  years	  difference,	  respectively)	  (Tremlett	  et	  al.,	  2008a).	  However,	  
the	   proportion	   of	   patients	   becoming	   bedbound	  was	   low,	   as	   shown	   by	   the	   Kaplan	  
Meier	  estimate,	  which	  was	  calculated	  for	  25%	  only.	   In	  addition,	  although	  a	  shorter	  
duration	  of	  the	  RR	  phase	  associated	  with	  a	  shorter	  evolution	  of	  the	  SP	  phase,	  those	  
older	  at	  the	  onset	  of	  the	  RR	  phase	  converted	  more	  quickly	  to	  SP	  MS,	  but	  took	  longer	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times	   to	   reach	   DSS	   8	   from	   onset	   of	   progression	   (Tremlett	   et	   al.,	   2008a).	   These	  
contradicting	  results	  were	  not	  addressed	  by	  the	  authors.	  
	  
6.1.4	  Aim	  of	  the	  study	  presented	  in	  this	  chapter	  
	  
Thanks	  to	  the	  high	  number	  of	  patients	  who	  had	  converted	  to	  SP	  MS,	  by	  the	  end	  of	  
the	   observation	   period,	   the	   LO	   database	   offered	   the	   opportunity	   to	   investigate	   in	  
details	   factors	   affecting	   the	   disease	   course	   before	   and	   after	   the	   onset	   of	   the	  
secondary	   progressive	   phase.	   This	   allowed	   to	   further	   elucidate	   the	   relationship	  
between	  mechanisms	  driving	  the	  evolution	  of	  the	  RR	  phase	  and	  the	  accumulation	  of	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6.2	  Methods	  
	  
Among	  relapsing	  onset	  patients,	  the	  Kaplan	  Meier	  analysis	  was	  used	  to	  estimate	  the	  
time	  to	  the	  onset	  of	  the	  SP	  phase	  and,	  among	  SP	  patients,	  to	  estimate	  the	  time	  to	  
attain	   DSS	   8,	   from	   the	   onset	   of	   progression.	   Patients	   were	   grouped	   according	   to	  
baseline	  clinical	  and	  demographic	  features,	  in	  order	  to	  test	  the	  predict	  effect	  of	  the	  
following	   variables:	   gender,	   the	   age	   at	   the	   disease	   onset,	   the	   number	   of	   relapses	  
during	   the	   first	   two	   years	   (early	   relapses),	   the	   type	   (motor,	   sensory,	   cerebellar,	  
brainstem,	   optic)	   and	   the	   number	   (1,	   >	   1)	   of	   neurological	   systems	   affected	   at	   the	  
disease	   onset.	   The	   Log	  Rank	   test	   assessed	   the	   differences	   among	   groups.	   Patients	  
not	  reaching	  DSS	  8	  or	  not	  reaching	  SP,	  but	   followed	  for	  known	  periods,	  were	  right	  
censored.	   In	   the	  analyses	  of	   the	   time	   to	   the	  onset	  of	   SP	  and	  of	   the	   time	   to	  DSS	  8	  
from	   the	   onset	   of	   SP,	   37	   and	   60	   patients,	   respectively,	  were	   excluded	   because	   of	  
missing	  information	  on	  the	  disease	  duration	  or	  on	  the	  time	  to	  the	  endpoint.	  	  
	  
Multiple	   Cox	   proportional	   hazard	   analysis	   was	   used	   to	   investigate	   the	   risk	   of	  
developing	   secondary	   progressive	   MS	   and	   of	   reaching	   DSS	   8	   from	   the	   onset	   of	  
progression,	   according	   to	   the	   concomitant	   effect	   of	   all	   clinical	   and	   demographic	  
features.	   Proportional	   hazards	   assumption	   was	   checked	   by	   visual	   inspection	   of	  
Schoenfeld	  residual	  plots	  and	  corresponding	  statistical	  tests.	   In	  addition,	  within	  the	  
SP	  MS	  group,	   the	  Kaplan	  Meier	  analysis	  was	  used	   for	  assessing	   (1)	   times	   from	   the	  
disease	  onset	  and	  from	  the	  onset	  of	  SP	  to	  DSS	  6	  and	  to	  DSS	  8,	  in	  patients	  stratified	  
by	  the	  duration	  of	  the	  RR	  phase	  (latency	  to	  SP:	  short=1–5	  years;	  intermediate=6–12	  
years;	  long	  ≥	  13	  years);	  (2)	  the	  time	  to	  DSS	  6	  and	  to	  DSS	  8,	  from	  the	  disease	  onset,	  in	  
patients	   stratified	   by	   the	   duration	   of	   the	   RR	   phase	   and	   by	   the	   number	   of	   total	  
relapses	  during	  the	  RR	  phase	  (low	  =	  1–2;	  intermediate	  =	  3–4;	  high	  ≥	  5	  attacks)	  and	  in	  
patients	   stratified	   by	   the	   duration	   of	   the	   RR	   phase	   and	   by	   the	   number	   of	   early	  
relapses	   (low	   =	   1;	   intermediate	   =	   2;	   high	   ≥	   3	   attacks).	   Groups	   were	   computed	   in	  
order	   to	   maintain,	   to	   the	   possible	   extent,	   similar	   numbers	   in	   each	   category.	  
However,	   the	   analyses	   were	   also	   carried	   out	   among	   patients	   with	   different	  
stratifications,	  for	  confirming	  results.	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Finally,	  the	  binary	  logistic	  regression	  analysis	  was	  used	  to	  calculate	  the	  independent	  
predictive	  effect	  of	  the	  disease	  duration,	  the	  frequency	  of	  early	  relapses	  and	  the	  age	  
at	   the	  disease	  onset	  on	  the	  probability	  of	  entering	  the	  SP	  phase,	  expressed	  by	  OR.	  
The	  multiple	  binary	  logistic	  regression	  analysis	  allowed	  to	  build	  up	  models	  predicting	  
the	  variation,	  according	  to	  the	  disease	  duration,	  of	  the	  probability	  of	  converting	  to	  


















































Table	  6.1	  Clinical	  and	  demographic	  features	  of	  patients	  stratified	  by	  the	  type	  of	  the	  disease	  course	  at	  
the	  end	  of	  the	  observation	  period	  (RR	  and	  SP	  MS).	  *	  Chi	  Square	  test;	  **	  Wilcoxon	  rank	  test.	  	  	  
	  	  
	  
Among	  relapsing	  onset	  patients	  (n	  =	  806),	  by	  the	  end	  of	  the	  observation	  period,	  66.3	  
%	   (n	  =	  534)	  had	  converted	   to	  SP	  MS	  and	  33.7%	   (n	  =	  272)	  had	   remained	   in	   the	  RR	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phase	   (Table	   6.1).	   In	   the	  RR	   group,	   compared	   to	   the	   SP	   group,	   there	  was	   a	   larger	  
percentage	   of	   women	   (76.5%	   versus	   64.8%;	   p	   <	   0.001),	   patients	   were	   slightly	  
younger	   at	   the	   disease	   onset	   (26.8	   versus	   29.4	   mean	   years;	   p	   <	   0.001)	   and	   had	  
shorter	  disease	  duration	  (20.3	  versus	  26.5	  mean	  years;	  p	  <	  0.001).	  However,	  in	  both	  
groups,	  the	  frequency	  of	  early	  relapses	  was	  similar	  (0.97	  versus	  0.91	  attacks/year;	  p	  
=	  0.18)	  and	  most	  of	  the	  patients	  presented	  with	  a	  mono-­‐symptomatic	  onset,	  which	  
was	  mainly	   characterized	   by	   sensory	   disturbances.	   Among	   those	  with	   SP	  MS,	   92%	  
reached	   DSS	   6,	   68%	   reached	   DSS	   8	   and	   23%	   reached	   DSS	   10;	   the	   times	   to	   the	  
endpoints	  were	  14,	   24	   and	  45	  median	   years	   from	  disease	  onset	   and	  3,	   12	   and	  30	  
median	  years	  from	  the	  onset	  of	  SP,	  respectively	  (Table	  6.1).	  	  	  
6.3.1	  The	  attainment	  of	  the	  secondary	  progressive	  phase	  	  
	  
The	  rate	  of	  conversion	  to	  SP	  MS	  increased	  proportionally	  over	  time.	  The	  percentage	  
of	  patients	  entering	  the	  SP	  phase	  was	  larger	  in	  the	  groups	  observed	  for	  longer	  time	  
(Figure	   6.1).	   Accordingly,	   the	   binary	   logistic	   regression	   analysis	   calculated	   that	   the	  
probability	  of	  becoming	  progressive	  became	  9%	  higher	  every	  5	  years	  of	  the	  disease	  
duration	   (OR	   =	   1.07	   per	   additional	   year;	   p	   <	   0.001).	   The	   hazard	   of	   attaining	   the	  
secondary	  progression	  doubled	  (OR	  =	  1.99,	  probability	  =	  43.9%)	  and	  quadrupled	  (OR	  
=	   3.97,	   probability	   =	   61.1%)	   after	   10	   and	   20	   years	   from	   the	   disease	   onset,	  
respectively	  (Figure	  6.2).	  This	  effect	  was	  independent	  of	  the	  age	  at	  the	  disease	  onset	  
(Chapter	  5).	  	  
	  
The	   Kaplan	   Meier	   analysis	   allowed	   to	   calculate	   the	   latency	   to	   progression	   in	   the	  
relapsing	   onset	   group;	   37	   patients	   were	   excluded	   from	   the	   analysis	   because	   of	  
missing	   information	   on	   the	   disease	   duration	   or	   on	   the	   time	   to	   SP.	   Among	   the	  
remaining	   769	  patients,	   the	   estimated	  mean	   time	   to	   enter	   the	   SP	  phase	  was	   21.4	  
(95%	  CI:	  19.5-­‐23.1)	  years.	  By	  6	  and	  15	  (median	  time)	  years	  from	  onset,	  25%	  (n	  =	  181)	  
and	  50%	   (n	  =	  387),	   respectively,	  had	  become	  SP	  MS.	   Few	  additional	  patients,	   to	  a	  
final	   total	   of	   66%,	   attained	   progression	   in	   the	   following	   20	   years	   (Figure	   6.3).	  
Accordingly,	   the	   rate	   of	   conversion	   to	   SP	  MS	  was	  much	   higher	   during	   the	   first	   15	  
years	  (25.8	  patients/year)	  of	  disease	  duration	  than	  during	  the	  following	  15	  years	  (8.1	  
	   360	  
patients/year).	  The	  comparison	  of	  the	  time	  to	  SP,	  between	  the	  total	  population	  and	  
the	  geographically	  ascertained	  subgroup	  from	  Middlesex	  County,	  did	  not	  show	  any	  
statically	  significant	  difference	  (Figure	  6.4).	  
	  
	  
Figure	  6.1	  Percentages	  (x-­‐axis)	  of	  patients	  converting	  to	  SP	  MS	  in	  each	  disease	  duration	  category	  (y-­‐
axis).	  Exact	  value	  is	  indicated	  next	  to	  each	  bar.	  	  
	  
	  	  	  	  
Figure	   6.2	   Binary	   logistic	   regression	  analysis:	   calculated	   risk	   (ORs	  on	  y-­‐axis)	  of	   converting	   to	   SP	  MS	  
according	  to	   the	  disease	  duration	   (x-­‐axis):	  OR	  per	  additional	  year	  =	  1.07.	  The	  probabilities	  of	  SP	   for	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Figure	  6.3	  Kaplan	  Meier	  analysis	  of	  time	  to	  SP:	  cumulative	  percentage	  (y-­‐axis)	  of	  patients,	  in	  the	  total	  
population,	  entering	  the	  SP	  phase	  over	  time	  (x-­‐axis).	  	  
	  





Figure	  6.4	  Kaplan	  Meier	  analysis	  of	  the	  time	  to	  SP:	  comparison	  between	  the	  total	  population	  and	  the	  
Middlesex	  County	  subgroup.	  P	  value	  was	  obtained	  with	  Log	  Rank	  test.	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Figure	  6.5	  Percentages	   (y-­‐axis)	  of	  SP	  patients	  entering	  the	  progressive	  phase	  at	  different	   time	  from	  
onset	  (x-­‐axis):	  percentages	  are	  calculated	  within	  each	  disease	  duration	  group	  (0-­‐5;	  6-­‐10;	  11-­‐15;	  16-­‐20;	  
21-­‐25;	  26-­‐30;	  31-­‐35;	  36-­‐40).	  Percentiles	  of	   time	   from	   the	  disease	  onset	   to	   the	  onset	  of	   SP	  are	  also	  
indicated.	  	  	  	  	  
	  	  	  	  
At	  end	  of	  the	  observation	  period,	  within	  the	  group	  of	  RR	  patients	  (n	  =	  272),	  50%	  had	  
been	   observed	   for	   20	   years	   (median	   disease	   duration).	   However,	   in	   26%	   (n	   =	   71)	  
progression	  did	  not	  supervene	  after	  ≥	  24	  years	  of	  disease	  duration,	  and	  for	  some	  (n	  
=	  13)	  of	  them	  not	  even	  after	  ≥	  40	  years.	  Among	  SPMS	  patients	  (n	  =	  534),	  the	  latency	  
to	   progression	   widely	   varied,	   from	   1	   to	   36	   years;	   it	   ranged	   from	   5	   years	   in	   the	  
quickest	  25%,	  to	  more	  than	  15	  years	  in	  the	  slowest	  25%	  (Figure	  6.5).	  The	  mean	  time	  
to	  enter	  the	  progressive	  phase	  was	  10.7	  years	  (95%	  CI	  =	  10.0-­‐11.3):	  by	  5,	  9	  (median	  
time)	  and	  15	  years,	  25%,	  50%	  and	  75%,	  respectively,	  converted	  to	  SP	  MS	  (Figure	  6.5).	  	  	  
6.3.2	  The	  latency	  to	  progression	  and	  the	  late	  outcomes	  	  	  
The	   association	   between	   the	   latency	   to	   progression	   and	   the	   risk	   of	   developing	  
severe	   disability	   was	   examined	   using	   the	   binary	   logistic	   regression	   analysis.	   The	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relationship	  between	  the	  time	  to	  SP	  and	  the	  probability	  of	  reaching	  the	  DSS	  levels.	  A	  
longer	  duration	  of	  the	  RR	  phase	  correlated	  with	  a	  proportionally	  lower	  probability	  of	  
attaining	   DSS	   6	   (regression	   coefficient	   =	   -­‐0.055;	   OR	   =	   0.95	   [95%	   CI	   0.90-­‐0.98]	   per	  
additional	  year;	  p	  =	  0.01)	  and	  DSS	  8	  	  (regression	  coefficient	  =	  -­‐0.055;	  OR	  =	  0.95	  [95%	  
CI	  0.92-­‐0.97]	  per	  additional	  year;	  p	  <	  0.001).	  Among	  patients	  free	  from	  progression	  
for	  5,	  10	  and	  15	  years,	  the	  hazard	  of	  requiring	  a	  walking	  aid	  was	  reduced	  by	  24%	  (OR	  
=	  0.76),	  43%	  (OR	  =	  0.58)	  and	  56%	  (OR	  =	  0.44),	  respectively	  (Figure	  6.6).	  	  
	  
The	  attainment	  of	  disability	  endpoints	  from	  the	  disease	  onset	  and	  from	  the	  onset	  of	  
SP	  was	  assessed	  among	  patients	  grouped	  by	  the	  duration	  of	  the	  RR	  phase	  	  (short	  =	  1-­‐
5	   yeas;	   intermediate	   =	   6-­‐12	   years;	   long	   ≥	   13	   years).	   The	   Kaplan	   Meier	   analysis	  
demonstrated	   that	   groups	   with	   a	   shorter	   latency	   to	   progression	   reached	   the	   DSS	  
levels,	   from	   the	   onset	   of	   the	   disease,	   in	   significantly	   shorter	   times.	   There	   was	   a	  
difference	  of	  15.6	  and	  16.4	  mean	  years	  for	  requiring	  a	  walking	  aid	  and	  for	  becoming	  
bedbound,	  respectively,	  between	  patients	  with	  a	  short	  and	   long	  time	  to	  SP	   (Figure	  
6.7).	  These	  differences	  disappeared	  once	  the	  SP	  phase	  supervened.	  Times	  to	  DSS	  6	  
and	   to	   DSS	   8,	   from	   the	   onset	   of	   SP	   were	   very	   similar,	   among	   groups,	   and	   were	  
largely	  unaffected	  by	  the	  duration	  of	  the	  RR	  phase	  (Figure	  6.8)	  	  	  	  	  
Figure	   6.6	   Binary	   logistic	   regression	   analysis:	   calculated	   risk	   (ORs	   on	   y-­‐axis)	   of	   attaining	   DSS	   6	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Figure	  6.7	  Kaplan	  Meier	  analysis:	  times	  from	  the	  disease	  onset	  to	  DSS	  6	  and	  to	  DSS	  8,	  among	  patients	  
stratified	  by	  the	  duration	  of	  the	  RR	  phase	  (short,	  intermediate	  and	  long).	  Percentiles	  of	  the	  estimated	  
times	  to	  disability	  endpoints	  in	  each	  group	  are	  indicated.	  P	  values	  were	  obtained	  with	  Log	  Rank	  test	  
by	  comparison	  with	  the	  reference	  category	  (*).	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Figure	  6.8	  Kaplan	  Meier	  analysis:	  times	  from	  the	  onset	  of	  SP	  to	  DSS	  6	  and	  to	  DSS	  8,	  among	  patients	  
stratified	  by	  the	  duration	  of	  the	  RR	  phase	  (short,	  intermediate	  and	  long).	  Percentiles	  of	  the	  estimated	  
times	  to	  disability	  endpoints	  in	  each	  group	  are	  indicated.	  P	  values	  were	  obtained	  with	  Log	  Rank	  test	  
by	  comparison	  with	  the	  reference	  category	  (*).	  	  	  	  	  
	  	  
	  
The	  predictive	  effect	  of	  the	  latency	  to	  progression	  was	  also	  assessed	  among	  patients	  
grouped	  by	  the	  number	  of	  early	  (Table	  6.3)	  and	  total	  (Table	  6.4)	  relapses.	  Even	  when	  
patients	   shared	   the	   same	   number	   of	   attacks	   during	   the	   first	   2	   years	   or	   the	   same	  
number	  of	  total	  attacks	  before	  the	  onset	  of	  progression,	  a	  shorter	  duration	  of	  the	  RR	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6.3.3	  Factors	  affecting	  the	  onset	  of	  SP	  MS	  	  	  	  
The	  Kaplan	  Meier	  survival	  analysis	  demonstrated	  that	  male	  sex,	  an	  older	  age	  at	  the	  
disease	   onset	   and	   a	   higher	   early	   relapse	   frequency	   associated	  with	   a	   significantly	  
shorter	  time	  to	  the	  onset	  of	  SP	  (Table	  6.4).	  There	  was	  a	  difference	  of	  6.5	  mean	  years	  
between	  males	   (15.9	  years)	  and	   females	   (22.4	  years)	   for	  becoming	  progressive.	  As	  
extensively	   discussed	   in	   Chapter	   4	   and	   5,	   a	   high	   early	   relapses	   frequency	   and	   an	  
older	  age	  at	   the	  onset	  of	   the	  RR	  phase	  predicted	  a	   shorter	   latency	   to	  progression.	  
The	   type	   and	   the	   number	   of	   symptoms	   at	   the	   clinical	   onset	   did	   not	   significantly	  
affect	   the	   duration	   of	   the	   RR	   phase.	   The	   multiple	   Cox	   regression	   analysis,	   which	  
assessed	   the	   concomitant	   predictive	   effect	   of	   all	   baseline	   features,	   confirmed	   a	  
higher	  probability	  of	  becoming	  SPMS	   in	  males	   (HR	  =	  1.41	  versus	   females),	   in	  those	  
older	  at	  the	  disease	  onset	   (HRs:	  age	  ≤	  20	  versus	  age	  >	  30	  =	  0.52;	  age	  21-­‐30	  versus	  
age	   >	   30	   =	   0.65)	   and	   in	   those	   with	   a	   high	   early	   relapse	   frequency	   (HRs:	   1	   attack	  
versus	  ≥	  3	  attacks	  =	  0.63,	  2	  attacks	  versus	  ≥	  3	  attacks	  =	  0.75)	  (Table	  6.4).	  	  
	  
The	  multiple	  binary	  logistic	  regression	  analysis	  allowed	  to	  calculate	  the	  probability	  of	  
becoming	  progressive	  based	  on	  the	  number	  of	  early	  relapses	  (regression	  coefficient	  
=	  0.101;	  OR	  =	  1.11	  [95%CI	  =	  0.96-­‐1.27]	  per	  additional	  relapse)	  and	  based	  on	  the	  age	  
at	  disease	  onset	   (regression	  coefficient	  =	  0.049;	  OR	  =	  1.05	   [95%CI	  =	  1.02-­‐1.07]	  per	  
additional	   year),	   and	   its	   variation	   according	   to	   the	   disease	   duration	   (regression	  
coefficient	  =	  0.074;	  OR	  =	  1.08	  [95%CI	  =	  1.05-­‐1.09]	  per	  additional	  year).	  By	  combining	  
the	   effect	   of	   the	   3	   variables,	   the	   risk	   of	   converting	   to	   SP	   MS	   was	   computed	   to	  
simulate	   hypothetical	   clinical	   scenarios	   (Figure	   6.9).	   Two	   years	   after	   the	   disease	  
onset,	  3	  relapses	  (grey	  columns)	  yielded	  OR	  4.1,	  6.7,	  10.9	  among	  patients	  aged	  20,	  
30	   or	   40	   at	   first	   symptom,	   respectively.	   In	   each	   subgroup,	   the	   probability	   of	  
becoming	  SP	  MS	  increased	  with	  the	  disease	  duration	  and	  became	  double	  at	  10	  years	  
(OR	  7.5,	  12.1,	  19.8,	  respectively),	  approximately	  5-­‐fold	  higher	  at	  20	  years	  (OR	  15.6,	  
25.5,	   41.4,	   respectively)	   and	   6-­‐fold	   higher	   at	   25	   years	   (OR	   22.6,	   36.9,	   60.0,	  
respectively),	  from	  the	  disease	  onset.	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Table	  6.4	  Kaplan	  Meier	  analysis:	  estimated	  times	  from	  the	  disease	  onset	  to	  the	  onset	  of	  the	  SP	  phase,	  
among	  patients	  grouped	  by	  clinical	  and	  demographic	  features.	  Multiple	  Cox	  regression	  analysis:	  risk	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Figure	   6.9	   Multiple	   binary	   Logistic	   regression	   analysis:	   calculated	   probability	   (ORs	   on	   y-­‐axis)	   of	  
converting	  to	  SP	  MS,	  according	  to	  the	  concomitant	  effect	  of	  the	  age	  at	  onset	  (20,	  30	  and	  40	  years),	  
the	  number	  of	  early	  relapses	  (1,	  2	  and	  ≥	  3	  attacks:	  blue,	  red	  and	  grey	  columns,	  respectively)	  and	  the	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6.3.4	  Factors	  affecting	  the	  evolution	  of	  SP	  MS	  	  
	  
Table	   6.5	   Kaplan	   Meier	   analysis:	   estimated	   times	   from	   the	   onset	   of	   SP	   to	   DSS	   8	   among	   patients	  
grouped	  by	  clinical	  and	  demographic	  features.	  Multiple	  Cox	  regression	  analysis:	  risk	  (HR)	  of	  attaining	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The	  Kaplan	  Meier	  analysis	  estimated	  15.2	  (95%	  CI:	  13.7-­‐16.5)	  mean	  years	  as	  the	  time	  
for	  reaching	  DSS	  8,	  from	  the	  onset	  of	  progression.	  Half	  of	  the	  patients	  attained	  the	  
endpoint	   within	   12	   years	   (median	   time),	   from	   the	   conversion	   to	   SPMS.	   Although	  
they	  predicted	  the	  time	  SPMS,	  gender	  and	  age	  at	  disease	  onset	  were	  found	  not	  to	  
affect	  the	  time	  from	  SP	  to	  DSS	  8	  (Table	  6.5).	  As	  previously	  shown	  (Chapter	  4),	  a	  high	  
early	  relapse	  frequency	  associated	  with	  a	  faster	  evolution	  of	  the	  progressive	  phase.	  
In	  addition,	  those	  who	  presented	  with	  brainstem	  and	  cerebellar	  symptoms	  at	  onset	  
attained	  more	  rapidly	  DSS	  8,	  from	  the	  onset	  of	  progression	  (Table	  6.5).	  These	  results	  
were	  confirmed	  by	  the	  Cox	  regression	  multiple	  analysis,	  which	  also	  showed	  a	  slightly	  
higher	  risk	  (HR=	  1.55)	  of	  becoming	  bedbound,	  from	  the	  onset	  of	  progression,	  among	  


























Among	  MS	   patients,	   the	   attainment	   of	   severe	   outcomes	   (DSS	   6	   or	   worse)	   almost	  
invariably	   results	   from	   the	   relentless	   accrual	   of	   disability,	   which	   characterizes	   the	  
progressive	   course.	   Undoubtedly,	   the	   onset	   of	   the	   progressive	   phase	   is	   the	   key	  
determinant	  of	  the	  long-­‐term	  disease	  evolution.	  The	  number	  of	  early	   inflammatory	  
attacks	   and	   the	   age	   at	   the	   disease	   onset,	   which	   are	   the	   strongest	   predictors	   of	  
prognosis,	   affect	   the	   attainment	   of	   late	   disability	   by	   increasing	   the	   probability	   of	  
entering	   the	   SP	   phase	   and	   by	   shortening	   the	   latency	   to	   progression	   (Figure	   4.10,	  
Chapter	   4	   and	   Figure	   5.5,	   Chapter	   5).	   However,	   the	   rate	   of	   the	   disability	  
accumulation	   during	   the	   progressive	   phase	  was	   shown	   to	   be	   uninfluenced	   by	   late	  
(Table	   4.17,	   Chapter	   4)	   and	   superimposed	   relapses	   (Confavreux	   et	   al.,	   2000;	  
Kremenchutzky	   et	   al.,	   1999a),	   to	   be	   homogeneous	   among	   progressive	   subtypes	  
(Kremenchutzky	  et	  al.,	  2006a)	  and	  to	  be	  independent	  of	  factors	  preceding	  its	  onset	  
(Confavreux	   et	   al.,	   2003;	   Eriksson	   et	   al.,	   2003;	   Leray	   et	   al.,	   2010;	   Tremlett	   et	   al.,	  
2008a).	   Therefore,	   the	   outcome	   is	   largely	   determined	   before	   the	   onset	   of	  
progression,	   by	   the	   mechanisms	   driving	   the	   evolution	   of	   the	   RR	   phase,	   and	   the	  
conversion	  to	  SP	  MS	  is	  a	  robust	  marker	  for	  late	  disability.	  	  
	  
Although	   factors	   affecting	   the	   probability	   of	   converting	   to	   SP	  MS	  were	   previously	  
investigated	  in	  other	  cohorts,	  results	  were	  not	  always	  consistent.	  The	  LO	  database	  is	  
advantaged	   by	   a	   long	   follow	   up,	   which	   allowed	   to	   observe	   a	   large	   proportion	   of	  
relapsing	   onset	   patients	   entering	   the	   SP	   phase.	   This	   offered	   the	   opportunity	   to	  
further	  investigate	  clinical	  and	  demographic	  features	  affecting	  the	  occurrence	  of	  the	  
progressive	  course	  and	  to	  elucidate	  the	  relationship	  between	  the	  evolution	  of	  the	  RR	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6.4.1	  Defining	  the	  onset	  of	  SP	  MS	  
	  
Defining	  the	  onset	  of	  the	  SP	  phase	  requires	  retrospective	  assessments	  and	  it	  is	  rarely	  
straightforward.	  Remission	   from	   inflammatory	  attacks	  can	  occur	  even	  after	  several	  
months,	   potentially	   clouding	   the	   clinical	   onset	   of	   the	   progressive	   phase	  
(Kremenchutzky	  et	  al.,	  2006a).	  Determining	  exactly	  when	  the	  transition	  from	  RR	  to	  
SP	  MS	  takes	  place	  can	  be	  particularly	  challenging	  in	  patients	  who	  start	  to	  progress,	  
but	   continue	   to	   relapse.	   In	   these	   cases	   the	   accrual	   of	   irreversible	  disability	   can	  be	  
caused	  either	  by	  the	  lack	  of	  recovery	  from	  the	  relapses	  or	  by	  the	  progressive	  phase,	  
and	   the	   two	   mechanisms	   are	   not	   easily	   discernable.	   This	   is	   less	   problematic	   if	  
progression	  supervenes	  after	  only	  few	  attacks	  or	  when	  the	  motor	  disability	  has	  not	  
developed	  yet	   (Kremenchutzky	  et	  al.,	  2006a).	  Despite	   this,	  evidence	  suggests	  good	  
inter-­‐examiner	  reliability	  in	  assigning	  the	  time	  to	  enter	  the	  progressive	  phase	  (Amato	  
et	   al.,	   2004b).	   In	   the	   EVALUED	   study,	   involving	   180	   patients	   from	   6	   European	  
centres,	  the	  2	  assessors	  from	  each	  clinic	  had	  substantial	  agreement	  (k	  =	  0.76)	  when	  
deciding	   on	   the	   development	   of	   secondary	   progression	   (both	   examiners	   agreed	  
within	  1	  years	  in	  72%	  of	  cases)	  (Amato	  et	  al.,	  2004b).	  	  
	  
Given	  its	  relevance	  as	  clinical	  outcome,	  the	  information	  on	  the	  onset	  of	  progression,	  
among	   LO	   patients,	   was	   extensively	   audited.	   In	   order	   to	   conform	   to	   the	   latest	  
international	   consensus	   on	   the	   classification	   of	   the	   disease	   course	   (Lublin	   and	  
Reingold,	   1996),	   clinical	   data	   of	   those	   cases	   previously	   defined	   as	   relapsing	  
progressive	  MS	  were	  carefully	  checked	  (Kremenchutzky	  et	  al.,	  1999a).	  Few	  of	  them	  
were	   categorized	   as	   RR	   MS,	   because	   they	   had	   a	   relapsing	   disease	   with	   no	  
progression	  between	  relapses.	  The	  remaining	  patients	  were	  allocated	   in	  the	  SP,	  PP	  
and	  PR	  groups.	   In	  view	  of	   the	  similar	  demographic	  and	  clinical	   features	  and	  of	   the	  
same	  long-­‐term	  outcome,	  those	  with	  PR	  MS	  were	  incorporated	  into	  the	  PP	  category	  
(Kremenchutzky	   et	   al.,	   1999a).	   According	   to	   the	   new	   definition,	   the	   progressive	  
disease,	  preceded	  or	  not	  by	  a	  RR	  phase,	  had	  to	  be	  characterized	  by	  at	  least	  1	  year	  of	  
continuous	   deterioration,	   regardless	   the	   rate	   of	   worsening.	   In	   the	   relentless	  
progressive	   course	   temporary	   improvements	   were	   allowed,	   although	   steady	  
accumulation	  of	  disability	  was	  the	  rule	  (Kremenchutzky	  et	  al.,	  1999a;	  Kremenchutzky	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et	   al.,	   2006a).	   This	   definition	   offered	   high	   reliability	   of	   a	   correct	   classification	   of	  
progressive	  patients,	  as	  the	  likelihood	  of	  remission	  after	  such	  a	  long	  interval	  is	  very	  
low.	   In	   addition,	   the	   yearly	   assessments,	   in	   most	   of	   the	   cases,	   facilitated	   the	  
retrospective	  determination	  of	   the	  onset	  of	   the	  progressive	  phase	   (Kremenchutzky	  
et	  al.,	  1999a).	  	  
	  
As	  extensively	  outlined	  in	  methods	  (Chapter	  2),	  during	  the	  latest	  data	  review	  of	  the	  
LO	  database	   special	  attention	  was	  paid	   to	  address	   the	  problem	  of	   the	  overlapping	  
between	   the	   relapsing	   and	   the	   progressive	   phase.	   Information	   on	   the	   onset	   of	  
progression	  were	  audited	  and	  researcher	  focused	  on	  patients	  who	  have	  had	  multiple	  
relapses	   but	   with	   complete	   recovery,	  making	   the	   insidious	   onset	   of	   the	   SP	   phase	  
identifiable	   at	   an	   early	   stage	   (DSS	   2),	  when	   they	   typically	   complained	   of	   exercise-­‐
induced	  impairment	  of	  the	  ambulation.	  With	  the	  advantage	  of	  frequent	  neurological	  
evaluations,	  in	  few	  cases	  the	  onset	  of	  progression	  could	  be	  even	  identified	  at	  DSS	  1,	  
by	  documenting	  the	  asymptomatic	  emergence	  of	   long	  tract	  signs.	  Overall,	  majority	  
of	  SP	  patients	  attained	   the	  progressive	  course	  at	  or	  before	  DSS	  3	   (Figure	  4.9),	  and	  
the	  great	  majority	  (84.8%)	  of	  SAP	  patients	  at	  or	  before	  DSS	  2	  (Kremenchutzky	  et	  al.,	  
2006a).	  The	  onset	  of	   the	  progressive	  course	  was	  predominantly	  characterized	  by	  a	  
distal	   central	  motor	  dysfunction	  and	   the	  progressive	  deficit	  was	  almost	  exclusively	  
localized	  to	  the	  distal	  lower	  extremity	  corticospinal	  tract	  fibres,	  and	  manifested	  with	  
ambulation	  impairment	  (Kremenchutzky	  et	  al.,	  2006a).	  
	  
This	  extensive	  review	  of	  the	  clinical	  data,	  along	  with	  the	  long	  follow	  up,	  allowing	  to	  
observe	  more	  than	  65%	  of	  relapsing	  patients	  entering	  the	  progressive	  phase,	  makes	  
the	   LO	   database	   particularly	   suitable	   for	   addressing	   in	   details	   the	   onset	   and	   the	  
evolution	  of	  SP	  MS.	  	  
	  
6.4.2	  The	  conversion	  to	  SP	  MS	  
	  
Unsurprisingly,	  the	  analysis	  confirmed	  that	  the	  number	  of	  patients	  converting	  to	  SP	  
MS	  increases	  over	  time.	  More	  than	  80%	  of	  patients	  observed	  for	  more	  than	  25	  years	  
had	   entered	   the	   progressive	   phase	   (Figure	   6.1).	   Accordingly,	   the	   binary	   logistic	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regression	  analysis	  demonstrated	  that	   the	  disease	  duration	   is	  a	  strong	  predictor	  of	  
the	   risk	   of	   becoming	   progressive	   (OR	   =	   1.07,	   for	   each	   additional	   year	   of	   disease	  
duration).	   This	   increased	   by	   9%	   every	   5	   years;	   at	   10	   and	   20	   years	   from	   onset,	  
patients	  had	  2	  (OR	  =	  1.99)	  and	  4	  (OR	  =	  3.97)	  times	  higher	  probability	  to	  covert	  to	  SP	  
MS,	  respectively	  (Figure	  6.2).	   Importantly,	  the	  predictive	  effect	  of	  the	  length	  of	  the	  
disease	  course	  was	   shown	   to	  be	   independent	  of	   the	  age	  at	  onset	  of	   the	  RR	  phase	  
(Chapter	  5).	  This	  has	  relevant	  implication	  for	  the	  patients’	  therapeutic	  management,	  
as	  groups	  with	  a	  longer	  disease	  duration	  are	  necessarily	  at	  higher	  risk	  of	  entering	  the	  
progressive	  course.	  	  
	  
In	  the	  relapsing	  onset	  group,	  the	  Kaplan	  Meier	  estimated	  mean	  time	  to	  SP	  was	  21.4	  
years.	  Half	  of	  patients	  entered	  the	  progressive	  phase	  in	  15	  years	  (median	  time),	  and	  
for	   25%	   progression	   supervened	   very	   rapidly	   (6	   years).	   It	   has	   been	   previously	  
suggested	   that	   the	   rate	   of	   conversion	   from	   a	   remitting	   to	   a	   progressive	   course	   is	  
constant	  over	  time	  (Broman	  et	  al.,	  1981;	  Confavreux	  et	  al.,	  1980;	  Mc	  and	  Compston,	  
1952).	  Nevertheless,	  in	  the	  LO	  population,	  25	  patients	  per	  year	  became	  progressive	  
during	   the	   first	  15	  years	   from	  onset,	   and,	  past	   this	   time	  point,	  only	  8	  patients	  per	  
year	   (Figure	   6.3).	   This	   obviously	   reflected	   the	   different	   disease	   duration,	   among	  
patients,	  but	  also	  depended	  on	  the	  different	  severity	  of	  the	  outcome.	  Indeed,	  among	  
all	  SP	  patients,	  the	  latency	  to	  progression	  largely	  varied	  from	  1	  to	  36	  years	  (median	  
time	   =	   9	   years).	   The	   progressive	   course	   occurred	   within	   5	   years	   in	   the	   quickest	  
quartile	  and	  in	  more	  than	  15	  years	  in	  the	  slowest	  quartile	  (Figure	  6.5).	  	  
	  
By	   the	   end	   of	   the	   observation	   period,	   about	   one	   third	   (n	   =	   272)	   of	   the	   relapsing	  
onset	   group	   had	   not	   entered	   the	   progressive	   phase,	   despite	   their	  median	   disease	  
duration	   of	   20	   years	   (Table	   6.1).	   Although	   most	   of	   the	   patients	   presumably	  
eventually	  developed	  the	  SP	  course,	  a	  minority	   (n	  =	  13;	  5%	  of	  RR	  patients)	  did	  not	  
experience	  progression	  even	  after	  40	  years	  or	  more	   from	  onset.	   	  This	   is	  consistent	  
with	  the	  recently	  reported	  proportion	  (5%)	  of	  patients	  with	  benign	  MS,	  free	  from	  SP	  
after	  50	  years	  of	  follow	  up	  (Skoog	  et	  al.,	  2012).	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As	   observed	   for	   late	   disability,	   among	   patients	   from	   the	   LO	   database,	   the	  median	  
time	   to	   convert	   to	   SP	  MS	   (15	   years)	   was	   slightly	   shorter	   (19	   years),	   compared	   to	  
other	   cohorts	   (Figure	  3.4,	  Chapter	  3).	   There	  are	   several	  possible	  explanations.	   The	  
proportion	  of	   censored	   information	   is	  unlikely	   to	  account	   for	   these	  differences,	   as	  
the	  number	  of	  patients	  attaining	  the	  SP	  phase	  was	  above	  50%	  in	  most	  of	  the	  other	  
databases.	  The	  ascertainment	  bias	  might	  have	  been	  responsible	  for	  the	  recruitment	  
of	   more	   severe	   cases	   among	   LO	   patients,	   however	   this	   seems	   improbable.	   The	  
comparison	   between	   the	   total	   population	   and	   the	   geographically	   ascertained	  
subgroup	   from	   Middlesex	   County	   demonstrated	   no	   difference	   in	   the	   time	   to	   SP	  
(Figure	   6.4).	   It	   remains	   possible	   that	   the	   LO	   patients	   exhibited	   a	  more	   aggressive	  
disease	  course.	  Nevertheless,	  in	  none	  of	  the	  other	  databases	  the	  clinical	  information	  
on	  the	  onset	  of	  progression	  were	  specifically	  reviewed,	  or	  at	  least	  this	  has	  not	  been	  
documented.	   A	   higher	   accuracy	   when	   pinpointing	   the	   clinical	   occurrence	   of	   the	  
steady	   progression	   results	   in	   an	   earlier	   detection	   of	   the	   progressive	   phase,	   which	  
might	   be	   mistakenly	   interpreted	   as	   a	   more	   rapid	   evolution	   of	   the	   RR	   phase,	  
compared	  to	  other	  cohorts.	   Indeed,	  the	  British	  Columbia	  patients	  had	  accumulated	  
an	  unusually	  high	  level	  of	  disability	  before	  starting	  to	  progress;	  more	  than	  50%	  were	  
scored	  between	  EDSS	  3	  and	  EDSS	  6	  and	  19%	  were	  scored	  between	  EDSS	  6	  and	  EDSS	  
8	   (Tremlett	   et	   al.,	   2008a).	   This	   might	   indicate	   that	   the	   onset	   of	   progression	   was	  
detected	  late	  and	  the	  time	  to	  SP	  was	  overestimated.	  	  
	  
6.4.3	  The	  predictive	  value	  of	  the	  latency	  to	  progression	  	  
	  
The	  analysis	  demonstrated	  that	   the	   latency	   to	  progression	  dictates	   the	  “tempo”	  of	  
the	   long-­‐term	   disease	   evolution.	   As	   widely	   evident	   from	   the	   clinical	   practice,	   an	  
earlier	   conversion	   to	   SP	  MS	  associated	  with	   a	  worse	  prognosis.	   The	  binary	   logistic	  
regression	   analysis	   indicated	   that	   the	   probability	   of	   attaining	   the	   disability	  
endpoints,	  from	  the	  disease	  onset,	  decreased	  proportionally	  with	  the	  duration	  of	  the	  
RR	   phase.	   Remaining	   free	   of	   progression	   for	   10	   and	   15	   years	   reduced	   the	   risk	   of	  
requiring	   a	   walking	   aid	   by	   43%	   (OR	   =	   0.58)	   and	   by	   56%	   (OR	   =	   0.44),	   respectively	  
(Figure	   6.6).	   Accordingly,	   when	   patients	   were	  matched	   by	   the	   duration	   of	   the	   RR	  
phase,	   the	   group	  with	   a	   shorter	   latency	   to	   progression	   attained	  DSS	   6	   and	  DSS	   8,	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from	   the	  disease	  onset,	   in	   significantly	   shorter	   times	   (Figure	  6.7).	   Importantly,	   the	  
differences	  among	  groups	  disappeared	  once	  the	  progressive	  phase	  occurred.	  Those	  
with	  short,	  intermediate	  and	  long	  time	  to	  SP	  reached	  the	  disability	  endpoints,	  from	  
the	  onset	  of	  progression,	  in	  similar	  times,	  demonstrating	  that	  the	  evolution	  of	  the	  SP	  
phase	   is	   largely	   unaffected	   by	   the	   duration	   of	   the	   RR	   phase.	   This	  might	   appear	   in	  
contrast	  with	   the	  mild	   predictive	   effect	   exerted	   by	   the	   time	   to	  DSS	   3	   (Table	   4.25,	  
Chapter	   4).	   Among	   relapsing	   onset	   patients,	   a	   shorter	   time	   to	  moderate	   disability	  
associated	   with	   modestly	   shorter	   times	   from	   DSS	   3	   to	   higher	   DSS	   levels.	   The	  
differences	  between	  the	  two	  analyses	  are	  probably	  explained	  by	  the	  selection	  bias,	  
as	  some	  of	  the	  patients	  who	  reached	  DSS	  3	  never	  attained	  higher	  levels	  of	  disability,	  
while	  SP	  patients	  are	  selected	  for	  a	  more	  aggressive	  disease	  course.	  	  
	  
Overall,	  these	  results	  further	  reinforce	  the	  concept	  that	  the	  late	  disease	  evolution	  is	  
amnestic	   of	   the	   initial	   disease	   course	   (Confavreux	   and	   Vukusic,	   2006a)	   and	   the	  
outcome	  is	  largely	  determined	  before	  the	  onset	  of	  progression,	  which	  represents	  the	  
true	   clinical	   watershed,	   separating	   two	   stages	   largely	   independent	   of	   each	   other	  
stages.	   The	   mechanisms,	   leading	   to	   the	   transition	   from	   relapsing	   to	   progressive	  
disease,	   account	   for	   the	   large	   variability	   of	   the	   clinical	   outcome	   among	   patients.	  
Interestingly,	  this	  was	  also	  observed	  when	  patients	  were	  matched	  by	  the	  number	  of	  
early	  and	  total	   relapses	   (Table	  6.2	  and	  6.3),	   further	   indicating	  a	  partial	  dissociation	  
between	  the	  focal	  inflammatory	  attacks	  and	  the	  mechanisms	  driving	  the	  evolution	  of	  
the	   RR	   phase.	   In	   each	   group,	   sharing	   the	   same	   attacks	   frequency,	   an	   earlier	  
conversion	   to	  SP	  MS	  predicted	  shorter	   times	   from	  the	  disease	  onset	   to	  DSS	   levels,	  
and	  the	  latency	  to	  progression	  differentiated	  the	  severity	  of	  the	  disease	  course.	  Even	  
among	  those	  with	  frequent	  early	  relapses	  (≥	  3	  attacks)	  the	  outcome	  largely	  varied,	  
according	   to	   the	   duration	   of	   the	   RR	   phase.	   There	   was	   a	   difference	   of	   15	  median	  
years	   for	   reaching	   DSS	   6,	   between	   the	   group	  with	   short	   and	   the	   group	  with	   long	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6.4.4	  Predicting	  the	  evolution	  of	  the	  RR	  phase	  and	  of	  the	  SP	  phase	  
	  
The	  analysis	  confirmed	  that	  a	  higher	  number	  of	  early	   relapses	  and	  an	  older	  age	  at	  
the	  disease	  onset	  are	  the	  two	  strongest	  predictors	  of	  the	  evolution	  of	  the	  RR	  phase.	  
Their	   predictive	   effect	   was	   also	   validated	   by	   the	   multivariate	   analysis,	   which	  
assessed	   the	   concomitant	   impact	   of	   all	   baseline	   variables	   on	   the	   probability	   of	  
converting	   to	   SP	  MS.	   In	   line	  with	   previous	   reports,	   the	  model	   also	   confirmed	   that	  
men	  had	  a	  higher	  (HR	  =	  1.41)	  risk	  of	  becoming	  progressive	  and	  took	  shorter	  time	  to	  
the	   onset	   of	   SP,	   compared	   to	   women	   (6.5	   mean	   years	   difference;	   p	   <	   0.001).	   In	  
addition,	   the	   features	   of	   the	   first	   attack	   did	   not	   influence	   the	   risk	   of	   SP	   and	   the	  
latency	  to	  progression.	   In	  contrast	  with	  some	  previous	  studies	   (Amato	  et	  al.,	  1999;	  
Bergamaschi	   et	   al.,	   2001;	   Debouverie	   et	   al.,	   2008;	   Eriksson	   et	   al.,	   2003;	   Phadke,	  
1990),	  the	  type	  and	  the	  number	  of	  symptoms	  involved	  at	  the	  clinical	  onset	  did	  not	  
affect	  the	  probability	  of	  MS	  becoming	  progressive.	  	  
	  
As	  previously	  reported	  (Confavreux	  et	  al.,	  2003;	  Kremenchutzky	  et	  al.,	  2006a;	  Leray	  
et	  al.,	  2010;	  Tremlett	  et	  al.,	  2008a),	   this	   study	  demonstrated	   that	   the	  evolution	  of	  
the	   SP	   phase	   is	   largely	   unaffected	   by	   factors	   preceding	   its	   onset.	   Among	   the	  
predictors	  of	  the	  evolution	  of	  the	  RR	  phase,	  only	  early	  relapses	  frequency	  influenced	  
the	   times	   from	   the	   onset	   of	   progression	   to	   DSS	   levels.	   In	   addition,	   patients	  
presenting	   with	   cerebellar	   and	   brainstem	   symptoms	   at	   onset	   had	   faster	  
accumulation	   of	   disability	   during	   the	   progressive	   phase.	   This	   might	   indicate	   that	  
when	   the	   degenerative	   process	   is	   more	   severe,	   brainstem	   and	   cerebellar	  
dysfunctions	  are	  more	  likely	  to	  emerge	  at	  clinical	  onset.	  	  
	  
6.4.5	  The	  conversion	  to	  SP	  MS	  as	  outcome	  measure	  in	  clinical	  trials	  
	  
The	   results	   in	   this	   study	   further	   highlighted	   the	   onset	   of	   the	   SP	   phase	   as	   the	  
overwhelming	   determinant	   of	   the	   long-­‐term	  prognosis	   and,	   therefore,	   as	   the	   only	  
robust	  surrogate	  marker	  for	  late	  disability.	  Factors	  affecting	  the	  evolution	  of	  the	  RR	  
phase	  strongly	  influence	  the	  attainment	  of	  late	  outcomes.	  Among	  patients	  with	  poor	  
prognosis,	  the	  faster	  attainment	  of	  DSS	  levels	  is	  secondary	  to	  the	  rapid	  conversion	  to	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SP	  MS	  (Figure	  6.7).	  A	  longer	  time	  free	  of	  progression	  associates	  with	  a	  proportionally	  
lower	   risk	   of	   developing	   severe	   disability	   (Figure	   6.6).	   Therefore,	   the	   delay	   or	  
prevention	   of	   the	   SP	   phase	   is	   the	   most	   relevant	   therapeutic	   target	   for	   future	  
treatments,	  and	  the	  RR	  phase	  represents	  the	  only	  plausible	  window	  of	  therapeutic	  
opportunity,	  at	  least	  with	  currently	  available	  DMTs.	  
	  
Predictive	  models	  based	  exclusively	  on	  the	  frequency	  of	  relapses	  are	  not	  sufficiently	  
reliable	  for	  detecting	  a	  potential	  effect	  of	  treatments	  on	  late	  outcomes.	  The	  number	  
of	   late	  and	  total	   relapses	   is	  not	  a	  good	   indicator	  of	   the	  evolution	  of	   the	  RR	  phase,	  
leading	  to	  the	  onset	  of	  progression	  (Figures	  4.16	  and	  4.21,	  Chapter	  4).	  Based	  on	  the	  
risk	  of	  experiencing	  the	  SP	  course,	  groups	  destined	  to	  have	  a	  faster	  disease	  course	  
should	  be	  identified	  for	  testing	  the	  risk/benefit	  ratio	  of	  more	  aggressive	  treatments.	  
The	  multiple	  binary	   logistic	  model	  provided	  some	  useful	   information	   that	  could	  be	  
used	   for	   designing	   future	   RCTs,	   assessing	   the	   potential	   effect	   of	   therapies	   on	   the	  
onset	   of	   SP.	   From	   hypothetical	   baseline	   clinical	   scenarios,	   in	   which	   patients	   are	  
stratified	   according	   to	   the	   number	   of	   early	   relapses	   and	   according	   to	   the	   age	   at	  
onset,	   the	  model	  allowed	   to	  calculate	   the	  variation	  over	   time	  of	   the	  probability	  of	  
becoming	  progressive	  (Figure	  6.9).	  	  
	  
In	  groups	  experiencing	  the	  clinical	  onset	  at	  older	  age	  and	  having	  a	  high	  number	  of	  
attacks	   during	   the	   first	   two	   years,	   the	   risk	   of	   converting	   from	   relapsing	   to	  
progressive	  MS	   increased	  dramatically	   in	   a	   short	   time	   from	  onset	   (Figure	  6.9).	   For	  
instance,	  among	  patients	  with	  high	  early	  relapse	  frequency	  (≥	  3	  attacks)	  and	  aged	  40	  
at	  onset,	  the	  baseline	  risk	  of	  entering	  the	  SP	  phase	  (OR	  =	  10.9)	  doubles	  after	  8	  years	  
(OR	  =	  19.8),	  and	  it	  is	  more	  than	  2	  times	  higher	  than	  in	  patients	  with	  the	  same	  relapse	  
frequency	   and	   disease	   duration,	   but	   younger	   (20	   years)	   at	   onset	   (OR	   =	   7.5).	  
Therefore,	  those	  experiencing	  disease	  onset	  at	  older	  age	  (≥	  40	  years)	  and	  with	  a	  high	  
frequency	  of	  attacks	  during	  the	  early	  phase	  of	  the	  disease	  (≥	  3	  relapses	  during	  the	  
first	  2	  years)	  are	  expected	  to	  convert	  very	  rapidly	  to	  SP	  MS	  and	  can	  be	  recruited	  in	  
small	  trials,	  assessing	  the	  potential	  impact	  of	  therapies	  on	  the	  probability	  of	  entering	  
the	  progressive	  phase.	   In	  addition,	  the	  frequency	  of	  early	  relapses	  and	  the	  age	  are	  
information,	   available	   early	   in	   the	  disease	   course,	  which	   can	  be	  used	   for	   selecting	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patients,	   who	   might	   benefit	   from	   an	   induction	   therapy	   with	   a	   strong	  
immunosuppression.	   Furthermore,	   the	   analysis	   demonstrated	   that	   the	   window	   of	  
therapeutic	   opportunity	   narrows	   over	   time,	   as	   the	   probability	   of	   entering	   the	  
progressive	   phase	   increases	   proportionally	   with	   the	   disease	   duration.	   This	   implies	  
that	   a	   therapeutic	   intervention	   is	   likely	   to	   exert	  most	  of	   its	   efficacy	   in	   the	  earliest	  
stage	  of	  the	  disease,	  supporting	  an	  early	  use	  of	  aggressive	  treatments.	  The	  number	  
of	   early	   attacks,	   the	   patients’	   age	   and	   the	   length	   of	   the	   disease	   course	   should	   be	  
regarded	   as	   important	   factors	   in	   the	   therapeutic	   decision	   making	   algorithm,	   and	  
should	  be	  considered	  as	  eligibility	  criteria	  in	  the	  randomization	  scheme	  of	  the	  clinical	  
trial	  using	  the	  onset	  of	  SP	  as	  endpoint.	  	  
	  
These	   results	   also	   emphasize	   the	   importance	   of	   improving	   the	   definition	   of	  
progressive	  disease,	  which	   remains	  ambiguous.	  The	  diagnosis	  of	  SP	  MS	  necessarily	  
requires	   retrospective	   assessments	   for	   satisfying	   the	   criterion	   of	   1	   year	   of	  
continuous	   deterioration.	   The	   current	   definition	   does	   not	   specify	   what	   type	   of	  
functional	   impairment	   should	  be	  observed,	   among	  patients	  at	   the	   clinical	  onset	  of	  
the	  progressive	  phase.	  Natural	  history	  studies	  showed	  that	  progression,	  both	   in	  SP	  
and	   PP	   patients,	   predominantly	   presents	   with	   a	   distal	   central	   motor	   dysfunction,	  
almost	   exclusively	   localized	   to	   the	   lower	   extremities,	   and	   causing	   ambulation	  
difficulties.	   Therefore,	   the	   onset	   of	   the	   progressive	   course	   might	   be	   more	  
appropriately	   defined	   as	   an	   insidious	  walking	   impairment,	   progressively	  worsening	  
for	  at	   least	  1	  year.	   In	  this	  context,	  the	  T25FW	  test	   (paragraph	  1.6.2)	  holds	  promise	  
for	  evaluating	  clinically	  relevant	  ambulation	  deterioration	  in	  trials,	  using	  the	  of	  onset	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7.1	  Mechanisms	  driving	  the	  disease	  evolution	  	  
	  
It	   is	   generally	   accepted	   that	   the	   focal	   inflammation	   plays	   a	   dominant	   role	   in	   the	  
formation	   of	   the	   demyelinated	   areas,	   which	   are	   the	   pathological	   substrate	   of	   the	  
clinical	   attacks	   (Lucchinetti	   et	   al.,	   2000).	   However,	   the	   axonal	   loss	   (Bjartmar	   and	  
Trapp,	   2001),	   is	   considered	   the	   major	   determinant	   of	   the	   permanent	   disability	  
(Lassmann	  et	  al.,	  2007;	  Trapp	  and	  Nave,	  2008).	  Evidence	  strongly	  suggests	  that	  the	  
inflammation	  and	  the	  axonal	  damage	  are	  connected	  (Frischer	  et	  al.,	  2009;	  Trapp	  and	  
Nave,	   2008),	   but	   it	   is	   unclear	   which	   process	   is	   the	   initial	   trigger	   in	   this	   complex	  
interaction.	  After	  decades	  of	  research,	  mechanisms	  driving	  the	  disease	  evolution	  are	  
still	  widely	  debated	  (Chaudhuri	  and	  Behan,	  2004;	  Lassmann,	  2007;	  Stys	  et	  al.,	  2012;	  
Trapp	  and	  Nave,	  2008).	  	  
	  
7.1.1	  The	  outside-­‐in	  and	  inside-­‐out	  hypotheses	  
	  
The	  “outside-­‐in”	  model	  of	  MS	  is	  based	  on	  the	  hypothesis	  that	  the	  pathophysiology	  of	  
the	  disease	  begins	  with	  a	  systemic	  dysregulation	  of	  the	  immune	  system,	  which	  then	  
targets	   the	   CNS.	   Therefore,	   the	   primary	   autoimmune	   inflammatory	   process	   is	  
considered	   the	   essential	   cause	   of	   the	   axonal	   damage.	   However,	   it	   has	   been	  
speculated	  that	  the	  inflammatory	  mechanisms	  might	  not	  be	  the	  driver	  of	  the	  disease	  
evolution,	   but	   rather	   an	   epiphenomenon	   of	   a	   primary	   degenerative	   disorder.	   The	  
“inside-­‐out”	   hypothesis	   proposes	   that	   the	   pathological	   insult	   initially	   targets	   the	  
oligodendrocytes	  and	  the	  myelin,	  presumably	  many	  years	  before	  the	  clinical	  onset.	  
The	   host	   reacts	   with	   an	   aberrant	   immune	   response	   to	   the	   release	   of	   highly	  
autoantigenic	   components,	   caused	   by	   the	   underlying	   degenerative	   process	  
(Chaudhuri	  and	  Behan,	  2004;	  Stys	  et	  al.,	  2012).	  	  
	  
7.1.2	  The	  white	  matter	  pathology	  	  
	  
The	   central	   role	   played	   by	   the	   immune	   system	   in	   the	   disease	   pathogenesis	   is	  
indisputable	   (Sospedra	   and	   Martin,	   2005).	   Reactive	   CD4+	   Th1	   cells	   are	   probably	  
	   384	  
activated	  in	  the	  peripheral	  immune	  system	  and	  subsequently	  migrate	  across	  the	  BBB	  
into	   the	   CNS,	   where	   they	   damage	   the	  myelin	   components	   (Sospedra	   and	  Martin,	  
2005).	   Expanded	   pro-­‐inflammatory	   CD8+	   T-­‐lymphocytes	   are	   present	   in	   the	  
peripheral	  blood	  and	  infiltrate	  the	  brain	  lesions	  (Annibali	  et	  al.,	  2011).	  In	  addition,	  B-­‐
lymphocytes	   and	   antibodies	   are	   also	   considered	   important	   players	   in	   the	  
pathological	  mechanisms	  of	  the	  disease	  (Barnett	  et	  al.,	  2009;	  Freedman	  et	  al.,	  2005).	  
Pathology	  studies	  indicate	  that	  inflammatory	  mechanisms	  are	  closely	  involved	  in	  the	  
progression	  of	  the	  disease,	  both	  during	  the	  early	  and	  late	  stages.	  The	  white	  matter	  
lesions	  are	  heavily	  infiltrated	  by	  T-­‐lymphocytes	  and	  macrophages,	  which	  tend	  to	  spill	  
into	   the	   surrounding	  parenchyma	   (Lassmann	  et	   al.,	   2001;	   Lucchinetti	   et	   al.,	   2000).	  
However,	   autopsy	   studies	   of	   tissue	   obtained	   during	   the	   very	   early	   phase	   of	   the	  
disease	  demonstrated	  only	  sparse	  inflammatory	  cells	  and	  little	  evidence	  of	  T	  and	  B	  
cells	   infiltration	   in	   the	   lesions,	   before	   the	   demyelination	   occurred	   (Barnett	   and	  
Prineas,	   2004;	   Gay	   et	   al.,	   1997;	   Henderson	   et	   al.,	   2009;	   Marik	   et	   al.,	   2007).	   This	  
suggests	  that	  the	  formation	  of	  focal	  white	  matter	  lesions	  is	  initially	  characterized	  by	  
“apoptosis-­‐like”	   cells	   death,	   accompanied	   by	   limited	   inflammation,	   and	   then	   by	   a	  
massive	  lymphocytes	  infiltration,	  when	  the	  myelin	  falls	  apart	  (Lassmann,	  2010).	  
	  
It	  has	  been	  speculated	  that	  the	  degeneration	  might	  occur	  before	  the	  demyelination,	  
explaining	   the	   relative	   sparse	   inflammatory	   cells	   in	   the	   lesions	   at	   the	   very	   early	  
stage.	   The	   formation	   of	   immune	   infiltrates	   in	   the	   chronic	   inflammatory	   plaques	  
might	  be	  secondary	  to	  the	  release	  of	  immunogenic	  debris,	  resulting	  from	  the	  myelin	  
destruction	  (Chaudhuri	  and	  Behan,	  2004;	  Stys	  et	  al.,	  2012).	  Indeed,	  myelin-­‐antigen	  T	  
cells	   are	   not	   specific	   for	  MS	   only,	   as	   they	   increase	   in	   the	   blood	   and	   in	   the	   CSF	   of	  
patients	   suffering	   from	   an	   acute	   stroke,	   suggesting	   that	   they	   might	   be	   just	   an	  
indicator	  of	  the	  brain	  tissue	  injury	  (Wang	  et	  al.,	  1992).	  The	  hypothesis	  that	  the	  white	  
matter	  degeneration	   can	   cause	   a	   secondary	   inflammatory	  disease	   finds	   support	   in	  
the	   pathological	   changes	   occurring	   among	   patients	   affected	   by	   the	   very	   rare	  
Harding’s	   syndrome.	   This	   is	   described	   as	   an	   association	   between	   the	   Leber’s	  
hereditary	  optic	  neuropathy	   (LHON),	  which	   is	  a	  mitochondrial	  genetic	  disease,	  and	  
RR	  MS	   (Kovacs	   et	   al.,	   2005).	   The	   coexistence	   of	   the	   two	   pathologies	   supports	   the	  
plausibility	  of	  a	  disease	  model	  where	  the	  inflammatory	  reaction	  in	  the	  CNS	  develops	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as	   consequence	  of	   an	  underlying	   degenerative	   process	   (Stadelmann,	   2011;	   Stys	   et	  
al.,	  2012;	  Trapp	  and	  Nave,	  2008).	  	  
	  
A	   large	   body	   of	   evidence	   suggests	   that	   the	   degeneration	   can	   take	   place	   in	   the	  
absence	   of	   inflammation.	   The	   axonal	   damage	  was	   shown	   to	   occur	   in	   the	   NAWM,	  
independently	  of	  the	  active	  demyelination	  (Bjartmar	  et	  al.,	  2001;	  DeLuca	  et	  al.,	  2006;	  
Evangelou	  et	  al.,	  2000;	  Frischer	  et	  al.,	  2009;	  Lovas	  et	  al.,	  2000;	  Seewann	  et	  al.,	  2009;	  
Trapp	   et	   al.,	   1998).	   In	   the	   spinal	   cord,	   which	   is	   ubiquitously	   involved	   during	   the	  
progressive	   phase	   of	   the	   disease,	   the	   extent	   of	   the	   axonal	   loss	   was	   found	   to	  
correlate	  poorly	  with	  the	  degree	  of	  demyelination	  (DeLuca	  et	  al.,	  2006;	  Lovas	  et	  al.,	  
2000).	  The	  axonal	  loss	  is	  already	  present	  in	  the	  early	  course	  of	  the	  disease,	  and	  does	  
not	   correlate	   with	   the	   baseline	   white	   matter	   inflammatory	   lesions	   volume	   (De	  
Stefano	  et	  al.,	  2003;	  Filippi	  et	  al.,	  2003).	  In	  addition,	  evidence	  of	  axonal	  damage	  was	  
recently	  found	  in	  a	  cohort	  of	  subjects	  with	  RIS	  (Stromillo	  et	  al.,	  2013),	  indicating	  that	  
the	  subtle	  degenerative	  process	  starts	  even	  before	  the	   initial	  clinical	  manifestation	  
of	   the	  disease.	   It	  has	  been	  suggested	  that	   the	  axonal	   injury	  might	  results	   from	  the	  
increased	   expression	   of	   sodium	   channels	   in	   the	   demyelinated	   axonal	  membranes,	  
which	   triggers	   an	   intracellular,	   calcium-­‐mediated,	   mitochondrial	   dysfunction,	  
eventually	  leading	  to	  the	  neurodegeneration	  (“the	  mitochondrial	  theory”)	  (Dutta	  et	  
al.,	   2006;	   Su	  et	  al.,	   2009;	  Waxman	  et	  al.,	   2004).	   Indeed,	  a	   sodium-­‐channel	  blocker	  
(phenytoin)	  was	   shown	   to	  preserve	  axons	   in	  EAE	   (Lo	  et	  al.,	  2003),	   in	   line	  with	   this	  
hypothesis.	  	  
	  
However,	   the	   presence	   of	   a	   diffuse	   axonal	   transection,	   within	   the	   acutely	  
demyelinated	  plaques	  (Kuhlmann	  et	  al.,	  2002;	  Trapp	  et	  al.,	  1998)	  and	  in	  the	  context	  
of	   the	  chronic	  demyelination	   (Frischer	  et	  al.,	   2009;	   Lovas	  et	  al.,	   2000),	   lend	   strong	  
support	   to	   a	   causal	   relationship	   between	   the	   inflammatory	   processes	   and	   the	  
degeneration.	  The	  extent	  of	  the	  axonal	  damage	  was	  found	  to	  correlate	  significantly	  
with	   the	   number	   of	   inflammatory	   cells	   and	   with	   the	   activated	   microglia	   in	   the	  
surrounding	  parenchyma	  (Ferguson	  et	  al.,	  1997;	  Kuhlmann	  et	  al.,	  2002;	  Trapp	  et	  al.,	  
1998).	  The	  residual	  disability	  following	  the	  relapses	  is	  probably	  caused	  by	  the	  axons	  
transection	  within	   the	   active	   lesions	   (Trapp	  et	   al.,	   1998).	   Inflammatory	   cells	  might	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have	  a	  direct	   toxic	  effect	  on	  axons,	  by	   releasing	  proteolytic	  enzymes,	  cytokine	  and	  
oxidative	  products	  (Smith	  et	  al.,	  2001;	  Trapp	  and	  Nave,	  2008;	  Weiner,	  2009).	  Despite	  
the	   early	   occurrence	   of	   the	   axonal	   loss,	   only	   little	   permanent	   disability	   normally	  
accumulates	  during	  the	  initial	  stage	  of	  the	  RR	  phase.	  This	  is	  possibly	  explained	  by	  the	  
compensatory	  effect	  of	  the	  remyelination,	  which	  restores	  the	  axonal	  function	  after	  
the	   acute	   demyelination	   (Franklin	   and	   Kotter,	   2008;	   Irvine	   and	   Blakemore,	   2008),	  
and	  by	  the	  adaptive	  functional	  reorganization	  of	  the	  brain	  function	  (Tomassini	  et	  al.,	  
2012).	   The	   attainment	   of	   late	   clinical	   outcomes	   almost	   invariably	   results	   from	   the	  
relentless	  disability	  accumulation,	  which	  characterizes	  the	  disease	  course	  during	  the	  
progressive	  phase,	  when	  the	   focal	   inflammation	  gradually	  becomes	   less	  prominent	  
(Revesz	  et	  al.,	  1994;	  Trapp	  and	  Nave,	  2008).	  This	  might	  indicate	  that,	  in	  late	  stages,	  
the	   disease	   evolves	   independently	   of	   inflammatory	   mechanisms.	   However,	   a	  
profound	   diffuse	   inflammation	   was	   also	   found	   in	   the	   brains	   of	   patients	   with	  
advanced,	  progressive	  disease	   (Frischer	  et	   al.,	   2009).	  Both	   in	   the	   slowly	  expanding	  
lesions	  and	  in	  the	  NAWM	  there	  was	  a	  strong	  correlation	  between	  inflammatory	  cells	  
and	   the	   axonal	   injury	   (Frischer	   et	   al.,	   2009).	   Although	   this	   correlation	   does	   not	  
necessarily	  implies	  that	  the	  neurodegenerative	  process	  is	  driven	  by	  the	  inflammation	  
(Lassmann,	  2010),	  the	  data	  seems	  to	  support	  a	  causal	  relationship	  between	  the	  two	  
mechanisms.	   It	   remains	   possible	   that	   the	   primary	   degeneration	   generates	   a	  
secondary,	   persistent,	   diffuse	   inflammatory	   response	   during	   the	   late	   stage	   of	   the	  
disease	  (Stys	  et	  al.,	  2012).	  
	  
7.1.3	  The	  grey	  matter	  pathology	  	  
	  
MRI	  studies	  have	  also	  greatly	  contributed	  to	  characterize	  the	  inflammatory	  nature	  of	  
the	   disease.	   The	   inflammation	   in	   the	   CNS	   is	   a	   dynamic	   process,	   which	   is	  
accompanied	   by	   a	   breakdown	   of	   the	   BBB	   (Thompson	   et	   al.,	   1992)	   and	   can	   occur	  
independently	  of	   the	   clinical	   activity	   (Barkhof,	   2002;	  Miller	   et	   al.,	   1996).	  However,	  
the	   association	   between	   the	   inflammatory	   white	   matter	   lesions	   load	   and	   the	  
development	   of	   late	   disability	   is	   poor	   (2008;	   Calabrese	   et	   al.,	   2013;	   Fisniku	   et	   al.,	  
2008a).	   More	   recently,	   the	   cortical	   demyelination	   was	   suggested	   as	   a	   potential	  
pathological	  driver	  of	  the	  disease	  progression	  (Calabrese	  et	  al.,	  2013;	  Geurts	  et	  al.,	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2012;	   Kutzelnigg	   et	   al.,	   2005).	   Several	   studies	   have	   demonstrated	   that	   the	   grey	  
matter	   damage	   (Calabrese	   et	   al.,	   2007b;	   Calabrese	   et	   al.,	   2009b;	   Calabrese	   et	   al.,	  
2013;	  Roosendaal	  et	  al.,	  2009)	  and	  the	  grey	  matter	  atrophy	  (Bakshi	  et	  al.,	  2001;	  De	  
Stefano	  et	  al.,	   2003;	  Fisniku	  et	  al.,	   2008b;	  Roosendaal	  et	  al.,	   2011;	  Tedeschi	  et	  al.,	  
2005)	  are	  good	  predictors	  of	  the	  accumulation	  of	  disability	  in	  the	  long	  term.	  As	  the	  
disease	  advances,	   the	  grey	  matter	  damage	  accumulates	  and	  probably	  accounts	   for	  
the	  transition	  from	  relapsing	  to	  progressive	  MS	  (Calabrese	  et	  al.,	  2013).	   In	  contrast	  
to	  the	  white	  matter	  lesions,	  in	  the	  context	  of	  the	  cortical	  plaques,	  little	  inflammation	  
is	   detected	   and	   the	   cause	   of	   the	   demyelination	   is	   still	   unknown	   (Bo	   et	   al.,	   2007;	  
Lassmann,	  2012).	  Cortical	  lesions	  occur	  in	  the	  absence	  of	  BBB	  disruption	  and	  do	  not	  
correlate	  with	  the	  extent	  of	  the	  focal	  inflammation	  (Bo	  et	  al.,	  2007;	  Kutzelnigg	  et	  al.,	  
2005).	   However,	   a	   recent	   large	   biopsy	   study	   demonstrated	   variable	   degree	   of	  
cortical	   demyelination,	   with	   diffuse	   inflammatory	   infiltrates,	   in	   nearly	   40%	   of	  
patients	  during	  the	  early	  stage	  of	  the	  disease	  (Lucchinetti	  et	  al.,	  2011),	  implying	  that	  
the	  cortex	  might	  be	  an	  early	  target	  of	  the	  focal	  inflammatory	  mechanisms.	  It	  remains	  
unclear	   if	   the	   cortical	   pathology	   might	   precede	   the	   white	   matter	   damage,	   and	  
therefore	   the	   focal	   demyelination	   might	   be	   secondary	   to	   the	   neuronal	   pathology	  
(Geurts	  et	  al.,	  2012).	  Indeed,	  the	  grey	  matter	  atrophy	  was	  shown	  to	  occur	  during	  the	  
very	  early	  stage	  of	  the	  disease	  (Calabrese	  et	  al.,	  2007a;	  Chard	  et	  al.,	  2002),	  even	  in	  
subjects	  with	  RIS	  (Giorgio	  et	  al.,	  2011).	  	  
	  
Other	   studies	   indicate	   that,	   over	   the	   disease	   course,	   inflammation	   becomes	  
increasingly	  compartmentalized	  in	  the	  perivascular	  spaces,	  behind	  a	  relatively	  intact	  
BBB	  (Meinl	  et	  al.,	  2008),	  and	  aggregates	  in	  follicle-­‐like	  structures	  at	  the	  level	  of	  the	  
meninges	   (Magliozzi	   et	   al.,	   2007).	   In	  both	  PP	  and	  SP	  MS,	   the	  demyelination	   in	   the	  
grey	  matter	  was	  found	  to	  be	  associated	  with	  profound	  meningeal	  inflammation	  and	  
microglia	   activation	   (Choi	   et	   al.,	   2012;	   Frischer	   et	   al.,	   2009;	   Howell	   et	   al.,	   2011;	  
Magliozzi	  et	  al.,	  2007;	  Magliozzi	  et	  al.,	  2010;	  Serafini	  et	  al.,	  2004).	  This	  indicates	  that	  
the	  cortical	  damage	  and	  demyelination	  are	  possibly	  caused	  by	  the	  inflammatory	  cells	  
within	   the	  meninges,	  which	   infiltrate	   the	  underlying	  parenchyma	  (Lassmann,	  2010;	  
Lassmann,	   2012).	   In	   support	   of	   this	   ,	   among	   SP	   MS	   patients,	   the	   presence	   of	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meningeal	   lymphatic	   follicles	   was	   found	   to	   associate	   with	   a	   more	   severe	   disease	  
course	  (Magliozzi	  et	  al.,	  2007).	  	  
	  
7.2	  The	  progressive	  phase	  
	  
7.2.1	  Primary	  and	  secondary	  progression:	  evidence	  from	  the	  pathology	  studies	  
	  
In	   the	  context	  of	   the	  controversial	   relationship	  between	   the	   inflammation	  and	   the	  
neurodegeneration,	   whether	   PP	   and	   SP	   MS	   share	   common	   pathogenesis	   or	   not,	  
becomes	   a	   particularly	   relevant	   topic.	   Imaging	   studies	   demonstrated	   that	   PP	  
patients	  have	  a	   lower	   inflammatory	   lesion	   load	   (Rovaris	  et	  al.,	   2000;	  Thompson	  et	  
al.,	  1990)	  and	  lower	  levels	  of	  BBB	  damage	  (Thompson	  et	  al.,	  1991).	  In	  some	  PP	  cases,	  
the	  diffuse	  abnormalities	  in	  the	  brain	  and	  in	  the	  spinal	  cord	  occurs	  in	  the	  absence	  of	  
focal	   inflammatory	   lesions,	   suggesting	   a	   complete	   lack	   of	   the	   adaptive	   immune	  
response	   (Zwemmer	   et	   al.,	   2008).	   Pathology	   assessments	   provided	   contradicting	  
evidence.	   Both	   subtypes	   are	   characterized	   by	   brain	   inflammatory	   lesions,	   more	  
prominently	   in	   SP	   patients,	   nonetheless	   suggesting	   that	   also	   PP	   MS	   is	   an	  
inflammatory	   disease	   (Revesz	   et	   al.,	   1994).	   It	   has	   been	   shown	   that	   the	   two	  
progressive	   subtypes	   share	   the	   same	   pattern	   of	   the	   brain	   tissue	   injury,	   with	  
demyelination,	  remyelination,	  loss	  of	  oligodendrocytes,	  and	  axonal	  damage	  (Frischer	  
et	   al.,	   2009;	   Prineas	   et	   al.,	   2001).	   However,	   studies	   comparing	   the	   extent	   of	   the	  
axonal	  loss	  between	  PP	  and	  SP	  MS	  are	  discordant.	  The	  axonal	  damage	  was	  found	  to	  
be	  similar	  between	  the	  two	  subtypes	  (Frischer	  et	  al.,	  2009;	  Prineas	  et	  al.,	  2001)	  or,	  
within	  the	  demyelinated	  areas,	  to	  be	  more	  pronounced,	  among	  SP	  MS	  patients,	  and	  
very	   limited	  among	  PP	  MS	  patients	   (Bitsch	  et	  al.,	  2000).	   In	  addition,	   in	   the	  cervical	  
cord,	  the	  extent	  of	  the	  axonal	  loss	  was	  shown	  to	  be	  larger	  in	  PP	  patients,	  compared	  
to	  SP	  patients,	  despite	  the	  higher	  degree	  of	  white	  and	  grey	  matter	  demyelination	  in	  
the	  SP	  group	  (Tallantyre	  et	  al.,	  2009).	  Interestingly,	  meningeal	  B	  cells	  follicles,	  which	  
are	  found	  in	  a	  large	  percentage	  of	  SP	  MS	  patients	  and	  are	  known	  to	  correlate	  with	  a	  
more	   severe	   disease	   course	   (Howell	   et	   al.,	   2011;	  Magliozzi	   et	   al.,	   2007),	  were	   not	  
observed	  in	  PP	  MS	  (Choi	  et	  al.,	  2012).	  Nevertheless,	  in	  both	  progressive	  subtypes	  it	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has	   been	   demonstrated	   a	   large	   degree	   of	   diffuse	   meningeal	   inflammation,	   which	  
associates	  with	  extensive	  axonal	  loss	  in	  the	  cortical	  tissue	  (Choi	  et	  al.,	  2012;	  Frischer	  
et	   al.,	   2009;	   Howell	   et	   al.,	   2011).	   It	   remains	   undetermined	   whether	   these	   data	  
indicate	  that	  the	  inflammatory	  mechanisms	  are	  a	  causative	  factor	  of	  the	  grey	  matter	  
damage	  or	  a	  simple	  concomitant	  (Lassmann,	  2010).	  	  
	  
7.2.2	  Primary	  and	  secondary	  progression:	  evidence	  from	  the	  natural	  history	  studies	  	  
	  
Natural	  history	  studies	  consistently	  showed	  remarkable	  similarities	  between	  primary	  
and	  secondary	  progressive	  MS.	  Among	  progressive	  patients,	   the	  progressive	  phase	  
starts	   at	   similar	   ages	   (Confavreux	   and	   Vukusic,	   2006a;	   Koch	   et	   al.,	   2007;	  
Kremenchutzky	   et	   al.,	   2006a;	   Tutuncu	   et	   al.,	   2013)	   and	   evolves	   at	   similar	   rate	  
(Kremenchutzky	   et	   al.,	   2006b),	   irrespective	   of	   whether	   it	   is	   preceded	   by	   the	   RR	  
phase	  or	  not.	  In	  the	  LO	  database,	  progressive	  patients	  with	  one	  (SAP),	  many	  (SP	  MS)	  
or	   no	   (PP	  MS)	   relapses	   before	   progression	   attained	   disability	   endpoints	   from	   the	  
onset	  of	  progression	  in	  almost	  the	  same	  time	  (Kremenchutzky	  et	  al.,	  2006a).	  In	  the	  3	  
French	   EDMUS	   cohorts	   (Confavreux	   and	   Vukusic,	   2006a;	   Debouverie	   et	   al.,	   2008;	  
Leray	  et	  al.,	  2010),	  times	  from	  DSS	  3	  and	  from	  DSS	  4	  to	  higher	  disability	  levels	  were	  
similar	  between	  PP	  and	  RR/SP,	  indicating	  that,	  once	  established	  disability	  occurs,	  the	  
disease	   evolution	   is	   not	   influenced	   by	   the	   clinical	   phenotype.	   As	   DSS	   3/DSS	   4	  
probably	   heralded	   the	  progressive	   phase	   for	  most	   of	   the	   relapsing	   onset	   patients,	  
these	  data	  confirmed	  a	  similar	  rate	  of	  late	  disability	  accumulation	  between	  the	  two	  
progressive	  subtypes.	  	  
	  
The	   work	   described	   in	   this	   thesis	   provided	   further	   evidence	   that	   progressive	   and	  
relapsing	   onset	   patients	   share	   much	   more	   than	   they	   differ.	   Both	   subgroups	   took	  
almost	   the	   same	   mean	   times	   to	   advance	   from	   one	   disability	   hallmark	   to	   the	  
following	  (Figure	  3.14	  B,	  Chapter	  3).	   In	  addition,	  the	  Kaplan	  Meier	  estimated	  times	  
from	  DSS	  3	  to	  DSS	  6	  and	  to	  DSS	  8	  differed	  little	  (3	  mean	  years	  difference)	  between	  
RR/SP	  and	  PP	  groups	  (Figure	  3.21,	  Chapter	  3),	  and	  were	  remarkably	  similar	  between	  
the	  PP	  and	  SP	   groups	   (Figure	  3.22,	  Chapter	  3).	   Furthermore,	   the	  age	  at	  which	   the	  
progressive	  phase	  started	  ranged	  by	  only	  2.8	  mean	  years	  among	  SP	  patients	  with	  1,	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2-­‐3	  and	  ≥	  4	  total	  attacks	  during	  the	  RR	  phase	  and	  PP	  patients	  (Figure	  5.14,	  Chapter	  
5).	   Finally,	   the	   evolution	   of	   progressive	   phase	   was	   similar	   among	   progressive	  
patients	  stratified	  by	  the	  age	  at	  the	  onset	  of	  progression	  (Figure	  5.18,	  Chapter	  5),	  the	  
disability	  accumulated	  while	  growing	  older	  at	  similar	  rate	  between	  PP	  and	  SP	  groups	  
(Figure	   5.21,	   Chapter	   5)	   and	   the	   ages	   at	   the	   attainment	   of	   DSS	   levels	   were	   not	  
affected	  by	  the	  type	  of	  the	  disease	  course	  (Figure	  5.23,	  Chapter	  5).	  
	  
Taken	  together,	   these	  data	  suggest	  common	  mechanisms	  driving	  the	  accumulation	  
of	   severe	   disability	   during	   the	   progressive	   phase	   and	   question	   the	   contribution	   of	  
the	  focal	  inflammatory	  processes,	  occurring	  during	  the	  RR	  phase,	  to	  the	  late	  disease	  
evolution.	   The	   similar	   outcome	   among	   all	  MS	   progressive	   subtypes	  might	   indicate	  
that	  the	  disease	  course	  evolves	   in	  two	  stages,	   independent	  of	  each	  other	  (Leray	  et	  
al.,	   2010).	   Biologically,	   the	   accumulation	   of	   moderate	   disability,	   probably	   by	  
heralding	   the	   onset	   of	   the	   progressive	   course,	   might	   mark	   the	   failure	   of	  
compensatory	  mechanisms	  (threshold	  effect),	  initially	  abating	  the	  axonal	  injury.	  The	  
inflammatory	  mechanisms	   seem	   to	   influence	   the	   accumulation	   of	   disability	   during	  
the	  early	  phase,	  but	  have	  no	  impact	  on	  the	  evolution	  of	  progressive	  MS.	  It	  remains	  
possible	   that,	   once	   the	   progressive	   course	   supervenes,	   the	   focal	   inflammation	  
gradually	  becomes	  compartmentalized	  in	  the	  meninges,	  and	  drives	  both	  primary	  and	  
secondary	  progression,	  by	  causing	  the	  cortical	  damage	  (Choi	  et	  al.,	  2012;	  Frischer	  et	  
al.,	   2009;	   Howell	   et	   al.,	   2011;	   Lassmann,	   2010).	   This	   would	   justify	   common	  
pathophysiological	   mechanisms,	   accounting	   for	   the	   similar	   evolution	   of	   the	  
progressive	  phases.	  However,	   this	   notion	   is	   not	   easily	   applicable	   to	   those	  patients	  
lacking	  the	  RR	  phase	  and	  experiencing	  a	  progressive	  course	  at	  onset.	  	  
	  
7.3	  The	  role	  of	  the	  inflammation	  	  	  
	  
7.3.1	  The	  therapeutic	  suppression	  of	  the	  inflammation	  
	  
The	   therapeutic	   suppression	   of	   relapses	   and	   of	   MRI	   inflammatory	   lesions,	   was	  
shown	  to	  prevent	  the	  disability	  progression	  during	  the	  RR	  phase	  (1993;	  1998a;	  Coles	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et	  al.,	  1999;	  Jacobs	  et	  al.,	  1996a;	  Johnson	  et	  al.,	  1995;	  Kappos	  et	  al.,	  2006a;	  Polman	  
et	   al.,	   2006).	   However,	   the	   limited	   impact	   of	   DMTs	   on	   the	   long	   term	   disease	  
evolution	  (Bermel	  et	  al.,	  2010;	  Ebers	  et	  al.,	  2010;	  Goodin	  et	  al.,	  2012;	  Kappos	  et	  al.,	  
2006c;	   Shirani	   et	   al.,	   2012)	   and	   in	   the	   progressive	   forms	   of	  MS	   (La	  Mantia	   et	   al.,	  
2012),	   cast	   doubt	   on	   the	   contribution	   of	   the	   focal	   inflammatory	   processes	   in	  
mechanisms	  driving	   the	  accumulation	  of	   late	  disability.	   It	   has	  been	   suggested	   that	  
the	  trapped	  diffuse	  inflammation	  behind	  a	  closed	  or	  repaired	  BBB,	  and	  therefore	  not	  
easily	   targetable,	   explains	   the	   poor	   efficacy	   of	   DMTs	   during	   the	   late	   phase	   of	   the	  
disease	   (Lassmann,	   2010).	   Alternatively,	   the	   early	   focal	   inflammation	  might	   set	   up	  
the	  brain	  for	  the	  degenerative	  process,	  which	  occurs	  later	  and	  is	  largely	  independent	  
of	   the	   initial	   focal	   inflammatory	   insult	   (Coles	   et	   al.,	   2006).	   In	   support	   of	   this	  
hypothesis,	   a	   profound	   immunosuppression	   with	   a	   monoclonal	   antibody	  
(Alemtuzumab),	   compared	   to	   treatment	  with	   IFN,	   exerted	   a	   dramatically	   different	  
effect,	  among	  patients	  with	  early	  or	  advanced	  disease.	  The	  marked	  reduction	  of	  the	  
inflammatory	  activity	  had	  no	  impact	  on	  the	  disease	  progression	  in	  SP	  patients	  (Coles	  
et	   al.,	   2006),	   but	   prevented	   the	   short-­‐term	   disability	   accumulation	   among	   early	  
active	   patients	   (Coles	   et	   al.,	   2006;	   Coles	   et	   al.,	   2008).	   In	   addition,	   the	   impact	   of	  
Alemtuzumab	   on	   the	   disease	   progression	  was	   shown	   to	   be	   larger	   among	   patients	  
with	  shorter	  (2.1	  mean	  years)	  (Cohen	  et	  al.,	  2012a),	  compared	  to	  those	  with	  a	  longer	  
disease	  duration	  (4.5	  mean	  years)	  (Coles	  et	  al.,	  2012b).	  Similarly,	  the	  treatment	  with	  
haemapoietic	  stem	  cell	  transplantation	  did	  not	  exert	  any	  significant	  beneficial	  effect	  
in	  progressive	  patients	  during	  the	  advance	  stage	  of	  the	  disease	  (Burt	  et	  al.,	  2003).	  In	  
contrast,	  in	  a	  group	  of	  RR	  patients	  early	  in	  the	  disease	  course	  (5	  median	  year	  disease	  
duration),	   autologous	   haemapoietic	   stem	   cell	   transplantation	   associated	   with	   a	  
reversal	   of	   the	  neurological	   disability	   and	  with	   an	   improvement	  of	   the	   EDSS	   score	  
(Burt	  et	  al.,	  2009a)	  	  	  
	  
7.3.2	  Relapses	  and	  the	  disease	  progression	  	  	  
	  
By	   assessing	   the	   relationship	   between	   clinical	   relapses	   and	   the	   long-­‐term	   disease	  
evolution,	  natural	  history	  studies	  can	  help	  to	  further	  elucidate	  the	  role	  of	  the	  focal	  
inflammatory	   mechanisms	   on	   the	   disease	   pathogenesis.	   Nevertheless,	   the	   partial	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dissociation	  between	  the	  biological	  activity	  and	  the	  clinical	  events,	  as	  highlighted	  by	  
imaging	   studies	   (Barkhof,	   2002;	   Filippi	   et	   al.,	   2003),	   limit	   the	   power	   to	   draw	  
definitive	  conclusion.	  
	  
7.3.2.1	  The	  focal	  inflammatory	  activity	  early	  in	  the	  disease	  course	  
	  
Results	  from	  different	  natural	  history	  cohorts,	  obtained	  with	  different	  methodology,	  
consistently	  demonstrated	   that	  patients	  with	  a	   large	  number	  of	  attacks	  during	   the	  
first	  two	  (Leray	  et	  al.,	  2010;	  Weinshenker	  et	  al.,	  1989c)	  and	  five	  (Confavreux	  et	  al.,	  
2003;	  Debouverie	  et	  al.,	  2008;	  Eriksson	  et	  al.,	  2003;	  Kantarci	  et	  al.,	  1998;	  Tremlett	  et	  
al.,	  2009a)	  years,	  experience	  a	  faster	  disease	  evolution	  (Table	  4.2,	  Chapter	  4).	  More	  
relapses	  during	  the	  initial	  stage	  of	  the	  disease	  correlated	  with	  a	  significantly	  higher	  
risk	   of	   reaching	   the	   SP	   phase	   and	   the	   DSS	   levels,	   and	   with	   shorter	   times	   to	   the	  
endpoints,	   suggesting	   that	   the	   early	   focal	   inflammatory	   activity	   contributes	  
significantly	  to	  the	  attainment	  of	  late	  disability.	  Interestingly,	  the	  strong	  association	  
between	   early	   clinical	   relapses	   and	   late	   outcomes	   partially	   diverges	   from	   MRI	  
studies,	  which	  showed	  only	  a	  limited	  correlation	  between	  the	  extent	  of	  the	  baseline	  
inflammatory	   lesions	   and	   the	   long-­‐term	   disease	   evolution	   (2008;	   Calabrese	   et	   al.,	  
2013;	  Fisniku	  et	  al.,	  2008a).	  This	  might	  be	  due	  to	  the	  limited	  pathological	  specificity	  
of	  the	  white	  matter	  lesions	  detected	  by	  the	  MRI	  T2	  sequences	  (Filippi	  et	  al.,	  2012).	  	  
	  
The	   analysis	   in	   this	   thesis	   confirmed	   the	   strong	   association	   between	   attacks	  
occurring	  during	  the	  first	  two	  years	  and	  the	  development	  of	  late	  disability.	  Patients	  
with	   a	   larger	   number	   of	   early	   relapses	   reached	   severe	   outcomes	   more	   rapidly,	  
secondary	   to	   the	   shorter	   conversion	   to	   SP	   MS	   (Table	   4.5,	   Chapter	   4).	   Previous	  
studies	   demonstrated	   that	   the	   disease	   evolution	   from	   DSS	   3/DSS	   4	   was	   not	  
influenced	  by	   the	  number	  of	   early	   inflammatory	  attacks,	   in	   line	  with	   the	  amnestic	  
nature	   of	   the	   late	   disease	   progression	   (Confavreux	   et	   al.,	   2003;	  Debouverie	   et	   al.,	  
2008;	  Leray	  et	  al.,	  2010).	  In	  contrast,	  among	  LO	  database	  patients,	  the	  frequency	  of	  
early	   attacks	  mildly	   influenced	   the	  disease	   evolution	   from	  moderate	   disability	   and	  
from	  the	  onset	  of	  progression	  (Table	  4.8,	  Chapter	  4).	  Therefore,	  the	  relapses	  during	  
the	  first	  two	  years	  affected	  the	  attainment	  of	  late	  outcomes	  primarily	  by	  increasing	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the	   risk	   of	   converting	   to	   SP	  MS,	   by	   shortening	   the	   latency	   to	   progression	   and,	   to	  
lesser	  degree,	  by	  influencing	  the	  slope	  of	  the	  SP	  phase.	  The	  results	  confirm	  that	  the	  
outcome	  is	  mainly	  determined	  by	  mechanisms	  driving	  the	  evolution	  of	  the	  RR	  phase	  
and	   leading	   to	   the	   conversion	   to	  SP	  MS.	   In	  addition,	   they	  underline	   the	  very	  early	  
phase	  of	  the	  disease	  as	  the	  crucial	  time	  when	  pathological	  changes,	  which	  will	  affect	  
the	   accumulation	  of	   severe	  disability	   in	   the	   long	   term,	   take	  place.	   Imaging	   studies	  
demonstrate	  that	  the	  biological	  onset	  of	  the	  disease	  might	  precede	  the	  clinical	  onset	  
(Granberg	  et	  al.,	  2013;	  Stromillo	  et	  al.,	  2013).	  Most	  likely,	  the	  factors	  responsible	  for	  
determining	  when	   the	   asymptomatic	   inflammatory	   activity	   becomes	   first	   clinically	  
evident	  are	  also	   implicated	   in	   the	  cascade	  of	  events,	  occurring	  early	   in	   the	  disease	  
course,	  that	  largely	  influences	  the	  individual	  outcome	  in	  the	  long	  term.	  
	  
The	   analyses	   of	   early	   relapses	   indicate	   that	   the	   early	   focal	   inflammation	   plays	   a	  
direct	  role	  in	  the	  pathological	  processes	  responsible	  for	  promoting	  the	  occurrence	  of	  
the	  progressive	  course	  and	   for	  driving	   the	  evolution	  of	   the	  progressive	  phase.	  This	  
suggests	   that	   the	   initial	   focal	   inflammatory	   white	   matter	   pathology	   might	   be	  
involved	  in	  the	  biological	  events	  leading	  to	  the	  axonal	  damage	  (Ferguson	  et	  al.,	  1997;	  
Kuhlmann	   et	   al.,	   2002;	   Trapp	   et	   al.,	   1998).	   In	   addition,	   the	   mild	   impact	   of	   early	  
relapses	   on	   the	   slope	   of	   the	   progressive	   phase	   supports	   the	   notion	   that	   the	   early	  
focal	   inflammatory	  activity	  contributes	   to	   set	  up	   the	  brain	   for	  a	   faster	   late	  disease	  
evolution	   (Coles	  et	  al.,	  2006).	  However,	  once	  the	   initial	   tissue	   injury	   is	  established,	  
the	  role	  of	  focal	  inflammation	  on	  the	  disease	  progression	  becomes	  less	  relevant.	  The	  
axonal	  degeneration,	  occurring	  during	  the	  progressive	  phase,	  might	  result	  from	  the	  
loss	  of	  trophic	  support,	  as	  a	  consequence	  of	  the	  focal	  inflammatory	  insult	  during	  the	  
initial	   stage	   of	   the	   disease	   (Coles	   et	   al.,	   2006).	   Alternatively,	   the	   RR	   and	   the	   SP	  
phases	  are	  possibly	  linked	  by	  inflammatory	  mechanisms,	  which	  are	  initially	  focalized	  
and	  gradually	  become	  diffuse.	  The	  demyelinated	  areas,	  where	  the	  axons	  are	  already	  
damaged	  during	  the	  early	  disease	  stage	  (Kuhlmann	  et	  al.,	  2002;	  Trapp	  et	  al.,	  1998),	  
might	   be	   the	   vulnerable	   niche	   where	   the	   focal	   inflammation	   initially	   becomes	  
compartmentalized	   and	   subsequently	   determines	   the	   cortical	   pathology,	   which	  
drives	   the	   disease	   evolution	   during	   the	   progressive	   phase	   (Frischer	   et	   al.,	   2009;	  
Howell	   et	   al.,	   2011).	   However,	   it	   can	   be	   speculated	   that	   this	   unifying	  mechanism	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would	   also	   imply	   similarities	   in	   the	   clinical	   pattern	   before	   and	   after	   the	   onset	   of	  
progression.	   Indeed,	   the	   SP	   phase	   is	   predominantly	   characterized	   by	   motor	  
disturbances,	   irrespective	   of	   the	   type	   of	   symptoms	   occurring	   during	   the	   RR	   phase	  
(Confavreux	   and	   Vukusic,	   2006a;	   Kremenchutzky	   et	   al.,	   2006a).	   Nevertheless,	   this	  
does	   not	   necessarily	   exclude	   that	   the	   diffuse	   inflammation	   is	   involved	   in	   the	  
evolution	  of	   the	  progressive	  phase.	  The	  cortical	  damage	  was	  shown	  to	  be	  strongly	  
associated	  with	  the	  EDDS	  score	  in	  the	  short	  term	  (Calabrese	  et	  al.,	  2012),	  suggesting	  
that	  the	  motor	  disability	  is	  more	  related	  to	  the	  grey	  matter	  than	  to	  the	  white	  matter	  
pathology.	   Therefore,	   among	   progressive	   patients,	   the	   abundant	   cortical	   lesions	  
(Calabrese	   et	   al.,	   2007b),	   potentially	   linked	   to	   the	  meningeal	   inflammation,	  would	  
explain	   the	  predominance	  of	  motor	   symptoms	  during	  both	  primary	  and	   secondary	  
progressive	  MS.	  	  
	  
The	  LO	  database	  offered	  the	  unique	  possibility	  of	  analysing	  the	  long-­‐term	  evolution,	  
among	   patients	   with	   ≥	   3	   relapses	   during	   the	   first	   two	   years	   (“frequent	   early	  
relapsers”),	  who	  were	  the	  main	  driver	  of	  the	  association	  between	  early	  relapses	  and	  
late	   outcomes.	   This	   allowed	   to	   further	   address	   the	   question	   whether	   early	  
inflammatory	  attacks	  are	  a	  causative	   factor	   for	  the	   late	  disability,	  developing	  years	  
later.	  Unexpectedly,	   in	   the	  group	  with	  early	  adverse	  clinical	   features,	   the	  outcome	  
was	   not	   homogeneous,	   but	   widely	   variable,	   ranging	   from	   one	   extreme	   to	   the	  
opposite	   of	   the	   disability	   spectrum.	  More	   than	   60%	   had	   the	   expected	   aggressive	  
disease	  course:	  they	  converted	  to	  SP	  MS	  in	  5	  median	  years	  and	  attained	  DSS	  6	  and	  
DSS	  8,	  from	  the	  disease	  onset,	  in	  7	  and	  17	  median	  years,	  respectively,	  and	  from	  the	  
onset	  of	  progression,	  in	  1	  and	  9	  median	  years,	  respectively	  (Table	  4.11,	  Chapter	  4).	  
These	  results	  further	  indicate	  that	  a	  very	  active	  early	  inflammation	  is	  responsible	  for	  
determining	  a	  remarkably	   fast	  disability	  accumulation,	  by	  accelerating	  the	  onset	  of	  
the	  progressive	  phase	  and	  its	  evolution.	  This	  lends	  further	  support	  to	  the	  hypothesis	  
that	   the	   initial	   focal	   inflammatory	   insult	   creates	   a	   pathological	   substrate,	   which	  
promotes	  the	  rapid	  degeneration	  of	  the	  axons	  (Coles	  et	  al.,	  2006).	  However,	  among	  
frequent	  early	   relapsers,	  more	   than	  30%	  of	  patients	  did	  not	   convert	   to	  SP	  MS	  and	  
had	  a	   remarkable	  benign	  disease	  course,	  despite	   the	   long	  disease	  duration	   (Figure	  
4.11,	  Chapter	  4).	  The	  opposite	  outcome	   in	   the	   two	  distinct	   subgroups,	   sharing	   the	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same	  high	  early	   inflammatory	  activity,	  was	  differentiated	  by	  whether	  the	  SP	  phase	  
occurred	  or	  not.	  This	  demonstrated	  that	   frequent	  early	  relapses	  do	  not	  necessarily	  
associate	   with	   a	   faster	   accumulation	   of	   severe	   disability,	   and	   suggested	   that	  
additional	  factors,	  other	  than	  the	  early	  inflammatory	  frequency,	  might	  be	  implicated	  
in	  the	  development	  of	  the	  progressive	  course.	  	  
	  
These	   results	   need	   confirmation	   in	   other	   suitable	   populations.	   A	   recent	   imaging	  
study	   analysed	   the	   disease	   course	   of	   334	   relapsing	   onset	   patients	   observed	   for	   5	  
years.	  Almost	  20%	   (n	  =	  66)	   rapidly	  converted	   to	  SP	  MS	   (4	  median	  year)	  and	  had	  a	  
significantly	  higher	  baseline	  T2	  white	  matter	  lesions	  volume,	  compared	  to	  those	  who	  
remained	  in	  the	  RR	  phase	  (Calabrese	  et	  al.,	  2013).	  However,	  the	  number	  of	  contrast	  
enhancing	   lesions	  was	   lower	   in	  the	  SP	  group,	  both	  at	  baseline	  and	  at	  5	  years,	  and,	  
after	  adjusting	  for	  the	  patients’	  age	  and	  disease	  duration,	  the	  best	  predictor	  of	  the	  
probability	   of	   entering	   the	   SP	   phase	   was	   the	   volume	   of	   the	   cortical	   lesions	  
(Calabrese	  et	  al.,	  2013).	   In	  view	  of	   the	  association	  between	  early	   relapses	  and	   late	  
outcomes	   it	  can	  be	  speculated	  that	   the	  same	  factors,	  accounting	   for	   the	  transition	  
from	  RIS	  to	  clinically	  isolated	  syndrome	  (CIS),	  might	  control	  the	  outcome	  severity	  in	  
the	   long	   term,	   by	   promoting	   the	   progressive	   course.	   The	   first	   attack	   may	   not	   be	  
occurring	  randomly	  but	  rather	  be	  intrinsically	   involved	  in	  mechanisms	  initiating	  the	  
clinical	  disease	  by	  targeting	  the	  grey	  matter,	  as	  shown	  by	  a	  recent	  CSF	  study	  in	  CIS	  
patients	  (Schutzer	  et	  al.,	  2013).	  In	  addition,	  the	  cortical	  damage	  might	  represent	  the	  
common	  pathological	  substrate	  between	  early	  relapses	  and	  age,	  both	  affecting	  the	  
disease	  evolution	  by	  promoting	  the	  onset	  of	  the	  progressive	  course.	  	  
	  
Overall,	   the	   extent	   of	   the	   cortical	   pathology	   was	   shown	   to	   be	   the	   strongest	  
determinant	  of	  the	  risk	  of	  entering	  the	  SP	  phase,	  independently	  of	  the	  inflammatory	  
activity	   (Calabrese	   et	   al.,	   2013).	   Similarly,	   the	   results	   from	   the	   analysis	   of	   the	  
frequent	  early	  relapses	  group	  suggest	  that	  the	  axonal	  vulnerability	  or	   its	  resistance	  
to	  the	  focal	  inflammation	  might	  be	  regulated	  by	  other	  factors.	  Indeed,	  the	  extent	  of	  
the	  axonal	  damage	   in	  the	  demyelinated	  plaques	  widely	  varies,	   ranging	   from	  nearly	  
normal	  to	  a	  loss	  of	  80%,	  and	  averaging	  60-­‐70%	  (Bjartmar	  and	  Trapp,	  2001;	  Mews	  et	  
al.,	  1998),	  highlighting	  different	  degrees	  of	   susceptibility	  among	  axons.	   It	  has	  been	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hypothesized	   that	   the	   clinical	   outcome	   could	   be	   influenced,	   to	   some	   extent,	   by	  
genetic	   factors.	   Indeed,	   it	   has	   been	   demonstrated	   that	   location	   (Mowry	   et	   al.,	  
2013a)	   and	   severity	   (Mowry	   et	   al.,	   2013b)	   of	   early	   clinical	  manifestations	  may	   be	  
influenced	  by	  the	  MS	  susceptibility	  polymorphisms.	  In	  addition,	  patients	  carrying	  the	  
allele	  HLA-­‐DRB1*15	  were	  recently	  shown	  to	  have	  a	  more	  pronounced	  inflammation	  
in	   the	   spinal	   cord,	   suggesting	   a	   higher	   predisposition	   to	   develop	   inflammatory	  
attacks	   (Deluca	   et	   al.,	   2013).	   The	   HLA-­‐DRB1*01	   allele	   was	   found	   to	   be	  
underrepresented	  among	  patients	  with	  an	  aggressive	  disease	  course,	   compared	   to	  
patients	  with	   a	   benign	   outcome,	   suggesting	   that	   it	  might	   exert	   a	   protective	   effect	  
(DeLuca	  et	  al.,	  2007).	  However,	  its	  axonal	  relevance	  has	  never	  been	  demonstrated.	  	  
	  
7.3.2.2	  The	  focal	  inflammatory	  activity	  late	  in	  the	  disease	  course	  
	  
Natural	   history	   studies	   consistently	   demonstrated	   that	   inflammatory	   attacks	  
occurring	  during	  the	  primary	  (Andersson	  et	  al.,	  1999;	  Kremenchutzky	  et	  al.,	  1999a)	  
and	   the	   secondary	   (Confavreux	   et	   al.,	   2000;	   Vukusic	   and	   Confavreux,	   2003)	  
progressive	   phase	   do	   not	   affect	   the	   development	   of	   disability.	   This	   confirms	   that	  
when	   the	   tissue	   damage	   is	   established,	   the	   focal	   inflammation	  has	   not	   detectable	  
impact	   on	   the	  mechanisms	   driving	   the	   disease	   evolution,	   probably	   explaining	   the	  
lack	   of	   efficacy	   of	   DMT	   in	   the	   progressive	   forms	   of	   the	   disease	   (La	  Mantia	   et	   al.,	  
2012;	  Wolinsky	  et	  al.,	  2007).	  	  
	  
The	   relationship	   between	   relapses	   during	   the	   late	   stage	   of	   the	   RR	   phase	   and	   late	  
outcomes	  was	  previously	  investigated	  in	  the	  British	  Columbia	  database.	  One	  attack,	  
occurring	   between	   5	   to	   10	   years	   after	   onset,	   modestly	   increased	   the	   hazard	   of	  
reaching	  SP	  (HR	  =	  1.23)	  and	  EDSS	  6	  (HR	  =	  1.31)	  within	  this	  period	  of	  time.	  However,	  
this	  effect	  was	  smaller	  than	  the	  effect	  of	  early	  relapses,	  and	  also	  smaller	  when	  the	  
two	   endpoints	   were	   attained	   after	   10	   years	   from	   onset	   (HR	   =	   1.07	   and	   1.06,	  
respectively).	   The	   authors	   concluded	   that	   late	   relapses	   pose	   an	   immediate	   risk	   on	  
the	  disease	  progression	  but	  their	  impact	  on	  the	  endpoints	  diminishes	  with	  time.	  As	  
outlined	   in	   Chapter	   4	   (paragraph	   4.4.2.2),	   this	   analysis	   was	   affected	   by	   some	  
methodological	  caveats.	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In	  contrast,	  among	  LO	  SP	  patients,	  relapses	  occurring	  from	  the	  third	  year	  up	  to	  the	  
onset	   of	   progression	   did	   not	   influence	   negatively	   the	   disease	   evolution.	  
Unexpectedly,	   a	   larger	   number	   of	   attacks	   after	   year	   2	   associated	   with	   a	   longer	  
latency	   to	   progression	   and	   with	   longer	   times	   to	   disability	   endpoints	   (Table	   4.16,	  
Chapter	   4),	   and	   did	   not	   affect	   the	   evolution	   of	   the	   progressive	   phase	   (Table	   4.17,	  
Chapter	  4).	  Therefore,	  the	  analysis	  highlighted	  a	  dichotomy	  between	  early	  and	  late	  
relapses,	   which	   related	   to	   the	   outcomes	   in	   an	   opposite	   way.	   After	   an	   early	  
watershed	   is	   reached,	   focal	   inflammatory	   attacks	   disconnect	   from	   mechanisms	  
driving	  the	  evolution	  of	  the	  RR	  and	  the	  SP	  phases.	  This	  reversal	  seems	  to	  take	  place	  
after	  year	  2	  however,	  methodological	  differences	  (paragraph	  4.4.5,	  Chapter	  4)	  make	  
early	  and	  late	  relapses	  difficult	  to	  compare,	  and	  it	  remains	  possible	  that	  the	  timing	  of	  
the	   watershed	   was	   slightly	   affected	   by	   the	   modality	   of	   the	   data	   collection.	   Late	  
relapses	  were	  counted,	  among	  SP	  patients,	  during	  the	  variable	  period	  of	  time	  from	  
year	   3	   up	   to	   the	   onset	   of	   progression,	  while	   early	   relapses	  were	   counted,	   among	  
relapsing	  onset	  patients,	  during	  the	  fixed	  first	  two	  years	  of	  the	  disease.	  However,	  the	  
analysis	  indisputably	  demonstrated	  that	  groups	  with	  a	  larger	  number	  of	  late	  relapses	  
had	  longer	  latency	  to	  progression	  and,	  consequently,	  took	  longer	  times	  to	  disability	  
endpoints	  (Figure	  4.16,	  Chapter	  4).	  In	  addition,	  SP	  patients	  with	  a	  larger	  number	  of	  
total	  attacks	  before	  the	  onset	  of	  progression,	  had	  a	  longer	  duration	  of	  the	  RR	  phase	  
(Figure	  4.21,	  Chapter	  4).	  	  
	  
These	  results	  challenge	  the	  hypothesis	  that	  the	  transition	  to	  progressive	  MS	  occurs	  
as	  a	  consequence	  of	  serial	  exacerbations,	  after	  compensatory	  mechanisms	  fail.	  If	  the	  
focal	   inflammatory	   insult,	   initially	   abated	   by	   the	   remyelination	   and	   by	   the	   brain	  
plasticity	   (Franklin	   and	  Kotter,	   2008;	   Irvine	   and	  Blakemore,	   2008;	   Tomassini	   et	   al.,	  
2012),	  causes	  the	  changing	  course	  of	  MS	  over	  time,	  a	  larger	  number	  of	  attacks	  would	  
be	   expected	   to	   correlate	   with	   a	   faster	   attainment	   of	   SP.	   Nevertheless,	   the	   early	  
disconnection	  between	  mechanisms	  underlying	  the	  inflammatory	  attacks	  and	  those	  
driving	   the	  evolution	  of	   the	  RR	  phase	   could	  mirror	   a	   gradual	   increment	  of	   a	  more	  
diffuse	   inflammatory	   activity,	   involving	   the	   NAWM	   and	   microglia	   (Frischer	   et	   al.,	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2009;	  Lassmann	  et	  al.,	  2012).	  This	  would	  imply	  that	  the	  compartmentalization	  of	  the	  
inflammation	  (Frischer	  et	  al.,	  2009)	  occurs	  much	  earlier	  than	  initially	  hypothesized.	  	  
	  
As	   highlighted	   by	   the	   analysis	   of	   early	   relapses	   (Figure	   4.10,	   Chapter	   4),	   the	  
pathological	  changes,	  determining	  the	  development	  of	  the	  progressive	  course,	  most	  
likely	  take	  place	  during	  the	  early	  phase	  of	  the	  disease.	  Indeed,	  the	  axonal	  damage	  is	  
known	   to	   occur	   already	   during	   the	   initial	   disease	   stage	   (De	   Stefano	   et	   al.,	   2003;	  
Filippi	  et	  al.,	  2003;	  Stromillo	  et	  al.,	  2013)	  and	   the	  cortical	  pathology	  was	  shown	  to	  
gradually	  take	  over	  the	  white	  matter	  pathology,	  during	  the	  transition	  to	  progressive	  
MS	   (Calabrese	   et	   al.,	   2013).	   Therefore,	   the	  dissociation	  between	   late	   relapses	   and	  
the	  disease	  evolution	  suggests	  that,	  the	  degenerative	  process,	  already	  set	  up	  early	  in	  
the	   disease	   course,	   slowly	   prevails	   on	   the	   focal	   inflammation	   and	   subtly	   becomes	  
clinically	   evident,	   hindering	   the	   clinical	   inflammatory	   attacks.	   It	   remains	   unclear	  
which	   factors	   cause	   the	   changes	   in	   this	   complex	   interaction	   between	   focal	  
inflammation	  and	  degeneration,	  and	  shifts	  the	  balance	  in	  favour	  of	  the	  latter.	  These	  
results	   imply	   a	   yet	   undetermined	   interaction	   between	   the	   development	   of	   the	  
progressive	   course	   and	   the	   suppression,	   or	   the	   masking,	   of	   relapses,	   possibly	  
analogous	   to	   what	   occurs	   in	   PP	   MS.	   Among	   patients	   with	   worse	   prognosis,	   the	  
anticipated	   and	   rapid	   onset	   of	   the	   progressive	   phase	   overlaps	   the	   episodic	   acute	  
clinical	  attacks,	  explaining	  why	  a	  lower	  number	  of	  late	  and	  total	  relapses	  associates	  
with	  a	  shorter	  duration	  of	  the	  RR	  phase	  (Figures	  4.16	  and	  4.21,	  Chapter	  4).	  Indeed,	  
the	  multivariate	  analysis	  of	  early	  and	  late	  relapses	  further	  demonstrated	  that,	  when	  
the	   disease	   is	   less	   aggressive	   and	   the	   occurrence	   of	   the	   progressive	   course	   is	  
delayed,	  the	  late	  inflammatory	  activity	  is	  clinically	  more	  prominent,	  and	  a	  higher	  late	  
attack	  frequency	  is	  a	  concomitant	  of	  a	  longer	  disease	  evolution	  (Figure	  4.23,	  Chapter	  
4).	  	  
	  
In	  addition,	  SP	  patients	  grouped	  by	  the	  number	  of	  total	  attacks	  during	  the	  RR	  phase	  
had	  remarkably	  similar	  outcome	  (Figure	  4.21,	  Chapter	  4).	  These	  results	  are	  probably	  
explained	  by	  early	  and	  late	  relapses	  neutralizing	  each	  other,	  among	  SP	  groups.	  Those	  
with	  high	  early	  attacks	  frequency,	  which	  associated	  with	  a	  fast	  disease	  evolution	  and	  
a	  short	   latency	  to	  progression,	  are	  counterbalanced	  by	  those	  with	  high	  late	  attacks	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frequency,	   which	   associated	   with	   a	   slower	   evolution	   and	   a	   longer	   time	   to	  
progression.	  Overall,	   the	  analysis	  of	   total	   relapses	   further	  confirmed	   that	   the	   focal	  
inflammation,	  after	  the	  initial	  disease	  stage,	  does	  not	  contribute	  to	  the	  development	  
of	  late	  disability.	  	  
	  
7.4	  Age	  and	  the	  disease	  progression	  	  	  
	  
7.4.1	  Age	  and	  the	  progressive	  course	  	  	  
	  
The	   analysis	   of	   relapses	   further	   underlined	   the	   complex	   interaction	   between	   the	  
focal	  inflammatory	  activity	  and	  the	  degenerative	  process.	  The	  balance	  between	  the	  
two	  mechanisms	  and	  their	  clinical	  counterparts	  changes	  over	  time,	  and	  other	  factors	  
might	   influence	   the	   disease	   course.	   The	   transition	   of	   the	   clinical	   phenotype,	   from	  
relapsing	   to	   progressive,	   could	   be	   determined	   by	   the	   evolution	   of	   the	   initial	  
pathological	   processes,	   implying	   separate	   clinical	   stages	   causally	   related	   and	  
occurring	  sequentially.	  However,	   it	   remains	  unclear	  why	  the	  progressive	  phase	  can	  
start	  “de	  novo”	  or	   following	   inflammatory	  attacks.	  The	  similar	  pattern	  of	   the	  brain	  
tissue	   injury	   (Frischer	   et	   al.,	   2009;	   Prineas	   et	   al.,	   2001)	   and	   the	   similar	   disease	  
evolution	  (Kremenchutzky	  et	  al.,	  2006b),	  among	  progressive	  subtypes,	  make	  unlikely	  
that	  PP	  MS	  is	  a	  separate	  clinical	  entity	  (Antel	  et	  al.,	  2012;	  Rice	  et	  al.,	  2013).	  In	  view	  of	  
the	  strikingly	  similar	  ages	  at	   the	  onset	  of	  progression,	  between	  PP	  and	  SP	  patients	  
(Table	   3.6,	   Chapter	   3)	   (Confavreux	   and	   Vukusic,	   2006a;	   Koch	   et	   al.,	   2007;	  
Kremenchutzky	  et	  al.,	  2006a;	  Tutuncu	  et	  al.,	  2013),	   it	  has	  been	  suggested	  that	  age	  
related	   degenerative	   mechanisms	   might	   determine	   the	   emergence	   of	   the	  
progressive	   phase	   and	   drive	   its	   evolution	   (Confavreux	   and	   Vukusic,	   2006b;	  
Kremenchutzky	  et	  al.,	  2006a).	  Indeed,	  progressive	  MS	  only	  rarely	  is	  observed	  during	  
childhood	   (Renoux	   et	   al.,	   2007).	   This	   leads	   to	   a	   unifying	   concept	   of	   the	   disease	  
course,	   characterized	   by	   a	   predefined	   pattern	   of	   accrual	   of	   disability	   during	   the	  
progressive	   phase,	   not	   influenced	   by	   relapses	   preceding	   its	   onset.	   The	   clinical	  
phenotype	  might	  be	  mainly	  a	  function	  of	  the	  different	  ages	  at	  which	  the	  pathological	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processes	   become	   clinically	   evident,	   rather	   than	   an	   effect	   of	   changing	   pathogenic	  
mechanisms	  (Confavreux	  and	  Vukusic,	  2006a).	  	  
	  
The	  analyses	  presented	  in	  this	  thesis	  demonstrated	  that	  age	  is	  an	  important	  driver	  of	  
the	   disability	   accumulation	   and	   affects	   the	   attainment	   of	   late	   outcomes	   by	  
influencing	   the	  evolution	  of	   the	  RR	  phase	  and	  by	  promoting	   the	  occurrence	  of	   the	  
progressive	  course.	  Among	  relapsing	  onset	  patients,	  being	  older	  at	  the	  disease	  onset	  
and	  growing	  older	  increased	  the	  probability	  of	  entering	  the	  SP	  phase,	  independently	  
of	  the	  disease	  duration	  (Figures	  5.5,	  5.19	  and	  Table	  5.12,	  Chapter	  5).	  An	  older	  age	  at	  
the	  onset	   of	   the	  RR	  phase	   associated	  with	   a	   shorter	   latency	   to	   progression	   (Table	  
5.6,	   Chapter	   5).	   Among	   all	   progressive	   subtypes,	   the	   age	   at	   the	   onset	   of	   the	  
progressive	  phase	  was	  unaffected	  by	  the	  clinical	  phenotype	  (Figure	  5.13,	  Chapter	  5),	  
and	  not	  influenced	  by	  the	  total	  relapses	  occurring	  during	  the	  RR	  phase	  (Figure	  5.14,	  
Chapter	   5).	   In	   addition,	   the	   age	   at	   the	   onset	   of	   progression	   was	   only	   marginally	  
influenced	   by	   the	   number	   of	   early	   relapses	   (Figure	   5.15,	   Chapter	   5).	   However,	  
considering	   progressive	   MS	   exclusively	   an	   age-­‐dependent	   disease	   would	   be	   an	  
oversimplification,	   as	   demonstrated	   by	   the	   widely	   variable	   age	   at	   the	   onset	   of	  
progression,	  among	  individuals	  (Figure	  5.12,	  Chapter	  5).	  	  
	  
Overall,	   these	   data	   strongly	   suggest	   that	   age	   related	   mechanisms	   are	   primarily	  
involved	   in	   the	   pathological	   processes	   responsible	   for	   the	   changes	   of	   the	   clinical	  
phenotype,	  over	  time.	  Age	  is	  the	  major	  determinant	  of	  the	  transition	  from	  relapsing	  
to	  progressive	  MS,	  and	   influences	  when	  the	  progressive	  courses	  becomes	  clinically	  
evident,	   irrespective	   of	   the	   disease	   duration.	   The	   almost	   identical	   ages	   when	  
patients	  entered	  the	  progressive	  phase,	  preceded	  or	  not	  by	  the	  RR	  phase,	  indicated	  
that	  the	  biological	  mechanisms,	  causing	  the	  permanent	  axonal	  damage	  and	  leading	  
to	  the	  onset	  of	  the	  progressive	  course,	  are	  active	  much	  before	  its	  clinical	  occurrence.	  
This	   is	   line	   with	   results	   from	   imaging	   studies,	   which	   demonstrated	   evidence	   of	  
axonal	   loss	  early	   in	   the	  disease	  course	   (De	  Stefano	  et	  al.,	  2003;	  Filippi	  et	  al.,	  2003;	  
Stromillo	  et	  al.,	  2013).	  In	  addition,	  the	  lack	  of	  impact	  of	  relapses	  on	  the	  age	  at	  onset	  
of	   SP	   MS	   (Figures	   5.14,	   5.15	   Chapter	   5)	   confirmed	   that	   the	   development	   of	   the	  
progressive	   course	   is	   largely	   independent	   of	   the	   focal	   inflammatory	   pathology,	  
	   401	  
occurring	  during	  the	  RR	  phase.	  However,	  the	  group	  with	  high	  early	  relapse	  frequency	  
(≥	  3	  attacks)	  diverged	  from	  the	  other	  progressive	  patients	  and	  attained	  progression	  
at	  significantly	  younger	  age	  (Figure	  5.15,	  Chapter	  5).	  This	  reinforced	  the	  concept	  that	  
a	   pronounced	   early	   inflammatory	   activity	   directly	   contributes	   to	   the	   mechanisms	  
responsible	  for	  accelerating	  the	  occurrence	  of	  the	  progressive	  course.	  	  
	  
Results	   from	   a	   recent	   longitudinal	   MRI	   study	   underlined	   the	   close	   interaction	  
between	  age	  and	  the	  grey	  matter	  damage,	  influencing	  the	  conversion	  from	  relapsing	  
to	   progressive	   MS.	   The	   multivariate	   model	   identified	   age	   and	   the	   volume	   of	   the	  
cortical	  pathology	  as	  the	  strongest	  predictors	  of	  the	  onset	  of	  the	  progressive	  phase,	  
and	   confirmed	   the	   limited	   role	   of	   the	   white	   matter	   damage	   in	   the	   late	   disability	  
progression	  (Calabrese	  et	  al.,	  2013).	  The	  grey	  matter	  damage	  was	  shown	  to	  occur	  in	  
the	  early	  phase	  of	   the	  disease	  (Calabrese	  et	  al.,	  2007b;	  Lucchinetti	  et	  al.,	  2011),	   to	  
increase	   over	   time	   (Calabrese	   et	   al.,	   2010)	   and	   to	   become	   diffuse	   during	   the	   SP	  
phase	   (Calabrese	   et	   al.,	   2007b).	   It	   is	   reasonable	   to	   assume	   that	   the	   failure	   of	  
compensatory	  mechanisms	  marks	  the	  attainment	  of	  a	  critical	  threshold,	  after	  which	  
further	   cortical	   damage	   determines	   the	   transition	   to	   progressive	  MS.	   Age	   related	  
mechanisms	  could	  directly	  contribute	  to	  the	  pathological	  processes	  driving	  the	  grey	  
matter	  pathology,	  or	  being	   indirectly	   involved	   in	   the	  occurrence	  of	   the	  progressive	  
phase,	  by	  affecting	  the	  efficiency	  of	  the	  mechanisms	  initially	  abating	  the	  damage.	  	  
	  
The	  remyelination	  by	  oligodendrocytes	  is	  known	  to	  protect	  the	  axons	  from	  the	  injury	  
(Irvine	  and	  Blakemore,	  2008;	  Kornek	  et	  al.,	  2000).	   It	   is	  a	   reparatory	  process,	  which	  
actively	  occurs	  during	  the	  RR	  phase	  (Prineas	  et	  al.,	  1993),	  but	  becomes	  less	  efficient	  
during	  the	  progressive	  phase	  (Lassmann	  et	  al.,	  2012;	  Patrikios	  et	  al.,	  2006).	  A	   large	  
body	  of	  evidence	   indicates	   that	   rate	  of	   remyelination	  decreases	  with	  age	   (Rist	  and	  
Franklin,	   2008;	   Ruckh	   et	   al.,	   2012;	   Sim	   et	   al.,	   2002),	   partially	   because	   of	   changes	  
within	  the	  aging	  olygodendrocytes	  precursor	  cells,	  which	  gradually	  loose	  their	  ability	  
of	  differentiating	   into	  remyelinating	  oligodendrocytes	  (Shen	  et	  al.,	  2008;	  Sim	  et	  al.,	  
2002).	  This	  age-­‐dependent	  pathological	  substrate	  might	  justify	  why,	  among	  patients,	  
the	  progressive	  course	  emerges	  while	  growing	  older,	   independently	  of	   the	  disease	  
duration.	   Indeed,	   oligodendrocytes	   precursor	   cells	  with	   lost	   ability	   to	   differentiate	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into	  remyelinating	  oligodendrocytes,	  were	  described	  in	  the	  chronically	  demyelinated	  
lesions	   (Kuhlmann	   et	   al.,	   2008),	  which	   are	   abundant	   during	   the	   progressive	   phase	  
(Frischer	  et	  al.,	  2009;	  Lovas	  et	  al.,	  2000).	   Interestingly,	  a	  recent	  experimental	  study	  
demonstrated	   that	   the	   capacity	   of	   remyelinate	   can	   be	   restored	   in	   aged	  
oligodendrocytes	   precursor	   cells,	   which	   can,	   therefore,	   be	   a	   potential	   target	   for	  
future	  remyelination-­‐enhancing	  therapies	  (Ruckh	  et	  al.,	  2012).	  
	  
It	   has	   also	   been	   hypothesized	   that	   the	   progressive	   failure	   of	   reparatory	  
remyelinating	  mechanisms	  might	  be	  mediated	  by	  an	   increment	  of	   iron	  deposits	   in	  
the	  CNS	  (Lassmann	  et	  al.,	  2012).	  Iron	  and	  ferritin	  are	  stored	  in	  the	  oligodendrocytes	  
of	  MS	  brains	  (Hulet	  et	  al.,	  1999)	  and,	  as	  shown	  by	  studies	   in	  vitro,	   its	  accumulation	  
might	   determine	   a	   higher	   susceptibility	   of	   these	   cells	   to	   degenerate,	   secondary	   to	  
the	  oxidative	  stress	  induced	  by	  the	  inflammation	  (Zhang	  et	  al.,	  2005).	  Following	  the	  
oligodendrocytes	  destruction,	   the	   accumulated	   iron	   is	   released	   in	   the	  extracellular	  
space,	   further	  enhancing	   the	  oxidative	  damage	  and	   increasing	   the	   susceptibility	  of	  
the	   surrounding	   tissue	   to	   the	   degeneration	   (Lassmann	   et	   al.,	   2012).	   Since	   iron	  
deposits	  are	  known	  to	  increase	  in	  human	  brain	  while	  growing	  older,	  and	  to	  reach	  a	  
peak	   between	   40	   and	   50	   years	   of	   age	   (Hallgren	   and	   Sourander,	   1958),	   an	   age-­‐
dependent	  iron	  accumulation	  might	  partially	  explain	  the	  age-­‐related	  changes	  of	  the	  
disease	  course.	  	  
	  
7.4.2	  Age	  and	  the	  relapsing	  phase	  	  	  
	  	  
Age	  influences	  when	  the	  progressive	  course	  becomes	  clinically	  evident,	  in	  addition,	  it	  
affects	   the	  presenting	  pattern	  of	   the	   clinical	   inflammatory	   activity.	   The	  number	  of	  
attacks	  is	  known	  to	  decrease	  over	  time,	  partially	  due	  to	  the	  regression	  to	  the	  mean	  
(Martinez-­‐Yelamos	  et	  al.,	  2006),	  proportionally	  to	  the	  patients’	  age	  (Tremlett	  et	  al.,	  
2008b)	  (Figure	  4.2,	  Chapter	  4).	  For	  the	  first	  time,	  the	  analyses	  in	  this	  thesis	  defined	  
more	   precisely	   the	   relationship	   between	   the	   age	   at	   the	   disease	   onset	   and	   the	  
frequency	   of	   relapses.	   Interestingly,	   a	   dichotomy	   was	   again	   highlighted	   between	  
early	   and	   late	   attacks,	   which	   correlated	   to	   the	   patients’	   age	   in	   an	   opposite	   way.	  
Among	   relapsing	  onset	  patients,	   the	  number	  of	   relapses	  during	   the	   first	   two	  years	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was	  not	  affected	  by	  the	  age	  at	  clinical	  presentation.	  This	  confirmed	  that	  the	  age	  and	  
the	  early	   inflammatory	  activity,	  which	  are	  the	  strongest	  predictors	  of	  the	  evolution	  
of	   the	   RR	   phase,	   exert	   an	   independent	   effect	   on	   the	  mechanisms	   responsible	   for	  
promoting	   the	   emergence	  of	   the	  progressive	   course.	   In	   contrast,	   patients	   older	   at	  
the	   first	   clinical	   manifestation	   had	   a	   significantly	   lower	   number	   of	   late	   and	   total	  
relapses	  (Figure	  5.8,	  Chapter	  5).	  The	  total	  number	  of	  attacks	  recorded	  during	  the	  RR	  
phase	   reduced	  proportionally	  with	   the	   increasing	  age	  at	  disease	  onset	   (Figure	  5.9,	  
Chapter	  5).	  Despite	  sharing	  almost	  the	  same	  age	  at	  the	  onset	  of	  progression,	  the	  SP	  
group	  with	  a	  high	  number	  of	  relapses,	  compared	  to	  the	  groups	  with	  a	  low	  number,	  
were	   significantly	   younger	   at	   the	   clinical	   presentation	   (Figure	   5.24).	   This	   might	  
indicate	   that	   the	   focal	   inflammation	   decreases	   while	   growing	   older	   because	   a	  
gradual	  compartmentalization	  (Frischer	  et	  al.,	  2009).	  Alternatively,	  the	  age	  when	  the	  
inflammatory	   activity	   becomes	   clinically	   evident	   might	   be	   controlled	   by	   genetic	  
factors,	   affecting	   the	   autoimmune	   mechanisms.	   A	   recent	   autopsy	   study	  
demonstrated	   that	   patients	   carrying	   the	   allele	   HLA-­‐DRB1*15,	   who	   are	   known	   to	  
develop	  the	  disease	  at	  younger	  age	  (Masterman	  et	  al.,	  2000),	  have	  significantly	  more	  
pronounced	   inflammation	   in	   the	   spinal	   cord,	   suggesting	   that	   they	   are	   more	  
susceptible	  to	  episodes	  of	  inflammatory	  attacks	  (Deluca	  et	  al.,	  2013).	  	  
	  
However,	  the	  analyses	  also	  demonstrated	  that	  the	  latency	  to	  progression	  is	  shorter,	  
among	  patients	  with	  older	  age	  at	  onset,	  and	  among	  patients	  with	  a	  smaller	  number	  
of	  late	  and	  total	  attacks.	  This	  highlights	  the	  complexity	  of	  the	  mechanisms	  regulating	  
the	  duration	  of	  the	  RR	  phase,	  the	  age	  at	  its	  onset	  and	  the	  relapses	  occurring	  during	  
its	   course.	   Age	   appears	   to	   be	   involved	   in	   the	   biological	   processes	   underlying	   the	  
opening	  and	  the	  closing	  of	  the	  time	  window,	  which	  spans	  from	  the	  first	  acute	  attack	  
to	   the	   gradual	   emergence	   of	   the	   relentless	   accrual	   of	   disability.	   Age	   related	  
degenerative	  mechanisms	  might	   be	   the	   primary	   pathological	   event,	   which	   affects	  
the	  latency	  to	  progression,	  and	  consequently,	  the	  number	  of	  relapses.	  With	  ageing,	  
the	   subtle	   degeneration	   gradually	   emerges	   and	   prevails	   over	   the	   inflammatory	  
mechanisms,	   suppressing	   or	   masking	   the	   clinical	   attacks.	   At	   a	   population	   level,	  
among	  progressive	  subtypes,	  the	  age	  of	  40	  is	  the	  landmark	  point	  in	  the	  patients’	  life	  
when	  the	  degenerative	  process,	  which	  remains	  subclinical	  for	  a	  certain	  time,	  is	  likely	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to	  become	  clinically	  evident.	  Therefore,	  among	  patients	  starting	  to	  relapse	  at	  older	  
age,	   close	   to	   the	   clinical	   occurrence	   of	   the	   progressive	   phase,	   the	   latency	   to	  
progression	  is	  shorter	  and	  the	  number	  of	  inflammatory	  attacks	  is	  lower.	  This	  unifying	  
hypothesis	   further	   defines	   MS	   as	   a	   disorder,	   where	   initially	   different	   clinical	  
phenotypes	  converge	  into	  a	  progressive	  course,	  under	  the	  dominant	  influence	  of	  age	  
related	  mechanisms.	  The	  age	  dependent	  clinical	  phenotypes,	  before	  the	  onset	  of	  the	  
progressive	  phase,	  broadly	  range.	  On	  one	  end	  of	  this	  spectrum	  are	  the	  SP	  patients,	  
who	  experience	  the	  disease	  onset	  at	  young	  age,	  have	  long	  duration	  of	  the	  RR	  phase	  
and	   a	   pronounced	   clinical	   inflammatory	   activity.	  On	   the	  opposite	   end	   are	   the	   SAP	  
patients,	  who	  have	  a	  single	  attack,	   followed	  by	  the	  progressive	  phase	  after	  a	  short	  
latency,	  and	  experience	  the	  disease	  onset	  at	  old	  age,	  close	  to	  the	  age	  at	  onset	  of	  PP	  
patients.	  	  
	  
In	  this	  unifying	  model	  of	  the	  disease,	  the	  primary	  and	  secondary	  progressive	  patients	  
accumulate	   disability	   at	   similar	   rate,	  while	   growing	   older	   (Figure	   5.21,	   Chapter	   5),	  
and	   attain	   the	   disability	   endpoint	   at	   similar	   age	   (Figure	   5.23,	   Chapter	   5).	   Both	  
subtypes	   are	   exposed	   to	   a	   diffuse	   meningeal	   inflammation	   (Choi	   et	   al.,	   2012;	  
Frischer	   et	   al.,	   2009;	   Howell	   et	   al.,	   2011),	   which	  might	   drive	   the	   evolution	   of	   the	  
progressive	   phase.	   However,	   it	   remains	   unclear	   why	   the	   early	   focal	   inflammation	  
would	  be	  less	  disposed	  to	  cause	  symptoms	  among	  patients	  with	  a	  progressive	  onset,	  
compared	   to	   patients	  with	   a	   relapsing	   onset.	   This	   is	   unlikely	   to	   be	   attributed	   to	   a	  
different	   location	   of	   the	   demyelinated	   lesions,	   as	   the	   spatial	   distribution	   is	   not	  
obviously	   different	   (Frischer	   et	   al.,	   2009;	   Revesz	   et	   al.,	   1994).	   Nevertheless,	   the	  
proportion	   of	   remyelinated	   plaques	   and	   the	   overall	   remyelination	   capacity	   was	  
shown	  to	  be	  higher	  in	  PP,	  compared	  to	  SP,	  brains	  (Bramow	  et	  al.,	  2010),	  which	  might	  
be	   a	   potential	   explanation	   of	   the	   different	   clinical	   pattern	   before	   the	   onset	   of	  
progression.	  In	  addition,	  the	  recovery	  from	  clinical	  attacks	  is	  related	  to	  a	  cessation	  of	  
the	   conduction	   block,	   following	   the	   resolution	   of	   the	   focal	   inflammation	   (Smith,	  
1994).	  Therefore,	   individual	  differences	   in	   the	   intensity	  of	   the	   inflammatory	   insult,	  
and	  of	  the	  compensatory	  response,	  might	  contribute	  to	  determine	  the	  variability	  of	  
the	  clinical	  inflammatory	  activity	  (Smith,	  1994).	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7.5	  Predicting	  the	  outcome	  
	  
Although	   groups	   at	   higher	   risk	   of	   experiencing	   a	   faster	   disease	   evolution	   can	   be	  
identified,	   the	   long-­‐term	   outcome	   of	   the	   disease,	   at	   individual	   level,	   remains	  
unpredictable.	  This	  was	  demonstrated	  by	  the	  wide	  variation,	  among	  patients,	  of	  the	  
time	  to	  DSS	   levels	   from	  the	  disease	  onset	   (Figures	  3.18,	  3.19,	  Chapter	  3)	  and	   from	  
the	  onset	  of	  progression	  (paragraph	  6.3.4,	  Chapter	  6),	  of	  the	  time	  to	  SP	  (Figure	  6.5,	  
Chapter	  6),	  and	  of	  the	  age	  at	  onset	  of	  the	  progressive	  phase	  (Figure	  5.12,	  Chapter	  5)	  
and	   at	   the	   attainment	   of	   disability	   landmarks	   (Figure	   5.20,	   Chapter	   5).	   It	   is	  worth	  
noticing	   that	   in	   a	   well-­‐ascertained	   MS	   cohort	   of	   untreated	   patients,	   the	   rate	   of	  
disability	  accumulation	  was	  not	  excessively	  fast.	  The	  results	  indicated	  that	  half	  of	  the	  
total	  population	  is	  expected	  to	  require	  a	  walking	  aid	  in	  15	  years.	  However,	  after	  15	  
years	   from	   the	   disease	   onset,	   30%	  of	   patients	   did	   not	   even	   accumulate	  moderate	  
disability,	  and	  after	  25	  years	  38%	  were	  still	  free	  of	  severe	  disability	  (<	  DSS	  6).	  
	  
The	   analyses	   provided	   strong	   evidence	   indicating	   that,	   among	   relapsing	   onset	  
patients,	  the	  late	  clinical	  outcome	  is	  determined	  primarily	  by	  the	  occurrence	  of	  the	  
progressive	   course,	   and	   by	   the	   latency	   to	   progression.	   Consequently,	  mechanisms	  
driving	  the	  evolution	  of	  the	  RR	  phase	  largely	  account	  for	  the	  disease	  severity.	  Early	  
relapses	   (Figures	   4.10,	   Chapter	   4)	   and	   the	   age	   at	   onset	   (Figure	   5.5,	   Chapter	   5)	  
affected	   the	   attainment	   of	   late	   outcome	   mainly	   by	   promoting	   the	   onset	   of	   the	  
progressive	  phase	  and	  by	  shortening	  the	  time	  to	  SP.	  A	  longer	  latency	  to	  progression	  
associated	  with	  a	  proportionally	  lower	  risk	  of	  becoming	  disabled	  (Figure	  6.6,	  Chapter	  
6).	   Among	   patients	   with	   poor	   outcome,	   the	   faster	   accumulation	   of	   disability	   was	  
secondary	   to	   the	   rapid	   conversion	   to	   SP	  MS	   (Figure	   6.7,	   Chapter	   6).	   This	  was	   also	  
observed	  among	  SP	  patients	  grouped	  by	  the	  frequency	  of	  relapses.	  Despite	  sharing	  
the	  same	  number	  of	  attacks,	  the	  rate	  of	  the	  disability	  accumulation	  varied	  according	  
to	   the	   latency	   to	  progression	   (Tables	   6.2,	   6.3,	   Chapter	   6).	   Similarly,	  when	  patients	  
were	  matched	   by	   the	   duration	   of	   the	   RR	   phase,	   the	   age	   at	   disease	   onset	   did	   not	  
exert	  any	  effect	  on	  the	  attainment	  of	  disability	  levels	  (Figure	  5.7,	  Chapter	  5).	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Unfortunately,	   predicting	   the	   long-­‐term	   outcome,	   based	   on	   the	   information	  
available	  at	  the	  onset	  of	  the	  disease,	  remains	  challenging.	  The	  analyses	  in	  this	  thesis	  
helped	   to	   better	   define	   the	   effect	   on	   the	   disease	   evolution	   of	   baseline	   variables,	  
which	  were	  already	  known	  to	  have	  a	  predictive	  value.	  In	  line	  with	  previous	  reports,	  
the	   characteristics	   of	   the	   onset	   attack	   (type	   and	   number	   of	   neurological	   systems	  
involved)	  were	   found	   to	   not	   impact	   on	   the	   attainment	   of	   the	   disability	   outcomes.	  
However,	  the	  predictive	  effect	  of	  the	  degree	  of	  recovery	  from	  the	  first	  relapse	  could	  
not	  be	  assessed	  (Chapter	  4).	  	  
	  
Overall,	  males	   had	   a	  worse	   outcome	   than	   females,	   although	   the	   differences	  were	  
rather	  small	  and	  not	  very	  significant	  in	  the	  context	  of	  the	  disease	  spanning	  over	  30-­‐
40	  years.	  Men	  become	  progressive	  (Table	  6.4,	  Chapter	  6)	  and	  reached	  death	  (Tables	  
3.19,	   3.21,	   3.22,	   3.23,	   3.24,	   Chapter	   3)	   in	  modestly	   shorter	   times,	   and	   they	   were	  
slightly	  younger	  at	  death	  (Table	  3.19,	  Chapter	  3).	  This	  was	  partially	  accounted	  for	  by	  
the	  larger	  percentage	  of	  PP	  MS	  cases	  among	  males.	  	  
	  
As	   extensively	   shown	   in	   previous	   paragraphs,	   although	   the	   primary	   progressive	  
course,	   compared	   to	   the	   relapsing	   onset	   course,	   associated	   with	   a	   faster	  
accumulation	   of	   disability	   from	   the	   disease	   onset,	   the	   two	   clinical	   phenotypes	  
differed	   little	   in	   the	   late	   disease	   progression	   (Figures	   3.21,	   3.22,	   Chapter	   3).	   In	  
addition,	  progressive	  and	  relapsing	  onset	  patients	  attained	  the	  disability	   landmarks	  
and	   died	   at	   very	   similar	   ages	   (Figure	   5.23,	   Chapter	   5).	   Interestingly,	   among	   dead	  
patients	  only	   (not	   including	   censoring	   information),	   the	   type	  of	   the	  disease	   course	  
did	  not	  affect	  the	  time	  to	  death	  (Tables	  3.15,	  3.19,	  Chapter	  3)	  and	  the	  probability	  of	  
dying	   from	   causes	   related	   to	  MS	   (Table	   3.17,	   Chapter	   3).	   However,	   patients	   with	  
initial	   relapsing	  disease	  had	  a	  worse	  outcome,	  as	   they	  died	  at	   slightly	  younger	  age	  
(Tables	  3.15,	  3.19,	  Chapter	  3).	  
	  
The	   frequency	   of	   early	   relapses	   and	   the	   age	   at	   the	   onset	   of	   the	   RR	   phase	   were	  
identified	   as	   the	   two	   strongest	   predictors	   of	   the	   long-­‐term	   disease	   evolution.	  
Patients	  older	  at	  first	  attack	  and	  experiencing	  a	  larger	  number	  of	  relapses	  within	  two	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years	   from	   onset	   were	   at	   higher	   risk	   of	   becoming	   progressive	   and	   had	   a	   shorter	  
duration	   of	   the	   RR	   phase.	   The	   hazard	   of	   converting	   to	   SP	  MS	  was	   1.5	   fold	   higher	  
among	   the	   group	   aged	   45	   at	   disease	   onset,	   compared	   to	   the	   group	   aged	   30.	   In	  
addition,	   the	  analyses	  demonstrated	  that	   the	  patients	  with	   frequent	  early	   relapses	  
(≥	   3	   attacks)	   have	   a	   high	   probability	   of	   accumulating	   disability	   very	   rapidly.	   They	  
converted	   to	  SP	  MS	   in	  9	  median	  years	  and	   reached	  DSS	  6	  and	  DSS	  8	   in	  10	  and	  21	  
median	  years	   from	   the	  disease	  onset,	   respectively	   (Table	  4.5,	  Chapter	  4),	   and	   in	  1	  
and	  9	  median	  years	  from	  the	  onset	  of	  progression,	  respectively	  (Table	  4.8,	  Chapter	  
4).	  Importantly,	  frequent	  early	  relapsers,	  who	  converted	  to	  SP	  MS,	  took	  only	  4	  mean	  
years	   to	   reach	   DSS	   3,	   indicating	   that	   the	   fast	   attainment	   of	   moderate	   disability	  
predicts	   a	   very	   poor	   outcome.	   This	   information	   can	   become	   available	   early	   in	   the	  
disease	   course	   and	   has	   relevant	   implications	   for	   the	   patients’	   therapeutic	  
management.	  	  	  
	  
Taken	   together,	   these	   data	   demonstrate	   that	   the	   individual	   risk	   of	   attaining	   the	  
disability	  landmarks	  in	  shorter	  or	  longer	  times	  is,	  to	  a	  large	  extent,	  determined	  in	  the	  
early	  stage	  of	  the	  disease,	  by	  mechanisms	  tide	  to	  the	  onset	  of	  the	  SP.	  However,	  the	  
outcome	  changes	  over	  time,	  and	  it	  is	  primarily	  influenced	  by	  the	  patients’	  age	  and	  by	  
the	   length	  of	   the	  disease	  course,	  both	  affecting	  the	  probability	  of	  converting	  to	  SP	  
MS.	   The	   hazard	   of	   becoming	   progressive	   increases	   by	   approximately	   9%	   every	   5	  
years	  of	  the	  disease	  duration	  (Figure	  6.2,	  Chapter	  6)	  and	  proportionally	  with	  ageing	  
(Figure	   5.19,	   Chapter	   5).	   Importantly,	   the	   disease	   duration	   exerted	   no	   predictive	  
effect	  when	  it	  was	  tested	  along	  with	  the	  patients’	  current	  age	  (Table	  5.12,	  Chapter	  
5).	   By	   growing	   older,	   patients	   necessarily	   become	   more	   likely	   to	   experience	   the	  
progressive	  course	  and	  to	  accumulate	  severe	  disability,	  independently	  of	  the	  length	  
of	  the	  disease	  course.	  The	  probability	  of	  reaching	  DSS	  6	  was	  approximately	  double	  in	  
a	   patient	   at	   the	   age	   of	   50,	   compared	   to	   a	   patient	   at	   the	   age	   of	   40	   (Figure	   5.19,	  
Chapter	   5).	   Unexpectedly,	   there	   was	   no	   evidence	   that	   the	   outcome,	   among	   SP	  
patient,	  changed	  according	  to	  the	  number	  of	  late	  attacks	  during	  the	  RR	  phase.	  This	  
discourages	  the	  use	  of	  the	  late	  relapse	  frequency	  as	  predictor	  of	  late	  outcomes.	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Only	   few	   variables	   were	   found	   to	   predict	   the	   evolution	   of	   the	   SP	   phase.	   A	   larger	  
number	   of	   early	   relapses	   associated	   with	   a	   slightly	   faster	   rate	   of	   disability	  
accumulation	   after	   the	   onset	   of	   progression.	   In	   addition,	   patients	   with	   brainstem	  
and	   cerebellar	   symptoms	   at	   clinical	   presentation	   took	   shorter	   times	   to	   DSS	   level	  
from	   the	   onset	   of	   progression.	   The	   analysis	   demonstrated	   that	   the	   disability	  
accumulation	  during	  the	  SP	  phase	  was	  largely	  unaffected	  by	  the	  duration	  of	  the	  RR	  
phase	   (Figure	   6.8,	   Chapter	   6).	   This	   is	   in	   line	  with	   the	   amnestic	   nature	   of	   the	   late	  
disease	   course	   (Confavreux	   et	   al.,	   2003;	   Leray	   et	   al.,	   2010)	   and	   reinforces	   the	  
concept	  that	  the	  outcome	  is	  mainly	  determined	  before	  the	  onset	  progression.	  	  
.	  
7.6	  Clinical	  indicators	  of	  the	  disease	  activity	  
	  
The	  number	  of	  relapses	  is	  considered	  a	  valid	  indicator	  of	  the	  disease	  activity	  and	  it	  is	  
used	  as	  a	  predictor	  of	  the	  response	  to	  DMTs	  (Freedman	  et	  al.,	  2004;	  Rio	  et	  al.,	  2011).	  
A	   standardized	   definition	   of	   the	   treatment	   response	   is	   still	   lacking	   and	   the	  
algorithms	  used	  for	  monitoring	  the	  disease	  evolution	  (Rio	  et	  al.,	  2011)	  are	  based	  on	  
data	  collected	  over	  a	  short	  period	  of	  time	  (Bosca	  et	  al.,	  2008;	  Rio	  et	  al.,	  2006;	  Rudick	  
et	  al.,	  2004;	  Sormani	  et	  al.,	  2007).	  	  
	  
The	  analysis	  of	  relapses	  demonstrated	  that,	   the	  number	  of	  attacks	  after	  year	  2	  did	  
not	  affect	  the	  time	  to	  SP	  and	  the	  times	  to	  hard	  disability	  outcomes,	  from	  the	  disease	  
onset	   (Figure	   4.16,	   Chapter	   4)	   and	   from	   the	   onset	   of	   progression	   (Table	   4.17,	  
Chapter	   4).	   Similarly,	   groups	   with	   different	   frequencies	   of	   total	   attacks,	   before	  
progression,	  had	  exactly	  the	  same	  long-­‐term	  outcome	  (Figure	  4.21,	  Chapter	  4).	  This	  
was	   even	   observed	   when	   comparing	   SAP	   patients	   versus	   those	   with	   ≥	   7	   attacks	  
(Figure	  4.22,	   Chapter	   4).	   There	  was	  no	   indication	   that,	   patients	  with	   an	   increasing	  
number	   of	   relapses	   after	   the	   first	   two	   years	   accumulated	   disability	   more	   rapidly.	  
Therefore,	   the	   frequency	   of	   late	   attacks	   is	   not	   a	   reliable	   indicator	   of	   the	   disease	  
evolution	  .	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These	   results	   caution	   again	   the	   use	   of	   the	   number	   of	   relapses	   for	  monitoring	   the	  
clinical	  activity,	  among	  patients	  under	  treatment	  (Freedman	  et	  al.,	  2004;	  Rio	  et	  al.,	  
2009b;	  Rio	  et	  al.,	  2011),	  and	  challenge	  the	  notion	  that	  the	  attacks	  frequency,	  during	  
the	   short	   observation	   time	   of	   RCTs,	   is	   a	   valid	   surrogate	  marker	   for	   late	   disability	  
(Sormani	  et	  al.,	  2011;	  Wolinsky	  and	  Beck,	  2011).	  However,	  it	  remains	  possible	  that,	  
in	  a	  population	  of	   treated	  patients,	   inflammatory	  attacks	  might	   relate	   to	   the	   long-­‐
term	  disease	  evolution	  (Bermel	  et	  al.,	  2013)	  in	  a	  different	  way,	  compared	  to	  natural	  
history	   studies.	   Among	   172	   patients	   from	   the	   original	   IFN-­‐b-­‐1a	   trial	   (Jacobs	   et	   al.,	  
1996b),	   the	   number	   of	   relapses	   and	   of	   MRI	   inflammatory	   lesions	   was	   found	   to	  
predict	   the	  disability	   score	  after	  15	  years	   from	   randomization.	  Nevertheless,	   these	  
results	  need	  further	  validation,	  especially	  because	  the	  EDSS	  score	  was	  assessed	  only	  
by	   using	   a	   questionnaire	   administered	   to	   the	   patients,	   potentially	   affecting	   the	  
conclusions	  of	   the	   study.	  The	  comparison	  between	   treated	  and	  untreated	  patients	  
was	   proven	   to	   be	   difficult	   (Shirani	   et	   al.,	   2012)	   and	   the	   lack	   of	   randomization	   in	  
observational	   studies	   does	   not	   allow	   conclusions	   to	   be	   drawn	   that	   are	   easily	  
applicable	   to	   clinical	   trials	   (Derfuss	   and	   Kappos,	   2012).	   The	   LO	   cohort	   was	   well	  
ascertained	   and	   therefore	   more	   representative	   of	   the	   whole	   MS	   population	  
compared	   to	   RCTs	   groups,	   which	   are	   inevitably	   subjected	   to	   ascertainment	   bias	  
towards	  more	  severe	  cases.	  	  	  
	  
7.7	  Optimizing	  the	  therapeutic	  approach	  
	  
Currently	   available	   DMTs	   have	   different	   efficacy	   and	   different	   safety	   profiles,	  
therefore	   optimizing	   the	   therapeutic	   approach	   is	   a	   crucial	   aspect	   of	   the	   disease	  
management.	   Patients	   at	   major	   risk	   of	   developing	   severe	   disability	   in	   rapid	   time	  
should	   be	   targeted	   with	  more	   intense	   therapies.	   Patients	   destined	   to	   have	   a	   less	  
aggressive	  disease	  should	  not	  be	  unnecessarily	  exposed	  to	  potentially	  toxic	  drugs.	  	  
	  
There	  are	  two	  therapeutic	  strategies	  for	  treating	  MS	  patients,	  the	  escalating	  and	  the	  
induction	  therapy.	  The	  escalating	  therapy	  is	  the	  most	  commonly	  used	  approach.	  This	  
implies	  starting	  patients	  on	  first	  line	  DMTs	  (glatiramer	  acetate	  and	  interferons	  beta),	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which	   are	   associated	   with	   a	   good	   safety	   profile,	   and,	   if	   clinical	   response	   is	   sub-­‐
optimal,	   switching	   to	  more	  powerful	   second	  or	   third	   line	   therapies,	   though	   at	   the	  
cost	   of	   more	   severe	   adverse	   effects	   (Rio	   et	   al.,	   2011).	   The	   lack	   of	   standardized	  
definition	  of	   treatment	  failure	  makes	  problematic	  to	  decide	  when	  to	   introduce	  the	  
next	  level	  therapeutic	  option.	  	  
	  
In	   addition,	   evidence	   suggests	   that	   the	   window	   of	   therapeutic	   opportunity	   is	  
restricted	  to	  the	  early	  phase	  of	  the	  disease	  and,	  once	  the	  permanent	  tissue	  injury	  is	  
established,	   the	   suppression	   of	   inflammation	   does	   not	   impact	   on	   the	   disease	  
evolution	   (Coles	   et	   al.,	   2006).	   This	   was	   initially	   suggested	   by	   the	   early	   trials	   with	  
Alemtuzumab,	   showing	   that	   the	   marked	   reduction	   of	   the	   inflammatory	   activity	  
exerted	  no	  beneficial	   effect	  on	  SP	  patients,	  but	  prevented	   the	  disease	  progression	  
among	  early	  active	  patients	  (Coles	  et	  al.,	  2006;	  Coles	  et	  al.,	  2008).	  The	  concept	  was	  
reinforced	   by	   the	   results	   of	   the	   phase	   III	   trials,	   demonstrating	   that	   the	   impact	   of	  
Alemtuzumab	  vs	  IFN	  on	  the	  disability	  accumulation	  was	  larger	  among	  patients	  with	  
shorter	   (2.1	  mean	   years)	   (Cohen	   et	   al.,	   2012a),	   compared	   to	   those	   with	   a	   longer	  
disease	  duration	  (4.5	  mean	  years)	  (Coles	  et	  al.,	  2012b).	  Similarly,	  the	  treatment	  with	  
haemapoietic	   stem	   cell	   transplantation	   had	   no	   beneficial	   effect	   in	   progressive	  
patients	   (Burt	   et	   al.,	   2003),	   however	   it	   improved	   the	   neurological	   disability	   in	   RR	  
patients,	   early	   in	   the	  disease	   course	   (5	  median	   year	   disease	  duration)	   (Burt	   et	   al.,	  
2009a).	  	  
	  
Based	   on	   these	   observations,	   despite	   the	   potential	   serious	   side	   effects,	   an	   initial	  
strong	   immunosuppression,	   with	   drugs	   normally	   used	   as	   second	   or	   third	   line	  
therapies,	  is	  indicated	  in	  patients	  with	  very	  active	  and	  aggressive	  disease	  (Edan	  and	  
Le	  Page,	  2013).	  The	  theoretical	  advantage	  of	   the	   induction	  therapy	   is	   to	   tackle	   the	  
disease	   hard	   and	   early	   in	   order	   to	   achieve	   a	   rapid	   control	   of	   the	   inflammation,	  
before	  the	  neurological	  function	  is	  permanently	  damaged.	  However,	  currently	  there	  
are	  no	  precise	  criteria	  for	  identifying	  patients	  requiring	  a	  more	  aggressive	  treatment	  
regime,	   making	   difficult	   to	   rationalize	   the	   use	   of	   the	   induction	   therapy,	   which	   is	  
limited	  by	  the	  safety	  concerns	  (Comi,	  2008).	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The	  data	  presented	  in	  this	  thesis	  strongly	  indicate	  that	  the	  prevention	  or	  the	  delay	  of	  
the	   conversion	   to	   SP	   MS	   should	   be	   considered	   the	   major	   therapeutic	   target	   for	  
future	   treatments.	   Results	   lend	   support	   to	   the	   notion	   that	   inflammatory	  
mechanisms	   responsible	   for	   determining	   the	  occurrence	  of	   the	  progressive	   course	  
are	  already	  active	  in	  the	  early	  phase	  of	  the	  disease.	  In	  line	  with	  the	  larger	  effect	  on	  
the	  disease	  progression	  exerted	  by	  Alemtuzumab	  in	  patients	  with	  very	  short	  disease	  
duration,	   the	   disconnection	   between	   early	   and	   later	   relapses	   implies	   that	   the	  
window	  of	  therapeutic	  opportunity	  is	  confined	  to	  the	  very	  early	  stage,	  and	  narrows	  
with	   time,	   along	   with	   the	   increasing	   disease	   duration.	   A	   permanent	   irreversible	  
damage	  probably	  occurs	  within	  a	  short	   time	  from	  the	  disease	  onset,	  and,	  past	   this	  
point,	  the	  role	  of	  the	  focal	   inflammatory	  activity	  on	  the	  disease	  evolution	  becomes	  
less	  relevant.	  This	  implies	  that	  the	  therapeutic	  suppression	  of	  the	  focal	  inflammation	  
is	  likely	  to	  exert	  most	  of	  its	  efficacy	  in	  the	  earliest	  stage	  of	  the	  disease	  and	  justifies	  
the	  use	  of	  aggressive	  treatments	  in	  virtually	  all	  patients,	  especially	  in	  those	  with	  high	  
early	  relapse	  frequency.	  The	  evidence	  indicates	  that	  this	  specific	  subgroup,	  with	  such	  
an	   exceptionally	   severe	   disease	   course,	   can	   be	   considered	   a	   target	   for	   induction	  
therapy.	   It	   remains	   unclear	   if	   the	   strong	   immunosuppression	   early	   in	   the	   disease	  
course	   can	   prevent	   the	   occurrence	   of	   the	   progressive	   course,	   and	   only	   long	   term	  
follow	  up	  studies	  will	  provide	  the	  answer.	  	  
	  
In	   addition,	   the	   analyses	   highlighted	   the	   importance	   of	   including	   age	   in	   the	  
therapeutic	  algorithm.	  Patients	   in	  young	  age	  are	  more	   likely	   to	   respond	   to	  current	  
DMTs,	   in	   view	   of	   their	   florid	   inflammatory	   activity	   (Figure	   5.24,	   Chapter	   5).	   In	  
contrast,	  being	  older	  at	   the	  disease	  onset	  and	  growing	  older,	   independently	  of	   the	  
length	   of	   the	   disease	   course,	   increase	   consistently	   the	   risk	   of	   experiencing	   a	  
progressive	  course	  in	  a	  short	  time	  and,	  therefore,	  should	  be	  considered	  a	  criteria	  for	  
implementing	  a	  more	  aggressive	  therapeutic	  approach.	  Overall,	  among	  RR	  patients,	  
the	   age	   at	   the	   disease	   onset	   and	   the	   early	   relapse	   frequency	   are	   important	  
information,	   which	   are	   available	   early	   in	   the	   disease	   course	   and	   can	   be	   used	   for	  
rationalizing	  the	  choice	  of	  DMTs.	  The	  therapeutic	  strategy	  during	  the	  disease	  course	  
should	   be	   then	   optimized	   by	   taking	   into	   account	   patients’	   age	   and	   the	   disease	  
duration.	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7.8	  Final	  conclusions	  
	  
Analyses	   presented	   in	   this	   thesis	   addressed	   in	   details	   the	   puzzling	   and	   widely	  
variable	  course	  of	  MS.	  To	  my	  knowledge,	  this	  was	  the	  most	  extensive	  assessment	  of	  
the	  relationship	  between	  relapses	  and	  the	  attainment	  of	  unambiguous,	  hard	  clinical	  
outcomes,	   in	   a	   well-­‐ascertained	   MS	   cohort.	   The	   analyses	   highlighted	   a	   true	  
dichotomy	   between	   early	   and	   late	   focal	   inflammatory	   activity,	   influencing	   the	  
disease	   evolution	   in	   an	   opposite	   way.	   As	   already	   suggested	   by	   imaging	   and	  
pathology	  studies,	  data	  indicated	  that	  the	  mechanisms	  underlying	  the	  inflammatory	  
attacks	   gradually	   disconnect	   from	   those	   responsible	   for	   the	   attainment	   of	   late	  
disability.	  Importantly,	  results	  demonstrated	  that	  the	  dissociation	  between	  the	  focal	  
inflammation	  and	  the	  pathological	  processes,	  leading	  to	  the	  onset	  of	  the	  progressive	  
phase,	  occurs	  much	  earlier	  than	  initially	  hypothesized.	  The	  crucial	  cascade	  of	  events,	  
determining	  the	  individual	  severity	  of	  the	  outcome,	  probably	  takes	  place	  during	  the	  
very	  early	  phase	  of	  the	  disease.	  This	   implies	  that	  the	  early	  stage	  of	  the	  RR	  phase	  is	  
the	   only	   plausible	   window	   of	   therapeutic	   opportunity,	   and	   supports	   the	   use	   of	  
aggressive	  treatments	  early	  in	  the	  disease	  course.	  	  
	  
In	   addition,	   the	   work	   presented	   in	   this	   thesis,	   for	   the	   first	   time,	   extensively	  
addressed	   the	   complex	   interaction	   between	   age,	   the	   disease	   evolution	   and	   the	  
clinical	  phenotypes.	  Age	  affects	  the	  outcome,	  by	  influencing	  the	  evolution	  of	  the	  RR	  
phase	   and	   by	   promoting	   the	   onset	   of	   the	   progressive	   course.	   Furthermore,	   age	  
related	   mechanisms	   probably	   account	   for	   the	   changes	   over	   time	   in	   the	   balance	  
between	   inflammation,	   degeneration	   and	   their	   clinical	   counterparts.	   The	   analyses	  
provided	  a	  large	  body	  of	  evidence,	  which	  indicated	  that	  age	  is	  not	  only	  implicated	  in	  
the	   clinical	   occurrence	   of	   the	   progressive	   course,	   but	   also	   influence	   the	   clinical	  
phenotype	  before	  the	  onset	  of	  progression.	  	  
	  
Overall,	   results	   highlighted	   the	   onset	   of	   the	   SP	   phase	   as	   the	   overwhelming	  
determinant	   of	   the	   long-­‐term	   disease	   evolution.	  Mechanisms	   tied	   to	   the	   onset	   of	  
progression,	  and	  driving	  the	  evolution	  of	   the	  RR	  phase,	  dictate	  the	  “tempo”	  of	   the	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disability	  accumulation	  and	  are	  responsible	  for	  the	  variability	  of	  the	  clinical	  outcome,	  
among	  patients.	  Therefore,	  the	  conversion	  to	  SP	  MS	  is	  a	  robust	  surrogate	  marker	  for	  
late	  disability	  and	  its	  prevention	  or	  delay	  should	  be	  the	  target	  of	  future	  treatments.	  	  
	  
The	   predictive	   models	   have	   successfully	   identified	   clinical	   features,	   early	   in	   the	  
disease	   course,	   than	   can	   help	   to	   select	   groups	   at	   high	   risk	   of	   experiencing	   a	   fast	  
disease	   progression,	   and	   therefore	   requiring	   a	   more	   aggressive	   therapeutic	  
approach.	   This	   has	   relevant	   implications	   for	   optimizing	   the	   patients’	   therapeutic	  
management	  and	  for	  rationalizing	  the	  use	  of	  the	  induction	  therapy.	  In	  addition,	  this	  
data	   can	   be	   used	   for	   improving	   the	   methodology	   of	   RCTs,	   testing	   the	   efficacy	   of	  
drugs	   with	   potential	   neuroprotective	   effect.	   Results	   indicated	   that	   the	   number	   of	  
attacks	  after	   the	   first	   two	  years	   is	  not	  a	   reliable	   indicator	  of	   the	  disease	  evolution,	  
cautioning	  against	  the	  use	  of	  the	  frequency	  of	  relapses	  as	  clinical	  endpoints.	  The	  age	  
at	  the	  disease	  onset,	  the	  early	  relapse	  number	  and	  the	  length	  of	  the	  disease	  course	  
should	  be	  utilized	  in	  the	  randomization	  schemes	  for	  selecting	  patients,	  who	  can	  be	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